As filed with the Securities and Exchange Commission on June 10, 2015
Registration No. 333-204577
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
AMENDMENT NO. 2
TO
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
TELADOC, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation or organization) |
7389
(Primary Standard Industrial Classification Code Number) |
04-3705970
(I.R.S. Employer Identification No.) |
2 Manhattanville Road
Suite 203
Purchase, New York 10577
(203) 635-2002
(Address, including zip code, and telephone number, including area code, of the registrant's principal executive offices)
Jason Gorevic
Mark Hirschhorn
Teladoc, Inc.
2 Manhattanville Road, Suite 203
Purchase, New York 10577
(203) 635-2002
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to: | ||||
Marc D. Jaffe Rachel W. Sheridan Brandon J. Bortner Latham & Watkins LLP 885 Third Avenue New York, NY 10022 (212) 906-1200 |
|
Adam C. Vandervoort Chief Legal Officer & Secretary Teladoc, Inc. 2 Manhattanville Road, Suite 203 Purchase, New York 10577 (203) 635-2002 |
|
Alexander D. Lynch Weil, Gotshal & Manges LLP 767 Fifth Avenue New York, NY 10153 (212) 310-8000 |
Approximate date of commencement of proposed sale to the public:
As soon as practicable after the effective date of this registration statement.
If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. o
If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o
If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o
If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer o | Accelerated filer o |
Non-accelerated filer
ý
(Do not check if a smaller reporting company) |
Smaller reporting company o |
The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until this registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.
Subject to completion, dated June 10, 2015
The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.
Prospectus
Shares
Common Stock
This is the initial public offering of shares of common stock of Teladoc, Inc. We are selling shares of common stock.
Prior to this offering, there has been no public market for our common stock. We expect the public offering price to be between $ and $ per share. We will apply for listing of our common stock on the New York Stock Exchange, or the NYSE, under the symbol "TDOC."
We are an "emerging growth company" as defined by the Jumpstart Our Business Startups Act of 2012 and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings. See "Prospectus SummaryImplications of Being an Emerging Growth Company."
Investing in our common stock involves risks that are described in the "Risk Factors" section beginning on page 20 of this prospectus.
|
Per Share | Total | |||||
Public offering price |
$ | $ | |||||
Underwriting discount |
$ | $ | |||||
Proceeds, before expenses, to us |
$ | $ |
We have granted the underwriters an option for a period of 30 days to purchase up to an additional shares of common stock.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The underwriters expect to deliver the shares to purchasers on or about , 2015.
J.P. Morgan | Deutsche Bank Securities |
William Blair | ||||
Wells Fargo Securities | SunTrust Robinson Humphrey |
, 2015
TABLE OF CONTENTS
You should rely only on the information contained in this prospectus and in any related free-writing prospectus we prepare or authorize. We have not, and the underwriters have not, authorized anyone to give you any other information and take no responsibility for any other information that others may give you. We are offering to sell, and seeking offers to buy, the common stock only in jurisdictions where offers and sales are permitted. The information in this document may only be accurate on the date of this document, regardless of its time of delivery or of any sales of the common stock. Our business, financial condition, results of operations or cash flows may have changed since such date.
i
Market, Industry and Other Data
This prospectus includes estimates regarding market and industry data and forecasts, which are based on publicly available information, industry publications and surveys, reports from government agencies, reports by market research firms or other independent sources and our own estimates based on our management's knowledge of and experience in the market sectors in which we compete.
Certain monetary amounts, percentages and other figures included in this prospectus have been subject to rounding adjustments. Accordingly, figures shown as totals in certain tables or charts may not be the arithmetic aggregation of the figures that precede them, and figures expressed as percentages in the text may not total 100% or, as applicable, when aggregated may not be the arithmetic aggregation of the percentages that precede them.
Trademarks
We own or otherwise have rights to the trademarks and service marks, including those mentioned in this prospectus, used in conjunction with the marketing and sale of our products and services. This prospectus includes trademarks, such as Teladoc and AmeriDoc, which are protected under applicable intellectual property laws and are our property and the property of our subsidiaries. This prospectus also contains trademarks, service marks, copyrights and trade names of other companies, which are the property of their respective owners. We do not intend our use or display of other companies' trademarks, copyrights or trade names to imply a relationship with, or endorsement or sponsorship of us by any other companies. Solely for convenience, our trademarks and trade names referred to in this prospectus may appear without the ® or symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks and trade names.
ii
This summary highlights information contained elsewhere in this prospectus. Because this is only a summary, it does not contain all of the information that may be important to you. You should read this entire prospectus and should consider, among other things, the matters set forth under "Risk Factors," "Selected Historical Financial Information" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," and our audited consolidated financial statements and related notes thereto appearing elsewhere in this prospectus before making your investment decision. Unless otherwise indicated or the context otherwise requires, references in this prospectus to "Teladoc," the "Company," "our company," "we," "us" and "our" refer to Teladoc, Inc., a Delaware corporation, together with its consolidated subsidiary. References herein to "fiscal year" refer to our fiscal years, which end on December 31.
Overview
We are the nation's first and largest telehealth platform, delivering on-demand healthcare anytime, anywhere, via mobile devices, the internet, video and phone. Our solution connects consumers, or our Members, with our over 1,100 board-certified physicians and behavioral health professionals, or our Providers, who treat a wide range of conditions and cases from acute diagnoses such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation. Nearly 11 million unique Members now benefit from access to Teladoc 24 hours a day, seven days a week, 365 days a year, at a cost of $40 per visit. Our solution is delivered with a median response time of less than ten minutes from the time a Member requests a telehealth visit to the time they speak with a Teladoc physician. We completed approximately 300,000 telehealth visits in 2014.
The Teladoc solution is transforming the access, cost and quality dynamics of healthcare delivery for all of our market participants. Our Members rely on Teladoc to remotely access affordable, on-demand healthcare whenever and wherever they choose. Employers, health plans and health systems, or our Clients, purchase our solution to reduce their healthcare spending while at the same time offering convenient, affordable, high-quality healthcare to their employees or beneficiaries. Our Providers have the ability to generate meaningful income and deliver their services more efficiently with no administrative burden. We believe the value proposition of our solution is evidenced by our overall Member satisfaction rate, which has exceeded 95% over the last six years, and a 104% annual net dollar retention rate among our Clients on average over the last three years. We further believe any consumer, employer or health plan or practitioner interested in a better approach to healthcare is a potential Teladoc Member, Client or Provider.
According to the Centers for Disease Control and Prevention, or the CDC, there are approximately 1.25 billion ambulatory care visits in the United States per year, including those at primary care offices, hospital emergency rooms, outpatient clinics and other settings. We estimate that approximately 417 million, or 33%, of these visits could be treated through telehealth.
The U.S. healthcare system is experiencing a growing crisis of access, cost and quality of care due to inefficiencies in today's healthcare system and barriers between participants. According to the National Association of Community Health Centers, or the NACHC, approximately 62 million individuals in the United States currently have no or inadequate access to primary care as a result of physician shortages. Additionally, according to the Department of Health and Human Services, the Patient Protection and Affordable Care Act, or PPACA, has already expanded coverage to 16.4 million of the 47 million previously uninsured Americans. This number is widely expected to increase over the next several years due to individual and employer mandates, premium subsidies, state health insurance exchanges and ban on withholding coverage due to pre-existing medical conditions, increasing demand for access to primary care physicians. Absent convenient access to a primary care physician, individuals will most likely either not seek care at all or visit emergency
1
rooms or urgent care clinics, the most expensive and often inefficient settings for their primary care needs. These market dynamics impact not only the consumers seeking care, but also the health plans and employers that ultimately bear all or a portion of these costs. According to the CDC, 79.7% of emergency room visits not resulting in a hospital admission were due to lack of access to an alternative provider, and a recent study published in The Journal of American Medical Association estimated that approximately $734 billion, or 27%, of all healthcare spending in 2011 was wasted due to factors such as the provision of unnecessary services, inefficient delivery of care and inflated prices.
Innovators in other industries have solved access, cost and quality inefficiencies through the implementation of technology platforms and business models that deliver products and services on-demand and create new economies by connecting and empowering both consumers and businesses. We have taken the same approach to solving the pervasive access, cost and quality challenges facing the current healthcare system. Consumers' ability to access high-quality, affordable care has been limited by many factors such as physician availability, prohibitive costs, physician office hours and geographic locations. Likewise, burdensome administration, cancellations, unfilled appointment slots, geographic constraints and business hour limitations have historically impacted physician efficiency and, as a result, constrained physicians' income. We have created a platform that is uniquely positioned to bridge the supply and demand gap between physicians and consumers by fundamentally changing the way market participants access and deliver healthcareeliminating traditional barriers and inefficiencies between participants and empowering them to engage in a healthcare marketplace anytime, anywhere. Our platform provides our Members with access to board-certified physicians, comprehensive clinical programs and consumer engagement strategies in an economic model that delivers multiple benefits to all participants. The unique combination of these features enables us to dynamically and efficiently match consumer demand and physician availability in real-time.
Our underlying technology platform is complex, deeply integrated and has been purpose-built over the last ten years for the evolving healthcare marketplace. Our platform is highly scalable and can support substantial growth in our current membership base. Our platform provides for broad interconnectivity between healthcare constituents and, we believe, uniquely positions us as a focal point in the rapidly evolving healthcare industry to introduce innovative, technology-based solutions, such as remote patient monitoring, post-discharge treatment plan adherence and in-home and chronic care.
Our solution offers our Clients substantial savings opportunities and an attractive return on investment, or ROI. We recently commissioned Veracity Healthcare Analytics, an independent healthcare data analytics company, to perform an independent study of the nation's largest home-improvement retailer, a Client since 2012, representing over 150,000 of our Members as of December 31, 2014. The study was prepared on behalf of Veracity Healthcare Analytics by two doctors of medicine and a doctor of science and pharmacy, in each case, professors at leading academic institutions. The study found that this Client saved $1,157 on average per employee when its employees received care through Teladoc instead of receiving care in other settings for the same diagnosis. The study also measured the total healthcare expenditure per-Member-per-month during the 16-month period immediately preceding the implementation of Teladoc in order to establish a trend and predict the Client's average monthly expenditure per-Member-per-month over the 20-month period following the introduction of Teladoc. The study demonstrated a meaningful reduction in average per-Member-per-month spending of $21.30 to the Client relative to predicted cost, or a monthly healthcare expenditure savings of 10.2% per Member. Additionally, during 2014 the Client achieved an ROI of approximately $9.00 for every $1.00 spent per Member. Finally, the study demonstrated that 92% of the Client's employees that used Teladoc for a medical issue resolved their issue completely and did not require a follow up visit at a physician's office, emergency room or other location. We believe these results are representative of the results
2
achieved by our other Clients as well as the value proposition we can provide the broader U.S. healthcare system.
We currently serve over 4,000 employers, health plans, health systems and other entities. These Clients collectively purchase access to our solution for our nearly 11 million Members. We believe our Business to Business to Consumer, or B2B2C, distribution strategy is the most efficient method by which to reach consumers and deliver telehealth to our Members. We have over 20 health plans as Clients, including some of the largest in the United States such as Aetna, Blue Shield of California, Highmark and Centene. Health plans serve as Clients as well as distribution channels to self-insured employer Clients that contract with us through a health plan relationship. Our over 1,600 direct and administrative services only, or ASO, employer Clients include 160 Fortune 1000 companies and industry leaders such as Accenture, Bank of America, Pepsi and Shell. We also have a number of health system Clients such as Henry Ford, Memorial Hermann and Mount Sinai. The remainder of our Clients are from channel partners such as brokers, resellers and consultants who sell into a range of small, medium and large enterprises. Over the past two years, we have more than doubled our client and membership bases. We believe telehealth is in the early stages of what eventually will become widespread adoption. A 2014 Towers Watson study suggests as many as 71% of employers with more than 1,000 employees are expected to offer telehealth by 2017.
We generate revenue from our Clients on a contractually recurring, per-Member-per-month, subscription access fee basis, which provides us with significant revenue visibility. In addition, under the majority of our Client contracts, we generate additional revenue on a per-telehealth visit basis, through a visit fee. Subscription access fees are paid by our Clients on behalf of their employees, dependents and other beneficiaries, while visit fees are paid by either Clients or Members. We generated $19.9 million and $43.5 million in revenue for the years ended December 31, 2013 and 2014, respectively, representing 119% year-over-year growth, and $9.4 million and $16.5 million for the three months ended March 31, 2014 and 2015, respectively, representing 75% year-over-year growth. For the three months ended March 31, 2015, 80% and 20% of our revenue were derived from subscription access fees and visit fees, respectively, and for the year ended December 31, 2014, 85% and 15% of our revenue were derived from subscription access fees and visit fees, respectively.
Industry Challenges and Our Opportunity
Barriers and inefficiencies in the current U.S. healthcare system present market participants with three major challenges: (i) consumers lack sufficient access to high-quality, cost-effective healthcare at appropriate sites of care, while bearing an increasing share of costs; (ii) employers and health plans lack an effective solution that reduces costs while enhancing healthcare access for beneficiaries and (iii) providers lack flexibility to increase productivity by delivering care on their own terms. Market participants are therefore increasingly unable to effectively and efficiently receive, deliver or administer healthcare. At the same time, the emergence of technology platforms solving massive structural challenges in other industries has highlighted the need for a similar solution in healthcare. We believe there is a significant opportunity to solve these challenges through a trusted solution, such as ours, that matches consumer demand and physician supply in real-time, while offering health plans and employers an attractive, cost-effective healthcare alternative for their beneficiaries.
Growing Healthcare Access Crisis for Consumers
Consumers in the United States are experiencing challenges in obtaining access to affordable, high-quality healthcare at appropriate sites of care. A 2014 NACHC report found that 62 million individuals in the United States have no or inadequate access to primary care as a result of local
3
physician shortages. According to a 2014 Merritt Hawkins study, the average lead time to see a primary care physician across various metro areas was 19 days. We believe provider supply is projected to further contract, evidenced by the 2014 Survey of America's Physicians: Practice Patterns and Perspectives, or the 2014 Survey of America's Physicians, where 81% of physicians describe themselves as either over-extended or at full capacity. Additionally, according to a 2010 Association of American Medical Colleges, or AAMC, report, the healthcare system will have a shortage of approximately 131,000 physicians by 2025, including a shortage of approximately 52,000 primary care physicians. Given expected population growth and aging in the United States, as well as the projected increase in healthcare demand from PPACA implementation, the supply and demand gap for access to healthcare services is expected to further widen, placing additional pressure on an already overburdened healthcare system that lacks physician capacity and diagnoses-appropriate access points.
This access crisis has resulted in U.S. consumers either seeking care at inappropriate, more costly settings, such as hospital emergency rooms, or foregoing needed care entirely. According to the CDC, there are approximately 1.25 billion in-person ambulatory care visits in the United States per year, including those at primary care offices, hospital emergency rooms, outpatient clinics and other settings. We estimate that approximately 417 million, or 33%, of these visits could be treated through telehealth.
Healthcare Cost Burden and Lack of Viable Options for Health Plans and Employers
The U.S. healthcare system is burdened by significant waste and extreme variations in access, cost and quality of care. A recent study published in The Journal of American Medical Association estimates that approximately $734 billion, or 27%, of all healthcare spending in 2011 was wasted due to factors such as the provision of unnecessary services, inefficient delivery of care and inflated prices. When consumers are forced to seek care at inappropriate and more costly sites of care, those cost inefficiencies impact not only the consumer, but also the health plans and employers that ultimately bear all or a portion of these costs.
The costs and associated burdens on health plans, employers and consumers are only expected to increase. The Centers for Medicare & Medicaid Services, or CMS, forecasted U.S. national health expenditures to reach $3.1 trillion, or approximately 18% of the U.S. Gross Domestic Product, or GDP, in 2014, and approximately 20% of GDP by 2022. A 2013 survey by the National Business Group on Health and Towers Watson indicated that employers bear on average approximately two-thirds of their employee's healthcare costs and CMS forecasted U.S. employers to spend approximately $660 billion on healthcare in 2015. Despite the significant amount of dollars spent, U.S. healthcare outcomes remain inferior relative to those of many other countries.
The unsustainable levels of spending on healthcare and extreme inefficiencies in the system have driven an increased focus by employers and health plans to control healthcare expenditures. Governments, private insurance companies and self-insured employers are implementing meaningful cost containment measures, including shifting financial responsibility to patients through higher co-pays and deductibles and delivering healthcare through alternative, more cost-effective methods. The increasing shift of financial responsibility to patients coupled with increased pricing transparency has, in turn, heightened beneficiary focus on healthcare alternatives. According to a 2013 survey for Prudential Insurance by MRops, Inc. and Oxygen Research Inc., 49% of employers are extremely or very likely to eventually offer only high deductible health plans, or HDHPs. As consumers take responsibility for a larger share of their healthcare costs and spend more on healthcare services, they are also demanding higher quality care, greater control in how and where they receive care, increased convenience and more service for every dollar spent.
4
Challenging Environment for Physicians is Constraining Supply
Physicians face declining compensation paired with diminishing productivity due to a combination of reimbursement cuts and an increasing administrative burden. These factors have contributed to physician dissatisfaction and negatively impacted their desire to practice medicine. Medscape's 2014 Physician Compensation Report shows that 50% of all physicians do not feel fairly compensated and 42% would not choose medicine as their career today.
In response to this growing dissatisfaction, physicians are reducing access to healthcare in a number of different ways. The 2014 Survey of America's Physicians indicated that 44% of physicians plan to take steps to limit access to their practices, including cutting back on the number of patients seen, working part-time, closing their practices to new members, seeking non-clinical jobs or retiring. Notably, 39% of surveyed physicians indicated they plan to accelerate retirement given changes in the healthcare environment. Further, administrative challenges are expected to increase. According to the same survey, 50% of physicians anticipate the implementation of the tenth revision of the International Statistical Classification of Diseases and Related Health Problems, or ICD-10, to cause severe administrative problems in their practices. This is expected to further increase the 20% of daily time surveyed physicians indicated they already spend on non-clinical paperwork, which is constraining their productivity. These constraints have driven physicians to seek more control over the way they deliver care to new and existing patients, increase their income and reduce the amount of time they spend on administration.
Opportunity to Remove Barriers Through an Innovative Platform that Benefits All Participants
We believe we have a significant opportunity to solve access, cost and quality of care challenges through a platform that matches consumer demand and physician availability in real-time, while offering health plans and employers an attractive, cost-effective alternative for their beneficiaries through our platform. As consumerism in healthcare increases and consumers and providers become accustomed to on-demand services in other industries, they are similarly demanding technology-powered solutions for their healthcare needs. The emergence and subsequent rapid adoption of technologies such as big data and analytics, cloud-based solutions, online video and mobile applications represents an enormous opportunity for healthcare innovation. We believe the confluence of consumer empowerment, emergence of broad technology solutions and focus by all constituents on providing high-quality, cost-effective healthcare creates a unique opportunity for a disruptive platform that transforms the way consumers access, providers deliver and employers and health plans administer high-quality, cost-efficient healthcare.
Our Value Proposition
We focus exclusively on delivering on-demand healthcare anytime, anywhere, via mobile devices, the internet, video and phone. We believe our solution provides market participants a value proposition that is differentiated from the traditional healthcare system.
Value Proposition for Members
Our philosophy is to center care around the Member. We believe we offer our Members the following value proposition.
5
Value Proposition for Clients
We believe we offer our Clients the following value proposition.
6
interaction as well as our initiatives to promote worksite marketing and executive sponsorship to drive awareness and adoption by Members.
Value Proposition for Providers
We believe we offer our Providers the following value proposition.
Our Competitive Strengths
We believe the following are our key competitive strengths.
Leading Solution and First-Mover Advantage
Our solution is composed of an integrated technology platform, high-quality Provider network, sophisticated consumer engagement strategies and entrenched distribution channels. We have developed a strong brand, established strong relationships with Clients and have become a leading telehealth platform in the United States. Our history of innovation and long-standing operating history provide us with a significant first-mover advantage, including what we believe are the following telehealth industry firsts:
7
healthcare-oriented organization founded in 1990 dedicated to improving healthcare quality and verifying adherence to national standards of excellence in the provision of healthcare.
Innovative Technology Platform
Our integrated solution positions us at the center of the patient, provider and payor relationship and as a key participant in the rapidly emerging, technology-powered healthcare industry. We continually incorporate new product features into our platform to meet the evolving needs of the highly complex healthcare industry. We believe our technology platform contains several differentiating features, including the following:
Significant and Measureable Return on Investment
Our solution offers our Clients substantial savings opportunities and an attractive ROI. We recently commissioned an independent study of the nation's largest home-improvement retailer, a Client that represented over 150,000 of our Members as of December 31, 2014. The study found that this Client saved $1,157 on average per telehealth visit when its employees received care through Teladoc instead of receiving care in other settings for the same diagnosis. The study also measured the total healthcare expenditure per-Member-per-month during the 16-month period immediately preceding the implementation of Teladoc in order to establish a trend and predict the Client's average monthly expenditure per-Member-per-month over the 20-month period following the introduction of Teladoc. The study demonstrated a meaningful reduction in average per-Member-per-month spending of $21.30 to the Client relative to predicted cost, or a monthly healthcare expenditure savings of 10.2% per Member. Additionally, during 2014 the Client achieved an ROI of approximately $9.00 for every $1.00 spent per Member. Finally, the study demonstrated that 92% of the Client's employees that used Teladoc for a medical issue resolved their issue completely and did not require a follow up visit at a physician's office, emergency room or other location. We believe these results are representative of the results achieved by our other Clients as well as the value proposition we can provide the broader U.S. healthcare system.
Highly Scalable Platform
Our platform is highly scalable and can currently provide the same level of Member support and response time for upwards of 10,000 visits per day versus our current rate of approximately 1,500 visits per day on average. Similarly, our platform is currently equipped to serve over 100 million Members and can be scaled quickly to serve even higher volumes. Further, our platform has been built to accommodate the seamless and quick introduction of new services and products,
8
such as behavioral health, dermatology and other services that are currently in development stages. We believe our highly scalable platform provides us with significant growth opportunities within our existing membership and client bases and allows us to grow with low capital expenditure requirements.
Clinical Capabilities Tailored to Telehealth
We believe that by directly recruiting, credentialing, training and contracting with our Providers we have built our clinical capabilities in a manner that supports the operational complexity of and commitment to clinical quality required in telehealth. Our Providers are board-certified with an average of 20 years of experience and are credentialed through an NCQA-certified process. The NCQA's accreditation process involves a comprehensive on-site and off-site review by a team of physicians and managed care experts that evaluates more than 60 quality-related healthcare standards, including quality management and improvement and utilization management. The results of the evaluation are reviewed by the NCQA's National Review Oversight Committee prior to their assigning an accreditation level. The NCQA's requirements are developed with the input and support of health plans, providers, purchasers, unions and consumer groups. Our clinical capabilities are designed specifically for telehealth. For example, our Members have the option to share a record of every visit and their electronic medical record, or EMR, with their existing physicians. Prior to every visit, the Provider reviews the Member's proprietary EMR and certifies to this review by completing a multi-step checklist. During and following the visit, the Provider references our over 100 proprietary Evidence Based clinical guidelines and other telehealth-specific content. In addition, Members and Providers remain connected following visits. Members receive personalized notes, patient education materials and are able to ask questions of our clinical team via the Teladoc Message Center. Over 10% of all visits are reviewed by our clinical quality assurance staff to ensure adherence to appropriate treatment and prescription patterns. We believe our track record of zero medical malpractice claims is a testament to our Providers' clinical quality.
Well-Established Distribution Channels and Strategic Alliances
We have spent over ten years developing sales channels and strategic alliances, which we believe provide an opportunity to sell our solution through trusted partners and are not easily replicated. Our solution is sold through a highly efficient and effective B2B2C distribution network wherein we reach consumers through our Clients and channel partners rather than marketing our solution directly to potential Members. We sell through a direct sales force to our Clients who in turn buy our solution on behalf of their beneficiaries. In addition, a range of third-parties including brokers, agents, benefits consultants and resellers, whom we refer to as channel partners, sell our solution to various end markets. Notably, many of our health plan Clients also act as channel partners because they resell our solution to their ASO accounts and other customers. We believe the breadth of our distribution strategy allows us to reach employers of nearly every size and in nearly every market, which are capable of purchasing our solution for a large number of beneficiaries, rather than attempting to sell our solution one consumer at a time.
Our Growth Strategies
The following are our key growth strategies.
Expand our Membership with New and Existing Clients
We intend to increase our membership by adding additional Members from both existing Clients and from new Clients. We plan to execute this strategy by further penetrating existing relationships and by pursuing new relationships through our distribution channels and an expanded sales team. Within existing accounts, we believe our current membership represents only a fraction of the potential Members available to us. Our existing health plan Clients and self-insured Clients
9
associated with these health plans currently purchase our solution for only 9% of their beneficiaries in the aggregate, which provides us the opportunity to grow our membership base by more than 50 million individuals within these existing Clients alone. Similarly, we have 160 Fortune 1000 Clients, representing a significant opportunity for new Client growth with large employers. We are investing heavily in new marketing technologies and support staff to aid our sales force in penetrating existing accounts, lead generation, new Client generation and implementations. We further believe that as market leader in the telehealth industry, we have a strong, established brand and are uniquely positioned to capitalize on the Business to Consumer, or B2C, channel in the future.
Expand into New Clinical Specialties
We currently offer our Clients access to over 1,100 board-certified physicians who treat a wide range of conditions and cases from acute diagnoses such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions. We also currently offer direct-to-Member access to behavioral health professionals who treat conditions such as anxiety and smoking cessation. We intend to leverage our highly scalable platform by expanding into new clinical specialties, such as standalone dermatology services, second opinions and chronic conditions such as diabetes, and by focusing on expanding our services amongst current Clients such as by offering behavioral health as a commercial service to our Clients. As we expand our clinical offerings, we intend to further eliminate gaps in continuity of care in order to provide coordinated care along the healthcare delivery continuum.
Leverage Existing Sales Channels and Penetrate New Markets
We have developed a highly effective distribution network to target large employers and we are committing incremental sales and marketing resources to the small and medium business, or SMB, sales channel to increase our penetration within this market. Additionally, we intend to further penetrate the provider market, notably hospitals and group physician practices, as we believe our solution offers these markets an attractive platform from which to generate substantial income by acquiring new patients and to better participate in emerging risk-sharing and value-based payment models, such as Accountable Care Organizations and Patient-Centered Medical Homes. Lastly, with expanded access to available health insurance as a result of PPACA implementation, we intend to pursue health insurance exchanges, which represent an attractive new sales channel.
Expand Across Care Settings and Use Cases
We intend to expand our solution across use cases and additional care settings. We also continually explore ancillary opportunities to broaden our business, including by expanding our relationship with Medicare Advantage and Medicaid Managed Care plans. We believe our services have wide applicability across new use cases, including home care, post discharge, wellness/screening and chronic care. We are also currently extending the number, range and functionality of our benefits applications, and will continue to respond quickly to evolving market needs with innovative solutions, including broadened health kiosk access, mobile applications, biometric devices and at-home testing.
Increase Engagement by Our Members
We believe there is significant opportunity within our existing membership base to increase engagement by continually increasing awareness of and loyalty to our solution. We believe our solution can become the single source for on-demand healthcare for our Members by continuing to add new and complementary products and services, third-party connections and other strategic alliances. We will continually refine and enhance our user experience, which is a critical driver of new and repeat engagement and we will continue validating our Member satisfaction with surveys
10
and other proactive tools. We are also building robust data repositories to strengthen our predictive models and multi-channel marketing strategies to provide a more complete picture of our Members, enhancing our ability to lead targeted and purposeful campaigns, and we will continue to invest heavily in marketing technologies that allow us to increase Member touch-points. Lastly, we will continue to actively engage Clients in benefit design, worksite marketing and executive sponsorship strategies to drive awareness about our solution.
Expand through Focused Acquisitions
We plan to continue to leverage our know-how and the scale of our platform to selectively pursue acquisitions. To date, we have completed three acquisitions that have expanded our distribution capabilities and broadened our service offering, including into areas such as behavioral health. Our acquisition strategy is centered on acquiring technologies, products, capabilities, clinical specialties and distribution channels that are highly scalable and rapidly growing. We will continue to evaluate and pursue acquisition opportunities that are complementary to our business.
Risks Related to Our Business
Investing in our common stock involves substantial risk. You should carefully consider all of the information in this prospectus prior to investing in our common stock. There are several risks related to our business and our ability to leverage our strengths described elsewhere in this prospectus that are described under "Risk Factors" elsewhere in this prospectus. Among these important risks are the following:
11
Implications of Being an Emerging Growth Company
As a company with less than $1.0 billion in revenue during our last fiscal year, we qualify as an "emerging growth company" as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, enacted in April 2012. An "emerging growth company" may take advantage of exemptions from some of the reporting requirements that are otherwise applicable to public companies that are not emerging growth companies. These exemptions include:
We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the last day of our fiscal year following the fifth anniversary of the completion of this offering. However, if certain events occur prior to the end of such five-year period, including, but not limited to, if we become a "large accelerated filer," or if our annual gross revenue exceeds $1.0 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.
We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and may elect to take advantage of some, but not all, of the reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than you might receive from other public reporting companies in which you hold equity interests.
In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.
12
Company Information
Teladoc, Inc. was incorporated in the State of Texas on June 13, 2002 and changed its state of incorporation to the State of Delaware on October 16, 2008. Our principal executive offices are located at 2 Manhattanville Road, Suite 203, Purchase, New York 10577, and our telephone number is (203) 635-2002. We also maintain offices and our physician network operations center at several facilities in the Dallas, Texas area. Our website address is www.teladoc.com. Information on, or accessible through, our website is not part of this prospectus, nor is such content incorporated by reference herein, and should not be relied upon in determining whether to make an investment in our common stock.
13
Common stock offered by us |
shares. | |
Common stock outstanding after this offering |
shares. |
|
Option to purchase additional shares |
We have granted the underwriters a 30-day option to purchase up to an additional shares of common stock. |
|
Use of proceeds |
We estimate the proceeds to us from this offering will be approximately $ million, based on an assumed public offering price of $ per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds from this offering for working capital and other general corporate purposes, including to expand our current business through acquisitions of, or investments in, other businesses, products or technologies. However, we have no commitments with respect to any such acquisitions or investments at this time. See "Use of Proceeds." |
|
Dividend policy |
We do not currently pay and do not currently anticipate paying dividends on our common stock following this offering. Any declaration and payment of future dividends to holders of our common stock may be limited by restrictive covenants in our debt agreements, and will be at the sole discretion of our board of directors. See "Dividend Policy," "Management's Discussion and Analysis of Financial Condition and Results of OperationsLiquidity and Capital ResourcesIndebtedness" and "Description of Capital Stock." |
|
Proposed NYSE symbol |
"TDOC" |
|
Risk factors |
See "Risk Factors" beginning on page 20 of this prospectus for a discussion of factors you should carefully consider before deciding to invest in our common stock. |
Unless we specifically state otherwise, throughout this prospectus the number of shares of our common stock to be outstanding after completion of this offering is based on shares outstanding as of June 4, 2015 and excludes:
14
Unless we specifically state otherwise, all information in this prospectus assumes:
15
SUMMARY HISTORICAL FINANCIAL INFORMATION
The following table sets forth our summary historical consolidated financial information for the periods and as of the dates indicated. The balance sheet data as of December 31, 2013 and 2014 and the statement of operations data for the years ended December 31, 2013 and 2014 have been derived from our audited consolidated financial statements included elsewhere in this prospectus. The balance sheet data as of March 31, 2015 and the statement of operations data for the three months ended March 31, 2014 and 2015 have been derived from our unaudited consolidated financial statements included elsewhere in this prospectus. The balance sheet data as of March 31, 2014 have been derived from our unaudited consolidated financial statements not included in this prospectus. We completed our acquisitions of Consult A Doctor, Inc., or Consult A Doctor, on August 29, 2013, AmeriDoc, LLC, or AmeriDoc, on May 1, 2014 and Compile, Inc., d/b/a BetterHelp, or BetterHelp, on January 23, 2015. The results of operations of Consult A Doctor and AmeriDoc since the respective acquisition dates have been included in our audited consolidated financial statements included elsewhere in this prospectus. The results of operations of Consult A Doctor, AmeriDoc and BetterHelp since the respective acquisition dates have been included in our unaudited consolidated financial statements included elsewhere in this prospectus. You should read the information contained in this table in conjunction with "Selected Historical Financial Information," "Capitalization," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our audited consolidated financial statements and the related notes thereto included elsewhere in this prospectus. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of our management, include all adjustments, consisting only of normal and recurring adjustments, necessary for a fair presentation of the information set forth herein. Interim financial results are not necessarily indicative of results that may be expected for the full fiscal year, and our historical results are not indicative of the results to be expected in the future.
16
|
Year Ended December 31, | Three Months Ended March 31, | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
2013 | 2014 | 2014 | 2015 | |||||||||
|
(dollars in thousands, except share and per share data)
|
||||||||||||
Consolidated Statements of Operations Data: |
|||||||||||||
Revenue |
$ | 19,906 | $ | 43,528 | $ | 9,407 | $ | 16,488 | |||||
Cost of revenue |
4,186 | 9,929 | 1,982 | 5,281 | |||||||||
| | | | | | | | | | | | | |
Gross profit |
15,720 | 33,599 | 7,425 | 11,207 | |||||||||
Operating expenses: |
|||||||||||||
Advertising and marketing |
4,090 | 7,662 | 2,518 | 4,341 | |||||||||
Sales |
4,441 | 11,571 | 2,145 | 3,682 | |||||||||
Technology and development |
3,532 | 7,573 | 1,192 | 2,906 | |||||||||
General and administrative |
8,772 | 19,623 | 3,344 | 11,968 | |||||||||
Depreciation and amortization |
754 | 2,320 | 414 | 903 | |||||||||
| | | | | | | | | | | | | |
Loss from operations |
(5,869 | ) | (15,150 | ) | (2,188 | ) | (12,593 | ) | |||||
Interest income (expense), net |
(56 | ) | (1,499 | ) | (54 | ) | (568 | ) | |||||
| | | | | | | | | | | | | |
Net loss before taxes |
(5,925 | ) | (16,649 | ) | (2,242 | ) | (13,161 | ) | |||||
Income tax provision (benefit) |
94 | 388 | 72 | (458 | ) | ||||||||
| | | | | | | | | | | | | |
Net loss |
$ | (6,019 | ) | $ | (17,037 | ) | $ | (2,314 | ) | $ | (12,703 | ) | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Per Share Data: |
|||||||||||||
Net loss per share, basic and diluted |
$ | (3.52 | ) | $ | (4.49 | ) | $ | 1.03 | $ | (2.57 | ) | ||
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Weighted-average shares used to compute basic and diluted net loss per share |
2,793,982 | 4,486,868 | 3,254,509 | 4,943,060 | |||||||||
Pro forma net loss per share, basic and diluted (unaudited) |
$ | (0.37 | ) | $ | (0.20 | ) | |||||||
Weighted-average shares used to compute basic and diluted pro forma net loss per share (unaudited) |
53,734,598 | 63,120,240 | |||||||||||
Other Data: |
|
|
|
|
|||||||||
Visits |
127,107 | 298,833 | 65,243 | 148,696 | |||||||||
Members |
6.2 million | 8.1 million | 7.1 million | 10.6 million | |||||||||
EBITDA(1) |
$ | (5,115 | ) | $ | (12,830 | ) | $ | (1,774 | ) | $ | (11,690 | ) |
|
As of March 31, 2015 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
|
Actual | Pro Forma(2) |
Pro Forma as
Adjusted(3)(4) |
|||||||
|
(in thousands)
|
|||||||||
Consolidated Balance Sheets Data: |
||||||||||
Cash and cash equivalents |
$ | 32,060 | $ | $ | ||||||
Working capital |
25,617 | |||||||||
Total assets |
87,361 | |||||||||
Total liabilities |
45,994 | |||||||||
Total stockholders' deficit |
(79,399 | ) |
17
investor's understanding of our financial performance. We further believe that this financial measure is a useful financial metric to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors. We utilize EBITDA as the primary measure of segment performance.
EBITDA consists of net income (loss) before interest, taxes, depreciation and amortization. We believe that making such adjustment provides investors meaningful information to understand our results of operations and ability to analyze financial and business trends on a period-to-period basis.
We believe these financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term EBITDA may vary from that of others in our industry. EBITDA should not be considered as an alternative to net loss before taxes, net loss, earnings per share or any other performance measures derived in accordance with U.S. GAAP as measures of performance.
EBITDA has an important limitation as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under U.S. GAAP. Some of these limitations are:
We compensate for these limitations by using EBITDA along with other comparative tools, together with U.S. GAAP measurements, to assist in the evaluation of operating performance. Such U.S. GAAP measurements include gross profit, net loss, net loss per share and other performance measures.
In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation. Our presentation of EBITDA should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.
The following table reconciles net loss to EBITDA for the periods presented:
|
Year Ended
December 31, |
Three Months
Ended March 31, |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
2013 | 2014 | 2014 | 2015 | |||||||||
|
(in thousands)
|
||||||||||||
Net loss |
$ | (6,019 | ) | $ | (17,037 | ) | $ | (2,314 | ) | $ | (12,703 | ) | |
Interest income (expense), net |
(56 | ) | (1,499 | ) | (54 | ) | (568 | ) | |||||
Income taxes |
94 | 388 | 72 | (458 | ) | ||||||||
Depreciation and amortization |
754 | 2,320 | 414 | 903 | |||||||||
| | | | | | | | | | | | | |
EBITDA |
$ | (5,115 | ) | $ | (12,830 | ) | $ | (1,774 | ) | $ | (11,690 | ) | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
18
19
An investment in our common stock involves a high degree of risk. You should consider carefully the following risks, together with the other information contained in this prospectus before you decide whether to buy our common stock. If any of the events contemplated by the following discussion of risks should occur, our business, financial condition, results of operations and cash flows could suffer significantly. As a result, the market price of our common stock could decline, and you may lose all or part of the money you paid to buy our common stock. The following is a summary of all the material risks known to us.
Risks Related to Our Business
Our business could be adversely affected by ongoing legal challenges to our business model or by new state actions restricting our ability to provide the full range of our services in certain states.
Our ability to conduct business in each state is dependent upon the state's treatment of telemedicine (and of remote healthcare delivery in general, such as the permissibility of, and requirements for, physician cross-coverage practice) under such state's laws, rules and policies governing the practice of medicine, which are subject to changing political, regulatory and other influences. Cross-coverage regulation refers to the state rules under which one doctor is permitted to treat the regular patients of another doctor remotely. Some state medical boards have established new rules or interpreted existing rules in a manner that limits or restricts our ability to conduct our business as currently conducted in other states. Some of these actions have resulted in litigation and the suspension of our operations in certain states.
For instance, the Texas Medical Board, or the TMB, asserted in 2011 that our Providers do not form the required relationships with our Members in the course of telehealth visits that would support the prescription of medications. As a result of this position, we initiated two lawsuits against the TMB, both of which are pending in Texas state courts. On December 31, 2014, the Austin Court of Appeals granted our request for summary judgment in the first suit, invalidating the TMB's prior position that our operations do not comply with the current TMB regulations governing the practice of medicine. This Court of Appeals decision may be subject to an appellate hearing in the Texas Supreme Court. In the second suit, we filed a request for a temporary injunction to restrain the TMB from communicating, implementing and enforcing an "emergency rule" it issued on January 16, 2015, purporting to amend the Texas Administrative Code to require an in-person examination of a patient before a Texas physician may lawfully prescribe medication. On February 2, 2015, the Travis County District Court granted our request for a temporary injunction, which remains in effect and prohibits the TMB from communicating, implementing and enforcing the emergency rule. The TMB's subsequent passage of the rule described below may have mooted one or both of these cases, but they remain active. We are currently unable to make a reasonable estimate of when either of these cases will be resolved, whether we will ultimately prevail, or the amount or range of loss that could result from an unfavorable outcome in either action.
On April 10, 2015, the TMB adopted revisions to the rules governing medical practice that would require, in most instances, in-person examinations prior to prescribing medications. Our present business model does not include in-person examinations of our Members before prescribing medications. We challenged these rule amendments on April 29, 2015 by filing a lawsuit against the TMB in the United States District Court for the Western District of Texas, Austin Division requesting that they be enjoined as unlawful under the Sherman Antitrust Act and the Commerce Clause of the U.S. Constitution, and a related hearing was held on May 22, 2015 on our motion for preliminary injunction. On May 29, 2015, this court granted our request for a preliminary injunction of the rule amendments, pending ultimate trial on the amendments' validity, which trial date has yet to be set. Accordingly, for so long as the preliminary injunction remains in place, the rule amendments as proposed will not go into effect in Texas.
20
Business in the State of Texas accounted for approximately $3.3 million, or 20%, and $10 million, or 23%, of our revenue during the three months ended March 31, 2015 and the year ended December 31, 2014, respectively. If the TMB's rule revisions go into effect as written and we are unable to adapt our business model in compliance with the TMB rule, our ability to operate our business in the State of Texas could be materially adversely affected, which would have a material adverse effect on our business, financial condition and results of operations.
In addition, during 2014, we voluntarily suspended our business operations in the States of Arkansas and Idaho in response to formal and informal communications among us, our affiliated physicians, and the respective boards of medicine in each state. In each state, the board of medicine took the position that our business model did not meet the state's applicable legal requirements in order for our affiliated physicians to prescribe medications for our Members. In March 2015, Idaho Governor Otter signed the Idaho Telehealth Access Act, which redefined telehealth services in Idaho in a manner that will allow us to resume operations in Idaho in July 2015. In addition, in April 2015, Arkansas enacted its own Telemedicine Act allowing a telehealth provider to establish a relationship with a patient through an in-person examination or through another manner adopted by rule of the Arkansas State Medical Board. We remain in active discussions with the relevant authorities in Arkansas to demonstrate the safety and benefits inherent to our business. Despite these discussions, we cannot guarantee that we will be able to resume operations in Arkansas.
It is possible that the laws and rules governing the practice of medicine in one or more states may change in a manner analogous to what occurred in Texas and Arkansas. If this were to happen, and we were unable to adapt our business model accordingly, our operations in such states would be disrupted, which could have a material adverse effect on our business, financial condition and results of operations.
We are dependent on our relationships with affiliated professional entities, which we do not own, to provide physician services, and our business would be adversely affected if those relationships were disrupted.
There is a risk that state authorities in some jurisdictions may find that our contractual relationships with our physicians violate laws prohibiting the corporate practice of medicine. These laws generally prohibit the practice of medicine by lay persons or entities and are intended to prevent unlicensed persons or entities from interfering with or inappropriately influencing the physician's professional judgment. The extent to which each state considers particular actions or contractual relationships to constitute improper influence of professional judgment varies across the states and is subject to change and to evolving interpretations by state boards of medicine and state attorneys general, among others. As such, we must monitor our compliance with laws in every jurisdiction in which we operate on an ongoing basis and we cannot guarantee that subsequent interpretation of the corporate practice of medicine laws will not further circumscribe our business operations. State corporate practice of medicine doctrines also often impose penalties on physicians themselves for aiding the corporate practice of medicine, which could discourage physicians from participating in our network of providers.
The corporate practice of medicine prohibition exists in some form, by statute, regulation, board of medicine or attorney general guidance, or case law, in at least 42 states, all of which we operate in, though the broad variation between state application and enforcement of the doctrine makes an exact count difficult. Due to the prevalence of the corporate practice of medicine doctrine, including in the states where we predominantly conduct our business, we contract for Provider services through a services agreement with Teladoc Physicians, P.A., or Teladoc PA, which is a 100% physician-owned independent entity that has agreements with several professional corporations, to contract with physicians and professional corporations that contract with physicians for the clinical and professional services provided to our Members. See "BusinessPhysicians and
21
Healthcare Professionals" for a more detailed discussion of the Services Agreement. We do not own Teladoc PA or the professional corporations with which it contracts. Teladoc PA is owned by Dr. Timothy Howard, one of our Providers, and the professional corporations are owned by physicians licensed in their respective states. While we expect that these relationships will continue, we cannot guarantee that they will. A material change in our relationship with Teladoc PA, or among Teladoc PA and the contracted professional corporations, whether resulting from a dispute among the entities, a change in government regulation, or the loss of these affiliations, could impair our ability to provide services to our Members and could have a material adverse effect on our business, financial condition and results of operations. In addition, the arrangement in which we have entered to comply with state corporate practice of medicine doctrines could subject us to additional scrutiny by federal and state regulatory bodies regarding federal and state fraud and abuse laws. Any scrutiny, investigation, or litigation with regard to our arrangement with Teladoc PA could have a material adverse effect on our business, financial condition and results of operations.
Evolving government regulations may require increased costs or adversely affect our results of operations.
In a regulatory climate that is uncertain, our operations may be subject to direct and indirect adoption, expansion or reinterpretation of various laws and regulations. Compliance with these future laws and regulations may require us to change our practices at an undeterminable and possibly significant initial monetary and annual expense. These additional monetary expenditures may increase future overhead, which could have a material adverse effect on our results of operations.
We have identified what we believe are the areas of government regulation that, if changed, would be costly to us. These include: rules governing the practice of medicine by physicians; licensure standards for doctors and behavioral health professionals; laws limiting the corporate practice of medicine; cybersecurity and privacy laws; laws and rules relating to the distinction between independent contractors and employees; and tax and other laws encouraging employer-sponsored health insurance. There could be laws and regulations applicable to our business that we have not identified or that, if changed, may be costly to us, and we cannot predict all the ways in which implementation of such laws and regulations may affect us.
In the states in which we operate, we believe we are in compliance with all applicable regulations, but, due to the uncertain regulatory environment, certain states may determine that we are in violation of their laws and regulations. In the event that we must remedy such violations, we may be required to modify our services and products in such states in a manner that undermines our solution's attractiveness to Clients, Members or Providers, we may become subject to fines or other penalties or, if we determine that the requirements to operate in compliance in such states are overly burdensome, we may elect to terminate our operations in such states. In each case, our revenue may decline and our business, financial condition and results of operations could be materially adversely affected.
Additionally, the introduction of new services may require us to comply with additional, yet undetermined, laws and regulations. Compliance may require obtaining appropriate state medical board licenses or certificates, increasing our security measures and expending additional resources to monitor developments in applicable rules and ensure compliance. The failure to adequately comply with these future laws and regulations may delay or possibly prevent some of our products or services from being offered to Clients and Members, which could have a material adverse effect on our business, financial condition and results of operations.
22
We conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, financial condition, and results of operations.
The healthcare industry is heavily regulated and closely scrutinized by federal, state and local governments. Comprehensive statutes and regulations govern the manner in which we provide and bill for services and collect reimbursement from governmental programs and private payors, our contractual relationships with our Providers, vendors and Clients, our marketing activities and other aspects of our operations. Of particular importance are:
23
Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Achieving and sustaining compliance with these laws may prove costly. Failure to comply with these laws and other laws can result in civil and criminal penalties such as fines, damages, overpayment recoupment loss of enrollment status and exclusion from the Medicare and Medicaid programs. The risk of our being found in violation of these laws and regulations is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are sometimes open to a variety of interpretations. Our failure to accurately anticipate the application of these laws and regulations to our business or any other failure to comply with regulatory requirements could create liability for us and negatively affect our business. Any action against us for violation of these laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management's attention from the operation of our business and result in adverse publicity.
To enforce compliance with the federal laws, the U.S. Department of Justice and the Department of Health and Human Services Office of Inspector General, or OIG, have recently increased their scrutiny of healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Dealing with investigations can be time- and resource-consuming and can divert management's attention from the business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business. In addition, because of the potential for large monetary exposure under the federal False Claims Act, which provides for treble damages and mandatory minimum penalties of $5,500 to $11,000 per false claim or statement, healthcare providers often resolve allegations without admissions of liability for significant and material amounts to avoid the uncertainty of treble damages that may be awarded in litigation proceedings. Such settlements often contain additional compliance and reporting requirements as part of a consent decree, settlement agreement or corporate integrity agreement. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers' compliance with the healthcare reimbursement rules and fraud and abuse laws.
The laws, regulations and standards governing the provision of healthcare services may change significantly in the future. We cannot assure you that any new or changed healthcare laws, regulations or standards will not materially adversely affect our business. We cannot assure you that a review of our business by judicial, law enforcement, regulatory or accreditation authorities will not result in a determination that could adversely affect our operations.
We have a history of cumulative losses, which we expect to continue, and we may never achieve or sustain profitability.
We have incurred significant losses in each period since our inception. We incurred net losses of $6.0 million and $17.0 million for the years ended December 31, 2013 and 2014, respectively, and $2.3 million and $12.7 million for the three months ended March 31, 2014 and 2015, respectively. As of March 31, 2015, we had an accumulated deficit of $85.2 million. These losses and accumulated deficit reflect the substantial investments we made to acquire new Clients, build our proprietary network of healthcare providers and develop our technology platform. We intend to
24
continue scaling our business to increase our client, member and provider bases, broaden the scope of services we offer and expand our applications of technology through which Members can access our services. Accordingly, we anticipate that cost of revenue and operating expenses will increase substantially in the foreseeable future. These efforts may prove more expensive than we currently anticipate and we may not succeed in increasing our revenue sufficiently to offset these higher expenses. We cannot assure you that we will achieve profitability in the future or that, if we do become profitable, we will be able to sustain or increase profitability. Our prior losses, combined with our expected future losses, have had and will continue to have an adverse effect on our stockholders' equity and working capital. As a result of these factors, we may need to raise additional capital through debt or equity financings in order to fund our operations, and such capital may not be available on reasonable terms, if at all. See "We may require additional capital to support business growth, and this capital may not be available to us on acceptable terms or at all."
The impact of recent healthcare reform legislation and other changes in the healthcare industry and in healthcare spending on us is currently unknown, but may adversely affect our business, financial condition and results of operations.
Our revenue is dependent on the healthcare industry and could be affected by changes in healthcare spending and policy. The healthcare industry is subject to changing political, regulatory and other influences. The PPACA made major changes in how healthcare is delivered and reimbursed, and increased access to health insurance benefits to the uninsured and underinsured population of the United States.
The PPACA, among other things, increased the number of individuals with Medicaid and private insurance coverage, implemented reimbursement policies that tie payment to quality, facilitated the creation of accountable care organizations that may use capitation and other alternative payment methodologies, strengthened enforcement of fraud and abuse laws and encouraged the use of information technology. Many of these changes require implementing regulations which have not yet been drafted or have been released only as proposed rules.
Such changes in the regulatory environment may also result in changes to our payor mix that may affect our operations and revenue. While the PPACA is expected to increase the number of persons with covered health benefits, we cannot accurately estimate the payment rates for any additional persons that are expected to be covered by health benefits. For example, the PPACA's expansion of Medicaid coverage could cause patients who otherwise would have selected private healthcare to participate in government sponsored healthcare programs, and Medicaid and other government programs typically reimburse providers at substantially lower rates than private payors. Our revenue may be adversely impacted if states pursue lower rates or cost-containment strategies as a result of any expansion of their existing Medicaid programs to include additional persons, particularly in states experiencing budget deficits. Exchanges created to facilitate coverage for new persons to be covered by health benefits may also place additional pricing pressure on all providers, regardless of payor. The full impact of many of the provisions under the PPACA is unknown at this time. For example, the PPACA established an Independent Payment Advisory Board that, beginning January 16, 2014, can recommend changes in payment for physicians under certain circumstances, which the Department of Health and Human Services, or HHS, generally would be required to implement unless Congress enacts superseding legislation. The PPACA also requires HHS to develop a budget-neutral, value-based payment modifier that provides for differential payment under the Medicare Physician Fee Schedule, or the MPFS, for physicians or groups of physicians that is linked to quality of care furnished compared to cost. Physicians in groups of 100 or more eligible professionals who submit claims to Medicare under a single tax identification number will be subject to the value modifier in 2015, based on their performance in calendar year 2013; the modifier will apply to all other physicians by 2017. HHS has not yet
25
developed a value-based payment modifier option for hospital-based physicians. We cannot assure you that our Clients will not impose similar payment modifiers for services that we provide.
Physician payments under the MPFS are updated on an annual basis according to a statutory formula. Because application of the statutory formula for the update factor would have resulted in a decrease in total physician payments for the past several years, Congress has intervened with interim legislation to prevent the reductions. For 2014, CMS projected a rate reduction of 20.1% from 2013 levels and earlier estimates had projected a 24.4% reduction. A series of laws was enacted that delayed the scheduled reduction in physician payments and provided for a 0.5% increase through December 31, 2014, and a zero percent update from 2014 payment amounts to the 2015 Physician Fee Schedule through March 31, 2015.
President Obama signed the Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, on April 16, 2015, which repealed and replaced the SGR formula for Medicare payment adjustments to physicians. MACRA provides a permanent end to the annual interim legislative updates that had previously been necessary to delay or prevent significant reductions to payments under the Physician Fee Schedule. MACRA extended existing payment rates under PAMA through June 30, 2015, with a 0.5% update for July 1, 2015, through December 31, 2015 and for each calendar year through 2019, after which there will be a 0% annual update each year through 2025. In addition, MACRA requires the establishment of the Merit-Based Incentive Payment System, beginning in 2019, under which physicians may receive performance-based payment incentives or payment reductions based on their performance with respect to clinical quality, resource use, clinical improvement activities, and meaningful use of electronic health records. MACRA also requires CMS, beginning in 2019, to provide incentive payments for physicians and other eligible professionals that participate in alternative payment models, such as accountable care organizations, that emphasize quality and value over the traditional volume-based fee-for-service model. MACRA is still new and the manner in which it will be implemented is not certain, but at this time, we do not believe that this law will have a material effect on our future revenues.
In November 2012, CMS adopted a rule under the PPACA that generally allowed physicians in certain specialties who provide eligible primary care services to be paid at the Medicare reimbursement rates in effect in calendar years 2013 and 2014 instead of state-established Medicaid reimbursement rates, referred to as the Medicaid-Medicare Parity. Generally, state Medicaid reimbursement rates are lower than federally established Medicare rates. During 2013, state agencies were required to submit their state plan amendments, or SPAs, outlining how they will implement the rule, including frequency and timing of payments to CMS for review and approval. In December 2013, CMS indicated that all SPAs had been approved for enhanced Medicaid-Medicare Parity reimbursement through December 2014. Congress did not act before the end of the year to extend the Medicaid-Medicare Parity and the rule expired. Legislation has been proposed to retroactively extend Medicaid-Medicare Parity for calendar year 2015 but has not yet been enacted. Certain states have decided to fully or partially extend the Medicaid-Medicare Parity. It is unclear at this time how these limited state increases or the continued failure to extend the rule at the federal level will impact our business.
In addition, certain provisions of the PPACA authorize voluntary demonstration projects, which include the development of bundling payments for acute, inpatient hospital services, physician services and postacute services for episodes of hospital care. The Medicare Acute Care Episode Demonstration is currently underway at several healthcare system demonstration sites. Further, the PPACA may adversely affect payors by increasing medical costs generally, which could have an effect on the industry and potentially impact our business and revenue as payors seek to offset these increases by reducing costs in other areas. The full impact of these changes on us cannot be determined at this time.
Finally, other legislative changes have been proposed and adopted in the United States since the PPACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was enacted, which,
26
among other things, created the Joint Select Committee on Deficit Reduction, or the Joint Committee, to recommend proposals in spending reductions to Congress. The Joint Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation's automatic reduction to several government programs. This included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2024 unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments and other third-party payors will pay for healthcare products and services, which could adversely affect our business, financial condition and results of operations.
A significant portion of our revenue comes from a limited number of Clients, the loss of which would have a material adverse effect on our business, financial condition and results of operations.
Historically, we have relied on a limited number of Clients for a substantial portion of our total revenue. For the year ended December 31, 2014, one Client represented approximately 4.5% of our total revenue. In addition, for the years ended December 31, 2014 and 2013, our top ten Clients by revenue accounted for 28.1% and 41.1% of our total revenue, respectively. We also rely on our reputation and recommendations from key Clients in order to promote our solution to potential new Clients. The loss of any of our key Clients, or a failure of some of them to renew or expand their subscriptions, could have a significant impact on the growth rate of our revenue, reputation and our ability to obtain new Clients. In addition, mergers and acquisitions involving our Clients could lead to cancellation or non-renewal of our contracts with those Clients or by the acquiring or combining companies, thereby reducing the number of our existing and potential Clients and Members.
The telehealth market is immature and volatile, and if it does not develop, if it develops more slowly than we expect, if it encounters negative publicity or if our solution does not drive Member engagement, the growth of our business will be harmed.
The telehealth market is relatively new and unproven, and it is uncertain whether it will achieve and sustain high levels of demand, consumer acceptance and market adoption. Our success will depend to a substantial extent on the willingness of our Members to use, and to increase the frequency and extent of their utilization of, our solution, as well as on our ability to demonstrate the value of telehealth to employers, health plans, government agencies and other purchasers of healthcare for beneficiaries. Negative publicity concerning our solution or the telehealth market as a whole could limit market acceptence of our solution. If our Clients and Members do not perceive the benefits of our solution, or if our solution does not drive Member engagement, then our market may not develop at all, or it may develop more slowly than we expect. Similarly, individual and healthcare industry concerns or negative publicity regarding patient confidentiality and privacy in the context of telehealth could limit market acceptance of our healthcare services. If any of these events occurs, it could have a material adverse effect on our business, financial condition or results of operations.
If the number of individuals covered by our employer, health plan and other Clients decreases, or the number of applications or services to which they subscribe decreases, our revenue will likely decrease.
Under most of our Client contracts, we base our fees on the number of individuals to whom our Clients provide benefits and the number of applications or services subscribed to by our Clients. Many factors may lead to a decrease in the number of individuals covered by our Clients
27
and the number of applications or services subscribed to by our Clients, including, but not limited to, the following:
If the number of individuals covered by our employer, health plan and other Clients decreases, or the number of applications or services to which they subscribe decreases, for any reason, our revenue will likely decrease.
Our growth depends in part on the success of our strategic relationships with third parties.
In order to grow our business, we anticipate that we will continue to depend on our relationships with third parties, including our partner organizations and technology and content providers. For example, we partner with a number of price transparency, HSA and other benefits platforms to deliver our solution to their consumers. Identifying partners, and negotiating and documenting relationships with them, requires significant time and resources. Our competitors may be effective in providing incentives to third parties to favor their products or services or to prevent or reduce subscriptions to, or utilization of, our products and services. In addition, acquisitions of our partners by our competitors could result in a decrease in the number of our current and potential Clients, as our partners may no longer facilitate the adoption of our applications by potential Clients. If we are unsuccessful in establishing or maintaining our relationships with third parties, our ability to compete in the marketplace or to grow our revenue could be impaired and our results of operations may suffer. Even if we are successful, we cannot assure you that these relationships will result in increased Client use of our applications or increased revenue.
Our business and growth strategy depend on our ability to maintain and expand a network of qualified Providers. If we are unable to do so, our future growth would be limited and our business, financial condition and results of operations would be harmed.
Our success is dependent upon our continued ability to maintain a network of qualified Providers. If we are unable to recruit and retain board-certified physicians and other healthcare professionals, it would have a material adverse effect on our business and ability to grow and would adversely affect our results of operations. In any particular market, Providers could demand higher payments or take other actions that could result in higher medical costs, less attractive service for our Clients or difficulty meeting regulatory or accreditation requirements. Our ability to develop and maintain satisfactory relationships with Providers also may be negatively impacted by other factors not associated with us, such as changes in Medicare and/or Medicaid reimbursement levels and other pressures on healthcare providers and consolidation activity among hospitals, physician groups and healthcare providers. The failure to maintain or to secure new cost-effective Provider contracts may result in a loss of or inability to grow our membership base, higher costs, healthcare provider network disruptions, less attractive service for our Clients and/or difficulty in meeting regulatory or accreditation requirements, any of which could have a material adverse effect on our business, financial condition and results of operations.
We may become subject to medical liability claims, which could cause us to incur significant expenses and may require us to pay significant damages if not covered by insurance.
Our business entails the risk of medical liability claims against both our Providers and us. Although we and Teladoc PA carry insurance covering medical malpractice claims in amounts that we believe are appropriate in light of the risks attendant to our business, successful medical liability claims could result in substantial damage awards that exceed the limits of our and Teladoc PA's
28
insurance coverage. Teladoc PA carries professional liability insurance covering $1.0 million per claim and $3.0 million in the aggregate for itself and each of its healthcare professionals (our Providers), and we separately carry a general insurance policy, which covers medical malpractice claims, covering $5.0 million per claim and $5.0 million in the aggregate. In addition, professional liability insurance is expensive and insurance premiums may increase significantly in the future, particularly as we expand our services. As a result, adequate professional liability insurance may not be available to our Providers or to us in the future at acceptable costs or at all.
Any claims made against us that are not fully covered by insurance could be costly to defend against, result in substantial damage awards against us and divert the attention of our management and our Providers from our operations, which could have a material adverse effect on our business, financial condition and results of operations. In addition, any claims may adversely affect our business or reputation.
Rapid technological change in our industry presents us with significant risks and challenges .
The telehealth market is characterized by rapid technological change, changing consumer requirements, short product lifecycles and evolving industry standards. Our success will depend on our ability to enhance our solution with next-generation technologies and to develop or to acquire and market new services to access new consumer populations. There is no guarantee that we will possess the resources, either financial or personnel, for the research, design and development of new applications or services, or that we will be able to utilize these resources successfully and avoid technological or market obsolescence. Further, there can be no assurance that technological advances by one or more of our competitors or future competitors will not result in our present or future applications and services becoming uncompetitive or obsolete.
A decline in the prevalence of employer-sponsored healthcare or the emergence of new technologies may render our solution obsolete or require us to expend significant resources in order to remain competitive.
The U.S. healthcare industry is massive, with a number of large market participants with conflicting agendas, is subject to significant government regulation and is currently undergoing significant change. Changes in our industry, for example, away from high-deductible health plans, or the emergence of new technologies as more competitors enter our market, could result in our solution being less desirable or relevant.
For example, we currently derive the majority of our revenue from sales to Clients that purchase healthcare for their employees (either via insurance or self-funded benefit plans). A large part of the demand for our solution depends on the need of these employers to manage the costs of healthcare services that they pay on behalf of their employees. Some experts have predicted that the PPACA will encourage employer-sponsored health insurance to become significantly less prevalent as employees migrate to obtaining their own insurance over the state-sponsored insurance marketplaces. Were this to occur, there is no guarantee that we would be able to compensate for the loss in revenue from employers by increasing sales of our solution to health insurance companies or to individuals or government agencies. In such a case, our results of operations would be adversely affected.
If healthcare benefits trends shift or entirely new technologies are developed that replace existing solutions, our existing or future solutions could be rendered obsolete and our business could be adversely affected. In addition, we may experience difficulties with software development, industry standards, design or marketing that could delay or prevent our development, introduction or implementation of new applications and enhancements.
29
If our new applications and services are not adopted by our Clients, or if we fail to continue to innovate and develop new applications and services that are adopted by our Clients, our revenue and results of operations will be adversely affected.
To date, we have derived a substantial majority of our revenue from sales of our primary care telehealth solution, and our longer-term results of operations and continued growth will depend on our ability successfully to develop and market new applications and services that our Clients want and are willing to purchase. In addition, we have invested, and will continue to invest, significant resources in research and development to enhance our existing solution and introduce new high-quality applications and services. If existing Clients are not willing to make additional payments for such new applications, or if new Clients and Members do not value such new applications, it could have a material adverse effect on our business, financial condition and results of operations. If we are unable to predict user preferences or if our industry changes, or if we are unable to modify our solution and services on a timely basis, we may lose Clients. Our results of operations would also suffer if our innovations are not responsive to the needs of our Clients, appropriately timed with market opportunity or effectively brought to market.
We rely on data center providers, Internet infrastructure, bandwidth providers, third-party computer hardware and software, other third parties and our own systems for providing services to our Clients and Members, and any failure or interruption in the services provided by these third parties or our own systems could expose us to litigation and negatively impact our relationships with Clients, adversely affecting our brand and our business.
We serve all of our Clients and Members from two data centers, one located in Dallas, Texas and the other located in the Metro New York City area. While we control and have access to our servers, we do not control the operation of these facilities. The owners of our data center facilities have no obligation to renew their agreements with us on commercially reasonable terms, or at all. If we are unable to renew these agreements on commercially reasonable terms, or if one of our data center operators is acquired, we may be required to transfer our servers and other infrastructure to new data center facilities, and we may incur significant costs and possible service interruption in connection with doing so. Problems faced by our third-party data center locations with the telecommunications network providers with whom we or they contract or with the systems by which our telecommunications providers allocate capacity among their clients, including us, could adversely affect the experience of our Clients and Members. Our third-party data center operators could decide to close their facilities without adequate notice. In addition, any financial difficulties, such as bankruptcy faced by our third-party data centers operators or any of the service providers with whom we or they contract may have negative effects on our business, the nature and extent of which are difficult to predict.
Additionally, if our data centers are unable to keep up with our growing needs for capacity, this could have an adverse effect on our business. For example, a rapid expansion of our business could affect the service levels at our data centers or cause such data centers and systems to fail. Any changes in third-party service levels at our data centers or any disruptions or other performance problems with our solution could adversely affect our reputation and may damage our Clients and Members' stored files or result in lengthy interruptions in our services. Interruptions in our services may reduce our revenue, cause us to issue refunds to Clients for prepaid and unused subscriptions, subject us to potential liability or adversely affect Client renewal rates.
In addition, our ability to deliver our internet-based services depends on the development and maintenance of the infrastructure of the Internet by third parties. This includes maintenance of a reliable network backbone with the necessary speed, data capacity, bandwidth capacity and security. Our services are designed to operate without interruption in accordance with our service level commitments. However, we have experienced and expect that we may experience future interruptions and delays in services and availability from time to time. In the event of a catastrophic
30
event with respect to one or more of our systems, we may experience an extended period of system unavailability, which could negatively impact our relationship with Clients and Members. To operate without interruption, both we and our service providers must guard against:
We also rely on computer hardware purchased or leased and software licensed from third parties in order to offer our services, including software from Apple Computer and Microsoft Corporation, and routers and network equipment from Cisco and Hewlett-Packard Company. These licenses are generally commercially available on varying terms. However, it is possible that this hardware and software may not continue to be available on commercially reasonable terms, or at all. Any loss of the right to use any of this hardware or software could result in delays in the provisioning of our services until equivalent technology is either developed by us, or, if available, is identified, obtained and integrated.
We exercise limited control over third-party vendors, which increases our vulnerability to problems with technology and information services they provide. Interruptions in our network access and services may in connection with third-party technology and information services reduce our revenue, cause us to issue refunds to Clients for prepaid and unused subscription services, subject us to potential liability or adversely affect Client renewal rates. Although we maintain a $5.0 million security and privacy damages policy and an additional $2.0 million in coverage under our general liability policy, the coverage under our policies may not be adequate to compensate us for all losses that may occur related to the services provided by our third-party vendors. In addition, we may not be able to continue to obtain adequate insurance coverage at an acceptable cost, if at all.
We could incur substantial costs as a result of any claim of infringement of another party's intellectual property rights.
In recent years, there has been significant litigation in the United States involving patents and other intellectual property rights. Companies in the Internet and technology industries are increasingly bringing and becoming subject to suits alleging infringement of proprietary rights, particularly patent rights, and our competitors and other third parties may hold patents or have pending patent applications, which could be related to our business. These risks have been amplified by the increase in third parties, which we refer to as non-practicing entities, whose sole primary business is to assert such claims. On June 8, 2015, American Well Corporation filed a complaint against our company in the United States District Court for the District of Massachusetts alleging that certain of our operating platform's technology infringes one of its patents that we are currently seeking to invalidate pursuant to a petition for inter partes review that we filed with the U.S. Patent and Trademark Office's Patent Trial and Appeals Board in March 2015. See "BusinessLegal Proceedings." Regardless of the merits of this or any other intellectual property litigation, we may be required to expend significant management time and financial resources on the defense of such claims, and any adverse outcome of any such claim or the above referenced review could have a material adverse effect on our business, financial condition or results of operations. We expect that we may receive in the future additional notices that claim we or our Clients using our solution have misappropriated or misused other parties' intellectual property rights, particularly as the number of competitors in our market grows and the functionality of applications amongst
31
competitors overlaps. Our existing or any future litigation, whether or not successful, could be extremely costly to defend, divert our management's time, attention and resources, damage our reputation and brand and substantially harm our business.
In addition, in most instances, we have agreed to indemnify our Clients against certain third-party claims, which may include claims that our solution infringes the intellectual property rights of such third parties. Our business could be adversely affected by any significant disputes between us and our Clients as to the applicability or scope of our indemnification obligations to them. The results of any intellectual property litigation to which we may become a party, or for which we are required to provide indemnification, may require us to do one or more of the following:
If we are required to make substantial payments or undertake any of the other actions noted above as a result of any intellectual property infringement claims against us or any obligation to indemnify our Clients for such claims, such payments or costs could have a material adverse effect on our business, financial condition and results of operations.
If our arrangements with our Providers or our Clients are found to violate state laws prohibiting the corporate practice of medicine or fee splitting, our business, financial condition and our ability to operate in those states could be adversely impacted.
The laws of many states, including states in which our Clients are located, prohibit us from exercising control over the medical judgments or decisions of physicians and from engaging in certain financial arrangements, such as splitting professional fees with physicians. These laws and their interpretations vary from state to state and are enforced by state courts and regulatory authorities, each with broad discretion. We enter into agreements with a professional association, Teladoc PA, which enters into contracts with our Providers pursuant to which they render professional medical services. In addition, we enter into contracts with our Clients to deliver professional services in exchange for fees. These contracts include management services agreements with our affiliated physician organizations pursuant to which the physician organizations reserve exclusive control and responsibility for all aspects of the practice of medicine and the delivery of medical services. Although we seek to substantially comply with applicable state prohibitions on the corporate practice of medicine and fee splitting, state officials who administer these laws or other third parties may successfully challenge our existing organization and contractual arrangements. If such a claim were successful, we could be subject to civil and criminal penalties and could be required to restructure or terminate the applicable contractual arrangements. A determination that these arrangements violate state statutes, or our inability to successfully restructure our relationships with our Providers to comply with these statutes, could eliminate Clients located in certain states from the market for our services, which would have a materially adverse effect on our business, financial condition and results of operations.
If our Providers are characterized as employees, we would be subject to employment and withholding liabilities.
We structure our relationships with our Providers in a manner that we believe results in an independent contractor relationship, not an employee relationship. An independent contractor is generally distinguished from an employee by his or her degree of autonomy and independence in providing services. A high degree of autonomy and independence is generally indicative of a contractor relationship, while a high degree of control is generally indicative of an employment
32
relationship. Although we believe that our Providers are properly characterized as independent contractors, tax or other regulatory authorities may in the future challenge our characterization of these relationships. If such regulatory authorities or state, federal or foreign courts were to determine that our Providers are employees, and not independent contractors, we would be required to withhold income taxes, to withhold and pay social security, Medicare and similar taxes and to pay unemployment and other related payroll taxes. We would also be liable for unpaid past taxes and subject to penalties. As a result, any determination that our Providers are our employees could have a material adverse effect on our business, financial condition and results of operations.
Any future litigation against us could be costly and time-consuming to defend.
We may become subject, from time to time, to legal proceedings and claims that arise in the ordinary course of business such as claims brought by our Clients in connection with commercial disputes or employment claims made by our current or former associates. Litigation may result in substantial costs and may divert management's attention and resources, which may substantially harm our business, financial condition and results of operations. Insurance may not cover such claims, may not provide sufficient payments to cover all of the costs to resolve one or more such claims and may not continue to be available on terms acceptable to us. A claim brought against us that is uninsured or underinsured could result in unanticipated costs, thereby reducing our revenue and leading analysts or potential investors to reduce their expectations of our performance, which could reduce the market price of our stock.
We will incur significantly increased costs and devote substantial management time as a result of operating as a public company.
As a public company, we will incur significant legal, accounting and other expenses that we do not incur as a private company. For example, we will be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and will be required to comply with the applicable requirements of the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and Consumer Protection Act, as well as rules and regulations subsequently implemented by the SEC and the NYSE, including the establishment and maintenance of effective disclosure and financial controls, changes in corporate governance practices and required filing of annual, quarterly and current reports with respect to our business and results of operations. We expect that compliance with these requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. In addition, we expect that our management and other personnel will need to divert attention from operational and other business matters to devote substantial time to these public company requirements. In particular, we expect to incur significant expenses and devote substantial management effort toward ensuring compliance with the requirements of Section 404 of the Sarbanes-Oxley Act, which will increase when we are no longer an emerging growth company. We may also need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge and may need to establish an internal audit function.
We also expect that operating as a public company will make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. This could also make it more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers.
Certain state tax authorities may assert that we have a state nexus and seek to impose state and local income taxes which could adversely affect our results of operations.
We are currently licensed to operate in all fifty states and file state income tax returns in 20 states. There is a risk that certain state tax authorities where we do not currently file a state income
33
tax return could assert that we are liable for state and local income taxes based upon income or gross receipts allocable to such states. States are becoming increasingly aggressive in asserting a nexus for state income tax purposes. We could be subject to state and local taxation, including penalties and interest attributable to prior periods, if a state tax authority successfully asserts that our activities give rise to a nexus. Such tax assessments, penalties and interest may adversely affect our results of operations.
Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations.
In general, under Section 382 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an "ownership change" is subject to limitations on its ability to utilize its pre-change net operating losses, or NOLs, to offset future taxable income. A Section 382 "ownership change" generally occurs if one or more stockholders or groups of stockholders who own at least 5% of our stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Similar rules may apply under state tax laws. As of March 31, 2015, we have approximately $65.8 million of federal net operating loss carryforwards available to offset future taxable income which, if not utilized, will begin to expire in 2024. Our ability to utilize NOLs may be currently subject to limitations due to a prior ownership change. In addition, this offering and future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the Code, further limiting our ability to utilize NOLs arising prior to such ownership change in the future. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to offset future income tax liabilities. We have recorded a full valuation allowance against the deferred tax assets attributable to our NOLs.
Our proprietary software may not operate properly, which could damage our reputation, give rise to claims against us or divert application of our resources from other purposes, any of which could harm our business, financial condition and results of operations.
The Teladoc proprietary application platform provides our Members and Providers with the ability to, among other things, register for our services; complete, view and edit medical history; request a visit (either scheduled or on demand) and conduct a visit (via video or phone). Proprietary software development is time-consuming, expensive and complex, and may involve unforeseen difficulties. We may encounter technical obstacles, and it is possible that we may discover additional problems that prevent our proprietary applications from operating properly. We are currently implementing software with respect to a number of new applications and services. If our solution does not function reliably or fails to achieve Client expectations in terms of performance, Clients could assert liability claims against us or attempt to cancel their contracts with us. This could damage our reputation and impair our ability to attract or maintain Clients.
Moreover, data services are complex and those we offer have in the past contained, and may in the future develop or contain, undetected defects or errors. Material performance problems, defects or errors in our existing or new software and applications and services may arise in the future and may result from interface of our solution with systems and data that we did not develop and the function of which is outside of our control or undetected in our testing. These defects and errors, and any failure by us to identify and address them, could result in loss of revenue or market share, diversion of development resources, harm to our reputation and increased service and maintenance costs. Defects or errors may discourage existing or potential Clients from purchasing our solution from us. Correction of defects or errors could prove to be impossible or impracticable. The costs incurred in correcting any defects or errors may be substantial and could have a material adverse effect on our business, financial condition and results of operations.
34
In order to support the growth of our business, we may need to incur additional indebtedness under our current credit facilities or seek capital through new equity or debt financings, which sources of additional capital may not be available to us on acceptable terms or at all.
Our operations have consumed substantial amounts of cash since inception and we intend to continue to make significant investments to support our business growth, respond to business challenges or opportunities, develop new applications and services, enhance our existing solution and services, enhance our operating infrastructure and potentially acquire complementary businesses and technologies. For the three months ended March 31, 2014 and 2015, our net cash used in operating activities was $2.2 million and $10.3 million, respectively. For the years ended December 31, 2013 and 2014, our net cash used in operating activities was $6.1 million and $11.4 million, respectively. As of March 31, 2015, we had $32.1 million of cash and cash equivalents, which are held for working capital purposes. As of March 31, 2015, we had borrowings of $22.5 million under our credit facilities and the ability to borrow up to an additional $7.3 million. Borrowings under our credit facilities are secured by substantially all of our properties, rights and assets. Additionally, the credit agreements governing our credit facilities contain certain customary restrictive covenants that limit our ability to incur additional indebtedness and liens, merge with other companies or consummate certain changes of control, acquire other companies, engage in new lines of business, make certain investments, pay dividends and transfer or dispose of assets as well as a financial covenant that requires us to maintain a specified level of recurring revenue growth. These covenants could limit our ability to seek capital through the incurrence of new indebtedness or, if we are unable to meet our recurring revenue growth obligation, require us to repay any outstanding amounts with sources of capital we may otherwise use to fund our business, operations and strategy.
Our future capital requirements may be significantly different from our current estimates and will depend on many factors, including our growth rate, subscription renewal activity, the timing and extent of spending to support development efforts, the expansion of sales and marketing activities, the introduction of new or enhanced services and the continuing market acceptance of telehealth. Accordingly, we may need to engage in equity or debt financings or collaborative arrangements to secure additional funds. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences and privileges superior to those of holders of our common stock. Any debt financing secured by us in the future could involve additional restrictive covenants relating to our capital-raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. In addition, during times of economic instability, it has been difficult for many companies to obtain financing in the public markets or to obtain debt financing, and we may not be able to obtain additional financing on commercially reasonable terms, if at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us, it could have a material adverse effect on our business, financial condition and results of operations.
Failure to adequately expand our direct sales force will impede our growth.
We believe that our future growth will depend on the continued development of our direct sales force and its ability to obtain new Clients and to manage our existing client base. Identifying and recruiting qualified personnel and training them requires significant time, expense and attention. It can take six months or longer before a new sales representative is fully trained and productive. Our business may be adversely affected if our efforts to expand and train our direct sales force do not generate a corresponding increase in revenue. In particular, if we are unable to hire and develop sufficient numbers of productive direct sales personnel or if new direct sales personnel are unable to achieve desired productivity levels in a reasonable period of time, sales of our services will suffer and our growth will be impeded.
35
We may be unable to successfully execute on our growth initiatives, business strategies or operating plans.
We are continually executing a number of growth initiatives, strategies and operating plans designed to enhance our business. For example, we recently entered into new specialist healthcare professional markets as well as into B2C markets. The anticipated benefits from these efforts are based on several assumptions that may prove to be inaccurate. Moreover, we may not be able to successfully complete these growth initiatives, strategies and operating plans and realize all of the benefits, including growth targets and cost savings, that we expect to achieve or it may be more costly to do so than we anticipate. A variety of risks could cause us not to realize some or all of the expected benefits. These risks include, among others, delays in the anticipated timing of activities related to such growth initiatives, strategies and operating plans, increased difficulty and cost in implementing these efforts, including difficulties in complying with new regulatory requirements and the incurrence of other unexpected costs associated with operating the business. Moreover, our continued implementation of these programs may disrupt our operations and performance. As a result, we cannot assure you that we will realize these benefits. If, for any reason, the benefits we realize are less than our estimates or the implementation of these growth initiatives, strategies and operating plans adversely affect our operations or cost more or take longer to effectuate than we expect, or if our assumptions prove inaccurate, our business, financial condition and results of operations may be materially adversely affected.
Our use and disclosure of personally identifiable information, including health information, is subject to federal and state privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm and, in turn, a material adverse effect on our client base, membership base and revenue.
Numerous state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability and integrity of personally identifiable information, or PII, including protected health information, or PHI. These laws and regulations include the Health Information Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations (referred to collectively as HIPAA). HIPAA establishes a set of basic national privacy and security standards for the protection of PHI by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services, which includes us.
HIPAA requires healthcare providers like us to develop and maintain policies and procedures with respect to PHI that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect such information. HIPAA also implemented the use of standard transaction code sets and standard identifiers that covered entities must use when submitting or receiving certain electronic healthcare transactions, including activities associated with the billing and collection of healthcare claims.
HIPAA imposes mandatory penalties for certain violations. Penalties for violations of HIPAA and its implementing regulations start at $100 per violation and are not to exceed $50,000 per violation, subject to a cap of $1.5 million for violations of the same standard in a single calendar year. However, a single breach incident can result in violations of multiple standards. HIPAA also authorizes state attorneys general to file suit on behalf of their residents. Courts will be able to award damages, costs and attorneys' fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.
36
In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA covered entities or business associates for compliance with the HIPAA Privacy and Security Standards. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a percentage of the Civil Monetary Penalty fine paid by the violator.
HIPAA further requires that patients be notified of any unauthorized acquisition, access, use or disclosure of their unsecured PHI that compromises the privacy or security of such information, with certain exceptions related to unintentional or inadvertent use or disclosure by employees or authorized individuals. HIPAA specifies that such notifications must be made "without unreasonable delay and in no case later than 60 calendar days after discovery of the breach." If a breach affects 500 patients or more, it must be reported to HHS without unreasonable delay, and HHS will post the name of the breaching entity on its public web site. Breaches affecting 500 patients or more in the same state or jurisdiction must also be reported to the local media. If a breach involves fewer than 500 people, the covered entity must record it in a log and notify HHS at least annually.
Numerous other federal and state laws protect the confidentiality, privacy, availability, integrity and security of PII, including PHI. These laws in many cases are more restrictive than, and may not be preempted by, the HIPAA rules and may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and our Clients and potentially exposing us to additional expense, adverse publicity and liability.
New health information standards, whether implemented pursuant to HIPAA, congressional action or otherwise, could have a significant effect on the manner in which we must handle healthcare related data, and the cost of complying with standards could be significant. If we do not comply with existing or new laws and regulations related to PHI, we could be subject to criminal or civil sanctions.
Because of the extreme sensitivity of the PII we store and transmit, the security features of our technology platform are very important. If our security measures, some of which are managed by third parties, are breached or fail, unauthorized persons may be able to obtain access to sensitive Client and Member data, including HIPAA-regulated PHI. As a result, our reputation could be severely damaged, adversely affecting Client and Member confidence. Members may curtail their use of or stop using our services or our client base could decrease, which would cause our business to suffer. In addition, we could face litigation, damages for contract breach, penalties and regulatory actions for violation of HIPAA and other applicable laws or regulations and significant costs for remediation, notification to individuals and for measures to prevent future occurrences. Any potential security breach could also result in increased costs associated with liability for stolen assets or information, repairing system damage that may have been caused by such breaches, incentives offered to Clients or other business partners in an effort to maintain our business relationships after a breach and implementing measures to prevent future occurrences, including organizational changes, deploying additional personnel and protection technologies, training employees and engaging third-party experts and consultants. While we maintain insurance covering certain security and privacy damages and claim expenses in the amount of $5.0 million per claim, we may not carry insurance or maintain coverage sufficient to compensate for all liability and in any event, insurance coverage would not address the reputational damage that could result from a security incident.
We outsource important aspects of the storage and transmission of Client and Member information, and thus rely on third parties to manage functions that have material cyber-security risks. We attempt to address these risks by requiring outsourcing subcontractors who handle Client and Member information to sign business associate agreements contractually requiring those subcontractors to adequately safeguard personal health data to the same extent that applies to us and in some cases by requiring such outsourcing subcontractors to undergo third-party security examinations. In addition, we periodically hire third-party security experts to assess and test our
37
security posture. However, we cannot assure you that these contractual measures and other safeguards will adequately protect us from the risks associated with the storage and transmission of Client and Members' proprietary and protected health information.
We also publish statements to our Members that describe how we handle and protect personal information. If federal or state regulatory authorities or private litigants consider any portion of these statements to be untrue, we may be subject to claims of deceptive practices, which could lead to significant liabilities and consequences, including, without limitation, costs of responding to investigations, defending against litigation, settling claims and complying with regulatory or court orders.
We also send SMS text messages to potential end users who are eligible to use our service through certain customers and partners. While we obtain consent from or on behalf of these individuals to send text messages, federal or state regulatory authorities or private litigants may claim that the notices and disclosures we provide, form of consents we obtain or our SMS texting practices, are not adequate. These SMS texting campaigns are potential sources of risk for class action lawsuits and liability for our company. Numerous class-action suits under federal and state laws have been filed in the past year against companies who conduct SMS texting programs, with many resulting in multi-million dollar settlements to the plaintiffs. Any future such litigation against us could be costly and time-consuming to defend.
Our quarterly results may fluctuate significantly, which could adversely impact the value of our common stock.
Our quarterly results of operations, including our revenue, gross margin, net loss and cash flows, has varied and may vary significantly in the future, and period-to-period comparisons of our results of operations may not be meaningful. Accordingly, our quarterly results should not be relied upon as an indication of future performance. Our quarterly financial results may fluctuate as a result of a variety of factors, many of which are outside of our control, including, without limitation, the following:
38
We are particularly subject to fluctuations in our quarterly results of operations because the costs associated with entering into Client contracts are generally incurred up front, while we generally recognize revenue over the term of the contract. Further, most of our revenue in any given quarter is derived from contracts entered into with our Clients during previous quarters. Consequently, a decline in new or renewed contracts in any one quarter may not be fully reflected in our revenue for that quarter. Such declines, however, would negatively affect our revenue in future periods and the effect of significant downturns in sales of and market demand for our solution, and potential changes in our rate of renewals or renewal terms, may not be fully reflected in our results of operations until future periods. Our subscription model also makes it difficult for us to rapidly increase our total revenue through additional sales in any period, with the exception of the first quarter during peak benefits enrollment, as revenue from new Clients must be recognized over the applicable term of the contract. Accordingly, the effect of changes in the industry impacting our business or changes we experience in our new sales may not be reflected in our short-term results of operations. Any fluctuation in our quarterly results may not accurately reflect the underlying performance of our business and could cause a decline in the trading price of our common stock.
If we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase and we may be unable to implement our business strategy.
We have experienced significant growth in recent periods, which puts strain on our business, operations and employees. For example, we grew from 95 full-time employees at December 31, 2013 to 222 full-time employees at December 31, 2014 and 259 full-time employees at March 31, 2015. We have also more than doubled our client and membership bases over the past two years. We anticipate that our operations will continue to rapidly expand. To manage our current and anticipated future growth effectively, we must continue to maintain and enhance our IT infrastructure, financial and accounting systems and controls. We must also attract, train and retain a significant number of qualified sales and marketing personnel, customer support personnel, professional services personnel, software engineers, technical personnel and management personnel, and the availability of such personnel, in particular software engineers, may be constrained.
A key aspect to managing our growth is our ability to scale our capabilities to implement our solution satisfactorily with respect to both large and demanding Clients, who currently constitute the substantial majority of our client base, as well as smaller Clients who are becoming an increasingly larger portion of our client base. Large Clients often require specific features or functions unique to their membership base, which, at a time of significant growth or during periods of high demand, may strain our implementation capacity and hinder our ability to successfully implement our solution to our Clients in a timely manner. We may also need to make further investments in our technology and automate portions of our solution or services to decrease our costs. If we are unable to address the needs of our Clients or Members, or our Clients or Members are unsatisfied with the quality of our solution or services, they may not renew their contracts, seek to cancel or terminate their relationship with us or renew on less favorable terms, any of which could cause our annual net dollar retention rate to decrease.
Failure to effectively manage our growth could also lead us to over-invest or under-invest in development and operations, result in weaknesses in our infrastructure, systems or controls, give rise to operational mistakes, financial losses, loss of productivity or business opportunities and result in loss of employees and reduced productivity of remaining employees. Our growth is expected to require significant capital expenditures and may divert financial resources from other projects such as the development of new applications and services. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our revenue may not increase or may grow more slowly than expected and we may be unable to implement our
39
business strategy. The quality of our services may also suffer, which could negatively affect our reputation and harm our ability to attract and retain Clients.
We incur significant upfront costs in our Client relationships, and if we are unable to maintain and grow these Client relationships over time, we are likely to fail to recover these costs, which could have a material adverse effect on our business, financial condition and results of operations.
We derive most of our revenue from subscription access fees. Accordingly, our business model depends heavily on achieving economies of scale because our initial upfront investment is costly and the associated revenue is recognized on a ratable basis. We devote significant resources to establish relationships with our Clients and implement our solution and related services. This is particularly so in the case of large enterprises that, to date, have comprised a substantial majority of our client base and revenue and often request or require specific features or functions unique to their particular business processes. Accordingly, our results of operations will depend in substantial part on our ability to deliver a successful experience for both Clients and Members and persuade our Clients to maintain and grow their relationship with us over time. Additionally, as our business is growing significantly, our Client acquisition costs could outpace our build-up of recurring revenue, and we may be unable to reduce our total operating costs through economies of scale such that we are unable to achieve profitability. If we fail to achieve appropriate economies of scale or if we fail to manage or anticipate the evolution and in future periods, demand, of the subscription access fee model, our business, financial condition and results of operations could be materially adversely affected.
If our existing Clients do not continue or renew their contracts with us, renew at lower fee levels or decline to purchase additional applications and services from us, it could have a material adverse effect on our business, financial condition and results of operations.
We expect to derive a significant portion of our revenue from renewal of existing Client contracts and sales of additional applications and services to existing Clients. As part of our growth strategy, for instance, we have recently focused on expanding our services amongst current Clients. As a result, achieving a high annual net dollar retention rate and selling additional applications and services are critical to our future business, revenue growth and results of operations.
Factors that may affect our annual net dollar retention rate and our ability to sell additional applications and services include, but are not limited to, the following:
We enter into subscription access contracts with our Clients. These contracts generally have stated initial terms of one year. Most of our Clients have no obligation to renew their subscriptions for our solution after the initial term expires. In addition, our Clients may negotiate terms less advantageous to us upon renewal, which may reduce our revenue from these Clients and may decrease our annual net dollar retention rate. Our future results of operations also depend, in part, on our ability to expand into new clinical specialties and across care settings and use cases. If our Clients fail to renew their contracts, renew their contracts upon less favorable terms or at lower fee levels or fail to purchase new products and services from us, our revenue may decline or our future revenue growth may be constrained.
40
In addition, after the initial contract year, a significant number of our Client contracts allow Clients to terminate such agreements for convenience at certain times, typically with one to three months advance notice. We typically incur the expenses associated with integrating a Client's data into our healthcare database and related training and support prior to recognizing meaningful revenue from such Client. Subscription access revenue is not recognized until our products are implemented for launch, which is generally from one to three months from contract signing. If a Client terminates its contract early and revenue and cash flows expected from a Client are not realized in the time period expected or not realized at all, our business, financial condition and results of operations could be adversely affected.
Our sales and implementation cycle can be long and unpredictable and requires considerable time and expense, which may cause our results of operations to fluctuate.
The sales cycle for our solution from initial contact with a potential lead to contract execution and implementation, varies widely by Client, ranging from a number of days to approximately 24 months. Some of our Clients undertake a significant and prolonged evaluation process, including to determine whether our services meet their unique healthcare needs, which frequently involves evaluation of not only our solution but also an evaluation of those of our competitors, which has in the past resulted in extended sales cycles. Our sales efforts involve educating our Clients about the use, technical capabilities and potential benefits of our solution. Moreover, our large enterprise Clients often begin to deploy our solution on a limited basis, but nevertheless demand extensive configuration, integration services and pricing concessions, which increase our upfront investment in the sales effort with no guarantee that these Clients will deploy our solution widely enough across their organization to justify our substantial upfront investment. It is possible that in the future we may experience even longer sales cycles, more complex Client needs, higher upfront sales costs and less predictability in completing some of our sales as we continue to expand our direct sales force, expand into new territories and market additional applications and services. If our sales cycle lengthens or our substantial upfront sales and implementation investments do not result in sufficient sales to justify our investments, it could have a material adverse effect on our business, financial condition and results of operations.
We operate in a competitive industry, and if we are not able to compete effectively, our business, financial condition and results of operations will be harmed.
While the telehealth market is in an early stage of development, it is competitive and we expect it to attract increased competition, which could make it difficult for us to succeed. We currently face competition in the telehealth industry for our solution from a range of companies, including specialized software and solution providers that offer similar solutions, often at substantially lower prices, and that are continuing to develop additional products and becoming more sophisticated and effective. These competitors include MDLIVE, Inc., American Well Corporation and Doctor on Demand, Inc. In addition, large, well-financed health plans have in some cases developed their own telehealth tools and may provide these solutions to their customers at discounted prices. Competition from specialized software and solution providers, health plans and other parties will result in continued pricing pressures, which is likely to lead to price declines in certain product segments, which could negatively impact our sales, profitability and market share.
Some of our competitors may have greater name recognition, longer operating histories and significantly greater resources than we do. Further, our current or potential competitors may be acquired by third parties with greater available resources. As a result, our competitors may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards or customer requirements and may have the ability to initiate or withstand substantial price competition. In addition, current and potential competitors have established, and may in the future establish, cooperative relationships with vendors of complementary products, technologies or services to increase the availability of their solutions in the marketplace.
41
Accordingly, new competitors or alliances may emerge that have greater market share, a larger customer base, more widely adopted proprietary technologies, greater marketing expertise, greater financial resources and larger sales forces than we have, which could put us at a competitive disadvantage. Our competitors could also be better positioned to serve certain segments of the telehealth market, which could create additional price pressure. In light of these factors, even if our solution is more effective than those of our competitors, current or potential Clients may accept competitive solutions in lieu of purchasing our solution. If we are unable to successfully compete in the telehealth market, our business, financial condition and results of operations could be materially adversely affected.
If we cannot implement our solution for Clients or resolve any technical issues in a timely manner, we may lose Clients and our reputation may be harmed.
Our Clients utilize a variety of data formats, applications and infrastructure and our solution must support our Clients' data formats and integrate with complex enterprise applications and infrastructures. If our platform does not currently support a Client's required data format or appropriately integrate with a Client's applications and infrastructure, then we must configure our platform to do so, which increases our expenses. Additionally, we do not control our Clients' implementation schedules. As a result, if our Clients do not allocate the internal resources necessary to meet their implementation responsibilities or if we face unanticipated implementation difficulties, the implementation may be delayed. If the Client implementation process is not executed successfully or if execution is delayed, we could incur significant costs, Clients could become dissatisfied and decide not to increase utilization of our solution or not to implement our solution beyond an initial period prior to their term commitment or, in some cases, revenue recognition could be delayed. In addition, competitors with more efficient operating models with lower implementation costs could jeopardize our Client relationships.
Our Clients and Members depend on our support services to resolve any technical issues relating to our solution and services, and we may be unable to respond quickly enough to accommodate short-term increases in Member demand for support services, particularly as we increase the size of our client and membership bases. We also may be unable to modify the format of our support services to compete with changes in support services provided by competitors. It is difficult to predict Member demand for technical support services, and if Member demand increases significantly, we may be unable to provide satisfactory support services to our Members. Further, if we are unable to address Members' needs in a timely fashion or further develop and enhance our solution, or if a Client or Member is not satisfied with the quality of work performed by us or with the technical support services rendered, then we could incur additional costs to address the situation or be required to issue credits or refunds for amounts related to unused services, and our profitability may be impaired and Clients' dissatisfaction with our solution could damage our ability to expand the number of applications and services purchased by such Clients. These Clients may not renew their contracts, seek to terminate their relationship with us or renew on less favorable terms. Moreover, negative publicity related to our Client relationships, regardless of its accuracy, may further damage our business by affecting our reputation or ability to compete for new business with current and prospective Clients. If any of these were to occur, our revenue may decline and our business, financial condition and results of operations could be adversely affected.
We depend on our senior management team, and the loss of one or more of our executive officers or key employees or an inability to attract and retain highly skilled employees could adversely affect our business.
Our success depends largely upon the continued services of our key executive officers. These executive officers are at-will employees and therefore they may terminate employment with us at any time with no advance notice. We maintain "key person" insurance in the amount of $4.0 million for Jason Gorevic, our Chief Executive Officer, but not for any of our other executive officers or any
42
of our other key employees. We also rely on our leadership team in the areas of research and development, marketing, services and general and administrative functions. From time to time, there may be changes in our executive management team resulting from the hiring or departure of executives, which could disrupt our business. The replacement of one or more of our executive officers or other key employees would likely involve significant time and costs and may significantly delay or prevent the achievement of our business objectives.
To continue to execute our growth strategy, we also must attract and retain highly skilled personnel. Competition is intense for qualified professionals. We may not be successful in continuing to attract and retain qualified personnel. We have from time to time in the past experienced, and we expect to continue to experience in the future, difficulty in hiring and retaining highly skilled personnel with appropriate qualifications. The pool of qualified personnel with experience working in the healthcare market is limited overall. In addition, many of the companies with which we compete for experienced personnel have greater resources than we have.
In addition, in making employment decisions, particularly in high-technology industries, job candidates often consider the value of the stock options or other equity instruments they are to receive in connection with their employment. Volatility in the price of our stock may, therefore, adversely affect our ability to attract or retain highly skilled personnel. Further, the requirement to expense stock options and other equity instruments may discourage us from granting the size or type of stock option or equity awards that job candidates require to join our company. Failure to attract new personnel or failure to retain and motivate our current personnel, could have a material adverse effect on our business, financial condition and results of operations.
If we fail to develop widespread brand awareness cost-effectively, our business may suffer.
We believe that developing and maintaining widespread awareness of our brand in a cost-effective manner is critical to achieving widespread adoption of our solution and attracting new Clients. Our brand promotion activities may not generate Client awareness or increase revenue, and even if they do, any increase in revenue may not offset the expenses we incur in building our brand. If we fail to successfully promote and maintain our brand, or incur substantial expenses in doing so, we may fail to attract or retain Clients necessary to realize a sufficient return on our brand-building efforts or to achieve the widespread brand awareness that is critical for broad Client adoption of our solution.
Our marketing efforts depend significantly on our ability to receive positive references from our existing Clients.
Our marketing efforts depend significantly on our ability to call upon our current Clients to provide positive references to new, potential Clients. Given our limited number of long-term Clients, the loss or dissatisfaction of any Client could substantially harm our brand and reputation, inhibit widespread adoption of our solution and impair our ability to attract new Clients and maintain existing Clients. Any of these consequences could lower our annual net dollar retention rate and have a material adverse effect on our business, financial condition and results of operations.
Any failure to protect our intellectual property rights could impair our ability to protect our technology and our brand.
Our success depends in part on our ability to enforce our intellectual property and other proprietary rights. We rely upon a combination of trademark and trade secret laws, as well as license and access agreements and other contractual provisions, to protect our intellectual property and other proprietary rights. In addition, we attempt to protect our intellectual property and proprietary information by requiring our employees, consultants and certain of our contractors to execute confidentiality and assignment of inventions agreements. These laws, procedures and restrictions provide only limited protection and any of our intellectual property rights may be challenged, invalidated, circumvented, infringed or misappropriated. To the extent that our
43
intellectual property and other proprietary rights are not adequately protected, third parties may gain access to our proprietary information, develop and market solutions similar to ours or use trademarks similar to ours, each of which could materially harm our business. Unauthorized parties may also attempt to copy or obtain and use our technology to develop applications with the same functionality as our solution, and policing unauthorized use of our technology and intellectual property rights is difficult and may not be effective. The failure to adequately protect our intellectual property and other proprietary rights could have a material adverse effect on our business, financial condition and results of operations.
We may acquire other companies or technologies, which could divert our management's attention, result in dilution to our stockholders and otherwise disrupt our operations and we may have difficulty integrating any such acquisitions successfully or realizing the anticipated benefits therefrom, any of which could have a material adverse effect on our business, financial condition and results of operations.
We may in the future seek to acquire or invest in businesses, applications and services or technologies that we believe could complement or expand our solution, enhance our technical capabilities or otherwise offer growth opportunities. The pursuit of potential acquisitions may divert the attention of management and cause us to incur various expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated.
In addition, we have limited experience in acquiring other businesses. If we acquire additional businesses, we may not be able to integrate the acquired personnel, operations and technologies successfully, or effectively manage the combined business following the acquisition. We also may not achieve the anticipated benefits from the acquired business due to a number of factors, including, but not limited to:
In addition, a significant portion of the purchase price of companies we acquire may be allocated to acquired goodwill and other intangible assets, which must be assessed for impairment at least annually. In the future, if our acquisitions do not yield expected returns, we may be required to take charges to our results of operations based on this impairment assessment process, which could adversely affect our results of operations.
44
Acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect our results of operations. In addition, if an acquired business fails to meet our expectations, our business, financial condition and results of operations may suffer.
Taxing authorities may successfully assert that we should have collected or in the future should collect sales and use or similar taxes which could adversely affect our results of operations.
We do not collect sales and use and similar taxes in any states based on our belief that our services are not subject to such taxes in any state. Sales and use and similar tax laws and rates vary greatly from state to state. Certain states in which we do not collect such taxes may assert that such taxes are applicable, which could result in tax assessments, penalties and interest with respect to past services, and we may be required to collect such taxes for services in the future. Such tax assessments, penalties and interest or future requirements may adversely affect our results of operations.
Economic uncertainties or downturns in the general economy or the industries in which our Clients operate could disproportionately affect the demand for our solution and negatively impact our results of operations.
General worldwide economic conditions have experienced significant downturns during the last ten years, and market volatility and uncertainty remain widespread, making it potentially very difficult for our Clients and us to accurately forecast and plan future business activities. During challenging economic times, our Clients may have difficulty gaining timely access to sufficient credit or obtaining credit on reasonable terms, which could impair their ability to make timely payments to us and adversely affect our revenue. If that were to occur, our financial results could be harmed. Further, challenging economic conditions may impair the ability of our Clients to pay for the applications and services they already have purchased from us and, as a result, our write-offs of accounts receivable could increase. We cannot predict the timing, strength or duration of any economic slowdown or recovery. If the condition of the general economy or markets in which we operate worsens, our business could be harmed.
The estimates of market opportunity and forecasts of market growth included in this prospectus may prove to be inaccurate, and even if the market in which we compete achieves the forecasted growth, our business could fail to grow at similar rates, if at all.
Market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. The estimates and forecasts in this prospectus relating to the size and expected growth of the telehealth market may prove to be inaccurate. Even if the market in which we compete meets our size estimates and forecasted growth, our business could fail to grow at similar rates, if at all.
Natural or man-made disasters and other similar events may significantly disrupt our business and negatively impact our business, financial condition and results of operations.
Our offices may be harmed or rendered inoperable by natural or man-made disasters, including earthquakes, power outages, fires, floods, nuclear disasters and acts of terrorism or other criminal activities, which may render it difficult or impossible for us to operate our business for some period of time. For example, our headquarters are located in the greater New York City area, a region with a history of terrorist attacks and hurricanes. Any disruptions in our operations related to the repair or replacement of our offices, could negatively impact our business and results of operations and harm our reputation. Although we maintain a $1.0 million insurance policy covering damage to property we rent and have an additional $2.0 million of coverage under our general
45
insurance policy, such insurance may not be sufficient to compensate for losses that may occur. Any such losses or damages could have a material adverse effect on our business, financial condition and results of operations. In addition, our Clients' facilities may be harmed or rendered inoperable by such natural or man-made disasters, which may cause disruptions, difficulties or material adverse effects on our business.
Future sales to Clients outside the United States or with international operations may expose us to risks inherent in international sales that, if realized, could adversely affect our business.
We may in the future expand internationally. Operating in international markets requires significant resources and management attention and will subject us to regulatory, economic and political risks that are different from those in the United States. Because of our limited experience with international operations, our international expansion efforts may not be successful in creating demand for our products and services outside of the United States or in effectively selling our solutions in the international markets we enter. In addition, we will face risks in doing business internationally that could adversely affect our business, including, but not limited to, the following:
If we denominate our international contracts in local currencies, fluctuations in the value of the U.S. dollar and foreign currencies may impact our results of operations when translated into U.S. dollars.
Risks Related to this Offering and Ownership of Our Common Stock
After this offering, our executive officers, directors and principal stockholders, if they choose to act together, will continue to retain significant voting power.
Upon the closing of this offering, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates
46
will, in the aggregate, hold shares representing approximately % of our outstanding common stock. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership control may:
We have an unremediated material weakness in internal control over financial reporting. Our failure to establish and maintain effective internal control over financial reporting could result in our failure to meet our reporting obligations and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our common stock to decline.
In connection with our most recent audit, we identified a material weakness in our internal control over financial reporting. A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.
The material weakness pertains to the breadth of our internal accounting team. Specifically, we do not have a sufficient number of accounting personnel to effectively design and operate proper internal controls over financial reporting. We are working to remediate the material weakness. We have begun taking steps and plan to take additional measures to remediate the underlying causes of the material weakness, primarily through the continued hiring of additional accounting personnel. The actions that we are taking are subject to ongoing senior management review, as well as audit committee oversight. Although we plan to complete this remediation process as quickly as possible, we cannot at this time estimate how long it will take to fully remediate the material weakness. If our remedial measures are insufficient to address the material weakness, or if significant deficiencies or material weaknesses in our internal control over financial reporting are discovered or occur in the future, it may adversely affect the results of our management evaluations and, when required, annual auditor attestation reports regarding the effectiveness of our internal control over financial reporting required by Section 404 of the Sarbanes-Oxley Act. In addition, if we are unable to successfully remediate the material weakness and if we are unable to produce accurate and timely financial statements or we are required to restate our financial results, our common stock price may be adversely affected and we may be unable to maintain compliance with the NYSE listing requirements.
If you purchase shares of common stock in this offering, you will suffer immediate dilution of your investment.
The initial public offering price of our common stock will be substantially higher than the net tangible book value per share of our common stock. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our net tangible book value per share after this offering. To the extent shares subsequently are issued under outstanding options or warrants, you will incur further dilution. Based on an assumed initial public offering price of $ per share, which is the midpoint of the price range set forth on the cover page of this prospectus, you will experience immediate dilution of $ per share,
47
representing the difference between our pro forma net tangible book value per share, after giving effect to this offering, and the assumed initial public offering price. In addition, purchasers of common stock in this offering will have contributed approximately % of the aggregate price paid by all purchasers of our stock but will own only approximately % of our common stock outstanding after this offering.
An active trading market for our common stock may not develop.
Prior to this offering, there has been no public market for our common stock. The initial public offering price for our common stock will be determined through negotiations with the underwriters. Although we intend to apply to have our common stock approved for listing on the NYSE, an active trading market for our common stock may never develop or be sustained following this offering. If an active market for our common stock does not develop, it may be difficult for you to sell the shares of our common stock you purchase in this offering without depressing the market price for our common stock or at all.
The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock in this offering.
Our stock price is likely to be volatile. The stock market has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above the initial public offering price. The market price for our common stock may be influenced by many factors, including, but not limited to:
We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.
Our management and board of directors will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. You may not agree with our decisions, and our use of the proceeds may not yield any return on your investment. We intend to use the net proceeds of this offering for working capital and general corporate purposes, including to expand our current business through acquisitions of, or investments in, other businesses, products or technologies. However, we have no commitments with respect to any such acquisitions or investments at this time, and our use of these proceeds may differ substantially from our current
48
plans. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our new applications and services. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. You will not have the opportunity to influence our decision on how to use our net proceeds from this offering.
A significant portion of our total outstanding shares are eligible to be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well.
Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. After this offering, we will have outstanding shares of common stock based on the number of shares outstanding as of , 2015. This includes the shares that we are selling in this offering, which may be resold in the public market immediately without restriction, unless purchased by our affiliates or existing stockholders. The remaining shares are currently restricted as a result of securities laws or lock-up agreements but will become eligible to be sold at various times beginning 180 days after this offering. Moreover, after this offering, holders of an aggregate of shares of our common stock will have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also intend to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and the lock-up agreements described in the "Underwriting" section of this prospectus.
We are an "emerging growth company," and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.
We are an "emerging growth company," as defined in the JOBS Act and may remain an emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:
We have taken advantage of reduced reporting burdens in this prospectus. In particular, in this prospectus, we have provided only two years of audited financial statements and have not included all of the executive compensation related information that would be required if we were not an emerging growth company. We cannot predict whether investors will find our common stock less
49
attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.
If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.
The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. If no or few securities or industry analysts commence coverage of us, the trading price for our common stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our results of operations fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.
Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws that will become effective upon the closing of this offering may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions include those establishing:
50
stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;
Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, or the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.
Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders, (3) any action asserting a claim arising pursuant to any provision of the DGCL or our amended and restated certificate of incorporation or amended and restated bylaws, (4) any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or amended and restated bylaws or (5) any action asserting a claim governed by the internal affairs doctrine. This choice of forum provision may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could have a material adverse effect our business, financial condition or results of operations.
51
Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation will be your sole source of gain, if any.
We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. Any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.
We could be subject to securities class action litigation.
In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. If we face such litigation, it could result in substantial costs and a diversion of management's attention and resources, which could have a material adverse effect on our business, financial condition or results of operations.
52
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Many statements made in this prospectus that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as "anticipate," "expect," "suggests," "plan," "believe," "intend," "estimates," "targets," "projects," "should," "could," "would," "may," "will," "forecast," and other similar expressions. These forward-looking statements and projections are contained throughout this prospectus, including the sections entitled "Prospectus Summary," "Risk Factors," "Capitalization," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Business." We base these forward-looking statements or projections on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances and at such time. As you read and consider this prospectus, you should understand that these statements are not guarantees of performance or results. The forward-looking statements and projections are subject to and involve risks, uncertainties and assumptions and you should not place undue reliance on these forward-looking statements or projections. Although we believe that these forward-looking statements and projections are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results or results of operations and could cause actual results to differ materially from those expressed in the forward-looking statements and projections. Factors that may materially affect such forward-looking statements and projections include, but are not limited to the following:
These cautionary statements should not be construed by you to be exhaustive and are made only as of the date of this prospectus. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should evaluate all forward-looking statements made in this prospectus in the context of these risks and uncertainties.
53
We estimate the proceeds to us from this offering will be approximately $ million, based on an assumed public offering price of $ per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters' option to purchase additional shares from us is exercised in full, we estimate that we will receive additional net proceeds of $ .
Each $1.00 increase (decrease) in the assumed public offering price would increase (decrease) the net proceeds to us by approximately $ million, after deducting estimated underwriting discounts and commissions and other estimated offering expenses payable by us, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. Each increase (decrease) of 1.0 million in the number of shares offered by us would increase (decrease) the net proceeds to us by approximately $ million, after deducting estimated underwriting discounts and commissions and other estimated offering expenses payable by us, assuming the public offering price of $ per share, which is the midpoint of the price range set forth on the cover page of this prospectus. Any increase or decrease in the net proceeds would not change our intended use of proceeds.
We intend to use the net proceeds from this offering for working capital and other general corporate purposes, including to expand our current business through acquisitions of, or investments in, other businesses, products or technologies. However, we have no commitments with respect to any such acquisitions or investments at this time.
Our management will have broad discretion in the application of the net proceeds from this offering to us, and investors will be relying on the judgment of our management regarding the application of the proceeds. Pending their use, we plan to invest our net proceeds from this offering in short-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.
54
We have never declared or paid dividends on our common stock. We do not expect to pay dividends on our common stock for the foreseeable future. Instead, we anticipate that all of our earnings, if any, will be used for the operation and growth of our business. Any future determination to declare cash dividends would be subject to the discretion of our board of directors and would depend upon various factors, including our results of operations, financial condition and liquidity requirements, restrictions that may be imposed by applicable law and our contracts and other factors deemed relevant by our board of directors.
55
The following table sets forth our cash and cash equivalents and capitalization as of March 31, 2015, as follows:
Our capitalization following the closing of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read this information in conjunction with our audited consolidated financial statements and the related notes appearing at the end of this prospectus and the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section and other financial information contained in this prospectus.
56
|
As of March 31, 2015 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
|
Actual | Pro Forma |
Pro Forma
As Adjusted(1) |
|||||||
|
(in thousands, except par value and share data)
|
|||||||||
Cash and cash equivalents |
$ | 32,060 | $ | $ | ||||||
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
Long-term bank and other debt |
25,054 | $ | $ | |||||||
Convertible preferred stock, $0.001 par value per share; 50,479,286 shares authorized, 50,452,939 shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted; aggregate liquidation value of $117,914 as of March 31, 2015 |
117,914 | |||||||||
Redeemable common stock, $0.001 par value: 258,978 common shares issued and outstanding |
2,852 | |||||||||
Stockholders' equity: |
||||||||||
Common stock, $0.001 par value per share: 73,559,000 shares authorized, 4,709,331 shares issued and outstanding, actual; shares authorized, pro forma and pro forma as adjusted; shares issued and outstanding, pro forma; shares issued and outstanding, pro forma as adjusted |
5 | |||||||||
Additional paid in capital |
5,791 | |||||||||
Accumulated deficit |
(85,195 | ) | ||||||||
| | | | | | | | | | |
Total stockholders' deficit |
(79,399 | ) | ||||||||
| | | | | | | | | | |
Total capitalization |
$ | 66,421 | $ | $ | ||||||
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
57
If you invest in our common stock, your interest will be diluted to the extent of the difference between the initial public offering price per share and the net tangible book value per share after this offering and the use of proceeds therefrom.
As of March 31, 2015, we had a historical net tangible book value (deficit) of approximately $(1.0) million, or $(0.21) per share. Our historical net tangible book value per share represents total tangible assets less total liabilities divided by the number of shares of common stock outstanding as of March 31, 2015.
Our pro forma net tangible book value as of March 31, 2015 was $ million, or $ per share, based on shares of our common stock outstanding as of March 31, 2015, after giving effect to the automatic conversion of all outstanding shares of our preferred stock into common stock upon the closing of this offering.
After giving further effect to the sale of shares of common stock in this offering at an assumed initial public offering price of $ per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of March 31, 2015 would have been approximately $ million, or approximately $ per share. This amount represents an immediate increase in pro forma net tangible book value of $ per share to our existing stockholders and an immediate dilution of approximately $ per share to new investors participating in this offering. We determine dilution by subtracting the pro forma as adjusted net tangible book value per share after this offering from the amount of cash that a new investor paid for a share of common stock. The following table illustrates this dilution:
Assumed initial public offering price per share |
$ | ||||||
Historical net tangible book value per share as of March 31, 2015 |
$ | ||||||
Increase per share attributable to the conversion of our preferred stock |
|||||||
Pro forma net tangible book value per share as of March 31, 2015 |
|||||||
| | | | | | | |
Increase per share attributable to this offering |
|||||||
Pro forma as adjusted net tangible book value per share after this offering |
|||||||
| | | | | | | |
Dilution per share to new investors in this offering |
$ | ||||||
| | | | | | | |
| | | | | | | |
| | | | | | | |
Each $1.00 increase (decrease) in the assumed initial public offering price of $ per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted net tangible book value per share after this offering by approximately $ , and dilution in pro forma net tangible book value per share to new investors by approximately $ , assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of 1.0 million shares in the number of shares offered by us would increase (decrease) our pro forma as adjusted net tangible book value per share after this offering by approximately $ per share and decrease (increase) the dilution to new investors by approximately $ per share, assuming that the assumed initial public offering price remains the same, and after deducting estimated underwriting discounts and commissions and the estimated offering expenses payable by us.
If the underwriters exercise their option to purchase additional shares of our common stock in full, the pro forma as adjusted net tangible book value after this offering would be $ per share, the increase in pro forma net tangible book value per share would be $ and the
58
dilution per share to new investors would be $ per share, in each case assuming an initial public offering price of $ per share, which is the midpoint of the price range set forth on the cover page of this prospectus.
The following table summarizes on the pro forma as adjusted basis described above, as of March 31, 2015, the differences between the number of shares purchased from us, the total consideration paid to us in cash and the average price per share that existing stockholders and new investors paid. The calculation below is based on an assumed initial public offering price of $ per share, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
|
Shares Purchased | Total Consideration |
|
|||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Average
Price Per Share |
|||||||||||||||
|
Number | Percent | Amount | Percent | ||||||||||||
|
(in thousands, other than shares and percentages)
|
|||||||||||||||
Existing stockholders |
% | $ | % | $ | ||||||||||||
New investors |
||||||||||||||||
| | | | | | | | | | | | | | | | |
Total |
100 | % | $ | 100 | % | $ | ||||||||||
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
To the extent any of these outstanding options or warrants is exercised, there will be further dilution to new investors. If all of such outstanding options and warrants had been exercised as of March 31, 2015, the pro forma as adjusted net tangible book value per share after this offering would be $ , and total dilution per share to new investors would be $ .
If the underwriters exercise their option to purchase additional shares of our common stock in full:
59
SELECTED HISTORICAL FINANCIAL INFORMATION
The following table sets forth our selected historical consolidated financial information. The balance sheet data as of December 31, 2013 and 2014 and the statement of operations and cash flow data for the years ended December 31, 2013 and 2014 have been derived from our audited consolidated financial statements included elsewhere in this prospectus. The balance sheet data as of March 31, 2015 and the statement of operations data for the three months ended March 31, 2014 and 2015 have been derived from our unaudited consolidated financial statements included elsewhere in this prospectus. The balance sheet data as of March 31, 2014 have been derived from our unaudited consolidated financial statements not included in this prospectus. We completed our acquisitions of Consult A Doctor on August 29, 2013, AmeriDoc on May 1, 2014 and BetterHelp on January 23, 2015. The results of operations of Consult A Doctor and AmeriDoc since the respective acquisition dates have been included in our audited consolidated financial statements included elsewhere in this prospectus. The results of operations of Consult A Doctor, AmeriDoc and BetterHelp since the respective acquisition dates have been included in our unaudited consolidated financial statements included elsewhere in this prospectus. You should read the information contained in this table in conjunction with "Capitalization," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the audited consolidated financial statements and the related notes thereto included elsewhere in this prospectus. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of our management, include all adjustments, consisting only of normal and recurring adjustments, necessary for a fair presentation of the information set forth herein. Interim financial results are not necessarily indicative of results that may be expected for the full fiscal year, and our historical results are not indicative of the results to be expected in the future.
60
|
Year Ended December 31, | Three Months Ended March 31, | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
2013 | 2014 | 2014 | 2015 | |||||||||
|
(dollars in thousands, except share and per share data)
|
||||||||||||
Consolidated Statements of Operations Data: |
|||||||||||||
Revenue |
$ | 19,906 | $ | 43,528 | $ | 9,407 | $ | 16,488 | |||||
Cost of revenue |
4,186 | 9,929 | 1,982 | 5,281 | |||||||||
| | | | | | | | | | | | | |
Gross profit |
15,720 | 33,599 | 7,425 | 11,207 | |||||||||
Operating expenses: |
|||||||||||||
Advertising and marketing |
4,090 | 7,662 | 2,518 | 4,341 | |||||||||
Sales |
4,441 | 11,571 | 2,145 | 3,682 | |||||||||
Technology and development |
3,532 | 7,573 | 1,192 | 2,906 | |||||||||
General and administrative |
8,772 | 19,623 | 3,344 | 11,968 | |||||||||
Depreciation and amortization |
754 | 2,320 | 414 | 903 | |||||||||
| | | | | | | | | | | | | |
Loss from operations |
(5,869 | ) | (15,150 | ) | (2,188 | ) | (12,593 | ) | |||||
Interest income (expense), net |
(56 | ) | (1,499 | ) | (54 | ) | (568 | ) | |||||
| | | | | | | | | | | | | |
Net loss before taxes |
5,925 | (16,649 | ) | (2,242 | ) | (13,161 | ) | ||||||
Income tax provision (benefit) |
94 | 388 | 72 | (458 | ) | ||||||||
| | | | | | | | | | | | | |
Net loss |
$ | (6,019 | ) | $ | (17,037 | ) | $ | (2,314 | ) | (12,703 | ) | ||
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Per Share Data: |
|||||||||||||
Net loss per share, basic and diluted |
$ | (3.52 | ) | $ | (4.49 | ) | $ | 1.03 | $ | (2.57 | ) | ||
Weighted-average shares used to compute basic and diluted net loss per share |
2,793,982 | 4,486,868 | 3,254,509 | 4,943,060 | |||||||||
Pro forma net loss per share, basic and diluted (unaudited) |
$ | (0.37 | ) | $ | $ | (0.20 | ) | ||||||
Weighted-average shares used to compute basic and diluted pro forma net loss per share (unaudited) |
53,734,598 | 63,120,240 | |||||||||||
Other Data: |
|
|
|
|
|||||||||
Visits |
127,107 | 298,833 | 65,243 | 148,696 | |||||||||
Members |
6.2 million | 8.1 million | 7.1 million | 10.6 million | |||||||||
EBITDA(1) |
$ | (5,115 | ) | $ | (12,830 | ) | $ | (1,774 | ) | $ | (11,690 | ) |
|
As of December 31, |
As of
March 31, |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
|
2013 | 2014 | 2015 | |||||||
|
(in thousands)
|
|||||||||
Consolidated Balance Sheets Data: |
||||||||||
Cash and cash equivalents |
$ | 3,212 | $ | 46,436 | $ | 32,060 | ||||
Working capital |
1,685 | 41,638 | 25,617 | |||||||
Total assets |
27,386 | 92,007 | 87,361 | |||||||
Total liabilities |
8,331 | 38,776 | 45,994 | |||||||
Total stockholders' deficit |
(55,452 | ) | (67,535 | ) | (79,399 | ) |
61
UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION
On May 1, 2014, we acquired AmeriDoc, LLC, or AmeriDoc, a provider of telemedicine solutions to small- and medium-sized businesses sold exclusively through brokers and resellers. AmeriDoc was acquired for $17.2 million.
On May 22, 2015, the Company and Stat Health Services Inc., or StatDoc, executed an Agreement and Plan of Merger. We anticipate closing on the proposed acquisition of StatDoc, on June 16, 2015. StatDoc is a telemedicine provider, focused on managed care, health system and self-insured clients. The purchase price for the proposed StatDoc acquisition is $30.5 million, comprised of $13.7 million of cash and $16.8 million of stock and any working capital adjustments as defined in the Agreement and Plan of Merger.
The following unaudited pro forma consolidated statement of operations and unaudited pro forma consolidated balance sheet has been derived from the audited consolidated financial statements of Teladoc for the year ended December 31, 2014, the audited consolidated financial statements of AmeriDoc for the period ended April 30, 2014 and the audited financial statements of StatDoc for the year ended December 31, 2014. The unaudited pro forma consolidated financial information has been adjusted for the acquisitions of AmeriDoc and StatDoc as if each had been completed on January 1, 2014, in the case of the unaudited pro forma consolidated statement of operations, and December 31, 2014, in the case of the unaudited pro forma consolidated balance sheet. The pro forma adjustments are based on the best information available and certain assumptions that management believes are reasonable under the circumstances. The assumptions underlying the pro forma adjustments are described in the accompanying notes, which should be read in conjunction with this unaudited pro forma financial information. The unaudited pro forma consolidated financial information is presented for illustrative and informative purposes only and is not intended to represent or be indicative of what our results of operations or financial position would have been had the acquisitions of AmeriDoc and StatDoc actually occurred on the dates indicated. The unaudited pro forma financial information should be read in conjunction with the information contained in our audited consolidated financial statements and the audited financial statements of each of AmeriDoc and StatDoc included elsewhere in this prospectus. The unaudited pro forma financial information also should not be considered representative of our future results of operations. The transactions have been accounted for as acquisitions of AmeriDoc and StatDoc. Under the acquisition method of accounting, with respect to each acquisition, the purchase price was allocated to the underlying tangible and intangible assets acquired and liabilities assumed based on their respective estimated fair market values with any excess purchase price allocated to goodwill. As of the date of this prospectus, the valuation studies for AmeriDoc were completed and deemed final and the estimated fair market value of the assets acquired and liabilities assumed and the related allocations of purchase price are based on the actual net tangible and intangible assets that existed as of the closing date of the acquisition.
For further information on the AmeriDoc acquisition, see Note 3 to our audited consolidated financial statements included elsewhere in this prospectus.
As of the date of this document, we have not yet performed the detailed final valuation studies necessary to arrive at the final required estimates of the fair market value of the StatDoc assets to be acquired and StatDoc liabilities to be assumed and the related allocations of purchase price, as the acquisition has not yet closed. Accordingly, we have made certain adjustments to the historical book values of the assets and liabilities of StatDoc to reflect preliminary estimates of the fair value of intangible assets acquired with the residual excess of the purchase price over the historical net assets of StatDoc recorded as goodwill and intangible assets. Actual results may differ from those reflected in the unaudited pro forma financial statements once we have completed the valuation studies necessary to finalize the required purchase price allocations and other acquisition related
62
adjustments for StatDoc. There can be no assurances that such finalization will not result in material changes.
UNAUDITED PRO FORMA CONSOLIDATED STATEMENT OF OPERATIONS
FOR THE YEAR ENDED DECEMBER 31, 2014
|
Teladoc
For the year ended December 31, 2014 |
AmeriDoc
For the period from January 1, 2014 to April 30, 2014 |
StatDoc
for the year ended December 31, 2014 |
Adjustments
Unaudited |
For the year ended
December 31, 2014 Pro Forma Unaudited |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
(in thousands, except share and per share data)
|
|||||||||||||||
Revenue |
$ | 43,528 | $ | 1,814 | $ | 2,317 | $ | | $ | 47,659 | ||||||
Cost of revenue |
9,929 | 568 | 460 | | 10,957 | |||||||||||
| | | | | | | | | | | | | | | | |
Gross profit |
33,599 | 1,246 | 1,857 | | 36,702 | |||||||||||
Operating expenses: |
||||||||||||||||
Advertising and marketing |
7,662 | 13 | 481 | | 8,156 | |||||||||||
Sales |
11,571 | 479 | 1,064 | | 13,114 | |||||||||||
Technology and development |
7,573 | 97 | 1,011 | | 8,681 | |||||||||||
General and administrative |
19,623 | 1,729 | 2,547 | | 23,899 | |||||||||||
Depreciation and amortization |
2,320 | 9 | 81 | 1,492 | (A,B) | 3,902 | ||||||||||
| | | | | | | | | | | | | | | | |
Loss from operations |
(15,150 | ) | (1,081 | ) | (3,327 | ) | (1,492 | ) | (21,050 | ) | ||||||
Other income |
| | 83 | | 83 | |||||||||||
Interest income (expense), net |
(1,499 | ) | (8 | ) | | 8 | (C) | (1,499 | ) | |||||||
| | | | | | | | | | | | | | | | |
Net loss before taxes |
(16,649 | ) | (1,089 | ) | (3,244 | ) | (1,484 | ) | (22,466 | ) | ||||||
Income taxes |
388 | 5 | | | 393 | |||||||||||
| | | | | | | | | | | | | | | | |
Net loss |
$ | (17,037 | ) | $ | (1,094 | ) | $ | (3,244 | ) | $ | (1,484) | (D) | $ | (22,859 | ) | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
Per share data: |
||||||||||||||||
Net loss per share, basic and diluted |
$ | (4.49 | ) | $ | (0.24 | ) | $ | (0.72 | ) | $ | (0.22 | ) | $ | (3.77 | ) | |
Weighted-average shares used to compute basic and diluted net loss per share |
4,486,868 | 4,486,868 | 4,486,868 | 6,883,298 | 6,883,298 | |||||||||||
Pro forma net loss per share, basic and diluted (unaudited) |
$ | (0.37 | ) | $ | (0.02 | ) | $ | (0.06 | ) | $ | (0.03 | ) | $ | (0.46 | ) | |
Weighted-average shares used to compute basic and diluted pro forma net loss per share (unaudited) |
53,734,598 | 53,734,598 | 53,734,598 | 56,131,028 | 56,131,028 |
See accompanying notes to unaudited pro forma consolidated statement of operations.
63
Notes to Unaudited Pro Forma Consolidated Statement of Operations
64
UNAUDITED PRO FORMA CONSOLIDATED BALANCE SHEET
AS OF DECEMBER 31, 2014
|
Teladoc
As of December 31, 2014 |
StatDoc
As of December 31, 2014 |
Adjustments
Unaudited |
As of
December 31, 2014 Pro Forma Unaudited |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
(in thousands, except share and per share information)
|
||||||||||||
Assets |
|||||||||||||
Current assets: |
|||||||||||||
Cash and cash equivalents |
$ | 46,436 | $ | 1,509 | $ | (13,725 | )(A) | $ | 34,220 | ||||
Accounts receivable, net |
6,839 | 193 | | 7,032 | |||||||||
Due from officer |
253 | 34 | | 287 | |||||||||
Prepaid expenses and other current assets |
1,122 | 7 | | 1,129 | |||||||||
Deferred taxes |
12 | | | 12 | |||||||||
| | | | | | | | | | | | | |
Total current assets |
54,662 | 1,743 | (13,725 | ) | 42,680 | ||||||||
Property and equipment, net |
1,065 | 35 | | 1,100 | |||||||||
Goodwill |
28,454 | | 21,897 | (B) | 50,351 | ||||||||
Intangible assets, net |
7,530 | 118 | 7,250 | (C) | 14,898 | ||||||||
Other assets |
296 | 29 | | 325 | |||||||||
| | | | | | | | | | | | | |
Total assets |
$ | 92,007 | $ | 1,925 | $ | 15,422 | $ | 109,354 | |||||
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Liabilities, convertible preferred stock and stockholders' deficit |
|||||||||||||
Current liabilities: |
|||||||||||||
Accounts payable |
$ | 2,210 | $ | 208 | $ | | $ | 2,418 | |||||
Accrued expenses and other current liabilities |
6,623 | 364 | | 6,987 | |||||||||
Accrued compensation |
3,358 | | | 3,358 | |||||||||
Long term bank and other debtcurrent |
833 | | | 833 | |||||||||
| | | | | | | | | | | | | |
Total current liabilities |
13,024 | 572 | | 13,596 | |||||||||
Other liabilities |
62 | | | 62 | |||||||||
Deferred taxes |
494 | | | 494 | |||||||||
Long term bank and other debt |
25,196 | | | 25,196 | |||||||||
Commitments and contingencies |
|
|
|
|
|||||||||
Convertible preferred stock |
117,914 | 17,638 | (17,638 | )(D) | 117,914 | ||||||||
Redeemable common stock |
2,852 | | | 2,852 | |||||||||
Stockholders' equity (deficit): |
|||||||||||||
Common stock |
5 | 2 | 22 | (E) | 29 | ||||||||
Additional paid-in capital |
4,952 | 2,904 | 13,847 | (F) | 21,703 | ||||||||
Accumulated deficit |
(72,492 | ) | (19,191 | ) | 19,191 | (G) | (72,492 | ) | |||||
| | | | | | | | | | | | | |
Total stockholders' deficit |
(67,535 | ) | (16,285 | ) | 33,060 | (50,760 | ) | ||||||
| | | | | | | | | | | | | |
Total liabilities, convertible preferred stock and stockholders' deficit |
$ | 92,007 | $ | 1,925 | $ | 15,422 | $ | 109,354 | |||||
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
See accompanying notes to unaudited pro forma consolidated balance sheet.
65
Notes to Unaudited Pro Forma Consolidated Balance Sheet
66
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion summarizes the significant factors affecting the results of operations, financial condition, liquidity and cash flows of our company as of and for the periods presented below. The following discussion and analysis should be read in conjunction with "Prospectus SummarySummary Historical Financial Information," "Selected Historical Financial Information" and the audited consolidated financial statements and the related notes thereto included elsewhere in this prospectus. The statements in this discussion regarding industry outlook, our expectations regarding our future performance, liquidity and capital resources and all other non-historical statements in this discussion are forward-looking statements and are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Actual results could differ materially from those discussed in or implied by forward-looking statements as a result of various factors, including those discussed below and elsewhere in this prospectus, particularly in the section entitled "Risk Factors."
Overview
We are the nation's first and largest telehealth platform, delivering on-demand healthcare anytime, anywhere, via mobile devices, the internet, video and phone. Our solution connects consumers, or our Members, with our over 1,100 board-certified physicians and behavioral health professionals who treat a wide range of conditions and cases from acute diagnoses such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation. Nearly 11 million unique Members now benefit from access to Teladoc 24 hours a day, seven days a week, 365 days a year, at a cost of $40 per visit. Our solution is delivered with a median response time of less than ten minutes from the time a Member requests a telehealth visit to the time they speak with a Teladoc physician. We completed approximately 300,000 telehealth visits in 2014.
The Teladoc solution is transforming the access, cost and quality dynamics of healthcare delivery for all of our market participants. Our Members rely on Teladoc to remotely access affordable, on-demand healthcare whenever and wherever they choose. Our Clients purchase our solution to reduce their healthcare spending while at the same time offering convenient, affordable, high-quality healthcare to their employees or beneficiaries. Our Providers have the ability to generate meaningful income and deliver their services more efficiently with no administrative burden. We believe the value proposition of our solution is evidenced by our overall Member satisfaction rate, which has exceeded 95% over the last six years, and a 104% annual net dollar retention rate among our Clients on average over the last three years. We further believe any consumer, employer or health plan or practitioner interested in a better approach to healthcare is a potential Teladoc Member, Client or Provider.
We generate revenue from our Clients on a contractually recurring, per-Member-per-month, subscription access fee basis, which provides us with significant revenue visibility. In addition, under the majority of our Client contracts, we generate additional revenue on a per-telehealth visit basis, through a visit fee. Subscription access fees are paid by our Clients on behalf of their employees, dependents and other beneficiaries, while visit fees are paid by either Clients or Members. We generated $19.9 million and $43.5 million in revenue for the years ended December 31, 2013 and 2014, respectively, representing 119% year-over-year growth, and $9.4 million and $16.5 million for the three months ended March 31, 2014 and 2015, respectively, representing 75% year-over-year growth. We had net losses of $6.0 million and $17.0 million for the years ended December 31, 2013 and 2014, respectively, and $2.3 million and $12.7 million for the three months ended March 31, 2014 and 2015, respectively. For the three months ended March 31, 2015, 80% and 20% of our revenue were derived from subscription access fees and visit fees, respectively, and for the year
67
ended December 31, 2014, 85% and 15% of our revenue were derived from subscription access fees and visit fees, respectively.
Acquisition History
We have scaled and intend to continue to scale our platform through the pursuit of selective acquisitions. To date, we have completed the three acquisitions detailed below, which we believe have expanded our distribution capabilities and broadened our service offering.
In August 2013 we acquired Consult A Doctor for $16.6 million, net of cash acquired. In May 2014, we acquired AmeriDoc for $17.2 million, net of cash acquired. Both of these acquired businesses specialized in providing telehealth solutions to small- and medium-sized businesses through broker distribution channels. These acquisitions added new distribution opportunities that we believe are an important element of our growth strategy. See Note 3 to our audited consolidated financial statements included elsewhere in this prospectus and the audited consolidated financial statements of Consult A Doctor and AmeriDoc included elsewhere in this prospectus.
In January 2015, we completed the acquisition of BetterHelp, a provider of direct-to-consumer, behavioral health services for $3.5 million in cash and a $1.0 million promissory note and we have agreed to make annual payments to the sellers equal to 15% of the total net revenue generated by the BetterHelp business for each of the next three years. We believe this acquisition will help us broaden our service into the direct-to-consumer and behavioral health sector. See Note 3 to our unaudited consolidated financial statements included elsewhere in this prospectus.
We anticipate closing on the proposed acquisition of StatDoc on June 16, 2015 for $30.5 million, comprised of $13.7 million of cash and $16.8 million of stock and any working capital adjustments as defined in the Agreement and Plan of Merger governing the acquisition. StatDoc is a telemedicine provider, focused on managed care, health system and self-insured clients. See the audited financial statements of StatDoc included elsewhere in this prospectus.
Key Factors Affecting Our Performance
Number of Members. Our revenue growth rate and long-term profitability are affected by our ability to increase our number of Members because we derive a substantial portion of our revenue from subscription access fees via Client contracts that provide Members access to our professional Provider network in exchange for a contractual based monthly fee. Revenue is driven primarily by the number of Clients, the number of Members in a Client's population, the number of services contracted for by a Client and the contractually negotiated prices of our services and the negotiated pricing that is specific to that particular Client. We believe that increasing our membership is an integral objective that will provide us with the ability to continually innovate our services and support initiatives that will enhance Member experiences and lead to increasing or maintaining our existing annual net dollar retention rate.
Number of Visits. We also realize revenue in connection with the completion of a visit. Accordingly, our visit revenue, or visit fees, increase as the number of visits increase. Visit fee revenue is driven primarily by the number of Clients, the number of Members in a Client's population, Member utilization of our Provider network services and the contractually negotiated prices of our services. We believe that increasing our current Member utilization rate is a key objective in order for our Clients to realize tangible healthcare savings with our service.
Annual Net Dollar Retention Rate. We disclose annual net dollar retention rate as a supplemental measure of our organic revenue growth. We believe annual net dollar retention rate is an important metric that provides insight into the long-term value and stability of our subscription agreements and our ability to retain and grow revenue from our existing Clients. Because we typically enter into annual contracts with our Clients, a large percentage of our Client agreements have reached the end of their original terms and, as a result, we have observed significant renewal
68
rates. We observed a 104% annual net dollar retention rate among our Clients on average over the last three years. We calculate annual net dollar retention rate as the aggregate annualized subscription contract value as of the last day of a calendar year from our Clients that have been under contract with us for at least 12 months divided by the aggregate annualized subscription contract value from all our Clients as of the last day of the prior calendar year. We calculate the annualized subscription contract value for each Client by multiplying the monthly recurring revenue of such Client by 12. For the purposes of annual net dollar retention rate, we count health plan Clients separately from each self-insured employer Client that contracts with us through a health plan relationship.
Seasonality. We typically experience the strongest increases in consecutive quarterly revenue during the fourth and first quarters of each year, which coincides with traditional annual benefit enrollment seasons. In particular, as a result of many Clients' introduction of new services at the very end of the current year, or the start of each year, the majority of our new Client contracts have an effective date of January 1. Additionally, as a result of national seasonal cold and flu trends, we experience our highest level of visit fees during the first and fourth quarters of each year when compared to other quarters of the year. Conversely, the second quarter of the year has historically been the period of lowest utilization of our Provider network services relative to the other quarters of the year. See "Risk FactorsRisks Related to Our BusinessOur quarterly results may fluctuate significantly, which could adversely impact the value of our common stock."
Components of Results of Operations
Revenue
We generate in excess of 80% of our revenue from our Clients who purchase access to our professional Provider network for their employees, dependents and other beneficiaries. Our Client contracts include a per-Member-per-month subscription access fee as well as a visit fee for each completed visit, which is either paid to us by the Client, the Member or both parties. Accordingly, we generate subscription access revenue from our subscription access fees and visit revenue from our visit fees.
Subscription access revenue accounted for approximately 83% and 85% of our total revenue during the years ended December 31, 2013 and 2014, respectively, and 85% and 80% during the three months ended March 31, 2014 and 2015, respectively. Subscription access revenue is driven primarily by the number of Clients, the number of Members in a Client's population, the number of services contracted for by a Client and the contractually negotiated prices of our services. Visit fee revenue is driven primarily by the number of Clients, the number of Members in a Client's population, Member utilization of our professional Provider network services and the contractually negotiated prices of our services.
We recognize subscription access fees monthly when the following criteria are met: (i) there is an executed subscription agreement, (ii) the Member has access to the service, (iii) collection of the fees is reasonably assured and (iv) the amount of fees to be paid by the Client and Member is fixed and determinable. Our agreements generally have a term of one year. The majority of Clients renew their contracts with us following their first year of services. We generally invoice our Members in advance on a monthly basis. Visit fees are recognized as incurred and billed in arrears.
See "Critical Accounting Policies and EstimatesRevenue Recognition" for a more detailed discussion of our revenue recognition policy.
Cost of Revenue
Cost of revenue primarily consists of fees paid to our Providers, costs incurred in connection with our Provider network operations, which include employee-related expenses (including salaries and benefits) and costs related to our contracted third-party call center and insurance, which includes coverage for medical malpractice claims. Cost of revenue is driven primarily by the
69
number of visits completed in each period. Many of the elements of the cost of revenue are relatively variable and semi-variable, and can be reduced in the near-term to offset any decline in our revenue. Our business and operational models are designed to be highly scalable and leverage variable costs to support revenue-generating activities. While we currently expect to grow our headcount to build our Provider network operations center and to enhance our sales and technology capabilities, we believe our increased investment in automation and integration capabilities and economies of scale in our Provider network operations center operating model, will position us to grow our revenue at a greater rate than our cost of revenue.
Gross Profit
Our gross profit is our total revenue minus our total cost of revenue, and our gross margin is our gross profit expressed as a percentage of our total revenue. Our gross margin has been and will continue to be affected by a number of factors, including the fees we charge our Clients, the number of visits we complete and the costs of running our Provider network operations center. We expect our annual gross margin to remain relatively steady over the near term, although our quarterly gross margin is expected to fluctuate from period to period depending on the interplay of these factors.
Advertising and Marketing Expenses
Advertising and marketing expenses consist primarily of personnel and related expenses for our marketing staff, including costs of communications materials that are produced to generate greater awareness and utilization among our Clients and Members. Marketing costs also include third-party independent research, trade shows and brand messages, public relations costs and stock-based compensation for our advertising and marketing employees. Our advertising and marketing expenses exclude any allocation of occupancy expense and depreciation and amortization.
We expect our advertising and marketing expenses to increase for the foreseeable future as we continue to increase the size of our advertising and marketing operations and expand into new products and markets. Our advertising and marketing expenses will fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our advertising and marketing expenses. We will continue to invest in advertising and marketing by hiring additional personnel and promoting our brand through a variety of marketing and public relations activities.
Sales Expenses
Sales expenses consist primarily of employee-related expenses, including salaries, benefits, commissions, employment taxes, travel and stock-based compensation costs for our employees engaged in sales, account management and sales support. Our sales expenses exclude any allocation of occupancy expense and depreciation and amortization.
We expect our sales expenses to increase as we strategically invest to expand our business. We expect to hire additional sales personnel and related account management and sales support personnel to capture an increasing amount of our market opportunity. As we scale our sales and related account management and sales support personnel in the short- to medium-term, we expect these expenses to increase in both absolute dollars and as a percentage of revenue. We will continue to invest in sales by hiring additional sales and account management and sales support personnel.
Technology and Development Expenses
Technology and development expenses include personnel and related expenses for software engineering, information technology infrastructure, security and compliance and product development. Technology and development expenses also include outsourced software engineering
70
services, the costs of operating our on-demand technology infrastructure and stock-based compensation for our technology and development employees. Our technology and development expenses exclude any allocation of occupancy expense and depreciation and amortization.
We expect our technology and development expenses to increase for the foreseeable future as we continue to invest in the development of our technology platform. Our technology and development expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our technology and development expenses. Historically, the majority of our technology and development expenses has been expensed.
General and Administrative Expenses
General and administrative expenses include personnel and related expenses of, and professional fees incurred by, our executive, finance, legal and human resources departments. They also include stock-based compensation and all facilities costs including, utilities, communications and facilities maintenance. Our general and administrative expenses exclude any allocation of depreciation and amortization.
We expect our general and administrative expenses to increase for the foreseeable future following the completion of this offering due to the additional legal, accounting, insurance, investor relations and other costs that we will incur as a public company, as well as other costs associated with continuing to grow our business. However, we expect our general and administrative expenses to remain steady as a percentage of our total revenue over the near-term. Our general and administrative expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our general and administrative expenses.
Depreciation and Amortization
Depreciation and amortization consists primarily of depreciation of fixed assets, amortization of capitalized software development costs and amortization of acquisition-related intangible assets.
Interest Income (Expense)
Interest income (expense) consists of interest costs associated with our bank and other debt.
Income Tax Provision (Benefit)
We account for income taxes using the liability method, under which deferred tax assets and liabilities are determined based on the future tax consequences attributable to differences between the financial reporting carrying amounts of existing assets and liabilities and their respective tax bases and tax credit and NOLs. Deferred tax assets and liabilities are measured using the enacted tax rates that are expected to be in effect when the differences are expected to reverse. We assess the likelihood that deferred tax assets will be recovered from future taxable income, and a valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized. We have also recorded deferred tax liabilities arising principally from the difference between treatment of the goodwill between tax and financial accounting book purposes. We have provided a full valuation allowance for our deferred tax assets at December 31, 2014 and March 31, 2015, due to the uncertainty surrounding the future realization of such assets. As of December 31, 2014 and March 31, 2015, we have approximately $54.1 million and $65.8 million, respectively, of federal NOLs available to offset future taxable income. If not utilized, the federal NOLs begin to expire in 2024 and 2025, respectively. See "Risk FactorsRisks Related to Our BusinessOur ability to use our net operating losses to offset future taxable income may be subject to certain limitations."
71
Results of Operations
Comparison of the Three Months Ended March 31, 2014 and 2015
The following table sets forth our consolidated statement of operations data for the three months ended March 31, 2014 and 2015 and the dollar and percentage change between the two periods:
|
Three Months Ended March 31, | Change | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
2014 | 2015 | $ | % | |||||||||
|
(in thousands, except percentages)
|
||||||||||||
Revenue |
$ | 9,407 | $ | 16,488 | $ | 7,081 | 75 | % | |||||
Cost of revenue |
1,982 | 5,281 | 3,299 | 166 | % | ||||||||
| | | | | | | | | | | | | |
Gross profit |
7,425 | 11,207 | 3,782 | 51 | % | ||||||||
Operating expenses: |
|
|
|
|
|||||||||
Advertising and marketing |
2,518 | 4,341 | 1,824 | 72 | % | ||||||||
Sales |
2,145 | 3,682 | 1,537 | 72 | % | ||||||||
Technology and development |
1,192 | 2,906 | 1,714 | 144 | % | ||||||||
General and administrative |
3,344 | 11,968 | 8,624 | 258 | % | ||||||||
| | | | | | | | | | | | | |
Total operating expenses |
9,199 | 22,897 | 13,698 | 149 | % | ||||||||
| | | | | | | | | | | | | |
EBITDA(1) |
(1,774 | ) | (11,690 | ) | (9,916 | ) | 559 | % | |||||
Depreciation and amortization |
414 | 903 | 489 | 118 | % | ||||||||
| | | | | | | | | | | | | |
Loss from operations |
(2,188 | ) | (12,593 | ) | (10,405 | ) | 475 | % | |||||
Interest income (expense), net |
(54 | ) | (568 | ) | 514 | 942 | % | ||||||
| | | | | | | | | | | | | |
Net loss before taxes |
(2,242 | ) | (13,161 | ) | (10,918 | ) | 487 | % | |||||
Income tax provision (benefit) |
72 | (458 | ) | 530 | 739 | % | |||||||
| | | | | | | | | | | | | |
Net loss |
$ | (2,314 | ) | $ | (12,703 | ) | $ | (10,389 | ) | 449 | % | ||
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
We completed our acquisitions of Consult A Doctor on August 29, 2013, AmeriDoc on May 1, 2014 and BetterHelp on January 23, 2015. The results of operations of Consult A Doctor and AmeriDoc since the respective acquisition dates have been included in our audited consolidated financial statements included elsewhere in this prospectus. The results of operations of Consult A Doctor, AmeriDoc and BetterHelp since the respective acquisition dates have been included in our unaudited consolidated financial statements included elsewhere in this prospectus.
Revenue. Total revenue was $9.4 million for the three months ended March 31, 2014, compared to $16.5 million during the three months ended March 31, 2015, an increase of $7.1 million, or 75%. The increase in revenue was substantially driven by an increase in new Clients and the number of new Members generating additional subscription access fees. The increase in subscription access fees was due to the addition of new Clients, as the number of Members increased by 48% from March 31, 2014 to March 31, 2015. We also experienced 65,243 visits, representing $1.4 million of visit fees for the three months ended March 31, 2014, compared to 148,696 visits, representing $3.3 million of visit fees during the three months ended March 31, 2015, an increase of $1.9 million, or 129%.
72
Cost of Revenue. Cost of revenue was $2.0 million for the three months ended March 31, 2014 compared to $5.3 million for the three months ended March 31, 2015, an increase of $3.3 million, or 166%. The increase was primarily due to increased costs associated with our third-party call center and hiring of additional personnel to manage our physician network operations and increased provider fees and insurance costs.
Gross Profit. Gross profit was $7.4 million, or 79% as a percentage of revenue, for the three months ended March 31, 2014 compared to $11.2 million, or 68%, as a percentage of revenue, for the three months ended March 31, 2015, an increase of $3.8 million, or 51%. This increase was primarily due to revenue growth.
Advertising and Marketing Expenses. Advertising and marketing expenses were $2.5 million for the three months ended March 31, 2014 compared to $4.3 million for the three months ended March 31, 2015, an increase of $1.8 million, or 72%. This increase primarily consisted of increased independent research initiatives, sponsorship of professional organizations and trade shows of $1.3 million, increased staffing of $0.2 million and other expenses of $0.3 million.
Sales Expenses. Sales expenses were $2.1 million for the three months ended March 31, 2014 compared to $3.7 million for the three months ended March 31, 2015, an increase of $1.6 million, or 74%. This increase primarily consisted of increased staffing and sales commissions of $1.1 million, increased travel and entertainment expenses of $0.3 million and an increase to other sales expenses of $0.2 million.
Technology and Development Expenses. Technology and development expenses were $1.2 million for the three months ended March 31, 2014 compared to $2.9 million for the three months ended March 31, 2015, an increase of $1.7 million, or 144%. This increase resulted primarily from hiring additional personnel totaling $1.2 million, professional fees of $0.3 million related to the ongoing project to improve and optimize our technology platform and other expenses of $0.2 million.
General and Administrative Expenses. General and administrative expenses were $3.3 million for the three months ended March 31, 2014 compared to $12.0 million for the three months ended March 31, 2015, an increase of $8.6 million, or 258%. This increase was driven primarily by an increase in employee-related expenses of approximately $3.4 million as a result of growth in total employee headcount to 259 at March 31, 2015 as compared to 95 at March 31, 2014. Additionally, costs incurred in our physician network operations center in connection with enhancing our Member services increased by $1.1 million and professional fees, principally legal, increased by $2.9 million for the three months ended March 31, 2015 as compared to March 31, 2014. Other expenses, which include charges related to severance costs totaling $0.9 million, the abandonment of our Greenwich, Connecticut office and bad debt expenses, increased from $0.9 million at March 31, 2014 to $2.2 million at March 31, 2015, an increase of $1.3 million.
Depreciation and Amortization. Depreciation and amortization was $0.4 million for the three months ended March 31, 2014 compared to $0.9 million for the year three months ended March 31, 2015, an increase of $0.5 million, or 118%. This increase was primarily due to amortization expense of acquisition-related intangible assets of $0.2 million, an increase in amortization expense of capitalized software of $0.1 million and an increase of $0.2 million of depreciation expense on an increased base of fixed assets that grew from $1.5 million at March 31, 2014 to $2.7 million at March 31, 2015.
Interest Expense. Interest expense was approximately $0.1 million for the three months ended March 31, 2014 compared to $0.6 million for the three months ended March 31, 2015, an increase of $0.5 million. Interest expense consists of interest costs associated with our bank and other debt.
73
Comparison of the Years Ended December 31, 2013 and 2014
The following table sets forth our consolidated statement of operations data for the years ended December 31, 2013 and 2014 and the dollar and percentage change between the two periods:
|
Year Ended December 31, | Change | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
2013 | 2014 | $ | % | |||||||||
|
(in thousands, except percentages)
|
||||||||||||
Revenue |
$ | 19,906 | $ | 43,528 | $ | 23,622 | 119 | % | |||||
Cost of revenue |
4,186 | 9,929 | 5,743 | 137 | % | ||||||||
| | | | | | | | | | | | | |
Gross profit |
15,720 | 33,599 | 17,879 | 114 | % | ||||||||
Operating expenses: |
|
|
|
|
|||||||||
Advertising and marketing |
4,090 | 7,662 | 3,572 | 87 | % | ||||||||
Sales |
4,441 | 11,571 | 7,130 | 161 | % | ||||||||
Technology and development |
3,532 | 7,573 | 4,041 | 114 | % | ||||||||
General and administrative |
8,772 | 19,623 | 10,851 | 124 | % | ||||||||
| | | | | | | | | | | | | |
Total operating expenses |
20,835 | 46,429 | 25,594 | 123 | % | ||||||||
| | | | | | | | | | | | | |
EBITDA(1) |
(5,115 | ) | (12,830 | ) | (7,715 | ) | 151 | % | |||||
Depreciation and amortization |
754 | 2,320 | 1,566 | 208 | % | ||||||||
| | | | | | | | | | | | | |
Loss from operations |
(5,869 | ) | (15,150 | ) | (9,281 | ) | 158 | % | |||||
Interest income (expense), net |
(56 | ) | (1,499 | ) | (1,443 | ) | 2,558 | % | |||||
| | | | | | | | | | | | | |
Net loss before taxes |
(5,925 | ) | (16,649 | ) | (10,724 | ) | 181 | % | |||||
Income taxes |
94 | 388 | 294 | 313 | % | ||||||||
| | | | | | | | | | | | | |
Net loss |
$ | (6,019 | ) | $ | (17,037 | ) | $ | (11,018 | ) | 183 | % | ||
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
We completed our acquisitions of Consult A Doctor on August 29, 2013 and AmeriDoc on May 1, 2014. The results of operations of Consult A Doctor and AmeriDoc since the respective acquisition dates have been included in our audited consolidated financial statements included elsewhere in this prospectus.
Revenue. Total revenue was $19.9 million for the year ended December 31, 2013, compared to $43.5 million during the year ended December 31, 2014, an increase of $23.6 million, or 119%. The increase in revenue was substantially driven by an increase in new Clients and the number of new Members generating additional subscription access fees. The increase in subscription access fees was due to the addition of new Clients, as the number of Members increased by 31% from December 31, 2013 to December 31, 2014. We also experienced 127,107 visits, representing $3.3 million of visit fees for the year ended December 31, 2013, compared to 298,833 visits, representing $6.5 million of visit fees during the year ended December 31, 2014, an increase of $3.2 million, or 97%.
Cost of Revenue. Cost of revenue was $4.2 million for the year ended December 31, 2013 compared to $9.9 million for the year ended December 31, 2014, an increase of $5.7 million, or 137%. The increase was primarily due to increased costs associated with our third-party call center and hiring of additional personnel to manage our physician network operations and increased provider fees and insurance costs.
74
Gross Profit. Gross profit was $15.7 million, or 79% as a percentage of revenue, for the year ended December 31, 2013 compared to $33.6 million, or 77%, as a percentage of revenue, for the year ended December 31, 2014, an increase of $17.9 million, or 114%. This increase was primarily due to revenue growth.
Advertising and Marketing Expenses. Advertising and marketing expenses were $4.1 million for the year ended December 31, 2013 compared to $7.7 million for the year ended December 31, 2014, an increase of $3.6 million, or 87%. This increase primarily consisted of increased independent research initiatives, sponsorship of professional organizations and trade shows of $1.7 million, increased staffing of $0.6 million and other expenses of $1.3 million.
Sales Expenses. Sales expenses were $4.4 million for the year ended December 31, 2013 compared to $11.6 million for the year ended December 31, 2014, an increase of $7.1 million, or 161%. This increase primarily consisted of increased staffing and sales commissions of $6.2 million, increased travel and entertainment expenses of $0.4 million and an increase to other sales expenses of $0.5 million.
Technology and Development Expenses. Technology and development expenses were $3.5 million for the year ended December 31, 2013 compared to $7.6 million for the year ended December 31, 2014, an increase of $4.0 million, or 114%. This increase resulted primarily from hiring additional personnel totaling $2.3 million, professional fees of $1.3 million related to the ongoing project to improve and optimize our technology platform and other expenses of $0.4 million.
General and Administrative Expenses. General and administrative expenses were $8.8 million for the year ended December 31, 2013 compared to $19.6 million for the year ended December 31, 2014, an increase of $10.9 million, or 124%. This increase was driven primarily by an increase in employee-related expenses of approximately $3.9 million as a result of growth in total employee headcount from 222 at December 31, 2014 as compared to 95 at December 31, 2013. Additionally, costs incurred in our physician network operations for Member service increased by $2.1 million and professional fees increased by $2.6 million for the year ended December 31, 2014 as compared to December 31, 2013. Other expenses, which include office-related charges and bad debt expenses, increased from $2.0 million at December 31, 2013 to $4.3 million at December 31, 2014, an increase of $2.2 million, and were incurred to support the growth of our business.
Depreciation and Amortization. Depreciation and amortization was $0.8 million for the year ended December 31, 2013 compared to $2.3 million for the year ended December 31, 2014, an increase of $1.6 million, or 208%. This increase was primarily due to amortization expense of acquisition-related intangible assets of $1.2 million, an increase in amortization expense of capitalized software of $0.2 million and an increase of $0.2 million of depreciation expense on an increased base of fixed assets that grew from $1.3 million at December 31, 2013 to $2.3 million at December 31, 2014.
Interest Expense. Interest expense was approximately $0.1 million for the year ended December 31, 2013 compared to $1.5 million for the year ended December 31, 2014, an increase of $1.4 million. Interest expense consists of interest costs associated with our bank and other debt.
Quarterly Results
The following tables set forth selected unaudited quarterly consolidated statements of operations data for each of the four quarters in the year ended December 31, 2014 and the first quarter ended March 31, 2015, expressed as dollar amounts and percentage of revenue for each such quarter. The information for each of these quarters has been prepared on the same basis as
75
the audited annual consolidated financial statements included elsewhere in this prospectus and, in the opinion of management, includes all adjustments, which includes all normal recurring adjustments, necessary for the fair presentation of the results of operations for these periods in accordance with U.S. GAAP. This data should be read in conjunction with our audited and unaudited consolidated financial statements and related notes included elsewhere in this prospectus. These quarterly results of operations are not necessarily indicative of our results of operations for a full year or any future period.
(in thousands, unaudited)
|
3/31/2014 |
% of
Revenue |
6/30/2014 |
% of
Revenue |
9/30/2014 |
% of
Revenue |
12/31/2014 |
% of
Revenue |
3/31/2015 |
% of
Revenue |
|||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue |
$ | 9,407 | 100 | % | $ | 10,289 | 100 | % | $ | 10,905 | 100 | % | $ | 12,927 | 100 | % | $ | 16,488 | 100 | % | |||||||||||
Cost of revenue |
1,982 | 21 | % | 2,027 | 20 | % | 2,151 | 20 | % | 3,769 | 29 | % | 5,281 | 32 | % | ||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Gross profit |
7,425 | 79 | % | 8,262 | 80 | % | 8,754 | 80 | % | 9,158 | 71 | % | 11,207 | 68 | % | ||||||||||||||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Advertising and marketing |
2,518 | 27 | % | 1,436 | 14 | % | 1,984 | 18 | % | 1,724 | 13 | % | 4,341 | 26 | % | ||||||||||||||||
Sales |
2,145 | 23 | % | 3,033 | 29 | % | 3,263 | 30 | % | 3,130 | 24 | % | 3,682 | 22 | % | ||||||||||||||||
Technology and development |
1,192 | 13 | % | 2,064 | 20 | % | 1,960 | 18 | % | 2,357 | 18 | % | 2,906 | 18 | % | ||||||||||||||||
General and administrative |
3,344 | 36 | % | 4,033 | 39 | % | 4,754 | 44 | % | 7,492 | 58 | % | 11,968 | 73 | % | ||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Total operating expenses |
9,199 | 98 | % | 10,566 | 103 | % | 11,961 | 110 | % | 14,703 | 114 | % | 22,897 | 139 | % | ||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Depreciation and amortization |
414 | 4 | % | 554 | 5 | % | 650 | 6 | % | 702 | 5 | % | 903 | 5 | % | ||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Loss from operations |
(2,188 | ) | (23 | )% | (2,858 | ) | (28 | )% | (3,857 | ) | (35 | )% | (6,247 | ) | (48 | )% | (12,593 | ) | (76 | )% | |||||||||||
Interest income (expense), net |
(54 | ) | (1 | )% | (350 | ) | (3 | )% | (510 | ) | (5 | )% | (585 | ) | (5 | )% | (568 | ) | (3 | )% | |||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Net loss before taxes |
(2,242 | ) | (24 | )% | (3,208 | ) | (31 | )% | (4,367 | ) | (40 | )% | (6,832 | ) | (53 | )% | (13,161 | ) | (80 | )% | |||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Income tax provision (benefit) |
72 | 1 | % | (7 | ) | 0 | % | 162 | 1 | % | 161 | 1 | % | (458 | ) | (3 | )% | ||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Net loss |
$ | (2,314 | ) | (25 | )% | $ | (3,201 | ) | (31 | )% | $ | (4,529 | ) | (42 | )% | $ | (6,993 | ) | (54 | )% | $ | (12,703 | ) | (77 | )% | ||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
We typically experience the strongest increases in consecutive quarterly revenue during the fourth and first quarters of each year, which coincides with traditional annual benefit enrollment seasons. See "Key Factors Affecting Our PerformanceSeasonality."
Liquidity and Capital Resources
The following table presents a summary of our cash flow activity for the periods set forth below:
|
Year Ended
December 31, |
Three Months
Ended March 31, |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
2013 | 2014 | 2014 | 2015 | |||||||||
|
(in thousands)
|
||||||||||||
Consolidated Statements of Cash Flows Data |
|||||||||||||
Net cash used in operating activities |
$ | (6,053 | ) | $ | (11,359 | ) | $ | (2,196 | ) | $ | (10,336 | ) | |
Net cash used in investing activities |
(17,756 | ) | (15,578 | ) | (401 | ) | (4,068 | ) | |||||
Net cash provided by financing activities |
18,327 | 70,161 | 385 | 28 | |||||||||
| | | | | | | | | | | | | |
Total |
$ | (5,482 | ) | $ | 43,224 | (2,212 | ) | $ | (14,376 | ) | |||
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Our principal sources of liquidity were cash and cash equivalents totaling $32.1 million as of March 31, 2015, which were held for working capital purposes. Our cash and cash equivalents are comprised of money market funds.
76
Since our inception, we have financed our operations primarily through private sales of equity securities and to a lesser extent, bank borrowings. We believe that our existing cash and cash equivalents will be sufficient to meet our working capital and capital expenditure needs for at least the next 12 months. Our future capital requirements will depend on many factors including our growth rate, contract renewal activity, number of visits, the timing and extent of spending to support product development efforts, our expansion of sales and marketing activities, the introduction of new and enhanced services offerings and the continuing market acceptance of telehealth. We may in the future enter into arrangements to acquire or invest in complementary businesses, services and technologies and intellectual property rights. We may be required to seek additional equity or debt financing. In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all. If we are unable to raise additional capital when desired, our business, financial condition and results of operations would be adversely affected. See "Risk FactorsRisks Related to Our BusinessOur quarterly results may fluctuate significantly, which could adversely impact the value of our common stock."
Cash Used in Operating Activities
For the year ended December 31, 2014, cash used in operating activities was $11.4 million. The negative cash flows resulted primarily from our net loss of $17.0 million, partially offset by depreciation and amortization of $2.3 million, allowance for doubtful debts of $1.3 million, deferred income taxes of $0.4 million and stock-based compensation of $0.5 million, as well as the effect of changes in working capital and other balance sheet accounts resulting in cash inflows of approximately $1.0 million, all of which was due to year-over-year growth.
For the year ended December 31, 2013, cash used in operating activities was $6.1 million. The cash used primarily related to our net loss of $6.0 million, partially offset by depreciation and amortization of $0.8 million, allowance for doubtful debts of $0.5 million, deferred income taxes of $0.1 million and stock-based compensation of $0.3 million and the effect of changes in working capital and other balance sheet accounts resulting in cash outflows of approximately $1.8 million, all of which was due to year-over-year growth.
For the three months ended March 31, 2015, cash used in operating activities was $2.2 million, as compared to $10.3 million for the three months ended March 31, 2015. The increase in cash used in operating activities of $8.1 million was primarily the result of additional headcount, increased marketing expenses, costs incurred to improve and optimize our technology platform, increases in our physician network operations and office-related charges to support the growth of our business.
Cash Used in Investing Activities
Cash used in investing activities of $15.6 million for the year ended December 31, 2014 principally due to our acquisition of AmeriDoc, which required cash payments of $13.6 million, and of purchases of property and equipment totaling $1.1 million and investments in internally developed capitalized software of $0.7 million.
Cash used in investing activities of $17.8 million for the year ended December 31, 2013 was principally due to our acquisition of Consult A Doctor, which required initial cash payments of $16.5 million, and of purchases of property and equipment totaling $0.2 million and investments in internally developed capitalized software of $1.1 million.
Cash used in investing activities was $0.4 million during the three months ended March 31, 2014, as compared to $4.1 million for the three months ended March 31, 2015. The increase in cash used in investing activities was primarily due to the acquisition of BetterHelp.
77
Cash Provided by Financing Activities
Our primary financing activities have consisted of private sales of preferred stock and bank and other borrowings.
Cash provided by financing activities for the year ended December 31, 2014 of $70.2 million was primarily due to $50.1 million in proceeds from the issuance of preferred stock and $0.7 million of proceeds from the exercise of employee stock options. During this period, we borrowed $19.7 million from a bank. We also repurchased $0.4 million of our preferred and common stock.
Cash provided by financing activities of $18.3 million for the year ended December 31, 2013 was primarily attributable to the issuance of preferred stock of $14.8 million and $0.6 million of proceeds from the exercise of employee stock options. During this period, we also borrowed $3.0 million from a bank and repurchased $0.1 million of preferred stock.
Cash provided by financing activities was $0.4 million during the three months ended March 31, 2014, as compared to $0.0 million during the three months ended March 31, 2015. The decrease in cash provided by financing activities of $0.4 million was primarily due to fewer options being exercised.
Indebtedness
In August 2013, we entered into a Loan and Security Agreement with Silicon Valley Bank, or SVB, that provided for a Term Loan facility in the amount of $7.0 million with an interest rate of prime rate plus 1%. The Term Loan facility is payable in 48 monthly installments commencing April 2015. Our maximum borrowings under this facility totaled $3.0 million in 2013. The Loan and Security Agreement also provided for a Revolving Advance facility that we did not utilize in 2013.
In May 2014, we entered into an Amended and Restated Loan and Security Agreement with SVB that provided for a Revolving Advance facility and a Term Loan facility, or the Amended Term Loan facility. The Revolving Advance facility provides for borrowings up to $12.0 million based on 300% of our monthly recurring revenue. Borrowings under the Revolving Advance facility were $4.7 million at December 31, 2014, and the facility carries interest at a rate of 0.75% above the prime rate per annum and matures in April 2016. Interest payments are payable monthly in arrears. We entered into an Amendment to the Revolving Advance Facility in March 2015 that extended its maturity to April 2017.
The Amended Term Loan facility provides for borrowings up to $5.0 million. As of December 31, 2014, the Company had utilized the total $5.0 million available under this facility. The Amended Term Loan facility carries interest at a rate of 1.00% above the prime rate per annum. Interest payments are payable monthly in arrears. Payments on the Amended Term Loan facility will commence in May 2015 and continue with 47 equal month payments of principal plus interest.
In May 2014, we entered into a Subordinated Loan and Security Agreement with SVB that provided for Mezzanine Term Loans totaling $13.0 million. The total $13.0 million drawdown of the mezzanine facility was completed in September 2014. The mezzanine facility carries interest at a rate of 10.00% per annum and matures in May 2017. Interest payments are payable monthly in arrears. In connection with entry into the mezzanine facility, we granted two affiliates of SVB warrants to purchase an aggregate of 300,000 shares of our common stock at an exercise price of $1.29 per share. The warrants are immediately exercisable and have a ten-year term. We also granted SVB a security interest in significantly all of our assets. The mezzanine facility has been used to fund the expansion of our business. We refer to the Amended Loan and Security Agreement together with the Subordinated Loan and Security Agreement as the SVB Facilities.
78
We incurred approximately $0.2 million of loan origination costs in connection with the SVB Facilities and amortized approximately $0.1 million of these costs during the year ended December 31, 2014.
Effective with the purchase of AmeriDoc, we executed a subordinated promissory note in the amount of $3.5 million payable to the seller of AmeriDoc on April 30, 2015. The subordinated promissory note carries interest at a rate of 10.00% annual interest and is subordinated to the SVB Facilities. In December 2014, we, the seller of AmeriDoc and SVB executed an amended and restated subordinated promissory note, or the AmeriDoc Promissory Note, that extended the maturity of the Note to April 30, 2017.
Effective with the purchase of BetterHelp, on January 23, 2015, we executed an unsecured, subordinated promissory note in the original principal amount of $1.0 million payable to the seller and an executive of BetterHelp, with all principal and interest, which bears at an annual rate of 5.00%, payable on the third anniversary of closing of the BetterHelp acquisition.
See Note 8 to our unaudited consolidated financial statements included elsewhere in this prospectus.
Contractual Obligations and Commitments
The following summarizes our contractual obligations as of December 31, 2014:
|
Payment Due by Period | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Total |
Less than
1 Year |
1 to 3
Years |
4 to 5
Years |
More than
5 Years |
|||||||||||
|
(in thousands)
|
|||||||||||||||
Operating leases |
$ | 2,467 | $ | 910 | $ | 1,557 | $ | | $ | | ||||||
Obligations under SVB Facilities and AmeriDoc Promissory Note |
26,200 | 833 | 24,950 | 417 | | |||||||||||
Interest associated with long-term debt |
4,791 | 2,041 | 2,747 | 3 | | |||||||||||
| | | | | | | | | | | | | | | | |
Total |
$ | 33,458 | $ | 3,784 | $ | 29,254 | $ | 420 | $ | | ||||||
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
Our existing office and hosting co-location facilities lease agreements provide us with the option to renew and generally provide for rental payments on a graduated basis. Our future operating lease obligations would change if we entered into additional operating lease agreements as we expand our operations and if we exercised the office and hosting co-location facilities lease options. The contractual commitment amounts in the table above are associated with agreements that are enforceable and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions and the approximate timing of the transaction. Obligations under contracts that we can cancel without a significant penalty are not included in the table above.
Off-Balance Sheet Arrangements
During the periods presented, we did not have, nor do we currently have, any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. We are therefore not exposed to the financing, liquidity, market or credit risk that could arise if we had engaged in those types of relationships.
79
Critical Accounting Policies and Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our audited consolidated financial statements and accompanying notes included elsewhere in this prospectus. We base our estimates on historical experience, current business factors and various other assumptions that we believe are necessary to consider to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses and the disclosure of contingent assets and liabilities. Our company is subject to uncertainties such as the impact of future events, economic and political factors and changes in our business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of our audited consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as our operating environment changes. Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to our audited consolidated financial statements. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the carrying value, capitalization and amortization of software development costs, the provision for income taxes and related deferred tax accounts, certain accrued liabilities, revenue recognition, contingencies, litigation and related legal accruals and the value attributed to employee stock options and other stock-based awards.
On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ from these estimates under different assumptions or conditions.
We believe that of our significant accounting policies, which are described in Note 2 to our audited consolidated financial statements included elsewhere in this prospectus, and specifically the following accounting policies involve a greater degree of judgment and complexity. Accordingly, these are the policies that we believe are the most critical to aid in fully understanding and evaluating our consolidated financial condition and results of operations.
Revenue Recognition
We offer two types of subscription access revenue contracts: (i) contracts that provide for a fixed monthly charge for access and unlimited visits per Member and (ii) contracts that provide for a fixed monthly charge for access and a contractually defined cost for each visit. Any visit fee revenue that is not included in the subscription access revenue is recognized when the service has been provided to the Member.
We recognize a substantial portion of our revenue from contracts that provide Clients with subscription access to our professional Provider network, on a subscription basis for a fixed monthly fee which entitles the Client's Members to unlimited consults, or visits. The contracts are generally for a one-year term and have an automatic renewal feature for additional years.
We commence revenue recognition for the subscription access service on the date that the services are made available to the Client and its Members, which is considered the implementation date, provided all of the following criteria are met:
80
Subscription Access Revenue
Subscription access revenue recognition commences on the date that our services are made available to the Client, which is considered the implementation date, provided all of the other criteria described above are met. Revenue is recognized over the term of the contract and is based on the terms in our Client contracts, which can provide for a variable periodic fee based upon the actual number of Members.
Revenue From Visit Fees
Revenue from visits is comprised of all revenue that is earned in connection with the completion of a visit. We recognize revenue as the visits are completed.
Our contracts do not generally contain refund provisions for fees earned related to services performed. However, certain of our contracts include performance guarantees that are based upon minimum employee or Member utilization and guarantees by us for specific service level performance of our services. When subscription access revenue is refundable, we defer revenue recognition until the end of the respective contractual period when the performance guarantees are met. We issued credits amounting to approximately $0.2 million and $0.4 million for the years ended December 31, 2013 and 2014, respectively, and $0.1 million and $0.04 million for the three months ended March 31, 2014 and 2015, respectively.
Cost of Revenue
Cost of revenue primarily consists of fees paid to the Providers, costs incurred in connection with our Provider network operations which include employee-related expenses (including salaries and benefits) and costs related to our contracted third-party call center and insurance, which includes coverage for medical malpractice claims.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective asset as follows:
Computer equipment | 3 years | |
Furniture and equipment | 5 years | |
Leasehold improvements | Shorter of the lease term or the estimated useful lives of the improvements |
Maintenance and repairs are charged to expense as incurred, and improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected in the consolidated statement of operations in the period realized.
Internal-Use Software
Internal-use software is included in intangible assets and is amortized on a straight-line basis over 3 years.
For our development costs related to our software development tools that enable our Members and Providers to interact, we capitalize costs incurred during the application development stage. Costs related to minor upgrades, minor enhancements and maintenance activities are expensed as incurred.
81
Goodwill and Other Intangible Assets
Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. Goodwill is not amortized, but is tested for impairment annually on October 1 or more frequently if events or changes in circumstances indicate that the asset may be impaired. Our impairment tests are based on a single operating segment and reporting unit structure. The goodwill impairment test involves a two-step process. The first step involves comparing the fair value of our reporting unit to its carrying value, including goodwill. The fair value of the reporting unit is estimated using a discounted cash flows analysis. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value.
Our annual goodwill impairment test resulted in no impairment charges in either of the years ended December 31, 2013 and 2014.
Other intangible assets resulted from business acquisitions and include Client relationships and non-compete agreements. Client relationships are amortized over a period of 2 to 10 years in relation to expected future cash flows, while non-compete agreements are amortized over a period of 3 to 5 years using the straight-line method, and trademarks are amortized over a period of 3 years using the straight-line method.
Income Taxes
We account for income taxes using the liability method, under which deferred tax assets and liabilities are determined based on the future tax consequences attributable to differences between the financial reporting carrying amounts of existing assets and liabilities and their respective tax bases and tax credit and net operating loss carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates that are expected to be in effect when the differences are expected to reverse.
We assess the likelihood that deferred tax assets will be recovered from future taxable income, and a valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized.
We recognize and measure uncertain tax positions using a two-step approach. The first step is to evaluate the tax position taken or expected to be taken by determining if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Significant judgment is required to evaluate uncertain tax positions. We evaluate our uncertain tax positions on a regular basis. Our evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of audit and effective settlement of audit issues.
Warranties and Indemnification
Our arrangements generally include certain provisions for indemnifying Clients against liabilities if there is a breach of a Client's data or if our service infringes a third party's intellectual property rights. To date, we have not incurred any material costs as a result of such indemnifications.
We have also agreed to indemnify our directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by
82
reason of the person's service as a director or officer, including any action by us, arising out of that person's services as our director or officer or that person's services provided to any other company or enterprise at our request. We maintain director and officer liability insurance coverage that would generally enable us to recover a portion of any future amounts paid. We may also be subject to indemnification obligations by law with respect to the actions of our employees under certain circumstances and in certain jurisdictions.
Concentrations of Risk and Significant Clients
Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits.
During the years ended December 31, 2013 and 2014 and the three months ended March 31, 2014 and 2015, all of our revenue was generated by Clients located in the United States. No Client represented over 10% of revenue for any of the years ended December 31, 2013 or 2014 or the three months ended March 31, 2014 or 2015.
One Client represented 22% of accounts receivable at December 31, 2013. As of December 31, 2014, March 31, 2014 and March 31, 2015, no Client accounted for more than 10% of accounts receivable.
Stock-Based Compensation
All stock-based awards are measured based on the grant-date fair value of the awards and are generally recognized in our consolidated statements of operations over the period during which the employee is required to perform services in exchange for the award (generally requiring a four-year vesting period for each award). We estimate the fair value of stock options granted using the Black-Scholes option-pricing model.
Given the absence of a public trading market, our board of directors considered numerous objective and subjective factors to determine the fair value of our common stock at each grant date. These factors included, but were not limited to, (i) contemporaneous valuations of common stock performed by unrelated third-party specialists; (ii) the prices for our preferred stock sold to outside investors; (iii) the rights, preferences and privileges of our preferred stock relative to our common stock; (iv) the lack of marketability of our common stock; (v) developments in the business; and (vi) the likelihood of achieving a liquidity event, such as an initial public offering or a merger or acquisition of our Company, given prevailing market conditions.
The assumptions used in the Black-Scholes option-pricing model were determined as follows:
83
The fair value of each employee stock option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions and fair value per share:
|
Year Ended
December 31, |
Three months Ended
March 31, |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
2013 | 2014 | 2014 | 2015 | |||||||||
Volatility |
51.0% - 53.4 | % | 53.3% - 53.7 | % | | 50.4% - 51.0 | % | ||||||
Expected life (in years) |
7.0 | 7.0 | | 7.0 | |||||||||
Risk-free interest rate |
1.15% - 2.21 | % | 1.92% - 2.30 | % | | 1.58% - 1.92 | % | ||||||
Dividend yield |
| | | | |||||||||
Weighted-average fair value of underlying common stock |
$0.47 | $2.42 | | $2.02 |
Total compensation costs charged as an expense for stock-based awards, including stock grants, recognized in the components of operating expenses in our consolidated statements of operations totaled $0.3 million and $0.5 million for the years ended December 31, 2013 and 2014, respectively and $0.2 million and $0.8 million for the three months ended March 31, 2014 and 2015, respectively.
As of March 31, 2015, we had $6.4 million in unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over a weighted-average period of approximately 3.6 years.
Stock Plan and Stock Options
Our Second Amended and Restated Stock Incentive Plan, or the Prior Plan, provides for the issuance of incentive and non-statutory options to our employees and non-employees. Options issued under the Prior Plan are exercisable for periods not to exceed ten years, vest over four years and are issued at the fair value of the shares of common stock on the date of grant as determined by our board of directors, which obtains periodic third-party valuations to assist their determination process.
The Prior Plan provides for the early exercise of stock options for certain individuals as determined by their respective option agreements.
84
Activity under the Prior Plan since January 2013 is as follows (in thousands, except share and per share amounts and years):
|
Shares
Available for Grant |
Number of
Shares Outstanding |
Weighted-Average
Exercise Price |
Weighted-Average
Remaining Contractual Life in Years |
Aggregate
Intrinsic Value |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Balance at January 1, 2013 |
757,724 | 4,908,722 | $ | 0.49 | 7.91 | $ | 1,425 | |||||||||
Increase in Prior Plan authorized shares |
2,512,662 | |||||||||||||||
Stock option grants |
(1,683,332 | ) | 1,683,332 | $ | 0.47 | |||||||||||
Stock options exercised |
| (1,686,073 | ) | $ | 0.35 | |||||||||||
Stock options cancelled |
| (71,145 | ) | $ | 0.44 | |||||||||||
| | | | | | | | | | | | | | | | |
Balance at December 31, 2013 |
1,587,054 | 4,834,836 | $ | 0.50 | 8.28 | $ | 4,058 | |||||||||
Increase in Prior Plan authorized shares |
3,707,262 | |||||||||||||||
Stock option grants |
(3,598,245 | ) | 3,598,245 | $ | 2.42 | |||||||||||
Stock options exercised |
| (1,796,887 | ) | $ | 0.42 | |||||||||||
Stock options cancelled |
| (63,989 | ) | $ | 0.70 | |||||||||||
| | | | | | | | | | | | | | | | |
Balance at December 31, 2014 |
1,696,071 | 6,572,205 | $ | 1.63 | 8.38 | $ | 6,758 | |||||||||
Stock option grants |
(1,438,952 | ) | 1,438,952 | $ | 3.81 | |||||||||||
Stock options exercised |
(50,669 | ) | $ | 0.56 | ||||||||||||
Stock options cancelled |
179,619 | (179,619 | ) | $ | 2.33 | |||||||||||
Stock options expired |
76,797 | (76,797 | ) | $ | 3.79 | |||||||||||
| | | | | | | | | | | | | | | | |
Balance at March 31, 2015 |
513,535 | 7,704,072 | $ | 1.97 | 8.89 | $ | 17,156 | |||||||||
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
Vested or expected to vest March 31, 2015 |
6,967,961 | $ | 1.92 | 8.83 | $ | 15,898 | ||||||||||
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
Exercisable as of March 31, 2015 |
1,439,374 | $ | 0.65 | 7.20 | $ | 5,105 | ||||||||||
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
The total grant-date fair value of stock options granted during the three months ended March 31, 2014 and 2015 was $0 million and $2.9 million, respectively. The total grant-date fair value of stock options vested during the three months ended March 31, 2014 and 2015 was $0.1 million and $0.3 million, respectively. The total intrinsic value of the options exercised during the three months ended March 31, 2014 and 2015, was $0.2 million and $0.1 million, respectively. The intrinsic value is the difference of the current fair value of the stock and the exercise price of the stock option.
85
Since January 2013 to the date immediately preceding the date of this prospectus, we have granted options to purchase shares of common stock as follows:
Grant
Date |
Options
Granted |
Exercise
Price |
Fair Value
Per Share |
Fair Value
per Option |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
April 2013 |
411,358 | $ | 0.73 | $ | 0.73 | $ | 0.39 | ||||||
December 2013 |
1,040,244 | 0.73 | 0.73 | 0.48 | |||||||||
April 2014 |
244,000 | 1.29 | 1.29 | 0.72 | |||||||||
August 2014 |
315,000 | 1.29 | 1.29 | 0.72 | |||||||||
September 2014 |
989,000 | 2.63 | 2.63 | 1.47 | |||||||||
December 2014 |
2,050,245 | 2.63 | 2.63 | 1.45 | |||||||||
February 2015 |
1,001,500 | 3.81 | 3.81 | 2.02 | |||||||||
March 2015 |
423,989 | 3.81 | 3.81 | 2.02 | |||||||||
March 2015 |
13,463 | 4.20 | 4.20 | 2.20 |
The aggregate intrinsic value of vested and unvested stock options as of March 31, 2015 was $17.2 million, based on a price of $1.97 per share, the estimated value of common stock based on the respective valuation report as of March 31, 2015.
The following discussion relates primarily to our determination of the fair value per share of our common stock for purposes of calculating stock-based compensation costs. A combination of the factors described below in each period led to the changes in the fair value of our common stock. Notwithstanding the fair value reassessments described below, we believe we applied a reasonable valuation method to determine the stock option exercise prices on the respective stock option grant dates.
December 31, 2012 Valuation
We determined the fair market value of our common stock to be $0.73 per share as of December 31, 2012. Our estimated fair market valuation applied 100% weighting to the Probability Weighted Expected Returns Method an Equity Allocation Method, which considered the present value of the future expected returns for the common shareholders. To arrive at the concluded value of $0.73 per share, we applied a discount for lack of marketability of 30% and a discount for lack of control of 23% to the fair market value of a single common share as of December 31, 2012. We applied a 0% weighting to Current Value Methods, specifically the Guideline Public Company Method and the Industry Transactions Method.
December 31, 2013 Valuation
We determined the fair market value of our common stock to be $1.29 per share as of December 31, 2013. Our estimated fair market valuation applied 100% weighting to the Probability Weighted Expected Returns Method an Equity Allocation Method, which considered the present value of the future expected returns for the common shareholders. To arrive at the concluded value of $1.29 per share, we applied a discount for lack of marketability of 25% and a discount for lack of control of 23% to the fair market value of a single common share as of December 31, 2013. We applied a 0% weighting to Current Value Methods, specifically the Discounted Cash Flow Method, the Guideline Public Company, the Industry Transactions Method and the Backsolve Method.
October 1, 2014 Valuation
We determined the fair market value of our common stock to be $2.63 per share as of October 1, 2014. Our estimated fair market valuation applied 100% weighting to the Probability Weighted Expected Returns Method an Equity Allocation Method, which considered the present value of the future expected returns for the common shareholders. To arrive at the concluded value
86
of $2.63 per share, we applied a discount for lack of marketability of 20% to the fair market value of a single common share as of October 1, 2014. Since our valuation inputs utilized were on a minority basis, no discount for lack of control was applied. We applied a 0% weighting to Current Value Methods, specifically the Discounted Cash Flow Method, the Guideline Public Company, the Industry Transactions Method and the Backsolve Method.
December 31, 2014 Valuation
We determined the fair market value of our common stock to be $3.81 per share as of December 31, 2014. Our estimated fair market valuation applied 100% weighting to the Probability Weighted Expected Returns Method an Equity Allocation Method, which considered the present value of the future expected returns for the common shareholders. To arrive at the concluded value of $3.81 per share, we applied a discount for lack of marketability of 20% to the fair market value of a single common share as of December 31, 2014. Since our valuation inputs utilized were on a minority basis, no discount for lack of control was applied. We applied a 0% weighting to Current Value Methods, specifically the Discounted Cash Flow Method, the Guideline Public Company, and the Industry Transactions Method.
March 31, 2015 Valuation
We determined the fair market value of our common stock to be $4.20 per share as of March 31, 2015. Our estimated fair market valuation applied 100% weighting to the Probability Weighted Expected Returns Method an Equity Allocation Method, which considered the present value of the future expected returns for the common shareholders. To arrive at the concluded value of $4.20 per share, we applied a discount for lack of marketability of 10% to the fair market value of a single common share as of March 31, 2015. Since our valuation inputs utilized were on a minority basis, no discount for lack of control was applied. We applied a 0% weighting to Current Value Methods, specifically the Discounted Cash Flow Method, the Guideline Public Company, and the Industry Transactions Method.
We expect to recognize total compensation expense of approximately $6.4 million for unvested stock options as of March 31, 2015, which is expected to be recognized during the four years ended March 31, 2019.
JOBS Act Accounting Election
In April 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period, and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.
Quantitative and Qualitative Disclosures about Market Risk
Interest Rate Sensitivity
We had cash and cash equivalents totaling $3.2 million, $46.4 million, $1.0 million and $32.1 million as of December 31, 2013 and 2014 and March 31, 2014 and 2015, respectively. This amount was invested primarily in money market funds. The cash and cash equivalents are held for working capital purposes. Our investments are made for capital preservation purposes. We do not enter into investments for trading or speculative purposes. All our investments are denominated in U.S. dollars.
87
Our cash equivalents are subject to market risk due to changes in interest rates. Fixed rate securities may have their market value adversely affected due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fall short of expectation due to changes in interest rates or we may suffer losses in principal if we are forced to sell securities that decline in market value due to changes in interest rates.
We do not believe that an increase or decrease in interest rates of 100-basis points would have a material effect on our business, financial condition or results of operations. Fluctuations in the value of our money market funds caused by a change in interest rates (gains or losses on the carrying value) are recorded in other income and are realized only if we sell the underlying securities.
Recently Issued and Adopted Accounting Pronouncements
In July 2013, the Financial Accounting Standards Board, or FASB, issued guidance regarding the presentation of unrecognized tax benefits when a net operating loss carryforward, similar tax loss, or tax credit carryforward exists. The new guidance requires that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, be presented in the audited consolidated financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward when settlement in this manner is available under the tax law. This guidance is effective on a prospective basis for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2013. Retrospective and early adoption is permitted. We adopted this guidance in our first quarter of 2014. The adoption of this guidance had no impact on our financial disclosures and results.
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) . This revenue recognition guidance supersedes existing U.S. GAAP guidance, including most industry-specific guidance. The core principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance identifies steps to apply in achieving this principle. This updated guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. We are currently evaluating the potential impact of this guidance on our financial disclosures and results, including whether we elect retrospective, or modified retrospective, adoption methods.
In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period , requiring that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. The amendments in this guidance are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. We are currently evaluating the potential impact of this guidance on our financial disclosures and results.
In August 2014, the FASB issued ASU 2014-15, Presentation of Financial StatementsGoing Concern . This guidance addresses management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. Management's evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. ASU 2014-15 is effective for interim or annual periods beginning after December 15, 2016. Early adoption is permitted. We do not expect to early adopt this guidance and are currently evaluating the impact of the adoption of this guidance on our financial disclosures and results.
In April 2015, the FASB issued ASU 2015-03, InterestImputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs , which requires that debt issuance costs related
88
to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The revised guidance is effective beginning in the quarter ending March 31, 2016 and is required to be applied retrospectively. Early adoption is permitted. We are currently evaluating the potential impact of this guidance on our financial disclosures and results.
In April 2015, the FASB issued ASU 2015-05, IntangiblesGoodwill and OtherInternal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement , which provides guidance in determining whether a cloud computing arrangement includes a software license. If it is determined that a cloud computing arrangement does include a software license, the software element should be accounted for consistent with the acquisition of other software licenses. If the arrangement does not include a software license, it should be accounted for as a service contract. The revised guidance is effective beginning in the quarter ending March 31, 2016 and can be applied prospectively to all arrangements entered into or materially modified after the effective date or retrospectively. Early adoption is permitted. We are currently evaluating the potential impact of this guidance on our financial disclosures and results.
89
Overview
We are the nation's first and largest telehealth platform, delivering on-demand healthcare anytime, anywhere, via mobile devices, the internet, video and phone. Our solution connects our Members, with our over 1,100 board-certified physicians and behavioral health professionals who treat a wide range of conditions and cases from acute diagnoses such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation. Nearly 11 million unique Members now benefit from access to Teladoc 24 hours a day, seven days a week, 365 days a year, at a cost of $40 per visit. Our solution is delivered with a median response time of less than ten minutes from the time a Member requests a telehealth visit to the time they speak with a Teladoc physician. We completed approximately 300,000 telehealth visits in 2014.
The Teladoc solution is transforming the access, cost and quality dynamics of healthcare delivery for all of our market participants. Our Members rely on Teladoc to remotely access affordable, on-demand healthcare whenever and wherever they choose. Our Clients purchase our solution to reduce their healthcare spending while at the same time offering convenient, affordable, high-quality healthcare to their employees or beneficiaries. Our Providers have the ability to generate meaningful income and deliver their services more efficiently with no administrative burden. We believe the value proposition of our solution is evidenced by our overall Member satisfaction rate, which has exceeded 95% over the last six years, and a 104% annual net dollar retention rate among our Clients on average over the last three years. We further believe any consumer, employer or health plan or healthcare professional interested in a better approach to healthcare is a potential Teladoc Member, Client or Provider.
According to the CDC, there are approximately 1.25 billion ambulatory care visits in the United States per year, including those at primary care offices, hospital emergency rooms, outpatient clinics and other settings. We estimate that approximately 417 million, or 33%, of these visits could be treated through telehealth. We believe that the total addressable market for telehealth in the United States consists of the ambulatory care telehealth opportunity, a subset of visits currently delivered in urgent and retail care settings and care foregone by those currently not accessing the healthcare delivery system.
The U.S. healthcare system is experiencing a growing crisis of access, cost and quality of care due to inefficiencies in today's healthcare system and barriers between participants. According to the NACHC, approximately 62 million individuals in the United States currently have no or inadequate access to primary care as a result of physician shortages. Additionally, according to the Department of Health and Human Services, the PPACA has already expanded coverage to 16.4 million of the 47 million previously uninsured Americans. This number is widely expected to increase over the next several years due to individual and employer mandates, premium subsidies, state health insurance exchanges and ban on withholding coverage due to pre-existing medical conditions, increasing demand for access to primary care physicians. Absent convenient access to a primary care physician, individuals will most likely either not seek care at all or visit emergency rooms or urgent care clinics, the most expensive and often inefficient settings for their primary care needs. These market dynamics impact not only the consumers seeking care, but also the health plans and employers that ultimately bear all or a portion of these costs. According to the CDC, 79.7% of emergency room visits not resulting in a hospital admission were due to lack of access to an alternative provider, and a recent study published in The Journal of American Medical Association estimated that approximately $734 billion, or 27%, of all healthcare spending in 2011 was wasted due to factors such as the provision of unnecessary services, inefficient delivery of care and inflated prices. In particular, according to Truven Analytics, 71% of emergency room visits by
90
patients with employer-sponsored insurance coverage are for causes that do not require immediate attention in the emergency room, or are preventable with proper outpatient care.
Innovators in other industries have solved access, cost and quality inefficiencies through the implementation of technology platforms and business models that deliver products and services on-demand and create new economies by connecting and empowering both consumers and businesses. We have taken the same approach to solving the pervasive access, cost and quality challenges facing the current healthcare system. Consumers' ability to access high-quality, affordable care has been limited by many factors such as physician availability, prohibitive costs, physician office hours and geographic locations. Likewise, burdensome administration, cancellations, unfilled appointment slots, geographic constraints and business hour limitations have historically impacted physician efficiency and, as a result, constrained physicians' income. We have created a platform that is uniquely positioned to bridge the supply and demand gap between physicians and consumers by fundamentally changing the way market participants access and deliver healthcareeliminating traditional barriers and inefficiencies between participants and empowering them to engage in a healthcare marketplace anytime, anywhere. Our platform provides our Members with access to board-certified physicians, comprehensive clinical programs and consumer engagement strategies in an economic model that delivers multiple benefits to all participants. The unique combination of these features enables us to dynamically and efficiently match consumer demand and physician availability in real-time.
Our underlying technology platform is complex, deeply integrated and purpose-built over the last ten years for the evolving healthcare marketplace. Our platform is highly scalable and can support substantial growth in our current membership base. Our platform provides for broad interconnectivity between healthcare constituents and, we believe, uniquely positions us as a focal point in the rapidly evolving healthcare industry to introduce innovative, technology-based solutions, such as remote patient monitoring, post-discharge treatment plan adherence and in-home and chronic care.
Our solution offers our Clients substantial savings opportunities and an attractive ROI. We recently commissioned Veracity Healthcare Analytics, an independent healthcare analytics company, to perform an independent study of the nation's largest home-improvement retailer, a Client since 2012, representing over 150,000 of our Members as of December 31, 2014. The study was prepared on behalf of Veracity Healthcare Analytics by two doctors of medicine and a doctor of science and pharmacy, in each case, professors at leading academic institutions. The study found that this Client saved $1,157 on average per employee when its employees received care through Teladoc instead of receiving care in other settings for the same diagnosis. The study also measured the total healthcare expenditure per-Member-per-month during the 16-month period immediately preceding the implementation of Teladoc in order to establish a trend and predict the Client's average monthly expenditure per-Member-per-month over the 20-month period following the introduction of Teladoc. The study demonstrated a meaningful reduction in average per-Member-per-month spending of $21.30 to the Client relative to predicted cost, or a monthly healthcare expenditure savings of 10.2% per Member. Additionally, during 2014 the Client achieved an ROI of approximately $9.00 for every $1.00 spent per Member. Finally, the study demonstrated that 92% of the Client's employees that used Teladoc for a medical issue resolved their issue completely and did not require a follow up visit at a physician's office, emergency room or other location. We believe these results are representative of the results achieved by our other Clients as well as the value proposition we can provide the broader U.S. healthcare system.
We currently serve over 4,000 employers, health plans, health systems and other entities. These Clients collectively purchase access to our solution for our nearly 11 million Members. We believe our B2B2C distribution strategy is the most efficient method by which to reach consumers and deliver telehealth to our Members. We have over 20 health plans as Clients, including some of
91
the largest in the United States such as Aetna, Blue Shield of California, Highmark and Centene. Health plans serve as Clients as well as distribution channels to self-insured employer Clients that contract with us through a health plan relationship. Our over 1,600 direct and ASO employer Clients include 160 Fortune 1000 companies and industry leaders such as Accenture, Bank of America, Pepsi and Shell. We also have a number of health system clients such as Henry Ford, Memorial Hermann and Mount Sinai. The remainder of our Clients are from channel partners such as brokers, resellers and consultants who sell into a range of small, medium and large enterprises. Over the past two years, we have more than doubled our client and membership bases. We believe telehealth is in the early stages of what eventually will become widespread adoption. A 2014 Towers Watson study suggests as many as 71% of employers with more than 1,000 employees are expected to offer telehealth by 2017.
We generate revenue from our Clients on a contractually recurring, per-Member-per-month, subscription access fee basis, which provides us with significant revenue visibility. In addition, under the majority of our Client contracts, we generate additional revenue on a per-telehealth visit basis, through a visit fee. Subscription access fees are paid by our Clients on behalf of their employees, dependents and other beneficiaries, while visit fees are paid by either Clients or Members. We generated $19.9 million and $43.5 million in revenue in 2013 and 2014, respectively, representing 119% year-over-year growth, and $9.4 million and $16.5 million for the three months ended March 31, 2014 and 2015, respectively, representing 75% year-over-year growth. For the three months ended March 31, 2015, 80% and 20% of our revenue were derived from subscription access fees and visit fees, respectively. For the year ended December 31, 2014, 85% and 15% of our revenue were derived from subscription access fees and visit fees, respectively.
Industry Challenges and Our Opportunity
Barriers and inefficiencies in the current U.S. healthcare system present market participants with three major challenges: (i) consumers lack sufficient access to high-quality, cost-effective healthcare at appropriate sites of care, while bearing an increasing share of costs; (ii) employers and health plans lack an effective solution that reduces costs while enhancing healthcare access for beneficiaries and (iii) providers lack flexibility to increase productivity by delivering care on their own terms. Market participants are therefore increasingly unable to effectively and efficiently receive, deliver or administer healthcare. At the same time, the emergence of technology platforms solving massive structural challenges in other industries has highlighted the need for a similar solution in healthcare. We believe there is a significant opportunity to solve these challenges through a trusted solution, such as ours, that matches consumer demand and physician supply in real-time, while offering health plans and employers an attractive, cost-effective healthcare alternative for their beneficiaries.
Growing Healthcare Access Crisis for Consumers
Consumers in the United States are experiencing challenges in obtaining access to affordable, high-quality healthcare at appropriate sites of care. A 2014 NACHC report found that 62 million individuals in the United States have no or inadequate access to primary care as a result of local physician shortages. According to a 2014 Merritt Hawkins study, the average lead time to see a primary care physician across various metro areas was 19 days. We believe provider supply is projected to further contract, evidenced by the 2014 Survey of America's Physicians, where 81% of physicians describe themselves as either over-extended or at full capacity. Additionally, according to a 2010 AAMC report, the healthcare system will have a shortage of approximately 131,000 physicians by 2025, including a shortage of approximately 52,000 primary care physicians. Given expected population growth and aging in the United States, as well as the projected increase in healthcare demand from PPACA implementation, the supply and demand gap for access to
92
healthcare services is expected to further widen, placing additional pressure on an already overburdened healthcare system that lacks physician capacity and diagnoses-appropriate access points.
This access crisis has resulted in U.S. consumers either seeking care at inappropriate, more costly settings such as hospital emergency rooms, or foregoing needed care entirely. According to the CDC, there are approximately 1.25 billion ambulatory care visits in the United States per year, including those at primary care offices, hospital emergency rooms, outpatient clinics and other settings. We estimate that approximately 417 million, or 33%, of these visits could be treated through telehealth.
Healthcare Cost Burden and Lack of Viable Options for Health Plans and Employers
The U.S. healthcare system is burdened by significant waste and extreme variations in access, cost and quality of care. A recent study published in The Journal of American Medical Association estimates that approximately $734 billion, or 27%, of all healthcare spending in 2011 was wasted due to factors such as the provision of unnecessary services, inefficient delivery of care and inflated prices. When consumers are forced to seek care at inappropriate and more costly sites of care, those cost inefficiencies impact not only the consumer, but also the health plans and employers that ultimately bear all or a portion of these costs.
The costs and associated burdens on health plans, employers and consumers are only expected to increase. CMS forecasted U.S. national health expenditures to reach $3.1 trillion, or approximately 18% of the U.S. GDP in 2014, and approximately 20% of GDP by 2022. A 2013 survey by the National Business Group on Health and Towers Watson indicated that employers bear on average approximately two-thirds of their employee's healthcare costs and CMS forecasted U.S. employers to spend approximately $660 billion on healthcare in 2015. Despite the significant amount of dollars spent, U.S. healthcare outcomes remain inferior relative to those of many other countries.
The unsustainable levels of spending on healthcare and extreme inefficiencies in the system have driven an increased focus by employers and health plans to control healthcare expenditures. Governments, private insurance companies and self-insured employers, are implementing meaningful cost containment measures, including shifting financial responsibility to patients through higher co-pays and deductibles and delivering healthcare through alternative, more cost-effective methods. The increasing shift of financial responsibility to patients coupled with increased pricing transparency has, in turn, heightened beneficiary focus on healthcare alternatives. According to a 2013 survey for Prudential Insurance by MRops, Inc. and Oxygen Research Inc., 49% of employers are extremely or very likely to eventually offer only HDHPs. As consumers take responsibility for a larger share of their healthcare costs and spend more on healthcare services, they are also demanding higher quality care, greater control in how and where they receive care, increased convenience and more service for every dollar spent.
Challenging Environment for Physicians is Constraining Supply
Physicians face declining compensation paired with diminishing productivity due to a combination of reimbursement cuts and an increasing administrative burden. These factors have contributed to physician dissatisfaction and negatively impacted their desire to practice medicine. Medscape's 2014 Physician Compensation Report shows that 50% of all physicians do not feel fairly compensated and 42% would not choose medicine as their career today.
In response to this growing dissatisfaction, physicians are reducing access to healthcare in a number of different ways. The 2014 Survey of America's Physicians indicated that 44% of physicians plan to take steps to limit access to their practices, including cutting back on the
93
number of patients seen, working part-time, closing their practices to new members, seeking non-clinical jobs or retiring. Notably, 39% of surveyed physicians indicated they plan to accelerate retirement given changes in the healthcare environment. Further, administrative challenges are expected to increase. According to the same survey, 50% of physicians anticipate the implementation of the tenth revision of the ICD-10 to cause severe administrative problems in their practices. This is expected to further increase the 20% of daily time surveyed physicians indicated they already spend on non-clinical paperwork, which is constraining their productivity. A study by Physicians for a National Health Program showed medical billing paperwork and insurance-related red tape cost the United States economy approximately $471 billion in 2012, 80% of which was wasted due to inefficiency. These constraints have driven physicians to seek more control over the way they deliver care to new and existing patients, increase their income and reduce the amount of time they spend on administration.
Physicians have responded to these challenges by shifting payment models and patient mix. Medscape's 2014 Physician Compensation Report showed a 100% increase from 2011 to 2013 in the percent of physicians transitioning to cash-only models, no longer accepting insurance. A 2014 Merritt Hawkins study found that 54.3% of physicians in the United States' 15 largest cities are not accepting new Medicaid patients. We believe there is a significant opportunity for a single source solution that addresses these physician needs.
Opportunity to Remove Barriers Through an Innovative Platform that Benefits All Participants
We believe we have a significant opportunity to solve access, cost and quality of care challenges through a platform that matches consumer demand and physician availability in real-time, while offering health plans and employers an attractive, cost-effective alternative for their beneficiaries through our platform. As consumerism in healthcare increases and consumers and providers become accustomed to on-demand services in other industries, they are similarly demanding technology-powered solutions for their healthcare needs. The emergence and subsequent rapid adoption of technologies such as big data and analytics, cloud-based solutions, online video and mobile applications represents an enormous opportunity for healthcare innovation. We believe the confluence of consumer empowerment, emergence of broad technology solutions and focus by all constituents on providing high-quality, cost-effective healthcare creates a unique opportunity for a disruptive platform that transforms the way consumers access, providers deliver and employers and health plans administer high-quality, cost-efficient healthcare.
Our Competitive Strengths
We believe the following are our key competitive strengths.
Leading Solution and First-Mover Advantage
Our solution is composed of an integrated technology platform, high-quality Provider network, sophisticated consumer engagement strategies and entrenched distribution channels. We have developed a strong brand, established strong relationships with Clients and have become a leading telehealth platform in the United States. Our history of innovation and long-standing operating history provide us with a significant first-mover advantage, including what we believe are the following telehealth industry firsts:
94
95
The following graphic outlines the simple, convenient and intuitive Teladoc Member experience supported by our integrated, scalable and responsive solution:
Innovative Technology Platform
Our integrated solution positions us at the center of the patient, provider and payor relationship and as a key participant in the rapidly emerging, technology-powered healthcare industry. We continually incorporate new product features into our platform to meet the evolving needs of the highly complex healthcare industry. We believe our technology platform contains several differentiating features, including the following.
96
community that enables us to uniquely provide real-time eligibility checking, real-time Member financial liability calculations and clinical data exchange.
Significant and Measureable Return on Investment
Our solution offers our Clients substantial savings opportunities and an attractive ROI. We recently commissioned an independent study of the nation's largest home-improvement retailer, a Client since 2012, representing over 150,000 of our Members as of December 31, 2014. The study found that this Client saved $1,157 on average per employee when its employees received care through Teladoc instead of receiving care in other settings for the same diagnosis. The study also measured the total healthcare expenditure per-Member-per-month during the 16-month period immediately preceding the implementation of Teladoc in order to establish a trend and predict the Client's average monthly expenditure per-Member-per-month over the 20-month period following the introduction of Teladoc. The study demonstrated a meaningful reduction in average per-Member-per-month spending of $21.30 to the Client relative to predicted cost, or a monthly healthcare expenditure savings of 10.2% per Member. Additionally, during 2014 the Client achieved an ROI of approximately $9.00 for every $1.00 spent per Member. Finally, the study demonstrated that 92% of the Client's employees that used Teladoc for a medical issue resolved their issue completely and did not require a follow up visit at a physician's office, emergency room or other location. We believe these results are representative of the results achieved by our other Clients as well as the value proposition we can provide the broader U.S. healthcare system.
Highly Scalable Platform
Our platform is highly scalable and can currently provide the same level of Member support and response time for upwards of 10,000 visits per day versus our current rate of approximately 1,500 visits per day on average. Similarly, our platform is currently equipped to serve over 100 million Members and can be scaled quickly to serve even higher volumes. Further, our platform has been built to accommodate the seamless and quick introduction of new services and products, such as behavioral health, dermatology and other services that are currently in the development stages. We have the ability to respond quickly to evolving market needs with innovative solutions, such as broadened health kiosk access, mobile applications, biometric devices and at-home testing, to enhance our solution and support our leadership position. We believe our highly scalable platform provides us with significant growth opportunities within our existing membership and client bases and allows us to grow with low capital expenditure requirements.
Clinical Capabilities Tailored to Telehealth
We believe that by directly recruiting, credentialing, training and contracting with our Providers we have built our clinical capabilities in a manner that supports the operational complexity of and commitment to clinical quality required in telehealth. Our Providers are board-certified with an average of 20 years of experience and are credentialed through an NCQA-certified process. The NCQA's accreditation process involves a comprehensive on-site and off-site review by a team of physicians and managed care experts that evaluates more than 60 quality-related healthcare
97
standards, including quality management and improvement and utilization management. The results of the evaluation are reviewed by the NCQA's National Review Oversight Committee prior to their assigning an accreditation level. The NCQA's requirements are developed with the input and support of health plans, providers, purchasers, unions and consumer groups. The NCQA's accreditation process is not telehealth specific; rather, since its formation in 1990, the NCQA established, and consistently updates, its quality standards and performance measures for a broad range of healthcare entities by building consensus around important health care quality issues. In determining its quality standards and performance measures, the NCQA works with large employers, policymakers, doctors, patients and health plans to determine areas of focus and how to promote improvement within them. Health plans in every state, the District of Columbia and Puerto Rico are NCQA accredited. According to the NCQA, these certified plans cover 109 million Americans or 70.5% of all Americans enrolled in health plans.
Our clinical capabilities are designed specifically for telehealth. For example, our Members have the option to share a record of every visit and their EMR with their existing physicians. In circumstances where a Member reports that they do not have a primary care physician, the Teladoc Provider educates the Member on the importance of establishing this relationship. Prior to every visit, the Provider reviews the Member's proprietary EMR and certifies to this review by completing a multi-step checklist. During and following the visit, the Provider references our over 100 proprietary Evidence Based clinical guidelines and other telehealth-specific content. In addition, Members and Providers remain connected following visits. Members receive personalized notes, patient education materials and are able to ask questions of our clinical team via the Teladoc Message Center. Over 10% of all visits are reviewed by our clinical quality assurance staff to ensure adherence to appropriate treatment and prescription patterns. We believe our track record of zero medical malpractice claims is a testament to our Providers' clinical quality.
Well-Established Distribution Channels and Strategic Alliances
We have spent over ten years developing sales channels and strategic alliances, which we believe provide an opportunity to sell our solution through trusted partners and are not easily replicated. Our solution is sold through a highly efficient and effective B2B2C distribution network wherein we reach consumers through our Clients and channel partners rather than marketing our solution directly to potential Members. We sell through a direct sales force to our Clients who in turn buy our solution on behalf of their beneficiaries. In addition, a range of third-parties including brokers, agents, benefits consultants and resellers, whom we refer to as channel partners, sell our solution to various end markets. Notably, many of our health plan Clients also act as channel partners because they resell our solution to their ASO accounts and other customers. We believe the breadth of our distribution strategy allows us to reach employers of nearly every size and in nearly every market, which are capable of purchasing our solution for a large number of beneficiaries, rather than attempting to sell our solution one consumer at a time.
Our Growth Strategies
The following are our key growth strategies.
Expand Our Membership with New and Existing Clients
We intend to increase our membership by adding additional Members from both existing Clients and from new Clients. We plan to execute this strategy by further penetrating existing relationships and by pursuing new relationships through our distribution channels and an expanded sales team. Within existing accounts, we believe our current membership represents only a fraction of the potential Members available to us. Our existing health plan Clients and self-insured Clients associated with these health plans currently purchase our solution for only 9% of their beneficiaries
98
in the aggregate, which provides us the opportunity to grow our membership base by more than 50 million individuals within these existing Clients alone. Similarly, we have 160 Fortune 1000 Clients, representing a significant opportunity for new Client growth with large employers. We are investing heavily in new marketing technologies and support staff to aid our sales force in penetrating existing accounts, lead generation, new Client generation and implementations. We further believe that as market leader in the telehealth industry, we have a strong, established brand and are uniquely positioned to capitalize on the B2C channel in the future.
Expand into New Clinical Specialties
We currently offer our Clients access to over 1,100 board-certified physicians who treat a wide range of conditions and cases from acute diagnoses such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions. We also currently offer direct-to-Member access to behavioral health professionals who treat conditions such as anxiety and smoking cessation. We intend to leverage our highly scalable platform by expanding into new clinical specialties, such as standalone dermatology services, second opinions and chronic conditions such as diabetes, and by focusing on expanding our services amongst current Clients such as by offering behavioral health as a commercial service to our Clients. As we expand our clinical offerings, we intend to further eliminate gaps in continuity of care in order to provide coordinated care along the healthcare delivery continuum. For example, we continue to expand our behavioral health product offering. According to the 2012 white paper from the U.S. Department of Health and Human Services, approximately 46 million adults in the U.S. suffer from mental illness with more than 11 million adults reporting an unmet need for mental healthcare. Compounding this unmet need, the shortage of psychiatrists and behavioral health resources has become acute nationwide. According to a 2014 Merritt Hawkins report, psychiatrists are essentially aging out of the workforce, with over 70% of psychiatrists 50 years of age or older. Furthermore, industry surveys indicate that turnover amongst mental health professionals is significantly higher than that of primary care physicians and in the future, the growing demand for psychiatric services is expected to be addressed by primary care physicians.
Leverage Existing Sales Channels and Penetrate New Markets
We have developed a highly effective distribution network to target large employers and we are committing incremental sales and marketing resources to the SMB sales channel to increase our penetration within this market. Additionally, we intend to further penetrate the provider market, notably hospitals and group physician practices, as we believe our solution offers these markets an attractive platform from which to generate substantial income by acquiring new patients and to better participate in emerging risk-sharing and value-based payment models, such as Accountable Care Organizations and Patient-Centered Medical Homes. Lastly, with expanded access to available health insurance as a result of PPACA implementation, we intend to pursue health insurance exchanges, which represent an attractive new sales channel.
Expand Across Care Settings and Use Cases
We intend to expand our solution across use cases and additional care settings. We also continually explore ancillary opportunities to broaden our business, including by expanding our relationship with Medicare Advantage and Medicaid Managed Care plans. We believe our services have wide applicability across new use cases, including home care, post discharge, wellness/screening and chronic care. We are also currently extending the number, range and functionality of our benefits applications, and will continue to respond quickly to evolving market needs with innovative solutions, including broadened health kiosk access, mobile applications, biometric devices and at-home testing.
99
Increase Engagement by Our Members
We believe there is significant opportunity within our existing membership base to increase engagement by continually increasing awareness of and loyalty to our solution. We believe our solution can become the single source for on-demand healthcare for our Members by continuing to add new and complementary products and services, third-party connections and other strategic alliances. We will continually refine and enhance our user experience, which is a critical driver of new and repeat engagement and we will continue validating our Member satisfaction with surveys and other proactive tools. For example, Members who download our mobile application are shown to be three times more likely to use our solution. We are in the process of redesigning our mobile application and website to further drive Member engagement. Further, we believe our current initiative to bring the remainder of our customer service function in-house will drive stronger relationships with our Members. We are also building robust data repositories to strengthen our predictive models and multi-channel marketing strategies to provide a more complete picture of our Members, enhancing our ability to lead targeted and purposeful campaigns and we will continue to invest heavily in marketing technologies that allow us to increase Member touch-points. Lastly, we will continue to actively engage Clients in benefit design, worksite marketing and executive sponsorship strategies to drive awareness about our solution.
Expand Through Focused Acquisitions
We plan to continue to leverage our know-how and the scale of our platform to selectively pursue acquisitions. To date, we have completed three acquisitions that have expanded our distribution capabilities and broadened our service offering, including into areas such as behavioral health. Our acquisition strategy is centered on acquiring technologies, products, capabilities, clinical specialties and distribution channels that are highly scalable and rapidly growing. We will continue to evaluate and pursue acquisition opportunities that are complementary to our business.
Technology and Operations
Our integrated platform supports rapid and efficient access to, and evaluation of, information from a variety of healthcare network participants. It has a user-friendly interface designed to empower Members and dependents to remotely access healthcare whenever and wherever each individual chooses (via mobile devices, the internet, video and phone).
Our enterprise scale platform is architected for real-time sharing of clinical and non-clinical data in real time among the Teladoc constituents, which include: Members, Providers, physician network operations center staff, nurses, SureScripts for electronic medication prescription writing, routing and fulfillment and health plans for real-time eligibility checking, real-time Member financial responsibility calculations, claims processing, clinical summaries and clinical alerts.
The Teladoc Provider network leverages our technology platform for managing custom visit queues that automatically and instantly route available visits to appropriate Providers based upon proprietary algorithms. Providers use our internet-based application or iOs app for viewing their visit queue, scheduling visits and following the proprietary Teladoc workflow for reviewing Members' medical history and symptoms, documenting the actual visits, e-Prescribing, if appropriate, and sending applicable medical content with follow up instructions to the Member via a secure message center.
We use data and analytics to predict demand patterns by geography and we recruit and manage our Provider network to meet the demands of our patients. Our complex algorithms enable us to effectively manage/allocate supply and onboard Providers to meet demand while maintaining one-hour guaranteed response times, with a median response time of less than ten minutes.
100
Additionally, our platform's external connectivity and easy integration with EMR and outside systems extends its functionality and customer features, which include:
REST is a stateless, scalable web services architecture that utilizes open communication standards such as HTTP and HTTPS, and has been widely adopted for system-to-system communications. Having a documented set of RESTful API's enables our Clients and Members to access our solution using a custom or pre-existing website. For example, a Teladoc health plan Client can offer its Members the ability to access our solution through their existing Member portal. Members can also register for Teladoc, complete their medical history, select a pharmacy and request a consult without having to access the Teladoc Member site. All of these functions are provided via the Client's website that makes system calls to the Teladoc API to process the requests.
The following graphic displays our robust technology architecture that supports our platform:
101
We host our applications and serve all of our Members from two redundant data centers in geographically diverse locations. We rely on third-party vendors to operate these data centers, which are designed to host computer systems that require high levels of availability and have redundant subsystems and compartmentalized security zones. We utilize commercially available hardware for our data center servers. Due to the sensitive nature of our Members and Clients' data, we have a heightened focus on data security and protection. We have implemented telehealth industry-standard processes, policies and tools through all levels of our software development and network administration, including regularly scheduled vulnerability scanning and third-party penetration testing in order to reduce the risk of vulnerabilities in our system. On an annual basis, we also undergo independent, third-party HIPAA and SSAE 16 audits.
We have achieved over 99.9% uptime over the last 12 months. Systems are continually monitored for any signs of problems and preemptive action is taken when necessary. Encrypted backup files are transmitted over secure connections to a redundant server storage device in a secondary data center. Our data center facilities employ advanced measures to ensure physical integrity, including redundant power and cooling systems and advanced fire and flood prevention.
We have also successfully grown our business to a level that supports the establishment of a Teladoc-owned physician network operations center that we expect to open by the end of May 2015. Through this internal operations center, our employees will service Teladoc Members and Clients and we expect to expand our customer service and compliance monitoring operations.
Sales and Marketing
We sell our services through our direct sales organization. Our direct sales team is comprised of enterprise-focused field sales professionals who are organized principally by geography and account size. Our field professionals are supported by a sales operations staff, including product technology experts, lead generation professionals and sales data experts. We maintain relationships with key industry participants including benefit consultants, brokers, group purchasing organizations and health plan and hospital partners.
We generate Client leads, accelerate sales opportunities and build brand awareness through our marketing programs. Our marketing programs target human resource, benefits and finance executives in addition to technology and health professionals, senior business leaders and healthcare channel partners. Our principal marketing programs include use of our website to provide information about our company and our solution, as well as learning opportunities for potential Members; demand generation; field marketing events; integrated marketing campaigns (including direct email and online advertising); and participation in industry events, trade shows and conferences.
Clients and Members
Our Clients consist of (i) employers, including 160 Fortune 1000 companies, (ii) health plans and (iii) health systems and other entities. As of March 1, 2015, we had over 4,000 Clients and our services reached nearly 11 million Members. The following is a selection of our Clients:
Within existing accounts, we believe our current membership represents only a fraction of the potential Members available to us. For example, our existing health plan Clients and self-insured Clients associated with these health plans currently purchase our solution for only 9% of their
102
beneficiaries in aggregate, reflecting a significant opportunity for membership growth. We believe there are in excess of 50 million potential Members within these existing Clients alone.
No Client represented over 10% of our revenue for the years ended December 31, 2013 or 2014 or for the three months ended March 31, 2014 or 2015.
Case Studies
We recently commissioned independent studies of two of our Clients. The results of those studies, as well as an example of our success with health plans, are demonstrated below. We believe these results are representative of the results achieved by our other Clients as well as the value proposition Teladoc can provide the broader U.S. healthcare system.
Commissioned Independent Studies
During the first quarter of 2014, we commissioned Veracity Healthcare Analytics, an independent healthcare data analytics company located in Chestnut Hill, Massachusetts that was founded in 2013, to perform resource utilization and health spending analyses on two of our largest Clients, the nation's largest home-improvement retailer and Rent-A-Center. The related studies were delivered to us during the first quarter of 2015 for an aggregate cost to us of $237,760 and were prepared on behalf of Veracity Healthcare Analytics by two doctors of medicine and a doctor of science and pharmacy, in each case, professors at leading academic institutions. We primarily commissioned these studies to assess the value of our solution from a Client cost-savings perspective and, in turn, to assist us in further developing sales, marketing and pricing strategies.
Veracity Healthcare Analytics employed two types of analyses in the studies it conducted. In both studies, it conducted an "episode-based" analysis, and in the study of the nation's largest home-improvement retailer, it also conducted a "per-Member-per-month" analysis. The purpose of each analysis was to compare spending on medical care and prescriptions before and after the implementation of Teladoc within these two large employers. While recent regulatory changes in the U.S. healthcare system were not specifically considered, we do not believe recent changes in the U.S. healthcare system, including the PPACA, impact the efficacy of the studies because, according to Veracity Healthcare Analytics, these regulations have a minimal impact on large employers with existing employee benefit plans, which constitute a significant number of our Clients.
Episode-Based Analysis Methodology
In each case, the "episode-based" analysis calculated short-term spending and resource use by the employer's beneficiaries who used Teladoc for the first time as compared to similar beneficiaries who instead received care for the same diagnosis during the same period of care in physician offices or emergency departments. The analysis for the nation's largest home-improvement retailer spanned a period of 20 months and the analysis for Rent-A-Center spanned 24 months, and in each case used claims data during the same benefits year to isolate the costs associated with a 30-day episode of care starting with a beneficiary's initial contact with the healthcare system via Teladoc or traditional point of care location, as applicable. To eliminate variability in the data due to population differences, a matching process was created from claims data to match Teladoc users with office or emergency department users on 16 different characteristics, including reason for the healthcare visit, age, gender, calendar quarter of visit, comorbidity score and number of prior hospitalizations, outpatient visits and emergency department visits. In order to identify follow-up care directly related to the reason patients first sought care from Teladoc or in an alternative setting, clinical review of the claims information was used to determine the subsequent claims and related costs associated with the initial condition, including whether a prescription covered by a claim was related to the initial diagnosis.
103
The matching process resulted in pairings with like profiles and allowed for the following subsets to be analyzed:
In both studies, the post-matching propensity score model predicting use of Teladoc services versus office and emergency department visits was determined to be well balanced on baseline characteristics indicating reliable comparisons. Specifically, Veracity Healthcare Analytics determined the c-statistic propensity score model predicting use of Teladoc services versus office and emergency department visits, in each case, to be 0.9 or above. A c-statistic propensity score is used to compare the goodness of fit of logistic regression models. Models are typically considered reasonable when the c-statistic is higher than 0.7 and strong when "c" exceeds 0.8. Further, Veracity Healthcare Analytics used p -values to evaluate the significance of the study results. P -values are used in the context of null hypothesis testing to quantify statistical significance. A p -value of less than 0.05 is a common measure of statistical significance and a p -value of less than 0.01 is considered a more stringent test. Both independent studies found p -values of less than 0.01, indicating statistical significance of the results. Accordingly, we believe the comparison groups for each medical condition analyzed provided a sufficiently large sample size with which to provide reliable comparisons regardless of whether a matched pair was in the same or different geographic locations. Additionally, a significant majority of pairs were matched based on the top ten medical conditions underlying calls to Teladoc among sampled beneficiaries and, as a result, we believe these studies not only provided a representative sample of cover episodes, but also correctly focused on the episodes most germane to assessing Teladoc's efficacy.
Costs were based upon the amounts allowed under the insurance claims and no restriction was made based on the diagnoses associated with these services. Costs include total cost of care (both medical and prescription drug spending). As the episode-based analysis focused solely on a comparison of cohorts during a predefined episode of care, these analyses did not assess episode costs relative to the employer's aggregate benefit costs.
Per-Member-Per-Month Analysis Methodology
The "per-Member-per-month" analysis deployed by Veracity Healthcare Analytics' study of the nation's largest home-improvement retailer compared the average use and spending patterns among 131,576 of the employer's beneficiaries, comparing the same beneficiaries both before and after May 2012, when Teladoc was first implemented by the employer as part of its benefits offering and made available to its beneficiaries. The per-Member-per-month analysis was an isolated comparison of total actual cost and use rates for these beneficiaries from May 2012 through December 2013 to their projected total cost and use rates during the same period based on claims information from these beneficiaries during the 16 months immediately prior to Teladoc's implementation (as a result, the projected cost and use rates assumed Teladoc was never implemented). Additionally of note, the analysis compared actual and projected spending under the same benefits scheme in order to minimize variability. In its study, Veracity Healthcare Analytics also noted that because the employer began offering Teladoc in the middle of a benefits year (May
104
2012) rather than at the beginning of one, the analysis was likely to have isolated the specific impact of Teladoc without confounding it with concurrent changes in employer benefit design or introduction of other quality improvement programs by the employer. As a result, we believe the claim information from the 16-month period from January 2011 to April 2012 prior to Teladoc's implementation is representative of the claim period from May 2012 to December 2013 notwithstanding the differing length of claims periods.
Study ResultsNation's Largest Home-Improvement Retailer
One of our most significant Clients is the nation's largest home-improvement retailer, a Client since 2012, representing over 150,000 of our Members as of December 31, 2014. As mentioned above, the independent study of this Client's Members was conducted using healthcare utilization data and employed two basic analytic approaches. A "per-Member-per-month" analysis that evaluated average resource use and spending among 131,576 beneficiaries of the Client, or 8.1% of our Members at the outset of the study. The study compared the same beneficiaries both before and after Teladoc began offering services in May 2012 over a period of 20 months. In addition, an "episode-based" analysis evaluated short-term spending and resource use by beneficiaries of the Client who used Teladoc as compared to similar beneficiaries who instead received care for the same conditions in physician offices or emergency rooms.
We determined estimated 2014 cost savings above based on the cost savings per episode identified by Veracity Healthcare Analytics during the study ( i.e. , $191 and $2,661 per office and emergency department visit, respectively). During 2014, the Client's beneficiaries accounted for 8,945 Teladoc visits. Of the 8,945 Member visits during 2014, we respectively applied $191 and $2,661 of estimated savings to each visit based on an analysis of Client claims data detailing the historical mix of office visits and emergency department visits for comparable episodes in the Client's beneficiary population. The gross cost savings were then reduced by the Client's $593,406 subscription access fee for 2014, which resulted in $5.36 million of estimated cost savings for the Client during 2014. The quotient of the Client's total net cost savings and related subscription access fee during 2014 resulted in the Client's ROI of approximately $9.00 to $1.00.
Study ResultsRent-A-Center
Rent-A-Center represented over 24,000 of our Members as of December 31, 2014. We believe Rent-A-Center is experiencing a meaningful ROI due to close collaboration with Teladoc resulting in strong corporate sponsorship, successful deployment and strong adoption by Members. Similar to the study of the nation's largest home-improvement retailer, the independent study we commissioned of Rent-A-Center, which was conducted on 21,308 of Rent-A-Center's beneficiaries, or 1.3% of our Members at the outset of the study, over a period of 24 months, examined the
105
impact on short-term spending and resource use of our solution, as compared to similar beneficiaries who instead received care for the same conditions in physician offices or emergency departments. Of the 21,308 beneficiaries, 3,418 Teladoc users had episodes during the period deemed eligible for matching with an episode from a Rent-A-Center beneficiary who did not use Teladoc, but did make an office or emergency department visit. As noted above under the heading "Episode-Based Analysis Methodology," this matching process resulted in 2,624 matched pairs of Teladoc episodes and office visit episodes and 1,845 matched pairs of Teladoc episodes and emergency department episodes. The study found that when comparing individuals who used Teladoc with similar individuals who received care in other settings for the same condition, spending was substantially lower for Teladoc users.
We determined estimated 2014 cost savings above based on the cost savings per episode identified by Veracity Healthcare Analytics during the study ( i.e. , $284 and $2,419 per office and emergency department visit, respectively). During 2014, Rent-A-Center's beneficiaries accounted for 4,098 Teladoc visits. Of the 4,098 Member visits during 2014, we respectively applied $284 and $2,419 of estimated savings to each visit based on an analysis of Rent-A-Center claims data detailing the historical mix of office visits and emergency department visits for comparable episodes in the Rent-A-Center beneficiary population. The gross cost savings were then reduced by Rent-A-Center's $146,610 subscription access fee for 2014, which resulted in $1.73 million of estimated cost savings to Rent-A-Center during 2014. The quotient of Rent-A-Center's total net cost savings and related subscription access fee during 2014 resulted in Rent-A-Center's $11.80 to $1.00 ROI.
Health Plan Case Studies
Aetna
We have a long-standing relationship with Aetna dating back to 2011. Aetna is one of the nation's largest health plans with 22.2 million beneficiaries as of December 31, 2014. Through a number of initiatives, we have grown membership to over 2.6 million Members with Aetna as of March 1, 2015. In addition to contracting with Aetna, we also contract directly with many organizations that are in ASO and other relationships with Aetna. Typically, these are self-insured employers. We plan to specifically continue to target national employers, mid-market accounts and fully-insured populations by partnering with Aetna.
We believe our success with Aetna is indicative of our ability to grow membership within existing accounts where considerable opportunity remains. Though we consider our membership with Aetna to be significant, at 2.6 million of a potential 22.2 million Members we believe there is considerable opportunity for growth in this account. The following highlights a number of our
106
successes with Aetna and our track record of increasing Membership across different business lines:
Year
|
New
Members |
Aggregate
Members |
Highlight | |||||
---|---|---|---|---|---|---|---|---|
2011 | 658,800 | 658,800 |
Aetna relationship begins with roll-out to select fully-insured populations |
|||||
2012 | 39,200 | 698,000 |
Aetna launches Teladoc in select self-insured national accounts Adds six ASO Clients and one fully-insured state |
|||||
2013 | 630,000 | 1,328,000 |
Aetna purchases Teladoc for its own employees Adds 49 ASO Clients and three fully-insured states |
|||||
2014 | 629,800 | 1,957,800 |
Adds 95 ASO Clients |
|||||
2015 | 663,200 | 2,621,000 |
Aetna implements our solution in select Managed Medicaid pilot population Aetna expands Teladoc to select additional national account Clients |
Oscar Health Insurance
Oscar Health Insurance, or Oscar, who has been a Client since 2013, is a consumer-oriented health insurance plan. Our solution is embedded directly into Oscar's interfaces for beneficiaries, a strategy that we intend to pursue aggressively with other health plans. We believe our close integration with Oscar is a primary driver of our high growth and Member engagement in this account.
Seasonality
A significantly higher proportion of our Members enter into new subscription agreements with us or renew previous agreements in the third and fourth quarters of the year compared to the first and second quarters. This seasonality is related to the employee benefits cycle, as Clients typically want to make our applications available at the beginning of a new benefits year, which generally occurs in the first quarter. We also experience a higher proportion of our visits in the first and fourth quarters of the year, primarily due to occurrence of the cold and flu season. These variations are expected to continue in the future. Consequently, it may be more meaningful to focus on annual rather than interim results.
Research and Development
Our ability to compete depends, in large part, on our continuous commitment to rapidly introduce new services, technologies, features and functionality. Our product development team, which as of December 31, 2014, consisted of 40 employees, is responsible for the design, development, testing and certification of our solution. In addition, we utilize certain third-party
107
development services to perform application development services. We focus our efforts on developing new products and further enhancing the usability, functionality, reliability, performance and flexibility of our solution.
Competition
We view as our competitors those companies that currently (or in the future will) (i) develop and market telehealth technology (devices and systems) or (ii) provide telehealth, such as the delivery of on-demand access to healthcare. In the provision of telehealth, competition focuses on, among other factors, experience in operation, customer service, quality of technology and know-how and reputation. Our key competitors in the telehealth market are Doctor On Demand, MDLive and American Well.
Physicians and Healthcare Professionals
We contract for our Providers' services through the Services Agreement with Teladoc PA, and, therefore, our Providers are not our employees. Under the Services Agreement, we have agreed to serve, on an exclusive basis, as manager and administrator of Teladoc PA's non-medical functions and services related to the provision of the telehealth services by physicians employed by or under contract with Teladoc PA. Teladoc PA has agreed to provide our Members, through its physicians, access to telehealth services and recommended treatment 24 hours per day, 365 days per year. The Services Agreement also requires Teladoc PA to maintain the state licensure and other credentialing requirements of its physicians. The non-medical functions and services we provide under the Services Agreement primarily include Member management services such as maintaining a call center for our Members to request a visit with Teladoc PA's physicians (our Providers), Member billing and collection administration and maintenance and storage of Member medical records. Under the Services Agreement, Teladoc PA currently pays us an access fee of $25,000 per month for call center and medical records maintenance, a fixed fee of $65,000 per month for our provision of management and administrative services and a license fee of $10,000 per month for the non-exclusive use of the Teladoc trade name. Additionally, we are required to maintain, for our company and our employees, general insurance of at least $1.0 million per occurrence and $3.0 million in the aggregate. Similarly, Teladoc PA is required to maintain, for itself and its physicians, professional liability insurance of at least $1.0 million per occurrence and $3.0 million in the aggregate. The Services Agreement has a 20-year term and expires in February 2025 unless earlier terminated upon mutual agreement of the parties or unilaterally by a party following the commencement of bankruptcy or liquidation proceeds by the non-terminating party, a material breach of the Services Agreement by the non-terminating party or a governmental or judicial termination order related to the Services Agreement.
Our Providers are paid promptly, every two weeks via direct deposit or check. Our Providers bear no out-of-pocket medical malpractice expenses when delivering care on our platform. Teladoc PA carries professional liability insurance covering $1.0 million per claim and $3.0 million in the aggregate for itself and each of its healthcare professionals (our Providers), and we separately carry a general insurance policy, which covers medical malpractice claims, covering $5.0 million per claim and $5.0 million in the aggregate. We have not had a medical malpractice claim in our over ten-year operating history.
Employees
As of March 31, 2015, we had 259 employees, including 51 in technology and development and 86 in sales and marketing. We consider our relationship with our employees to be good. None of our employees are represented by a labor union or party to a collective bargaining agreement.
108
Facilities
Our principal executive offices are located in Dallas, Texas, where we occupy facilities totaling approximately 7,495 square feet under a lease that expires in April 2017, and in Purchase, New York, where we occupy facilities totaling approximately 15,868 square feet under a lease that expires in August 2018. We use these facilities for administration, sales and marketing, technology and development and customer support. We also lease offices elsewhere in the United States.
We are also in the process of opening a physician network operations center in a 57,000 square foot leased space in Dallas, Texas that we expect to open by the end of May 2015. Our physician network operations center will assume, among other functions, the customer service and Member-to-Provider routing functions that we have historically outsourced to a third-party call center, Connextions (an Optum company). We formally terminated our contractual relationship with Connextions on April 16, 2015. Connextions has agreed to continue to provide its services to us through September 2015 while we concurrently increase our in-house physician network operations center resources leading-up to our full internalization of the functions previously outsourced to Connextions on or prior to September 30, 2015.
We intend to procure additional space as we add employees and expand geographically. We believe that our facilities are adequate to meet our needs for the immediate future, and that, should it be needed, suitable additional space will be available to accommodate any such expansion of our operations.
Government Regulation
The healthcare industry and the practice of medicine are extensively regulated at both the state and federal levels. Our ability to operate profitably will depend in part upon our ability, and that of our affiliated Providers, to maintain all necessary licenses and to operate in compliance with applicable laws and rules. Those laws and rules continue to evolve, and we therefore devote significant resources to monitoring developments in healthcare and medical practice regulation. As the applicable laws and rules change, we are likely to make conforming modifications in our business processes from time to time. In many jurisdictions where we operate, neither our current nor our anticipated business model has been the subject of judicial or administrative interpretation. We cannot assure you that a review of our business by courts or regulatory authorities will not result in determinations that could adversely affect our operations or that the healthcare regulatory environment will not change in a way that restricts our operations.
Provider Licensing, Medical Practice, Certification and Related Laws and Guidelines
The practice of medicine, including the provision of behavioral health services, is subject to various federal, state and local certification and licensing laws, regulations and approvals, relating to, among other things, the adequacy of medical care, the practice of medicine (including the provision of remote care and cross-coverage practice), equipment, personnel, operating policies and procedures and the prerequisites for the prescription of medication. The application of some of these laws to telehealth is unclear and subject to differing interpretation.
Physicians and behavioral health professionals who provide professional medical or behavioral health services to a patient via telehealth must, in most instances, hold a valid license to practice medicine or to provide behavioral health treatment in the state in which the patient is located. In addition, certain states require a physician providing telehealth to be physically located in the same state as the patient. We have established systems for ensuring that our affiliated physicians and behavioral health professionals are appropriately licensed under applicable state law and that their provision of telehealth to our Members occurs in each instance in compliance with applicable rules governing telehealth. Failure to comply with these laws and regulations could result in our services
109
being found to be non-reimbursable or prior payments being subject to recoupments and can give rise to civil or criminal penalties.
Corporate Practice of Medicine; Fee-Splitting
We contract with physicians or physician-owned professional associations and professional corporations to deliver our services to their patients. We frequently enter into management services contracts with these physicians and physician-owned professional associations and professional corporations pursuant to which we provide them with billing, scheduling and a wide range of other services, and they pay us for those services out of the fees they collect from patients and third-party payors. These contractual relationships are subject to various state laws, including those of New York, Texas and California, that prohibit fee-splitting or the practice of medicine by lay entities or persons and are intended to prevent unlicensed persons from interfering with or influencing the physician's professional judgment. In addition, various state laws also generally prohibit the sharing of professional services income with nonprofessional or business interests. Activities other than those directly related to the delivery of healthcare may be considered an element of the practice of medicine in many states. Under the corporate practice of medicine restrictions of certain states, decisions and activities such as scheduling, contracting, setting rates and the hiring and management of non-clinical personnel may implicate the restrictions on the corporate practice of medicine.
State corporate practice of medicine and fee-splitting laws vary from state to state and are not always consistent among states. In addition, these requirements are subject to broad powers of interpretation and enforcement by state regulators. Some of these requirements may apply to us even if we do not have a physical presence in the state, based solely on our engagement of a Provider licensed in the state or the provision of telehealth to a resident of the state. However, regulatory authorities or other parties, including our Providers, may assert that, despite these arrangements, we are engaged in the corporate practice of medicine or that our contractual arrangements with affiliated physician groups constitute unlawful fee-splitting. In this event, failure to comply could lead to adverse judicial or administrative action against us and/or our Providers, civil or criminal penalties, receipt of cease-and-desist orders from state regulators, loss of Provider licenses, the need to make changes to the terms of engagement of our Providers that interfere with our business and other materially adverse consequences.
Federal and State Fraud and Abuse Laws
Federal Stark Law
We are subject to the federal self-referral prohibitions, commonly known as the Stark Law. Where applicable, this law prohibits a physician from referring Medicare patients to an entity providing "designated health services" if the physician or a member of such physician's immediate family has a "financial relationship" with the entity, unless an exception applies. The penalties for violating the Stark Law include the denial of payment for services ordered in violation of the statute, mandatory refunds of any sums paid for such services, civil penalties of up to $15,000 for each violation and twice the dollar value of each such service and possible exclusion from future participation in the federally-funded healthcare programs. A person who engages in a scheme to circumvent the Stark Law's prohibitions may be fined up to $100,000 for each applicable arrangement or scheme. The Stark Law is a strict liability statute, which means proof of specific intent to violate the law is not required. In addition, the government and some courts have taken the position that claims presented in violation of the various statutes, including the Stark Law can be considered a violation of the federal False Claims Act (described below) based on the contention that a provider impliedly certifies compliance with all applicable laws, regulations and other rules when submitting claims for reimbursement. A determination of liability under the Stark
110
Law could have a material adverse effect on our business, financial condition and results of operations.
Federal Anti-Kickback Statute
We are also subject to the federal Anti-Kickback Statute. The Anti-Kickback Statute is broadly worded and prohibits the knowing and willful offer, payment, solicitation or receipt of any form of remuneration in return for, or to induce, (i) the referral of a person covered by Medicare, Medicaid or other governmental programs, (ii) the furnishing or arranging for the furnishing of items or services reimbursable under Medicare, Medicaid or other governmental programs or (iii) the purchasing, leasing or ordering or arranging or recommending purchasing, leasing or ordering of any item or service reimbursable under Medicare, Medicaid or other governmental programs. Certain federal courts have held that the Anti-Kickback Statute can be violated if "one purpose" of a payment is to induce referrals. In addition, a person or entity no longer does not need to have actual knowledge of this statute or specific intent to violate it to have committed a violation, making it easier for the government to prove that a defendant had the requisite state of mind or "scienter" required for a violation. Moreover, the government may assert that a claim including items or services resulting from a violation of the Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act, as discussed below. Violations of the Anti-Kickback Statute can result in exclusion from Medicare, Medicaid or other governmental programs as well as civil and criminal penalties, including fines of $50,000 per violation and three times the amount of the unlawful remuneration. Imposition of any of these remedies could have a material adverse effect on our business, financial condition and results of operations. In addition to a few statutory exceptions, OIG has published safe harbor regulations that outline categories of activities that are deemed protected from prosecution under the Anti-Kickback Statute provided all applicable criteria are met. The failure of a financial relationship to meet all of the applicable safe harbor criteria does not necessarily mean that the particular arrangement violates the Anti-Kickback Statute. However, conduct and business arrangements that do not fully satisfy each applicable safe harbor may result in increased scrutiny by government enforcement authorities, such as the OIG.
False Claims Act
Both federal and state government agencies have continued civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare companies and their executives and managers. Although there are a number of civil and criminal statutes that can be applied to healthcare providers, a significant number of these investigations involve the federal False Claims Act. These investigations can be initiated not only by the government but also by a private party asserting direct knowledge of fraud. These "qui tam" whistleblower lawsuits may be initiated against any person or entity alleging such person or entity has knowingly or recklessly presented, or caused to be presented, a false or fraudulent request for payment from the federal government, or has made a false statement or used a false record to get a claim approved. In addition, the improper retention of an overpayment for 60 days or more is also a basis for a False Claim Act action, even if the claim was originally submitted appropriately. Penalties for False Claims Act violations include fines ranging from $5,500 to $11,000 for each false claim, plus up to three times the amount of damages sustained by the federal government. A False Claims Act violation may provide the basis for exclusion from the federally-funded healthcare programs. In addition, some states have adopted similar fraud, whistleblower and false claims provisions.
State Fraud and Abuse Laws
Several states in which we operate have also adopted similar fraud and abuse laws as described above. The scope of these laws and the interpretations of them vary from state to state and are enforced by state courts and regulatory authorities, each with broad discretion. Some state
111
fraud and abuse laws apply to items or services reimbursed by any third-party payor, including commercial insurers, not just those reimbursed by a federally-funded healthcare program. A determination of liability under such state fraud and abuse laws could result in fines and penalties and restrictions on our ability to operate in these jurisdictions.
Other Healthcare Laws
HIPAA established several separate criminal penalties for making false or fraudulent claims to insurance companies and other non-governmental payors of healthcare services. Under HIPAA, these two additional federal crimes are: "Healthcare Fraud" and "False Statements Relating to Healthcare Matters." The Healthcare Fraud statute prohibits knowingly and recklessly executing a scheme or artifice to defraud any healthcare benefit program, including private payors. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from government-sponsored programs. The False Statements Relating to Healthcare Matters statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact by any trick, scheme or device or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. A violation of this statute is a felony and may result in fines or imprisonment. This statute could be used by the government to assert criminal liability if a healthcare provider knowingly fails to refund an overpayment. These provisions are intended to punish some of the same conduct in the submission of claims to private payors as the federal False Claims Act covers in connection with governmental health programs.
In addition, the Civil Monetary Penalties Law imposes civil administrative sanctions for, among other violations, inappropriate billing of services to federally funded healthcare programs and employing or contracting with individuals or entities who are excluded from participation in federally funded healthcare programs. Moreover, a person who offers or transfers to a Medicare or Medicaid beneficiary any remuneration, including waivers of co-payments and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary's selection of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services may be liable for civil monetary penalties of up to $10,000 for each wrongful act. Moreover, in certain cases, providers who routinely waive copayments and deductibles for Medicare and Medicaid beneficiaries can also be held liable under the Anti-Kickback Statute and civil False Claims Act, which can impose additional penalties associated with the wrongful act. One of the statutory exceptions to the prohibition is non-routine, unadvertised waivers of copayments or deductible amounts based on individualized determinations of financial need or exhaustion of reasonable collection efforts. The OIG emphasizes, however, that this exception should only be used occasionally to address special financial needs of a particular patient. Although this prohibition applies only to federal healthcare program beneficiaries, the routine waivers of copayments and deductibles offered to patients covered by commercial payers may implicate applicable state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud.
State and Federal Health Information Privacy and Security Laws
There are numerous U.S. federal and state laws and regulations related to the privacy and security of PII, including health information. In particular, the federal Health Insurance Portability and Accountability Act of 1996, as amended by HITECH, and their implementing regulations, which we collectively refer to as HIPAA, establish privacy and security standards that limit the use and disclosure of PHI and require the implementation of administrative, physical, and technical safeguards to ensure the confidentiality, integrity and availability of individually identifiable health information in electronic form. Teladoc, our Providers and our health plan Clients are all regulated as covered entities under HIPAA. Since the effective date of the HIPAA Omnibus Final Rule on September 23, 2013, HIPAA's requirements are also directly applicable to the independent
112
contractors, agents and other "business associates" of covered entities that create, receive, maintain or transmit PHI in connection with providing services to covered entities. Although we are a covered entity under HIPAA, we are also a business associate of other covered entities when we are working on behalf of our affiliated medical groups.
Violations of HIPAA may result in civil and criminal penalties. The civil penalties range from $100 to $50,000 per violation, with a cap of $1.5 million per year for violations of the same standard during the same calendar year. However, a single breach incident can result in violations of multiple standards. We must also comply with HIPAA's breach notification rule. Under the breach notification rule, covered entities must notify affected individuals without unreasonable delay in the case of a breach of unsecured PHI, which may compromise the privacy, security or integrity of the PHI. In addition, notification must be provided to the HHS and the local media in cases where a breach affects more than 500 individuals. Breaches affecting fewer than 500 individuals must be reported to HHS on an annual basis. The regulations also require business associates of covered entities to notify the covered entity of breaches by the business associate.
State attorneys general also have the right to prosecute HIPAA violations committed against residents of their states. While HIPAA does not create a private right of action that would allow individuals to sue in civil court for a HIPAA violation, its standards have been used as the basis for the duty of care in state civil suits, such as those for negligence or recklessness in misusing personal information. In addition, HIPAA mandates that HHS conduct periodic compliance audits of HIPAA covered entities and their business associates for compliance. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a percentage of the Civil Monetary Penalty fine paid by the violator. In light of the HIPAA Omnibus Final Rule, recent enforcement activity, and statements from HHS, we expect increased federal and state HIPAA privacy and security enforcement efforts.
HIPAA also required HHS to adopt national standards establishing electronic transaction standards that all healthcare providers must use when submitting or receiving certain healthcare transactions electronically. On January 16, 2009, HHS released the final rule mandating that everyone covered by HIPAA must implement ICD-10 for medical coding on October 1, 2013, which has since been subsequently extended to October 1, 2015.
Many states in which we operate and in which our patients reside also have laws that protect the privacy and security of sensitive and personal information, including health information. These laws may be similar to or even more protective than HIPAA and other federal privacy laws. For example, the laws of the State of California, in which we operate, are more restrictive than HIPAA. Where state laws are more protective than HIPAA, we must comply with the state laws we are subject to, in addition to HIPAA. In certain cases, it may be necessary to modify our planned operations and procedures to comply with these more stringent state laws. Not only may some of these state laws impose fines and penalties upon violators, but also some, unlike HIPAA, may afford private rights of action to individuals who believe their personal information has been misused. In addition, state laws are changing rapidly, and there is discussion of a new federal privacy law or federal breach notification law, to which we may be subject.
In addition to HIPAA, state health information privacy and state health information privacy laws, we may be subject to other state and federal privacy laws, including laws that prohibit unfair privacy and security practices and deceptive statements about privacy and security and laws that place specific requirements on certain types of activities, such as data security and texting.
In recent years, there have been a number of well-publicized data breaches involving the improper use and disclosure of PII. Many states have responded to these incidents by enacting laws requiring holders of personal information to maintain safeguards and to take certain actions in response to a data breach, such as providing prompt notification of the breach to affected
113
individuals and state officials. In addition, under HIPAA and pursuant to the related contracts that we enter into with our business associates, we must report breaches of unsecured PHI to our contractual partners following discovery of the breach. Notification must also be made in certain circumstances to affected individuals, federal authorities and others.
Intellectual Property
We own and use trademarks and service marks on or in connection with our services, including both unregistered common law marks and issued trademark registrations in the United States. We also have trademark applications pending to register marks in the United States. In addition, we rely on certain intellectual property rights that we license from third parties and on other forms of intellectual property rights and measures, including trade secrets, know-how and other unpatented proprietary processes and nondisclosure agreements, to maintain and protect proprietary aspects of our products and technologies. Other than the trademark Teladoc (and design), which is pending registration and which is not subject to any known rights of others, including any impairments, assignments or pledges, we do not believe our business is dependent to a material degree on trademarks, patents, copyrights or trade secrets. We require our employees, consultants and certain of our contractors to execute confidentiality, agreements in connection with their employment or consulting relationships with us. We also require our employees and consultants to disclose and assign to us all inventions conceived during the term of their employment or engagement while using our property or which relate to our business.
On June 8, 2015, American Well Corporation filed a complaint against our company in the United States District Court for the District of Massachusetts alleging that certain of our operating platform's technology infringes one of its patents that we are currently seeking to invalidate pursuant to an inter partes review that we filed with the Patent Trial and Appeals Board in March 2015. See "Legal Proceedings."
Legal Proceedings
From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Except as described below, we are not presently a party to any legal proceedings that, in the opinion of our management, would individually or taken together have a material adverse effect on our business, financial condition, results of operations or cash flows. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.
We are the plaintiff in three lawsuits in the Texas courts against the Texas Medical Board, or the TMB. In the first suit, Teladoc v. TMB and Leshikar , on December 31, 2014, the Austin Court of Appeals granted our request for summary judgment, invalidating the TMB's prior assertion that our Providers do not form "proper professional relationships" with our Members in the course of telehealth visits such as would support the prescription of medications. The TMB has filed a petition for review with the Texas Supreme Court to ask that Court if it will allow the TMB to appeal the Court of Appeals' decision. In the second suit, Teladoc v. TMB and Freshour , on February 2, 2015, the Travis County District Court granted our request for a temporary injunction restraining the TMB from enforcing an "emergency rule" it issued on January 16, 2015 purporting to amend the Texas Administrative Code so as to require a "face-to-face" examination of a patient before a Texas physician may lawfully prescribe medication. This suit is set for trial on November 9, 2015. In the third suit, Teladoc et al. v. TMB et al., the United States District Court for the Western District of Texas, Austin Division, held a hearing on May 22, 2015, on our motion for preliminary injunction of the rule amendments the TMB adopted on April 10, 2015, that seek to effect substantively identical restrictions as the issues in the two prior lawsuits. On May 29, 2015, this court granted our request for a preliminary injunction of the rule amendments, pending ultimate trial on the merits, which trial
114
date has yet to be set. Management is unable to make a reasonable estimate of when these matters will be resolved or the amount or range of loss that could result from an unfavorable outcome in these matters. See "Risk FactorsRisks Related to Our BusinessOur business could be adversely affected by ongoing legal challenges to our business model or by new state actions restricting our ability to provide the full range of our services in certain states."
On June 8, 2015, American Well Corporation filed a complaint against our company in the United States District Court for the District of Massachusetts alleging that certain of our operating platform's technology infringes U.S. Patent No. 7,590,550, or the '550 patent, entitled, "Connecting consumers with services providers," and seeking both injunctive and monetary relief. We believe this claim was in direct response to the preemptive challenge to the validity of the '550 patent that we commenced in March 2015 by filing a petition requesting that the U.S. Patent and Trademark Office's Patent Trial and Appeals Board, or the PTAB, conduct an inter partes review of certain claims of the '550 patent. We intend to continue to pursue our preemptive challenge to the validity of the '550 patent before the PTAB and also vigorously defend the claims made in American Well Corporation's subsequent lawsuit. We may be required to expend significant management time and financial resources on the defense of such claims, which could harm our business or results of operations. The legal cost of this litigation is not estimable at this time, and we expect to expense the cost of the litigation as it is incurred. See "Risk FactorsRisks Related to Our BusinessWe could incur substantial costs as a result of any claim of infringement of another party's intellectual property rights."
115
The following table provides information regarding our executive officers and our board of directors:
Name
|
Age
|
Position
|
||
---|---|---|---|---|
Jason Gorevic |
43 | President, Chief Executive Officer and Director | ||
Mark Hirschhorn |
50 |
Executive Vice President and Chief Financial Officer |
||
Adam C. Vandervoort |
40 |
Chief Legal Officer and Secretary |
||
Henry DePhillips, M.D. |
55 |
Chief Medical Officer |
||
Michael King |
51 |
Chief Sales Officer |
||
Jeff Nadler |
51 |
Chief Technology Officer |
||
Daniel Trencher |
43 |
Senior Vice President of Product and Strategy |
||
Andrew Turitz |
42 |
Senior Vice President of Business Development |
||
Kevin Williamson |
44 |
Chief Marketing Officer |
||
Martin R. Felsenthal |
46 |
Director |
||
William H. Frist, M.D. |
63 |
Director |
||
Michael Goldstein |
73 |
Director |
||
Thomas Mawhinney |
46 |
Director |
||
Thomas G. McKinley |
63 |
Director |
||
Dana G. Mead, Jr. |
56 |
Director |
||
Arneek Multani |
41 |
Director |
||
James Outland |
49 |
Director |
||
David B. Snow, Jr. |
60 |
Director and Chairman of the Board |
Jason Gorevic has been our President and Chief Executive Officer and a member of our board of directors since June 2009. Prior to joining Teladoc, Mr. Gorevic worked in various capacities at WellPoint, Inc., including President of Empire BlueCross BlueShield and Senior Vice President and Chief Sales and Product Officer. From 2002 to 2005, Mr. Gorevic was a member of Empire BlueCross BlueShield's leadership team, as Chief Sales and Marketing Officer. From July 2000 to December 2001, Mr. Gorevic served as Chief Executive Officer of Gemfinity, an electronic marketplace and purchasing aggregator that he founded. From July 1999 to July 2000, he served as General Manager of Business Messaging at Mail.com, Inc., a provider of Internet messaging services, and from April 1998 to June 1999, he served as Mail.com's Vice President of Operations. From 1993 to 1998, Mr. Gorevic worked at Oxford Health Plans, Inc., and held a variety of positions in marketing, medical management and operations as well as Director of Service Strategy. Mr. Gorevic earned a B.A. in international relations from the University of Pennsylvania. Our board of directors has concluded that Mr. Gorevic should serve as a director because of his leadership role with our company and his broad experience in the healthcare industry.
Mark Hirschhorn became our Executive Vice President and Chief Financial Officer in October 2012. Mr. Hirschhorn is an experienced senior financial executive who has worked with numerous entrepreneurial ventures in a variety of different market segments. From April 2004 to October 2012,
116
Mr. Hirschhorn served as Executive Vice President and Chief Financial Officer of RCS/Media Monitors, an international software technology company that serves the media and entertainment markets. From 2000 to 2003, Mr. Hirschhorn served as the Chief Financial Officer in a number of technology companies, including BT Radianz. From 1996 to 2000, he spent five years as the Vice President and Global Controller of RSL Communications, a publicly traded multinational telecommunications company, and as Chief Financial Officer of Deltathree Communications, a publicly traded RSL subsidiary and pioneer in VOIP technology. He started his professional career with Deloitte and spent nine years with the firm. Mr. Hirschhorn earned a B.A. from Rutgers University and an M.B.A. from Rutgers Business School. Mr. Hirschhorn is a CPA and a member of American Institute of Certified Public Accountants.
Adam C. Vandervoort became our Chief Legal Officer and Secretary in February 2015. From 2006 through January 2015, Mr. Vandervoort was Corporate Vice President, General Counsel and Secretary of Independence Holding Company (IHC), a public insurance holding company. Prior to that, he was an in-house attorney with FedEx Corporation and practiced corporate law with a large firm. Mr. Vandervoort holds A.B. and A.M. degrees from the University of Chicago and a J.D. from the University of Pennsylvania Law School. He is admitted to practice law in the states of California, Connecticut, New York and Tennessee.
Henry DePhillips, M.D. became our Chief Medical Officer in April 2013. Prior to joining Teladoc, Dr. DePhillips held leadership positions in healthcare consulting, health insurance, and healthcare information technology sectors, including Executive Vice President and Chief Medical Officer for Audax Health, a consumer engagement technology company, Head of Business Development, North America for McKinsey's Health Systems Institute and Chief Medical Officer for PDR Network, an electronic patient safety communications company. Dr. DePhillips also served as Executive Vice President and Chief Medical Officer of MEDecision, a clinical care management software company from 2003 to 2007 and as Senior Medical Director of Independence Blue Cross of Pennsylvania from 1996 to 2004. He currently serves on the board of directors of eRounds, LLC, a surgical device physician-to-physician information sharing company and is a member of Oliter Holdings, LLC, a commercial real estate development company. Dr. DePhillips earned an undergraduate degree in Biochemistry from Trinity College and an M.D. at Hahnemann University School of Medicine. He performed his residency in Family and Community Medicine at the Medical Center of Delaware.
Michael King became our Chief Sales Officer in July 2010. Prior to joining Teladoc, Mr. King held various positions at Healthways, Inc., beginning in 2001, and was most recently Senior Vice President of Insight and Innovations after serving as Senior Vice President of Sales. During his tenure, he was responsible for the creation, implementation, and execution of all sales business plans. In addition to sales operation, he also directed consultant relationship management, product marketing, and messaging. Prior to his time with Healthways, Mr. King held various positions at CareSteps.com, WellPath Community Health Plans, Doctors Health Plan, and Aetna. Mr. King earned a B.S. in Employment Relations and Management from Michigan State University and attended the General Managers program at Harvard Business School.
Jeff Nadler became our Chief Technology Officer in August 2010. Prior to joining Teladoc, Mr. Nadler served as chief technology officer for ActiveHealth Management, a leading vendor of products and services for the healthcare industry in the areas of disease management, wellness, personal health records, analytics, lifestyle coaching, UM/CM, and clinical decision support. Previously, he served as Senior Vice President, Enterprise Technology Group, at Marsh and McLennan Companies and was a director and program manager at Cambridge Technology Partners. Mr. Nadler earned a B.S. in Electrical Engineering from Union College, Schenectady, N.Y.
Daniel Trencher became our Senior Vice President of Product and Strategy in January 2015 after serving for three years as our Senior Vice President of Business Development since 2011.
117
Prior to joining Teladoc, Mr. Trencher served as Vice President for Corporate Strategy at WellPoint, Inc. In earlier roles with WellPoint, he also led market strategy and Specialty Dental and Vision lines and led a product development team in strategic medical insurance products. Prior to his time with WellPoint, Mr. Trencher held positions with Booz & Co.'s Communications, Media and Technology practice, and PricewaterhouseCoopers. He earned a B.A. in Economics from the University of Pennsylvania and an M.B.A. from the University of Chicago.
Andrew Turitz became our Senior Vice President of Business Development in January 2015. Prior to joining Teladoc, Mr. Turitz was a Vice President at Aetna, where he led business development for Healthagen, a division focused on population health management and enablement of accountable care. Prior to his time at Aetna, Mr. Turitz served as Managing Director at Sandbox Industries, which manages venture investments for BlueCross BlueShield. He was also a Vice President at Banc of America Securities focused on Healthcare M&A. Mr. Turitz served as a Director of the Board for ZeOmega, Change Healthcare, and Invivolink, and as a Board Observer for Bloom Health. Mr. Turitz earned a B.A. from Stanford University and an M.B.A. in Accounting and Finance from the Kellogg School of Management.
Kevin Williamson became our Chief Marketing Officer in May 2009. Before joining Teladoc, Mr. Williamson served as vice president of Clinical Innovation and Strategy-Health Management Corp., a subsidiary of WellPoint, Inc. In 2001, he served as director of Web Product Strategy at Empire Blue Cross Blue Shield and was promoted to regional vice president of B2B and Senior Marketing. Mr. Williamson was required to manage large accounts in earlier roles as an Account Manager at Icon Medialab and as a Manager at Ernst & Young. Mr. Williamson earned a Bachelor of Industrial Engineering and Master of Science in Industrial Engineering with Health Systems Emphasis from Georgia Institute of Technology. He also served as a graduate research assistant at Emory University Hospital System in Atlanta, GA.
Martin R. Felsenthal, became a member of our board of directors in November 2009. Mr. Felsenthal has been a Partner of HLM Venture Partners, a venture capital firm since 2007. Mr. Felsenthal was previously a General Partner of Salix Ventures, a venture capital firm, where he focused on investments in healthcare services and healthcare information technology. He joined Salix Ventures in 1997. Mr. Felsenthal is currently a director of Vericare Management, Inc., OnShift, Inc. and ClearDATA Networks. Previously, he served on the boards of Aperio Technologies, Inc., Change Healthcare Corporation, Titan Health, U.S. Renal Care, PayerPath and CombiMatrix Corporation. In 2014, Mr. Felsenthal began working as an Advisor to California Healthcare Foundation Health Innovation Fund, which supports business models with the potential to significantly lower the cost of care or to improve access to care for underserved populations. Mr. Felsenthal earned a B.A. from Princeton University and an M.B.A. from the Stanford University Graduate School of Business. Our board of directors has concluded that Mr. Felsenthal should serve as a director because of his broad experience in the healthcare industry and his significant directorship experience.
William H. Frist, M.D. became a member of our board of directors in September 2014. Senator Frist is a Partner in Cressey & Company, a private equity firm focused exclusively on investing in and building leading healthcare businesses. He is Chairman of the Cressey Distinguished Executive Council. As a U.S. Senator, he represented Tennessee for 12 years where he served on both the Finance and HELP committees responsible for writing all health legislation. He served as U.S. Senate Majority Leader from 2003 to 2006. Prior to the Senate, Senator Frist spent 20 years in clinical medicine, completing surgical training at Harvard's Massachusetts General Hospital and Stanford and he subsequently founded the Vanderbilt Multi-Organ Transplant Center. Senator Frist serves as an adjunct professor of Cardiac Surgery at Vanderbilt University and Clinical Professor of Surgery at Meharry Medical College. His previous board service includes Princeton University, the Smithsonian Institution and the Clinton Bush Haiti Fund. Senator Frist currently serves as a director of the publicly held companies Select Medical and AECOM. In addition, he is
118
on the boards of Theranos, Unitek, Aegis, Aspire, MDSave, Cognosante and Accolade. He previously served as a director of URS Corporation from November 2009 to 2014, and on the board of Third National Bank from 1990 to1994. He is chairman of Hope Through Healing Hands, a nonprofit which focuses on maternal and child health, and SCORE, a collaborative K12 education reform organization. His current board services include the Robert Wood Johnson Foundation, Kaiser Family Foundation, Harvard Medical School Board of Fellows, Center for Strategic and International Studies, Partnership for a Healthier America campaign to fight childhood obesity and the Nashville Health Center Care Council. He is a Senior Fellow at the Bipartisan Policy Center, where he is co-leader of the Health Project. Senator Frist earned his B.A. from Princeton University and M.D. from Harvard Medical School. Our board of directors has concluded that Senator Frist should serve as a director because of his significant directorship experience and his broad experience in the healthcare industry.
Michael Goldstein became a member of our board of directors in February 2015. Mr. Goldstein was employed by Ernst & Young (and its predecessor firms) from 1963 to 1979, including six years as an audit partner. Mr. Goldstein served as Chairman of Toys "R" Us, Inc. from 1998 to 2001, Chief Executive Officer from 1999 to 2000, Vice Chairman and Chief Executive Officer from 1994 to 1998 and Chief Financial Officer from 1983 to 1994. Mr. Goldstein is a director and chairman of the audit committee of Pacsun since 2004 and a director, chairman of the governance, compliance and nominating committee and member of the audit committee and corporate strategy committee of Bioscrip since 2015. Mr. Goldstein has served as director of various private companies and not-for-profit charitable organizations. Mr. Goldstein served on the boards of the following public companies within the last five years: Charming Shoppes, Inc. from 2008 to 2012; 4 Kids Entertainment, Inc. from 2002 to 2012; Martha Stewart Living Omnimedia, Inc. from 2004 to 2010; and Medco Health Solutions, Inc. from 2005 to 2012. Our board of directors believes Mr. Goldstein is qualified to serve as a director of the Company due to his experience and governance leadership roles on the Boards of various other public companies, as well as his extensive background in finance, both as an audit partner and as a finance executive and chief executive officer of a large public corporation.
Thomas Mawhinney became a member of our board of directors in September 2014. He is currently a General Partner of Icon Ventures, a technology venture capital firm, having joined the firm in 2003. Before joining Icon, Mr. Mawhinney was with Canaan Partners, an early-stage venture capital firm with $2 billion under management, from 2001 to 2003. As an entrepreneur, Mr. Mawhinney co-founded and spent five years as President and Chief Operating Officer of North Systems, a venture-backed software company. Prior to his time with North Systems, he developed his skills as a technology investor and entrepreneur working as a Senior Associate at Summer Partners. Mr. Mawhinney is on the Boards of Directors of or actively involved with Awarepoint, Bill.com, Groundwork, Huddle, Ionic Security, KIXEYE, MarketLive, Reputation.com, Voltage Security, Xambala, Yodle and Zephyr Health and previously served on the board at Monitise. Mr. Mawhinney graduated with honors, earning a B.A. from Harvard University and received his M.B.A. from the Stanford University Graduate School of Business. Our board of directors has concluded that Mr. Mawhinney should serve as a director because of his significant directorship experience and his broad experience in the technology industry.
Thomas G. McKinley became a member of our board of directors in November 2009. Mr. McKinley is a General Partner and the West Coast Representative for Cardinal Partners, a venture capital firm focused exclusively on healthcare investing. Prior to joining Cardinal, Mr. McKinley was the co-founder and Co-Managing Partner of Partech International. Mr. McKinley has over 35 years of investment experience. Mr. McKinley currently serves on the board of directors of lifeIMAGE, a cloud-based medical imaging sharing platform for hospitals, physicians, and patients. Mr. McKinley earned an undergraduate degree in Economics from Harvard University, an M.S. in Accounting from New York University and an M.B.A. from the Stanford University Graduate
119
School of Business. Our board of directors has concluded that Mr. McKinley should serve as a director because of his significant directorship experience and his broad experience in the healthcare and technology industries.
Dana G. Mead, Jr. became a member of our board of directors in August 2011. Mr. Mead is a strategic advisor to Kleiner Perkins Caufield & Byers, where he served as a partner in the life sciences practice from 2005 to 2015. Mr. Mead currently serves on the boards of Intersect ENT as well as several privately held Kleiner Perkins Caufield & Byers portfolio companies. From 1992 to 2005, Mr. Mead worked for Guidant where he held numerous positions including, most recently, President of Guidant Vascular Intervention. Mr. Mead earned a B.A. from Lafayette College and an M.B.A. from the University of Southern California. Our board of directors has concluded that Mr. Mead should serve as a director because of his significant directorship experience and his broad experience in the healthcare industry.
Arneek Multani became a member of our board of directors in 2008. Mr. Multani is a Managing Director of Trident Capital and joined the firm in 2002. He leads Trident's Healthcare Information Technology practice and co-leads Trident's Growth Equity practice. Prior to joining Trident, Mr. Multani was an Associate at McCown De Leeuw, a private equity firm specializing in leveraged buy-outs, where he focused on investing in the health and fitness industries. He started his career as an analyst at Morgan Stanley & Co in the Media & Telecommunications area of the Mergers & Acquisitions Group. Mr. Multani currently sits on the board of directors of Imagine Health, MedSave USA, HealthMEDX, Acclaris, and is a Board Observer at Advanced ICU Care. Mr. Multani's past directorships and observerships include Resolution Health and Profex. He earned a B.S. in Economics from Wharton School of Business and a B.A.S. in Systems Engineering from the Moore School of Engineering at the University of Pennsylvania, where he graduated summa cum laude. He earned his M.B.A. from the Stanford University Graduate School of Business. Our board of directors has concluded that Mr. Multani should serve as a director because of his broad experience in the healthcare industry and his significant core business skills, including financial and strategic planning.
James Outland became a member of our board of directors in May 2006. Mr. Outland is a Managing Partner and co-founder of New Capital Partners, a private equity firm which invests in high growth companies primarily in the Southeastern United States and Texas. He has over 25 years of private equity, mergers and acquisitions and business development leadership experience in both entrepreneurial business ventures and well-established corporations. Prior to co-founding New Capital Partners, Mr. Outland served in various key roles in the healthcare industry as an officer of UnitedHealth Group after its acquisition of Complete Health Services and as a Principal at Momentum Health Services where he specialized in mergers & acquisitions. He began his career developing an entrepreneurial business within ProServ, Inc., a leader in the sports marketing industry which was subsequently acquired by SFX and later Clear Channel. He opened a West Coast office and later led the business development for ProServ athletes and properties in the Southeast. Mr. Outland also served as the Chief Executive Officer for Senior Whole Health during its first years of operation, in addition to his role as Chairman of the Board. He has led numerous private equity investments and currently serves as Chairman of the Board for Repay Holdings, MDnetSolutions and Medsurant LLC. He previously served on the Boards of PrismPointe Technologies, Senior Whole Health and Styx Capital. He graduated from Southern Methodist University with a B.A. in Political Science and a B.F.A. in Advertising. Our board of directors has concluded that Mr. Outland should serve as a director because of his broad experience in the healthcare industry and his significant core business skills, including financial and strategic planning.
David B. Snow, Jr. became a member of our board of directors in February 2014 and became Chairman of our board of directors in December 2014. Mr. Snow currently serves as Chairman and chief executive officer of Cedar Gate Technologies, Inc., a provider of analytic and information
120
technology services to doctor and hospital organizations entering risk-based reimbursement arrangements with insurers, since February 2014. Until April 2012, Mr. Snow was Chairman and Chief Executive Officer of Medco Health Solutions, Inc., a leading pharmacy benefit manager. His current board service includes CareCentrix and Pitney Bowes, Inc., where he has been a director since 2006. He formerly served as a director of Medco Health Solutions, Inc. In addition to his experience as the chief executive officer of a public company, Mr. Snow has a strong background in operations, having served in leadership positions at several companies including WellChoice (Empire Blue Cross Blue Shield) and Oxford Health Plans. Mr. Snow earned a B.S. in Economics from Bates College and a Master's Degree in Health Care Administration from Duke University. Our board of directors has concluded that Mr. Snow should serve as a director because of his broad experience in the healthcare industry and his significant core business skills, including financial and strategic planning.
Board Composition and Election of Directors
Subject to the rights of the holders of any series of preferred stock to elect additional directors under specified circumstances, our board of directors may establish the authorized number of directors from time to time by resolution. Our board of directors currently consists of ten members. Our current certificate of incorporation and investors' rights agreement (as defined below in "Certain Relationships and Related Person Transactions") among certain investors, including entities associated with Kleiner Perkins Caufield & Byers, HLM Venture Partners, Cardinal Partners, Trident Capital Partners, New Capital Partners and Icon Ventures, entered into in connection with our convertible preferred stock financings, provide for one director to be elected by holders of our Series A convertible preferred stock and Series A-1 convertible preferred stock, one director to be elected by holders of our Series B convertible preferred stock, two directors to be elected by holders of our Series C convertible preferred stock, one director to be elected by holders of our Series D convertible preferred stock, one director to be elected by holders of our Series F convertible preferred stock, one director constituting the individual serving as the then-current Chief Executive Officer, or the CEO Designee, of the Company and two directors to be elected by a majority of the other members of our board of directors, or the Mutual Designees. Mr. Outland is the designee of our Series A and Series A-1 convertible preferred stock, Mr. Multani is the designee of our Series B convertible preferred stock, Messrs. Felsenthal and McKinley are the designees of our Series C-1 convertible preferred stock, Mr. Mead is the designee of our Series D convertible preferred stock, Mr. Mawhinney is the designee of our Series F convertible preferred stock, Mr. Gorevic is the CEO Designee and Mr. Snow, Senator Frist and Mr. Goldstein are the Mutual Designees.
The provisions of the investors' rights agreement and of our certificate of incorporation by which Messrs. Outland, Multani, Felsenthal, McKinley, Mead and Mawhinney were elected will no longer be in effect upon the consummation of this offering and there will be no other contractual obligations regarding the election of our directors. Each of our current directors will continue to serve until the election and qualification of his or her successor, or his or her earlier death, resignation or removal.
Director Independence
Our board of directors currently consists of ten members. Our board of directors has determined that all of our directors except Mr. Gorevic do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is "independent" as that term is defined under the rules of the NYSE. There are no family relationships among any of our directors or executive officers.
121
Classified Board of Directors
In accordance with our amended and restated certificate of incorporation that will go into effect upon the closing of this offering, our board of directors will be divided into three classes with staggered, three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Effective upon the closing of this offering, our directors will be divided among the three classes as follows:
Our amended and restated certificate of incorporation that will go into effect upon the closing of this offering will provide that the authorized number of directors may be changed only by resolution of our board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control of our company. Our directors may be removed only for cause by the affirmative vote of the holders of at least two-thirds of our outstanding voting stock entitled to vote in the election of directors. See "Risk FactorsRisks Related to this Offering and Ownership of Our Common StockProvisions in our amended and restated certificate of incorporation and amended and restated bylaws and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management."
Role of the Board in Risk Oversight
One of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors does not have a standing risk management committee, but rather administers this oversight function directly through our board of directors as a whole, as well as through various standing committees of our board of directors that address risks inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure and our audit committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The audit committee also monitors compliance with legal and regulatory requirements. Our compensation committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire board is regularly informed through committee reports about such risks.
Board Committees
Our board of directors directs the management of our business and affairs and conducts its business through meetings of our board of directors and three standing committees: the audit committee, the compensation committee and the regulatory and compliance committee. Effective upon completion of this offering, we expect that our board of directors will also have a nominating
122
and corporate governance committee. In addition, from time to time, other committees may be established under the direction of our board of directors when necessary or advisable to address specific issues.
Each of the audit committee, the compensation committee, the regulatory and compliance committee and the nominating and corporate governance committee will operate under a charter that will be approved by our board of directors in connection with this offering. A copy of each of the audit committee, compensation committee and nominating and corporate governance committee charters will be available on our website upon completion of this offering.
Audit Committee
Our audit committee, which following this offering will consist of Messrs. , will be responsible for, among its other duties and responsibilities, assisting our board of directors in overseeing: our accounting and financial reporting processes and other internal control processes, the audits and integrity of our financial statements, our compliance with legal and regulatory requirements, the qualifications and independence of our independent registered public accounting firm and the performance of our internal audit function and independent registered public accounting firm. Our audit committee will be directly responsible for the appointment, compensation, retention and oversight of our independent registered public accounting firm.
Our board of directors has determined that Messrs. are each an "audit committee financial expert" as such term is defined under the applicable regulations of the SEC and have the requisite accounting or related financial management expertise and financial sophistication under the applicable rules and regulations of the NYSE. Our board of directors has also determined that Messrs. are independent under Rule 10A-3 under the Exchange Act and the NYSE standard, for purposes of the audit committee.
Compensation Committee
Our compensation committee, which following this offering will consist of Messrs. , will be responsible for, among its other duties and responsibilities, reviewing and approving the compensation philosophy for our Chief Executive Officer, reviewing and approving all forms of compensation and benefits to be provided to our other executive officers and reviewing and overseeing the administration of our equity incentive plans.
Our board has determined that each of and is independent under the applicable rules and regulations, is a "non-employee director" as defined in Rule 16b-3 promulgated under the Exchange Act and is an "outside director" as that term is defined in Section 162(m) of the Code.
Regulatory and Compliance Committee
Our regulatory and compliance committee, which following this offering will consist of Messrs. , will be responsible for assisting our board of directors in discharging its responsibilities relating to legal and regulatory compliance (excluding matters of financial compliance, which are subject to the oversight of the Audit Committee).
Nominating and Corporate Governance Committee
Our nominating and corporate governance committee, which following this offering we expect will consist of Messrs. , will be responsible for, among its other duties and responsibilities, identifying and recommending candidates to our board of directors for election to our board of directors, reviewing the composition of members of our board of directors and its committees, developing and recommending to our board of directors corporate governance
123
guidelines that are applicable to us and overseeing our board of directors and its committees evaluations.
Compensation Committee Interlocks and Insider Participation
During the fiscal year ended December 31, 2014, the members of our compensation committee were Messrs. McKinley and Multani. No member of our compensation committee is or has been our current or former officer or employee. None of our executive officers served as a director or a member of a compensation committee (or other committee serving an equivalent function) of any other entity, one of whose executive officers served as a director or member of our compensation committee during the fiscal year ended December 31, 2014.
Code of Ethics and Code of Conduct
We will adopt a written code of business conduct and ethics, to be effective upon the closing of this offering, that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions. Upon completion of this offering, our code of business conduct and ethics will be available on our website at www.teladoc.com . In addition, we intend to post on our website all disclosures that are required by law or the listing standards of concerning any amendments to, or waivers from, any provision of the code. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website and you should not consider it to be a part of this prospectus.
124
EXECUTIVE AND DIRECTOR COMPENSATION
The following contains forward-looking statements that are based on our current plans and expectations regarding future compensation programs. See "Special Note Regarding Forward-Looking Statements." Actual compensation programs that we adopt may differ from the programs summarized in this discussion.
Executive Compensation
This section discusses the material components of the executive compensation program offered to our named executive officers identified below. For 2014, our named executive officers were:
We are an "emerging growth company," within the meaning of the JOBS Act, and have elected to comply with the reduced compensation disclosure requirements available to emerging growth companies under the JOBS Act.
2014 Summary Compensation Table
Name and Principal Position
|
Year |
Salary
($) |
Bonus
($)(1) |
Option
Awards ($)(2) |
Non-Equity
Incentive Plan Compensation ($)(3) |
All Other
Compensation ($) |
Total
($) |
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jason Gorevic |
2014 | 361,084 | 68,530 | 516,124 | 168,987 | 21,219 | (4) | 1,135,944 | ||||||||||||||
President and Chief Executive Officer |
||||||||||||||||||||||
Mark Hirschhorn |
2014 |
309,500 |
|
473,887 |
100,588 |
21,219 |
(5) |
905,194 |
||||||||||||||
Executive Vice President and Chief Financial Officer |
||||||||||||||||||||||
Michael King |
2014 |
259,000 |
|
207,772 |
509,537 |
16,400 |
(6) |
992,709 |
||||||||||||||
Chief Sales Officer |
125
Narrative Disclosure to Summary Compensation Table
The primary elements of compensation for our named executive officers are base salary, annual performance bonuses, commissions and equity-based compensation awards. The named executive officers also participate in employee benefit plans and programs that we offer to our other full-time employees on the same basis.
Base Salaries
We pay our named executive officers a base salary to compensate them for the satisfactory performance of services rendered to our company. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive's skill set, experience, role and responsibilities. Base salaries for our named executive officers have generally been set at levels deemed necessary to attract and retain individuals with superior talent.
Effective March 16, 2014, our board of directors approved an increase in Mr. Gorevic's base salary from $350,000 to $364,000, Mr. Hirschhorn's base salary from $300,000 to $312,000 and Mr. King's base salary from $240,000 to $264,000.
Performance Bonuses
We offer our named executive officers the opportunity to earn annual cash incentives to compensate them for attaining short-term company and individual performance goals. Each of Messrs. Gorevic and Hirschhorn has an annual target bonus that that is expressed as a percentage of his annual base salary. The 2014 target bonus percentages for our named executive officers were 36% for Mr. Gorevic and 25% for Mr. Hirschhorn. Mr. King's short-term incentive compensation for 2014 was commissions based.
Our compensation committee, based upon the recommendation of our Chief Executive Officer, establishes company performance goals each year and, at the completion of the year, determines actual bonus payouts after assessing company performance against these goals and a named executive officer's individual performance and contributions to the company's achievements. The 2014 company performance goals for Messrs. Gorevic and Hirschhorn were based on our revenue, EBITDA, member satisfaction, total revenue and current year's and completed telehealth visits.
For 2014, Mr. King was entitled to receive commissions based on a percentage of incremental revenue generated from sales to new Clients, subject to achievement of a threshold annual incremental revenue amount.
The actual cash bonuses earned by our named executive officers, and the actual sales commission earned by Mr. King, for 2014 are reported under the "Non-Equity Incentive Plan Compensation" column of the 2014 Summary Compensation Table above.
Equity Compensation
We grant stock options to our named executive officers as the long-term incentive component of their compensation. We have historically granted stock options to named executive officers when they commenced employment with us and have from time to time thereafter made additional grants as and when our board of directors determined appropriate to reward, retain or encourage particular named executive officers.
Our stock options typically have an exercise price equal to the fair market value of our common stock on the date of grant, as determined by our board of directors, and vest as to 25% of the underlying shares on the first anniversary of the date of grant and in equal monthly installments
126
over the following 36 months, subject to the holder's continued employment with us. From time to time, our board of directors may also construct alternate vesting schedules as it determines are appropriate to motivate particular employees. Our stock options may be intended to qualify as incentive stock options under the Code. Stock options granted to our named executive officers may be subject to accelerated vesting in certain circumstances, as described in the section titled "Employment Arrangements."
We granted stock options in the following amounts to our named executive officers during 2014:
Named Executive Officer
|
2014 Options Granted
(#) |
|||
---|---|---|---|---|
Jason Gorevic |
355,500 | |||
Mark Hirschhorn |
325,657 | |||
Michael King |
143,111 |
These options were granted under the Prior Plan, subject to our standard option terms described above.
In connection with this offering, we intend to adopt a 2015 Incentive Award Plan, or the 2015 Plan, to facilitate the grant of cash and equity incentives to our directors, employees (including our named executive officers) and consultants and to enable our company to obtain and retain the services of these individuals, which we believe is essential to our long-term success. Following the effective date of our 2015 Plan, we will not make any further grants under our Prior Plan. However, the Prior Plan will continue to govern the terms and conditions of the outstanding awards granted under it. For further information about the 2015 Plan, see "2015 Incentive Award Plan" below.
Retirement, Health, Welfare and Additional Benefits
Our named executive officers are eligible to participate in our employee benefit plans and programs, including medical and dental benefits, flexible spending accounts and short- and long-term disability and life insurance, to the same extent as our other full-time employees, subject to the terms and eligibility requirements of those plans, except that we pay the full cost of the healthcare coverage for our named executive officers. We also sponsor a 401(k) defined contribution plan in which our named executive officers may participate, subject to limits imposed by the Code, to the same extent as our other full-time employees. Currently, we match 100% of contributions made by participants in the 401(k) plan up to 4% of eligible annual compensation. All matching contributions are fully vested when made.
127
Outstanding Equity Awards at 2014 Fiscal Year-End
|
|
Option Awards | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Name
|
Grant Date |
Number of
Securities Underlying Unexercised Options (#) Exercisable |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
Equity Incentive
Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) |
Option
Exercise Price ($) |
Option
Expiration Date |
|||||||||||||
Jason Gorevic |
12/22/2014 | | 355,500 | (1) | 2.63 | 12/22/2024 | |||||||||||||
|
12/11/2013 | | | 204,830 | (2) | 0.73 | 12/11/2023 | ||||||||||||
|
12/11/2013 | | 204,830 | (3) | 0.73 | 12/11/2023 | |||||||||||||
|
4/16/2012 | 330,053 | 389,363 | (1) | 0.47 | 4/16/2022 | |||||||||||||
|
1/25/2011 | 74,169 | 8,241 | (1) | 0.35 | 1/25/2021 | |||||||||||||
Mark Hirschhorn |
12/22/2014 | | 250,657 | (1) | 2.63 | 12/22/2024 | |||||||||||||
|
9/10/2014 | | 75,000 | (1) | 2.63 | 9/10/2024 | |||||||||||||
|
12/11/2013 | | | 54,958 | (2) | 0.73 | 12/11/2023 | ||||||||||||
|
12/11/2013 | | 54,958 | (3) | 0.73 | 12/11/2023 | |||||||||||||
|
12/31/2012 | | 289,665 | (1) | 0.47 | 12/31/2022 | |||||||||||||
Michael King |
12/22/2014 | | 143,111 | (1) | 2.63 | 12/22/2024 | |||||||||||||
|
12/11/2013 | | | 36,350 | (2) | 0.73 | 12/11/2023 | ||||||||||||
|
12/11/2013 | | 35,350 | (3) | 0.73 | 12/11/2023 | |||||||||||||
|
4/16/2013 | 56,738 | 79,434 | (1) | 0.47 | 4/16/2023 | |||||||||||||
|
1/25/2011 | 19,933 | 1,117 | (1) | 0.35 | 1/25/2021 | |||||||||||||
|
7/26/2010 | 16,874 | | 0.35 | 7/26/2020 |
Employment Arrangements
We have entered into employment agreements with each of our named executive officers that will become effective on the closing of this offering. Certain key terms of these agreements are described below.
Jason Gorevic
The employment agreement with Mr. Gorevic entitles him to an initial annual base salary of $425,000 and an annual target bonus opportunity of 100% of his gross base salary wages for 2015
128
and his annual base salary thereafter. In addition, Mr. Gorevic is eligible to earn a potential bonus for over-performance of at least 150% of his annual base salary.
In the event Mr. Gorevic is terminated by us without cause or he resigns for good reason, subject to his timely executing a release of claims in our favor, he is entitled to receive: (i) 18 months of continued base salary and life insurance; (ii) up to 18 months of continued medical, dental or vision coverage pursuant to COBRA, if elected; (iii) a pro rata portion of the bonus he would have earned for the year of termination and (iv) accelerated vesting of time-based equity awards scheduled to vest within 12 months following the date of termination and continued eligibility to vest in awards subject to performance-based vesting conditions if and to the extent such performance conditions are satisfied during that 12-month period. If the termination occurs within 12 months following a change in control, subject to his timely executing a release of claims in our favor, Mr. Gorevic is entitled to receive the following in lieu of the severance benefits described in the previous sentence: (i) a lump-sum payment equal to 150% of his base salary plus target bonus opportunity; (ii) 18 months of continued life insurance; (iii) up to 18 months of continued medical, dental or vision coverage pursuant to COBRA, if elected; (iv) a pro rata portion of the bonus he would have earned for the year of termination and (v) accelerated vesting of his time-based equity awards and continued eligibility to vest in awards subject to performance-based vesting conditions if and to the extent such performance conditions are thereafter satisfied.
The employment agreement contains restrictive covenants pursuant to which Mr. Gorevic has agreed to refrain from competing with us or soliciting our employees or customers for a period of 18 months following his termination of employment, provided that Mr. Gorevic may perform services for competitors with multiple lines of business if he (i) does not participate in any material respect in the competing business and (ii) if multiple lines of business report to Mr. Gorevic, any competing business lines account for less than 15% of the net revenue over the prior year for the business lines reporting to him.
For purposes of the employment agreement:
Mark Hirschhorn and Michael King
The employment agreements with Messrs. Hirschhorn and King are for an unspecified term and entitle them to initial annual base salaries of $335,000 and $274,600, respectively, subject to annual review and adjustment. Mr. Hirschhorn is entitled to an annual target bonus opportunity of
129
65% of his gross base salary wages for 2015 and his annual base salary thereafter. Mr. King is entitled to an annual bonus opportunity based on certain corporate, new business and net-dollar retention goals for a portion of 2015 and 2016, and an annual target bonus opportunity of 75% of his annual base salary thereafter.
In the event either of Messrs. Hirschhorn or King is terminated by us without cause or he resigns for good reason, subject to his timely executing a release of claims in our favor, he is entitled to receive: (i) 12 months of continued base salary and life insurance; (ii) up to 12 months of continued medical, dental or vision coverage pursuant to COBRA, if elected and (iii) accelerated vesting of time-based equity awards scheduled to vest within 6 months following the date of termination and continued eligibility to vest in awards subject to performance-based vesting conditions if and to the extent such performance conditions are satisfied during that 6-month period. If either of Messrs. Hirschhorn's or King's termination occurs within 12 months following a change in control, subject to his timely executing a release of claims in our favor, he is entitled to receive the following in lieu of the severance benefits described in the previous sentence: (i) a lump-sum payment equal to his base salary plus target bonus opportunity; (ii) 12 months of continued life insurance; (iii) up to 12 months of continued medical, dental or vision coverage pursuant to COBRA, if elected; (iv) a pro rata portion of the bonus he would have earned for the year of termination and (v) accelerated vesting of his time-based equity awards and continued eligibility to vest in awards subject to performance-based vesting conditions if and to the extent such performance conditions are thereafter satisfied.
The employment agreements contain restrictive covenants pursuant to which each of Mr. Hirschhorn and Mr. King has agreed to refrain from competing with us or soliciting our employees or customers following his termination of employment for a period of 12 months.
For purposes of the employment agreements, "cause" has the same meaning as in Mr. Gorevic's employment agreement. "Good reason" generally means, with respect to Mr. Hirschhorn or Mr. King, subject to certain notice requirements and cure rights, (i) a material reduction in the aggregate amount of his base salary and target bonus without his consent (except for a reduction applicable to the management team generally); (ii) a material reduction in his overall responsibilities or authority, or scope of duties (except following a change in control in certain circumstances with respect to Mr. King); (iii) a requirement that he relocate his principal place of employment outside of the New York City metropolitan area or (iv) our material breach of the employment agreement.
Long-Term Incentive Plans
The following summarizes the material terms of the long-term incentive plans in which our employees, including the named executive officers, participate.
2015 Incentive Award Plan
Effective the day prior to commencing this offering, we adopted and our stockholders approved the 2015 Plan, under which we may grant cash and equity incentive awards to eligible service providers in order to attract, motivate and retain the talent for which we compete. The material terms of the 2015 Plan, are summarized below.
Eligibility and Administration. Our employees, consultants and directors, and employees, consultants and directors of our subsidiaries will be eligible to receive awards under the 2015 Plan. Following our initial public offering, the 2015 Plan will generally be administered by our board of directors with respect to awards to non-employee directors and by our compensation committee with respect to other participants, each of which may delegate its duties and responsibilities to committees of our directors and/or officers (referred to collectively as the plan administrator below),
130
subject to certain limitations that may be imposed under the 2015 Plan, Section 16 of the Exchange Act and/or stock exchange rules, as applicable. The plan administrator will have the authority to make all determinations and interpretations under, prescribe all forms for use with, and adopt rules for the administration of, the 2015 Plan, subject to its express terms and conditions. The plan administrator will also set the terms and conditions of all awards under the 2015 Plan, including any vesting and vesting acceleration conditions.
Limitation on Awards and Shares Available. An aggregate of 4,923,000 shares of our common stock will initially be available for issuance under awards granted pursuant to the 2015 Plan. The number of shares initially available for issuance will be increased by (i) the number of shares represented by awards outstanding under our Prior Plan that are forfeited, lapse unexercised or are settled in cash and which following the effective date of the 2015 Plan are not issued under the Prior Plan and (ii) an annual increase on January 1 of each calendar year beginning in 2016 and ending in 2025, equal to the least of (A) 4,226,000 shares, (B) 5 percent of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (C) such smaller number of shares as determined by our board of directors. No more than 47,183,000 shares of common stock may be issued upon the exercise of incentive stock options. Shares issued under the 2015 Plan may be authorized but unissued shares, shares purchased in the open market or treasury shares.
If an award under the 2015 Plan is forfeited, expires or is settled for cash, any shares subject to such award may, to the extent of such forfeiture, expiration or cash settlement, be used again for new grants under the 2015 Plan. Awards granted under the 2015 Plan upon the assumption of, or in substitution for, awards authorized or outstanding under a qualifying equity plan maintained by an entity with which we enter into a merger or similar corporate transaction will not reduce the shares available for grant under the 2015 Plan.
Awards. The 2015 Plan provides for the grant of stock options, including incentive stock options, or ISOs, and nonqualified stock options, or NSOs, restricted stock, dividend equivalents, stock payments, restricted stock units, or RSUs, stock appreciation rights, or SARs, and other stock or cash based awards. Certain awards under the 2015 Plan may constitute or provide for a deferral of compensation, subject to Section 409A of the Code, which may impose additional requirements on the terms and conditions of such awards. All awards under the 2015 Plan will be set forth in award agreements, which will detail the terms and conditions of the awards, including any applicable vesting and payment terms and post-termination exercise limitations. Awards other than cash awards generally will be settled in shares of our common stock, but the plan administrator may provide for cash settlement of any award. A brief description of each award type follows.
131
value of the underlying share on the date of grant (except with respect to certain substitute SARs granted in connection with a corporate transaction), and the term of a SAR may not be longer than ten years. Vesting conditions determined by the plan administrator may apply to SARs and may include continued service, performance and/or other conditions.
Performance Awards. Performance awards include any of the foregoing awards that are granted subject to vesting and/or payment based on the attainment of specified performance goals or other criteria the plan administrator may determine, which may or may not be objectively determinable. Performance criteria upon which performance goals are established by the plan administrator may include but are not limited to: net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization and non-cash equity-based compensation expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including but not limited to gross profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or operating margin, budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash flow (including operating cash flow and free cash flow or cash flow return on capital); return on assets; return on capital or invested capital; cost of capital; return on stockholders' equity; total stockholder return; return on sales; costs, reductions in costs and cost control measures; expenses; working capital; earnings or loss per share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment of objectives relating to research, development, regulatory, commercial or strategic milestones or developments; market share; economic value or economic value added models; division, group or corporate financial goals; customer satisfaction/growth; customer service; employee satisfaction; recruitment and maintenance of personnel; human resources management; supervision of litigation and other legal matters; strategic partnerships and transactions; financial ratios (including those measuring liquidity, activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand; acquisition activity; investment sourcing activity; and marketing initiatives, any of which may be measured in absolute terms or as
132
compared to any incremental increase or decrease, peer group results or market performance indicators or indices.
Certain Transactions. In connection with certain transactions and events affecting our common stock, including a change in control, or change in any applicable laws or accounting principles, the plan administrator has broad discretion to take action under the 2015 Plan to prevent the dilution or enlargement of intended benefits, facilitate such transaction or event, or give effect to such change in applicable laws or accounting principles. This includes canceling awards, accelerating the vesting of awards, providing for the assumption or substitution of awards by a successor entity, adjusting the number and type of shares available and replacing or terminating awards under the 2015 Plan. In addition, in the event of certain non-reciprocal transactions with our stockholders, or an "equity restructuring," the plan administrator will make equitable adjustments to the 2015 Plan and outstanding awards as it deems appropriate to reflect the equity restructuring.
Provisions of the 2015 Plan Relating to Director Compensation. The 2015 Plan provides that the plan administrator may establish compensation for non-employee directors from time to time subject to the 2015 Plan's limitations. Prior to commencing this offering, our stockholders approved the initial terms of our non-employee director compensation program, which is described below under the heading "Director Compensation." Our board of directors or its authorized committee may modify the non-employee director compensation program from time to time in the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time, provided that the sum of any cash compensation or other compensation and the grant date fair value of any equity awards granted as compensation for services as a non-employee director during any fiscal year may not exceed $650,000. The plan administrator may make exceptions to this limit for individual non-employee directors in extraordinary circumstances, as the plan administrator may determine in its discretion, provided that the non-employee director receiving such additional compensation may not participate in the decision to award such compensation or in other compensation decisions involving non-employee directors.
Plan Amendment and Termination. Our board of directors may amend or terminate the 2015 Plan at any time; however, except in connection with certain changes in our capital structure, stockholder approval will be required for any amendment that increases the number of shares available under the 2015 Plan. The plan administrator will have the authority, without the approval of our stockholders, to amend any outstanding stock option or SAR to reduce its price per share. No award may be granted pursuant to the 2015 Plan after the tenth anniversary of the date on which our board of directors adopted the 2015 Plan.
Foreign Participants, Claw-Back Provisions, Transferability and Participant Payments. With respect to foreign participants, the plan administrator may modify award terms, establish subplans and/or adjust other terms and conditions of awards, subject to the share limits described above. All awards will be subject to the provisions of any claw-back policy implemented by our company to the extent set forth in such claw-back policy and/or in the applicable award agreement. With limited exceptions for estate planning, domestic relations orders, certain beneficiary designations and the laws of descent and distribution, awards under the 2015 Plan are generally non-transferable prior to vesting and are exercisable only by the participant. With regard to tax withholding obligations arising in connection with awards under the 2015 Plan, and exercise price obligations arising in connection with the exercise of stock options under the 2015 Plan, the plan administrator may, in its discretion, accept cash, wire transfer or check, shares of our common stock that meet specified conditions, a promissory note, a "market sell order," such other consideration as it deems suitable or any combination of the foregoing.
133
2015 Employee Stock Purchase Plan
Effective the day prior to commencing this offering, our board of directors adopted and our stockholders approved a 2015 Employee Stock Purchase Plan, or the ESPP. The material terms of the ESPP, as it is currently contemplated, are summarized below.
Shares Available; Administration. A total of 821,000 shares of our common stock are initially reserved for issuance under our ESPP. In addition, the number of shares available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2016 and ending in 2025, by an amount equal to the least of: (a) 211,000 shares, (b) 0.25% of the shares outstanding on the final day of the immediately preceding calendar year and (c) such smaller number of shares as is determined by our board of directors.
Our board of directors or the compensation committee will have authority to interpret the terms of the ESPP and determine eligibility of participants. We expect that the compensation committee of our board of directors will be the initial administrator of the ESPP.
Eligibility. Our employees are eligible to participate in the ESPP if they are customarily employed by us or a participating subsidiary for more than 20 hours per week and more than five months in any calendar year. However, an employee may not be granted rights to purchase common stock under our ESPP if such employee, immediately after the grant, would own (directly or through attribution) stock possessing 5% or more of the total combined voting power or value of all classes of our common or other class of stock.
Grant of Rights. The ESPP is intended to qualify under Section 423 of the Code and stock will be offered under the ESPP during offering periods. The length of the offering periods under the ESPP will be determined by the plan administrator and may be up to 27 months long. Employee payroll deductions will be used to purchase shares on each purchase date during an offering period. The purchase dates for each offering period will be the final trading day in each offering period. Offering periods under the ESPP will commence when determined by the plan administrator. The plan administrator may, in its discretion, modify the terms of future offering periods.
The ESPP permits participants to purchase common stock through payroll deductions of up to 25% of their eligible compensation, which includes a participant's gross base compensation for services to us, including overtime payments, and excluding sales commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits and other special payments. The plan administrator will establish a maximum number of shares that may be purchased by a participant during any offering period, which, in the absence of a contrary designation, will be 25,000 shares. In addition, no employee will be permitted to accrue the right to purchase stock under the ESPP at a rate in excess of $25,000 worth of shares during any calendar year during which such a purchase right is outstanding (based on the fair market value per share of our common stock as of the first day of the offering period).
On the first trading day of each offering period, each participant will automatically be granted an option to purchase shares of our common stock. The option will expire at the end of the applicable offering period, and will be exercised at that time to the extent of the payroll deductions accumulated during the offering period. Unless the plan administrator otherwise determines, the purchase price of the shares will be 85% of the lower of the fair market value of our common stock on the first trading day of the offering period or on the purchase date, which will be the final trading day of the offering period. Participants may voluntarily end their participation in the ESPP at any time at least one week prior to the end of the applicable offering period, and will be paid their accrued payroll deductions that have not yet been used to purchase shares of common stock. Participation ends automatically upon a participant's termination of employment.
134
A participant may not transfer rights granted under the ESPP other than by will, the laws of descent and distribution or as otherwise provided under the ESPP.
Certain Transactions. In the event of certain transactions or events affecting our common stock, such as any stock dividend or other distribution, change in control, reorganization, merger, consolidation or other corporate transaction, the plan administrator will make equitable adjustments to the ESPP and outstanding rights. In addition, in the event of the foregoing transactions or events or certain significant transactions, including a change in control, the plan administrator may provide for (1) either the replacement of outstanding rights with other rights or property or termination of outstanding rights in exchange for cash, (2) the assumption or substitution of outstanding rights by the successor or survivor corporation or parent or subsidiary thereof, if any, (3) the adjustment in the number and type of shares of stock subject to outstanding rights, (4) the use of participants' accumulated payroll deductions to purchase stock on a new purchase date prior to the next scheduled purchase date and termination of any rights under ongoing offering periods or (5) the termination of all outstanding rights.
Plan Amendment. The plan administrator may amend, suspend or terminate the ESPP at any time. However, stockholder approval of any amendment to the ESPP will be obtained for any amendment which increases the aggregate number or changes the type of shares that may be sold pursuant to rights under the ESPP, changes the corporations or classes of corporations whose employees are eligible to participate in the ESPP or changes the ESPP in any manner that would cause the ESPP to no longer be an employee stock purchase plan within the meaning of Section 423(b) of the Code.
Prior Plan
Our board of directors and stockholders have approved the Prior Plan, under which we may grant stock options and restricted stock awards to employees, directors and consultants or other service providers of our company or its affiliates. We have reserved a total of 12,770,388 shares of our common stock for issuance under the Prior Plan.
Following the effectiveness of the 2015 Plan, we will not make any further grants under the Prior Plan. However, the Prior Plan will continue to govern the terms and conditions of the outstanding awards granted under it. Shares of our common stock subject to awards granted under the Prior Plan that are forfeited, lapse unexercised or are settled in cash and which following the effective date of the 2015 Plan are not issued under the Prior Plan will be available for issuance under the 2015 Plan.
Administration. Our board of directors administers the Prior Plan and has the authority to issue awards under the Prior Plan, to interpret the Prior Plan and awards outstanding thereunder, to select the employees, directors, consultants and other service providers who will participate in the Prior Plan, to determine the size and type of awards under the Prior Plan, to prescribe, amend and waive rules and regulations relating to the Prior Plan, to determine the terms and provisions of award agreements under the Prior Plan, to amend the terms and conditions of any outstanding award (as provided in and subject to the Prior Plan) and to make all other determinations in the judgment of our board of directors that are necessary and desirable for the administration of the Prior Plan. Our board of directors may delegate its authority under the Prior Plan to a committee. Following the effectiveness of this offering, we anticipate that our board of directors will delegate its general administrative authority under the Prior Plan to its compensation committee.
Types of Awards. The Prior Plan provides for the grant of non-qualified and incentive stock options to employees, directors and consultants or other service providers of the company or its affiliates, except that stock options intended to qualify as incentive stock options under the Code
135
may only be granted to employees. As of the date of this prospectus, stock option awards are outstanding under the Prior Plan.
Certain Transactions. In the event of any change in corporate capitalization, such as a stock split, or a corporate transaction, such as any merger, consolidation, separation, including a spin-off, or other distribution of stock or property of the company, any reorganization or any partial or complete liquidation of the company, the number and class of shares that may be delivered under the Prior Plan and the number and class of and/or price of shares subject to outstanding awards granted under the Prior Plan, may be adjusted as determined to be appropriate by our board of directors, in its sole discretion, to prevent dilution or enlargement of rights.
Amendment and Termination. Our board of directors may terminate, suspend, alter or amend the Prior Plan from time to time, provided that no termination, amendment or modification may adversely affect in any material way an outstanding award without the holder's written consent.
Director Compensation
We have not historically paid our non-employee directors for their service on our board of directors. Mr. Gorevic, our Chief Executive Officer, also serves on our board of directors but receives no additional compensation for this service.
In February 2014, we began paying Mr. Snow cash fees in the amount of $10,000 per calendar quarter as compensation for his service on our board of directors. In September 2014, we began paying Senator Frist cash fees in the amount of $10,000 per calendar quarter as compensation for his service on our board of directors. We also granted stock options to Mr. Snow and Senator Frist as compensation during 2014. The terms of these awards are described below.
No other non-employee director received compensation for service on our board of directors in 2014.
Effective upon the effectiveness of the registration statement of which this prospectus forms a part, our board of directors granted each of Messrs. Felsenthal, Mawhinney, McKinley, Mead, Multani and Outland an option to purchase 42,000 shares of our common stock at an exercise price per share equal to the public offering price of our common stock in this offering. These options will vest in three substantially equal annual installments following the date of grant, subject to the director's continued service as a non-employee director through the applicable vesting date. Vesting of the options will accelerate in full immediately prior to a change in control or if the director serves the remainder of his term as a director during which the options are granted and either voluntarily elects not to stand for reelection or elects to stand for reelection and is not reelected by stockholders, in each case, at the first annual meeting of stockholders that occurs on or after the end of such term.
136
2014 Director Compensation Table
Name
|
Fees Earned or
Paid in Cash ($) |
Option
Awards ($)(3) |
All Other
Compensation ($) |
Total
($) |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
David B. Snow, Jr. |
33,333 | 237,065 | | 270,398 | |||||||||
William H. Frist, M.D. |
13,333 | 294,737 | | 308,070 | |||||||||
Martin R. Felsenthal |
| | | | |||||||||
Thomas Mawhinney |
| | | | |||||||||
Thomas G. McKinley |
| | | | |||||||||
Dana G. Mead, Jr. |
| | | | |||||||||
Arneek Multani |
| | | | |||||||||
James Outland |
| | | | |||||||||
John Reardon(1) |
| | | | |||||||||
Sam Havens(2) |
| | 90,593 | 90,593 |
Name
|
Options Outstanding at
Fiscal Year End |
|||
---|---|---|---|---|
David B. Snow, Jr. |
233,000 | (a) | ||
William H. Frist, M.D. |
201,000 | (b) | ||
Martin R. Felsenthal |
| |||
Thomas Mawhinney |
| |||
Thomas G. McKinley |
| |||
Dana G. Mead, Jr. |
| |||
Arneek Multani |
| |||
James Outland |
| |||
John Reardon |
| |||
Sam Havens |
|
137
on September 10, 2015 and in equal monthly installments over the following 36 months, subject to Senator Frist's continued service and accelerated vesting in connection with a change in control. In addition, in connection with this offering, 50% of the unvested options will become vested.
In connection with this offering, we expect to implement a compensation program for our non-employee directors under which each non-employee director will receive the following amounts for their services on our board of directors:
Stock options granted to our non-employee directors under the program will have an exercise price equal to the fair market value of our common stock on the date of grant and will expire not later than ten years after the date of grant. The stock options granted upon a director's initial election or appointment will vest in three substantially equal annual installments following the date of grant. The stock options granted annually to directors will vest in a single installment on the earlier of the day before the next annual meeting of stockholders or the first anniversary of the date of grant. In addition, all unvested stock options will vest in full upon the occurrence of a change in control.
Director fees under the program will be payable in arrears in four equal quarterly installments not later than the 15th day following the final day of each fiscal quarter, provided that the amount of each payment will be prorated for any portion of a quarter that a director is not serving on our board of directors and no fee will be payable in respect of any period prior to the effective date of the registration statement of which this prospectus is a part.
Each member of our board of directors is entitled to be reimbursed for reasonable travel and other expenses incurred in connection with attending meetings of our board of directors and any committee of our board of directors on which he or she serves.
138
CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS
The following includes a summary of transactions since January 1, 2012 to which we have been a party, in which the amount involved exceeded or will exceed $120,000 and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under "Executive and Director Compensation." We also describe below certain other transactions with our directors, executive officers and stockholders.
Preferred Stock Financing
On September 9, 2014 we sold to investors in private placements an aggregate of 11,329,068 shares of our Series F preferred stock at a purchase price of $4.4355 per share, for aggregate consideration of $50.3 million.
On August 28, 2013 we sold to investors in private placements an aggregate of 6,227,169 shares of our Series E preferred stock at a purchase price of $2.4088 per share, for aggregate consideration of $15.0 million.
The following table sets forth the aggregate number of shares of preferred stock acquired by the listed holders of more than 5% of our capital stock. Each share of our preferred stock identified in the following table will convert into shares of common stock immediately prior to the closing of this offering.
Participants
|
Series F
Preferred Stock |
Series E
Preferred Stock |
|||||
---|---|---|---|---|---|---|---|
5% or greater stockholders (1) |
|||||||
Entities affiliated with Icon Ventures |
4,509,076 | | |||||
CHP III, L.P. |
980,568 | 2,490,867 | |||||
HLM Venture Partners II, L.P. |
980,568 | 2,490,867 | |||||
KPCB Holdings, Inc., as nominee |
662,565 | | |||||
Entities affiliated with Trident Capital |
584,381 | 999,113 |
Investors' Rights Agreement
We have entered into our Fifth Amended and Restated Investors' Rights Agreement, dated as of September 10, 2014, as amended by the First Amendment to the Fifth Amended and Restated Investors' Rights Agreement, dated as of February 9, 2015 or, collectively, our investors' rights agreement, with certain holders of our convertible preferred stock, including entities with which certain of our directors are affiliated. These stockholders are entitled to rights with respect to the registration of their shares following this offering under the Securities Act of 1933, as amended, or the Securities Act. For a description of these registration rights, see "Description of Capital StockRegistration Rights."
139
Employment Agreements
In connection with this offering, we intend to enter into new employment agreements with our named executive officers. For more information regarding these agreements, see "Executive and Director CompensationEmployment Arrangements."
Indemnification Agreements
We intend to enter into indemnification agreements with each of our directors and executive officers. These agreements, among other things, require us or will require us to indemnify each director (and in certain cases their related venture capital funds) and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys' fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person's services as a director or executive officer, as applicable. For further information, see "Description of Capital StockLimitations on Liability and Indemnification of Officers and Directors."
Stock Option Grants to Executive Officers and Directors
We have granted stock options to our executive officers and certain of our directors as more fully described in the section entitled "Executive and Director Compensation."
Employee Loan
In May 2013, we loaned Jason Gorevic, our Chief Executive Officer, $0.3 million in connection with his exercise of options to purchase 714,285 shares of our common stock, or the Exercise Shares. The loan was evidenced by a full recourse promissory note, accruing interest on the outstanding principal amount at a rate of 2% per annum, and was secured by a pledge of the Exercise Shares. The entire principal amount and all accrued and unpaid interest of the loan was repaid in full in February 2015. See Note 10 to our audited consolidated financial statements and Note 9 to our unaudited consolidated financial statements, each included elsewhere in this prospectus.
Policies and Procedures for Related Person Transactions
Our board of directors will adopt a written related person transaction policy, to be effective upon the closing of this offering, setting forth the policies and procedures for the review and approval or ratification of related person transactions. This policy will cover, with certain exceptions set forth in Item 404 of Regulation S-K under the Securities Act, any transaction, arrangement or relationship or any series of similar transactions, arrangements or relationships, in which we were or are to be a participant, where the amount involved exceeds $120,000 in any fiscal year and a related person had, has or will have a direct or indirect material interest, including, without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our board of directors is tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm's length transaction and the extent of the related person's interest in the transaction. Any member of our board of directors who is a related person with respect to a transaction under review will not be permitted to participate in the discussions or approval or ratification of the transaction. However, such member of our board of directors will provide all material information concerning the transaction to our board of directors. All of the transactions described in this section occurred prior to the adoption of this policy.
140
The following table sets forth information with respect to the beneficial ownership of our common stock, as of June 4, 2015 by:
The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power. Applicable percentage ownership is based on 5,097,241 shares of our common stock outstanding as of June 4, 2015, assuming the conversion of all outstanding shares of preferred stock into common stock, which will automatically occur immediately prior to the closing of this offering. As of June 4, 2015, our preferred stock was convertible into 58,177,180 shares of our common stock. In computing the number of shares beneficially owned by an individual or entity and the percentage ownership of that person, shares of common stock subject to options or other rights held by such person that are currently exercisable or will become exercisable within 60 days of June 4, 2015 are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person. Unless noted otherwise, the address of all listed stockholders is c/o 2 Manhattanville Road, Suite 203, Purchase, New York 10577. Each of the stockholders listed has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable.
|
Shares beneficially
owned prior to the offering |
Shares beneficially
owned after the offering |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Name of beneficial owner
|
Number | Percent | Number | Percent | |||||||||
5% stockholders |
|||||||||||||
CHP III, L.P.(1) |
11,384,851 | 18.0 | % | ||||||||||
HLM Venture Partners II, L.P.(2) |
11,384,851 | 18.0 | |||||||||||
Entities affiliated with Trident Capital(3) |
11,091,703 | 17.4 | |||||||||||
KPCB Holdings, Inc., as nominee(4) |
7,628,243 | 12.1 | |||||||||||
Entities affiliated with Icon Ventures(5) |
4,509,076 | 7.1 | |||||||||||
Named executive officers and directors |
|||||||||||||
Jason Gorevic(6) |
2,656,084 | 4.2 | |||||||||||
Mark Hirschhorn(7) |
565,594 | * | |||||||||||
Michael King(8) |
469,269 | * | |||||||||||
Martin R. Felsenthal |
| | |||||||||||
William H. Frist, M.D. |
| | |||||||||||
Michael Goldstein |
| | |||||||||||
Thomas Mawhinney |
| | |||||||||||
Thomas G. McKinley |
| | |||||||||||
Dana G. Mead, Jr. |
| | |||||||||||
Arneek Multani |
| | |||||||||||
James Outland(9) |
2,050 | * | |||||||||||
David B. Snow, Jr.(10) |
77,667 | * | |||||||||||
All executive officers and directors as a group (18 persons)(11) |
4,610,060 | 7.2 |
141
142
143
General
The following description summarizes some of the terms of our common stock, amended and restated certificate of incorporation and amended and restated bylaws that will become effective upon the closing of this offering, the investors' rights agreement and of the DGCL. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description, you should refer to our amended and restated certificate of incorporation, amended and restated bylaws and the investors' rights agreement, copies of which have been or will be filed as exhibits to the registration statement of which this prospectus forms a part, as well as the relevant provisions of the DGCL. The description of our common stock and preferred stock reflects changes to our capital structure that will occur upon the closing of this offering.
Following the closing of this offering, our authorized capital stock will consist of shares of common stock, par value $0.001 per share, and shares of preferred stock, par value $0.001 per share.
As of June 4, 2015, we had 5,097,241 shares of our common stock outstanding held of record by 92 holders and 50,452,939 shares of our preferred stock convertible into 58,177,180 shares of our common stock as of such date. Pursuant to our amended and restated certificate of incorporation, all of our outstanding shares of preferred stock will automatically be converted into shares of our common stock immediately prior to the closing of this offering.
Common Stock
Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of our amended and restated certificate of incorporation. See below under "Anti-takeover Effects of Delaware Law and Our Certificate of Incorporation and BylawsAmendment of Charter Provisions." Holders of our common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future.
In the event of our liquidation or dissolution, the holders of our common stock are entitled to receive proportionately our net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of our common stock have no preemptive, subscription, redemption or conversion rights. Our outstanding shares of common stock are, and the shares offered by us in this offering will be, when issued and paid for, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.
144
Warrants
As of June 4, 2015, we had outstanding two warrants to purchase an aggregate of 300,000 shares of our common stock at an exercise price of $1.29 per share. The warrants have a ten-year term. See Note 13 to our unaudited consolidated financial statements included elsewhere in this prospectus.
Preferred Stock
Under the terms of our amended and restated certificate of incorporation that will become effective upon the closing of this offering, our board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.
The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third-party to acquire, or could discourage a third-party from seeking to acquire, a majority of our outstanding voting stock. Upon the closing of this offering, there will be no shares of preferred stock outstanding and we have no present plans to issue any shares of preferred stock.
Options
As of June 4, 2015, our outstanding options to purchase common stock consisted of options to purchase 12,770,388 shares of our common stock under the Prior Plan.
Registration Rights
Upon the closing of this offering, pursuant to the investors' rights agreement, holders of shares of our common stock or their transferees will be entitled to the following rights with respect to the registration of such shares for public resale under the Securities Act. If exercised, these registration rights would enable holders to transfer these shares without restriction under the Securities Act when the applicable registration statement is declared effective.
Subject to the 180-day lock-up restrictions described elsewhere in this prospectus, following the closing of this offering, holders of a majority of our common stock issued upon the conversion of our preferred stock, may request in writing that we effect a resale registration under the Securities Act with respect to all or part of our common stock held by them, subject to certain exceptions. If the holders requesting registration intend to distribute their shares by means of an underwriting, the managing underwriter of such offering will have the right to limit the numbers of shares to be underwritten for reasons related to the marketing of the shares.
Piggyback Registration Rights
Under the investors' rights agreement, at any time after this offering we propose to register any of our stock or other securities under the Securities Act, subject to certain exceptions, the holders of registrable securities will be entitled to notice of the registration and to include their shares of registrable securities in the registration. If our proposed registered offering is an underwritten offering, the managing underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares.
145
Form S-3 Registration Rights
If, at any time after we become entitled under the Securities Act to register our shares on a registration statement on Form S-3, the holders of at least 20% of the registrable securities underlying our preferred stock may request that we file a resale registration statement on Form S-3 with respect to their registrable securities provided the aggregate price to the public in the offering would be at least $5.0 million.
Expenses
Ordinarily, other than underwriting discounts and commissions, we will be required to pay all expenses incurred by us related to any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling security holders and blue sky fees and expenses.
Termination of Registration Rights
The registration rights will continue for five years following the completion of this offering, or for any particular stockholder holding registrable securities, the earlier of the time the stockholder can sell all of its registrable securities in compliance with Rule 144 under the Securities Act in a 90-day period.
Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws
Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares.
These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.
Undesignated Preferred Stock
The ability of our board of directors, without action by the stockholders, to issue up to shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.
Stockholder Meetings
Our amended and restated bylaws provide that a special meeting of stockholders may be called only by our chairman of the board, chief executive officer or president (in the absence of a chief executive officer), or by a resolution adopted by a majority of our directors.
146
Requirements for Advance Notification of Stockholder Nominations and Proposals
Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of our board of directors or a committee of our board of directors.
Elimination of Stockholder Action by Written Consent
Our amended and restated certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting.
Staggered Board
Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class of directors being elected each year by our stockholders. For more information on the classified board, see "ManagementBoard Composition and Election of Directors." This system of electing and removing directors may tend to discourage a third-party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.
Removal of Directors
Our amended and restated certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote in the election of directors.
Stockholders not Entitled to Cumulative Voting
Our amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect.
Delaware Anti-Takeover Statute
We are subject to Section 203 of the DGCL, which prohibits persons deemed to be "interested stockholders" from engaging in a "business combination" with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an "interested stockholder" is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation's voting stock. Generally, a "business combination" includes a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by our board of directors.
Choice of Forum
Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (1) any derivative action or proceeding brought on our behalf;
147
(2) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3) any action asserting a claim against us arising pursuant to any provision of the DGCL or our amended and restated certificate of incorporation or amended and restated bylaws; (4) any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or amended and restated bylaws; or (5) any action asserting a claim governed by the internal affairs doctrine. Our amended and restated certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the choice of forum provision contained in our amended and restated certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise. This choice of forum provision has important consequences to our stockholders. See "Risk FactorsRisks Related to this Offering and Ownership of Our Common StockOur amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees."
Amendment of Charter Provisions
The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock and the provision prohibiting cumulative voting, would require approval by holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote thereon.
The provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.
Limitations on Liability and Indemnification of Officers and Directors
The DGCL authorizes corporations to limit or eliminate the personal liability of directors to corporations and their stockholders for monetary damages for breaches of directors' fiduciary duties, subject to certain exceptions. Our amended and restated certificate of incorporation will include a provision that eliminates the personal liability of directors for monetary damages for any breach of fiduciary duty as a director, except to the extent such exemption from liability or limitation thereof is not permitted under the DGCL. The effect of these provisions will be to eliminate the rights of us and our stockholders, through stockholders' derivative suits on our behalf, to recover monetary damages from a director for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior. However, exculpation will not apply to any director if the director has acted in bad faith, knowingly or intentionally violated the law, authorized illegal dividends or redemptions or derived an improper benefit from his or her actions as a director.
Our amended and restated bylaws will provide that we must indemnify and advance expenses to our directors and officers to the fullest extent authorized by the DGCL. We also will be expressly authorized to carry directors' and officers' liability insurance providing indemnification for our directors, officers and certain employees for some liabilities. We believe that these indemnification and advancement provisions and insurance will be useful to attract and retain qualified directors and officers.
148
The limitation of liability, indemnification and advancement provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. In addition, your investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.
There is currently no pending material litigation or proceeding involving any of our directors, officers or employees for which indemnification is sought.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock will be .
Listing
We plan to apply to have our common stock listed on the NYSE under the symbol "TDOC."
149
SHARES ELIGIBLE FOR FUTURE SALE
Immediately prior to this offering, there was no public market for our common stock. Future sales of substantial amounts of common stock in the public market, or the perception that such sales may occur, could adversely affect the market price of our common stock.
Upon the closing of this offering, we will have outstanding an aggregate of shares of common stock, assuming the issuance of shares of common stock offered by us in this offering, the automatic conversion of all outstanding shares of our preferred stock into shares of our common stock and no exercise of options after March 31, 2015. Of these shares, all shares sold in this offering will be freely tradable without restriction or further registration under the Securities Act, except for any shares purchased by our "affiliates," as that term is defined in Rule 144 under the Securities Act, or Rule 144, whose sales would be subject to Rule 144 resale restrictions described below, other than the holding period requirement.
The remaining shares of common stock will be "restricted securities," as that term is defined in Rule 144 under the Securities Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rules 144 or 701 under the Securities Act, which are summarized below. We expect that substantially all of these shares will be subject to the 180-day lock-up period under the lock-up agreements described below. Upon expiration of the lock-up period, we estimate that approximately shares will be available for sale in the public market, subject in some cases to applicable volume limitations under Rule 144.
In addition, of the shares of our common stock that were subject to stock options outstanding as of March 31, 2015, options to purchase shares of common stock were vested as of March 31, 2015 and, upon exercise, these shares will be eligible for sale subject to the lock-up agreements described below and Rules 144 and 701 under the Securities Act.
Lock-Up Agreements
In connection with this offering, we and each of our directors and executive officers and holders of substantially all of our outstanding capital stock, will agree that, without the prior written consent of the representatives of the underwriters, we and they will not, subject to limited exceptions, during the period ending 180 days after the date of this prospectus:
whether any transaction described above is to be settled by delivery of our common stock or such other securities, in cash or otherwise.
Upon the expiration of the applicable lock-up periods, substantially all of the shares subject to such lock-up restrictions will become eligible for sale, subject to the limitations discussed above. For a further description of these lock-up agreements, please see "Underwriting."
150
Rule 144
Affiliate Resales of Restricted Securities
In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is an affiliate of ours, or who was an affiliate at any time during the 90 days before a sale, who has beneficially owned shares of our common stock for at least six months would be entitled to sell in "broker's transactions" or certain "riskless principal transactions" or to market makers, a number of shares within any three-month period that does not exceed the greater of:
Affiliate resales under Rule 144 are also subject to the availability of current public information about us. In addition, if the number of shares being sold under Rule 144 by an affiliate during any three-month period exceeds 5,000 shares or has an aggregate sale price in excess of $50,000, the seller must file a notice on Form 144 with the SEC and the NYSE concurrently with either the placing of a sale order with the broker or the execution directly with a market maker.
Non-Affiliate Resales of Restricted Securities
In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is not an affiliate of ours at the time of sale, and has not been an affiliate at any time during the three months preceding a sale, and who has beneficially owned shares of our common stock for at least six months but less than a year, is entitled to sell such shares subject only to the availability of current public information about us. If such person has held our shares for at least one year, such person can resell under Rule 144(b)(1) without regard to any Rule 144 restrictions, including the 90-day public company requirement and the current public information requirement.
Non-affiliate resales are not subject to the manner of sale, volume limitation or notice filing provisions of Rule 144.
Rule 701
In general, under Rule 701 under the Securities Act, or Rule 701, any of an issuer's employees, directors, officers, consultants or advisors who purchases shares from the issuer in connection with a compensatory stock or option plan or other written agreement before the effective date of a registration statement under the Securities Act is entitled to sell such shares 90 days after such effective date in reliance on Rule 144. An affiliate of the issuer can resell shares in reliance on Rule 144 without having to comply with the holding period requirement and non-affiliates of the issuer can resell shares in reliance on Rule 144 without having to comply with the current public information and holding period requirements.
The SEC has indicated that Rule 701 will apply to typical stock options granted by an issuer before it becomes subject to the reporting requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after an issuer becomes subject to the reporting requirements of the Exchange Act.
151
Equity Plans
We intend to file one or more registration statements on Form S-8 under the Securities Act to register all shares of common stock subject to outstanding stock options and common stock issued or issuable under our stock plans. We expect to file the registration statement covering shares offered pursuant to our stock plans shortly after the date of this prospectus, permitting the resale of such shares by nonaffiliates in the public market without restriction under the Securities Act and the sale by affiliates in the public market, subject to compliance with the resale provisions of Rule 144.
Registration Rights
Upon the closing of this offering, the holders of shares of common stock, which includes all of the shares of common stock issuable upon the automatic conversion of our preferred stock upon the closing of this offering, or their transferees will be entitled to various rights with respect to the registration of these shares under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration, except for shares purchased by affiliates. See "Description of Capital StockRegistration Rights" for additional information. Shares covered by a registration statement will be eligible for sale in the public market upon the expiration or release from the terms of any lock-up agreements.
152
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS
The following discussion is a summary of the material U.S. federal income tax consequences to Non-U.S. Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws are not discussed. This discussion is based on the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a Non-U.S. Holder of our common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock.
This discussion is limited to Non-U.S. Holders that hold our common stock as a "capital asset" within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a Non-U.S. Holder's particular circumstances, including the impact of the Medicare contribution tax on net investment income. In addition, it does not address consequences relevant to Non-U.S. Holders subject to special rules, including, without limitation:
If an entity treated as a partnership for U.S. federal income tax purposes holds our common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them.
153
THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.
Definition of a Non-U.S. Holder
For purposes of this discussion, a "Non-U.S. Holder" is any beneficial owner of our common stock that is neither a "U.S. person" nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following:
Distributions
As described in the section entitled "Dividend Policy," we do not anticipate declaring or paying dividends to holders of our common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and first be applied against and reduce a Non-U.S. Holder's adjusted tax basis in its common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under "Sale or Other Taxable Disposition."
Subject to the discussion below on effectively connected income, backup withholding and FATCA (as defined below), dividends paid to a Non-U.S. Holder of our common stock will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the Non-U.S. Holder furnishes a valid IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable (or other applicable documentation), certifying qualification for the lower treaty rate). If a Non-U.S. Holder holds the stock through a financial institution or other intermediary, the Non-U.S. Holder will be required to provide appropriate documentation to the intermediary, which then will be required to provide certification to the applicable withholding agent, either directly or through other intermediaries. A Non-U.S. Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an
154
appropriate claim for refund with the IRS. Non-U.S. Holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty.
If dividends paid to a Non-U.S. Holder are effectively connected with the Non-U.S. Holder's conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment or fixed base in the United States to which such dividends are attributable), the Non-U.S. Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the Non-U.S. Holder must furnish to the applicable withholding agent a valid IRS Form W-8ECI, certifying that the dividends are effectively connected with the Non-U.S. Holder's conduct of a trade or business within the United States.
Any such effectively connected dividends generally will be subject to U.S. federal income tax on a net income basis at the regular graduated rates. A Non-U.S. Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. Non-U.S. Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules.
Sale or Other Taxable Disposition
Subject to the discussion of FATCA below, a Non-U.S. Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our common stock unless:
Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular graduated rates. A Non-U.S. Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items.
Gain described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty), which may be offset by U.S. source capital losses of the Non-U.S. Holder (even though the individual is not considered a resident of the United States), provided the Non-U.S. Holder has timely filed U.S. federal income tax returns with respect to such losses.
With respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Because the determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our non-U.S. real property interests and our other business assets, there can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to become
155
a USRPHC, gain arising from the sale or other taxable disposition by a Non-U.S. Holder of our common stock will not be subject to U.S. federal income tax if our common stock is "regularly traded," as defined by applicable Treasury Regulations, on an established securities market and such Non-U.S. Holder owned, actually or constructively, 5% or less of our common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the Non-U.S. Holder's holding period.
Non-U.S. Holders should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules.
Information Reporting and Backup Withholding
Payments of dividends on our common stock will not be subject to backup withholding, provided the applicable withholding agent does not have actual knowledge or reason to know the holder is a United States person and the holder either certifies its non-U.S. status, such as by furnishing a valid IRS Form W-8BEN or W-8BEN-E, as applicable, or W-8ECI, or otherwise establishes an exemption. However, information returns are required to be filed with the IRS in connection with any dividends on our common stock paid to the Non-U.S. Holder, regardless of whether any tax was actually withheld. In addition, proceeds of the sale or other taxable disposition of our common stock within the United States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding or information reporting if the applicable withholding agent receives the certification described above and does not have actual knowledge or reason to know that such holder is a United States person, or the holder otherwise establishes an exemption. Proceeds of a disposition of our common stock conducted through a non-U.S. office of a non-U.S. broker generally will not be subject to backup withholding or information reporting.
Copies of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the tax authorities of the country in which the Non-U.S. Holder resides or is established.
Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a Non-U.S. Holder's U.S. federal income tax liability, provided the required information is timely furnished to the IRS.
Additional Withholding Tax on Payments Made to Foreign Accounts
Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as the Foreign Account Tax Compliance Act, or FATCA) on certain types of payments made to non-U.S. financial institutions and certain other non-U.S. entities. Specifically, a 30% withholding tax may be imposed on dividends on, or gross proceeds from the sale or other disposition of, our common stock paid to a "foreign financial institution" or a "non-financial foreign entity" (each as defined in the Code), unless (1) the foreign financial institution undertakes certain diligence and reporting obligations, (2) the non-financial foreign entity either certifies it does not have any "substantial United States owners" (as defined in the Code) or furnishes identifying information regarding each substantial United States owner or (3) the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements in (1) above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain "specified United States persons" or "United States-owned foreign entities" (each as defined in the Code), annually report certain information about such accounts and withhold 30% on certain payments to non-compliant foreign financial institutions and certain other account holders. Foreign financial institutions located in
156
jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules.
Under the applicable Treasury Regulations and IRS guidance, withholding under FATCA generally will apply to payments of dividends on our common stock and, on or after January 1, 2017, to payments of gross proceeds from the sale or other disposition of such stock.
Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our common stock.
THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.
157
We are offering the shares of common stock described in this prospectus through a number of underwriters. J.P. Morgan Securities LLC and Deutsche Bank Securities Inc. are acting as joint book-running managers of the offering and as representatives of the underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus, the number of shares of common stock listed next to its name in the following table:
Name
|
Number
of Shares |
|||
---|---|---|---|---|
J.P. Morgan Securities LLC |
||||
Deutsche Bank Securities Inc. |
||||
William Blair & Company, L.L.C. |
||||
Wells Fargo Securities, LLC |
||||
SunTrust Robinson Humphrey, Inc. |
||||
| | | | |
Total |
||||
| | | | |
| | | | |
| | | | |
The underwriters are committed to purchase all the shares of common stock offered by us if they purchase any shares. The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of non-defaulting underwriters may also be increased or the offering may be terminated.
The underwriters propose to offer the shares directly to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers at that price less a concession not in excess of $ per share. After the initial public offering of the shares, the offering price and other selling terms may be changed by the underwriters. Sales of shares made outside of the United States may be made by affiliates of the underwriters.
The underwriters have an option to buy up to additional shares of common stock from us to cover sales of shares by the underwriters which exceed the number of shares specified in the table above. The underwriters have 30 days from the date of this prospectus to exercise this over-allotment option. If any shares are purchased with this over-allotment option, the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional shares of common stock are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being offered.
The underwriting fee is equal to the public offering price per share of common stock less the amount paid by the underwriters to us per share of common stock. The underwriting fee is $ per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise of the underwriters' option to purchase additional shares.
|
Without
over-allotment exercise |
With full
over-allotment exercise |
|||||
---|---|---|---|---|---|---|---|
Per Share |
$ | $ | |||||
Total |
$ | $ |
We estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and legal and accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $ . We have also agreed to pay the filing fees incident to,
158
and the fees and disbursements of counsel for the underwriters in connection with, the required review by FINRA in connection with this offering, as set forth in the underwriting agreement.
A prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations.
We have agreed that, subject to limited exceptions, we will not (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly, or file with the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exchangeable or exercisable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, disposition or filing, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC and Deutsche Bank Securities Inc. for a period of 180 days after the date of this prospectus.
Our directors and executive officers, and certain of our significant shareholders have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each of these persons or entities has agreed, subject to limited exceptions, for a period of 180 days after the date of this prospectus not to, without the prior written consent of J.P. Morgan Securities LLC and Deutsche Bank Securities Inc., (1) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock (including, without limitation, common stock or such other securities which may be deemed to be beneficially owned by such directors, executive officers, managers and members in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant) or (2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the common stock or such other securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of common stock or such other securities, in cash or otherwise, or (3) make any demand for or exercise any right with respect to the registration of any shares of our common stock or any security convertible into or exercisable or exchangeable for our common stock.
We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act.
We will apply to have our common stock approved for listing/quotation on the NYSE under the symbol "TDOC."
In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling shares of common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making short sales of the common stock, which involves the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of
159
common stock on the open market to cover positions created by short sales. Short sales may be "covered" shorts, which are short positions in an amount not greater than the underwriters' over-allotment option referred to above, or may be "naked" shorts, which are short positions in excess of that amount. The underwriters may close out any covered short position either by exercising their over-allotment option, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the over-allotment option. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position.
The underwriters have advised us that, pursuant to Regulation M of the Securities Act, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common stock in the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them.
These activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding a decline in the market price of the common stock and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The underwriters may carry out these transactions on the NYSE, in the over-the-counter market or otherwise.
Prior to this offering, there has been no public market for our common stock. The initial public offering price will be determined by negotiations between us and the representatives of the underwriters. In determining the initial public offering price, we and the representatives of the underwriters expect to consider a number of factors including:
Neither we nor the underwriters can assure investors that an active trading market will develop for our common stock or that the shares will trade in the public market at or above the initial public offering price.
Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves
160
or their customers, long or short positions in our debt or equity securities or loans, and may do so in the future.
Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.
Notice to Prospective Investors in the European Economic Area
In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a "Relevant Member State"), from and including the date on which the European Union Prospectus Directive (the "EU Prospectus Directive") was implemented in that Relevant Member State (the "Relevant Implementation Date") an offer of securities described in this prospectus may not be made to the public in that Relevant Member State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant Member State or, where appropriate, approved in another Relevant Member State and notified to the competent authority in that Relevant Member State, all in accordance with the EU Prospectus Directive, except that, with effect from and including the Relevant Implementation Date, an offer of securities described in this prospectus may be made to the public in that Relevant Member State at any time:
For the purposes of this provision, the expression an "offer of securities to the public" in relation to any securities in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase or subscribe for the securities, as the same may be varied in that Member State by any measure implementing the EU Prospectus Directive in that Member State. The expression "EU Prospectus Directive" means Directive 2003/71/EC (and any amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State) and includes any relevant implementing measure in each Relevant Member State, and the expression "2010 PD Amending Directive" means Directive 2010/73/EU.
Notice to Prospective Investors in the United Kingdom
In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are "qualified investors" (as defined in the Prospectus Directive) (i) who have professional experience in matters
161
relating to investments falling within Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") and/or (ii) who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). This document must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom, any investment or investment activity to which this document relates is only available to, and will be engaged in with, relevant persons.
Notice to Prospective Investors in Switzerland
The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange ("SIX") or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland.
Neither this document nor any other offering or marketing material relating to the offering, us or the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA ("FINMA"), and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes ("CISA"). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares.
Notice to Prospective Investors in Hong Kong
This prospectus has not been approved by or registered with the Securities and Futures Commission of Hong Kong or the Registrar of Companies of Hong Kong. The shares may not be offered or sold in Hong Kong by means of any document other than (i) in circumstances which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong), (ii) to "professional investors" as defined in the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder or (iii) in other circumstances which do not result in the document being a "prospectus" within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong) and no advertisement, invitation or document relating to the shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder.
Notice to Prospective Investors in Singapore
This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore
162
(the "SFA"), (ii) to a relevant person pursuant to Section 275(1), or any person pursuant to Section 275(1A), and in accordance with the conditions specified in Section 275 of the SFA or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to compliance with conditions set forth in the SFA.
Where the shares are subscribed or purchased under Section 275 of the SFA by a relevant person which is: (a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, shares, debentures and units of shares and debentures of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section 275 of the SFA except: (i) to an institutional investor (for corporations, under Section 274 of the SFA) or to a relevant person defined in Section 275(2) of the SFA, or to any person pursuant to an offer that is made on terms that such shares, debentures and units of shares and debentures of that corporation or such rights and interest in that trust are acquired at a consideration of not less than S$200,000 (or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of securities or other assets, and further for corporations, in accordance with the conditions specified in Section 275 of the SFA; (ii) where no consideration is or will be given for the transfer; or (iii) where the transfer is by operation of law.
163
The validity of the shares being sold in this offering will be passed upon for us by Latham & Watkins LLP, New York, New York. Certain legal matters will be passed upon on behalf of the underwriters by Weil, Gotshal & Manges LLP, New York, New York.
The consolidated financial statements of Teladoc, Inc. at December 31, 2013 and 2014, and for each of the two years in the period ended December 31, 2014, appearing in this Prospectus and Registration Statement have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.
The consolidated financial statements of Consult A Doctor, Inc. at August 29, 2013, and for the period from January 1, 2013 to August 29, 2013, appearing in this Prospectus and Registration Statement have been audited by Ernst & Young LLP, independent auditors, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.
The consolidated financial statements of AmeriDoc, LLC at December 31, 2013 and April 30, 2014, and for the year ended December 31, 2013 and the period from January 1, 2014 to April 30, 2014, appearing in this Prospectus and Registration Statement have been audited by Ernst & Young LLP, independent auditors, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.
The financial statements of Stat Health Services Inc. at December 31, 2014 and for the year ended December 31, 2014, appearing in this Prospectus and Registration Statement have been audited by Ernst & Young, LLP, independent auditors, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.
WHERE YOU CAN FIND MORE INFORMATION
We have filed with the SEC a registration statement on Form S-1 pursuant to the Securities Act. This prospectus, which constitutes part of the registration statement, does not contain all the information set forth in the registration statement. For further information, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Statements contained in this prospectus as to the contents of any contract or other document filed as an exhibit to the registration statement are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, we refer you to the copy of the contract or document that has been filed.
You may inspect a copy of the registration statement and the exhibits and schedules to the registration statement without charge at the Public Reference Room of the SEC at 100 F Street, NE, Washington, DC 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. You can receive copies of these documents upon payment of a duplicating fee by writing to the SEC. The SEC maintains a web site at www.sec.gov that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. You can also inspect our registration statement on this web site.
164
Upon completion of this offering, we will become subject to the information and reporting requirements of the Exchange Act pursuant to Section 13 thereof. Our filings with the SEC (other than those exhibits specifically incorporated by reference into the registration statement of which this prospectus forms a part) are not incorporated by reference into this prospectus.
You may obtain a copy of any of our filings, at no cost, by writing or telephoning us at:
Teladoc,
Inc.
2 Manhattanville Road, Suite 203
Purchase, New York 10577
(203) 635-2002
165
F-1
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The
Board of Directors and Stockholders of
Teladoc, Inc.
We have audited the accompanying consolidated balance sheets of Teladoc, Inc. as of December 31, 2013 and 2014, and the related consolidated statements of operations, convertible preferred stock and stockholders' deficit, and cash flows for each of the two years in the period ended December 31, 2014. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company's internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Teladoc, Inc. at December 31, 2013 and 2014, and the consolidated results of their operations and their cash flows for each of the two years in the period ended December 31, 2014, in conformity with U.S. generally accepted accounting principles.
|
/s/ Ernst & Young LLP |
New
York, New York
March 24, 2015 except for Note 18,
as to which the date is June 4, 2015
F-2
TELADOC, INC.
Consolidated Balance Sheets
(in thousands, except share and per share data)
|
|
|
Pro Forma
Stockholders' Equity as of December 31, 2014 |
|||||||
---|---|---|---|---|---|---|---|---|---|---|
|
As of December 31, | |||||||||
|
2013 | 2014 | ||||||||
|
|
|
(unaudited)
|
|||||||
Assets |
||||||||||
Current assets: |
||||||||||
Cash and cash equivalents |
$ | 3,212 | $ | 46,436 | ||||||
Accounts receivable, net of allowance of $728 and $1,785, respectively |
2,610 | 6,839 | ||||||||
Due from officer |
253 | 253 | ||||||||
Prepaid expenses and other current assets |
743 | 1,122 | ||||||||
Deferred taxes |
8 | 12 | ||||||||
| | | | | | | | | | |
Total current assets |
6,826 | 54,662 | ||||||||
Property and equipment, net |
331 | 1,065 | ||||||||
Goodwill |
14,786 | 28,454 | ||||||||
Intangible assets, net |
5,350 | 7,530 | ||||||||
Other assets |
93 | 296 | ||||||||
| | | | | | | | | | |
Total assets |
$ | 27,386 | $ | 92,007 | ||||||
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
Liabilities, convertible preferred stock and stockholders' deficit |
||||||||||
Current liabilities: |
||||||||||
Accounts payable |
$ | 67 | $ | 2,210 | ||||||
Accrued expenses and other current liabilities |
3,687 | 6,623 | ||||||||
Accrued compensation |
1,387 | 3,358 | ||||||||
Long-term bank and other debt-current |
| 833 | ||||||||
| | | | | | | | | | |
Total current liabilities |
5,141 | 13,024 | ||||||||
Other liabilities |
88 | 62 | ||||||||
Deferred taxes |
102 | 494 | ||||||||
Long term bank and other debt |
3,000 | 25,196 | ||||||||
Commitments and contingencies |
||||||||||
Convertible preferred stock, $0.001 par value; 39,081,371 and 50,479,286 shares authorized as of December 31, 2013 and 2014; 37,590,286 and 50,452,939 shares issued as of December 31, 2013 and 2014 with liquidation preference of $71,655 and $117,914 as of December 31, 2013 and 2014; no shares authorized or issued and outstanding pro forma (unaudited) |
71,655 | 117,914 | $ | | ||||||
Redeemable common stock, $0.001 par value; 258,978 common shares issued and outstanding |
2,852 | 2,852 | | |||||||
Stockholders' equity (deficit): |
||||||||||
Common stock, $0.001 par value; 60,548,148 and 73,559,000 shares authorized as of December 31, 2013 and 2014; 2,977,976 and 4,658,662 shares issued and outstanding as of December 31, 2013 and 2014, 73,559,000 shares authorized and issued pro forma (unaudited); |
3 | 5 | 63 | |||||||
Additional paid-in capital |
| 4,952 | 122,808 | |||||||
Accumulated deficit |
(55,455 | ) | (72,492 | ) | (72,492 | ) | ||||
| | | | | | | | | | |
Total stockholders' equity (deficit) |
(55,452 | ) | (67,535 | ) | 50,379 | |||||
| | | | | | | | | | |
Total liabilities, convertible preferred stock and stockholders' deficit |
$ | 27,386 | $ | 92,007 | $ | |||||
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
See accompanying notes to audited consolidated financial statements.
F-3
TELADOC, INC.
Consolidated Statements of Operations
(in thousands, except per share data)
|
Year Ended December 31, | ||||||
---|---|---|---|---|---|---|---|
|
2013 | 2014 | |||||
Revenue |
$ | 19,906 | $ | 43,528 | |||
Cost of revenue |
4,186 | 9,929 | |||||
| | | | | | | |
Gross profit |
15,720 | 33,599 | |||||
Operating expenses: |
|||||||
Advertising and marketing |
4,090 | 7,662 | |||||
Sales |
4,441 | 11,571 | |||||
Technology and development |
3,532 | 7,573 | |||||
General and administrative |
8,772 | 19,623 | |||||
Depreciation and amortization |
754 | 2,320 | |||||
| | | | | | | |
Loss from operations |
(5,869 | ) | (15,150 | ) | |||
Interest income(expense), net |
(56 | ) | (1,499 | ) | |||
| | | | | | | |
Net loss before taxes |
(5,925 | ) | (16,649 | ) | |||
Income taxes |
94 | 388 | |||||
| | | | | | | |
Net loss |
$ | (6,019 | ) | $ | (17,037 | ) | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Net loss per share, basic and diluted |
$ | (3.52 | ) | $ | (4.49 | ) | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Weighted-average shares used to compute basic and diluted net loss per share |
2,793,982 | 4,486,868 | |||||
| | | | | | | |
| | | | | | | |
| | | | | | | |
Pro forma net loss per share, basic and diluted (unaudited) |
$ | (0.37 | ) | ||||
| | | | | | | |
| | | | | | | |
| | | | | | | |
Weighted-average shares used to compute basic and diluted pro forma net loss per share (unaudited) |
53,734,598 | ||||||
| | | | | | | |
| | | | | | | |
| | | | | | | |
See accompanying notes to audited consolidated financial statements.
F-4
TELADOC, INC.
Consolidated Statements of Convertible Preferred Stock
and Stockholders' Deficit
(in thousands, except share data)
|
Convertible
Preferred Stock |
Redeemable
Common Stock |
|
|
|
|
|
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Common Stock |
|
|
|
|||||||||||||||||||||||||
|
|
Additional
Paid-In Capital |
Accumulated
Deficit |
Total
Stockholders' Deficit |
||||||||||||||||||||||||||
|
Shares | Amount | Shares | Amount |
|
Shares | Amount | |||||||||||||||||||||||
Balance as of January 1, 2013 |
31,371,102 | $ | 53,130 | 258,978 | $ | 2,852 | 1,291,903 | $ | 1 | $ | | $ | (46,534 | ) | $ | (46,533 | ) | |||||||||||||
Issuance of Series E preferred stock for cash, net of issuance costs |
6,227,169 | 14,803 | | | | | | | | |||||||||||||||||||||
Accretion of Series E Preferred Stock to redemption amount |
| 197 | | | | | (197 | ) | | (197 | ) | |||||||||||||||||||
Repurchase of convertible preferred stock |
(7,985 | ) | (99 | ) | | | | | 28 | | 28 | |||||||||||||||||||
Exercise of stock options |
| | | | 1,686,073 | 2 | 593 | | 595 | |||||||||||||||||||||
Preferred dividend |
| 3,624 | | | | | (722 | ) | (2,902 | ) | (3,624 | ) | ||||||||||||||||||
Stock Based Compensation |
| | | | | | 298 | | 298 | |||||||||||||||||||||
Net Loss |
| | | | | | | (6,019 | ) | (6,019 | ) | |||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Balance as of December 31, 2013 |
37,590,286 | $ | 71,655 | 258,978 | $ | 2,852 | 2,977,976 | $ | 3 | $ | | $ | (55,455 | ) | $ | (55,452 | ) | |||||||||||||
Issuance of Series F preferred stock for cash, net of issuance costs |
11,329,068 | 50,082 | | | | | | | | |||||||||||||||||||||
Accretion of Series F Preferred Stock to redemption amount |
| 168 | | | | | (168 | ) | | (168 | ) | |||||||||||||||||||
Preferred dividend |
| 2,920 | | | | | (2,920 | ) | | (2,920 | ) | |||||||||||||||||||
Preferred dividends retired and converted to Series F preferred stock |
1,553,917 | (6,892 | ) | | | | | 6,892 | | 6,892 | ||||||||||||||||||||
Warrants issued |
| | | | | | 219 | | 219 | |||||||||||||||||||||
Repurchase of convertible preferred stock and common stock |
(20,332 | ) | (19 | ) | | | (116,201 | ) | | (349 | ) | | (349 | ) | ||||||||||||||||
Exercise of stock options, net |
| | | | 1,796,887 | 2 | 745 | | 747 | |||||||||||||||||||||
Stock Based Compensation |
| | | | | | 533 | | 533 | |||||||||||||||||||||
Net Loss |
| | | | | | | (17,037 | ) | (17,037 | ) | |||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Balance as of December 31, 2014 |
50,452,939 | $ | 117,914 | 258,978 | $ | 2,852 | 4,658,662 | $ | 5 | $ | 4,952 | $ | (72,492 | ) | $ | (67,535 | ) | |||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
See accompanying notes to audited consolidated financial statements.
F-5
TELADOC, INC.
Consolidated Statements of Cash Flows
(in thousands)
|
Year Ended December 31, | ||||||
---|---|---|---|---|---|---|---|
|
2013 | 2014 | |||||
Operating activities: |
|||||||
Net loss |
$ | (6,019 | ) | $ | (17,037 | ) | |
Adjustments to reconcile net loss to net cash used in operating activities: |
|||||||
Depreciation and amortization |
754 | 2,320 | |||||
Allowance for doubtful debts |
504 | 1,308 | |||||
Stock-based compensation |
298 | 533 | |||||
Deferred income taxes |
94 | 388 | |||||
Accretion of interest |
2 | 106 | |||||
Changes in operating assets and liabilities: |
|||||||
Accounts receivable |
(928 | ) | (5,079 | ) | |||
Due from officer |
(253 | ) | | ||||
Prepaid expenses and other current assets |
(663 | ) | (436 | ) | |||
Other assets |
37 | (185 | ) | ||||
Accounts payable |
(1,099 | ) | 2,099 | ||||
Accrued expenses and other current liabilities |
329 | 2,679 | |||||
Accrued compensation |
802 | 1,971 | |||||
Other liabilities |
89 | (26 | ) | ||||
| | | | | | | |
Net cash used in operating activities |
(6,053 | ) | (11,359 | ) | |||
| | | | | | | |
Investing activities: |
|
|
|||||
Purchase of property and equipment |
(204 | ) | (1,069 | ) | |||
Purchase of internal software |
(1,090 | ) | (665 | ) | |||
Acquisition of business, net of cash acquired |
(16,462 | ) | (13,844 | ) | |||
| | | | | | | |
Net cash used in investing activities |
(17,756 | ) | (15,578 | ) | |||
Financing activities: |
|
|
|||||
Proceeds from the exercise of stock options and warrants |
595 | 747 | |||||
Proceeds from issuance of convertible preferred stock |
14,803 | 50,082 | |||||
Proceeds from borrowing under bank and other debt |
3,000 | 19,700 | |||||
Repurchase of stock |
(71 | ) | (368 | ) | |||
| | | | | | | |
Net cash provided by financing activities |
18,327 | 70,161 | |||||
| | | | | | | |
Net (decrease) increase in cash and cash equivalents |
(5,482 | ) | 43,224 | ||||
Cash and cash equivalents at beginning of year |
8,694 | 3,212 | |||||
| | | | | | | |
Cash and cash equivalents at end of year |
$ | 3,212 | 46,436 | ||||
| | | | | | | |
| | | | | | | |
| | | | | | | |
Interest paid: |
$ | 32 | $ | 1,191 |
See accompanying notes to audited consolidated financial statements.
F-6
Note 1. Organization and Description of Business
Teladoc, Inc. ("Teladoc", or the "Company") was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. The Company's principal executive offices are located in Dallas, Texas and Purchase, New York. Teladoc is the nation's largest telehealth company.
The Company completed the acquisition of Consult A Doctor, Inc. ("CADR") and AmeriDoc, LLC ("AmeriDoc"), two companies engaged in telehealth activities similar to Teladoc, in 2013 and 2014, respectively. Upon the effective date of each respective merger, each entity merged with and into Teladoc.
Note 2. Summary of Significant Accounting Policies
Basis of Presentation and Principles of Consolidation
These consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). The consolidated financial statements include the results of Teladoc, a professional association and six professional corporations: Teladoc Physicians, P.A., Teladoc Physicians, P.C. formed and operated in Alaska; Teladoc Physicians, P.C. formed and operated in California; Teladoc Physicians, P.C. formed and operated in Colorado; Teladoc Physicians, P.C. formed and operated in Michigan; Teladoc Physicians, P.C. formed and operated in New Jersey; and Teladoc Physicians, P.C. formed and operated in New York (collectively, the "Association").
Teladoc Physicians, P.A. is party to a Services Agreement by and among it and the six professional corporations noted above pursuant to which each professional corporation provides services to Teladoc Physicians, P.A. Each professional corporation is established pursuant to the requirements of its respective domestic jurisdiction governing the corporate practice of medicine.
The Company holds a variable interest in the Association which contracts with physicians and other health professionals in order to provide services to Teladoc. The Association is considered a variable interest entity ("VIE") since it does not have sufficient equity to finance its activities without additional subordinated financial support. An enterprise having a controlling financial interest in a VIE, must consolidate the VIE if it has both power and benefitsthat is, it has (1) the power to direct the activities of a VIE that most significantly impact the VIE's economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits). The Company has the power and rights to control all activities of the Association and funds and absorbs all losses of the VIE. Total revenue and net loss for the VIE were $3.3 million and $(1.0) million and $6.5 million and $(3.9) million for the years ended December 31, 2013 and 2014, respectively. The VIE's total assets were $1.0 million and $2.1 million at December 31, 2013 and 2014, respectively. Total liabilities for the VIE were $6.1 million and $11.2 million at December 31, 2013 and 2014, respectively. The VIE total stockholders' deficit was $5.2 million and $9.1 million at December 31, 2013 and 2014, respectively.
All significant intercompany transactions and balances have been eliminated.
F-7
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
Business Combinations
The Company accounts for its business combinations using the acquisition method of accounting. The cost of an acquisition is measured as the aggregate of the acquisition date fair values of the assets transferred and liabilities assumed by the Company to the sellers and equity instruments issued. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. The excess of (i) the total costs of acquisition over (ii) the fair value of the identifiable net assets of the acquiree is recorded as goodwill.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business factors, and various other assumptions that the Company believes are necessary to consider to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company's business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company's financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company's operating environment changes.
Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the consolidated financial statements. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the carrying value, capitalization and amortization of software development costs, the provision for income taxes and related deferred tax accounts, certain accrued liabilities, revenue recognition, contingencies, litigation and related legal accruals and the value attributed to employee stock options and other stock-based awards.
Pro Forma Stockholders' Equity and Net Loss Per Share (Unaudited)
In January 2015, the Company's board of directors approved the filing of a registration statement relating to an initial public offering of its common stock. Upon the effectiveness of the Registration Statement, all of the outstanding shares of convertible preferred stock (the "Preferred Stock") will automatically convert into shares of common stock of the Company, provided that the initial public offering (i) is at a price per share (equal to at least $7.2264) and (ii) results in net proceeds to the Company of at least $40.0 million of proceeds, in each case, net of any underwriting discount and commissions. The December 31, 2014 unaudited pro forma stockholders' equity data has been prepared assuming the conversion of the Preferred Stock outstanding into shares of common stock of the Company. Pro forma basic and diluted net loss per share were computed to give effect to the conversion of the Preferred Stock into common stock of the Company using the if-converted method as though the conversion and reclassification had occurred as of the beginning of the first period presented or on the original date of issuance, if later.
F-8
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
Segment Information
The Company's chief operating decision maker, its Chief Executive Officer ("CEO"), reviews the financial information presented on a consolidated basis for purposes of allocating resources and evaluating its financial performance. Accordingly, the Company has determined that it operates in a single reporting segmenthealth services.
Revenue Recognition
The Company offers two types of subscription access revenue contracts: (i) contracts that provide for a fixed monthly charge for access and unlimited visits per Member and (ii) contracts that provide for a fixed monthly charge for access and a contractually defined cost for each visit. Any visit fee revenue that is not included in the subscription access revenue is recognized when the service has been provided to the Member.
The Company recognizes a substantial portion of its revenue from contracts that provide employers and health plans ("Clients") with subscription access to the Company's network of physicians and other healthcare professionals ("Providers") on a subscription basis for a fixed monthly fee which entitles the Client's employees and their beneficiaries ("Members") to unlimited consultations ("visits"). The contracts are generally for a one-year term and have an automatic renewal feature for additional years.
The Company commences revenue recognition for the subscription access service on the date that the services are made available to the Client and its Members, which is considered the implementation date, provided all of the following criteria are met:
Subscription Access Revenue
Subscription access revenue recognition commences on the date that the Company's services are made available to the Client, which is considered the implementation date, provided all of the other criteria described above are met. Revenue is recognized over the term of the Client contract and is based on the terms in the Client contracts, which can provide for a variable periodic fee based upon the actual number of Members.
Revenue From Visit Fees
Revenue from visits is comprised of all revenue that is earned in connection with the completion of a visit. The Company recognizes revenue as the visits are completed.
The Company's contracts do not generally contain refund provisions for fees earned related to services performed. However, certain of the Company's contracts include performance guarantees that are based upon minimum employee or Member utilization and guarantees by the Company for specific service level performance of the Company's services. The Company defers revenue recognition when subscription access revenue is refundable until the end of the respective contractual period when the performance guarantees are met. The Company issued credits
F-9
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
amounting to approximately $0.2 million and $0.4 million for the years ended December 31, 2013 and 2014, respectively.
Cost of Revenue
Cost of revenue primarily consists of fees paid to the Providers, costs incurred in connection with the Company's Provider network operations, which include employee-related expenses (including salaries and benefits) and costs related to the contracted third-party call center and medical malpractice insurance.
Cash and Cash Equivalents
Cash and cash equivalents consist of highly liquid investments with original maturities of three months or less from the date of purchase. The Company's cash and cash equivalents generally consist of investments in money market funds, U.S. treasury securities and U.S. government-issued obligations. Cash and cash equivalents are stated at fair value.
Accounts Receivable and Allowance for Doubtful Accounts
Accounts receivable are recorded at the invoiced amount, net of allowances for doubtful accounts. The allowance for doubtful accounts is based on the Company's assessment of the collectability of accounts. The Company regularly reviews the adequacy of the allowance for doubtful accounts by considering the age of each outstanding invoice and the collection history of each customer to determine whether a specific allowance is appropriate. Accounts receivable deemed uncollectable are charged against the allowance for doubtful accounts when identified.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective asset as follows:
Computer equipment | 3 years | |
Furniture and equipment | 5 years | |
Leasehold improvements | Shorter of the lease term or the estimated useful lives of the improvements |
Maintenance and repairs are charged to expense as incurred, and improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected in the consolidated statement of operations in the period realized.
Internal-Use Software
Internal-use software is included in intangible assets and is amortized on a straight-line basis over 3 years. For the Company's development costs related to its software development tools that enable its Members and Providers to interact, the Company capitalizes costs incurred during the application development stage. Costs related to minor upgrades, minor enhancements and maintenance activities are expensed as incurred.
F-10
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
Goodwill and Other Intangible Assets
Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. Goodwill is not amortized, but is tested for impairment annually on October 1 or more frequently if events or changes in circumstances indicate that the asset may be impaired. The Company's impairment tests are based on a single operating segment and reporting unit structure. The goodwill impairment test involves a two-step process. The first step involves comparing the fair value of the Company's reporting unit to its carrying value, including goodwill. The fair value of the reporting unit is estimated using a discounted cash flows analysis. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value.
The Company's annual goodwill impairment test resulted in no impairment charges in any of the periods presented in the consolidated financial statements.
Other intangible assets resulted from business acquisitions and include Client relationships and non-compete agreements. Client relationships are amortized over a period of 10 years in relation to expected future cash flows, while non-compete agreements are amortized over a period of 3 to 5 years using the straight-line method.
Stock-Based Compensation
All stock-based compensation is measured based on the grant-date fair value of the awards and recognized on a straight-line basis over the period during which the employee is required to perform services in exchange for the award (generally the vesting period of the award). The Company estimates the fair value of employee stock options using the Black-Scholes option-pricing model.
Income Taxes
The Company accounts for income taxes using the liability method, under which deferred tax assets and liabilities are determined based on the future tax consequences attributable to differences between the financial reporting carrying amounts of existing assets and liabilities and their respective tax bases and tax credit and net operating loss carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates that are expected to be in effect when the differences are expected to reverse.
The Company assesses the likelihood that deferred tax assets will be recovered from future taxable income, and a valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized.
The Company recognizes and measures uncertain tax positions using a two-step approach. The first step is to evaluate the tax position taken or expected to be taken by determining if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Significant judgment is required to evaluate uncertain tax positions. The Company evaluates its uncertain tax positions on a regular basis. Its evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law,
F-11
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
correspondence with tax authorities during the course of audit and effective settlement of audit issues.
Warranties and Indemnification
The Company's arrangements generally include certain provisions for indemnifying Clients against liabilities if there is a breach of a Client's data or if the Company's service infringes a third party's intellectual property rights. To date, the Company has not incurred any material costs as a result of such indemnifications.
The Company has also agreed to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person's service as a director or officer, including any action by the Company, arising out of that person's services as a director or officer or that person's services provided to any other company or enterprise at the Company's request. The Company maintains director and officer liability insurance coverage that would generally enable it to recover a portion of any future amounts paid. The Company may also be subject to indemnification obligations by law with respect to the actions of its employees under certain circumstances and in certain jurisdictions.
Advertising and Marketing Expenses
Advertising and marketing include all communications and campaigns to the Company's Clients and Members and related employees' costs and are expensed as incurred. For the years ended December 31, 2013 and 2014, advertising expenses were $3.0 million and $6.0 million, respectively.
Concentrations of Risk and Significant Clients
The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents, and accounts receivable. Although the Company deposits its cash with multiple financial institutions, its deposits, at times, may exceed federally insured limits.
During the years ended December 31, 2013 and 2014, all of the Company's revenue was generated by Clients located in the United States. No Client represented over 10% of revenue for the years ended December 31, 2013 and 2014.
One Client represented 22% of accounts receivable at December 31, 2013. As of December 31, 2014, no Client accounted for more than 10% of accounts receivable.
Recently Issued and Adopted Accounting Pronouncements
In July 2013, the Financial Accounting Standards Board ("FASB") issued guidance regarding the presentation of unrecognized tax benefits when a net operating loss carryforward, similar tax loss, or tax credit carryforward exists. The new guidance requires that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, be presented in the consolidated financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward when settlement in this manner is available under the tax law. This guidance is effective on a prospective basis for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2013. Retrospective and early
F-12
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
adoption is permitted. The Company adopted this guidance in the first quarter of 2014. The adoption of this guidance had no impact on the consolidated financial statements.
In May 2014, the FASB issued updated guidance on revenue from contracts with customers. This revenue recognition guidance supersedes existing GAAP guidance, including most industry-specific guidance. The core principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance identifies steps to apply in achieving this principle. This updated guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. We are currently evaluating the potential impact of this guidance on its financial disclosures and results, including whether the Company elects retrospective, or modified retrospective, adoption methods.
In June 2014, the FASB issued stock compensation guidance requiring that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. The amendments in this guidance are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The Company is currently evaluating the potential impact of this guidance on its financial disclosures and results.
In August 2014, the FASB issued ASU 2014-15, Presentation of Financial StatementsGoing Concern. This guidance addresses management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. Management's evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. ASU 2014-15 is effective for interim or annual periods beginning after December 15, 2016. Early adoption is permitted. The Company does not expect to early adopt this guidance and is currently evaluating the impact of the adoption of this guidance on its financial disclosures and results.
Note 3. Business Acquisitions
On August 29, 2013, the Company completed the acquisition of CADR, a company engaged in telehealth activities similar to Teladoc, through the purchase of 100% of CADR's outstanding common stock for $16.6 million, net of cash acquired, including adjustments for a working capital in the amount of $0.2 million, which was paid in 2014. CADR was acquired to help the Company expand its presence into the local and regional insurance broker markets to reach Clients that previously did not have access to the Company's services. Upon the effective date of the merger, CADR merged with and into Teladoc. The acquisition is considered an asset acquisition for tax purposes and as such, the goodwill resulting from this acquisition is tax deductible.
On May 1, 2014, the Company completed the acquisition of AmeriDoc, a company engaged in telehealth activities similar to Teladoc, through the purchase of 100% of AmeriDoc's outstanding members' interests for $17.2 million, net of cash acquired, including a $3.5 million promissory note and adjustments for working capital in the amount of $0.2 million. AmeriDoc was acquired to help the Company expand its initial investment in the local and regional insurance broker markets to reach clients that previously did not have access to the Company's services. Upon the effective date of the merger, AmeriDoc merged with and into Teladoc. The acquisition is considered an asset acquisition for tax purposes and as such, the goodwill resulting from this acquisition is tax deductible.
F-13
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
The two acquisitions were accounted for using the acquisition method of accounting, which requires, among other things, the assets acquired and the liabilities assumed be recognized at their fair values as of the acquisition date. The results of CADR were included within the consolidated financial statements commencing August 29, 2013. The results of AmeriDoc were included within the consolidated financial statements commencing May 1, 2014.
The purchase price of the acquisitions was allocated based upon the fair value of the assets acquired and liabilities assumed at the date of acquisition.
The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at each acquisition date. The Company, with the assistance of third-party valuations, estimated the fair value of the acquired tangible and intangible assets.
Identifiable assets acquired and liabilities assumed (in thousands):
|
CADR | AmeriDoc | |||||
---|---|---|---|---|---|---|---|
Purchase price |
$ | 17,187 | $ | 17,214 | |||
Less: |
|||||||
Cash |
538 | 57 | |||||
Accounts receivable |
558 | 458 | |||||
Other assets |
37 | 18 | |||||
Client relationships |
3,810 | 2,980 | |||||
Non-compete agreements |
910 | 520 | |||||
Accounts payable |
(934 | ) | (43 | ) | |||
Uncertain tax position |
(2,705 | ) | | ||||
Other liabilities |
| (257 | ) | ||||
| | | | | | | |
Goodwill |
$ | 14,973 | $ | 13,481 | |||
| | | | | | | |
| | | | | | | |
| | | | | | | |
The value of the goodwill is expected to be 73% deductible for income tax purposes for CADR and 100% deductible for AmeriDoc.
The Company's unaudited pro forma revenue and net loss for 2013 and 2014 below have been prepared as if CADR had been purchased on January 1, 2013 and AmeriDoc had been purchased on January 1, 2013.
|
Pro Forma | ||||||
---|---|---|---|---|---|---|---|
(in thousands)
|
2013 | 2014 | |||||
Revenue |
$ | 26,304 | $ | 45,342 | |||
Net loss |
$ | (9,087 | ) | $ | (18,280 | ) |
Note 4. Property and Equipment, Net
Property and equipment, net, consist of the following (in thousands):
|
As of December 31, | ||||||
---|---|---|---|---|---|---|---|
|
2013 | 2014 | |||||
Computer equipment |
$ | 1,025 | 1,959 | ||||
Furniture and equipment |
233 | 368 | |||||
| | | | | | | |
Total |
1,258 | 2,327 | |||||
Accumulated depreciation |
(927 | ) | (1,262 | ) | |||
| | | | | | | |
Property and equipment, net |
$ | 331 | $ | 1,065 | |||
| | | | | | | |
| | | | | | | |
| | | | | | | |
Depreciation expense for the years ended December 31, 2013 and 2014 was $0.2 million and $0.3 million respectively.
F-14
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
Note 5. Intangible Assets, Net
Intangible assets consist of the following (in thousands):
|
Useful
Life |
Gross Value |
Accumulated
Amortization |
Net Carrying
Value |
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
December 31, 2013 |
||||||||||||
Client relationships |
10 years | $ | 3,810 | $ | (327 | ) | $ | 3,483 | ||||
Non-compete agreements |
3 years | 910 | (101 | ) | 809 | |||||||
Internal software |
3 years | 1,220 | (162 | ) | 1,058 | |||||||
| | | | | | | | | | | | |
Intangible assets, net |
$ | 5,940 | $ | (590 | ) | $ | 5,350 | |||||
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
December 31, 2014 |
||||||||||||
Client relationships |
10 years | $ | 6,790 | $ | (1,565 | ) | $ | 5,225 | ||||
Non-compete agreements |
3 to 5 years | 1,430 | (474 | ) | 956 | |||||||
Internal software |
3 years | 1,885 | (536 | ) | 1,349 | |||||||
| | | | | | | | | | | | |
Intangible assets, net |
$ | 10,105 | $ | (2,575 | ) | $ | 7,530 | |||||
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
Amortization expense for intangible assets was $0.6 million and $2.0 million for the years ended December 31, 2013 and 2014, respectively.
Periodic amortization that will be charged to expense over the remaining life of the intangible assets as of December 31, 2014 is as follows (in thousands):
Note 6. Goodwill
Goodwill consists of the following (in thousands):
|
As of December 31, | ||||||
---|---|---|---|---|---|---|---|
|
2013 | 2014 | |||||
Beginning balance |
$ | | $ | 14,786 | |||
Additions |
14,786 | 13,267 | |||||
Net working capital adjustments (CADR and AmeriDoc acquisitions) |
| 401 | |||||
| | | | | | | |
Goodwill |
$ | 14,786 | $ | 28,454 | |||
| | | | | | | |
| | | | | | | |
| | | | | | | |
F-15
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
Note 7. Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consist of the following (in thousands):
|
As of December 31, | ||||||
---|---|---|---|---|---|---|---|
|
2013 | 2014 | |||||
Professional fees |
$ | | $ | 963 | |||
Consulting/customer service fees |
413 | 1,118 | |||||
Uncertain tax position |
2,705 | 2,705 | |||||
Others |
569 | 1,837 | |||||
| | | | | | | |
Total |
$ | 3,687 | $ | 6,623 | |||
| | | | | | | |
| | | | | | | |
| | | | | | | |
Note 8. Fair Value Measurements
Assets and Liabilities that are Measured at Fair Value on a Recurring Basis
The Company measures its financial assets and liabilities at fair value at each reporting period using a fair value hierarchy that requires it to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument's classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value:
Level 1Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2Include other inputs that are directly or indirectly observable in the marketplace.
Level 3Unobservable inputs that are supported by little or no market activity.
The Company measures its cash equivalents at fair value on a recurring basis. The Company classifies its cash equivalents within Level 1 because they are valued using observable inputs that reflect quoted prices for identical assets in active markets.
The following tables present information about the Company's assets that are measured at fair value on a recurring basis using the above input categories (in thousands):
|
December 31, 2013 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
|
Level 1 | Level 2 | Level 3 | |||||||
Cash and cash equivalents |
$ | 3,212 | $ | | $ | | ||||
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
|
December 31, 2014 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
|
Level 1 | Level 2 | Level 3 | |||||||
Cash and cash equivalents |
$ | 46,436 | $ | | $ | | ||||
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
Assets and Liabilities that are Measured at Fair Value on a Non-recurring Basis
Assets and liabilities that are measured at fair value on a non-recurring basis relate primarily to the Company's tangible fixed assets, goodwill and other intangible assets, which are remeasured when the derived fair value is below carrying value on the Company's consolidated balance sheets. For these assets, the Company does not periodically adjust carrying value to fair value except in the event of impairment. When the Company determines that impairment has occurred, the carrying
F-16
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
value of the asset is reduced to fair value and the difference is recorded within operating income in the consolidated statements of operations.
Note 9. Long Term Bank and Other Debt
Long-term bank and other debt consist of the following (in thousands):
|
As of December 31, | ||||||
---|---|---|---|---|---|---|---|
|
2013 | 2014 | |||||
SVB Mezzanine Term Loan less debt discount of $171 for warrants |
$ | | $ | 12,829 | |||
SVB Term Loan facility |
3,000 | 5,000 | |||||
SVB Revolving Advance facility |
| 4,700 | |||||
Subordinated Promissory Note |
| 3,500 | |||||
| | | | | | | |
Total |
$ | 3,000 | $ | 26,029 | |||
Less: current portion |
| (833 | ) | ||||
| | | | | | | |
Long term bank and other debt |
$ | 3,000 | $ | 25,196 | |||
| | | | | | | |
| | | | | | | |
| | | | | | | |
Long term bank and other debt are stated at amortized cost, which approximates fair value.
In August 2013, the Company entered into a Loan and Security Agreement with Silicon Valley Bank ("SVB") that provided for a Term Loan facility in the amount of $7.0 million with an interest rate of prime rate plus 1%. The Term Loan facility is payable in 48 monthly installments commencing April 2015. The Company's maximum borrowings under this facility totaled $3.0 million in 2013. The Loan and Security Agreement also provided the Company with a $3.0 million Revolving Advance facility that the Company did not utilize in 2013.
In May 2014, the Company entered into an Amended and Restated Loan and Security Agreement with SVB that provided for a Revolving Advance facility and a Term Loan facility (the "Amended Term Loan facility"). The Revolving Advance facility provides for borrowings up to $12.0 million based on 300% of the Company's monthly recurring revenue, as defined therein. Borrowings under the Revolving Advance facility were $4.7 million at December 31, 2014, and the facility carries interest at a rate of 0.75% above the prime rate per annum and matures in April 2016. Interest payments are payable monthly in arrears. The Company entered into an amendment to the Revolving Advance Facility in March 2015 that extended its maturity to April 2017.
The Amended Term Loan facility provides for borrowings up to $5.0 million. As of December 31, 2014, the Company had utilized the total $5.0 million available under this facility. The Amended Term Loan facility carries interest at a rate of 1.00% above the prime rate per annum. Interest payments are payable monthly in arrears. Payments on the Amended Term Loan facility will commence in May 2015 and continue with 47 equal monthly payments of principal plus interest.
In May 2014, the Company entered into a Subordinated Loan and Security Agreement with SVB that provided for Mezzanine Term Loans totaling $13.0 million. The total $13.0 million drawdown of the mezzanine facility was completed in September 2014. The mezzanine facility carries interest at a rate of 10.00% per annum and matures in May 2017. Interest payments are payable monthly in arrears. In connection with entry into the mezzanine facility, the Company granted two affiliates of SVB warrants to purchase an aggregate of 300,000 shares of common stock of the Company at an exercise price of $1.29 per share. The warrants are immediately exercisable and have a 10-year term. The Company also granted SVB a security interest in significantly all of the Company's assets. The mezzanine facility has been used to fund the expansion of the Company's business. The Amended Loan and Security Agreement and the Subordinated Loan and Security Agreement are collectively referred to as the "SVB Facilities."
F-17
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
The Company incurred approximately $0.2 million of loan origination costs in connection with the SVB facilities and amortized approximately $0.1 million of these costs during the year ended December 31, 2014.
Effective with the purchase of AmeriDoc, the Company executed a Subordinated Promissory Note in the amount of $3.5 million payable to the seller of AmeriDoc on April 30, 2015. The Subordinated Promissory Note carries interest at a rate of 10.00% annual interest and is subordinated to the SVB Facilities. In March 2015, the Company, the seller of AmeriDoc and SVB executed an Amended and Restated Subordinated Promissory Note that extended the maturity of the Note to April 30, 2017.
Payments due are as follows (in thousands):
|
Total | |||
---|---|---|---|---|
2015 |
$ | 833 | ||
2016 |
5,950 | |||
2017 |
17,750 | |||
2018 |
1,250 | |||
2019 and thereafter |
417 | |||
| | | | |
Total |
$ | 26,200 | ||
| | | | |
| | | | |
| | | | |
Note 10. Related Party Transaction
In May 2013, the Company issued a loan to an officer of the Company in the amount of $0.3 million. This was a non-cash transaction, whereby the loan proceeds were used to exercise options to purchase 714,285 shares of common stock options of the Company at an exercise price of $0.35 per share. The loan carries interest at the rate of 2% per annum and is due and payable upon the earlier of (i) May 13, 2017 and (ii) the occurrence of a "Change of Control" as defined in the promissory note evidencing the loan. The officer is required to make monthly interest payments. At December 31, 2013 and 2014, the balance of the loan was $0.3 million. The loan was repaid in full to the Company in February 2015.
Note 11. Commitments and Contingencies
Leases and Contractual Obligations
The Company leases office space under non-cancelable operating leases in Greenwich, Connecticut; Purchase, New York and Dallas, Texas. As of December 31, 2014, the future minimum lease payments under non-cancelable operating leases are as follows (in thousands):
|
Operating
Leases |
|||
---|---|---|---|---|
2015 |
$ | 910 | ||
2016 |
924 | |||
2017 |
427 | |||
2018 |
206 | |||
2019 and thereafter |
| |||
| | | | |
|
$ | 2,467 | ||
| | | | |
| | | | |
| | | | |
F-18
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
All of the total future minimum lease payments relate to facilities space. The facility lease agreements generally provide for rental payments on a graduated basis and for options to renew, which could increase future minimum lease payments if exercised. The Company recognizes rent expense on a straight-line basis over the lease period and have accrued for rent expense incurred but not paid. Deferred rent represents the difference between actual operating lease payments due and straight-line rent expense. The excess is recorded as a deferred rent liability in the early periods of the lease, when cash payments are generally lower than straight-line rent expense, and are reduced in the later periods of the lease when payments begin to exceed the straight-line expense. Rent expense for the years ended December 31, 2013 and 2014 was $0.5 million and $0.8 million, respectively.
Letter of Credit
In November 2014, the Company arranged for SVB to issue a Letter of Credit on its behalf in the amount of $0.3 million in lieu of a cash deposit in connection with the Company's Purchase, NY office lease. This Letter of Credit expires by its terms at the lease expiration date in September 2018.
Note 12. Convertible Preferred Stock (the "Preferred Stock")
At December 31, the Preferred Stock consists of the following:
December 31, 2013
|
Shares
Authorized |
Shares
Outstanding |
Common
Shares Upon Conversion |
Liquidation
Preference |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series A |
418,634 | 418,634 | 3,722,590 | $ | 6,525,816 | ||||||||
Series A-1 |
53,957 | 53,957 | 646,200 | 1,146,000 | |||||||||
Series B |
263,839 | 263,839 | 4,091,881 | 7,216,736 | |||||||||
Series C-1 |
18,287,483 | 18,287,483 | 18,287,483 | 19,501,104 | |||||||||
Series D |
13,000,000 | 12,339,204 | 12,339,204 | 21,883,033 | |||||||||
Series E |
7,057,458 | 6,227,169 | 6,227,169 | 15,382,197 | |||||||||
| | | | | | | | | | | | | |
|
39,081,371 | 37,590,286 | 45,314,527 | $ | 71,654,886 | ||||||||
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
December 31, 2014
|
Shares
Authorized |
Shares
Outstanding |
Common
Shares Upon Conversion |
Liquidation
Preference |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series A |
418,634 | 418,634 | 3,722,590 | $ | 5,232,925 | ||||||||
Series A-1 |
53,957 | 53,957 | 646,200 | 918,955 | |||||||||
Series B |
263,839 | 263,839 | 4,091,881 | 5,768,378 | |||||||||
Series C-1 |
18,287,483 | 18,267,759 | 18,267,759 | 15,253,579 | |||||||||
Series D |
12,339,204 | 12,339,204 | 12,339,204 | 18,600,005 | |||||||||
Series E |
6,227,169 | 6,227,169 | 6,227,169 | 15,000,005 | |||||||||
Series F |
12,889,000 | 12,882,377 | 12,882,377 | 57,139,783 | |||||||||
| | | | | | | | | | | | | |
|
50,479,286 | 50,452,939 | 58,177,180 | $ | 117,913,630 | ||||||||
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
As of December 31, 2014, the significant terms applicable to the Series A through Series F Preferred Stock were as follows:
F-19
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
Dividend Rights
Prior to the issuance of the Series F Preferred Stock, the Series AE Preferred Stock accrued cumulative dividends at the per annum rate of 7.5% of the respective original purchase price (as previously adjusted for a reverse stock split and, with respect to the Series A, A-1 and B Preferred Stock, anti-dilution protection) for each such series of Preferred Stock. Such dividends were payable when, as and if declared by the Company's board of directors, but prior and in preference to any dividend on the common stock of the Company. In connection with the issuance of the Series F Preferred Stock, all such accrued and accumulated dividends (which totaled approximately $13.8 million at August 31, 2014) were converted into Series F Preferred Stock at a rate of $0.50 of Series F Preferred Stock per $1.00 in accrued dividends, resulting in the issuance of approximately 1,554,000 shares of Series F Preferred Stock on September 10, 2014. There are no longer any accrued or unpaid dividends on the Preferred Stock, and no such dividends are required to accrue or be declared by the Company.
Conversion Rights
Each share of Preferred Stock is convertible, at any time and at the option of the holder of such share, into shares of the common stock of the Company, at the following ratios (subject to adjustment as described below):
Series of Preferred Stock
|
Original
Issue Price |
Conversion
Price |
Number of Shares of
Common Stock Issued for each Preferred Share Upon Conversion (= Original Issue Price/ Conversion Price) |
|||||||
---|---|---|---|---|---|---|---|---|---|---|
Series F |
$ | 4.4355 | $ | 4.4355 | 1.0000 | |||||
Series E |
$ | 2.4088 | $ | 2.4088 | 1.0000 | |||||
Series D |
$ | 1.5074 | $ | 1.5074 | 1.0000 | |||||
Series C-1 |
$ | 0.835 | $ | 0.835 | 1.0000 | |||||
Series B |
$ | 12.95 | $ | 0.835 | 15.5090 | |||||
Series A-1 |
$ | 10.00 | $ | 0.835 | 11.9760 | |||||
Series A |
$ | 7.425 | $ | 0.835 | 8.8922 |
Additionally, all shares of the Preferred Stock will be automatically converted into shares of common stock of the Company at the ratios set forth above (subject to adjustment as described below) upon (i) the approval of the holders of a majority of the outstanding shares of the Preferred Stock (voting as a single class on an as-converted basis, and which includes holders of at least a majority of the outstanding shares of Series F Preferred Stock) or (ii) the closing of a firmly underwritten public offering of the common stock of the Company at a per share price of at least $7.2264 (prior to underwriting discounts and commissions) and that results in aggregate proceeds to the Company of at least $40 million (net of underwriting discounts and commissions).
Subject to limited exceptions, the conversion price for each series of the Preferred Stock will be subject to an adjustment to reduce dilution in the event that the Company issues additional equity securities at a purchase price less than the applicable conversion price for such series of the Preferred Stock.
F-20
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
Liquidation Rights
In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the assets of the Company available for distribution will be distributed to the Company's stockholders in the following order of priority:
F-21
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
Subject to limited exceptions, unless waived by holders of at least (i) a majority of the outstanding shares of Preferred Stock (voting together as a single class on an as-converted to common stock basis), and (ii) a majority of the outstanding Series F Preferred Stock, a merger, combination, consolidation, or sale of voting control of the Company or sale or transfer of substantially all of the assets of the Company, in each case in which the Company's stockholders do not own a majority of the voting shares of the surviving or acquiring corporation, will be deemed to be a liquidation event. If such deemed liquidation event is structured as a merger, combination, consolidation or sale of voting control, the proceeds of such transaction must be distributed to the stockholders in the order described above. If, alternatively, the deemed liquidation event is structured as a sale of assets, and the Company does not dissolve within 90 days after such deemed liquidation event, the holders of Preferred Stock may elect (pursuant to a procedure and in an order of priority similar to that described under "Redemption" below) to have their shares redeemed by the Company in exchange applicable Liquidation Amount described above.
Protective Provisions
Subject to limited exceptions and certain additional restrictions, so long as at least three million shares of Preferred Stock remain outstanding, the Company may not do any of the following without the consent of holders of a majority of the Preferred Stock (voting together as a single class on an as-converted to common stock basis):
F-22
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
Additionally, for so long as at least twenty-five percent (25%) of the number of shares of any series of Preferred Stock remain issued and outstanding, the Company may not (i) take any action that materially and adversely alters the rights of such series of the Preferred Stock unless substantially similar action is taken with respect to all of the other series of the Preferred Stock or (ii) create any additional class or series of capital stock which ranks senior or pari passu to such series of the Preferred Stock, in each such case without the consent of the holders of a majority (which majority must, in certain cases, include the consent of certain named institutional investors) of the outstanding shares of the respective, affected series of the Preferred Stock, voting as a separate class.
Redemption
On and after September 1, 2019, the holders of shares Preferred Stock may require that such shares be redeemed by the Company out of lawfully available funds, as follows:
F-23
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
All shares of the Preferred Stock have been presented outside of permanent stockholders' deficit, because there are redemption events outside of the Company's control.
Note 13. Common Stock and Stockholders' Deficit
Capitalization
Subject to limited exceptions, the Company may issue common stock subject to approval by (i) the board of directors of the Company (including the approval of the director appointed by the holders of Series D Preferred Stock and the director appointed by the holders of Series F Preferred Stock), or (ii) holders of a majority of the Preferred Stock (voting together as a single class on an as-converted to common stock basis). The aggregate number of shares of common stock that the Company will have authority to issue is 73,559,000 shares of common stock, having a par value of $0.001 per share.
Redeemable Common Stock
The holders of at least a majority of the Preferred Stock have agreed that, following the redemption of all the Preferred Stock, the total 134,977 shares of Series A Common Stock will be subject to a redemption price equal to the greater of (i) the sum of (A) 2.25 times the Series A Investors Common Stock price, plus (B) any dividends declared but unpaid thereon and (ii) the Series A Investors Common Stock appraised value.
The holders of at least a majority of the Preferred Stock have agreed that, following the redemption of all the Preferred Stock, the total 124,001 shares of Series B Common Stock will be subject to a redemption price equal to the greater of (1) the sum of (A) 2.25 times the Series B Investors Common Stock price, plus (B) any dividends declared but unpaid thereon and (ii) the Series B Investors Common Stock appraised value. The Company has recorded the Series B Common Stock $2.1 million redemption value and the Series A Common Stock $.8 million value together in mezzanine equity in the accompanying consolidated balance sheets.
F-24
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
Warrants
On May 2, 2014, the Company issued 300,000 common stock warrants to purchase an aggregate of 300,000 shares of its common stock at an exercise price of $1.29 per share to two entities affiliated with SVB. The common stock warrants were immediately exercisable upon issuance and have a 10-year term. The fair value of the common stock warrants on the date of issue was approximately $0.2 million which was recorded as an increase to additional paid in capital and as a debt discount.
Stock Plan and Stock Options
The Company's Second Amended and Restated Stock Incentive Plan (the "Plan") provides for the issuance of incentive and nonstatutory options to its employees and non-employees. Options issued under the Plan are exercisable for periods not to exceed ten years, vest over four years and are issued at the fair value of the shares of common stock on the date of grant as determined by the Company's board of directors, which obtains periodic third-party valuations to assist their determination process.
The Plan provides for the early exercise of stock options for certain individuals as determined by their respective option agreements.
Activity under the Plan is as follows (in thousands, except share and per share amounts and years):
|
Shares
Available for Grant |
Number of
Shares Outstanding |
Weighted-
Average Exercise Price |
Weighted-
Average Remaining Contractual Life in Years |
Aggregate
Intrinsic Value |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Balance at January 1, 2013 |
757,724 | 4,908,722 | $ | 0.49 | 7.91 | $ | 1,425 | |||||||||
Increase in Plan authorized shares |
2,512,662 | |||||||||||||||
Stock option grants |
(1,683,332 | ) | 1,683,332 | $ | 0.47 | |||||||||||
Stock options exercised |
| (1,686,073 | ) | $ | 0.35 | |||||||||||
Stock options cancelled |
| (71,145 | ) | $ | 0.44 | |||||||||||
| | | | | | | | | | | | | | | | |
Balance at December 31, 2013 |
1,587,054 | 4,834,836 | $ | 0.50 | 8.28 | $ | 4,058 | |||||||||
Increase in Plan authorized shares |
3,707,262 | |||||||||||||||
Stock option grants |
(3,598,245 | ) | 3,598,245 | $ | 2.42 | |||||||||||
Stock options exercised |
(1,796,887 | ) | $ | 0.42 | ||||||||||||
Stock options cancelled |
(63,989 | ) | $ | 0.70 | ||||||||||||
| | | | | | | | | | | | | | | | |
Balance at December 31, 2014 |
1,696,071 | 6,572,205 | $ | 1.63 | 8.38 | $ | 6,758 | |||||||||
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
Vested or expected to vest December 31, 2014 |
6,224,065 | $ | 1.61 | 8.81 | $ | 6,496 | ||||||||||
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
Exercisable as of December 31, 2014 |
1,851,398 | $ | 1.00 | 7.46 | $ | 3,182 | ||||||||||
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
The total grant-date fair value of stock options granted during the years ended December 31, 2013 and 2014, was $0.7 million, and $4.8 million, respectively. The total grant-date fair value of stock options vested during the years ended December 31, 2013 and 2014 was $0.3 million and $0.8 million, respectively. The total intrinsic value of the options exercised during the years ended
F-25
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
December 31, 2013 and 2014, was $1.6 million and $3.8 million, respectively. The intrinsic value is the difference of the current fair value of the stock and the exercise price of the stock option.
Stock-Based Compensation
All stock-based awards to employees are measured based on the grant-date fair value of the awards and are generally recognized in the Company's consolidated statement of operations over the period during which the employee is required to perform services in exchange for the award (generally requiring a four-year vesting period for each award). The Company estimates the fair value of stock options granted using the Black-Scholes option-pricing model. Compensation cost is generally recognized over the vesting period of the applicable award using the straight-line method.
Given the absence of a public trading market, the Company's board of directors considered numerous objective and subjective factors to determine the fair value of its common stock at each grant date. These factors included, but were not limited to, (i) contemporaneous valuations of common stock performed by unrelated third-party specialists; (ii) the prices for the Preferred Stock sold to outside investors; (iii) the rights, preferences and privileges of the Preferred Stock relative to the common stock; (iv) the lack of marketability of the common stock; (v) developments in the business; and (vi) the likelihood of achieving a liquidity event, such as an initial public offering or a merger or acquisition of the Company, given prevailing market conditions.
The assumptions used in the Black-Scholes option-pricing model were determined as follows:
Volatility. Since the Company does not have a trading history for its common stock, the expected volatility was derived from the historical stock volatilities of several unrelated public companies within its industry that it considers to be comparable to its business over a period equivalent to the expected term of the stock option grants.
Risk-Free Interest Rate. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term on the options.
Expected Term. The expected term represents the period that the stock-based awards are expected to be outstanding. When establishing the expected term assumption, the Company used the "simplified" method because the Company does not have adequate historical data.
Dividend Yield. The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, it used an expected dividend yield of zero.
Forfeiture rate. The Company uses historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest.
The fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions and fair value per share:
|
Year Ended
December 31, |
|||
---|---|---|---|---|
|
2013 | 2014 | ||
Volatility |
51.0% 53.4% | 53.3% 53.7% | ||
Expected life (in years) |
7.0 | 7.0 | ||
Risk-free interest rate |
1.15% 2.21% | 1.92% 2.30% | ||
Dividend yield |
| | ||
Weighted-average fair value of underlying common stock |
$0.47 | $2.42 |
F-26
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
Total compensation costs charged as an expense for stock-based awards, including stock options, recognized in the components of operating expenses are as follows (in thousands):
|
Year Ended
December 31, |
||||||
---|---|---|---|---|---|---|---|
|
2013 | 2014 | |||||
Administrative and marketing |
$ | 11 | $ | 23 | |||
Sales |
14 | 75 | |||||
Technology and development |
12 | 39 | |||||
General and administrative |
261 | 396 | |||||
| | | | | | | |
Total stock-based compensation expense |
$ | 298 | $ | 533 | |||
| | | | | | | |
| | | | | | | |
| | | | | | | |
As of December 31, 2014, the Company had $5.3 million in unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over a weighted-average period of approximately 3.7 years.
Note 14. Income Taxes
The components of loss from continuing operations before income taxes were generated solely in the United States as follows (in thousands):
|
Year Ended
December 31, |
||||||
---|---|---|---|---|---|---|---|
|
2013 | 2014 | |||||
United States |
$ | (5,925 | ) | $ | (16,649 | ) |
As a result of the Company's history of net operating losses and full valuation allowance against its deferred tax assets, only the timing differences attributable to the treatment of the amortization of goodwill generated the income tax provision for the years ended December 31, 2013 and 2014.
Reconciliations of the statutory federal income tax rate and the Company's effective tax rate consist of the following (in thousands):
|
Year Ended
December 31, |
||||||
---|---|---|---|---|---|---|---|
|
2013 | 2014 | |||||
Tax at federal statutory rate |
$ | (2,014 | ) | $ | (5,661 | ) | |
State and local tax |
(326 | ) | (916 | ) | |||
Non-deductible stock compensation |
116 | 210 | |||||
Non-deductible expenses |
41 | 87 | |||||
Change in valuation allowance |
2,277 | 6,668 | |||||
| | | | | | | |
Income tax |
$ | 94 | $ | 388 | |||
| | | | | | | |
| | | | | | | |
| | | | | | | |
F-27
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
Significant components of the Company's deferred tax assets and liabilities were as follows (in thousands):
|
As of
December 31, |
||||||
---|---|---|---|---|---|---|---|
Deferred tax assets (liabilities): |
2013 | 2014 | |||||
| | | | | | | |
Net operating loss carryforwards |
$ | 15,556 | $ | 21,381 | |||
Accrued expenses |
287 | 705 | |||||
Stock-based compensation |
205 | 198 | |||||
Amortization |
34 | (87 | ) | ||||
Property and equipment |
(434 | ) | (321 | ) | |||
Valuation allowance |
(15,742 | ) | (22,358 | ) | |||
| | | | | | | |
Net deferred tax assets (liabilities) |
$ | (94 | ) | $ | (482 | ) | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
The Company has provided a full valuation allowance for its deferred tax assets at December 31, 2013 and 2014, due to the uncertainty surrounding the future realization of such assets. Therefore, no benefit has been recognized for the net operating loss carryforwards and other deferred tax assets.
The valuation allowance increased by $2.3 million and $6.6 million during the years ended December 31, 2013 and 2014, respectively.
As of December 31, 2014, the Company had approximately $54.1 million of federal net operating loss carryforwards available to offset future taxable income. If not utilized, the federal net operating loss carryforwards begin to expire in 2024. The deferred tax asset related to its net operating losses include no excess tax benefit of stock option exercises, which, when realized, will be recorded as a credit to additional paid-in capital.
The Company's ability to utilize the net operating loss and tax credit carryforwards in the future may be subject to substantial restrictions in the event of past or future ownership changes as defined in Section 382 of the U.S. Internal Revenue Code of 1986, as amended (the "Internal Revenue Code"). In the event the Company should experience an ownership change, as defined in the Internal Revenue Code, utilization of its net operating loss carryforwards and tax credits could be limited.
The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. In 2013, the Company recorded an uncertain tax position of $2.3 million. There were no additional uncertain tax positions in 2014.
The Company does not anticipate that the total amounts of unrecognized tax benefits will significantly increase or decrease in the next 12 months.
F-28
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
In 2013 and 2014, the Company recognized approximately $0.1 million and $0.1 million, respectively, of interest expense related to unrecognized tax benefits. At December 31, 2013 and 2014, the Company had a liability for the payment of interest and penalties of approximately $0.4 million and $0.5 million, respectively, related to unrecognized tax benefits.
The Company's policy is to include interest and penalties related to unrecognized tax benefits as a component of "Interest income (expense), net" in the Company's consolidated statement of operations.
The Company's primary tax jurisdiction is the United States. The Company's 2011 through 2014 tax years are open to examination by U.S. federal and state tax authorities.
Note 15. Net Loss per Share
Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock of the Company outstanding during the period. Diluted net loss per share is computed by giving effect to all potential shares of common stock of the Company, including the Preferred Stock and outstanding stock options and warrants, to the extent dilutive. Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential shares of common stock of the Company outstanding would have been anti-dilutive.
The following table presents the calculation of basic and diluted net loss per share for the Company's common stock (in thousands, except per share data):
The following securities were excluded from the calculation of diluted net loss per share for common stock because their effect would have been anti-dilutive for the periods presented (in thousands):
|
Year Ended
December 31, |
||||||
---|---|---|---|---|---|---|---|
|
2013 | 2014 | |||||
Stock options |
51 | 51 | |||||
| | | | | | | |
| | | | | | | |
| | | | | | | |
Preferred stock |
37,590 | 50,453 | |||||
| | | | | | | |
| | | | | | | |
| | | | | | | |
Unaudited Pro Forma Net Loss per Share
Pro forma basic and diluted net loss per share were computed to give effect to the conversion of the Preferred Stock into common stock of the Company using the if-converted method as though
F-29
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
the conversion and reclassification had occurred as of the beginning of the first period presented or the original date of issuance, if later.
The following table presents the calculation of basic and diluted pro forma net loss per share (in thousands, except net loss per share data):
|
Year Ended
December 31, 2014 |
|||
---|---|---|---|---|
Net loss |
$ | (17,037 | ) | |
Preferred stock dividends |
(2,920 | ) | ||
Accretion of preferred stock |
(168 | ) | ||
| | | | |
Net loss available to common stockholders |
$ | (20,125 | ) | |
| | | | |
| | | | |
| | | | |
Pro Forma net loss per share - weighted average shares |
53,735 | |||
Pro Forma basic and diluted net loss per share |
$ | (0.37 | ) | |
| | | | |
| | | | |
| | | | |
Basic net loss per share - weighted average shares |
4,487 |
|||
Preferred conversion |
49,248 | |||
| | | | |
Pro Forma net loss per share - weighted average shares |
53,735 | |||
| | | | |
| | | | |
| | | | |
Note 16. 401(k) Plan
The Company has established a 401(k) plan that qualifies as a deferred compensation arrangement under Section 401 of the Internal Revenue Code. All employees over the age of 21 are eligible to participate in the plan. The Company contributes 100% of an employee's elective deferral up to 4% of eligible earnings up to a maximum of $0.3 million. The Company made matching contributions to participants' accounts totaling $0.2 million and $0.4 million during the years ended December 31, 2013 and 2014, respectively.
Note 17. Subsequent Events
For the consolidated financial statements for the year ended and as of December 31, 2014, the Company evaluated subsequent events through March 24, 2015, which is the date the consolidated financial statements were available to be issued.
On January 23, 2015, the Company completed the acquisition of Compile, Inc. d/b/a BetterHelp ("BetterHelp"), through a merger in which BetterHelp became a wholly-owned subsidiary of the Company. The merger consideration paid by the Company in connection with this acquisition consisted of (i) $3.5 million in cash at closing (subject to certain adjustments, including adjustments for any working capital deficiency at closing), (ii) an unsecured, subordinated promissory note in the original principal amount of $1.0 million, with all principal and interest being payable on the third anniversary of closing, and (iii) revenue sharing equal to 15% of the annual net revenue of the BetterHelp business (but not the Company's other business) for three years following closing. BetterHelp was acquired to help the Company expand its operations in the direct-to-consumer and behavioral health sector.
In February 2015, the Company executed a lease agreement for approximately 57,000 square feet of office space near Dallas, Texas that it intends to use for its physician network operations center and administrative purposes. In connection with this lease, the Company arranged for SVB
F-30
TELADOC, INC.
Notes to Audited Consolidated Financial Statements
to issue a letter of credit on its behalf in the amount of $1.0 million in lieu of a cash deposit. The letter of credit expires in February 2016.
The Company intends to consolidate its three other Dallas office locations into this new facility. The lease has a ten-year initial term and provides for two five-year extensions. Future minimum lease and associated utility payments under this agreement are approximately $9.4 million. The minimum annual lease and associated utility payments under this agreement are approximately $0.9 million.
In connection with the Company's planned abandonment of its Greenwich, Connecticut office, the Company intends to recognize an abandonment expense of approximately $0.4 million in its March 31, 2015 consolidated financial statements.
On March 11, 2015, the Company executed an amendment to the Revolving Advance facility that extended its maturity to April 2017.
Note 18. Legal Matters
The Company may become subject to legal proceedings, claims and litigation arising in the ordinary course of business. At December 31, 2014, the Company was party to the following legal proceedings:
Teladoc is plaintiff in three lawsuits in the Texas courts against the Texas Medical Board (the "TMB"). In the first suit , Teladoc v. TMB and Leshikar , on December 31, 2014, the Austin Court of Appeals granted Teladoc's request for summary judgment, invalidating the TMB's prior assertion that Teladoc's doctors do not form "proper professional relationships" with Teladoc's members in the course of telehealth consultations such as would support the prescription of medications. The TMB has filed a petition for review with the Texas Supreme Court to ask that Court if it will allow the TMB to appeal the Court of Appeals's decision. In the second suit, Teladoc v. TMB and Freshour , on February 2, 2015, the Travis County District Court granted Teladoc's request for a temporary injunction restraining the TMB from enforcing an "emergency rule" it issued on January 16, 2015 purporting to amend the Texas Administrative Code so as to require a "face-to-face" examination of a patient before a Texas physician may lawfully prescribe medication. This suit is set for trial on November 9, 2015. In the third suit, Teladoc et al. v. TMB et al., the United States District Court for the Western District of Texas, Austin Division, held a hearing on May 22, 2015 on Teladoc's motion for preliminary injunction of the rule amendments the TMB adopted on April 10, 2015, that seek to effect substantively identical restrictions as the issues in the two prior lawsuits. On May 29, 2015, this court granted Teladoc's request for a preliminary injunction of the rule amendments, pending ultimate trial on the merits, which trial date has yet to be set. Given the nature and status of these lawsuits, the Company cannot yet determine the amount or reasonable range of a potential loss, if any, though it does not believe a material loss is probable in connection with any of the lawsuits.
Business in the State of Texas accounted for $10 million of the Company's consolidated revenue during the year ended December 31, 2014. If the TMB's revisions go into effect as written and Teladoc is unable to adapt its business model in compliance with the TMB rule, its ability to operate its business in the State of Texas could be materially adversely affected, which would have a material adverse effect on its business, financial condition and results of operations.
Teladoc may become subject to legal proceedings, claims and litigation arising in the ordinary course of its business. Other than as stated the Company is not a party to any material legal proceeding, and it is not aware of any pending or threatened litigation that would have a material adverse effect on its business, results of operations, cash flows or financial condition should such litigation be resolved unfavorably.
F-31
Report of Independent Auditors
To
the Board of Directors and Stockholders of
Consult A Doctor, Inc.
We have audited the accompanying consolidated financial statements of Consult A Doctor, Inc., which comprise the consolidated balance sheet as of August 29, 2013, and the related consolidated statement of operations, changes in stockholders' deficit and cash flows for the period from January 1, 2013 to August 29, 2013, and the related notes to the consolidated financial statements.
Management's Responsibility for the Financial Statements
Management is responsible for the preparation and fair presentation of these financial statements in conformity with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.
Auditor's Responsibility
Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
Opinion
In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Consult A Doctor, Inc. at August 29, 2013, and the consolidated results of their operations and their cash flows for the period from January 1, 2013 to August 29, 2013 in conformity with U.S. generally accepted accounting principles.
|
|
/s/ Ernst & Young LLP |
New
York, New York
March 24, 2015
F-32
CONSULT A DOCTOR, INC.
Consolidated Balance Sheet
|
August 29, 2013 | |||
---|---|---|---|---|
Assets |
||||
Cash and cash equivalents |
$ | 538,496 | ||
Accounts receivable, net of allowance for doubtful accounts of $33,963 |
558,090 | |||
Prepaid expenses and other current assets |
37,038 | |||
| | | | |
Total current assets |
1,133,624 | |||
Property and equipment, net |
8,664 | |||
| | | | |
Total assets |
$ | 1,142,288 | ||
| | | | |
| | | | |
| | | | |
Liabilities and stockholders' deficit |
||||
Accounts payable |
$ | 245,278 | ||
Accrued expenses and other current liabilities |
1,561,572 | |||
Series A preferred stockwarrant liability |
123,984 | |||
Due to Teladoc |
1,500,000 | |||
Convertible notes, net of debt discount of $227,051 |
1,675,449 | |||
| | | | |
Total current liabilities |
5,106,283 | |||
Stockholders' deficit |
|
|||
Series A preferred stock$0.001 par value, 8,000,000 shares authorized and 6,363,670 shares issued and outstanding |
6,300 | |||
Common stock$0.001 par value, 10,000,000 shares authorized and 2,505,500 shares issued and outstanding |
2,506 | |||
Additional paid-in capital |
8,510,955 | |||
Accumulated deficit |
(12,483,756 | ) | ||
| | | | |
Total stockholders' deficit |
(3,963,995 | ) | ||
| | | | |
Total liabilities and stockholders' deficit |
$ | 1,142,288 | ||
| | | | |
| | | | |
| | | | |
See accompanying notes to audited consolidated financial statements.
F-33
CONSULT A DOCTOR, INC.
Consolidated Statement of Operations
For the period from January 1, 2013 to August 29, 2013
Revenue |
$ | 3,192,713 | ||
Cost of revenue |
1,459,168 | |||
| | | | |
Gross profit |
1,733,545 | |||
Advertising and marketing expenses |
137,957 | |||
Sales expenses |
618,949 | |||
Technology and development expenses |
754,845 | |||
General and administrative expenses |
2,063,448 | |||
Asset impairment charges |
363,606 | |||
Depreciation |
5,373 | |||
| | | | |
Loss from operations |
(2,210,633 | ) | ||
Other income (expense) |
||||
Change in fair value of embedded derivative and warrant liability |
728,255 | |||
Interest expense |
(537,544 | ) | ||
| | | | |
Net loss before taxes |
(2,019,922 | ) | ||
Income taxes |
| |||
| | | | |
Net loss |
$ | (2,019,922 | ) | |
| | | | |
| | | | |
| | | | |
See accompanying notes to audited consolidated financial statements.
F-34
CONSULT A DOCTOR, INC.
Consolidated Statement of Changes in Stockholders' Deficit
For the period from January 1, 2013 to August 29, 2013
|
Preferred Stock | Common Stock |
|
|
|
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Additional
Paid-in Capital |
Accumulated
Deficit |
|
|||||||||||||||||||
|
Shares | Par Value | Shares | Par Value | Total | |||||||||||||||||
Balance, January 1, 2013 |
6,363,670 | $ | 6,300 | 2,365,500 | $ | 2,366 | $ | 8,496,343 | $ | (10,463,834 | ) | $ | (1,958,825 | ) | ||||||||
Stock option exercises |
| | 140,000 | 140 | | | 140 | |||||||||||||||
Stock-based compensation |
| | | | 48,612 | | 48,612 | |||||||||||||||
Repurchase of options |
| | | | (34,000 | ) | | (34,000 | ) | |||||||||||||
Net loss |
| | | | | (2,019,922 | ) | (2,019,922 | ) | |||||||||||||
| | | | | | | | | | | | | | | | | | | | | | |
Balance, August 29, 2013 |
6,363,670 | $ | 6,300 | 2,505,500 | $ | 2,506 | $ | 8,510,955 | $ | (12,483,756 | ) | $ | (3,963,995 | ) | ||||||||
| | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | |
See accompanying notes to audited consolidated financial statements.
F-35
CONSULT A DOCTOR, INC.
Consolidated Statement of Cash Flows
For the period from January 1, 2013 to August 29, 2013
Cash flows used in operating activities |
||||
Net loss |
$ | (2,019,922 | ) | |
Adjustments to reconcile net loss to net cash used in operating activities: |
||||
Depreciation |
5,373 | |||
Bad debt expense |
35,764 | |||
Asset impairment charges |
363,606 | |||
Stock-based compensation |
48,612 | |||
Accretion of interest |
380,773 | |||
Change in fair value of embedded derivative and warrant liability |
(728,255 | ) | ||
Changes in operating assets and liabilities: |
||||
Receivables |
(155,098 | ) | ||
Prepaid expenses and other current assets |
(13,982 | ) | ||
Accounts payable |
(106,011 | ) | ||
Accrued expenses and other current liabilities |
992,040 | |||
| | | | |
Net cash used in operating activities |
(1,197,100 | ) | ||
| | | | |
Cash flows from financing activities |
||||
Proceeds from Teladoc |
1,500,000 | |||
Purchase of stock options |
(34,000 | ) | ||
Stock option exercises |
140 | |||
Repayments on line of credit |
(299,670 | ) | ||
Issuance of convertible notes |
535,000 | |||
| | | | |
Net cash provided by financing activities |
1,701,470 | |||
| | | | |
Net increase in cash and cash equivalents |
504,370 | |||
Cash and cash equivalents, beginning of year |
34,126 | |||
| | | | |
Cash and cash equivalents, end of year |
$ | 538,496 | ||
| | | | |
| | | | |
| | | | |
Interest paid |
8,091 |
See accompanying notes to audited consolidated financial statements
F-36
CONSULT A DOCTOR, INC.
Notes to Consolidated Financial Statements
1. Nature of Business
Consult A Doctor, Inc. (the "Company" or "Consult A Doctor") is a Delaware corporation that provides telehealth services to clients and their customers.
The Company executed an Agreement and Plan of Merger dated as of August 29, 2013, providing for the sale of 100% of the common stock and 100% of the preferred stock (the "Series A Preferred Stock") of the Company to Teladoc, Inc. ("Teladoc"). Upon the effective date of the merger, the Company merged with and into Teladoc which continues as the surviving corporation (see Note 12).
2. Summary of Significant Accounting Policies
Principles of Consolidation
The consolidated financial statements include the accounts of Consult A Doctor, Inc. and its wholly-owned subsidiary, Telemed Physician Solutions, LLC. All significant intercompany transactions and balances have been eliminated.
Basis of Preparation
These consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). The following is a summary of the significant accounting and reporting policies used in preparing the consolidated financial statements.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the consolidated financial position and results of operations. Significant estimates and assumptions affect the allowance for doubtful accounts, the carrying value, capitalization, and amortization of software and website development costs, warrant liability, convertible note derivative liability, and the value attributed to employee stock options.
Revenue Recognition
The Company recognizes a substantial portion of its revenue from contracts that provide clients with subscription access to the Company's professional provider network for a fixed monthly fee which entitles the client's members to unlimited consultations ("visits"). The contracts are generally for a one year term and automatically renew for additional years.
The Company commences revenue recognition for the subscription access service on the date that the services are made available to the client and its members, which is considered the implementation date, provided all of the following criteria are met:
F-37
CONSULT A DOCTOR, INC.
Notes to Consolidated Financial Statements
Any consultation revenue that is not included in the subscription access service is recognized when the service has been provided to the member.
Cost of Revenue
Cost of revenue primarily consists of fees paid to the physician network providers, costs incurred in connection with the provider network operations which include employee-related expenses (including salaries, benefits and stock-based compensation) and costs related to medical malpractice insurance.
Advertising and Marketing Expenses
Advertising and marketing costs are expensed as incurred.
Sales Expenses
Sales expenses consists principally of employee-related costs and travel.
Cash and Cash Equivalents
Cash and cash equivalents consist of highly liquid investments with original maturities of three months or less from the date of purchase. Cash and cash equivalents generally consist of investments in money market funds, U.S. treasury securities and U.S. government-issued obligations. Cash and cash equivalents are stated at fair value.
Accounts Receivable and Allowance for Doubtful Accounts
Accounts receivable are recorded at the invoiced amount, net of allowances for doubtful accounts. The allowance for doubtful accounts is based on the Company's assessment of the collectability of accounts. The Company regularly reviews the adequacy of the allowance for doubtful accounts by considering the age of each outstanding invoice and the collection history of each customer to determine whether a specific allowance is appropriate. Accounts receivable deemed uncollectable are charged against the allowance for doubtful accounts when identified.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk are cash and cash equivalents and accounts receivable. At times, the Company's deposits in banks may exceed federally insured limits. In addition, other cash equivalents may expose the Company to certain credit risks. The Company has not experienced any losses in such accounts and does not believe it is exposed to any significant risk. The Company assesses the creditworthiness of its customers before extending credit. Accounts receivable are written off only when all efforts to collect the accounts have been exhausted.
One customer represented 28% of total revenue for the period from January 1, 2013 to August 29, 2013 and accounted for 43% of accounts receivable at August 29, 2013.
F-38
CONSULT A DOCTOR, INC.
Notes to Consolidated Financial Statements
Although the Company does not expect that the customer will fail to meet its obligations, the Company is potentially exposed to concentrations of credit risk if the customer failed to perform according to the terms of the contracts.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective asset as follows:
Computer equipment |
3 years | |
Furniture and equipment |
5 years |
Maintenance and minor repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected in the consolidated statement of operation.
Income Taxes
The Company accounts for income taxes using the liability method, under which deferred tax assets and liabilities are determined based on the future tax consequences attributable to differences between the financial reporting carrying amounts of existing assets and liabilities and their respective tax bases and tax credit and net operating loss carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates that are expected to be in effect when the differences are expected to reverse.
The Company has assessed the likelihood that deferred tax assets will be recovered from future taxable income, and a valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized.
The Company recognizes and measures uncertain tax positions using a two-step approach. The first step is to evaluate the tax position taken or expected to be taken by determining if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Significant judgment is required to evaluate uncertain tax positions. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of audit and effective settlement of audit issues. The Company recognizes interest and penalties related to uncertain tax positions in income taxes. There were no interest and penalties recorded on uncertain tax positions for the period from January 1, 2013 to August 29, 2013.
Long-lived Assets
The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the sum of the undiscounted expected cash flows is less than the carrying amount of the asset, an impairment loss is recognized as the amount by which the carrying amount of the asset exceeds its fair value.
F-39
CONSULT A DOCTOR, INC.
Notes to Consolidated Financial Statements
From the period from January 1, 2013 to August 29, 2013, the Company recognized $363,606 of asset impairment charge for the cost of internal developed software projects abandoned.
Stock-based Compensation
All stock-based compensation to employees is measured based on the grant-date fair value of the awards and recognized on a straight-line basis over the period during which the employee is required to perform services in exchange for the award (generally the vesting period of the award). The Company estimates the fair value of stock options granted using the Black-Scholes option-pricing model.
Warranties and Indemnification
The Company's contracts generally include certain provisions for indemnifying customers against liabilities if there is a breach of a customer's data or if the Company's service infringes a third party's intellectual property rights. To date, the Company has not incurred any material costs as a result of such indemnifications and has not accrued any liabilities related to such obligations in these consolidated financial statements.
The Company has also agreed to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person's service as a director or officer, including any action by the Company, arising out of that person's services as our director or officer or that person's services provided to any other company or enterprise at our request. The Company maintains director and officer insurance coverage that would generally enable the Company to recover a portion of any future amounts paid. The Company may also be subject to indemnification obligation by law with respect to the actions of our employees under certain circumstances and in certain jurisdictions.
3. Property and Equipment, Net
Property and equipment, net consists of the following:
|
August 29, 2013 | |||
---|---|---|---|---|
Computer equipment |
$ | 41,655 | ||
Office furniture and equipment |
11,878 | |||
| | | | |
Total |
53,533 | |||
Accumulated depreciation |
(44,869 | ) | ||
| | | | |
Property and equipment, net |
$ | 8,664 | ||
| | | | |
| | | | |
| | | | |
Depreciation expense for the period from January 1, 2013 to August 29, 2013 was $5,373.
F-40
CONSULT A DOCTOR, INC.
Notes to Consolidated Financial Statements
4. Accrued Expenses
As of August 29, 2013, accrued expenses consisted of the following:
Professional fees |
$ | 714,448 | ||
Compensation |
557,382 | |||
Interest |
244,714 | |||
Other |
45,028 | |||
| | | | |
Total |
$ | 1,561,572 | ||
| | | | |
| | | | |
| | | | |
5. Fair Value Measurements
The Company measures financial assets and liabilities at fair value at each reporting period using a fair value hierarchy that requires that they maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument's classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Company classifies financial instruments in Level 3 of the fair value hierarchy when there is reliance on at least one significant unobservable impact to the valuation model. In addition to these unobservable inputs, the valuation models for Level 3 financial instruments typically also rely on a number of inputs that are readily observable either directly or indirectly.
Level 1Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2Include other inputs that are directly or indirectly observable in the marketplace.
Level 3Unobservable inputs that are supported by little or no market activity.
The Company measures cash and cash equivalents, Series A preferred stock warrant liability and derivative liability related to convertible notes at fair value on a recurring basis. Cash equivalents are classified within Level 1 because they are valued using observable inputs that reflect quoted prices for identical assets in active markets and the Series A preferred stock warrants and derivative liabilities within Level 3 because they are valued using valuation techniques using certain inputs which are unobservable in the market. The Company classifies financial instruments in Level 3 of the fair value hierarchy when there is reliance on at least one significant unobservable input to the valuation model. In addition to these unobservable inputs, the valuation models for Level 3 financial instruments typically also rely on a number of inputs that are readily observable either directly or indirectly.
|
Level 1 | Level 2 | Level 3 | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Cash and cash equivalents |
$ | 538,496 | $ | | $ | | ||||
Series A preferred stock warrant liability |
| | 123,984 | |||||||
Derivative liability |
| | | |||||||
| | | | | | | | | | |
Total |
$ | 538,496 | $ | | $ | 123,984 | ||||
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
F-41
CONSULT A DOCTOR, INC.
Notes to Consolidated Financial Statements
The following table reconciles the beginning and ending balance of the Company's Level 3 liabilities:
Series A preferred stock warrants |
||||
Fair value at January 1, 2013 |
$ | 114,297 | ||
Warrants issued |
9,850 | |||
Change in fair value recorded in operations |
(163 | ) | ||
| | | | |
Fair value at August 29, 2013 |
$ | 123,984 | ||
| | | | |
| | | | |
| | | | |
Derivative liability |
||||
Fair value at January 1, 2013 |
$ | 533,199 | ||
Derivative issued |
194,893 | |||
Change in fair value recorded in operations |
(728,092 | ) | ||
| | | | |
Fair value at August 29, 2013 |
$ | | ||
| | | | |
| | | | |
| | | | |
6. Line of Credit
The Company had a $300,000 facility under a Line of Credit Agreement with a bank. Prior to closing of the sale of the Company to Teladoc, the Company repaid the total amount outstanding of $299,670 and terminated the Line of Credit Agreement.
7. Income Taxes
The Company has no provision or benefit for income taxes for the period from January 1, 2013 to August 29, 2013.
Significant components of the Company's deferred income taxes as of August 29, 2013 are shown below:
Deferred tax assets: |
||||
Net operating loss carry-forward |
$ | 2,914,374 | ||
Accrued expenses |
13,415 | |||
| | | | |
Total deferred tax assets |
2,927,789 | |||
Deferred tax liabilities: |
|
|||
Depreciation |
(3,423 | ) | ||
Prepaid expenses |
(14,630 | ) | ||
| | | | |
Total deferred tax liabilities |
(18,053 | ) | ||
Less: valuation allowance |
(2,909,736 |
) |
||
| | | | |
Net deferred tax assets |
$ | | ||
| | | | |
| | | | |
| | | | |
The Company has provided a full valuation allowance for the deferred tax assets at August 29, 2013, due to the uncertainty surrounding the future realization of such assets. Therefore, no benefit has been recognized for the net operating loss carryforwards and other deferred tax assets. The Company's total valuation allowance increased by $796,132 during the period from January 1, 2013 to August 29, 2013.
F-42
CONSULT A DOCTOR, INC.
Notes to Consolidated Financial Statements
The Company has available net operating loss carry-forwards of approximately $7,378,000 which are available to offset future taxable income, if any. If not utilized, the federal net operating loss carryforwards begin to expire in 2029.
The Company's ability to utilize the net operating loss and tax credit carryforwards in the future may be subject to substantial restrictions in the event of past or future ownership changes as defined in Section 382 of the U.S. Internal Revenue Code of 1986, as amended. In the event the Company should experience an ownership change, as defined, utilization of our net operating loss carryforwards and tax credits could be limited.
The Company's 2010 to 2013 tax return remains subject to examination by the Internal Revenue Service.
8. Debt
Due to Teladoc
In connection with the July 2013 execution of Teladoc's Letter of Intent to acquire the Company (see Note 12), Teladoc and the Company executed a Loan and Security Agreement pursuant to which Teladoc provided the Company with a $1,500,000 secured loan. In the event Teladoc did not complete the acquisition of the Company by August 31, 2013, Teladoc had agreed to pay a breakup fee in the sum of $500,000 (net against the loan) and the remaining loan amount of $1,000,000 was to accrue interest at 5% per year, to be paid in seven equal installment of $142,857.14 plus interest beginning June 30, 2014 with the final payment due to Teladoc on December 31, 2014. This loan was to be due and payable on Teladoc's demand at any time following a transaction that provides the Company, or shareholders of the Company, cash or cash equivalents in excess of $5,000,000.
Convertible Notes
During various dates in 2012 and 2013, the Company issued convertible notes (collectively, the "Notes") in the aggregate principal sum of $1,367,500 and $535,000, respectively, each accruing interest at a rate of 12% per annum. The Notes mature on December 31, 2013, at which time principal and accrued interest thereon become due, unless automatically converted prior to maturity upon the occurrence of a Qualified Equity Financing into Series B Preferred Stock (or equivalent securities), as defined, at the price applicable to the new investors, less a 30% discount. A Qualified Equity Financing is defined as the Company's sale of Series B Preferred Stock (or equivalent shares) for aggregate cash consideration of at least $3,000,000 in gross proceeds on or before December 31, 2013.
In conjunction with the issuance of the Notes, the Company bifurcated an embedded derivative, which represents the discount feature upon the occurrence of a conversion, as described above. The fair value of the embedded derivative was recorded as a debt discount. The Company is required to mark to market the derivative each reporting period, as well as amortize the debt discount, using the effective interest rate method with the change in fair value of the derivative instrument recorded through the statement of operations and the amortization of the debt discount recorded as interest expense. The change in the fair value of derivative and the amortization of the debt discount for the period from January 1, 2013 to August 29, 2013 amount to $728,092 and $380,773, respectively.
F-43
CONSULT A DOCTOR, INC.
Notes to Consolidated Financial Statements
Warrants
In conjunction with the issuance of the Notes, the Company also issued in the lenders' Series A preferred stock purchase warrants (the "Warrants"). These detachable Warrants were issued to induce the lenders into making the loan to the Company. The Warrants grant the holders the right to purchase for $1 per share, at any time until expiration in 2022, an aggregate of 204,103 shares of the Company's Series A preferred stock. The exercise price and number of shares are subject to adjustments for increases or decreases in the number of shares outstanding that may result from dividends or other distributions payable in such shares, or subdivisions, splits or reverse splits involving such shares. In addition, the Warrants entitle the holders to participate on a pro rata basis in any offering by the Company of rights to purchase the preferred shares. In the event of a capital reorganization, capital reclassification, consolidation or merger, as defined, the Warrants may be exercised or exchanged for cash or other assets to which holders of the shares would be entitled.
The fair value for these Warrants upon issuance was calculated using the Black-Scholes option-pricing model. As the underlying preferred shares of the outstanding warrants are redeemable at the option of the holder, the fair value is re-measured each reporting period. The Company recorded income of $163 associated with these Warrants for period from January 1, 2013 to August 29, 2013.
The assumptions used in the Black-Scholes option-pricing model were determined as follows:
Volatility. Since the Company does not have a trading history for its common stock, the expected volatility was derived from the historical stock volatilities of several unrelated public companies within our industry that the Company considers to be comparable to its business over a period equivalent to the expected term of the warrants.
Risk-Free Interest Rate. The risk-free rate that the Company used is based on U.S. Treasury zero-coupon issues with terms similar to the expected term on the options.
Expected Life. The expected term represents the remaining contractual term of the warrants.
Dividend Yield. The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, it uses an expected dividend yield of zero.
9. Equity-Based Compensation
The Company established the 2013 Equity Incentive Plan with an effective date of February 4, 2013. Under this plan, current employees who had shares issued under previous plans were given options to replace those that had been granted. The shares generally vest in four years after the grant date as long as the individual is an employee of the Company and have a contractual term of 10 years. The shares provide for accelerated vesting upon the consummation of a sale of the Company. The Company recorded $14,752 of incremental stock based compensation as a result of the sale of the Company.
All stock-based payments to employees are measured based on the grant-date fair value of the awards and are recognized in our statement of operations over the period during which the employee is required to perform services in exchange for the award (generally the vesting period of
F-44
CONSULT A DOCTOR, INC.
Notes to Consolidated Financial Statements
the award). The Company estimates the fair value of stock options granted using the Black-Scholes option-pricing model.
Given the absence of a public trading market, the Company's board of directors considered recent sales of common stock to determine the fair value of the common stock at each grant date.
|
Shares
Available for Grant |
Number of
Shares Outstanding |
Weighted-
Average Exercise Price |
Weighted-
Average Remaining Contractual Life in Years |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Balance at January 1, 2013 |
780,587 | 140,000 | $ | 0.01 | 9.0 | ||||||||
Stock option grants |
(489,687 | ) | 489,687 | 0.22 | 9.4 | ||||||||
Stock options exercised |
(140,000 | ) | 0.01 | | |||||||||
Surrender/purchase in connection with the purchase of the Company |
(452,187 | ) | 0.22 | | |||||||||
| | | | | | | | | | | | | |
Balance at August 29, 2013 |
290,900 | 37,500 | 0.22 | 9.4 | |||||||||
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Vested or expected to vest August 29, 2013 |
37,500 | 0.22 | 9.4 | ||||||||||
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Exercisable as of August 29, 2013 |
37,500 | 0.22 | 9.4 | ||||||||||
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
The assumptions used in the Black-Scholes option-pricing model were determined as follows:
Volatility. Since the Company does not have a trading history for its common stock, the expected volatility was derived from the historical stock volatilities of several unrelated public companies within its industry that we consider to be comparable to its business over a period equivalent to the expected term of the stock option grants.
Risk-Free Interest Rate. The risk-free rate that we used is based on U.S. Treasury zero-coupon issues with terms similar to the expected term on the options.
Expected Life. The expected life represents the period that the Company's stock-based awards are expected to be outstanding. When establishing the expected life assumption, the Company used the "simplified" method prescribed in ASC Topic 718 for companies that do not have adequate historical data.
Dividend Yield. The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, it uses an expected dividend yield of zero.
The fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions and fair value per share:
Volatility |
53.4 | % | ||
Expected life (in years) |
7.0 | |||
Risk-free interest rate |
1.36 | % | ||
Dividend yield |
| |||
Fair value of underlying common stock |
$ | 0.22 |
F-45
CONSULT A DOCTOR, INC.
Notes to Consolidated Financial Statements
The total stock units from previous plans that were converted into options on February 4, 2013 were 267,187 and there were 222,500 granted throughout the year.
10. Shareholders' Deficit
Common Stock
At August 29, 2013, the Company had 10,000,000 shares of common stock authorized, with a par value of $0.001 with 2,505,000 shares, issued and outstanding. Common stockholders are entitled to one vote per share.
Series A Preferred Stock
Prior to January 1, 2013, the Company issued 6,363,670 shares of Series A Preferred Stock at $1 per share. Significant terms of the Series A preferred stock are as follows:
Dividends
From the date of the issuance of any shares of Series A Preferred Stock, dividends at the rate of ten percent (10%) per annum of the applicable Series A Original Issue Price ($1.00) per share shall accrue on such shares of Series A Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series A Preferred Stock), and compound annually on December 31. Accruing dividends shall accrue from day to day (whether or not declared), shall be cumulative, and, when and if declared by the Board, shall be payable (i) in cash or, (ii) with respect to up to seventy percent (70%) of any dividends owed to the holders of Series A Preferred Stock, at the option of, and in the percentage specified by, each of the holders of Series A Preferred Stock, shall be payable in shares of Series A Preferred Stock valued at the Series A Conversion Price in effect of the date such divided accrued. Accruing dividends on the Series A Preferred Stock shall be paid in full upon the consummation of a qualified initial public offering, at a conversion time or other Series A mandatory conversion time. Cumulative undeclared dividends at August 29, 2013 were $1,812,524.
Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales
In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, each holder of shares of Series A Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders before any payment shall be made to the holders of its common stock by reason of their ownership thereof, an amount per share of Series A Preferred Stock equal to two times (2x) the Series A Original Issue Price plus any Accruing Dividends accrued but unpaid thereon, whether or not declared, together with any other dividends declared but unpaid thereon. If upon any such liquidation, dissolution or winding up of the Company, the assets of the Company available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series A Preferred Stock the full amount to which they shall be entitled, the holders of shares of Series A Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. As of August 29, 2013 the liquidation preference amounted to $12,727,340.
Voting
On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of
F-46
CONSULT A DOCTOR, INC.
Notes to Consolidated Financial Statements
meeting), each holder of outstanding shares of Series A Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of Series A Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter; provided however that the holders of Series A Preferred Stock shall have no right to vote on the election of the Common Directors, as defined. Holders of Series A Preferred Stock shall vote together with the holders of common stock as a single class.
Conversion
Each share of Series A Preferred Stock shall be convertible, at the option of the holder, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and non-assessable shares of common stock as is determined by dividing the Series A Original Issue Price by the Series A Conversion Price in effect at the time of conversion. The "Series A Conversion Price" shall initially be equal to $1.00.
Redemption
Shares of Series A Preferred Stock shall be redeemed by the Company out at a price equal to the highest of (i) the Series A Original Issue Price, plus all accrued but unpaid dividends; and (ii) Fair Market Value as of the date of the applicable redemption request, at any time on or after the fifth (5th) anniversary of the original issue date, after receipt by the Company of written notice requesting redemption of shares of Series A Preferred Stock from the holders of a requisite majority of the Series A Preferred Stock on a date not less than ninety (90) days after the date of the Redemption Request.
The remaining 636,330 authorized Series A Preferred Stock are "undesignated" and may be used for future conversion of the outstanding convertible notes and warrants. The Series A Preferred Stock will have liquidation preference over all other classes and of equity in any event of liquidation, dissolution or winding up of the Company. In the event of any voluntary or involuntary liquidation or dissolution of the Company, each holder of shares of Series A Preferred Stock then outstanding shall be entitled to be paid out of the assets of the company available for distribution to its Series A Preferred Stockholders before any payment shall be made to the holders of common stock. Holders of the outstanding shares of Series A Preferred Stock are entitled to an ordinary dividend at an annual rate of 10% per share. Dividends shall accrue cumulatively and compound annually on December 31 of each year. Dividends shall be payable when, as and if declared by the Board of Directors in cash or in equivalent shares as defined by the Amended and Restated Certificate of Incorporation of the Company.
11. Commitments and Contingencies
At August 29, 2013, the Company was subject to various claims and legal actions which are being handled in the ordinary course of business. In management's opinion, these matters are not expected to have a material adverse effect upon the Company's consolidated financial position, results of operations or cash flows.
12. Subsequent Events
Subsequent events were evaluated through March 24, 2015, which is the date these consolidated financial statements were available to be issued.
The Company executed an Agreement and Plan of Merger dated as of August 29, 2013, providing for the sale of all of its issued and outstanding common and Series A preferred stock to Teladoc. The aggregate cash consideration of $16.6 million which reflected the impact of certain working capital deficiencies at closing working capital. Upon the effective date of the merger, the Company merged with and into Teladoc, which continued as the surviving corporation.
F-47
Report of Independent Auditors
To
Members of
AmeriDoc, LLC
We have audited the accompanying consolidated financial statements of AmeriDoc, LLC, which comprise the consolidated balance sheets as of December 31, 2013 and April 30, 2014, and the related consolidated statements of operations, changes in members' deficit and cash flows for the year ended December 31, 2013 and the period from January 1, 2014 to April 30, 2014, and the related notes to the consolidated financial statements.
Management's Responsibility for the Financial Statements
Management is responsible for the preparation and fair presentation of these financial statements in conformity with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.
Auditor's Responsibility
Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
Opinion
In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of AmeriDoc, LLC at December 31, 2013 and April 30, 2014, and the consolidated results of their operations and their cash flows for the year ended December 31, 2013 and the period from January 1, 2014 to April 30, 2014 in conformity with U.S. generally accepted accounting principles.
|
|
/s/ Ernst & Young LLP |
New
York, New York
March 24, 2015
F-48
AMERIDOC, LLC
Consolidated Balance Sheets
|
December 31, 2013 | April 30, 2014 | |||||
---|---|---|---|---|---|---|---|
Assets |
|||||||
Cash and cash equivalents |
$ | 35,045 | $ | 57,202 | |||
Accounts receivable |
353,745 | 456,229 | |||||
Other receivables |
1,706 | 1,180 | |||||
Prepaid expenses |
69,506 | 65,869 | |||||
| | | | | | | |
Total current assets |
460,002 | 580,480 | |||||
Property and equipment, net |
187,008 |
178,288 |
|||||
Investment in equity investee |
521,000 | 521,000 | |||||
Other assets |
15,695 | 15,695 | |||||
| | | | | | | |
Total assets |
$ | 1,183,705 | $ | 1,295,463 | |||
| | | | | | | |
| | | | | | | |
| | | | | | | |
Liabilities and members' deficit |
|||||||
Accounts payable |
$ | 89,866 | $ | 43,270 | |||
Accrued expenses |
303,805 | 1,598,742 | |||||
Line of credit |
99,262 | 96,350 | |||||
Current portion of long-term debt |
220,000 | 388,800 | |||||
Due to related parties |
447,039 | 480,128 | |||||
| | | | | | | |
Total current liabilities |
1,159,972 | 2,607,290 | |||||
Long-term portion of debt |
226,000 |
|
|||||
Other long-term liabilities |
196,037 | 180,996 | |||||
Members' deficit |
(398,304 | ) | (1,492,823 | ) | |||
| | | | | | | |
Total liabilities and members' deficit |
$ | 1,183,705 | $ | 1,295,463 | |||
| | | | | | | |
| | | | | | | |
| | | | | | | |
See accompanying notes to audited consolidated financial statements.
F-49
AMERIDOC, LLC
Consolidated Statements of Operations
|
For the year ended
December 31, 2013 |
For the period from
January 1, 2014 to April 30, 2014 |
|||||
---|---|---|---|---|---|---|---|
Revenue |
$ | 3,204,741 | $ | 1,813,701 | |||
Cost of revenue |
886,987 | 568,224 | |||||
| | | | | | | |
Gross profit |
2,317,754 | 1,245,477 | |||||
Advertising and marketing expenses |
52,916 |
13,177 |
|||||
Sales |
810,727 | 479,230 | |||||
Technology and development expenses |
451,627 | 97,047 | |||||
General and administrative expenses |
1,141,712 | 1,728,411 | |||||
Depreciation |
29,014 | 8,720 | |||||
| | | | | | | |
Loss from operations |
(168,242 | ) | (1,081,108 | ) | |||
Interest expense |
2,246 | 7,657 | |||||
| | | | | | | |
Loss before taxes |
(170,488 | ) | (1,088,765 | ) | |||
Income taxes |
29,461 | 5,681 | |||||
| | | | | | | |
Net loss |
$ | (199,949 | ) | $ | (1,094,446 | ) | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
See accompanying notes to audited consolidated financial statements.
F-50
AMERIDOC, LLC
Consolidated Statements of Members' Deficit
Members' deficit as of January 1, 2013 |
$ | (192,617 | ) | |
Distributions |
(5,738 |
) |
||
Net loss |
(199,949 | ) | ||
| | | | |
Members' deficit as of December 31, 2013 |
(398,304 |
) |
||
Distributions |
(73 |
) |
||
Net loss |
(1,094,446 | ) | ||
| | | | |
Members' deficit as of April 30, 2014 |
$ | (1,492,823 | ) | |
| | | | |
| | | | |
| | | | |
See accompanying notes to audited consolidated financial statements.
F-51
AMERIDOC, LLC
Consolidated Statements of Cash Flows
|
For the year ended
December 31, 2013 |
For the period from
January 1, 2014 to April 30, 2014 |
|||||
---|---|---|---|---|---|---|---|
Cash flows from operating activities |
|||||||
Net loss |
$ | (199,949 | ) | $ | (1,094,446 | ) | |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities |
|||||||
Depreciation |
29,014 | 8,720 | |||||
Forgiveness of debt |
| (13,200 | ) | ||||
Changes in operating assets and liabilities: |
|||||||
Accounts receivable and other receivables |
(90,038 | ) | (101,958 | ) | |||
Prepaid expenses and other assets |
(47,006 | ) | 3,637 | ||||
Accounts payable |
78,462 | (46,596 | ) | ||||
Accrued expenses and other long-term liabilities |
120,454 | 1,279,896 | |||||
| | | | | | | |
Net cash provided by (used in) operating activities |
(109,063 | ) | 36,053 | ||||
| | | | | | | |
Cash flows from investing activities
|
(75,000 | ) | (44,000 | ) | |||
| | | | | | | |
Net cash used in investing activities |
(75,000 | ) | (44,000 | ) | |||
| | | | | | | |
Cash flows from financing activities |
|||||||
Advances from related parties, net |
109,657 | 33,089 | |||||
Borrowings on line of credit |
99,262 | | |||||
Repayments on line of credit |
| (2,912 | ) | ||||
Repayments on long term debt |
(150,000 | ) | | ||||
Distributions to members |
(5,738 | ) | (73 | ) | |||
| | | | | | | |
Net cash provided by financing activities |
53,181 | 30,104 | |||||
| | | | | | | |
Net increase (decrease) in cash and cash equivalents |
(130,882 | ) | 22,157 | ||||
Cash and cash equivalents, beginning of year |
165,927 | 35,045 | |||||
| | | | | | | |
Cash and cash equivalents, end of year |
$ | 35,045 | $ | 57,202 | |||
| | | | | | | |
| | | | | | | |
| | | | | | | |
Interest paid |
$ | 2,246 | $ | 7,657 |
See accompanying notes to audited consolidated financial statements.
F-52
AMERIDOC, LLC
Notes to Consolidated Financial Statements
1. Nature of Business
AmeriDoc, LLC (the "Company") is a Texas limited liability company that provides telehealth services to clients and their customers.
The Company and its Members executed an Agreement and Plan of Merger dated as of May 1, 2014, providing for the sale of all of the membership interests of the Company to Teladoc, Inc. ("Teladoc"). Upon the effective date of the merger, the Company merged with and into Teladoc, which continued as the surviving corporation (see Note 9).
2. Summary of Significant Accounting Policies
Principles of Consolidation
The consolidated financial statements include the accounts of AmeriDoc, LLC and its wholly-owned subsidiary, AmeriDoc Physicians Network, LLC. All significant intercompany transactions and balances have been eliminated.
Basis of Preparation
The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). The following is a summary of the significant accounting and reporting policies used in preparing the consolidated financial statements.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the consolidated financial position and results of operations.
Revenue Recognition
The Company recognizes a substantial portion of its revenue from contracts that provide clients with subscription access to the Company's professional provider network for a fixed monthly fee which entitles the client's members to unlimited consultations ("visits"). The contracts are generally for a one year term and automatically renew for additional years.
The Company commences revenue recognition for the subscription access service on the date that the services are made available to the client and its members, which is considered the implementation date, provided all of the following criteria are met:
Any consultation revenue that is not included in the subscription access service is recognized when the service has been provided to the member.
F-53
AMERIDOC, LLC
Notes to Consolidated Financial Statements
Cost of Revenue
Cost of revenue primarily consists of fees paid to the physician network providers, costs incurred in connection with the provider network operations which include employee-related expenses (including salaries and benefits) and costs related to medical malpractice insurance.
Cash and Cash Equivalents
Cash and cash equivalents consist of highly liquid investments with original maturities of three months or less from the date of purchase. Cash and cash equivalents generally consist of investments in money market funds, U.S. treasury securities and U.S. government-issued obligations. Cash and cash equivalents are stated at fair value and represent a level 1 disclosure according to the fair value hierarchy for which there are observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
Accounts Receivable and Allowance for Doubtful Accounts
Accounts receivable are recorded at the invoiced amount, net of allowances for doubtful accounts. The allowance for doubtful accounts is based on the Company's assessment of the collectability of accounts. The Company regularly reviews the adequacy of the allowance for doubtful accounts by considering the age of each outstanding invoice and the collection history of each customer to determine whether a specific allowance is appropriate. Accounts receivable deemed uncollectable are charged against the allowance for doubtful accounts when identified. There was no allowance for doubtful accounts recorded as of April 30, 2014 and December 31, 2013.
Advertising and Marketing Expenses
Advertising and marketing costs are expensed as incurred. For the year ended December 31, 2013 and for the period from January 1, 2014 to April 30, 2014, advertising expenses were $52,916 and $13,177, respectively.
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk are cash and cash equivalents and accounts receivable. At times, the Company's deposits in banks may exceed federally insured limits. In addition, other cash equivalents may expose the Company to certain credit risks. The Company has not experienced any losses in such accounts and does not believe it is exposed to any significant risk. The Company assesses the creditworthiness of its customers before extending credit. Accounts receivable are written off only when all efforts to collect the accounts have been exhausted.
Two customers represented 26% and 19%, respectively, of total revenue for the year ended December 31, 2013. Three customers represented 16%, 11% and 10%, respectively, of total revenue for the period from January 1, 2014 to April 30, 2014.
Two customers accounted for 40% and 23% of accounts receivable at December 31, 2013. Two customers accounted for 33% and 24% of accounts receivable at April 30, 2014.
F-54
AMERIDOC, LLC
Notes to Consolidated Financial Statements
Although the Company does not expect that these customers will fail to meet their obligations, the Company is potentially exposed to concentrations of credit risk if these customers fail to perform according to the terms of the contracts.
Members' Equity
As of both December 31, 2013 and April 30, 2014, the Company had three members with ownership interests of 79%, 14% and 7%. The membership agreement provides that each member has the right to vote in proportion to their membership percentage interest with respect to any matter, that members will not be personally liable to any third party for any debt, obligation or liability of the Company, whether that liability or obligation arises in contract, tort or otherwise, and that the failure of the Company to observe any formalities or requirements relating to the exercise of its powers or management of its business or affairs under the Company's operating agreement will not be grounds for imposing personal liability on the members for liabilities of the Company.
Operating Leases
The Company leases office space under an operating lease expiring in 2020. This lease agreement contains rent holidays and rent escalation provisions for which the Company has recognized a deferred rent liability. The Company recognizes rent expense on a straight-line basis over the lease period.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective asset as follows:
Computer equipment |
3 years | |
Furniture and equipment |
5 years | |
Leasehold improvements |
Shorter of the lease term or the estimated useful lives of the improvements |
Maintenance and repairs are charged to expense as incurred, and improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the consolidated statement of operations.
Income Taxes
The Company is taxed as a partnership and therefore does not incur income taxes at the Federal level. The Company's earnings and losses are included in the personal returns of the members.
Long-lived Assets
The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the sum of the undiscounted expected cash flows is less than the carrying amount of the asset, an impairment loss is recognized as the amount by which the carrying amount of the asset exceeds its fair value.
F-55
AMERIDOC, LLC
Notes to Consolidated Financial Statements
There has been no impairment charges recorded in any of the periods presented in the consolidated financial statements.
3. Property and Equipment, net
Property and equipment, net consisted of the following:
|
December 31, 2013 | April 30, 2014 | |||||
---|---|---|---|---|---|---|---|
Furniture and equipment |
$ | 17,504 | $ | 17,504 | |||
Leasehold improvements |
209,287 | 209,287 | |||||
| | | | | | | |
Total |
226,791 | 226,791 | |||||
Accumulated depreciation |
(39,783 | ) | (48,503 | ) | |||
| | | | | | | |
Property and equipment, net |
$ | 187,008 | $ | 178,288 | |||
| | | | | | | |
| | | | | | | |
| | | | | | | |
Depreciation expense for the year ended December 31, 2013 and for the period from January 1, 2014 to April 30, 2014 was $29,014 and $8,720, respectively.
4. Investment in Equity Investee
On December 24, 2013, the Company completed an acquisition, in the amount of $521,000, for a 15.57% equity interest in Telemed Services LLC ("Telemed"), which is 79% owned by the majority Member of the Company. The Company accounts for its investment in Telemed as an equity method investment since the Company had the ability to exercise significant influence over Telemed but did not exercise control.
The Company continually reviews its equity method investment to determine whether a decline in fair value below the carrying value is other than temporary. The primary factors the Company considers in its determination are the length of time that the fair value of the investment is below the Company's carrying value and the financial condition, operating performance and the prospects of the equity investee. If the decline in fair value is deemed to be other than temporary, the carrying value of the equity investee is written down to fair value. There were no impairment charges on the Company's investment for the year ended December 31, 2013 and during the period from January 1, 2014 to April 30, 2014.
5. Accrued Expenses
Accrued expenses consisted of the following:
|
December 31, 2013 | April 30, 2014 | |||||
---|---|---|---|---|---|---|---|
Accrued fees |
$ | | $ | 1,241,624 | |||
Accrued compensation |
207,272 | 264,139 | |||||
Accrued rent |
12,480 | 16,621 | |||||
Lease improvement allowance |
26,161 | 26,161 | |||||
Accrued franchise tax payable |
29,461 | 34,983 | |||||
Other |
28,431 | 15,214 | |||||
| | | | | | | |
|
$ | 303,805 | $ | 1,598,742 | |||
| | | | | | | |
| | | | | | | |
| | | | | | | |
F-56
AMERIDOC, LLC
Notes to Consolidated Financial Statements
6. Debt
Line of Credit
The Company has a line of credit with a financial institution in the amount of up to $100,000. Interest on the line of credit is payable monthly at 7.25%. The line of credit is secured by the personal guarantee of the Company's controlling member. The balance payable on the line of credit as of April 30, 2014 and December 31, 2013, was $96,350 and $99,262, respectively.
Long-Term Debt
On December 24, 2013, the Company acquired the Telemed interest for the sum of $521,000, payable as follows: $75,000 paid on December 24, 2013 with the balance payable in 18 equal monthly installment payments of $22,000 per month commencing March 20, 2014 with a final payment of $50,000 in September 2015. During 2014, $13,200 of the outstanding balance was forgiven by the equity interest seller.
7. Due to Related Parties
The Company received advances from certain of its members to fund its operations during 2014 and 2013. These advances are non-interest bearing. Total amounts were $365,696 and $344,131 as of December 31, 2013 and April 30, 2014, respectively.
On October 7, 2013, the Company executed a note with one of its members in the amount of $144,000 with a maturity date of October 7, 2015. The note accrues interest at the rate of 12.95%. The Company is required to make monthly interest-only installments through March 2014. Monthly installments of principal and interest are payable effective April 2014. During 2013, the Company repaid a portion of the loan such that $81,343 remained outstanding as of December 31, 2013. During 2014, the Company borrowed an additional $50,000 under this note. At April 30, 2014, the balance of the note, including accrued interest was $135,997.
8. Commitments and Contingencies
At December 31, 2013 and April 30, 2014, the Company is obligated for future lease payments under its office lease. The lease expires October 31, 2020. Total rent expense for the year ended December 31, 2013 and for the period from January 1, 2014 to April 30, 2014 was $80,555 and $30,335, respectively. Annual minimum lease payments under the non-cancellable operating lease as of April 30, 2014 are as follows:
|
Total Gross
Commitment |
|||
---|---|---|---|---|
2014 |
$ | 74,113 | ||
2015 |
133,403 | |||
2016 |
178,743 | |||
2017 |
183,103 | |||
2018 |
183,974 | |||
2019 and thereafter |
345,279 | |||
| | | | |
|
$ | 1,098,615 | ||
| | | | |
| | | | |
| | | | |
F-57
AMERIDOC, LLC
Notes to Consolidated Financial Statements
The Company is reimbursed for 40% of its office rental costs by a related party, based on the amount of square footage of the leased office space that the related party occupies.
At December 31, 2013 and April 30, 2014, the Company was subject to various claims and legal actions which are being handled in the ordinary course of business. In management's opinion, these matters are not expected to have a material adverse effect upon the Company's consolidated financial position, results of operations or cash flows.
9. Subsequent Events
Subsequent events were evaluated through March 24, 2015, which is the date the financial statements were available to be issued.
The Company and its members executed an Agreement and Plan of Merger dated as of May 1, 2014, providing for the sale of all of the membership interests of the Company to Teladoc. The aggregate cash consideration of $17.2 million included adjustments for a working capital excess at closing. Upon the effective date of the merger, the Company merged with and into Teladoc, which continued as the surviving corporation.
F-58
Report of Independent Auditors
To the Board of Directors and Stockholders of
Stat Health Services Inc.
We have audited the accompanying financial statements of Stat Health Services Inc. (the Company) which comprise the balance sheet as of December 31, 2014, and the related statements of operations, changes in convertible preferred stock and stockholders' deficit and cash flows for the year then ended, and the related notes to the financial statements.
Management's Responsibility for the Financial Statements
Management is responsible for the preparation and fair presentation of these financial statements in conformity with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.
Auditor's Responsibility
Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
Opinion
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Stat Health Services Inc. at December 31, 2014, and the results of its operations and its cash flows for the year ended December 31, 2014 in conformity with U.S. generally accepted accounting principles.
Stat Health Services Inc.'s Ability to Continue as a Going Concern
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has losses from operations that raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
|
|
/s/ Ernst & Young LLP |
Denver, Colorado
June 5, 2015
F-59
STAT HEALTH SERVICES INC.
Balance Sheet
|
December 31, 2014 | |||
---|---|---|---|---|
Assets |
||||
Cash and cash equivalents |
$ | 1,508,819 | ||
Accounts receivable |
193,240 | |||
Accounts receivable from significant shareholders and affiliates |
34,358 | |||
Prepaid expenses and other current assets |
6,726 | |||
| | | | |
Total current assets |
1,743,143 | |||
Property and equipment, net |
34,595 | |||
Intangible assets, net |
117,851 | |||
Notes receivable from employees |
21,100 | |||
Other assets |
7,877 | |||
| | | | |
Total assets |
$ | 1,924,566 | ||
| | | | |
| | | | |
| | | | |
Liabilities, convertible preferred stock and stockholders' deficit |
|
|||
Accounts payable |
$ | 208,247 | ||
Accounts payable to significant shareholders and affiliates |
155,072 | |||
Accrued expenses |
38,326 | |||
Deferred income |
170,087 | |||
| | | | |
Total current liabilities |
571,732 | |||
Commitments and Contingencies |
|
|||
Convertible Preferred Stock-Series A$0.001 par value, 23,000,000 shares authorized and 22,602,794 shares issued and outstanding |
17,637,905 | |||
Stockholders' deficit |
|
|||
Common Stock$0.001 par value, 32,000,000 shares authorized and 2,226,767 shares issued and outstanding |
2,227 | |||
Additional paid-in capital |
2,903,583 | |||
Accumulated deficit |
(19,190,881 | ) | ||
| | | | |
Total stockholders' deficit |
(16,285,071 | ) | ||
| | | | |
Total liabilities, convertible preferred stock and stockholders' deficit |
$ | 1,924,566 | ||
| | | | |
| | | | |
| | | | |
See accompanying notes to audited financial statements.
F-60
STAT HEALTH SERVICES INC.
Statement of Operations
For the year ended December 31, 2014
Revenue |
$ | 2,317,417 | ||
Cost of revenue |
460,778 | |||
| | | | |
Gross profit |
1,856,639 | |||
Operating expenses: |
||||
Marketing and advertising |
481,689 | |||
Selling expenses |
1,063,723 | |||
Technology and development |
1,010,862 | |||
General and administrative |
2,546,865 | |||
Depreciation and amortization |
80,905 | |||
| | | | |
Loss from operations |
(3,327,405 | ) | ||
Other income (expense) |
||||
Grant income |
83,333 | |||
Interest income |
1,830 | |||
Interest expense |
(1,447 | ) | ||
| | | | |
Net loss before taxes |
(3,243,689 | ) | ||
Income taxes |
| |||
| | | | |
Net loss |
$ | (3,243,689 | ) | |
| | | | |
| | | | |
| | | | |
See accompanying notes to audited financial statements.
F-61
STAT HEALTH SERVICES INC.
Statement of Changes in Convertible Preferred Stock and Stockholders' Deficit
For the year ended December 31, 2014
|
Convertible
Preferred Stock |
|
|
|
|
|
|
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Common Stock |
|
|
|
|||||||||||||||||||
|
|
Additional
Paid-In Capital |
Accumulated
Deficit |
|
||||||||||||||||||||
|
Shares | Amount |
|
Shares | Amount | Total | ||||||||||||||||||
Balance, January 1, 2014 |
| $ | | 18,191,533 | $ | 18,191 | $ | 10,683,623 | $ | (10,985,040 | ) | $ | (283,226 | ) | ||||||||||
Issuance of Common Stock |
| | 2,110,000 | 2,110 | 18,990 | | 21,100 | |||||||||||||||||
Issuance of Convertible Stock Preferred Stock |
4,469,528 | 3,438,107 | | | | | | |||||||||||||||||
Exchange of Common Stock to Convertible Preferred Stock |
18,133,266 | 14,199,798 | (18,133,266 | ) | (18,133 | ) | (9,219,513 | ) | (4,962,152 | ) | (14,199,798 | ) | ||||||||||||
Stock option exercise |
| | 58,500 | 59 | 29,191 | | 29,250 | |||||||||||||||||
Stock-based compensation |
| | | | 1,391,292 | | 1,391,292 | |||||||||||||||||
Net loss |
| | | | | (3,243,689 | ) | (3,243,689 | ) | |||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | |
Balance, December 31, 2014 |
22,602,794 | $ | 17,637,905 | 2,226,767 | $ | 2,227 | $ | 2,903,583 | $ | (19,190,881 | ) | $ | (16,285,071 | ) | ||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
See accompanying notes to audited financial statements.
F-62
STAT HEALTH SERVICES INC.
Statement of Cash Flows
For the year ended December 31, 2014
Cash flows used in operating activities |
||||
Net loss |
$ | (3,243,689 | ) | |
Adjustments to reconcile net loss to net cash used in operating activities: |
||||
Depreciation and amortization |
80,905 | |||
Stock-based compensation |
1,391,292 | |||
Changes in operating assets and liabilities: |
||||
Accounts receivable |
(89,251 | ) | ||
Prepaid expenses and other current assets |
(3,419 | ) | ||
Other assets |
17,533 | |||
Accounts payable |
52,383 | |||
Accrued expenses |
(109,760 | ) | ||
Deferred income |
(163,371 | ) | ||
| | | | |
Net cash used in operating activities |
(2,067,377 | ) | ||
| | | | |
Cash flows used in investing activities |
||||
Purchase of property and equipment |
(33,747 | ) | ||
| | | | |
Cash flows from financing activities |
||||
Proceeds from issuance of convertible preferred stock |
3,438,107 | |||
| | | | |
Net increase in cash and cash equivalents |
1,336,983 | |||
Cash and cash equivalents, beginning of year |
171,836 | |||
| | | | |
Cash and cash equivalents, end of year |
$ | 1,508,819 | ||
| | | | |
| | | | |
| | | | |
Supplemental cash flow information: |
||||
Cash paid for interest |
$ | 1,447 |
See accompanying notes to audited financial statements.
F-63
STAT HEALTH SERVICES INC.
Notes to Audited Financial Statements
1. Nature of Business
Stat Health Services Inc. (the "Company") is a Delaware corporation that provides telehealth services to clients and their customers.
The Company has incurred a net loss of $3,243,689 for the year ended December 31, 2014, and the accumulated deficit is $19,190,881 as of December 31, 2014. In addition, net cash flows used in operations were $2,067,377 for the year ended December 31, 2014. The Company's ability to continue operations and fund its expenditures is dependent on continued ongoing contributions and support of the existing shareholders, further investments from outside investors or a sale of the Company. There can be no assurance the Company will be able to obtain additional funding.
The Company executed an Agreement and Plan of Merger dated as of May 22, 2015, providing for the merger of the Company into a wholly owned subsidiary of Teladoc, Inc. ("Teladoc"). Upon the effective date of the merger, the Company will merge with and into a wholly owned subsidiary of Teladoc, which subsidiary will continue as the surviving corporation of the merger and the separate existence of the Company will cease.
2. Summary of Significant Accounting Policies
Basis of Preparation
These financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). The following is a summary of the significant accounting and reporting policies used in preparing the financial statements.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the financial position and results of operations. Significant estimates and assumptions affect the allowance for doubtful accounts, the carrying value, capitalization and amortization of software and website development costs, warrants, and the value attributed to stock options.
Revenue Recognition
The Company provides tele-health services to its customers. The Company recognizes a substantial portion of its revenue from contracts that provide clients with subscription access to the Company's professional provider network of physicians for a fixed monthly fee which entitles the client's members to consultations with physicians ("visits") for a per visit fee. The contracts are generally for a one to two year term and automatically renew for additional years.
The Company recognizes revenue for the subscription access service on the date that the services are made available to the client and its members, which is considered the implementation date, provided all of the following criteria are met:
F-64
STAT HEALTH SERVICES INC.
Notes to Audited Financial Statements
Any consultation revenue that is not included in the subscription access service is recognized when the service has been provided to the member by the physician.
Costs of Revenue
Costs of revenue primarily consist of fees paid to the physician network providers and direct costs incurred in connection with the provider network operations.
Marketing and Advertising Expenses
Marketing and advertising costs are expensed as incurred. For the year-ended December 31, 2014 market and advertising expenses were $267,577.
Selling Expenses
Selling expenses consist principally of sales commissions, employee-related cost and travel.
Cash and Cash Equivalents
Cash and cash equivalents consist of highly liquid investments with original maturities of three months or less from the date of purchase. Cash and cash equivalents generally consist of investments in money market funds and are stated at fair value.
Accounts Receivable and Allowance for Doubtful Accounts
Accounts receivable are recorded at the invoiced amount, net of allowances for doubtful accounts. The allowance for doubtful accounts is based on the Company's assessment of the collectability of accounts. The Company regularly reviews the adequacy of the allowance for doubtful accounts by considering the age of each outstanding invoice and the collection history of each customer to determine whether a specific allowance is appropriate. Accounts receivable deemed uncollectable are charged against the allowance for doubtful accounts when identified. Management determined no allowance was necessary at December 31, 2014.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk are cash and cash equivalents and accounts receivable. At times, the Company's deposits in banks may exceed federally insured limits. In addition, other cash equivalents may expose the Company to certain credit risks. The Company has not experienced any losses in such accounts and does not believe it is exposed to any significant risk. The Company assesses the creditworthiness of its customers before extending credit. Accounts receivable are written off only when all efforts to collect the accounts have been exhausted.
Two customers represented approximately 22% and 11%, respectively, of total revenue for the year ended December 31, 2014. One of these customers accounted for approximately 11% of accounts receivable at December 31, 2014. Although the Company does not expect that these customers will fail to meet their obligations, the Company is potentially exposed to concentrations of credit risk if these customers failed to perform according to the terms of the contracts.
F-65
STAT HEALTH SERVICES INC.
Notes to Audited Financial Statements
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective asset as follows:
Computer equipment |
3 years | |
Furniture and equipment |
5 years | |
Leasehold improvements |
Shorter of useful life or lease term |
Expenditures for additions and betterments that extend the useful lives of equipment are capitalized and depreciated over the estimated remaining useful lives of the related assets. Expenditures for repairs and maintenance are charged to expense as incurred. Gains and losses on sales and retirements are reflected in income during the year of actual sale or retirement.
Intangible Assets
Internal use software is included in intangible assets and is amortized on a straight-line basis over three years. For the Company's development costs related to its software development tools that enable it members and service providers to interact, the Company capitalizes costs incurred during the application development stage. Costs related to minor upgrades, minor enhancements and maintenance activities are expensed as incurred.
Long-lived Assets
In accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 360, Property, Plant and Equipment , long-lived assets, such as equipment and leaseholds, and identified intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated future undiscounted cash flows expected to be generated by an asset. For this test, assets are grouped with other assets to the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. If the carrying amount of an asset grouping exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset grouping. Management determined that no impairment of long-lived assets existed as of December 31, 2014.
Income Taxes
The Company accounts for income taxes using the liability method, under which deferred tax assets and liabilities are determined based on the future tax consequences attributable to differences between the financial reporting carrying amounts of existing assets and liabilities and their respective tax bases and tax credit and net operating loss carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates that are expected to be in effect when the differences are expected to reverse.
The Company assesses likelihood that deferred tax assets will be recovered from future taxable income, and a valuation allowance is established when necessary to reduce deferred tax assets to amounts more likely than not expected to be realized.
F-66
STAT HEALTH SERVICES INC.
Notes to Audited Financial Statements
The Company recognizes and measures uncertain tax positions using a two-step approach. The first step is to evaluate the tax position taken or expected to be taken by determining if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Significant judgment is required to evaluate uncertain tax positions. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of audit and effective settlement of audit issues. The Company recognizes interest and penalties to uncertain tax positions in income tax expense. There were no interest and penalties recorded on uncertain tax positions for the year-ended December 31, 2014.
Stock-based Compensation
The Company accounts for service and performance stock options under the recognition and measurement provisions of ASC 718, CompensationStock Compensation . This guidance requires that compensation cost relating to share-based payment transactions with service conditions be recognized in the financial statements. That cost is measured based on the fair value of the equity or liability instruments issued. The standard requires entities to measure the cost of employee services received in exchange for stock options based on the grant-date fair value of the award and to recognize the cost over the period the employee is required to provide services for the award. The Company recognizes compensation expense under ASC 718 over the requisite service period using the straight-line method. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its share-based payments for stock options with service conditions.
The accounting guidance requires that compensation cost for awards with performance conditions be recognized if and when the Company concludes that it is probable that the performance condition will be achieved, net of an estimate of pre-vesting forfeitures. The Company is required to reassess the probability of vesting at each reporting period for awards with performance conditions and adjust compensation expense based on its probability assessment. In certain situations, a company may not be able to determine that it is probable that a performance condition will be satisfied until the event occurs.
Warranties and Indemnification
The Company's contracts generally includes certain provisions for mutual indemnification from damages, liabilities and expenses sustained in connection with the breach or performance of any of the obligations under such agreement. To date, the Company has not incurred any material costs as a result of such indemnifications and has not accrued any liabilities related to such obligations in the financial statements. The Company has entered into service-level agreements with certain customers warranting defined levels of performance and response and permitting those customers to receive credits or refunds of amounts paid to the Company related to access subscription services in the event that we fail to meet those levels. To date, the Company has not experienced any significant failures to meet defined levels of performance and response as a result of those agreements, and accordingly, the Company has not accrued any liabilities in the financial statements.
F-67
STAT HEALTH SERVICES INC.
Notes to Audited Financial Statements
The Company has also agreed to indemnify its directors and executive officers for liabilities, losses, or expenses reasonably incurred by such person in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person's service as a director or officer, including any action by the Company, arising out of that person's services as a director or officer or that person's services provided to any other company or enterprise at the Company's request. The Company provides such indemnification through the Company's certificate of incorporation and bylaws, and in some instances, indemnification agreements with directors and officers. The Company maintains director and officer insurance coverage that would generally enable the Company to recover a portion of any future amounts paid. The Company may also be subject to indemnification obligation by law with respect to the actions of employees under certain circumstances and in certain jurisdictions.
3. Property and Equipment, Net
Property and equipment, net consists of the following:
|
December 31, 2014 | |||
---|---|---|---|---|
Computer equipment |
$ | 41,569 | ||
Furniture and equipment |
24,164 | |||
Leasehold improvements |
9,497 | |||
| | | | |
Total |
75,230 | |||
Accumulated depreciation |
(40,635 | ) | ||
| | | | |
Property and equipment, net |
$ | 34,595 | ||
| | | | |
| | | | |
| | | | |
Depreciation expense for the year ended December 31, 2014 was $21,980.
4. Lease Commitment
The lease on the Company's office facilities expires in March 2016. Rent expense for the year ended December 31, 2014 was approximately $60,350. In connection with this lease, the Company has issued warrants to the lessor to purchase 17,604 shares of Class A Common Stock at a price of $0.001 per share. These warrants were exercised in April, 2015.
5. Intangible Assets, Net
Intangible assets consist of the following at December 31:
|
|
2014 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Average Useful
Life (Years) |
Gross
Carrying Amount |
Accumulated
Amortization |
Net
Carrying Amount |
|||||||||
Mobile Platform Costs |
3 | $ | 176,776 | $ | (58,925 | ) | $ | 117,851 | |||||
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Amortization expense for the year ended December 31, 2014 was $58,925. Estimated aggregate amortization expense is $58,925 for each year ending December 31, 2015 and 2016. The Company has not recognized any impairment losses as of December 31, 2014.
F-68
STAT HEALTH SERVICES INC.
Notes to Audited Financial Statements
6. Grant Income
In 2013, the Company received a grant from the state of Arizona for $250,000. The grant was provided for costs to be incurred by the Company on mobile application and related technology including hiring of senior developer. As a condition of the grant if, the Company relocates any or all corporate facilities of the Company within three years of the effective date of the grant agreement, it shall repay the grant payment to the State of Arizona. The Company is recognizing this grant as other income over a three year period.
7. Income Taxes
The Company has no provision or benefit for income taxes for year-ended December 31, 2014.
Significant components of the Company's deferred income taxes as of December 31, 2014 are shown below:
Deferred tax assets: |
||||
Deferred revenue |
$ | 37,000 | ||
Property and equipment |
3,000 | |||
Intangibles |
826,000 | |||
Stock compensation |
138,000 | |||
Federal NOL carry forward |
3,144,000 | |||
State NOL carry forward |
348,000 | |||
Other |
10,000 | |||
| | | | |
Total deferred tax assets |
4,506,000 | |||
Less: valuation allowance |
(4,506,000 | ) | ||
| | | | |
Net deferred tax assets |
$ | | ||
| | | | |
| | | | |
| | | | |
The Company has provided a full valuation allowance for the deferred tax assets at December 31, 2014, due to the uncertainty surrounding the future realization of such assets. Therefore, no benefit has been recognized for the net operating loss carryforwards and other deferred tax assets. The Company's total valuation allowance increased by $506,000 during the period.
The Company has available net operating loss carry-forwards of $9,247,000 which are available to offset future taxable income, if any. If not utilized, the federal net operating loss carryforwards begin to expire in 2030.
The Company's ability to utilize the net operating loss and tax credit carryforwards in the future may be subject to substantial restrictions in the event of past or future ownership changes as defined in Section 382 of the U.S. Internal Revenue Code of 1986 as amended. In the event the Company should experience an ownership change, as defined, utilization of the net operating loss carryforwards and tax credits could be limited.
The Company's 2010 to 2013 tax returns remain subject to examination by the IRS.
8. Stock-Based Compensation
The Company established the four separate equity incentive plans: (a) 2009 Equity Incentive PlanPlan A; (b) 2009 Equity Incentive PlanPlan B; (c) 2010 Equity Incentive PlanPlan A; and
F-69
STAT HEALTH SERVICES INC.
Notes to Audited Financial Statements
(d) 2010 Equity Incentive PlanPlan B (collectively, the "Plans"). Under the Plans, rights to exercise the options granted generally vest over a three-year period following the grant date so long as the recipient remains in continuous service to Company and have a contractual term of 10 years. The terms of the options provide for accelerated vesting upon a change in control of Company in the event a successor company refuses to assume or substitute the term of the options.
All stock-based payments to employees are measured based on the grant-date fair value of the awards and are recognized in the statement of operations over the period during which the employee is required to perform services in exchange for the award (generally the vesting period of the award). The Company estimates the fair value of stock options granted using the Black-Scholes option-pricing model.
Given the absence of a public trading market, the board of directors considered recent sales of common stock to determine the fair value of the common stock at each grant date, as well as a recent third-party valuation.
The Company has also issued stock options to non-employees which are recognized as expense at fair value when the services are performed. Non-employee options are included in the table below.
|
Shares
Available for Grant |
Number of
Shares Outstanding |
Weighted-
Average Exercise Price |
Weighted-
Average Remaining Contractual Life in Years |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Balance at January 1, 2014 |
174,750 | 3,325,250 | 0.50 | 7.74 | |||||||||
Stock option grants |
(2,204,000 | ) | 1,196,500 | 0.52 | 9.45 | ||||||||
Stock options exercised |
| (58,500 | ) | 0.52 | | ||||||||
Cancelled / forfeited |
2,302,750 | (2,302,750 | ) | ||||||||||
| | | | | | | | | | | | | |
Balance at December 31, 2014 |
273,500 | 2,160,500 | 0.52 | 8.67 | |||||||||
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Vested or expected to vest December 31, 2014 |
2,160,500 | ||||||||||||
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Exercisable as of December 31, 2014 |
611,114 | ||||||||||||
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
The total grant-date fair value of stock options granted during the year ended December 31, 2014 was $492,381. The total grant-date fair value of stock options vested during the year ended December 31, 2014 was $287,483. The total intrinsic value of the options exercised during the year ended December 31, 2014 was $29,250. The intrinsic value is the difference of the current fair value of the stock and the exercise price of the stock option.
The fair value of each option grant was estimated on the date of grant for employees and when the services were performed for non-employees using the Black-Scholes option-pricing model with the following assumptions and fair value per share:
Volatility |
85.00 | % | ||
Expected life (in years) |
7.00 | |||
Risk-free interest rate |
2.17% 2.71 | % | ||
Dividend yield |
| |||
Fair value of underlying common stock |
$.52 |
F-70
STAT HEALTH SERVICES INC.
Notes to Audited Financial Statements
The assumptions used in the Black-Scholes option-pricing model were determined as follows:
Volatility. Since there is no trading history for the Company's common stock, the expected volatility was derived from the historical stock volatilities of several unrelated public companies within the industry that were considered to be comparable to the business over a period equivalent to the expected term of the stock option grants.
Expected life. The expected term represents the period that the stock-based awards are expected to be outstanding.
Risk-free interest rate. The risk-free rate used is based on U.S. Treasury zero-coupon issues with terms similar to the expected term on the options.
Dividend yield. No cash dividends have been declared or paid and the Company does not plan to pay cash dividends in the foreseeable future; therefore, the Company used an expected dividend yield of zero.
Total compensation cost charged as an expense for stock based awards, including stock options recognized in the components of operating expenses are as follows:
Cost of sales |
$ | 28,119 | ||
Advertising and marketing |
19,714 | |||
Selling expenses |
35,726 | |||
Technology and development |
83,171 | |||
General and administrative |
1,224,562 | |||
| | | | |
Total |
$ | 1,391,292 | ||
| | | | |
| | | | |
| | | | |
As of December 31, 2014, the Company had $481,520 in unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over a weighted average period of approximately 1.7 years.
In 2014, the Company also issued 2,110,000 shares of common stock to certain key executives in exchange for previously held stock options. This resulted in approximately $1,100,000 of additional stock-based compensation expense.
In 2014, the Company granted a board member a bonus, in lieu of requiring a cash payment, to exercise 58,500 options.
9. Common Stock
At December 31, 2014, there were 32,000,000 shares of common stock, par value of $0.001 ("Common Stock") authorized, of which 2,226,767 shares were issued and outstanding. The holders of Common Stock are entitled to one vote for each share on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Subject to the preferences that may be applicable to any then-outstanding preferred stock, the holders of Common Stock will be entitled to receive such dividends, if any, as may be declared by the Board of Directors from time to time out of legally available funds. Upon the liquidation, dissolution, or winding up of the Company, after payment of all debts and other liabilities and subject to the prior rights of holders of any preferred stock then outstanding, the holders of Common Stock will be entitled to share ratably in all assets that are legally available for distribution. The holders of common stock have no preemptive, subscription, redemption, or conversion rights
F-71
STAT HEALTH SERVICES INC.
Notes to Audited Financial Statements
10. Convertible Preferred StockSeries A
At December 31, 2014, there were 23,000,000 shares of Series A Convertible Preferred Stock, par value of $0.001 ("Series A Preferred") authorized, of which 22,602,794 shares were issued and outstanding. The Series A Preferred have an aggregate liquidation preference of approximately $0.9176 per Series A Preferred share. The Series A Preferred are convertible into common shares, at the option of the holder, at the conversion rate in effect at the time multiplied by the number of Series A Preferred being converted as defined in the Series A Preferred agreement (one-to-one at December 31, 2014). Each share of Series A Preferred will convert automatically into shares of Common Stock, at the conversion rate in effect at the time, upon (a) the closing of a Qualified Public Offering (as defined), or (b) the date specified by unanimous vote or consent of the Key Investors (as defined). Holders of Series A Preferred are entitled to one vote per share, on an as-if-converted to Common Stock basis. The holders of Series A Preferred are also entitled to dividends, when, as, and if declared by the Board of Directors, at a rate determined by the Board of Directors, payable in preference and priority to any payment of any cash dividend on Common Stock. The dividends on Series A Preferred will not accrue and are not cumulative. Upon the liquidation, dissolution, or winding up of the Company, and after the receipt of the liquidation preference, the holders of Series A Preferred will not participate further in the assets then remaining for distribution and all remaining assets available for distribution, if any, will be distributed among the holders of Common Stock on a pro-rata basis.
One holder of Series A Preferred will have the right, upon the occurrence of certain events, to redeem up to 4,469,528 shares of Series A Preferred at a price equal to the fair market value of such Series A Preferred on the date such redemption notice is delivered. If such redemption notice is received, the Company will have the obligation to redeem the shares of Series A Preferred from such holder in three equal annual installments, commencing on the one year anniversary date of the redemption date. The right to request redemption of the shares of Series A Preferred is not transferrable by the holder.
Recapitalization
In connection with the issuance of Series A Preferred Stock discussed above, each holder of Company's Class A Common Stock immediately prior to the Series A Preferred Stock issuance was offered the right to exchange each share of Class A Common Stock for one share of Company's Series A Preferred Stock. At the same time, the Company issued 2,110,000 shares of its common stock to certain key executives as discussed in Note 8.
11. Commitments and Contingencies
At December 31, 2014 there were no claims or legal actions which, in management's opinion, are expected to have a material adverse effect upon the Company's financial position, results of operations or cash flows.
The Company has entered into several employment agreements with key employees which if terminated without cause require payment of six months' salary as severance.
12. Related Party Transactions
For the year-ended December 31, 2014, revenue includes $136,237, cost of revenue includes $390,842 and general and administrative expenses includes $60,000 of expenses from significant
F-72
STAT HEALTH SERVICES INC.
Notes to Audited Financial Statements
shareholders and their affiliates. The balance sheet reflects $34,358 of accounts receivables from and $155,072 accounts payable to significant shareholders and their affiliates as of December 31, 2014.
The Company has notes receivable from certain key executives of $21,100 as of December 31, 2014. Notes receivable carry interest at the rate of 3% per annum and shall be due and payable upon the earlier of i) February 27, 2019 and ii) a liquidation event as defined in the notes receivable agreements or sale of common stock by the executives.
13. Subsequent Events
Subsequent events were evaluated through June 5, 2015, which is the date the financial statements were available to be issued.
Subsequent to the year end, the Company signed an amendment agreement with a professional services provider, a significant shareholder, and its affiliates to terminate the Company's obligation to pay future bonuses or share of the Company's retained profits to the service provider. As a result of these terminations, the Company is required to pay an amount of $441,080 in twelve equal installments starting from earlier of i) completion of the Company's Series B financing, if any and ii) September 1, 2015. The amount becomes due and payable as lump sum if the Company is acquired or there is a change in control. Under the amendment agreement, the Company is also obligated to reimburse the service provider for future certain state licensing, credentialing, and other expenses necessary to permit participation in the programs offered by the Company.
Subsequent to the year end, the Company signed a settlement and release agreement with a previous professional service provider to terminate the Company's obligations to pay bonus fee based on the Company's future retained earnings and per member visit revenue payments to the service provider. As a result of these terminations, the Company is required to pay an amount of $190,000 within 30 days of any equity financing of the Company and not later than 90 days of the agreement date.
F-73
TELADOC, INC.
Consolidated Balance Sheets
(in thousands, except share and per share data)
|
As of
December 31, 2014 |
As of
March 31, 2015 |
Pro Forma
Stockholders' Equity as of March 31, 2015 |
|||||||
---|---|---|---|---|---|---|---|---|---|---|
|
|
(unaudited)
|
(unaudited)
|
|||||||
Assets |
||||||||||
Current assets: |
||||||||||
Cash and cash equivalents |
$ | 46,436 | $ | 32,060 | ||||||
Accounts receivable, net of allowance of $2,635 and $1,785, respectively |
6,839 | 8,680 | ||||||||
Due from officer |
253 | | ||||||||
Prepaid expenses and other current assets |
1,122 | 2,695 | ||||||||
Deferred taxes |
12 | 27 | ||||||||
| | | | | | | | | | |
Total current assets |
54,662 | 43,462 | ||||||||
Property and equipment, net |
1,065 | 1,218 | ||||||||
Goodwill |
28,454 | 33,149 | ||||||||
Intangible assets, net |
7,530 | 9,247 | ||||||||
Other assets |
296 | 285 | ||||||||
| | | | | | | | | | |
Total assets |
$ | 92,007 | $ | 87,361 | ||||||
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
Liabilities, convertible preferred stock and stockholders' deficit |
||||||||||
Current liabilities: |
||||||||||
Accounts payable |
$ | 2,210 | $ | 3,572 | ||||||
Accrued expenses and other current liabilities |
6,623 | 10,439 | ||||||||
Accrued compensation |
3,358 | 2,688 | ||||||||
Long-term bank and other debt-current |
833 | 1,146 | ||||||||
| | | | | | | | | | |
Total current liabilities |
13,024 | 17,845 | ||||||||
Other liabilities |
62 | 2,521 | ||||||||
Deferred taxes |
494 | 726 | ||||||||
Long term bank and other debt |
25,196 | 24,902 | ||||||||
Commitments and contingencies |
||||||||||
Convertible preferred stock, $0.001 par value; 50,479,286 shares authorized as of March 31, 2015 and December 31, 2014; 50,452,939 shares issued as of March 31, 2015 and December 31, 2014 with liquidation preference of $117,914 as of March 31, 2015 and December 31, 2014; no shares authorized or issued and outstanding pro forma (unaudited) |
117,914 | 117,914 | $ | | ||||||
Redeemable common stock, $0.001 par value; 258,978 common shares issued and outstanding |
2,852 | 2,852 | | |||||||
Stockholders' equity (deficit): |
||||||||||
Common stock, $0.001 par value; 73,559,000 shares authorized as of March 31, 2015 and December 31, 2014; 4,709,331 and 4,658,662 shares issued and outstanding as of March 31, 2015 and December 31, 2014, 73,559,000 shares authorized and issued pro forma (unaudited); |
5 | 5 | 63 | |||||||
Additional paid-in capital |
4,952 | 5,791 | 126,499 | |||||||
Accumulated deficit |
(72,492 | ) | (85,195 | ) | (85,195 | ) | ||||
| | | | | | | | | | |
Total stockholders' equity (deficit) |
(67,535 | ) | (79,399 | ) | $ | 41,367 | ||||
| | | | | | | | | | |
Total liabilities, convertible preferred stock and stockholders' deficit |
$ | 92,007 | $ | 87,361 | ||||||
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
See accompanying notes to unaudited consolidated financial statements.
F-74
TELADOC, INC.
Consolidated Statements of Operations
(in thousands, except per share data, unaudited)
|
Three Months
Ended March 31, |
||||||
---|---|---|---|---|---|---|---|
|
2014 | 2015 | |||||
Revenue |
$ | 9,407 | $ | 16,488 | |||
Cost of revenue |
1,982 | 5,281 | |||||
| | | | | | | |
Gross profit |
7,425 | 11,207 | |||||
Operating expenses: |
|||||||
Advertising and marketing |
2,518 | 4,341 | |||||
Sales |
2,145 | 3,682 | |||||
Technology and development |
1,192 | 2,906 | |||||
General and administrative |
3,344 | 11,968 | |||||
Depreciation and amortization |
414 | 903 | |||||
| | | | | | | |
Loss from operations |
(2,188 | ) | (12,593 | ) | |||
Interest income(expense), net |
(54 | ) | (568 | ) | |||
| | | | | | | |
Net loss before taxes |
(2,242 | ) | (13,161 | ) | |||
Income tax provision (benefit) |
72 | (458 | ) | ||||
| | | | | | | |
Net loss |
$ | (2,314 | ) | $ | (12,703 | ) | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Net loss per share, basic and diluted |
$ | (1.03 | ) | $ | (2.57 | ) | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Weighted-average shares used to compute basic and diluted net loss per share |
3,254,509 | 4,943,060 | |||||
| | | | | | | |
| | | | | | | |
| | | | | | | |
Pro forma net loss per share, basic and diluted (unaudited) |
$ | (0.20 | ) | ||||
| | | | | | | |
| | | | | | | |
| | | | | | | |
Weighted-average shares used to compute basic and diluted pro forma net loss per share (unaudited) |
63,120,240 | ||||||
| | | | | | | |
| | | | | | | |
| | | | | | | |
See accompanying notes to unaudited consolidated financial statements.
F-75
TELADOC, INC.
Consolidated Statement of Convertible Preferred Stock
and Stockholders' Deficit
(in thousands, except share data, unaudited)
|
Convertible
Preferred Stock |
Redeemable
Common Stock |
|
|
|
|
|
|||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Common Stock |
|
|
|
||||||||||||||||||||||||
|
Additional
Paid-In Capital |
Accumulated
Deficit |
Total
Stockholders' Deficit |
|||||||||||||||||||||||||
|
Shares | Amount | Shares | Amount | Shares | Amount | ||||||||||||||||||||||
Balance as of December 31, 2014 |
50,452,939 | $ | 117,914 | 258,978 | $ | 2,852 | 4,658,662 | $ | 5 | $ | 4,952 | $ | (72,492 | ) | $ | (67,535 | ) | |||||||||||
Exercise of stock options, net |
| | | | 50,669 | | 28 | | 28 | |||||||||||||||||||
Stock based compensation |
| | | | | | 811 | | 811 | |||||||||||||||||||
Net loss |
| | | | | | | (12,703 | ) | (12,703 | ) | |||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Balance as of March 31, 2015 |
50,452,939 | $ | 117,914 | 258,978 | $ | 2,852 | 4,709,331 | $ | 5 | $ | 5,791 | $ | (85,195 | ) | $ | (79,399 | ) | |||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
See accompanying notes to unaudited consolidated financial statements.
F-76
TELADOC, INC.
Consolidated Statements of Cash Flows
(in thousands, unaudited)
|
Three Months Ended March 31, | ||||||
---|---|---|---|---|---|---|---|
|
2014 | 2015 | |||||
Operating activities: |
|||||||
Net loss |
$ | (2,314 | ) | $ | (12,703 | ) | |
Adjustments to reconcile net loss to net cash used in operating activities: |
|||||||
Depreciation and amortization |
414 | 903 | |||||
Allowance for doubtful debts |
255 | 451 | |||||
Stock-based compensation |
162 | 811 | |||||
Deferred income taxes |
72 | (458 | ) | ||||
Accretion of interest |
2 | 39 | |||||
Changes in operating assets and liabilities: |
|||||||
Accounts receivable |
(3,067 | ) | (2,281 | ) | |||
Due from officer |
| 253 | |||||
Prepaid expenses and other current assets |
4 | (1,593 | ) | ||||
Other assets |
(6 | ) | 12 | ||||
Accounts payable |
1,858 | 1,357 | |||||
Accrued expenses and other current liabilities |
256 | 3,475 | |||||
Accrued compensation |
161 | (670 | ) | ||||
Other liabilities |
7 | 68 | |||||
| | | | | | | |
Net cash used in operating activities |
(2,196 | ) | (10,336 | ) | |||
| | | | | | | |
Investing activities: |
|
|
|||||
Purchase of property and equipment |
(219 | ) | (365 | ) | |||
Purchase of internal software |
(182 | ) | (434 | ) | |||
Acquisition of business, net of cash acquired |
| (3,269 | ) | ||||
| | | | | | | |
Net cash used in investing activities |
(401 | ) | (4,068 | ) | |||
Financing activities: |
|
|
|||||
Proceeds from the exercise of stock options and warrants |
385 | 28 | |||||
| | | | | | | |
Net cash provided by financing activities |
385 | 28 | |||||
| | | | | | | |
Net decrease in cash and cash equivalents |
(2,212 | ) | (14,376 | ) | |||
Cash and cash equivalents at beginning of year |
3,212 | 46,436 | |||||
| | | | | | | |
Cash and cash equivalents at end of year |
1,000 | $ | 32,060 | ||||
| | | | | | | |
| | | | | | | |
| | | | | | | |
Interest paid: |
$ | 32 | $ | 424 |
See accompanying notes to unaudited consolidated financial statements.
F-77
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
Note 1. Organization and Description of Business
Teladoc, Inc. ("Teladoc", or the "Company") was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. The Company's principal executive offices are located in Dallas, Texas and Purchase, New York. Teladoc is the nation's largest telehealth company.
The Company completed the acquisition of Consult A Doctor, Inc. ("CADR"), AmeriDoc, LLC ("AmeriDoc") and Compile, Inc. d/b/a BetterHelp ("BetterHelp"), three companies engaged in telehealth activities similar to Teladoc, in 2013, 2014 and 2015, respectively. Upon the effective date of each respective merger, each entity merged with and into Teladoc.
Note 2. Summary of Significant Accounting Policies
Basis of Presentation and Principles of Consolidation
These unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company's management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary to present fairly the financial postion, results of operations and cash flows of th Company at the dates and for the periods indicated. The interim results for the period ended March 31, 2015 are not necessarily indicative of results for the full 2015 fiscal year or any other future interim periods.
The unaudited consolidated financial statements include the results of Teladoc, a professional association and six professional corporations: Teladoc Physicians, P.A., Teladoc Physicians, P.C. formed and operated in Alaska; Teladoc Physicians, P.C. formed and operated in California; Teladoc Physicians, P.C. formed and operated in Colorado; Teladoc Physicians, P.C. formed and operated in Michigan; Teladoc Physicians, P.C. formed and operated in New Jersey; and Teladoc Physicians, P.C. formed and operated in New York (collectively, the "Association").
Teladoc Physicians, P.A. is party to a Services Agreement by and among it and the six professional corporations noted above pursuant to which each professional corporation provides services to Teladoc Physicians, P.A. Each professional corporation is established pursuant to the requirements of its respective domestic jurisdiction governing the corporate practice of medicine.
The Company holds a variable interest in the Association which contracts with physicians and other health professionals in order to provide services to Teladoc. The Association is considered a variable interest entity ("VIE") since it does not have sufficient equity to finance its activities without additional subordinated financial support. An enterprise having a controlling financial interest in a VIE, must consolidate the VIE if it has both power and benefitsthat is, it has (1) the power to direct the activities of a VIE that most significantly impact the VIE's economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits). The Company has the power and rights to control all activities of the Association and funds and absorbs all losses of the VIE. Total revenue and net loss for the VIE were $3.3 million and $(2.4) million and $1.4 million and $(0.6) million for the three months ended March 31, 2015
F-78
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
and 2014, respectively. The VIE's total assets were $1.9 million and $2.1 million at March 31, 2015 and December 31, 2014, respectively. Total liabilities for the VIE were $13.5 million and $11.2 million at March 31, 2015 and December 31, 2014, respectively. The VIE total stockholders' deficit was $11.5 million and $9.1 million at March 31, 2015 and December 31, 2014, respectively.
All significant intercompany transactions and balances have been eliminated.
Business Combinations
The Company accounts for its business combinations using the acquisition method of accounting. The cost of an acquisition is measured as the aggregate of the acquisition date fair values of the assets transferred and liabilities assumed by the Company to the sellers and equity instruments issued. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. The excess of (i) the total costs of acquisition over (ii) the fair value of the identifiable net assets of the acquiree is recorded as goodwill.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business factors, and various other assumptions that the Company believes are necessary to consider to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company's business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company's financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company's operating environment changes.
Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the consolidated financial statements. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the carrying value, capitalization and amortization of software development costs, the calculation of a contingent liability in connection with an earn-out, the provision for income taxes and related deferred tax accounts, certain accrued liabilities, revenue recognition, contingencies, litigation and related legal accruals and the value attributed to employee stock options and other stock-based awards.
Pro Forma Stockholders' Equity and Net Loss Per Share (Unaudited)
In January 2015, the Company's board of directors approved the filing of a registration statement relating to an initial public offering of its common stock. Upon the effectiveness of the Registration Statement, all of the outstanding shares of convertible preferred stock (the "Preferred
F-79
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
Stock") will automatically convert into shares of common stock of the Company, provided that the initial public offering (i) is at a price per share (equal to at least $7.2264) and (ii) results in net proceeds to the Company of at least $40.0 million of proceeds, in each case, net of any underwriting discount and commissions. The March 31, 2015 unaudited pro forma stockholders' equity data has been prepared assuming the conversion of the Preferred Stock outstanding into shares of common stock of the Company. Pro forma basic and diluted net loss per share were computed to give effect to the conversion of the Preferred Stock into common stock of the Company using the if-converted method as though the conversion and reclassification had occurred as of the beginning of the first period presented or on the original date of issuance, if later.
Segment Information
The Company's chief operating decision maker, its Chief Executive Officer ("CEO"), reviews the financial information presented on a consolidated basis for purposes of allocating resources and evaluating its financial performance. Accordingly, the Company has determined that it operates in a single reporting segmenthealth services.
Revenue Recognition
The Company offers two types of subscription access revenue contracts: (i) contracts that provide for a fixed monthly charge for access and unlimited visits per Member and (ii) contracts that provide for a fixed monthly charge for access and a contractually defined cost for each visit. Any visit fee revenue that is not included in the subscription access revenue is recognized when the service has been provided to the Member.
The Company recognizes a substantial portion of its revenue from contracts that provide employers and health plans ("Clients") with subscription access to the Company's network of physicians and other healthcare professionals ("Providers") on a subscription basis for a fixed monthly fee which entitles the Client's employees and their beneficiaries ("Members") to unlimited consultations ("visits"). The contracts are generally for a one-year term and have an automatic renewal feature for additional years.
The Company commences revenue recognition for the subscription access service on the date that the services are made available to the Client and its Members, which is considered the implementation date, provided all of the following criteria are met:
Subscription Access Revenue
Subscription access revenue recognition commences on the date that the Company's services are made available to the Client, which is considered the implementation date, provided all of the other criteria described above are met. Revenue is recognized over the term of the Client contract
F-80
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
and is based on the terms in the Client contracts, which can provide for a variable periodic fee based upon the actual number of Members.
Revenue From Visit Fees
Revenue from visits is comprised of all revenue that is earned in connection with the completion of a visit. The Company recognizes revenue as the visits are completed.
The Company's contracts do not generally contain refund provisions for fees earned related to services performed. However, certain of the Company's contracts include performance guarantees that are based upon minimum employee or Member utilization and guarantees by the Company for specific service level performance of the Company's services. The Company defers revenue recognition when subscription access revenue is refundable until the end of the respective contractual period when the performance guarantees are met. The Company issued credits amounting to approximately $0.1 million for each of the three months ended March 31, 2015 and 2014.
Accounts Receivable and Allowance for Doubtful Accounts
Accounts receivable are recorded at the invoiced amount, net of allowances for doubtful accounts. The allowance for doubtful accounts is based on the Company's assessment of the collectability of accounts. The Company regularly reviews the adequacy of the allowance for doubtful accounts by considering the age of each outstanding invoice and the collection history of each customer to determine whether a specific allowance is appropriate. Accounts receivable deemed uncollectable are charged against the allowance for doubtful accounts when identified.
Goodwill and Other Intangible Assets
Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. Goodwill is not amortized, but is tested for impairment annually on October 1 or more frequently if events or changes in circumstances indicate that the asset may be impaired. The Company's impairment tests are based on a single operating segment and reporting unit structure. The goodwill impairment test involves a two- step process. The first step involves comparing the fair value of the Company's reporting unit to its carrying value, including goodwill. The fair value of the reporting unit is estimated using a discounted cash flows analysis. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value.
The Company's annual goodwill impairment test resulted in no impairment charges in any of the periods presented in the consolidated financial statements.
Other intangible assets resulted from business acquisitions and include Client relationships, non-compete agreements and trademarks. Client relationships are amortized over a period 10 years for CADR and AmeriDoc and 2 years for BetterHelp, a recent acquisition, in relation to expected future cash flows, while non-compete agreements are amortized over a period of 3 to 5 years using
F-81
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
the straight-line method. Trademarks are amortized over a period of 3 years using the straight-line method.
Stock-Based Compensation
All stock-based compensation is measured based on the grant- date fair value of the awards and recognized on a straight-line basis over the period during which the employee is required to perform services in exchange for the award (generally the vesting period of the award). The Company estimates the fair value of employee stock options using the Black-Scholes option-pricing model.
Income Taxes
The Company accounts for income taxes using the liability method, under which deferred tax assets and liabilities are determined based on the future tax consequences attributable to differences between the financial reporting carrying amounts of existing assets and liabilities and their respective tax bases and tax credit and net operating loss carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates that are expected to be in effect when the differences are expected to reverse.
The Company assesses the likelihood that deferred tax assets will be recovered from future taxable income, and a valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized.
The Company recognizes and measures uncertain tax positions using a two- step approach. The first step is to evaluate the tax position taken or expected to be taken by determining if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Significant judgment is required to evaluate uncertain tax positions. The Company evaluates its uncertain tax positions on a regular basis. Its evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of audit and effective settlement of audit issues.
Recently Issued and Adopted Accounting Pronouncements
In July 2013, the Financial Accounting Standards Board ("FASB") issued guidance regarding the presentation of unrecognized tax benefits when a net operating loss carryforward, similar tax loss, or tax credit carryforward exists. The new guidance requires that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, be presented in the consolidated financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward when settlement in this manner is available under the tax law. This guidance is effective on a prospective basis for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2013. Retrospective and early adoption is permitted. The Company adopted this guidance in the first quarter of 2014. The adoption of this guidance had no impact on the consolidated financial statements.
F-82
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) . This revenue recognition guidance supersedes existing GAAP guidance, including most industry-specific guidance. The core principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance identifies steps to apply in achieving this principle. This updated guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The Company is currently evaluating the potential impact of this guidance on its financial disclosures and results, including whether the Company elects retrospective, or modified retrospective, adoption methods.
In June 2014, the FASB issued issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period , requiring that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. The amendments in this guidance are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The Company is currently evaluating the potential impact of this guidance on its financial disclosures and results.
In August 2014, the FASB issued ASU 2014-15, Presentation of Financial StatementsGoing Concern . This guidance addresses management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. Management's evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. ASU 2014-15 is effective for interim or annual periods beginning after December 15, 2016. Early adoption is permitted. The Company does not expect to early adopt this guidance and is currently evaluating the impact of the adoption of this guidance on its financial disclosures and results.
In April 2015, the FASB issued ASU 2015-03, InterestImputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs , which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The revised guidance is effective for the Company beginning in the quarter ending March 31, 2016 and is required to be applied retrospectively. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its financial disclosures and results.
In April 2015, the FASB issued ASU 2015-05, IntangiblesGoodwill and OtherInternal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement , which provides guidance in determining whether a cloud computing arrangement includes a software license. If it is determined that a cloud computing arrangement does include a software license, the software element should be accounted for consistent with the acquisition of other software licenses. If the arrangement does not include a software license, it should be accounted for as a service contract. The revised guidance is effective for the Company beginning in the quarter ending March 31, 2016 and can be applied prospectively to all arrangements entered into or materially modified after the effective date or retrospectively. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its financial disclosures and results.
F-83
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
Note 3. Business Acquisitions
On May 1, 2014, the Company completed the acquisition of AmeriDoc, a company engaged in telehealth activities similar to Teladoc, through the purchase of 100% of AmeriDoc's outstanding members' interests for $17.2 million, net of cash acquired, including a $3.5 million promissory note and adjustments for working capital in the amount of $0.2 million. AmeriDoc was acquired to help the Company expand its initial investment in the local and regional insurance broker markets to reach clients that previously did not have access to the Company's services. Upon the effective date of the merger, AmeriDoc merged with and into Teladoc. The acquisition is considered an asset acquisition for tax purposes and as such, the goodwill resulting from this acquisition is tax deductible.
On January 23, 2015, the Company completed the acquisition of BetterHelp, through a merger in which BetterHelp became a wholly-owned subsidiary of the Company. The merger consideration paid by the Company in connection with this acquisition consisted of (i) $3.5 million in cash at closing and adjustments for working capital deficiency in the amount of $0.2 million and (ii) earn-out payments equal to 15% of the annual net revenue of the BetterHelp business (but not the Company's other business) for three years following closing. The Company has computed the value of these future payments from internally produced revenue projections and has recorded a contingent liability in the amount of $2.4 million as of March 31, 2015. The earn-out payments are considered as additional purchase consideration. The Company also issued an unsecured, subordinated promissory note in the amount of $1.0 million, with all principal and interest at a rate of 5% per annum being payable on the third anniversary of the closing to the selling shareholders and another executive of BetterHelp. If the employment of the promissory note holders is terminated, then they forfeit their right to receive the promissory note. As such, the Company has determined the promissory note to be compensatory and is accruing the expense over the service term. BetterHelp was acquired to help the Company expand its operations in the direct-to-consumer and behavioral health sector. The acquisition is considered a stock acquisition for tax purposes and as such, the goodwill resulting from this acquisition is not tax deductible.
The two acquisitions were accounted for using the acquisition method of accounting, which requires, among other things, the assets acquired and the liabilities assumed be recognized at their fair values as of the acquisition date. The results of AmeriDoc were included within the consolidated financial statements commencing May 1, 2014. The results of BetterHelp were included within the consolidated financial statements commencing January 23, 2015.
The purchase price of the acquisitions was allocated based upon the fair value of the assets acquired and liabilities assumed at the date of acquisition.
The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed at each acquisition date. The Company, with the assistance of third-party valuations, estimated the fair value of the acquired tangible and intangible assets.
F-84
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
Identifiable assets acquired and liabilities assumed (in thousands):
|
BetterHelp | AmeriDoc | |||||
---|---|---|---|---|---|---|---|
Purchase price |
$ | 5,749 | $ | 17,214 | |||
Less: |
|||||||
Cash |
89 | 57 | |||||
Accounts receivable |
11 | 458 | |||||
Other assets |
4 | 18 | |||||
Client relationships |
141 | 2,980 | |||||
Non-compete agreements |
910 | 520 | |||||
Internal software |
780 | | |||||
Trademarks |
140 | | |||||
Accounts payable |
(6 | ) | (43 | ) | |||
Deferred tax |
(675 | ) | | ||||
Other liabilities |
(340 | ) | (257 | ) | |||
| | | | | | | |
Goodwill |
$ | 4,695 | $ | 13,481 | |||
| | | | | | | |
| | | | | | | |
| | | | | | | |
The Company's unaudited pro forma revenue and net loss for the three months ended March 31, 2015 below have been prepared as if BetterHelp had been purchased on January 1, 2015.
|
Pro Forma | |||
---|---|---|---|---|
|
Three Months
Ended March 31, |
|||
(in thousands)
|
2015 | |||
Revenue |
$ | 16,614 | ||
Net loss |
$ | (12,722 | ) |
Note 4. Intangible Assets, Net
Intangible assets consist of the following (in thousands):
|
Useful
Life |
Gross Value |
Accumulated
Amortization |
Net Carrying
Value |
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
March 31, 2015 |
||||||||||||
Client relationships |
2-10 years | $ | 6,931 | $ | (1,947 | ) | $ | 4,984 | ||||
Non-compete agreements |
3 to 5 years | 2,340 | (633 | ) | 1,707 | |||||||
Trademarks |
3 years | 140 | (10 | ) | 130 | |||||||
Internal software |
3 years | 3,099 | (673 | ) | 2,426 | |||||||
| | | | | | | | | | | | |
Intangible assets, net |
$ | 12,510 | $ | (3,263 | ) | $ | 9,247 | |||||
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
December 31, 2014 |
||||||||||||
Client relationships |
10 years | $ | 6,790 | $ | (1,565 | ) | $ | 5,225 | ||||
Non-compete agreements |
3 to 5 years | 1,430 | (474 | ) | 956 | |||||||
Internal software |
3 years | 1,885 | (536 | ) | 1,349 | |||||||
| | | | | | | | | | | | |
Intangible assets, net |
$ | 10,105 | $ | (2,575 | ) | $ | 7,530 | |||||
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
Amortization expense for intangible assets was $0.7 million and $0.4 million for the three months ended March 31, 2015 and 2014, respectively.
F-85
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
Note 5. Goodwill
Goodwill consists of the following (in thousands):
Beginning balanceDecember 31, 2014 |
$ | 28,454 | ||
AdditionsBetterHelp acquisition |
4,695 | |||
| | | | |
Ending balanceMarch 31, 2015 |
$ | 33,149 | ||
| | | | |
| | | | |
| | | | |
Note 6. Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consist of the following (in thousands):
|
As of December 31, | As of March 31, | |||||
---|---|---|---|---|---|---|---|
|
2014 | 2015 | |||||
Professional fees |
$ | 963 | $ | 1,934 | |||
Consulting/customer service fees |
1,118 | 877 | |||||
Uncertain tax position |
2,705 | 2,705 | |||||
Legal fees |
389 | 1,929 | |||||
Others |
1,448 | 2,994 | |||||
| | | | | | | |
Total |
$ | 6,623 | $ | 10,439 | |||
| | | | | | | |
| | | | | | | |
| | | | | | | |
Note 7. Fair Value Measurements
Assets and Liabilities that are Measured at Fair Value on a Recurring Basis
The Company measures its financial assets and liabilities at fair value at each reporting period using a fair value hierarchy that requires it to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument's classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value:
Level 1Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2Include other inputs that are directly or indirectly observable in the marketplace.
Level 3Unobservable inputs that are supported by little or no market activity.
The Company measures its cash equivalents at fair value on a recurring basis. The Company classifies its cash equivalents within Level 1 because they are valued using observable inputs that reflect quoted prices for identical assets in active markets.
The following tables present information about the Company's assets and liabilities that are measured at fair value on a recurring basis using the above input categories (in thousands):
|
March 31, 2015 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
|
Level 1 | Level 2 | Level 3 | |||||||
Cash and cash equivalents |
$ | 32,060 | $ | | $ | | ||||
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
Contingent liability |
| | $ | 2,298 | ||||||
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
F-86
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
|
December 31, 2014 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
|
Level 1 | Level 2 | Level 3 | |||||||
Cash and cash equivalents |
$ | 46,436 | $ | | $ | | ||||
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
There were no transfers between fair value measurement levels during the three months ended March 31, 2015.
The following table reconciles the beginning and ending balance of the Company's Level 3 liabilities:
Contingent liability |
|
|||
Fair value at inception |
$ | 2,391 | ||
Payments earned |
(36 | ) | ||
Change in fair value |
(57 | ) | ||
| | | | |
Fair value at March 31, 2015 |
$ | 2,298 | ||
| | | | |
| | | | |
| | | | |
Note 8. Long Term Bank and Other Debt
Long-term bank and other debt consist of the following (in thousands):
|
As of December 31, | As of March 31, | |||||
---|---|---|---|---|---|---|---|
|
2014 | 2015 | |||||
SVB Mezzanine Term Loan less debt discount of $152 and $171 for warrants |
$ | 12,829 | $ | 12,848 | |||
SVB Term Loan facility |
5,000 | 5,000 | |||||
SVB Revolving Advance facility |
4,700 | 4,700 | |||||
Subordinated Promissory Note |
3,500 | 3,500 | |||||
| | | | | | | |
Total |
$ | 26,029 | $ | 26,048 | |||
Less: current portion |
(833 | ) | (1,146 | ) | |||
| | | | | | | |
Long term bank and other debt |
$ | 25,196 | $ | 24,902 | |||
| | | | | | | |
| | | | | | | |
| | | | | | | |
Long term bank and other debt are stated at amortized cost, which approximates fair value.
In August 2013, the Company entered into a Loan and Security Agreement with Silicon Valley Bank ("SVB") that provided for a Term Loan facility in the amount of $7.0 million with an interest rate of prime rate plus 1%. The Term Loan facility is payable in 48 monthly installments commencing April 2015. The Company's maximum borrowings under this facility totaled $3.0 million in 2013. The Loan and Security Agreement also provided the Company with a $3.0 million Revolving Advance facility that the Company did not utilize in 2013.
In May 2014, the Company entered into an Amended and Restated Loan and Security Agreement with SVB that provided for a Revolving Advance facility and a Term Loan facility (the "Amended Term Loan facility"). The Revolving Advance facility provides for borrowings up to $12.0 million based on 300% of the Company's monthly recurring revenue, as defined therein. Borrowings under the Revolving Advance facility were $4.7 million at December 31, 2014, and the facility carries interest at a rate of 0.75% above the prime rate per annum and matures in April 2016. Interest payments are payable monthly in arrears. The Company entered into an amendment
F-87
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
to the Revolving Advance Facility in March 2015 that extended its maturity to April 2017. In May 2015, the Company increased the borrowings to $11.5 million.
The Amended Term Loan facility provides for borrowings up to $5.0 million. As of December 31, 2014, the Company had utilized the total $5.0 million available under this facility. The Amended Term Loan facility carries interest at a rate of 1.00% above the prime rate per annum. Interest payments are payable monthly in arrears. Payments on the Amended Term Loan facility will commence in May 2015 and continue with 47 equal monthly payments of principal plus interest.
In May 2014, the Company entered into a Subordinated Loan and Security Agreement with SVB that provided for Mezzanine Term Loans totaling $13.0 million. The total $13.0 million drawdown of the mezzanine facility was completed in September 2014. The mezzanine facility carries interest at a rate of 10.00% per annum and matures in May 2017. Interest payments are payable monthly in arrears. In connection with entry into the mezzanine facility, the Company granted two affiliates of SVB warrants to purchase an aggregate of 300,000 shares of common stock of the Company at an exercise price of $1.29 per share. The warrants are immediately exercisable and have a 10-year term. The Company also granted SVB a security interest in significantly all of the Company's assets. The mezzanine facility has been used to fund the expansion of the Company's business. The Amended Loan and Security Agreement and the Subordinated Loan and Security Agreement are collectively referred to as the "SVB Facilities."
The Company incurred approximately $0.2 million of loan origination costs in connection with the SVB facilities and amortized approximately $0.1 million of these costs during the three months ended March 31, 2015.
Effective with the purchase of AmeriDoc, the Company executed a Subordinated Promissory Note in the amount of $3.5 million payable to the seller of AmeriDoc on April 30, 2015. The Subordinated Promissory Note carries interest at a rate of 10.00% annual interest and is subordinated to the SVB Facilities. In March 2015, the Company, the seller of AmeriDoc and SVB executed an Amended and Restated Subordinated Promissory Note that extended the maturity of the Note to April 30, 2017.
Note 9. Related Party Transaction
In May 2013, the Company issued a loan to an officer of the Company in the amount of $0.3 million. This was a non-cash transaction, whereby the loan proceeds were used to exercise options to purchase 714,285 shares of common stock options of the Company at an exercise price of $0.35 per share. The loan carries interest at the rate of 2% per annum and is due and payable upon the earlier of (i) May 13, 2017 and (ii) the occurrence of a "Change of Control" as defined in the promissory note evidencing the loan. The officer is required to make monthly interest payments. At December 31, 2013 and 2014, the balance of the loan was $0.3 million. The loan was repaid in full to the Company in February 2015.
Note 10. Lease Abandonment Charge
In connection with the Company's abandonment of its Greenwich, Connecticut office, the Company incurred $0.4 million in lease abandonment charges during the three months ended
F-88
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
March 31, 2015 included within general and administrative expenses in the consolidated income statement. The following table details the associated liability (in thousands):
Balance January 1, 2015 |
$ | | ||
Charged to expense |
375 | |||
Paid or otherwise settled |
| |||
| | | | |
Balance March 31, 2015 |
$ | 375 | ||
| | | | |
| | | | |
| | | | |
Note 11. Commitments and Contingencies
Legal Matters
The Company may become subject to legal proceedings, claims and litigation arising in the ordinary course of its business.
Teladoc is plaintiff in three lawsuits in the Texas courts against the Texas Medical Board (the "TMB"). In the first suit, Teladoc v. TMB and Leshikar , on December 31, 2014, the Austin Court of Appeals granted Teladoc's request for summary judgment, invalidating the TMB's prior assertion that Teladoc's doctors do not form "proper professional relationships" with Teladoc's members in the course of telehealth consultations such as would support the prescription of medications. The TMB has filed a petition for review with the Texas Supreme Court to ask that Court if it will allow the TMB to appeal the Court of Appeals's decision. In the second suit, Teladoc v. TMB and Freshour , on February 2, 2015, the Travis County District Court granted Teladoc's request for a temporary injunction restraining the TMB from enforcing an "emergency rule" it issued on January 16, 2015 purporting to amend the Texas Administrative Code so as to require a "face-to-face" examination of a patient before a Texas physician may lawfully prescribe medication. This suit is set for trial on November 9, 2015. In the third suit, Teladoc et al. v. TMB et al. , the United States District Court for the Western District of Texas, Austin Division, held a hearing on May 22, 2015 on Teladoc's motion for preliminary injunction of the rule amendments the TMB adopted on April 10, 2015 that seek to effect substantively identical restrictions as the issues in the two prior lawsuits. On May 29, 2015, the court granted Teladoc's request for a preliminary injunction of the rule amendments, pending ultimate trial on the amendments' validity, which trial date has yet to be set. Given the nature and status of these lawsuits, the Company cannot yet determine the amount or reasonable range of a potential loss, if any, though it does not believe a material loss is probable in connection with any of the lawsuits.
Business in the State of Texas accounted for approximately $10 million of the Company's consolidated revenue during the year ended December 31, 2014. If the TMB's revisions go into effect as written and Teladoc is unable to adapt its business model in compliance with the TMB rule, its ability to operate its business in the State of Texas could be materially adversely affected, which would have a material adverse effect on its business, financial condition and results of operations.
The Company routinely assess all of its litigation and threatened litigation as to the probability of ultimately incurring a liability and records its best estimate of the ultimate loss in situations where it assesses the likelihood of loss as probable and estimable. In this regard, the Company establishes accrual estimates for various lawsuits, claims, investigations and proceedings when it is probable that an asset has been impaired or a liability incurred at the date of the financial statements and the loss can be reasonably estimated. At March 31, 2015, the Company has established accruals for certain of its various lawsuits, claims, investigations and proceedings based
F-89
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
upon estimates of the most likely outcome in a range of loss or the minimum amounts in a range of loss if no amount within a range is a more likely estimate. The Company does not believe that at March 31, 2015 any reasonably possible losses in excess of the amounts accrued would be material to the unaudited consolidated financial statements.
Note 12. Convertible Preferred Stock (the "Preferred Stock")
The Preferred Stock consists of the following:
March 31, 2015
|
Shares
Authorized |
Shares
Outstanding |
Common
Shares Upon Conversion |
Liquidation
Preference |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series A |
418,634 | 418,634 | 3,722,590 | $ | 5,232,925 | ||||||||
Series A-1 |
53,957 | 53,957 | 646,200 | 918,955 | |||||||||
Series B |
263,839 | 263,839 | 4,091,881 | 5,768,378 | |||||||||
Series C-1 |
18,287,483 | 18,267,759 | 18,267,759 | 15,253,579 | |||||||||
Series D |
12,339,204 | 12,339,204 | 12,339,204 | 18,600,005 | |||||||||
Series E |
6,227,169 | 6,227,169 | 6,227,169 | 15,000,005 | |||||||||
Series F |
12,889,000 | 12,882,377 | 12,882,377 | 57,139,783 | |||||||||
| | | | | | | | | | | | | |
|
50,479,286 | 50,452,939 | 58,177,180 | $ | 117,913,630 | ||||||||
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
December 31, 2014
|
Shares
Authorized |
Shares
Outstanding |
Common
Shares Upon Conversion |
Liquidation
Preference |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series A |
418,634 | 418,634 | 3,722,590 | $ | 5,232,925 | ||||||||
Series A-1 |
53,957 | 53,957 | 646,200 | 918,955 | |||||||||
Series B |
263,839 | 263,839 | 4,091,881 | 5,768,378 | |||||||||
Series C-1 |
18,287,483 | 18,267,759 | 18,267,759 | 15,253,579 | |||||||||
Series D |
12,339,204 | 12,339,204 | 12,339,204 | 18,600,005 | |||||||||
Series E |
6,227,169 | 6,227,169 | 6,227,169 | 15,000,005 | |||||||||
Series F |
12,889,000 | 12,882,377 | 12,882,377 | 57,139,783 | |||||||||
| | | | | | | | | | | | | |
|
50,479,286 | 50,452,939 | 58,177,180 | $ | 117,913,630 | ||||||||
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
As of March 31, 2015, the significant terms applicable to the Series A through Series F Preferred Stock were as follows:
Dividend Rights
Prior to the issuance of the Series F Preferred Stock, the Series AE Preferred Stock accrued cumulative dividends at the per annum rate of 7.5% of the respective original purchase price (as previously adjusted for a reverse stock split and, with respect to the Series A, A-1 and B Preferred Stock, anti-dilution protection) for each such series of Preferred Stock. Such dividends were payable when, as and if declared by the Company's board of directors, but prior and in preference to any dividend on the common stock of the Company. In connection with the issuance of the Series F Preferred Stock, all such accrued and accumulated dividends (which totaled approximately $13.8 million at August 31, 2014) were converted into Series F Preferred Stock at a rate of $0.50 of Series F Preferred Stock per $1.00 in accrued dividends, resulting in the issuance of approximately 1,554,000 shares of Series F Preferred Stock on September 10, 2014. There are no longer any accrued or unpaid dividends on the Preferred Stock, and no such dividends are required to accrue or be declared by the Company.
F-90
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
Conversion Rights
Each share of Preferred Stock is convertible, at any time and at the option of the holder of such share, into shares of the common stock of the Company, at the following ratios (subject to adjustment as described below):
Series of Preferred Stock
|
Original
Issue Price |
Conversion
Price |
Number of Shares of
Common Stock Issued for each Preferred Share Upon Conversion (= Original Issue Price/ Conversion Price) |
|||||||
---|---|---|---|---|---|---|---|---|---|---|
Series F |
$ | 4.4355 | $ | 4.4355 | 1.0000 | |||||
Series E |
$ | 2.4088 | $ | 2.4088 | 1.0000 | |||||
Series D |
$ | 1.5074 | $ | 1.5074 | 1.0000 | |||||
Series C-1 |
$ | 0.835 | $ | 0.835 | 1.0000 | |||||
Series B |
$ | 12.95 | $ | 0.835 | 15.5090 | |||||
Series A-1 |
$ | 10.00 | $ | 0.835 | 11.9760 | |||||
Series A |
$ | 7.425 | $ | 0.835 | 8.8922 |
Additionally, all shares of the Preferred Stock will be automatically converted into shares of common stock of the Company at the ratios set forth above (subject to adjustment as described below) upon (i) the approval of the holders of a majority of the outstanding shares of the Preferred Stock (voting as a single class on an as-converted basis, and which includes holders of at least a majority of the outstanding shares of Series F Preferred Stock) or (ii) the closing of a firmly underwritten public offering of the common stock of the Company at a per share price of at least $7.2264 (prior to underwriting discounts and commissions) and that results in aggregate proceeds to the Company of at least $40 million (net of underwriting discounts and commissions).
Subject to limited exceptions, the conversion price for each series of the Preferred Stock will be subject to an adjustment to reduce dilution in the event that the Company issues additional equity securities at a purchase price less than the applicable conversion price for such series of the Preferred Stock.
Liquidation Rights
In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the assets of the Company available for distribution will be distributed to the Company's stockholders in the following order of priority:
F-91
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
Subject to limited exceptions, unless waived by holders of at least (i) a majority of the outstanding shares of Preferred Stock (voting together as a single class on an as-converted to common stock basis), and (ii) a majority of the outstanding Series F Preferred Stock, a merger, combination, consolidation, or sale of voting control of the Company or sale or transfer of substantially all of the assets of the Company, in each case in which the Company's stockholders do not own a majority of the voting shares of the surviving or acquiring corporation, will be deemed to be a liquidation event. If such deemed liquidation event is structured as a merger, combination, consolidation or sale of voting control, the proceeds of such transaction must be distributed to the stockholders in the order described above. If, alternatively, the deemed liquidation event is
F-92
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
structured as a sale of assets, and the Company does not dissolve within 90 days after such deemed liquidation event, the holders of Preferred Stock may elect (pursuant to a procedure and in an order of priority similar to that described under "Redemption" below) to have their shares redeemed by the Company in exchange applicable Liquidation Amount described above.
Protective Provisions
Subject to limited exceptions and certain additional restrictions, so long as at least three million shares of Preferred Stock remain outstanding, the Company may not do any of the following without the consent of holders of a majority of the Preferred Stock (voting together as a single class on an as-converted to common stock basis):
Additionally, for so long as at least twenty-five percent (25%) of the number of shares of any series of Preferred Stock remain issued and outstanding, the Company may not (i) take any action that materially and adversely alters the rights of such series of the Preferred Stock unless substantially similar action is taken with respect to all of the other series of the Preferred Stock or
F-93
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
(ii) create any additional class or series of capital stock which ranks senior or pari passu to such series of the Preferred Stock, in each such case without the consent of the holders of a majority (which majority must, in certain cases, include the consent of certain named institutional investors) of the outstanding shares of the respective, affected series of the Preferred Stock, voting as a separate class.
Redemption
On and after September 1, 2019, the holders of shares Preferred Stock may require that such shares be redeemed by the Company out of lawfully available funds, as follows:
All shares of the Preferred Stock have been presented outside of permanent stockholders' deficit, because there are redemption events outside of the Company's control.
F-94
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
Note 13. Common Stock and Stockholders' Deficit
Capitalization
Subject to limited exceptions, the Company may issue common stock subject to approval by (i) the board of directors of the Company (including the approval of the director appointed by the holders of Series D Preferred Stock and the director appointed by the holders of Series F Preferred Stock), or (ii) holders of a majority of the Preferred Stock (voting together as a single class on an as-converted to common stock basis). The aggregate number of shares of common stock that the Company will have authority to issue is 73,559,000 shares of common stock, having a par value of $0.001 per share.
Redeemable Common Stock
The holders of at least a majority of the Preferred Stock have agreed that, following the redemption of all the Preferred Stock, the total 134,977 shares of Series A Common Stock will be subject to a redemption price equal to the greater of (i) the sum of (A) 2.25 times the Series A Investors Common Stock price, plus (B) any dividends declared but unpaid thereon and (ii) the Series A Investors Common Stock appraised value.
The holders of at least a majority of the Preferred Stock have agreed that, following the redemption of all the Preferred Stock, the total 124,001 shares of Series B Common Stock will be subject to a redemption price equal to the greater of (1) the sum of (A) 2.25 times the Series B Investors Common Stock price, plus (B) any dividends declared but unpaid thereon and (ii) the Series B Investors Common Stock appraised value. The Company has recorded the Series B Common Stock $2.1 million redemption value and the Series A Common Stock $.8 million value together in mezzanine equity in the accompanying consolidated balance sheets.
Warrants
On May 2, 2014, the Company issued 300,000 common stock warrants to purchase an aggregate of 300,000 shares of its common stock at an exercise price of $1.29 per share to two entities affiliated with SVB. The common stock warrants were immediately exercisable upon issuance and have a 10-year term. The fair value of the common stock warrants on the date of issue was approximately $0.2 million which was recorded as an increase to additional paid in capital and as a debt discount.
Stock Plan and Stock Options
The Company's Second Amended and Restated Stock Incentive Plan (the "Plan") provides for the issuance of incentive and nonstatutory options to its employees and non-employees. Options issued under the Plan are exercisable for periods not to exceed ten years, vest over four years and are issued at the fair value of the shares of common stock on the date of grant as determined by the Company's board of directors, which obtains periodic third-party valuations to assist their determination process.
The Plan provides for the early exercise of stock options for certain individuals as determined by their respective option agreements.
F-95
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
Activity under the Plan is as follows (in thousands, except share and per share amounts and years):
|
Shares
Available for Grant |
Number of
Shares Outstanding |
Weighted-
Average Exercise Price |
Weighted-
Average Remaining Contractual Life in Years |
Aggregate
Intrinsic Value |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Balance at December 31, 2014 |
1,696,071 | 6,572,205 | $ | 1.63 | 8.38 | $ | 6,758 | |||||||||
Increase in Plan authorized shares |
||||||||||||||||
Stock option grants |
(1,438,952 | ) | 1,438,952 | $ | 3.81 | |||||||||||
Stock options exercised |
(50,669 | ) | $ | 0.56 | ||||||||||||
Stock options cancelled |
178,090 | (179,619 | ) | $ | 2.33 | |||||||||||
Stock options expired |
76,797 | (76,797 | ) | $ | 3.79 | |||||||||||
| | | | | | | | | | | | | | | | |
Balance at March 31, 2015 |
513,535 | 7,704,072 | $ | 1.97 | 8.89 | $ | 17,156 | |||||||||
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
Vested or expected to vest March 31, 2015 |
6,967,961 | $ | 1.92 | 8.83 | $ | 15,898 | ||||||||||
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
Exercisable as of March 31, 2015 |
1,439,374 | $ | 0.65 | 7.20 | $ | 5,105 | ||||||||||
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
The total grant-date fair value of stock options granted during the three months ended March 31, 2014 and 2015 was $0 million and $2.9 million, respectively.
Stock-Based Compensation
All stock-based awards to employees are measured based on the grant-date fair value of the awards and are generally recognized in the Company's consolidated statement of operations over the period during which the employee is required to perform services in exchange for the award (generally requiring a four-year vesting period for each award). The Company estimates the fair value of stock options granted using the Black-Scholes option-pricing model. Compensation cost is generally recognized over the vesting period of the applicable award using the straight-line method.
Given the absence of a public trading market, the Company's board of directors considered numerous objective and subjective factors to determine the fair value of its common stock at each grant date. These factors included, but were not limited to, (i) contemporaneous valuations of common stock performed by unrelated third-party specialists; (ii) the prices for the Preferred Stock sold to outside investors; (iii) the rights, preferences and privileges of the Preferred Stock relative to the common stock; (iv) the lack of marketability of the common stock; (v) developments in the business; and (vi) the likelihood of achieving a liquidity event, such as an initial public offering or a merger or acquisition of the Company, given prevailing market conditions.
The assumptions used in the Black-Scholes option-pricing model were determined as follows:
Volatility. Since the Company does not have a trading history for its common stock, the expected volatility was derived from the historical stock volatilities of several unrelated public companies within its industry that it considers to be comparable to its business over a period equivalent to the expected term of the stock option grants.
Risk-Free Interest Rate. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term on the options.
Expected Term. The expected term represents the period that the stock-based awards are expected to be outstanding. When establishing the expected term assumption, the Company used the "simplified" method because the Company does not have adequate historical data.
F-96
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
Dividend Yield. The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, it used an expected dividend yield of zero.
Forfeiture rate. The Company uses historical data to estimate pre- vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest.
The fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions and fair value per share:
|
Three Months
Ended March 31, |
Three Months
Ended March 31, |
||
---|---|---|---|---|
|
2014 | 2015 | ||
Volatility |
| 50.4% 51.0% | ||
Expected life (in years) |
| 7.0 | ||
Risk-free interest rate |
| 1.58% 1.92% | ||
Dividend yield |
| | ||
Weighted-average fair value of underlying common stock |
| $2.02 |
Total compensation costs charged as an expense for stock-based awards, including stock options, recognized in the components of operating expenses are as follows (in thousands):
|
Three Months
Ended March 31, |
Three Months
Ended March 31, |
|||||
---|---|---|---|---|---|---|---|
|
2014 | 2015 | |||||
Administrative and marketing |
$ | 6 | $ | 17 | |||
Sales |
27 | 71 | |||||
Technology and development |
13 | 40 | |||||
General and administrative |
116 | 683 | |||||
| | | | | | | |
Total stock-based compensation expense |
$ | 162 | $ | 811 | |||
| | | | | | | |
| | | | | | | |
| | | | | | | |
As of March 31, 2015, the Company had $6.4 million in unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over a weighted-average period of approximately 3.6 years.
Note 14. Income Taxes
As a result of the Company's history of net operating losses, the Company has provided for a full valuation allowance against its deferred tax assets for assets more-likely-than-not not to be realized. A deferred tax provision was recognized for each of the three months ended March 31, 2014 and 2015, attributable to the timing differences with respect to the treatment of the amortization of goodwill. Additionally, a deferred tax benefit was recognized for the three months ended March 31, 2015, resulting from business combinations and the related temporary differences.
All of the Company's operations, and resulting deferred tax assets, were generated in the United States.
Note 15. Net Loss per Share
Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock of the Company outstanding during the period. Diluted net loss per share is computed by giving effect to all potential shares of common stock of the Company,
F-97
TELADOC, INC.
Notes to Unaudited Consolidated Financial Statements
including the Preferred Stock and outstanding stock options and warrants, to the extent dilutive. Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential shares of common stock of the Company outstanding would have been anti-dilutive.
The following table presents the calculation of basic and diluted net loss per share for the Company's common stock (in thousands, except per share data):
|
Three Months Ended
March 31, |
||||||
---|---|---|---|---|---|---|---|
|
2014 | 2015 | |||||
Net loss |
$ | (2,314 | ) | $ | (12,703 | ) | |
Preferred stock dividends |
(1,031 | ) | | ||||
| | | | | | | |
Net loss available to common stockholders |
$ | (3,345 | ) | $ | (12,703 | ) | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Weighted-average shares used to compute basic and diluted net loss per share |
3,255 | 4,943 | |||||
Basic and diluted net loss per share |
$ | (1.03 | ) | $ | (2.57 | ) | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
The following securities were excluded from the calculation of diluted net loss per share for common stock because their effect would have been anti-dilutive for the periods presented (in thousands):
|
Three Months Ended
March 31, |
||||||
---|---|---|---|---|---|---|---|
|
2014 | 2015 | |||||
Stock options |
51 | | |||||
| | | | | | | |
| | | | | | | |
| | | | | | | |
Preferred stock |
37,591 | 50,453 | |||||
| | | | | | | |
| | | | | | | |
| | | | | | | |
Unaudited Pro Forma Net Loss per Share
Pro forma basic and diluted net loss per share were computed to give effect to the conversion of the Preferred Stock into common stock of the Company using the if-converted method as though the conversion and reclassification had occurred as of the beginning of the first period presented or the original date of issuance, if later.
The following table presents the calculation of basic and diluted pro forma net loss per share (in thousands, except net loss per share data):
|
Three Months Ended
March 31, |
|||
---|---|---|---|---|
|
2015 | |||
Net loss |
$ | (12,703 | ) | |
Preferred stock dividends |
| |||
| | | | |
Net loss available to common stockholders |
$ | (12,703 | ||
| | | | |
| | | | |
| | | | |
Pro Forma net loss per shareweighted average shares |
63,120 | |||
Pro Forma basic and diluted net loss per share |
$ | (0.20 | ) | |
| | | | |
| | | | |
| | | | |
Basic net loss per shareweighted average shares |
4,943 | |||
Preferred conversion |
58,177 | |||
| | | | |
Pro Forma net loss per shareweighted average shares |
63,120 | |||
| | | | |
| | | | |
| | | | |
Note 16. Subsequent Events
For the unaudited consolidated financial statements for the three months ended March 31, 2015, the Company evaluated subsequent events through May 15, 2015, which is the date the unaudited consolidated financial statements were available to be issued.
F-98
Shares
Common Stock
Prospectus
J.P. Morgan | Deutsche Bank Securities | |||
|
|
William Blair |
|
|
Wells Fargo Securities |
|
|
|
SunTrust Robinson Humphrey |
Through and including , 2015 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 13. Other Expenses of Issuance and Distribution
The actual and estimated expenses in connection with this offering, all of which will be borne by us, are as follows:
SEC Registration Fee |
$ | 11,620 | ||
FINRA Filing Fee |
15,500 | |||
Printing and Engraving Expense |
||||
Legal Fees |
||||
Accounting Fees |
||||
Blue Sky Fees |
||||
NYSE Listing Fees |
||||
Transfer Agent Fee |
||||
Miscellaneous |
||||
| | | | |
Total |
$ | |||
| | | | |
| | | | |
| | | | |
Item 14. Indemnification of Directors and Officers
Reference is made to Section 102(b)(7) of the DGCL, which enables a corporation in its original certificate of incorporation or an amendment thereto to eliminate or limit the personal liability of a director for violations of the director's fiduciary duty, except (1) for any breach of the director's duty of loyalty to the corporation or its stockholders, (2) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3) pursuant to Section 174 of the DGCL, which provides for liability of directors for unlawful payments of dividends of unlawful stock purchase or redemptions or (4) for any transaction from which a director derived an improper personal benefit.
Reference is also made to Section 145 of the DGCL, which provides that a corporation may indemnify any person, including an officer or director, who was or is threatened to be made, party to any threatened, pending or completed legal action, suit or proceeding, whether civil, criminal, administrative or investigative, other than an action by or in the right of such corporation, by reason of the fact that such person was an officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such officer, director, employee or agent acted in good faith and in a manner he reasonably believed to be in, or not opposed to, our best interest and, for criminal proceedings, had no reasonable cause to believe that his conduct was unlawful. A Delaware corporation may indemnify any officer or director in an action by or in the right of the corporation under the same conditions, except that no indemnification is permitted without judicial approval if the officer or director is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him against the expenses that such officer or director actually and reasonably incurred.
Our amended and restated certificate of incorporation to be filed as an exhibit to this registration statement will provide that our directors will not be personally liable to us or our stockholders for monetary damages resulting from breach of their fiduciary duties. However, nothing contained in such provision will eliminate or limit the liability of directors (1) for any breach of the
II-1
director's duty of loyalty to us or our stockholders, (2) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of the law, (3) under Section 174 of the DGCL or (4) for any transaction from which the director derived an improper personal benefit.
Our amended and restated certificate of incorporation and our amended and restated bylaws will provide for indemnification of the officers and directors to the full extent permitted by applicable law.
In addition, we will enter into agreements to indemnify our directors and executive officers containing provisions, which are in some respects broader than the specific indemnification provisions contained in the DGCL. The indemnification agreements may require us, among other things, to indemnify such persons against expenses, including attorneys' fees, judgments, liabilities, fines and settlement amounts incurred by any such person in actions or proceedings, including actions by us or in our right, that may arise by reason of their status or service as our director or executive officer and to advance expenses incurred by them in connection with any such proceedings. The proposed form of such indemnification agreement is to be filed as Exhibit 10.7 to this Registration Statement.
The proposed form of Underwriting Agreement, to be filed by amendment as Exhibit 1.1 to this Registration Statement, will provide for indemnification by the underwriters of the registrant and its officers and directors for certain liabilities arising under the Securities Act, or otherwise.
Item 15. Recent Sales of Unregistered Securities
The information presented in this Item 15 does not give effect to the -for- stock split, which was effectuated with the filing of the certificate of amendment to our certificate of incorporation on , 2015. Since January 1, 2012, we have granted to our directors, officers and employees options to purchase an aggregate of 8,657,518 shares of our common stock with per share exercise prices equal to $0.47, $0.73, $1.29, $2.63 or $3.81 under our Second Amended and Restated Stock Incentive Plan, which we refer to as the existing equity incentive plan.
Since January 1, 2012, 20 of our directors, officers and current and former employees have exercised options and purchased an aggregate of 3,522,094 shares of our common stock, net of exercise price and tax withholding, at per share prices equal to $0.35, $0.47 or $0.73 under the existing equity incentive plan.
On September 9, 2014, we issued 11,329,068 shares of Series F Preferred Stock for aggregate consideration of $50.3 million to accredited investors pursuant to Section 4(a)(2) of the Securities Act and Rule 506 thereunder.
On August 28, 2013, we issued 6,227,169 shares of Series E Preferred Stock for aggregate consideration of $15.0 million to accredited investors pursuant to Section 4(a)(2) of the Securities Act and Rule 506 thereunder.
On May 2, 2014, we issued warrants to purchase 300,000 shares of our common stock at an exercise price of $1.29 per share to accredited investors pursuant to Section 4(a)(2) of the Securities Act and Rule 506 thereunder.
Unless otherwise stated, the sales of the above securities were deemed to be exempt from registration under the Securities Act in reliance upon Section 4(2) of the Securities Act or Regulation D promulgated thereunder, or Rule 701 promulgated under Section 3(b) of the Securities Act as transactions by an issuer not involving any public offering or pursuant to benefit plans and contracts relating to compensation as provided under Rule 701. Individuals who purchased stock as described above represented their intention to acquire the stock for investment only and not with
II-2
a view to or for sale in connection with any distribution thereof, and appropriate legends were affixed to the share certificates issued in such transactions.
Item 16. Exhibits and Financial Statement Schedules
Exhibit No. | Description of Exhibit | ||
---|---|---|---|
1.1 | * | Form of Underwriting Agreement | |
|
2.1 |
|
Agreement and Plan of Merger, dated as of August 29, 2013, among Consult A Doctor, Inc., Douglas L. O'Keefe, as Stockholder Representative, Wolf Shlagman, John J. Karabees, Morgenthau Accelerator Fund, LP, Arturo Castillo, Promociones Bursatiles, S.A., New World Angels VI (Consult a Doctor), LLC and Teladoc, Inc. |
|
2.2 |
|
Agreement and Plan of Merger, dated as of May 1, 2014, among AmeriDoc, LLC, David E. Lindsey, Michael R. Thompson, David E. Lindsey, as Member Representative, and Teladoc, Inc. |
|
2.3 |
|
Agreement and Plan of Merger, dated as of May 22, 2015, among Teladoc, Inc., Stat Health, LLC, Stat Health Services Inc. and John Barravecchia, as Equityholder Representative |
|
3.1 |
* |
Form of Amended and Restated Certificate of Incorporation of Teladoc, Inc. |
|
3.2 |
* |
Form of Amended and Restated Bylaws of Teladoc, Inc. |
|
4.1 |
** |
Fifth Amended and Restated Investors' Rights Agreement, dated as of September 10, 2014 |
|
4.2 |
** |
First Amendment to the Fifth Amended and Restated Investors' Rights Agreement, dated as of February 9, 2015 |
|
4.3 |
** |
Amended and Restated Subordinated Promissory Note, dated as of May 2, 2014, by and between Teladoc, Inc. and David E. Lindsey, as Member Representative |
|
4.4 |
** |
Subordinated Promissory Note, dated as of January 23, 2015, by and between Teladoc, Inc. and Alon Matas, as Seller Representative |
|
5.1 |
* |
Form of Opinion of Latham & Watkins LLP |
|
10.1 |
** |
Amended and Restated Loan and Security Agreement, dated as of May 2, 2014, by and between Silicon Valley Bank and Teladoc, Inc. |
|
10.2 |
** |
Intellectual Property Security Agreement, dated as of May 2, 2014, by and between Silicon Valley Bank and Teladoc, Inc. |
|
10.3 |
** |
Subordinated Loan and Security Agreement, dated as of May 2, 2014, by and between Silicon Valley Bank and Teladoc, Inc. |
|
10.4 |
** |
First Loan Modification Agreement in respect of the Amended and Restated Loan and Security Agreement, dated as of March 11, 2015, by and between Silicon Valley Bank and Teladoc, Inc. |
|
10.5 |
** |
First Loan Modification Agreement in respect of the Subordinated Loan and Security Agreement, dated as of March 11, 2015, by and between Silicon Valley Bank and Teladoc, Inc. |
|
10.6 |
|
[Reserved] |
II-3
Exhibit No. | Description of Exhibit | ||
---|---|---|---|
10.7 | * | Form of Indemnification Agreement | |
|
10.8 |
|
Teladoc, Inc. Second Amended and Restated Stock Incentive Plan |
|
10.9 |
|
Form of Stock Option Agreement under the Teladoc, Inc. Second Amended and Restated Stock Incentive Plan |
|
10.10 |
* |
Teladoc, Inc. 2015 Incentive Award Plan |
|
10.11 |
* |
Form of Stock Option Agreement under the Teladoc, Inc. 2015 Incentive Award Plan |
|
10.12 |
* |
Form of Restricted Stock Agreement under the Teladoc, Inc. 2015 Incentive Award Plan |
|
10.13 |
* |
Form of Restricted Stock Unit Agreement under the Teladoc, Inc. 2015 Incentive Award Plan |
|
10.14 |
* |
Teladoc, Inc. Employee Stock Purchase Plan |
|
10.15 |
** |
Amended and Restated Services Agreement, dated as of February 15, 2015, between Teladoc, Inc. and Teladoc Physicians, P.A. |
|
10.16 |
** |
Office Building Lease, dated as of February 26, 2015, between Blackhorse Lakepointe, LP and Teladoc, Inc. |
|
10.17 |
|
Agreement to Serve as Director, dated as of February 27, 2014, between David B. Snow, Jr. and Teladoc, Inc. |
|
10.18 |
|
Agreement to Serve as Director, dated as of September 10, 2014, between Senator William H. Frist, M.D. and Teladoc, Inc. |
|
10.19 |
* |
Executive Employment Agreement between Teladoc Inc. and Jason Gorevic |
|
10.20 |
* |
Executive Employment Agreement between Teladoc Inc. and Mark Hirschhorn |
|
10.21 |
* |
Executive Employment Agreement between Teladoc Inc. and Michael King |
|
21.1 |
** |
List of Subsidiaries |
|
23.1 |
* |
Consent of Latham & Watkins LLP (included in Exhibit 5.1) |
|
23.2 |
|
Consent of Ernst & Young LLP as to Teladoc, Inc. |
|
23.3 |
|
Consent of Ernst & Young LLP as to Consult A Doctor, Inc. and AmeriDoc, LLC |
|
23.4 |
|
Consent of Ernst & Young LLP as to Stat Health Services Inc. |
|
24.1 |
** |
Powers of Attorney (included in the signature pages to this registration statement) |
The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.
II-4
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by us of expenses incurred or paid by a director, officer or controlling person of us in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
We hereby undertake that:
II-5
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Purchase, state of New York, on June 10, 2015.
|
|
TELADOC, INC. |
||
|
|
By: |
|
/s/ JASON GOREVIC |
Jason Gorevic President and Chief Executive Officer |
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and as of the dates indicated.
Signature
|
Title
|
Date
|
||||
---|---|---|---|---|---|---|
|
|
|
|
|
|
|
/s/ JASON GOREVIC
Jason Gorevic |
President, Chief Executive Officer and Director (Principal Executive Officer) | June 10, 2015 | ||||
/s/ MARK HIRSCHHORN Mark Hirschhorn |
|
Executive Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
|
June 10, 2015 |
||
* Martin R. Felsenthal |
|
Director |
|
June 10, 2015 |
||
* William H. Frist, M.D. |
|
Director |
|
June 10, 2015 |
||
* Michael Goldstein |
|
Director |
|
June 10, 2015 |
||
* Thomas Mawhinney |
|
Director |
|
June 10, 2015 |
||
* Thomas G. McKinley |
|
Director |
|
June 10, 2015 |
||
* Dana G. Mead, Jr. |
|
Director |
|
June 10, 2015 |
||
* Arneek Multani |
|
Director |
|
June 10, 2015 |
II-6
Signature
|
Title
|
Date
|
||||
---|---|---|---|---|---|---|
|
|
|
|
|
|
|
*
James Outland |
Director | June 10, 2015 | ||||
* David B. Snow, Jr. |
|
Director |
|
June 10, 2015 |
||
*By: |
|
/s/ MARK HIRSCHHORN Mark Hirschhorn Attorney-in-fact |
|
|
|
|
II-7
Exhibit
No. |
Description of Exhibit | ||
---|---|---|---|
1.1 | * | Form of Underwriting Agreement | |
|
2.1 |
|
Agreement and Plan of Merger, dated as of August 29, 2013, among Consult A Doctor, Inc., Douglas L. O'Keefe, as Stockholder Representative, Wolf Shlagman, John J. Karabees, Morgenthau Accelerator Fund, LP, Arturo Castillo, Promociones Bursatiles, S.A., New World Angels VI (Consult a Doctor), LLC and Teladoc, Inc. |
|
2.2 |
|
Agreement and Plan of Merger, dated as of May 1, 2014, among AmeriDoc, LLC, David E. Lindsey, Michael R. Thompson, David E. Lindsey, as Member Representative, and Teladoc, Inc. |
|
2.3 |
|
Agreement and Plan of Merger, dated as of May 22, 2015, among Teladoc, Inc., Stat Health, LLC, Stat Health Services Inc. and John Barravecchia, as Equityholder Representative |
|
3.1 |
* |
Form of Amended and Restated Certificate of Incorporation of Teladoc, Inc. |
|
3.2 |
* |
Form of Amended and Restated Bylaws of Teladoc, Inc. |
|
4.1 |
** |
Fifth Amended and Restated Investors' Rights Agreement, dated as of September 10, 2014 |
|
4.2 |
** |
First Amendment to the Fifth Amended and Restated Investors' rights agreement, dated as of February 9, 2015 |
|
4.3 |
** |
Amended and Restated Subordinated Promissory Note, dated as of May 2, 2014, by and between Teladoc, Inc. and David E. Lindsey, as Member Representative |
|
4.4 |
** |
Subordinated Promissory Note, dated as of January 23, 2015, by and between Teladoc, Inc. and Alon Matas, as Seller Representative |
|
5.1 |
* |
Form of Opinion of Latham & Watkins LLP |
|
10.1 |
** |
Amended and Restated Loan and Security Agreement, dated as of May 2, 2014, by and between Silicon Valley Bank and Teladoc, Inc. |
|
10.2 |
** |
Intellectual Property Security Agreement, dated as of May 2, 2014, by and between Silicon Valley Bank and Teladoc, Inc. |
|
10.3 |
** |
Subordinated Loan and Security Agreement, dated as of May 2, 2014, by and between Silicon Valley Bank and Teladoc, Inc. |
|
10.4 |
** |
First Loan Modification Agreement in respect of the Amended and Restated Loan and Security Agreement, dated as of March 11, 2015, by and between Silicon Valley Bank and Teladoc, Inc. |
|
10.5 |
** |
First Loan Modification Agreement in respect of the Subordinated Loan and Security Agreement, dated as of March 11, 2015, by and between Silicon Valley Bank and Teladoc, Inc. |
|
10.6 |
|
[Reserved] |
|
10.7 |
* |
Form of Indemnification Agreement |
|
10.8 |
|
Teladoc, Inc. Second Amended and Restated Stock Incentive Plan |
|
10.9 |
|
Form of Stock Option Agreement under the Teladoc, Inc. Second Amended and Restated Stock Incentive Plan |
II-8
Exhibit
No. |
Description of Exhibit | ||
---|---|---|---|
10.10 | * | Teladoc, Inc. 2015 Incentive Award Plan | |
|
10.11 |
* |
Form of Stock Option Agreement under the Teladoc, Inc. 2015 Incentive Award Plan |
|
10.12 |
* |
Form of Restricted Stock Agreement under the Teladoc, Inc. 2015 Incentive Award Plan |
|
10.13 |
* |
Form of Restricted Stock Unit Agreement under the Teladoc, Inc. 2015 Incentive Award Plan |
|
10.14 |
* |
Teladoc, Inc. Employee Stock Purchase Plan |
|
10.15 |
** |
Amended and Restated Services Agreement, dated as of February 15, 2015, between Teladoc, Inc. and Teladoc Physicians, P.A. |
|
10.16 |
** |
Office Building Lease, dated as of February 26, 2015, between Blackhorse Lakepointe, LP and Teladoc, Inc. |
|
10.17 |
|
Agreement to Serve as Director, dated as of February 27, 2014, between David B. Snow, Jr. and Teladoc, Inc. |
|
10.18 |
|
Agreement to Serve as Director, dated as of September 10, 2014, between Senator William H. Frist, M.D. and Teladoc, Inc. |
|
10.19 |
* |
Executive Employment Agreement between Teladoc Inc. and Jason Gorevic |
|
10.20 |
* |
Executive Employment Agreement between Teladoc Inc. and Mark Hirschhorn |
|
10.21 |
* |
Executive Employment Agreement between Teladoc Inc. and Michael King |
|
21.1 |
** |
List of Subsidiaries |
|
23.1 |
* |
Consent of Latham & Watkins LLP (included in Exhibit 5.1) |
|
23.2 |
|
Consent of Ernst & Young LLP as to Teladoc, Inc. |
|
23.3 |
|
Consent of Ernst & Young LLP as to Consult A Doctor, Inc. and AmeriDoc, LLC |
|
23.4 |
|
Consent of Ernst & Young LLP as to Stat Health Services Inc. |
|
24.1 |
** |
Powers of Attorney (included in the signature pages to this registration statement) |
II-9
Exhibit 2.1
EXECUTION VERSION
AGREEMENT AND PLAN OF MERGER
among
CONSULT A DOCTOR, INC.,
WOLF SHLAGMAN, JOHN J. KARABEES, MORGENTHAU ACCELERATOR FUND, LP, ARTURO CASTILLO, PROMOCIONES BURSATILES, S.A., NEW WORLD ANGELS VI (CONSULT A DOCTOR), LLC,
DOUGLAS L. OKEEFE, AS STOCKHOLDER REPRESENTATIVE,
AND
TELADOC, INC.,
dated as of
August 29, 2013
TABLE OF CONTENTS
ARTICLE I DEFINITIONS |
2 |
|
|
|
|
ARTICLE II TRANSACTIONS AND TERMS OF THE MERGER |
13 |
|
|
|
|
Section 2.01 |
The Merger |
13 |
Section 2.02 |
Certificate of Incorporation and Bylaws |
14 |
Section 2.03 |
Directors and Officers |
14 |
Section 2.04 |
Conversion of Shares |
14 |
Section 2.05 |
[RESERVED] |
15 |
Section 2.06 |
Withholding |
15 |
Section 2.07 |
Merger Consideration |
15 |
Section 2.08 |
[RESERVED] |
16 |
Section 2.09 |
Dissenting Shares |
16 |
Section 2.10 |
Exchange of Shares |
17 |
Section 2.11 |
No Further Rights |
18 |
Section 2.12 |
Closing of Transfer Books |
18 |
Section 2.13 |
Purchase Price Adjustment |
18 |
Section 2.14 |
Third Party Consents |
22 |
|
|
|
ARTICLE III CLOSING |
22 |
|
|
|
|
Section 3.01 |
Closing |
22 |
Section 3.02 |
Closing Deliverables |
22 |
|
|
|
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE TARGET |
25 |
|
|
|
|
Section 4.01 |
Organization, Qualification and Capitalization of Target and Telemed |
25 |
Section 4.02 |
Authority |
26 |
Section 4.03 |
No Conflicts; Consents |
27 |
Section 4.04 |
Financial Statements |
27 |
Section 4.05 |
Books and Records |
28 |
Section 4.06 |
Undisclosed Liabilities |
28 |
Section 4.07 |
Absence of Certain Changes, Events and Conditions |
28 |
Section 4.08 |
Material Contracts |
30 |
Section 4.09 |
Title to Assets |
31 |
Section 4.10 |
[Reserved] |
32 |
Section 4.11 |
Real Property |
32 |
Section 4.12 |
Intellectual Property |
33 |
Section 4.13 |
Accounts Receivable and Accounts Payable |
35 |
Section 4.14 |
Customers and Suppliers |
35 |
Section 4.15 |
Insurance |
36 |
Section 4.16 |
Legal Proceedings; Governmental Orders |
37 |
Section 4.17 |
Compliance with Laws; Permits |
37 |
Section 4.18 |
Environmental Matters |
39 |
Section 4.19 |
Employee Benefit Matters |
39 |
Section 4.20 |
Employment Matters |
42 |
Section 4.21 |
Taxes |
43 |
Section 4.22 |
Brokers |
45 |
Section 4.23 |
Network Redundancy and Computer Back Up |
45 |
Section 4.24 |
Privacy of Customer Information |
46 |
Section 4.25 |
Inspections and Investigations |
46 |
Section 4.26 |
Rates and Reimbursement Policies |
46 |
Section 4.27 |
No Disagreements with Accountants and Lawyers |
46 |
Section 4.28 |
Solvency |
47 |
Section 4.29 |
Full Disclosure |
47 |
|
|
|
ARTICLE V REPRESENTATIONS AND WARRANTIES OF PARENT |
47 |
|
|
|
|
Section 5.01 |
Organization of Parent |
47 |
Section 5.02 |
Authority of Parent |
47 |
Section 5.03 |
No Conflicts; Consents |
48 |
Section 5.04 |
Brokers |
48 |
Section 5.05 |
Legal Proceedings |
48 |
Section 5.06 |
Independent Investigation |
48 |
|
|
|
ARTICLE VI COVENANTS |
48 |
|
|
|
|
Section 6.01 |
[RESERVED] |
48 |
Section 6.02 |
Confidentiality |
48 |
Section 6.03 |
Approvals and Consents |
49 |
Section 6.04 |
Books and Records |
50 |
Section 6.05 |
Tax Matters |
50 |
Section 6.06 |
Public Announcements |
52 |
Section 6.07 |
Stockholder and Employee Claims |
52 |
Section 6.08 |
CONSENT OF PRINCIPALS; WAIVER OF APPRAISAL AND DISSENTERS RIGHTS |
52 |
Section 6.09 |
Further Assurances |
53 |
|
|
|
ARTICLE VII [RESERVED] |
53 |
|
|
|
|
ARTICLE VIII INDEMNIFICATION |
53 |
|
|
|
|
Section 8.01 |
Survival |
53 |
Section 8.02 |
Indemnification by the Stockholders |
53 |
Section 8.03 |
Indemnification by Parent |
54 |
Section 8.04 |
Certain Limitations |
55 |
Section 8.05 |
Indemnification Procedures |
56 |
Section 8.06 |
Payments |
58 |
Section 8.07 |
Tax Treatment of Indemnification Payments |
59 |
Section 8.08 |
Effect of Investigation |
59 |
Section 8.09 |
Exclusive Remedies |
59 |
Section 8.10 |
Authority of the Stockholder Representative |
59 |
Section 8.11 |
Calculation of Losses |
59 |
|
|
|
ARTICLE IX STOCKHOLDER REPRESENTATIVE |
60 |
|
|
|
|
Section 9.01 |
Appointment of Stockholder Representative; Power of Attorney |
60 |
Section 9.02 |
Irrevocable Appointment |
60 |
Section 9.03 |
Reliance |
61 |
Section 9.04 |
Replacement |
61 |
|
|
|
ARTICLE X MISCELLANEOUS |
61 |
|
|
|
|
Section 10.01 |
Expenses |
61 |
Section 10.02 |
Notices |
61 |
Section 10.03 |
Interpretation |
62 |
Section 10.04 |
Headings |
63 |
Section 10.05 |
Severability |
63 |
Section 10.06 |
Entire Agreement |
63 |
Section 10.07 |
Successors and Assigns |
63 |
Section 10.08 |
No Third-party Beneficiaries |
63 |
Section 10.09 |
Amendment and Modification; Waiver |
63 |
Section 10.10 |
Governing Law; Waiver of Jury Trial |
64 |
Section 10.11 |
Specific Performance |
64 |
Section 10.12 |
Counterparts |
64 |
LIST OF EXHIBITS
Exhibits :
Exhibit A |
Form of Certificate of Merger |
Exhibit B |
Form of Escrow Agreement |
Exhibit C |
Form of Release Agreement |
Exhibit D |
Form of Letter of Transmittal |
Exhibit E |
Form of Working Capital Statement |
Exhibit F |
Form of Target Opinion |
Exhibit G |
Form of Parent Opinion |
Exhibit H |
Form of Noncompetition Agreement |
AGREEMENT AND PLAN OF MERGER
This Agreement and Plan of Merger (this Agreement ), dated as of August 29, 2013, is entered into by and among Teladoc, Inc., a Delaware corporation ( Parent ), Douglas L. OKeefe, in his capacity as representative for the Stockholders (the Stockholder Representative ), Consult A Doctor, Inc., a Delaware corporation ( Target ), Wolf Shlagman ( Shlagman ), John J. Karabees ( Karabees ), Morgenthau Accelerator Fund, LP, a Delaware limited partnership ( Morgenthau ), Arturo Castillo ( Castillo ), New World Angels VI (Consult A Doctor), LLC ( NWA ) and Promociones Bursatiles, S.A. ( Promociones and together with Morgenthau, Castillo and NWA, the Principal Series A Stockholders ) (the Principal Series A Stockholders together with Karabees and Shlagman are referred to herein as the Principals ) (the Principals and Target are sometimes referred to herein as a Target Party and collectively as the Target Parties ).
RECITALS
WHEREAS, Target is engaged in the business of providing access to telemedicine and telehealth services to its customers (the Business );
WHEREAS, as of the date of this Agreement, the Principals collectively own a majority of the issued and outstanding shares of Targets (a) Series A Preferred Stock, $.001 par value per share (the Series A Preferred Stock ), and (b) common stock, $.001 par value per share (the Target Common Stock , and together with the Series A Preferred Stock, the Target Stock );
WHEREAS, Target will merge directly with and into Parent (the Merger ), with Parent continuing as the surviving corporation;
WHEREAS, the respective boards of directors of Parent and Target have, on the terms and subject to the conditions set forth in this Agreement, (a) determined and declared that the Merger is advisable to, and in the best interest of, each such Person and its respective equityholders, (b) authorized and approved this Agreement, the Merger and the consummation of the transactions contemplated hereby, and (c) in the case of Targets board of directors, has recommended the adoption and approval of this Agreement and the Merger by its Stockholders, in accordance with the Delaware General Corporation Law, as amended (the DGCL );
WHEREAS, Targets Stockholders have adopted and approved of this Agreement and the Merger in accordance with the DGCL; and
WHEREAS, the parties hereto desire to make certain representations, warranties, covenants and agreements in connection with the Merger and to prescribe various conditions to the Merger.
NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
ARTICLE I
DEFINITIONS
The following terms have the meanings specified or referred to in this ARTICLE I :
409A Authorities has the meaning set forth in Section 4.19(k) .
Accounts Receivable means all accounts or notes receivable held by Target as of the Closing Date, and any security, claim, remedy or other right related to any of the foregoing.
Action means any claim, action, cause of action, demand, lawsuit, arbitration, inquiry, audit, notice of violation, proceeding, litigation, citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether at law or in equity.
Adverse Consequences means all dues, penalties, fines, costs, amounts paid in settlement, liabilities, obligations, Taxes, Encumbrances, losses, damages, deficiencies, costs of investigation, court costs, and other expenses (including interest, penalties and reasonable attorneys fees and expenses).
Affiliate of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first Person. The term control (including the terms controlled by and under common control with) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.
Aggregate Merger Consideration has the meaning set forth in Section 2.07(a) .
Agreement has the meaning set forth in the preamble.
Annual Financial Statements has the meaning set forth in Section 4.04 .
Balance Sheet has the meaning set forth in Section 4.04(a) .
Balance Sheet Date has the meaning set forth in Section 4.04(a) .
Benefit Agreement means any employment, deferred compensation, consulting, severance, change of control, termination, retention, indemnification, loan or similar agreement between the Target or Telemed, on the one hand, and any Participant, on the other hand.
Benefit Plan means any employment, bonus, pension, profit sharing, retirement, deferred compensation, incentive compensation, stock ownership, equity or equity-based compensation, paid time off, perquisite, fringe benefit, vacation, change of control, severance, retention, disability, death benefit, hospitalization, medical, welfare benefit or other plan, program, policy, arrangement, agreement or understanding (whether or not legally binding) sponsored, maintained, contributed to or required to be sponsored, maintained or contributed to by the Target or Telemed or any other Affiliate thereof, in each case, providing benefits to any Participant, but not including any Benefit Agreement.
Books and Records means all books and records of Target, including, but not limited to, books of account, ledgers and general, financial and accounting records, machinery and equipment maintenance files, customer lists, customer purchasing histories, price lists, distribution lists, supplier lists, production data, quality control records and procedures, customer complaints and inquiry files, research and development files, records and data (including all correspondence with any Governmental Authority), sales material and records (including pricing history, total sales, terms and conditions of sale, sales and pricing policies and practices), strategic plans, internal financial statements, marketing and promotional surveys, material and research and intellectual property files relating to the Intellectual Property Assets and the Intellectual Property Licenses.
Broker has the meaning set forth in Section 4.22 .
Broker Release has the meaning set forth in Section 3.02(e) .
Business has the meaning set forth in the recitals.
Business Day means any day except Saturday, Sunday or any other day on which commercial banks located in New York City, New York are authorized or required by Law to be closed for business.
Castillo has the meaning set forth in the preamble.
Certificate of Merger means a certificate of merger in the form attached hereto as Exhibit A .
Closing has the meaning set forth in Section 3.01 .
Closing Accrued Tax Amount means the sum, without duplication, of all unpaid Taxes (whether accrued or otherwise) of Target with respect to all periods ending on or prior to the Closing Date.
Closing Balance Sheet has the meaning set forth in Section 2.13(c)(i)(A) .
Closing Date has the meaning set forth in Section 3.01 .
Closing Indebtedness means the amount of all Indebtedness of Target outstanding as of the Closing Date and immediately prior to the Effective Time, other than the amount of the indebtedness of Target under the Loan Agreement. Notwithstanding the foregoing definition of Closing Indebtedness, in order to avoid duplication of any deductions to the calculation of Aggregate Merger Consideration: (a) to the extent any Indebtedness is included in Current Liabilities and taken into account in the calculation of Closing Working Capital, such Indebtedness shall not be included as an item of Closing Indebtedness, and (b) to the extent any Taxes relating to Indebtedness are included in the calculation of Closing Accrued Tax Amount and taken into account in the calculation of Aggregate Merger Consideration, such Taxes shall not be included as an item of Closing Indebtedness.
Closing Payment Amounts means each Stockholders respective Net Allocated Share minus (A) the amount equal to the Escrow Amount multiplied by such Stockholders Participating Percentage and (B) the amount equal to the Stockholder Representative Holdback Amount multiplied by such Stockholders Participating Percentage. The Closing Payment Amounts for each Stockholder are as set forth in Section 1.1 of the Disclosure Schedule opposite such Stockholders name.
Closing Statement has the meaning set forth in Section 2.13(c)(i) .
Closing Transaction Expenses means Transaction Expenses of Target incurred in connection with this Agreement, the Transaction Documents and the transactions contemplated hereby and thereby that remain unpaid at the Closing.
Closing Working Capital has the meaning set forth in Section 2.13(a) .
Code means the Internal Revenue Code of 1986, as amended.
Compliance Plan has the meaning set forth in Section 4.17(c) .
Contracts means all contracts, leases, deeds, mortgages, licenses, instruments, notes, commitments, undertakings, indentures, joint ventures and all other agreements, commitments and legally binding arrangements, whether written or oral.
Current Assets means the sum of the line items of the consolidated balance sheet of the Target and its Subsidiaries that are listed on the Form of Working Capital Statement and calculated in accordance with GAAP (which sum shall specifically exclude the Deposit Amount).
Current Liabilities means the sum of the line items of the consolidated balance sheet of the Target and its Subsidiaries that are listed on the Form of Working Capital Statement and calculated in accordance with GAAP (which sum shall specifically exclude any indebtedness under the Loan Agreement and deferred revenue).
Debt Payoff Recipients has the meaning set forth in Section 2.07(c)(i) .
Deposit Amount means an amount equal to $1,500,000, which amount has been paid by Parent to Target as a good faith deposit prior to the date hereof pursuant to the Loan Agreement and shall be applied towards the Aggregate Merger Consideration at Closing.
DGCL has the meaning set forth in the recitals.
Direct Claim has the meaning set forth in Section 8.05(c) .
Disclosure Schedules means the Disclosure Schedules delivered by Target concurrently with the execution and delivery of this Agreement.
Disputed Amounts has the meaning set forth in Section 2.13(d)(iii) .
Dissenting Shares has the meaning set forth in Section 2.09(a) .
Dollars or $ means the lawful currency of the United States.
Edison means Edison Venture Fund VII.
Edison Liabilities has the meaning set forth in Section 8.02(g) .
Effective Time means the time at which the Certificate of Merger is filed and becomes effective with the Secretary of State of the State of Delaware in accordance with the DGCL (or at such later time as shall be agreed upon by Parent and Target and set forth in the Certificate of Merger).
Encumbrance means any charge, claim, community property interest, pledge, condition, equitable interest, lien (statutory or other), option, security interest, mortgage, easement, encroachment, right of way, right of first refusal, or restriction of any kind, including any restriction on use, voting, transfer, receipt of income or exercise of any other attribute of ownership.
Engaged Professional has the meaning set forth in Section 4.17(b) .
Environmental Claim means any Action, Governmental Order, lien, fine, penalty, or, as to each, any settlement or judgment arising therefrom, by or from any Person alleging liability of whatever kind or nature (including liability or responsibility for the costs of enforcement proceedings, investigations, cleanup, governmental response, removal or remediation, natural resources damages, property damages, personal injuries, medical monitoring, penalties, contribution, indemnification and injunctive relief) arising out of, based on or resulting from: (a) the presence, Release of, or exposure to, any Hazardous Materials; or (b) any actual or alleged non-compliance with any Environmental Law or term or condition of any Environmental Permit.
Environmental Law means any applicable Law, and any Governmental Order or binding agreement with any Governmental Authority: (a) relating to pollution (or the cleanup thereof) or the protection of natural resources, endangered or threatened species, human health or safety, or the environment (including ambient air, soil, surface water or groundwater, or subsurface strata); or (b) concerning the presence of, exposure to, or the management, manufacture, use, containment, storage, recycling, reclamation, reuse, treatment, generation, discharge, transportation, processing, production, disposal or remediation of any Hazardous Materials. The term Environmental Law includes, without limitation, the following (including their implementing regulations and any state analogs): the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended by the Superfund Amendments and Reauthorization Act of 1986, 42 U.S.C. §§ 9601 et seq.; the Solid Waste Disposal Act, as amended by the Resource Conservation and Recovery Act of 1976, as amended by the Hazardous and Solid Waste Amendments of 1984, 42 U.S.C. §§ 6901 et seq.; the Federal Water Pollution Control Act of 1972, as amended by the Clean Water Act of 1977, 33 U.S.C. §§ 1251 et seq.; the Toxic Substances Control Act of 1976, as amended, 15 U.S.C. §§ 2601 et seq.; the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. §§ 11001 et seq.; the Clean Air Act of 1966, as amended by the Clean Air Act Amendments of 1990, 42 U.S.C.
§§ 7401 et seq.; and the Occupational Safety and Health Act of 1970, as amended, 29 U.S.C. §§ 651 et seq.
Environmental Notice means any written directive, notice of violation or infraction, or notice respecting any Environmental Claim relating to actual or alleged non-compliance with any Environmental Law or any term or condition of any Environmental Permit.
Environmental Permit means any Permit, letter, clearance, consent, waiver, closure, exemption, decision or other action required under or issued, granted, given, authorized by or made pursuant to Environmental Law.
Equity Interest and equity security mean any equity security as such term is defined in the Securities and Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
ERISA means the Employee Retirement Income Security Act of 1974, as amended.
ERISA Affiliate means any trade or business, whether or not incorporated, which together with the Target is treated as a single employer under Section 414(b) or (c) of the Code.
Escrow Account means that certain escrow account established pursuant to the Escrow Agreement.
Escrow Agent means the entity designated to serve as escrow agent under the Escrow Agreement.
Escrow Agreement means the Escrow Agreement among Parent, Stockholder Representative and the Escrow Agent, to be executed and delivered at the Closing in the form attached hereto as Exhibit B .
Escrow Amount means the sum of $2,550,000.00 to be deposited with the Escrow Agent and held in escrow pursuant to the Escrow Agreement.
Estimated Closing Accrued Tax Amount has the meaning set forth in Section 2.13(b)(i)(C) .
Estimated Closing Balance Sheet has the meaning set forth in Section 2.13(b)(i)(A) .
Estimated Closing Indebtedness has the meaning set forth in Section 2.13(b)(i)(D) .
Estimated Closing Working Capital has the meaning set forth in Section 2.13(b)(i)(B) .
Final Closing Accrued Tax Amount has the meaning set forth in Section 2.13(c)(ii) .
Final Closing Indebtedness has the meaning set forth in Section 2.13(c)(ii) .
Final Closing Working Capital has the meaning set forth in Section 2.13(c)(ii) .
Financial Statements has the meaning set forth in Section 4.04 .
Form of Working Capital Statement has the meaning set forth in Section 2.13(a) .
Fundamental Representations has the meaning set forth in Section 8.01 .
GAAP means United States generally accepted accounting principles in effect from time to time.
Governmental Authority means any federal, state, or local government or political subdivision thereof, or any agency or instrumentality of such government or political subdivision, or any self-regulated organization or other non-governmental regulatory authority or quasi-governmental authority (to the extent that the rules, regulations or orders of such organization or authority have the force of Law), or any arbitrator, court or tribunal of competent jurisdiction.
Governmental Order means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any Governmental Authority.
Hazardous Materials means: (a) any material, substance, chemical, waste, product, derivative, compound, mixture, solid, liquid, mineral or gas, in each case, whether naturally occurring or manmade, that is hazardous, acutely hazardous, toxic, or words of similar import or regulatory effect under Environmental Laws; and (b) any petroleum or petroleum-derived products, radon, radioactive materials or wastes, asbestos in any form, lead or lead-containing materials, urea formaldehyde foam insulation and polychlorinated biphenyls.
Healthcare Information Laws has the meaning set forth in Section 4.17(c) .
Income Tax means all federal, state and local income or profits taxes, taxes measured by income, profits or earned surplus, excise taxes and other governmental charges arising from income, profits or other revenue similar in nature to any of the foregoing, including any interest, penalties or other additions to tax that may become payable in respect thereof, imposed by any Governmental Authority.
Indebtedness means any of the following: (a) any indebtedness for borrowed money (including any obligation for principal, interest, premiums, penalties, fees, expenses and breakage costs), (b) any obligations evidenced by bonds, debentures, notes or other similar instruments, (c) all interest expense accrued but unpaid on or relating to any such obligations described in clauses (a) and (b) above, (d) any obligations to pay the deferred purchase price of property or services, except trade accounts payable, (e) any obligations, contingent or otherwise, under acceptance credit, letters of credit or similar facilities, and (f) unpaid fees, prepayment or redemption premiums or penalties or breakage costs associated with the repayment of the types of obligations described in clauses (a) through (e) above, and (g) all outstanding obligations of the types described in clauses (a) through (f) above of any Person, the payment for which Target is responsible or liable, directly or indirectly, as obligor, guarantor or surety, including guarantees of such obligations; provided, however, that Indebtedness shall not include any accrued income Tax Liabilities or any indebtedness owed to Parent pursuant to the Loan Agreement.
Indemnified Party has the meaning set forth in Section 8.05 .
Indemnifying Party has the meaning set forth in Section 8.05 .
Independent Accountants has the meaning set forth in Section 2.13(d)(iii) .
Insolvent has the meaning set forth in Section 4.28(a) .
Insurance Policies has the meaning set forth in Section 4.15 .
Intellectual Property means all of the following and similar intangible property and related proprietary rights, interests and protections, however arising, pursuant to the Laws of any jurisdiction throughout the world: (a) trademarks, service marks, trade names, brand names, logos, trade dress and other proprietary indicia of goods and services, whether registered or unregistered, and all registrations and applications for registration of such trademarks, including intent-to-use applications, all issuances, extensions and renewals of such registrations and applications and the goodwill connected with the use of and symbolized by any of the foregoing; (b) internet domain names, whether or not trademarks, registered in any top-level domain by any authorized private registrar or Governmental Authority; (c) original works of authorship in any medium of expression, whether or not published, all copyrights (whether registered or unregistered), all registrations and applications for registration of such copyrights, and all issuances, extensions and renewals of such registrations and applications; (d) confidential information, formulas, designs, devices, technology, know-how, research and development, inventions, methods, processes, compositions and other trade secrets, whether or not patentable; (e) patented and patentable designs and inventions, all design, plant and utility patents, letters patent, utility models, pending patent applications and provisional applications and all issuances, divisions, continuations, continuations-in-part, reissues, extensions, reexaminations and renewals of such patents and applications; and (f) all rights to sue and recover and retain damages, costs and attorneys fees for past, present and future infringement and any other rights relating to any of the foregoing.
Intellectual Property Assets means all Intellectual Property that is owned by Target.
Intellectual Property Licenses means all licenses, sublicenses and other agreements by or through which other Persons, including Targets Affiliates, grant Target exclusive or non-exclusive rights or interests in or to any Intellectual Property.
Intellectual Property Registrations means all Intellectual Property Assets that are subject to any issuance, registration, application or other filing by, to or with any Governmental Authority or authorized private registrar in any jurisdiction, including registered trademarks, domain names and copyrights, issued and reissued patents and pending applications for any of the foregoing.
Interim Balance Sheet has the meaning set forth in Section 4.04(a) .
Interim Balance Sheet Date has the meaning set forth in Section 4.04(a) .
Interim Financial Statements has the meaning set forth in Section 4.04(a) .
Karabees has the meaning set forth in the preamble.
Knowledge of the Target Parties or Target Parties Knowledge or any other similar knowledge qualification, means the (i) actual knowledge of Karabees, after due inquiry with the Targets employees and (ii) actual knowledge of any Target Party (other than Karabees) or any director or officer of such Target Party.
Law means any statute, law, ordinance, regulation, rule, code, order, constitution, treaty, common law, judgment, decree, other requirement or rule of law of any Governmental Authority.
Leased Real Property has the meaning set forth in Section 4.11(b) .
Leases has the meaning set forth in Section 4.11(b) .
Lender has the meaning set forth in Section 3.02(f) .
Letter of Transmittal has the meaning set forth in Section 2.10(a) .
Liabilities means liabilities, obligations or commitments of any nature whatsoever, asserted or unasserted, known or unknown, absolute or contingent, accrued or unaccrued, matured or unmatured or otherwise.
Loan Agreement shall mean that certain Loan and Security Agreement dated July 3, 2013 by and between Parent and Target, as the same may be amended from time to time.
Losses means losses, damages, liabilities, deficiencies, diminution in value, Actions, judgments, interest, awards, penalties, fines, costs or expenses of whatever kind, including reasonable attorneys fees and the cost of enforcing any right to indemnification hereunder and the cost of pursuing any insurance providers.
Material Adverse Effect means any event, occurrence, fact, condition or change that is, or could reasonably be expected to become, individually or in the aggregate, materially adverse to (a) the aggregate value of the Target Stock, (b) the aggregate value of the Targets assets or properties or (c) the ability of the Target Parties to consummate the transactions contemplated hereby on a timely basis.
Material Contracts has the meaning set forth in Section 4.08(a) .
Material Customer Contracts has the meaning set forth in Section 4.08(a)(ix) .
Material Customers has the meaning set forth in Section 4.14(a) .
Material Suppliers has the meaning set forth in Section 4.14(b) .
Merger has the meaning set forth in the recitals.
Morgenthau has the meaning set forth in the preamble.
Net Allocated Share means, with respect to each Stockholder, such Stockholders respective portion of the Aggregate Merger Consideration (calculated using (A) the Estimated Closing Working Capital in lieu of the Final Closing Working Capital for purposes of Section 2.07(a)(ii) , (B) the Estimated Closing Accrued Tax Amount in lieu of the Final Closing Accrued Tax Amount for purposes of Section 2.07(a)(iv) , and (C) the Estimated Closing Indebtedness in lieu of the Final Closing Indebtedness for purposes of Section 2.07(a)(v)) . The Net Allocated Share for each Stockholder is set forth on Section 1.1 of the Disclosure Schedules. Section 1.1 of the Disclosure Schedules shall also provide the methodology used to calculate each Net Allocated Share.
Noncompetition Agreement has the meaning set forth in Section 3.02(d) .
Nonqualified Deferred Compensation Plan has the meaning set forth in Section 4.19(k) .
NWA has the meaning set forth in the preamble.
Option Liabilities has the meaning set forth in Section 8.02(f) .
Parent has the meaning set forth in the preamble.
Parent Indemnitees has the meaning set forth in Section 8.02 .
Parent Opinion has the meaning set forth in Section 3.02(b)(iv) .
Parents Accountants means Fox, Byrd and Company, P.C.
Participant means any current or former director, officer, employee or consultant of the Target or Telemed.
Participating Percentage means, with respect to each Stockholder, the percentage derived by dividing (a) the Net Allocated Share to be received by such Stockholder pursuant to this Agreement by (b) the aggregate Net Allocated Share to be received by all Stockholders under this Agreement. The Participating Percentages of the Stockholders are set forth on Section 1.1 of the Disclosure Schedules.
Payoff Letters has the meaning set forth in Section 2.13(b)(i)(D) .
Permits means all permits, licenses, franchises, approvals, authorizations, registrations, certificates, variances and similar rights obtained, or required to be obtained, from Governmental Authorities.
Permitted Encumbrances has the meaning set forth in Section 4.09 .
Person means an individual, corporation, partnership, joint venture, limited liability company, Governmental Authority, unincorporated organization, trust, association or other entity.
Phantom Equity Rights has the meaning set forth in Section 4.01(c) .
Phantom Plan means that certain 2010 Phantom Stock Plan of Target.
Post-Closing Adjustment has the meaning set forth in Section 2.13(c)(ii) .
Pre-Closing Statement has the meaning set forth in Section 2.13(b)(i) .
Pre-Closing Tax Period means any taxable period ending on or before the Closing Date and, with respect to any taxable period beginning before and ending after the Closing Date, the portion of such taxable period ending on and including the Closing Date.
Principal Series A Stockholders has the meaning set forth in the preamble.
Principals has the meaning set forth in the preamble.
Promociones has the meaning set forth in the preamble.
Release means any actual or threatened release, spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, dumping, abandonment, disposing or allowing to escape or migrate into or through the environment (including, without limitation, ambient air (indoor or outdoor), surface water, groundwater, land surface or subsurface strata or within any building, structure, facility or fixture).
Release Agreement means a release document substantially in the form attached hereto as Exhibit C .
Representative means, with respect to any Person, any and all directors, officers, employees, consultants, financial advisors, counsel, accountants and other agents of such Person.
Resolution Period has the meaning set forth in Section 2.13(d)(ii) .
Review Period has the meaning set forth in Section 2.13(d)(i) .
Securities Act means the Securities Act of 1933, as amended.
Series A Preferred Stock has the meaning set forth in the recitals.
Shlagman has the meaning set forth in the preamble.
Statement of Objections has the meaning set forth in Section 2.13(d)(ii) .
Stockholder means any holder of outstanding shares of Target Stock immediately prior to the Effective Time, each of which is set forth on Section 1.1 of the Disclosure Schedules.
Stockholder and Employee Claims means any and all Adverse Consequences incurred by Parent or any of its Affiliates (including, following the Effective Time, the Surviving Corporation) as a result of any claim brought by or for the benefit of any Stockholder, employee
or former employee of Target in respect of such Persons status as such relating to events, facts, conditions or circumstances existing or arising prior to the Closing Date or in connection with this Agreement, the Merger and the transactions contemplated hereby (including (i) any such matters relating to the exercise of any rights or remedies by any Stockholder in connection with the exercise of dissenters rights, appraisal rights or any similar rights in connection with this Agreement or the Merger, and (ii) any such matters arising out of or related to the Targets organizational documents, stock plans, employment agreements with employees or otherwise), including, without limitation, (x) any of the foregoing arising from matters disclosed to Parent or its Affiliates or otherwise referenced in this Agreement, and whether any related claim arises before or after the Closing, (y) whether such matters are known or unknown, contingent or otherwise, whether accrued, liquidated, matured or unmatured, and (z) all costs of investigation, defense, insurance claims processing, and insurance deductibles associated therewith.
Stockholder Indemnitees has the meaning set forth in Section 8.03 .
Stockholder Representative has the meaning set forth in the preamble.
Stockholder Representative Holdback Amount means the sum of $50,000.00 to be deposited to the account specified by Stockholder Representative prior to the Closing.
Straddle Period has the meaning set forth in Section 6.05(a)(iii) .
Subsidiary with respect to any Person (the Owner ), any corporation or other Person of which securities or other interests having the power to elect a majority of that corporations or other Persons board of directors or similar governing body, or otherwise having the power to direct the business and policies of that corporation or other Person are held by the Owner or one or more of its Subsidiaries.
Surviving Corporation means Parent, as the surviving corporation in the Merger.
Target has the meaning set forth in the preamble.
Target Common Stock has the meaning set forth in the recitals.
Target Opinion has the meaning set forth in Section 3.02(a)(iv) .
Target Option means any option or similar right to purchase shares of Target Common Stock.
Target Ownership Interests has the meaning set forth in Section 4.01(c) .
Target Party and Target Parties have the meanings set forth in the preamble.
Target Stock has the meaning set forth in the recitals.
Target Working Capital has the meaning set forth in Section 2.13(a) .
Targets Accountants means Crowe Horwath LLP.
Tax Return means any return, declaration, report, claim for refund, information return or statement or other document relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof.
Taxes means all federal, state, local, foreign and other income, gross receipts, sales, use, production, ad valorem, transfer, documentary, franchise, registration, profits, license, lease, service, service use, withholding, payroll, employment, unemployment, estimated, excise, severance, environmental, stamp, occupation, premium, property (real or personal), real property gains, windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatsoever, together with any interest, additions or penalties with respect thereto and any interest in respect of such additions or penalties.
Telemed means Telemed Physician Solutions, LLC, a Florida limited liability company and a wholly owned Subsidiary of Target prior to the Closing Date.
Third Party Claim has the meaning set forth in Section 8.05(a) .
Third Party Payments has the meaning set forth in Section 8.04(e) .
Transaction Documents means this Agreement, the Escrow Agreement and the other agreements, instruments and documents required to be delivered at the Closing.
Transaction Expenses means the sum of the following without duplication, all unpaid (whether or not accrued and whether or not disclosed) fees, costs, expenses (including attorneys, accountants, financial advisors or finders fees) or similar amounts that are owed on or prior to the Effective Time by Target in connection with the negotiation of this Agreement and the other Transaction Documents, and the consummation of the transactions contemplated hereby.
Union has the meaning set forth in Section 4.20(b) .
Waiver Notice has the meaning set forth in Section 8.05(c) .
WARN Act means the federal Worker Adjustment and Retraining Notification Act of 1988, and similar state, local and foreign laws related to plant closings, relocations, mass layoffs and employment losses.
Working Capital has the meaning set forth in Section 2.13(a) .
ARTICLE II
TRANSACTIONS AND TERMS OF THE MERGER
Section 2.01 The Merger . Upon the terms and subject to the conditions of this Agreement, and in accordance with the relevant provisions of the DGCL, Target shall be merged with and into Parent at the Effective Time. From and after the Effective Time, the separate corporate existence of Target shall cease and Parent shall continue as the Surviving Corporation. The Merger shall have the effects set forth in the DGCL and this Agreement. At the Closing, Target and Parent shall cause the Certificate of Merger to be executed, acknowledged and filed with the Secretary of State of the State of Delaware, and to make all other filings and recordings
and take such other actions as required by the DGCL in connection with the Merger. The Merger shall be consummated by filing the Certificate of Merger with the Secretary of State of the State of Delaware, as is required by, and executed in accordance with, the relevant provisions of the DGCL.
Section 2.02 Certificate of Incorporation and Bylaws .
(a) The certificate of incorporation of the Surviving Corporation immediately following the Effective Time shall initially be the same as the certificate of formation of the Parent immediately prior to the Effective Time.
(b) The bylaws of the Surviving Corporation immediately following the Effective Time shall be the same as the bylaws of Parent immediately prior to the Effective Time.
Section 2.03 Directors and Officers .
(a) The directors of the Surviving Corporation immediately following the Effective Time shall be the same as the directors of Parent immediately prior to the Effective Time.
(b) The officers of the Surviving Corporation immediately following the Effective Time shall be the same as the officers of Parent immediately prior to the Effective Time.
Section 2.04 Conversion of Shares . On the terms and subject to the conditions of this Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of Target, Parent, or the stockholders of either of the foregoing, the shares of capital stock of the constituent corporations shall be converted as follows:
(a) Series A Preferred Stock and Target Common Stock .
(i) Each share of Target Common Stock or Series A Preferred Stock that is issued and outstanding immediately prior to the Effective Time (other than Dissenting Shares) shall be canceled, extinguished and converted into and the holders thereof shall become entitled to receive, without interest, an amount in cash equal to the Closing Payment Amount set forth opposite such Stockholders name in Section 1.1 of the Disclosure Schedule, payable in the manner provided in accordance with Section 2.07(c)(v) and the right to such Stockholders applicable pro-rata portion (based upon such Stockholders Participating Percentage) of (a) any positive Post-Closing Adjustment, (b) the Escrow Amount and (c) the Stockholder Representative Holdback Amount, in each case when such amounts are distributed to Stockholders pursuant to this Agreement, upon surrender of the certificate that formerly evidenced such share of Series A Preferred Stock or Target Common Stock (or affidavit of loss and indemnity agreement in accordance with Section 2.10(f) , as applicable, and delivery of a duly executed Letter of Transmittal.
(ii) The parties hereto agree that Section 1.1 of the Disclosure Schedule sets forth a calculation of the Closing Payment Amount that would be received by each Stockholder at the Effective Time assuming there are no changes in the ownership of Target Stock. A final version of Section 1.1 of the Disclosure Schedule shall be mutually agreed among and countersigned by Parent, Target and Stockholder Representative and attached hereto on or before
the Effective Time, and notwithstanding any provisions herein regarding allocation of Aggregate Merger Consideration to the Stockholders, such final version of Section 1.1 of the Disclosure Schedule shall be dispositive and binding on the parties hereto.
(b) Shares Held in Treasury . Each share of Series A Preferred Stock or Target Common Stock held by Target (including each such share held in Targets treasury) shall be canceled and retired at the Effective Time.
(c) Parent . Each share of capital stock of Parent issued and outstanding immediately prior to the Effective Time shall remain issued and outstanding from and after the Effective Time.
Section 2.05 [RESERVED] .
Section 2.06 Withholding . Notwithstanding anything else in this Agreement to the contrary, Parent, Target and the Surviving Corporation shall be entitled to withhold from any amounts otherwise payable under this Agreement to any Person such amounts as are required to be withheld or deducted under the Code or any provision of applicable Law with respect to the making of such payment. To the extent that amounts are so deducted and withheld, such deducted and withheld amounts shall be promptly paid over to the applicable Governmental Authority on behalf of the applicable Person in respect of which such deduction and withholding were made, and such deducted and withheld amounts shall be treated for all purposes of this Agreement as having been paid to the applicable Person in respect of which such deduction and withholding were made.
Section 2.07 Merger Consideration .
(a) Merger Consideration . The aggregate merger consideration to be paid by Parent by reason of the Merger (the Aggregate Merger Consideration ) shall be an amount in cash equal to the result of the following:
(i) Seventeen Million and 00/100 Dollars ($17,000,000);
(ii) either ( x ) if the Final Closing Working Capital is greater than the Target Working Capital, plus the amount equal to the Final Closing Working Capital minus the Target Working Capital, or ( y ) if the Final Closing Working Capital is less than the Target Working Capital, minus the absolute value of the Final Closing Working Capital minus the Target Working Capital;
(iii) minus the Deposit Amount;
(iv) minus the Final Closing Accrued Tax Amount;
(v) minus the aggregate amount of Final Closing Indebtedness to the extent not included in Final Closing Working Capital; and
(vi) minus the aggregate amount of Closing Transaction Expenses to the extent not included in Final Closing Working Capital, in each case without duplication or double counting.
(b) [RESERVED]
(c) Payment at Closing . Parent shall make, or cause to be made, the following payments at Closing (or upon receipt by the Target of a duly executed Letter of Transmittal, in the case of each Stockholder, with respect to payment for such Stockholders Target Stock), with each payment to be made by wire transfer of immediately available funds pursuant to wire transfer instructions delivered to Parent prior to the Effective Time, unless otherwise designated by the payee thereof:
(i) to the accounts of Persons to whom the Closing Indebtedness is owed (the Debt Payoff Recipients ), an amount equal to the Closing Indebtedness owing to such Debt Payoff Recipients as set forth in the Payoff Letters, which payments, in the aggregate, shall be sufficient to satisfy any and all obligations of Target with respect to any Closing Indebtedness;
(ii) to the accounts of Persons to whom Closing Transaction Expenses are owed as designated in the Pre-Closing Statement, an amount equal to the Closing Transaction Expenses owing to such Persons;
(iii) to the Escrow Agent, by wire transfer of immediately available funds into an account designated by the Escrow Agent, the Escrow Amount, which Escrow Amount shall be held and distributed in accordance with the terms of the Escrow Agreement to satisfy (x) any adjustment to the Aggregate Merger Consideration in favor of Parent pursuant to Section 2.13 , and (y) any sums due to Parent or any other Parent Indemnitee pursuant to ARTICLE VIII ;
(iv) to the Stockholder Representative, by wire transfer of immediately available funds into an account designated by the Stockholder Representative, the Stockholder Representative Holdback Amount;
(v) to each Stockholder, with respect to such Stockholders Target Stock (other than with respect to Dissenting Shares), an amount equal to each Stockholders Closing Payment Amount.
Section 2.08 [RESERVED] .
Section 2.09 Dissenting Shares .
(a) Notwithstanding anything in this Agreement to the contrary, any shares of Target Stock that are issued and outstanding as of the Effective Time and that are held by a holder who is entitled to and has properly complied with the provisions of Section 262 of the DGCL (the Dissenting Shares ), shall not be converted into the right to receive the respective portion of the Aggregate Merger Consideration determined pursuant to this Agreement and shall instead have such rights as may be available under the DGCL, unless and until such holder shall have failed to perfect, or shall have effectively withdrawn or lost, such holders right to appraisal under the DGCL and to receive such consideration as may be determined to be due with respect
to such Dissenting Shares pursuant to and subject to the requirements of the DGCL. If, after the Effective Time, any such holder shall have failed to perfect or shall have effectively withdrawn or lost such right, each of such holders shares of Target Stock shall thereupon be deemed to have been converted into and to have become, as of the Effective Time, the right to receive, without interest or dividends thereon net of withholding Taxes, the respective portion of the Aggregate Merger Consideration determined pursuant to this Agreement. From and after the Effective Time, no Stockholder who has properly exercised and perfected appraisal rights pursuant to Section 262 of the DGCL shall be entitled to vote his, her or its shares of Target Stock for any purpose or receive payment of dividends or other distributions with respect to his or her shares of Target Stock (except dividends and distributions payable to Stockholders of record at a date which is prior to the Effective Time).
(b) No later than ten (10) days following the date on which the Effective Time occurs, the Parent shall provide all holders of Target Stock immediately prior to the Effective Time with the written notice in a form that is approved by Parent and required by Section 262(d) of the DGCL. Parent and Stockholder Representative shall give to the other prompt notice of any demands for appraisal of Target Stock, and any withdrawals of such demands and any other related instruments, received by such party. The Stockholder Representative shall direct all negotiations and proceedings with respect to any such demands, and the Stockholders shall indemnify the Surviving Corporation in respect thereof in accordance with Section 8.02(d) .
Section 2.10 Exchange of Shares .
(a) Each Stockholder shall deliver to Parent a duly executed Letter of Transmittal and Joinder substantially in the applicable form of Exhibit D ( Letter of Transmittal ) and all certificate or certificates representing shares of Target Stock held by such Stockholder immediately prior to the Effective Time. All certificates representing shares of Target Stock surrendered to the Target shall be cancelled at the Effective Time.
(b) Except as set forth on Section 2.10(b) of the Disclosure Schedule, at or prior to Closing, each holder of Target Options and Phantom Equity Rights issued and outstanding immediately prior to the Effective Time shall have delivered to the Target a duly executed Release Agreement.
(c) At Closing, Parent shall pay, or shall cause to be paid to each Stockholder who has tendered a duly executed Letter of Transmittal along with certificates representing the Target Stock it held immediately prior to the Effective Time (other than with respect to Dissenting Shares), the consideration payable in respect of such Target Stock as provided in Section 2.07(c)(v) . If Letters of Transmittal are received by Parent after Closing, Parent shall pay, or shall cause to be paid to each Stockholder, upon receipt of such Letter of Transmittal along with certificates representing the Target Stock it held immediately prior to the Effective Time (other than with respect to Dissenting Shares), the consideration payable in respect of such Target Stock as provided in Section 2.07(c)(v) .
(d) No interest will be paid or accrued on the amounts payable upon the surrender of the certificates or agreements formerly representing Target Stock. Until surrendered to the
Target, each certificate representing Target Stock shall represent for all purposes, only the right to receive the consideration provided by Section 2.04 .
(e) If payment in respect of cancelled stock certificates is to be made to a Person other than the Person in whose name a surrendered certificate is registered, it shall be a condition to such payment that the certificate so surrendered shall be properly endorsed or shall be otherwise in proper form for transfer and that the Person requesting such payment shall have paid any transfer and other Taxes required by reason of such payment in a name other than that of the registered holder of the certificate surrendered or shall have established to the reasonable satisfaction of Parent that such Tax either has been paid or is not payable.
(f) In the event any certificates formerly representing Target Stock shall have been lost, stolen or destroyed, Parent shall make such payment in accordance with Section 2.07(c)(v) in exchange for such lost, stolen or destroyed certificates upon the holder thereof delivering to Parent a duly executed Letter of Transmittal and affidavit of loss and indemnity agreement in a form reasonably acceptable to Parent.
Section 2.11 No Further Rights . From and after the Effective Time, no Target Stock shall be deemed to be outstanding, and holders of certificates formerly representing Target Stock shall cease to have any rights with respect thereto except as provided herein.
Section 2.12 Closing of Transfer Books . At the Effective Time, the stock transfer books of the Target shall be closed and no transfer of Target Stock shall thereafter be made. If, after the Effective Time, certificates formerly representing Target Stock are presented to Parent or the Surviving Corporation, they shall be cancelled and exchanged for the Closing Payment Amounts applicable thereto in accordance with Section 2.04 and the right to such Stockholders applicable pro-rata portion (based upon such Stockholders Participating Percentage) of (a) any positive Post-Closing Adjustment, (b) the Escrow Amount and (c) the Stockholder Representative Holdback Amount, in each case when such amounts are distributed to Stockholders pursuant to this Agreement.
Section 2.13 Purchase Price Adjustment .
(a) Working Capital Adjustments Generally . The parties have contemplated that the Working Capital of Target as of 11:59 P.M., New York City, New York time, on the Closing Date (the Closing Working Capital ) will be zero dollars ($0) (the Target Working Capital ). Working Capita l means, as of any given date, Current Assets minus Current Liabilities, in each case, as of such date, calculated in accordance with GAAP and the Form of Working Capital Statement attached hereto as Exhibit E (the Form of Working Capital Statement ).
(b) Delivery of Pre-Closing Statement .
(i) Not less than one (1) Business Day prior to the Closing Date, Target shall have delivered to Parent a statement, which statement shall be in substantially the form of Section 2.13 of the Disclosure Schedules (the Pre-Closing Statement ), attaching the following items and certifying as to Targets good faith preparation and calculation of the following items:
(A) an unaudited pro forma estimated consolidated balance sheet of Target as of 11:59 P.M., New York City, New York time, on the Closing Date (the Estimated Closing Balance Sheet );
(B) an estimate of the Closing Working Capital based on the Estimated Closing Balance Sheet (the Estimated Closing Working Capital ), together with such schedules and data with respect to the determination of the Estimated Closing Working Capital as may be appropriate to support such calculation of Estimated Closing Working Capital;
(C) an estimate of the Closing Accrued Tax Amount (the Estimated Closing Accrued Tax Amount ), together with a list of each component item thereof, and such schedules and data with respect to the determination of the. Estimated Closing Accrued Tax Amount as may be appropriate to support such calculation;
(D) a statement setting forth an estimate of each item of Closing Indebtedness (the Estimated Closing Indebtedness ), together with such schedules and data with respect to the determination of the Estimated Closing Indebtedness as may be appropriate to support such calculation of Estimated Closing Indebtedness, along with pay off letters therefor reasonably satisfactory to Parent ( Payoff Letters ) and wire instructions for each Person to whom Closing Indebtedness is owed; and
(E) a statement setting forth all Closing Transaction Expenses (together with invoices therefor and wire instructions), as derived from invoices provided by the Persons entitled to payment on account thereof.
(ii) The Estimated Closing Balance Sheet and Estimated Closing Working Capital shall be determined in accordance with GAAP and the Estimated Closing Working Capital shall be presented in the Form of Working Capital Statement.
(c) Post-Closing Adjustment .
(i) Within 45 days after the Closing Date, Parent shall prepare and deliver to the Stockholder Representative a statement, which statement shall be substantially in the form of Section 2.13 of the Disclosure Schedules (the Closing Statement ), attaching the following items and certifying as to Parents good faith preparation and calculation of the following items:
(A) an unaudited consolidated balance sheet of Target as of 11:59 P.M., New York City, New York time, on the Closing Date (the Closing Balance Sheet );
(B) the Closing Working Capital based on the Closing Balance Sheet, together with a calculation of the variance between the Estimated Closing Working Capital and Closing Working Capital;
(C) the Closing Accrued Tax Amount (including each component item), together with a calculation of the variance between the Estimated Closing Accrued Tax Amount and the Closing Accrued Tax Amount;
(D) the Closing Indebtedness (including each component item), together with a calculation of the variance between the Estimated Closing Indebtedness and the Closing Indebtedness; and
(E) a calculation of the Post-Closing Adjustment.
(ii) After each of the Closing Working Capital, Closing Accrued Tax Amount, Closing Indebtedness has been finally determined in accordance with this Section 2.13 (the Closing Working Capital, Closing Accrued Tax Amount, Closing Indebtedness, in each case, as so finally determined being referred to herein as the Final Closing Working Capital , Final Closing Accrued Tax Amount , and Final Closing Indebtedness ), the Aggregate Merger Consideration shall be, if necessary, further adjusted to reflect the Post-Closing Adjustment. The Post-Closing Adjustment shall be an amount equal to (A) the sum of the Final Closing Working Capital, minus the Final Closing Accrued Tax Amount, and minus the Final Closing Indebtedness, minus (B) the sum of the Estimated Closing Working Capital, minus the Estimated Closing Accrued Tax Amount, and minus the Estimated Closing Indebtedness. If the Post-Closing Adjustment is a positive number, Parent shall pay (or shall cause the Surviving Corporation to pay) to the Stockholders (on a pro rata basis in accordance with their respective Participating Percentages) an amount equal to the Post-Closing Adjustment. If the Post-Closing Adjustment is a negative number, Parent shall be entitled to payment of an amount equal to the Post-Closing Adjustment from the Escrow Account.
(d) Examination and Review .
(i) Examination . After receipt of the Closing Statement, Stockholder Representative shall have 30 days (the Review Period ) to review the Closing Statement. During the Review Period, Stockholder Representative and Targets Accountants shall have full access to the relevant books and records of Parent and the Surviving Corporation, the personnel of, and work papers prepared by, Parent, the Surviving Corporation and/or Parents Accountants to the extent that they relate to the Closing Statement and to such historical financial information (to the extent in Parents or the Surviving Corporations possession) relating to the Closing Statement as Stockholder Representative may reasonably request for the purpose of reviewing the Closing Statement and to prepare a Statement of Objections (defined below), provided, that such access shall be in a manner that does not interfere with the normal business operations of Parent or the Surviving Corporation.
(ii) Objection . On or prior to the last day of the Review Period, Stockholder Representative may object to the Closing Statement by delivering to Parent a written statement
setting forth Stockholder Representatives objections in reasonable detail, indicating each disputed item or amount and the basis for Stockholder Representatives disagreement therewith (the Statement of Objections ). If Stockholder Representative fails to deliver the Statement of Objections before the expiration of the Review Period, the Closing Statement, the Post-Closing Adjustment and the other calculations reflected in the Closing Statement shall be deemed to have been accepted by Stockholder Representative. If Stockholder Representative delivers the Statement of Objections before the expiration of the Review Period, Parent and Stockholder Representative shall negotiate in good faith to resolve such objections within 30 days after the delivery of the Statement of Objections (the Resolution Period ), and, if the same are so resolved within the Resolution Period, the Post-Closing Adjustment, the Closing Statement and the calculations reflected in the Closing Statement, with such changes as may have been previously agreed in writing by Parent and Stockholder Representative, shall be final and binding.
(iii) Resolution of Disputes . If Stockholder Representative and Parent fail to reach an agreement with respect to all of the matters set forth in the Statement of Objections before expiration of the Resolution Period, then any amounts remaining in dispute ( Disputed Amounts ) shall be submitted for resolution to an impartial firm of independent certified public accountants mutually selected by Parent and Stockholder Representative, other than Targets Accountants or Parents Accountants (the Independent Accountants ) who, acting as experts and not arbitrators, shall resolve the Disputed Amounts only and make any adjustments to the Post-Closing Adjustment, as the case may be, and the Closing Statement. The parties hereto agree that all adjustments shall be made without regard to materiality. The Independent Accountants shall only decide the specific items under dispute by the parties and their decision for each Disputed Amount must be within the range of values assigned to each such item in the Closing Statement and the Statement of Objections, respectively.
(iv) Fees of the Independent Accountants . Fees and expenses of the Independent Accountants shall be paid 50% by the Escrow Agent from the Escrow Account to the extent there are sufficient funds remaining in the Escrow Account pursuant to the terms of the Escrow Agreement and 50% by Parent. To the extent there are not sufficient funds remaining in the Escrow Account, the deficiency shall be paid by the Stockholders (on a pro rata basis in accordance with their Participating Percentages) by wire transfer of immediately available funds to such account as directed by the Parent.
(v) Determination by Independent Accountants . The Independent Accountants shall make a determination as soon as practicable within 30 days (or such other time as the Parent and Stockholder Representative shall agree in writing) after their engagement, and their resolution of the Disputed Amounts and their adjustments to the Closing Statement, Post-Closing Adjustment and/or the other calculations set forth in the Closing Statement shall be conclusive and binding upon the parties hereto.
(vi) Payments of Post-Closing Adjustment . Except as otherwise provided herein, any payment of the Post-Closing Adjustment shall be due within five (5) Business Days after the calculations set forth in the Closing Statement become final and binding in accordance with clauses (ii) (v) above. Any amount payable to the Stockholders in respect of their Target Stock pursuant to Section 2.13(c)(ii) shall be paid to them (via wire transfer of immediately
available funds, using the same payment instructions that were used in making payments to them pursuant to Section 2.07(c)(v)) pro-rata pursuant to each Stockholders respective Participating Percentage within five (5) Business Days after the calculations set forth in the Closing Statement become final and binding in accordance with clauses (ii) (v) above. Any amount due to Parent pursuant to Section 2.13(c)(ii) , shall be paid by the Escrow Agent from the Escrow Account to the extent that there are sufficient funds remaining in the Escrow Account pursuant to the terms of the Escrow Agreement. To the extent there are not sufficient funds remaining in the Escrow Account, the deficiency shall be paid by the Stockholders (on a pro rata basis in accordance with their Participating Percentages) by wire transfer of immediately available funds to such account as directed by the Parent.
(e) Adjustments for Tax Purposes . Any payments made pursuant to Section 2.13 shall be treated as an adjustment to the Aggregate Merger Consideration by the parties for Tax purposes, unless otherwise required by Law.
Section 2.14 Third Party Consents . To the extent that Targets rights under any Contract, Permit or other asset may not be assigned (by way of the Merger) to the Surviving Corporation without the consent of another Person which has not been obtained, this Agreement shall not constitute an agreement to assign the same if an attempted assignment would constitute a breach thereof or be unlawful, and the Stockholder Representative, at the Stockholders expense, shall use its reasonable best efforts to obtain any such required consent(s) as promptly as possible. If any such consent shall not be obtained or if any attempted assignment would be ineffective or would impair the Surviving Corporations rights under the Contract, Permit or asset in question so that the Surviving Corporation would not in effect acquire the benefit of all such rights, the Stockholder Representative, to the maximum extent permitted by Law, shall act after the Closing as the Surviving Corporations agent in order to obtain for the Surviving Corporation the benefits thereunder and shall cooperate, to the maximum extent permitted by Law and the, with the Surviving Corporation in any other reasonable arrangement designed to provide such benefits to the Surviving Corporation. Notwithstanding any provision in this Section 2.14 to the contrary, nothing will affect the liability, if any, of any Target Party pursuant to this Agreement for failing to disclose the need for, or for failing to obtain, such consent or approval.
ARTICLE III
CLOSING
Section 3.01 Closing . Subject to the terms and conditions of this Agreement, the consummation of the transactions contemplated by this Agreement (the Closing) shall take place at the offices of Carey Rodriguez Greenberg OKeefe LLP, 1395 Brickell Avenue, Suite 700, Miami, Florida 33131, at 3:00 p.m., CST, or at such other time, date or place as Target and Parent may mutually agree upon. The date on which the Closing is to occur is herein referred to as the Closing Date .
Section 3.02 Closing Deliverables .
(a) At the Closing, Target shall deliver to Parent the following:
(i) the Escrow Agreement duly executed by the Stockholder Representative;
(ii) a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Target certifying that attached thereto are true and complete copies of all resolutions adopted by the board of directors and Stockholders of Target authorizing the execution, delivery and performance of this Agreement and the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby (including approval by Stockholders holding at least 50% of the Target Common Stock and 66.67% of the Series A Preferred Stock of this Agreement, the Merger and the other transactions contemplated hereby), and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated hereby and thereby;
(iii) a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Target certifying the names and signatures of the officers of Target authorized to sign this Agreement, the Transaction Documents and the other documents to be delivered hereunder and thereunder;
(iv) an original legal opinion of Carey Rodriguez Greenberg OKeefe, LLP, counsel for the Target, covering the matters set forth on Exhibit F (the Target Opinion );
(v) [RESERVED];
(vi) certificates of account status or good standing for Target issued by the Secretary of State of Delaware dated as of a date that is not more than ten (10) days prior to the Closing Date;
(vii) such documentation or other evidence reasonably satisfactory to Parent that all of the Permits, consents, approvals, authorizations and clearances listed in Section 4.03 of the Disclosure Schedule related to (x) Material Customer Contracts representing at least seventy-five percent (75%) of Targets revenues for the twelve (12) months ending July 31, 2013 and (y) those Contracts designated in Section 4.03 of the Disclosure Schedule as Material Supplier Contracts that are required for the Closing have been obtained;
(viii) such documentation or other evidence reasonably satisfactory to Parent that Telemed is spun-off from Target and is no longer a Subsidiary of Target as of the Closing Date;
(ix) such documentation or other evidence reasonably satisfactory to Parent that Target shall have taken all action reasonably required to cause the termination of all of the Contracts listed in Part V of Section 4.08(a) of the Disclosure Schedule;
(x) such documentation or other evidence reasonably satisfactory to Parent that Target shall have taken all action reasonably required to cause the termination of all of its Benefit Plans;
(xi) Letters of Transmittal (attaching stock certificates or lost stock affidavits, as applicable, evidencing the applicable Stockholders equity ownership in Target immediately prior to the Effective Time) duly executed by each Stockholder;
(xii) Release Agreements duly executed by each holder of Target Options and Phantom Equity Rights issued and outstanding immediately prior to the Effective Time other than the Persons listed on Section 2.10(b) of the Disclosure Schedule;
(xiii) resignation letters, duly executed, by each director and officer of Target;
(xiv) such other customary instruments of transfer, assumption, filings or documents, in form and substance reasonably satisfactory to Parent, as may be required to give effect to this Agreement.
(b) At the Closing, Parent shall deliver to Target and the Stockholder Representative, unless otherwise specified below, the following:
(i) the Escrow Agreement duly executed by Parent;
(ii) a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Parent certifying that attached thereto are true and complete copies of all resolutions adopted by the boards of directors of Parent authorizing the execution, delivery and performance of this Agreement and the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby, and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated hereby and thereby;
(iii) a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Parent certifying the names and signatures of the officers of Parent authorized to sign this Agreement, the Transaction Documents and the other documents to be delivered hereunder and thereunder;
(iv) an original legal opinion of Jackson Walker L.L.P., counsel for the Parent, covering the matters set forth on Exhibit G (the Parent Opinion ); and
(v) a release of any indebtedness owed to Parent by Target arising from the Loan Agreement.
(c) At the Closing, Parent shall make, or cause the Surviving Corporation to make, the payments described in Section 2.07(c) .
(d) Each of Karabees and Shlagman shall deliver to Parent an executed Noncompetition/Nonsolicitation Agreement in the form of Exhibit H attached hereto (the Noncompetition Agreement ).
(e) Target shall deliver to Parent a release for each Broker (including, without limitation, Archpoint Partners) and executed by each Broker, (i) acknowledging that all fees payable to such Broker due to the consummation of this Agreement have been paid and (ii) releasing Parent, the Surviving Corporation and Target from any claims in connection therewith (the Broker Release ).
(f) Target shall deliver to Parent a release for Targets Indebtedness with Wells Fargo Bank (the Lender ) and executed by the Lender, (i) acknowledging that all amounts due to Lender have been paid and (ii) releasing Parent, the Surviving Corporation and Target from any claims in connection therewith.
(g) Target shall deliver to Parent a release executed by Shlagman, in form and substance reasonably satisfactory to Parent, (i) acknowledging that all fees payable to him due to the consummation of this Agreement and the termination of his employment agreement have been paid and (ii) releasing Parent, the Surviving Corporation and Target Parties from any claims in connection therewith.
(h) The parties acknowledge and agree that as of the Closing Date, the Loan Agreement shall terminate and the Deposit Amount shall be credited towards the Aggregate Merger Consideration as set forth in Section 2.07(a)(iii) .
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF THE TARGET
Except as set forth in the correspondingly numbered Section of the Disclosure Schedules, Target represents and warrants to Parent that the statements contained in this ARTICLE IV are true and correct as of the date hereof and as of the Closing.
Section 4.01 Organization, Qualification and Capitalization of Target and Telemed .
(a) Target is a corporation duly organized, validly existing and in good standing under the Laws of the state of Delaware. Telemed is a limited liability company duly organized, validly existing and in good standing under the Laws of the state of Florida. Each of Target and Telemed has full corporate power and authority to own, operate or lease the properties and assets now owned, operated or leased by it and to carry on its business as currently conducted by it. Section 4.01(a) of the Disclosure Schedules sets forth each jurisdiction in which Target or Telemed are licensed or qualified to do business. Except as specified in Section 4.01(a) of the Disclosure Schedules, each of Target and Telemed is duly licensed or qualified to do business and is in good standing in each jurisdiction in which the ownership of its assets or the operation of its business as currently conducted makes such licensing or qualification necessary.
(b) Immediately prior to the Effective Time, (i) the authorized capital stock of Target consists of 3,000,000 shares of Target Common Stock, and 7,000,000 shares of Series A Preferred Stock and (ii) 2,060,500 shares of Target Common Stock and 6,587,191 shares of Series A Preferred Stock are issued and outstanding. Except as set forth in Section 2.10(b) of the Disclosure Schedule, as of the Effective Time, there are no existing (i) options, warrants, calls, subscriptions or other rights, convertible securities, agreements or commitments of any character obligating the Target or any of its Subsidiaries to issue, transfer or sell any shares of capital stock or other equity interest in, the Target or any of its Subsidiaries, (ii) contractual obligations of the Target or any of its Subsidiaries to repurchase, redeem or otherwise acquire any capital stock of the Target or any of its Subsidiaries or (iii) voting trusts or similar
agreements to which the Target is a party with respect to the voting of the capital stock of the Target.
(c) Section 4.01(c) of the Disclosure Schedules contains a full, complete and accurate schedule of the holders of all of the issued and outstanding Equity Interests of Target (including, without limitation, Target Common Stock, Series A Preferred Stock and Target Options) (the Target Ownership Interests ). The Target Ownership Interests have been duly authorized and validly issued and are fully paid and non-assessable. Except for the Target Ownership Interests or as specified in Section 4.01(c) of the Disclosure Schedules, there are no outstanding Equity Interests or other equity securities of Target, including (i) securities which are convertible into or exchangeable for any capital stock of Target, (ii) Contracts, arrangements, commitments or restrictions relating to the issuance, sale, transfer, purchase or obtaining of capital stock or other equity securities of Target, or (iii) options, warrants, rights, calls or commitments of any character granted or issued by Target governing the issuance of shares of its capital stock. None of the Target Ownership Interests were issued in violation of the Securities Act or any other Law. Except as set forth in Section 4.01(c) of the Disclosure Schedules, there are no outstanding or authorized equity appreciation, phantom equity, profit participation, or similar rights with respect to Target, including without limitation such rights issued under the Phantom Plan (collectively, the Phantom Equity Rights ). Except as set forth in Section 4.01(c) of the Disclosure Schedules, there are no (i) voting trusts, proxies, or other Contracts with respect to the voting of the Target Ownership Interests, or (ii) obligations of Target to repurchase, redeem or otherwise acquire any Target Ownership Interest or to provide funds to, or make any investment (in the form of a loan, capital contribution or otherwise) in, the any other Person.
(d) Neither Target nor Telemed (i) has any Subsidiaries, (ii) owns any Equity Interests in any other Person, (iii) provides medical services through any Person, or (iv) is party to any services or similar agreement with any professional association or entity regarding telemedicine or telehealth services; provided that it is acknowledged that, prior to the Closing, (i) Target owned one hundred percent (100%) of the issued and outstanding Equity Interests of Telemed and (ii) Target and Telemed provided medical services through Telemed and the Engaged Professionals.
Section 4.02 Authority . Each Target Party (i) if a natural person, is of the age of majority and has full power and authority and is competent to enter into this Agreement and the other Transaction Documents to which such Target Party is a party, to carry out its obligations hereunder and thereunder, and to consummate the transactions contemplated hereby and thereby, and (ii) if other than a natural person, has full corporate power and authority to enter into this Agreement and the other Transaction Documents to which such Target Party is a party, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. With respect to each Target Party that is not a natural person, the execution and delivery by such Target Party of this Agreement and any other Transaction Document to which such Target Party is a party, the performance by such Target Party of its obligations hereunder and thereunder and the consummation by such Target Party of the transactions contemplated hereby and thereby have been duly authorized by all requisite corporate action on the part of such Target Party. This Agreement has been duly executed and delivered by each Target Party, and (assuming due authorization, execution and delivery by Parent) this Agreement constitutes a legal, valid and binding obligation of each Target Party enforceable against each
Target Party in accordance with its terms. When each other Transaction Document to which each Target Party is or will be a party has been duly executed and delivered by such Target Party (assuming due authorization, execution and delivery by each other party thereto), such Transaction Document will constitute a legal and binding obligation of such Target Party enforceable against it in accordance with its terms.
Section 4.03 No Conflicts; Consents . The execution, delivery and performance by each Target Party of this Agreement and the other Transaction Documents to which it is a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not: (a) conflict with or result in a violation or breach of, or default under, any provision of the certificate of incorporation, by-laws or other organizational documents of such Target Party or any resolution adopted by the governing body or owners of such Target Party; (b) conflict with or result in a material violation or breach of any provision of any Law or Governmental Order applicable to any Target Party, the Target Stock, the Target Options or Targets business or assets; (c) except as set forth in Section 4.03 of the Disclosure Schedules, require the consent, notice or other action by any Person under, conflict with, result in a violation or breach of, constitute a default or an event that, with or without notice or lapse of time or both, would constitute a default under, result in the acceleration of or create in any party the right to accelerate, terminate, modify or cancel any Contract or Permit to which any Target Party is a party or by which any Target Party or its business is bound or to which any of its assets are subject (including any Material Contract); (d) result in the creation or imposition of any Encumbrance other than Permitted Encumbrances on the Target Stock, the Target Options or Targets assets; or (e) cause Parent to become subject to, or to become liable for the payment of any Tax. Other than the filing of the Certificate of Merger with the Secretary of State of the State of Delaware, no consent, approval, Permit, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required by or with respect to any Target Party in connection with the execution and delivery of this Agreement or any of the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby.
Section 4.04 Financial Statements .
(a) Complete copies of the unaudited financial statements consisting of the balance sheet of the Target as of December 31 in each of the years 2010, 2011 and 2012 and the related statements of income and retained earnings, stockholders equity and cash flow for the years then ended (the Annual Financial Statements ), and unaudited financial statements consisting of the balance sheet of the Business as of June 30, 2013 and the related statements of income and retained earnings, stockholders equity and cash flow for the six (6) month period then ended (the Interim Financial Statements and together with the Annual Financial Statements, the Financial Statements ) are included in Section 4.04 of the Disclosure Schedules. The Financial Statements have been prepared in accordance with GAAP applied on a consistent basis throughout the period involved, subject, in the case of the Interim Financial Statements, to normal and recurring year-end adjustments (the effect of which will not be materially adverse) and the absence of notes (that, if presented, would not differ materially from those presented in the Annual Financial Statements). The Financial Statements are based on the books and records of the Business, and fairly and accurately present the financial condition of the Business as of the respective dates they were prepared and the results of the operations of the Business for the periods indicated. The balance sheet of the Business as of December 31, 2012 is referred to
herein as the Balance Sheet and the date thereof as the Balance Sheet Date and the balance sheet of the Business as of June 30, 2013 is referred to herein as the Interim Balance Sheet and the date thereof as the Interim Balance Sheet Date . Target maintains a standard system of accounting for its business established and administered in accordance with GAAP.
(b) Target has also delivered to Parent copies of all letters from Targets and auditors to Targets board of directors or the audit committee thereof during the thirty-six (36) months preceding the execution of this Agreement, together with copies of all responses thereto.
Section 4.05 Books and Records . The books of account and other financial records of Target and Telemed, all of which have been made available to Parent, are complete and correct and represent actual, bona fide transactions and have been maintained in accordance with sound business practices and the requirements of Law, including the maintenance of an adequate system of internal controls.
Section 4.06 Undisclosed Liabilities . Neither Target nor Telemed has Liabilities, except (a) those which are adequately reflected or reserved against in the Balance Sheet as of the Balance Sheet Date, and (b) those which have been incurred in the ordinary course of business consistent with past practice since the Balance Sheet Date and which are not, individually or in the aggregate, material in amount.
Section 4.07 Absence of Certain Changes, Events and Conditions . Except as set forth in Section 4.07 of the Disclosure Schedules, since the Balance Sheet Date, and other than in the ordinary course of business consistent with past practice, there has not been any of the following with respect to Target, Telemed or the Target Ownership Interests:
(a) event, occurrence or development that has had, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect;
(b) change in the authorized or issued Equity Interests of Target or Telemed;
(c) amendment to the governing documents of Target or Telemed;
(d) declaration or payment of any dividends or distributions on or in respect of any of Target Ownership Interests or redemption, purchase or acquisition of any Target Ownership Interests;
(e) material change in any method of accounting or accounting practice for the Business, except as required by GAAP or as disclosed in the notes to the Financial Statements;
(f) material change in cash management practices and policies, practices and procedures with respect to collection of Accounts Receivable, establishment of reserves for uncollectible Accounts Receivable, accrual of Accounts Receivable, inventory control, prepayment of expenses, payment of trade accounts payable, accrual of other expenses, deferral of revenue and acceptance of customer deposits;
(g) entry into any Contract that would constitute a Material Contract;
(h) incurrence, assumption or guarantee of any indebtedness for borrowed money except unsecured current obligations and Liabilities incurred in the ordinary course of business consistent with past practice or pursuant to the Loan Agreement;
(i) transfer, assignment, sale or other disposition of any of the assets shown or reflected in the Balance Sheet;
(j) cancellation of any debts or claims or amendment, termination or waiver of any rights;
(k) transfer, assignment or grant of any license or sublicense of any material rights under or with respect to any Intellectual Property Assets or Intellectual Property Licenses other than non-exclusive licenses granted in the ordinary course of business;
(l) material damage, destruction or loss, or any material interruption in use, of any Targets or Telemeds assets, whether or not covered by insurance;
(m) acceleration, termination, material modification to or cancellation of any Material Contract or Permit;
(n) material capital expenditures;
(o) imposition of any Encumbrance upon any of the Target Ownership Interests or the assets of Target or Telemed;
(p) (i) grant of any bonuses, whether monetary or otherwise, or increase in any wages, salary, severance, pension or other compensation or benefits in respect of any employees, officers, directors, independent contractors or consultants, other than as, provided for in any written agreements or required by applicable Law, (ii) change in the terms of employment for any employee or any termination of any employees for which the aggregate costs and expenses exceed $25,000 or (iii) action to accelerate the vesting or payment of any compensation or benefit for any employee, officer, director, consultant or independent contractor;
(q) adoption, modification or termination of any: (i) employment, severance, retention or other agreement with any current or former employee, officer, director, independent contractor or consultant, (ii) Benefit Plan, or (iii) collective bargaining or other agreement with a Union, in each case whether written or oral;
(r) any loan to (or forgiveness of any loan to), or entry into any other transaction with, any directors, officers or employees;
(s) adoption of any plan of merger, consolidation, reorganization, liquidation or dissolution or filing of a petition in bankruptcy under any provisions of federal or state bankruptcy Law or consent to the filing of any bankruptcy petition against it under any similar Law;
(t) purchase, lease or other acquisition of the right to own, use or lease any property or assets for an amount in excess of $10,000 individually (in the case of a lease, per annum) or
$25,000 in the aggregate (in the case of a lease, for the entire term of the lease, not including any option term), except for purchases of supplies in the ordinary course of business consistent with past practice;
(u) any Contract to do any of the foregoing, or any action or omission that would result in any of the foregoing.
Section 4.08 Material Contracts .
(a) Section 4.08(a) of the Disclosure Schedules lists each of the following Contracts (x) by which any of the Target Ownership Interests are bound or affected or (y) to which either Target or Telemed is a party or by which it is bound (such Contracts, together with all Leases listed or otherwise disclosed in Section 4.11(b) of the Disclosure Schedules and all Contracts relating to Intellectual Property set forth in Section 4.12(c) and Section 4.12(e) of the Disclosure Schedules, being Material Contracts ):
(i) all Contracts involving aggregate consideration in excess of $25,000 on an annual basis;
(ii) all Contracts which cannot be cancelled without a penalty exceeding $10,000, or without more than 60 days notice;
(iii) all Contracts that require Target or Telemed to purchase or sell a stated portion of the requirements or outputs or that contain take or pay provisions;
(iv) all Contracts that provide for the indemnification of any Person or the assumption of any Tax, environmental or other Liability of any Person;
(v) all Contracts that relate to the acquisition or disposition of any business, a material amount of stock or assets of any other Person or any real property (whether by merger, sale of stock, sale of assets or otherwise) other than previous term sheets regarding sales of Target Stock that were terminated;
(vi) all broker, distributor, dealer, manufacturers representative, franchise, agency, sales promotion, market research, marketing consulting and advertising Contracts;
(vii) except for Contracts relating to trade receivables, all Contracts relating to indebtedness (including, without limitation, guarantees) exceeding $2,500 individually or $10,000 in the aggregate;
(viii) all Contracts with any Governmental Authority;
(ix) all Contracts with customers, insurers, employers, managed care entities, payors or other purchasers of services from Telemed or Target from which Target derives at least $35,000 in annual revenues (the Material Customer Contracts );
(x) all Contracts that limit or purport to limit the ability of Target or Telemed to compete in any line of business or with any Person or in any geographic area or during any period of time;
(xi) all joint venture, partnership or similar Contracts;
(xii) all Contracts for the sale of any of the Target Ownership Interests or for the grant to any Person of any option, right of first refusal or preferential or similar right to purchase any of the Target Ownership Interests;
(xiii) all powers of attorney with respect to the Target, Telemed or any of the Target Ownership Interests;
(xiv) all collective bargaining agreements or Contracts with any Union;
(xv) all Contracts under which the consequences of a default or termination could reasonably be expected to have a Material Adverse Effect; and
(xvi) all Contracts with physicians and healthcare providers, or otherwise involving the provision of medical services by or for the benefit of Target or Telemed.
(b) Each Material Contract is valid and binding on Target or Telemed, as applicable, and to the Knowledge of the Target Parties, to the each other party thereto in accordance with its terms and is in full force and effect. Except as set forth in Section 4.08(b) of the Disclosure Schedules, each of Target and Telemed has duly performed in all material respects its obligations under each Material Contract to which it is a party (to the extent that such obligations to perform have accrued). Neither Target, Telemed nor, to the Knowledge of the Target Parties, any other party thereto is in breach of or default under (or is alleged to be in breach of or default under), or has provided or received any notice of any intention to terminate, any Material Contract. To the Knowledge of the Target Parties, no counterparty to any Material Contract intends to terminate such Material Contract prior to the scheduled expiration of term of such Material Contract, decline renewal following the current term of such Material Contract or to materially alter the terms on which business is conducted under such Material Contract. No event or circumstance has occurred that, with notice or lapse of time or both, would constitute an event of default by Target under any Material Contract or result in a termination thereof or would cause or permit the acceleration or other changes of any right or obligation or the loss of any benefit thereunder. Complete and correct copies of each Material Contract (including all modifications, amendments and supplements thereto and waivers thereunder) have been made available to Parent. Except as set forth in Section 4.08(b) of the Disclosure Schedules, there are no material disputes pending or threatened under any Material Contract or any other Contract to which Target or Telemed are parties or by which their assets or the Target Ownership Interests are bound.
Section 4.09 Title to Assets . Target and Telemed have good, marketable and valid title to, or a valid leasehold interest in, all of the assets used thereby in connection with their respective businesses or otherwise purported to be owned or leased thereby. All such assets (including leasehold interests) are free and clear of Encumbrances except for the following (collectively referred to as Permitted Encumbrances ):
(a) Encumbrances granted in favor of Parent under the Loan Agreement or the other agreements executed in connection therewith;
(b) liens for Taxes not yet due and payable or being contested in good faith by appropriate procedures and for which there are adequate accruals or reserves on the Balance Sheet and the Interim Balance Sheet;
(c) mechanics, carriers, workmens, repairmens or other like liens arising or incurred in the ordinary course of business consistent with past practice or amounts that are not delinquent and which are not, individually or in the aggregate, material to Target or Telemed and for which there are adequate accruals or reserves on the Balance Sheet and the Interim Balance Sheet; and
(d) workers or unemployment compensation liens arising in the ordinary course of business, which are not delinquent or past due.
Section 4.10 [Reserved] .
Section 4.11 Real Property .
(a) Neither Target nor Telemed owns, has an ownership interest in, or has ever owned, any real property.
(b) Section 4.11(b) of the Disclosure Schedules sets forth each parcel of real property leased by Target or Telemed and used in or necessary for the conduct of their respective business as currently conducted (together with all rights, title and interest of Target and Telemed in and to leasehold improvements relating thereto, including, but not limited to, security deposits, reserves or prepaid rents paid in connection therewith, collectively, the Leased Real Property ), and a true and complete list of all leases, subleases, licenses, concessions and other agreements (whether written or oral), including all amendments, extensions renewals, guaranties and other agreements with respect thereto, pursuant to which Target or Telemed holds any Leased Real Property (collectively, the Leases ). The Target Parties have delivered to Parent a true and complete copy of each Lease. With respect to each Lease:
(i) such Lease is valid, binding, enforceable and in full force and effect, and Target and Telemed enjoy peaceful and undisturbed possession of the Leased Real Property;
(ii) neither Target nor Telemed in breach or default under such Lease, and other than previous breaches that have been cured or waived, no event has occurred or circumstance exists which, with the delivery of notice, passage of time or both, would constitute such a breach or default, and Target and Telemed have paid all rent due and payable under such Lease;
(iii) No Target Party has received nor given any notice of any default or event that with notice or lapse of time, or both, would constitute a default by Target or Telemed under any of the Leases and, to the Knowledge of the Target Parties, no other party is in default thereof, and no party to any Lease has exercised any termination rights with respect thereto, other than notices regarding previous breaches that have been cured or waived;
(iv) Neither Target nor Telemed subleased, assigned or otherwise granted to any Person the right to use or occupy such Leased Real Property or any portion thereof; and
(v) Neither Target nor Telemed pledged, mortgaged or otherwise granted an Encumbrance on its leasehold interest in any Leased Real Property.
(c) No Target Party has received any written notice of (i) violations of building codes and/or zoning ordinances or other governmental or regulatory Laws affecting the Leased Real Property, (ii) existing, pending or threatened condemnation proceedings affecting the Leased Real Property, or (iii) existing, pending or threatened zoning, building code or other moratorium proceedings, or similar matters which could reasonably be expected to adversely affect the ability to operate the Leased Real Property as currently operated. No material portion of any Leased Real Property has been damaged or destroyed by fire or other casualty.
Section 4.12 Intellectual Property .
(a) Section 4.12(a) of the Disclosure Schedules lists all (i) Intellectual Property Registrations and (ii) Intellectual Property Assets that are not registered but that are material to the operation of Targets or Telemeds business. All required filings and fees related to the Intellectual Property Registrations have been timely filed with and paid to the relevant Governmental Authorities and authorized registrars, and all Intellectual Property Registrations are otherwise in good standing. The Target Parties have provided Parent with true and complete copies of file histories, documents, certificates, office actions, correspondence and other materials related to all Intellectual Property Registrations.
(b) Target and Telemed own, exclusively or jointly with other Persons, all right, title and interest in and to the Intellectual Property Assets, free and clear of Encumbrances. Without limiting the generality of the foregoing, Target and Telemed entered into binding, written agreements with every current and former employee thereof, and with every current and former independent contractor, whereby such employees and independent contractors (i) assign to Target or Telemed, as applicable, any ownership interest and right they may have in the Intellectual Property Assets; and (ii) acknowledge Target or Telemeds, as applicable, exclusive ownership of all Intellectual Property Assets. The Target Parties have provided Parent with true and complete copies of all such agreements. Each of Target and Telemed is in full compliance with all legal requirements applicable to the Intellectual Property Assets and the ownership and use thereof. With respect to each of the Intellectual Property Assets, except as specified in Section 4.12(b) of the Disclosure Schedules, (i) each Intellectual Property Asset is not subject to any outstanding injunction, judgment, order, decree, ruling, or charge; (ii) action, suit, proceeding, hearing, investigation, charge, complaint, claim, or demand is pending or, to the Knowledge of the Target Parties, is threatened which challenges the legality, validity, enforceability, use, or ownership of the Intellectual Property Assets; (iii) neither Target nor Telemed has agreed to indemnify any Person for or against any interference, infringement, misappropriation, or other conflict with respect to the Intellectual Property Assets; and (iv) no loss or expiration of the Intellectual Property Assets is threatened, or pending, except for patents or trademarks expiring at the end of their statutory terms or domain registrations expiring at the end of their contractual terms.
(c) Section 4.12(c) of the Disclosure Schedules lists all material Intellectual Property Licenses and the third party that owns the Intellectual Property subject to such Intellectual Property Licenses. The Target Parties have provided Parent with true and complete copies of all such material Intellectual Property Licenses. All such material Intellectual Property Licenses are valid, binding and enforceable between Target or Telemed, as applicable, and the other parties thereto, and Target, Telemed and to the Knowledge of the Target Parties, such other parties are in full compliance with the terms and conditions of such Intellectual Property Licenses. Target and Telemed have obtained and possesses valid licenses to use all of the software programs present on the computers and other software-enabled electronic devices owned or leased thereby or that have otherwise been provided to their employees for their use in connection with the Business.
(d) The Intellectual Property Assets and Intellectual Property Licenses as currently or formerly owned, licensed or used by Target and Telemed, and the conduct of their respective businesses as currently and formerly conducted by Target and Telemed have not, do not and will not infringe, violate or misappropriate the Intellectual Property of any Person. No Target Party has received any communication, and no Action has been instituted, settled or, to the Knowledge of the Target Parties, threatened that alleges any such infringement, violation or misappropriation, and none of the Intellectual Property are subject to any outstanding Governmental Order.
(e) Section 4.12(e) of the Disclosure Schedules lists all licenses, sublicenses and other agreements pursuant to which Target or Telemed grants rights or authority to any Person with respect to any Intellectual Property Assets or Intellectual Property Licenses. The Target Parties have provided Parent with true and complete copies of all such agreements. All such agreements are valid, binding and enforceable between Target or Telemed, as applicable, and the other parties thereto, and Target, Telemed and to the Knowledge of the Target Parties, such other parties are in full compliance with the terms and conditions of such agreements. To the Knowledge of the Target Parties, no Person has infringed, violated or misappropriated, or is infringing, violating or misappropriating, any Intellectual Property Assets.
(f) Target and Telemed have taken all necessary action to maintain and protect all of the material Intellectual Property Assets so as not to adversely affect the validity or enforceability thereof
(g) Neither Target nor Telemed use any inventions of any of their employees made prior to their employment by Target or Telemed, as applicable. Each employee has assigned to Target or Telemed all Intellectual Property rights he or she developed while employed by Target that are related to Targets Business.
(h) Neither Target nor Telemed has embedded any open source, copyright or community source code in any of its products generally available or in development, including but not limited to any libraries or code licensed under any license arrangement.
(i) Targets and Telemeds owned and licensed software and the related computer hardware used in connection with their respective businesses are adequate in all material
respects, when taken together with their other assets, to run their respective businesses in the same manner as such business is now conducted.
(j) Target and Telemed complied with all privacy regulations as mandated by Law and/or as required by third parties, as well as all privacy regulations set forth within the Targets or Telemeds privacy policies and websites.
Section 4.13 Accounts Receivable and Accounts Payable .
(a) The Accounts Receivable reflected on the Interim Balance Sheet and the Accounts Receivable arising after the date thereof (a) have arisen from bona fide transactions entered into by Target involving the sale of goods or the rendering of services in the ordinary course of business consistent with past practice; (b) constitute only valid, undisputed claims of Target not subject to Encumbrances or claims of set-off or other defenses or counterclaims; and (c) subject to a reserve for bad debts shown on the Interim Balance Sheet or, with respect to Accounts Receivable arising after the Interim Balance Sheet Date, on the accounting records of Target, are collectible in full, without any set-off within 90 days after billing. The reserve for bad debts shown on the Interim Balance Sheet or, with respect to Accounts Receivable arising after the Interim Balance Sheet Date, on the accounting records of Target have been determined in accordance with GAAP, consistently applied, subject to normal year-end adjustments and the absence of disclosures normally made in footnotes. Section 4.13(a) of the Disclosure Schedules set forth a complete and accurate list of all Accounts Receivable as of the Interim Balance Sheet Date, including the aging of each Account Receivable. No account debtor with respect to any of such Accounts Receivable is a Governmental Authority (including any Federal healthcare program). No Target Party has received notice of the bankruptcy or insolvency of the account debtor of any Accounts Receivable. None of such Accounts Receivable is evidenced by a judgment or chattel paper.
(b) All accounts payable reflected on the Interim Balance Sheet or arising thereafter are the result of bona fide transactions in the ordinary course of business and have been paid, are not yet due or payable or are otherwise subject to good faith dispute by Target or Telemed and described on Section 4.13(b) of the Disclosure Schedules. Since the Balance Sheet Date, neither Target nor Telemed has not altered in any material respects their practices for the payment of such accounts payable.
Section 4.14 Customers and Suppliers .
(a) Section 4.14(a) of the Disclosure Schedules sets forth with respect to Target and Telemed (i) each customer (including without limitation any insurer, managed care entity, payor, employer, or other provider) who has accounted for aggregate gross revenue of Target and Telemed in an amount greater than or equal to $35,000 during the twelve (12) months ended July 31, 2013 (collectively, the Material Customers ); and (ii) the amount of consideration paid by each Material Customer during such periods. Except as specified in Section 4.14(a) of the Disclosure Schedules, no Target Party has received any notice, and or has reason to believe, that any of the Material Customers has ceased, or intends to cease after the Closing, to use the goods or services of Target or to otherwise terminate or materially reduce its relationship with Target. Each Material Customer has transacted business with Target and Telemed and otherwise
acted substantially in accordance with the terms of its Contract consistent with the established course of conduct over the last twelve (12) months. Except as specified in Section 4.14(a) of the Disclosure Schedules, no such Material Customer has sought a material reduction in the prices it currently pays for services of Target and Telemed, the level or scope of services it receives from Target or Telemed or any other material modification of any payment term or other material term applicable to its purchases of services from Target or Telemed, and to the Knowledge of the Target Parties, except as specified in Section 4.14(a) of the Disclosure Schedules, there are no facts which may reasonably be expected to indicate that any material adverse change may occur in the business relationship with any Material Customer..
(b) Section 4.14(b) of the Disclosure Schedules sets forth with respect to Target and Telemed (i) each supplier or vendor to whom Target and Telemed paid aggregate consideration for goods or services rendered in an amount greater than or equal to $10,000 during the twelve (12) months ended July 31, 2013 (collectively, the Material Suppliers ); and (ii) the amount of purchases from each Material Supplier during such periods. Except as specified in Section 4.14(a) of the Disclosure Schedules No Target Party has received any notice, and or has reason to believe, that any of the Material Suppliers has ceased, or intends to cease, to supply goods or services to Target or to otherwise terminate or materially reduce its relationship with Target. Each Material Supplier has transacted business with Target and Telemed and otherwise acted substantially in accordance with the terms of its Contract consistent with the established course of conduct over the last twelve (12) months. No such Material Supplier has sought a material increase in the prices it currently charges for services or products it provides to Target or Telemed, the level or scope of products or services it provides to Target or Telemed or any other material modification of any payment term or other material term applicable to its sales of products or services to Target or Telemed, and to the Knowledge of the Target Parties, except as specified in Section 4.14(b) of the Disclosure Schedules, there are no facts which may reasonably be expected to indicate that any material adverse change may occur in the business relationship with any such Material Supplier.
Section 4.15 Insurance . Section 4.15 of the Disclosure Schedules sets forth (a) a true and complete list of all current policies or binders of fire, liability, product liability, umbrella liability, real and personal property, workers compensation, vehicular, fiduciary liability and other casualty and property insurance maintained by Target, Telemed or their Affiliates (collectively, the Insurance Policies ); (b) each Insurance Policys applicable deductibles, coverage limits and whether or not such Insurance Policy provides coverage on an occurrence basis; and (c) a list of all pending claims and the claims history for Target and Telemed for the past five (5) years. To the Knowledge of the Target Parties, there are no grounds to believe that Target will not be able to renew such insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost. There are no claims related to Target or Telemed pending under any such Insurance Policies as to which coverage has been questioned, denied or disputed or in respect of which there is an outstanding reservation of rights. Neither Target, Telemed nor their Affiliates has received any written notice of cancellation of, premium increase with respect to, or alteration of coverage under, any of such Insurance Policies, that has not been cured or withdrawn. All premiums due on such Insurance Policies have either been paid or, if not yet due, accrued. All such Insurance Policies (a) are in full force and effect and enforceable in accordance with their terms; (b) are provided by carriers who are financially solvent; and
(c) have not been subject to any lapse in coverage. None of Target, Telemed nor their Affiliates is in default under, or has otherwise failed to comply with, in any material respect, any provision contained in any such Insurance Policy. Neither Target nor Telemed has reached or exceeded its policy limits for any insurance policy in effect at any time during the past five (5) years. The Insurance Policies are of the type and in the amounts customarily carried by Persons conducting a business similar to the Business and are sufficient for compliance with all applicable Laws and Contracts to which Target or Telemed is a party or by which they is bound. True and complete copies of the Insurance Policies have been made available to Parent.
Section 4.16 Legal Proceedings; Governmental Orders .
(a) Except as specified in Section 4.16(a) of the Disclosure Schedules, there is not currently, nor within the last three (3) years have there been, any Actions pending or, to the Knowledge of the Target Parties, threatened (a) against, related to or involving Target, Telemed, or their respective businesses, or any officer, director, employee or agent of Target or Telemed relating to Target, Telemed, or their respective businesses; (b) that challenge or seek to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement or the Transaction Documents; or (c) that would otherwise reasonably be expected to have a Material Adverse Effect. To the Knowledge of the Target Parties, no event has occurred or circumstances exist that may give rise to, or serve as a basis for, any such Action. There is no Action pending by Target or Telemed, or which Target or Telemed intend to initiate.
(b) Except as specified in Section 4.16(a) of the Disclosure Schedules, there are no outstanding Governmental Orders and no unsatisfied judgments, penalties or awards against, relating to or affecting the Target, Telemed, or their respective businesses or any officer, director, employee or agent of Target or Telemed.
Section 4.17 Compliance with Laws; Permits .
(a) Except as specified in Section 4.17(a) of the Disclosure Schedules, each of Target, Telemed and their respective businesses has been operated at all times since its inception, and currently is, in compliance in all respects with all Laws or other rules or regulations of any Governmental Authority applicable to Target, Telemed, their respective businesses or the Target Ownership Interests, or by which any property, business or asset of Target or Telemed is bound or affected, relating to the operation of its business as heretofore conducted, including without limitation: (i) Laws or other rules or regulations of any Governmental Authority governing any federal health care program, including without limitation the Medicare and Medicaid programs and Law relating to health care fraud and abuse and referrals, including, without limitation: (A) the Anti-Kickback Law, 42 U.S.C. § 1320a 7b, 42 C.F.R. § 1001.952, (B) the Civil Monetary Penalties Law, 42 U.S.C. § 1320a 7a, (C) the physician self-referral prohibition, 42 U.S.C. § 1395nn, 42 C.F.R. § 411.351 et seq., (D) the False Claims Act, 31 U.S.C. § 3729 et seq., (E) the CHAMPUS statute (10 U.S.C. § 1071 et seq.), (F) the False Statement Accountability Act (18 U.S.C. § 1001), and (G) the Program Fraud Civil Penalties Act (31 U.S.C. § 3810 et seq.); (ii) state Laws or other rules or regulations relating to health care fraud and abuse and referrals; (iii) state Laws or other rules or regulations relating to Medicaid or any other state health care or health insurance programs; (iv) state Laws or other rules or regulations (including those rules and regulations followed by state boards of medicine) relating
to the unlawful practice of medicine by physicians or corporations, aiding or abetting the unlicensed practice of medicine, unprofessional conduct, false, deceptive or misleading advertising, filling prescriptions or providing medical care across state lines, fee-splitting, or the payment of referral fees; (v) federal or state Laws or other rules or regulations relating to the manner of handling, processing, and timely paying claims for payment for health care items or services; and (vi) other federal or state Laws or other rules or regulations relating to fraudulent, abusive or unlawful practices connected in any way with the provision of health care items or services or the billing or payment for such items or services.
(b) Since its inception, neither Target, Telemed nor any director, officer, employee or agent thereof, with respect to actions taken on behalf of Target or Telemed, or any physician employed by or under contract with Target or Telemed (an Engaged Professional ) with respect to actions taken on behalf of Target or Telemed (i) has been assessed a civil money penalty under Section 1128A of the Social Security Act (42 U.S.C. § 1320a 7a) or any regulations promulgated thereunder, (ii) has been excluded from participation in any federal health care program or state health care program (as such terms are defined by the Social Security Act), (iii) has been convicted of any criminal offense or has engaged in any act or conduct that would be a grounds for mandatory or permissive exclusion from participation in any federal health care program under Section 1128 of the Social Security Act (42 U.S.C. § 1320a 7), or (iv) is a party to or subject to any action or proceeding concerning any of the matters described above in clauses (i) through (iii).
(c) Target, Telemed, their respective businesses and to the Knowledge of the Target Parties each Engaged Professional, is in compliance, to the extent applicable, with the terms and provisions of all Laws or other rules or regulations of any Governmental Authority relating to patient or individual healthcare information, including, without limitation, the Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104 191, as amended, and any rules or regulations promulgated thereunder and similar state laws (collectively, the Healthcare Information Laws ). Except as specified in Section 4.17(c) of the Disclosure Schedules, Target and Telemed have (i) undertaken all necessary surveys, audits, inventories, reviews, analyses, or assessments (including any necessary risk assessments) on all privacy, security and other areas required for compliance under all Healthcare Information Laws to the extent applicable to Targets and Telemeds operations as heretofore conducted, (ii) taken all steps necessary to be in compliance with all Healthcare Information Laws to the extent applicable to Targets and Telemeds operations as heretofore conducted (the Compliance Plan ) and (iii) implemented those provisions of the Compliance Plan to ensure that Target, Telemed, their respective businesses and each Engaged Professional are and will remain in compliance with all Healthcare Information Laws.
(d) All Permits required for Target, Telemed, and to the Knowledge of the Target Parties each Engaged Professional to conduct their respective businesses as currently conducted or for the ownership and use of their respective assets have been obtained by Target, Telemed and each Engaged Professional and are valid and in full force and effect. Each of Target, Telemed and each Engaged Professional is in compliance with all such Permits, and there are no provisions in, or Contracts relating to, any such Permits which preclude or restrict Target or Telemed from operating their respective businesses as they are currently operated. All fees and charges with respect to such Permits as of the date hereof have been paid in full. Section 4.17(d)
of the Disclosure Schedules lists all current Permits issued to Target or Telemed, including the names of the Permits and their respective dates of issuance and expiration. No event has occurred that, with or without notice or lapse of time or both, would reasonably be expected to result in the revocation, suspension, lapse or limitation of any Permit required to be set forth in Section 4.17(d) of the Disclosure Schedules.
(e) None of Target, Telemed nor any Engaged Professional acting on their behalf has performed services for, nor received payment for services from, any Governmental Authority (including any federal healthcare program).
Section 4.18 Environmental Matters .
(a) The operations of Target, Telemed and their respective businesses are currently and have at all times been in compliance with all Environmental Laws. No Target Party has received from any Person, with respect to Target, Telemed or their respective businesses, any: (i) Environmental Notice or Environmental Claim; or (ii) written request for information pursuant to Environmental Law, which, in each case, either remains pending or unresolved, or is the source of ongoing obligations or requirements.
(b) There has been no Release of Hazardous Materials in contravention of Environmental Law with respect to the business of Target or Telemed or any real property currently or formerly owned, leased or operated by Target or Telemed, and no Target Party has received an Environmental Notice that any of the business of Target or Telemed or real property currently or formerly owned, leased or operated by Target or Telemed (including soils, groundwater, surface water, buildings and other structure located thereon) has been contaminated with any Hazardous Material which could reasonably be expected to result in an Environmental Claim against, or a violation of Environmental Law or term of any Environmental Permit by, Target or Telemed.
(c) Neither Target nor Telemed has retained or assumed, by Contract or operation of Law, any liabilities or obligations of third parties under Environmental Law.
Section 4.19 Employee Benefit Matters .
(a) Section 4.19(a) of the Disclosure Schedules sets forth a correct and complete list of all Benefit Plans and Benefit Agreements.
(b) Each Benefit Plan that is intended to be qualified under Section 401(a) of the Code, and each trust that is related to a Benefit Plan and intended to be Tax exempt under Section 501(a) of the Code, has been determined by the Internal Revenue Service to be qualified under Section 401(a) of the Code or exempt from taxation under Section 501(a) of the Code or the Target has received an opinion letter from the Internal Revenue Service with respect to the compliance in form of such Benefit Plan documents with Section 401(a) of the Code and, to the Knowledge of the Target Parties, nothing has occurred that would adversely affect the qualification or Tax exemption of any such Benefit Plan or related trust. Each Benefit Plan has been administered in all material respects in accordance with its terms. The Target, Telemed and all the Benefit Plans are all in compliance in all material respects with the applicable provisions of ERISA, the Code and all other applicable Laws, including Laws of foreign jurisdictions. To
the Knowledge of the Target Parties, with respect to each Benefit Plan and Benefit Agreement, the Target and Telemed have provided to participants all material communications or disclosures required by Law or by the terms of such Benefit Plan or Benefit Agreement.
(c) No Benefit Plan or employee benefit plan maintained by an ERISA Affiliate (i) is subject to Title IV of ERISA or Section 412 of the Code or is a multiemployer pension plan (within the meaning of Section 3(37) or 4001(a)(3) of ERISA) or a multiple employer plan (within the meaning of Section 4063 of ERISA) or (ii) provides for post-retirement or other post-employment welfare benefits (other than health care continuation coverage as required by applicable Law). Neither the Target nor any other Person that, together with the Target, is treated as a single employer under Section 414 of the Code has, within the prior six (6) years, sponsored, maintained, contributed to or been required to contribute to any such plan.
(d) Except as may be required by applicable Law, or as contemplated under this Agreement, neither the Target nor Telemed has any announced plan or commitment to create any additional Benefit Plans which are intended to cover employees or former employees of the Target or Telemed or to amend or modify any existing Benefit Plan which covers or has covered employees or former employees of the Target or Telemed, or to create, amend or modify any Benefit Agreement.
(e) To the extent applicable, correct and complete copies of the following have been delivered or made available to Parent by the Target: (i) all Benefit Plans and Benefit Agreements (including all amendments and attachments thereto); (ii) written summaries of any Benefit Plan and any Benefit Agreement not in writing; (iii) all related trust documents; (iv) all insurance Contracts or other funding arrangements; (v) the most recent annual report (Form 5500) filed with the Internal Revenue Service; (vi) the most recent determination letter from the Internal Revenue Service, if any; and (vii) the most recent summary plan description and any summary of material modification thereto.
(f) There are no investigations, examinations, audits or proceedings by any Governmental Authority with respect to or involving any Benefit Plan or any fiduciary thereof, and to the Knowledge of the Target Parties, there are not any facts that would reasonably be expected to give rise to any such investigation, examination, audit or proceeding. There are no Actions, claims, suits or proceeding against or involving any Benefit Plan or Benefit Agreement or asserting any rights or claims to benefits under any Benefit Plan or Benefit Agreement (except claims for benefits payable in the normal operation of the Benefit Plan or Benefit Agreement), and, to the Knowledge of the Target Parties, there are not any facts that would reasonably be expected to give rise to any such Action, claim, suit or proceeding.
(g) With respect to each Benefit Plan, (i) (A) there has not occurred prior to the date hereof any prohibited transaction (within the meaning of Section 406 of ERISA or Section 4975 of the Code) that could subject the Target or Telemed or any of their respective employees to any material liability and (B) following the date hereof, there will not occur any prohibited transaction (within the meaning of Section 406 of ERISA or Section 4975 of the Code) that could subject Parent of the Surviving Corporation or any of their respective employees to any Liabilities that, in the case of this clause (i)(B), would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect and (ii) neither the Target nor Telemed
nor any of their directors, employees or agents has engaged in any transaction or acted in a manner, or failed to act in a manner, that would reasonably be expected to subject the Target or Telemed or any of their respective employees to liability for breach of fiduciary duty under ERISA or any other applicable Law.
(h) Section 4.19(h) of the Disclosure Schedules discloses whether each Benefit Plan and each Benefit Agreement that is an employee welfare benefit plan is (i) unfunded or self-insured, (ii) funded through a welfare benefit fund, as such term is defined in Section 419(e) of the Code, or other funding mechanism or (iii) insured.
(i) None of the execution and delivery of this Agreement nor the Transaction Documents, the obtaining of the approval of Targets Stockholders or the consummation of the Merger or any other transaction contemplated hereby or thereby (whether alone or as a result of any termination of employment on or following the Effective Time) will, except as expressly contemplated by this Agreement, (i) entitle any Participant to severance, termination, retention, change in control or similar compensation or benefits, (ii) accelerate the time of payment or vesting, or trigger any payment or funding (through a grantor trust or otherwise) of, compensation or benefits under, increase the amount payable or trigger any other material obligation pursuant to any Benefit Plan or Benefit Agreement or (iii) prohibit any Benefit Plan or Benefit Agreement from being amended or terminated.
(j) Except as would not reasonably be expected to give rise to material Liability, the Target and Telemed have correctly classified each individual who performs services for the Target or Telemed as a common law employee, an independent contractor, or a leased employee, as applicable, in accordance with the provisions of each Benefit Plan, and in accordance with ERISA, the Code, and other applicable Laws.
(k) Each Benefit Plan and each Benefit Agreement that is a nonqualified deferred compensation plan within the meaning of Section 409A(d)(1) of the Code (a Nonqualified Deferred Compensation Plan ) subject to Section 409A of the Code was, as of January 1, 2005, in good faith compliance with Section 409A of the Code and the then applicable guidance issued by the Internal Revenue Service thereunder (together, the 409A Authorities ). Since December 31, 2008, each Nonqualified Deferred Compensation Plan has remained in documentary and operational compliance with the 409A Authorities. No Participant is entitled to any gross-up, make-whole or other additional payment from the Target or Telemed in respect of any Tax (including federal, state, local or foreign income, excise or other Taxes (including Taxes imposed under Sections 280G and 409A of the Code)) or interest or penalty related thereto.
(l) Other than payments or benefits that may be made to the Persons listed in Section 4.19(1) of the Disclosure Schedules, no amount or other entitlement or economic benefit that could be received (whether in cash or property or the vesting of property) as a result of the execution and delivery of this Agreement or the Transaction Documents, the obtaining of the approval of Targets Stockholders or the consummation of the Merger or any other transaction contemplated hereby or thereby (alone or in combination with any other event, including as a result of termination of employment on or following the Effective Time) by or for the benefit of any Person who is a disqualified individual (as defined in Treasury Regulation Section 1.280G-1) with respect to the Target under any Benefit Plan, Benefit Agreement or
otherwise would be characterized as an excess parachute payment (as defined in Section 280G(b)(1) of the Code).
(m) With respect to each Benefit Plan that is an employee pension benefit plan (as such term is defined in Section 3(2) of ERISA), all contributions (including all employer contributions and employee salary reduction contributions) that are due have been made within the time periods prescribed by ERISA and the Code, and all contributions for any period ending on or before the Effective Time which are not yet due have been made to each such employee pension benefit plan or accrued in accordance with GAAP. With respect to each Benefit Plan that is an employee welfare benefit plan (as such term is defined in Section 3(1) of ERISA), all premiums or other payments for all periods ending on or before the Effective Time have been paid or accrued in accordance with GAAP.
Section 4.20 Employment Matters .
(a) Section 4.20(a) of the Disclosure Schedules contains a list of all Persons who are currently employees, independent contractors or consultants of Target or Telemed (including all Engaged Professionals currently engaged or employed by Target or Telemed), and sets forth for each such individual the following: (i) name; (ii) title or position (including whether full or part time); (iii) hire date; (iv) current annual base compensation rate; (v) commission, bonus or other incentive-based compensation; and (vi) a description of the fringe benefits currently provided to each such individual. Except as set forth on Section 4.20(a) of the Disclosure Schedules, neither Target nor Telemed is party to any employee agreement, independent contractor agreement or other Contract with any employee or independent contractor. As of the date hereof, all compensation, including wages, commissions and bonuses payable to employees, independent contractors or consultants of Target or Telemed (including all Engaged Professionals) for services performed on or prior to the date hereof have been paid in full.
(b) Neither Target nor Telemed is, or has ever been, a party to, bound by, or negotiating any collective bargaining agreement or other Contract with a union, works council or labor organization (collectively, Union ), and there is not now, nor have there ever been, any Union representing or purporting to represent any employee of Target or Telemed, and, to the Knowledge of the Target Parties, no Union or group of employees is seeking or has sought to organize employees for the purpose of collective bargaining. Except as set forth in Section 4.20(b) of the Disclosure Schedules, there has never been, nor has there been any threat of, any strike, slowdown, work stoppage, lockout, concerted refusal to work overtime or other similar labor disruption or dispute affecting Target, Telemed or any employees, independent contractors or consultants of Target or Telemed (including any Engaged Professionals). Neither Target nor Target has any duty to bargain with any Union.
(c) Each of Target and Telemed is and has been in compliance with all applicable Laws pertaining to employment and employment practices, including all Laws relating to labor relations, equal employment opportunities, fair employment practices, employment discrimination, harassment, retaliation, reasonable accommodation, disability rights or benefits, immigration, wages, hours, overtime compensation, child labor, hiring, promotion and termination of employees, working conditions, meal and break periods, privacy, health and safety, workers compensation, leaves of absence and unemployment insurance. All individuals
characterized and treated by Target or Telemed as consultants or independent contractors of Target or Telemed are properly treated as independent contractors under all applicable Laws. All employees of Target or Telemed classified as exempt under the Fair Labor Standards Act and state and local wage and hour laws are properly classified. There are no Actions against Target or Telemed pending, or to the Knowledge of the Target Parties, threatened to be brought or filed, by or with any Governmental Authority or arbitrator in connection with the employment of any current or former applicant, employee, consultant or independent contractor of Target or Telemed, including, without limitation, any claim relating to unfair labor practices, employment discrimination, harassment, retaliation, equal pay, wages and hours or any other employment related matter arising under applicable Laws.
(d) Each of Target and Telemed has complied in all respects with the WARN Act.
Section 4.21 Taxes . Except as set forth in Section 4.21 of the Disclosure Schedules:
(a) All Tax Returns required to be filed by Target or Telemed for any Pre-Closing Tax Period have been, or will be, timely filed. Such Tax Returns are, or will be, true, complete and correct in all respects. All Taxes due and owing by Target or Telemed (whether or not shown on any Tax Return) have been, or will be, timely paid.
(b) To the Knowledge of the Target Parties, the unpaid Taxes of Target and Telemed for all Tax periods do not exceed the Estimated Closing Accrued Tax Amount.
(c) Target and Telemed have withheld and paid each Tax required to have been withheld and paid in connection with amounts paid or owing to any employee, independent contractor, creditor, customer, stockholder or other party, and complied with all information reporting and backup withholding provisions of applicable Law.
(d) Target and Telemed have delivered or made available to Parent (i) complete and correct copies of all Tax Returns of Target and Telemed relating to Taxes for all taxable periods for which the applicable statute of limitations has not yet expired, (ii) complete and correct copies of all private letter rulings, revenue agent reports, information document requests, notices of proposed deficiencies, deficiency notices, protests, petitions, closing agreements, settlement agreements, pending ruling requests and any similar documents submitted by, received by, or agreed to by or on behalf of Target or Telemed relating to Taxes for any taxable period for which the statute of limitations has not yet expired and (iii) complete and correct copies of all material agreements, rulings, settlements or other Tax documents with or from any Governmental Authority relating to Tax incentives of the Target or Telemed.
(e) No extensions or waivers of statutes of limitations have been given or requested with respect to any Taxes of Target or Telemed.
(f) All deficiencies asserted, or assessments made, against Target or Telemed as a result of any examinations by any taxing authority have been fully paid.
(g) Neither Target nor Telemed is a party to any Action by any taxing authority. There are no pending or, to the Knowledge of the Target Parties, threatened Actions by any
taxing authority against or involving Target, Telemed, their respective businesses or the Target Ownership Interests.
(h) Neither Target nor Telemed is (or within the past three (3) calendar years has been) a party to any engagement relating to the sharing of Tax benefits or Liabilities.
(i) Neither Target nor Telemed has been informed by any jurisdiction that such entity has not filed a Tax Return that the jurisdiction believes Target or Telemed was required to file.
(j) Neither Target nor Telemed is or has ever been a member of a group of corporations with which it has filed (or been required to file) consolidated, combined or unitary Tax Returns. Neither Target nor Telemed has any actual or potential liability under Treasury Regulations Section 1.1502-6 (or any comparable or similar provision of state, local or foreign Law), as a transferee or successor, pursuant to any contractual obligation, or otherwise for any Taxes of any Person other than Target or Telemed.
(k) There are no Encumbrances for Taxes upon any of the assets of Target or Telemed nor, to the Knowledge of the Target Parties, is any taxing authority in the process of imposing any Encumbrances for Taxes on any of the assets of Target or Telemed (other than for current Taxes not yet due and payable).
(l) Neither Target nor Telemed is, or has been, a United States real property holding corporation within the meaning of Section 897(c) of the Code during the applicable period specified in Code Section 897(c)(1)(A)(ii).
(m) Neither Target nor Telemed is, or has been, a party to, or a promoter of, a reportable transaction within the meaning of Section 6707A(c)(1) of the Code and Treasury Regulations Section 1.6011-4(b).
(n) None of the assets of Target or Telemed is tax-exempt use property within the meaning of Section 168(h) of the Code.
(o) The consummation of the transactions contemplated by this Agreement will not result in any liability to Target, Telemed, Parent, or the Surviving Corporation for transfer, documentary, sales, use, stamp, registration, value added and other such Taxes and fees (including any penalties and interest) incurred in connection with this Agreement and the other Transaction Documents (including any real property transfer Tax and any other similar Tax).
(p) Neither Target nor Telemed (i) is a party to any joint venture, partnership, or other arrangement that is treated as a partnership for federal income Tax purposes, (ii) has made an entity classification (check-the-box) election under Section 7701, (iii) is or, to the Knowledge of the Target Parties, has ever been a stockholder of a controlled foreign corporation as defined in Section 957 of the Code (or any similar provision of state, local or foreign Law), or (iv) is or, to the Knowledge of the Target Parties, has ever been a stockholder in a passive foreign investment company within the meaning of Section 1297 of the Code.
(q) Neither Target nor Telemed has a request for a private letter ruling, a request for administrative relief, a request for technical advice, a request for a change of any method of
accounting, or any other similar request that is in progress or pending with any Governmental Authority with respect to Taxes or Tax Returns.
(r) Neither Parent nor the Surviving Corporation shall be required to include an item of income, or exclude an item of deduction, for any period after the Closing Date as a result of: (i) an installment sale transaction by Target or Telemed occurring on or before the Closing governed by Section 453 of the Code (or any similar provision of state, local or non-U.S. Laws); (ii) a transaction by Target or Telemed occurring on or before the Closing Date reported as an open transaction for U.S. federal Income Tax purposes (or any similar doctrine under state, local or non-U.S. Laws); (iii) any prepaid amounts received on or prior to the Closing Date by Target or Telemed; (iv) a change in any Targets or Telemeds method of accounting on or prior to the Closing Date; or (v) an agreement entered into by Target or Telemed with any Governmental Authority (including a closing agreement under Section 7121 of the Code) on or prior to the Closing Date. Neither Target nor Telemed has made an election (including a protective election) pursuant to Section 108(i) of the Code. Neither Target nor Telemed has any long-term contracts that are subject to a method of accounting provided for in Section 460 of the Code.
(s) Neither Target nor Telemed has made any payment, nor is obligated to make any payment or is a party to any agreement, Contract, arrangement or plan that could obligate it to make any payment, that may be treated as an excess parachute payment under Section 280G of the Code.
(t) Except as set forth on Section 4.21 of the Disclosure Schedules, neither Target nor Telemed is a party to any agreement to pay, gross up or otherwise indemnify any employee, consultant or independent contractor for any Taxes, including potential Taxes imposed under Sections 409A or 4999 of the Code, incurred with respect to services provided to Target or Telemed.
(u) Target has not distributed to its stockholders or securityholders any stock or securities of a controlled corporation, nor has stock or securities of Target been distributed, in a transaction to which Section 355 of the Code applies in the two (2) years prior to the date of this Agreement.
(v) Telemed has been since its formation treated as a disregarded entity for federal income Tax purposes. No election is pending to change the income Tax treatment of Telemed. No Governmental Authority has challenged the federal income Tax treatment of Telemed.
Section 4.22 Brokers . Except set forth on Section 4.22 of the Disclosure Schedules (any Persons listed on Section 4.22 of the Disclosure Schedules being referred to herein as a Broker ), no broker, finder or investment banker is entitled to any brokerage, finders or other fee or commission in connection with the transactions contemplated by this Agreement or any other Transaction Document based upon arrangements made by or on behalf of any Target Party.
Section 4.23 Network Redundancy and Computer Back Up . Except as could not reasonably be expected to have a Material Adverse Effect, Target has made backups of all computer software and databases utilized by it and maintains such software and databases at a secure off site location. Target and Telemed have established a data recovery plan sufficient to
restore service in a commercially reasonable amount of time in the event of a critical system failure or employs a remote failover system.
Section 4.24 Privacy of Customer Information . Neither Target nor Telemed uses any of the customer information it receives through its website or otherwise in a manner violative of the Targets and Telemeds privacy policy or the privacy rights of its customers under applicable Law.
Section 4.25 Inspections and Investigations . Except as set forth and described in Section 4.25 of the Disclosure Schedules, (i) neither Target, Telemed, nor to the Knowledge of the Target Parties, any Engaged Professional or other Person affiliated with the Target or Telemed or who has provided services to Target or Telemed during the past seven (7) years, has been the subject of any inspection, investigation, survey, audit, monitoring or other form of review by any Governmental Authority, trade association, professional review organization, accrediting organization or certifying agency based upon any alleged improper activity on the part of Target, Telemed or such individual where such alleged improper activity related to the operations of Target or Telemed, nor has any Target Party received any notice of deficiency during the past seven (7) years in connection with the operations of the Target or Telemed; (ii) there are not presently any outstanding deficiencies or orders of any Governmental Authority having jurisdiction over Target, Telemed or any of their assets or properties, or requiring conformity to any applicable agreement, Law, regulation, ordinance or bylaw; and (iii) there is not any notice of any claim, requirement or demand of any licensing or certifying agency or other third party supervising or having authority over the Target, Telemed or their assets or properties to conform to or comply with any existing Law, code, rule, regulation or standard. Attached as part of Section 4.25 of the Disclosure Schedules are copies of all reports, correspondence, notices and other documents relating to any matter described or referenced therein.
Section 4.26 Rates and Reimbursement Policies . Except for ethical limitations, the jurisdictions in which Target and Telemed conduct business do not currently impose any restrictions or limitations on rates which may be charged to patients receiving services provided by Target or Telemed. Neither Target nor Telemed has any rate appeal currently pending before any Governmental Authority. No Target Party has Knowledge of any applicable Law, which has been enacted, promulgated or issued within the twenty four (24) months preceding the date of this Agreement, or of any such legal requirement proposed or currently pending in the jurisdictions in which Target and Telemed do business, which could reasonably be expected to have a Material Adverse Effect or may require the Target to obtain any necessary authorization which it does not currently possess.
Section 4.27 No Disagreements with Accountants and Lawyers . Except as set forth in Section 4.27 of the Disclosure Schedules, there are no disagreements of any kind presently existing, or reasonably anticipated by the Target Parties to arise, between the accountants and lawyers formerly or presently employed by Target or Telemed, and Target and Telemed is current with respect to any fees owed to their accountants and lawyers.
Section 4.28 Solvency .
(a) Neither Target nor Telemed is Insolvent, and will not be rendered Insolvent by any of the transactions contemplated by this Agreement. As used in this Section, Insolvent means that the sum of the debts and other probable Liabilities of a Person exceeds the present fair saleable value of such Persons assets.
(b) Immediately after giving effect to the consummation of the transactions contemplated by this Agreement, (A) each of Target and Telemed (i) will be able to pay its Liabilities as they become due in the usual course of its business, (ii) will not have unreasonably small capital with which to conduct its present or proposed business, and (iii) will have assets (calculated at fair market value) that exceed its Liabilities, and (B) taking into account all pending and threatened litigation, final judgments against each of Target and Telemed in actions for money damages are not reasonably anticipated to be rendered at a time when, or in amounts such that, Target or Telemed will be unable to satisfy any such judgments promptly in accordance with their terms (taking into account the maximum probable amount of such judgments in any such actions and the earliest reasonable time at which such judgments might be rendered) as well as all other obligations of Target or Telemed.
Section 4.29 Full Disclosure . No representation or warranty by any Target Party in this Agreement and no statement contained in the Disclosure Schedules to this Agreement contains any untrue statement of a material fact, or omits to state a material fact necessary to make the statements contained therein, in light of the circumstances in which they are made, not misleading.
ARTICLE V
REPRESENTATIONS AND WARRANTIES OF PARENT
Parent represents and warrants to Target that the statements contained in this ARTICLE V are true and correct as of the date hereof and as of the Closing.
Section 5.01 Organization of Parent . Parent is a corporation duly organized, validly existing and in good standing under the Laws of the state of Delaware.
Section 5.02 Authority of Parent . Parent has full corporate power and authority to enter into this Agreement and the other Transaction Documents to which it is a party, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery by Parent of this Agreement and any other Transaction Document to which it is a party, the performance by it of its obligations hereunder and thereunder and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all requisite corporate action on the part of Parent. This Agreement has been duly executed and delivered by Parent, and (assuming due authorization, execution and delivery by Target) this Agreement constitutes a legal, valid and binding obligation of Parent enforceable against Parent in accordance with its terms. When each other Transaction Document to which Parent is or will be a party has been duly executed and delivered thereby (assuming due authorization, execution and delivery by each other party thereto), such
Transaction Document will constitute a legal and binding obligation of Parent, as applicable, enforceable against it in accordance with its terms.
Section 5.03 No Conflicts; Consents . The execution, delivery and performance by Parent of this Agreement and the other Transaction Documents to which it is a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not: (a) conflict with or result in a violation or breach of, or default under, any provision of the certificate of incorporation, by-laws or other organizational documents of Parent; (b) conflict with or result in a violation or breach of any provision of any Law or Governmental Order applicable to Parent; or (c) require the consent, notice or other action by any Person under any Contract to which Parent is a party. Other than the filing of the Certificate of Merger with the Secretary of State of the State of Delaware, no consent, approval, Permit, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required by or with respect to Parent in connection with the execution and delivery of this Agreement and the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby.
Section 5.04 Brokers . No broker, finder or investment banker is entitled to any brokerage, finders or other fee or commission in connection with the transactions contemplated by this Agreement or any other Transaction Document based upon arrangements made by or on behalf of Parent.
Section 5.05 Legal Proceedings . There are no Actions pending or, to Parents knowledge, threatened against or by Parent, or any Affiliate of Parent that challenge or seek to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement. No event has occurred or circumstances exist that may give rise or serve as a basis for any such Action.
Section 5.06 Independent Investigation . Parent acknowledges and agrees that: (a) in making its decision to enter into this Agreement and to consummate the transactions contemplated hereby, it has relied solely upon its own investigation and the express representations and warranties of Target set forth in ARTICLE IV of this Agreement (including related portions of the Disclosure Schedules); and (b) neither Target nor any other Person has made any representation or warranty as to Target, the Target Ownership Interests or this Agreement, except as expressly set forth in ARTICLE IV of this Agreement (including the related portions of the Disclosure Schedules).
ARTICLE VI
COVENANTS
Section 6.01 [RESERVED] .
Section 6.02 Confidentiality . From and after the Closing, each Principal shall, and shall cause its Affiliates to, hold, and shall use its reasonable best efforts to cause its or their respective Representatives to hold, in confidence any and all information, whether written or oral, concerning the Target or its business, except to the extent that such Principal can show that such information (a) is generally available to and known by the public through no fault of such Principal, any of its Affiliates or their respective Representatives; or (b) is lawfully acquired by
such Principal, any of its Affiliates or their respective Representatives from and after the Closing from sources which are not prohibited from disclosing such information by a legal, contractual or fiduciary obligation. If any Principal or any of its Affiliates or their respective Representatives are compelled to disclose any information by judicial or administrative process or by other requirements of Law, such Principal shall promptly notify Parent in writing and shall disclose only that portion of such information which such Principal is advised by its counsel in writing is legally required to be disclosed, provided that such Principal shall use reasonable best efforts to obtain an appropriate protective order or other reasonable assurance that confidential treatment will be accorded such information.
Section 6.03 Approvals and Consents .
(a) Each party hereto shall, as promptly as possible, (i) make, or cause or be made, all filings and submissions required under any Law applicable to such party or any of its Affiliates; and (ii) use reasonable best efforts to obtain, or cause to be obtained, all consents, authorizations, orders and approvals from all Governmental Authorities that may be or become necessary for its execution and delivery of this Agreement and the performance of its obligations pursuant to this Agreement and the other Transaction Documents. Each party shall cooperate fully with the other party and its Affiliates in promptly seeking to obtain all such consents, authorizations, orders and approvals. The parties hereto shall not willfully take any action that will have the effect of delaying, impairing or impeding the receipt of any required consents, authorizations, orders and approvals.
(b) Target and Parent shall use reasonable best efforts to give all notices to, and obtain all consents from, all third parties that are described in Section 4.03 of the Disclosure Schedules.
(c) Without limiting the generality of the parties undertakings pursuant to subsections (a) and (b) above, each of the parties hereto shall use all reasonable best efforts to:
(i) respond to any inquiries by any Governmental Authority regarding antitrust or other matters with respect to the transactions contemplated by this Agreement or any other Transaction Document;
(ii) avoid the imposition of any order or the taking of any action that would restrain, alter or enjoin the transactions contemplated by this Agreement or any other Transaction Document; and
(iii) in the event any Governmental Order adversely affecting the ability of the parties to consummate the transactions contemplated by this Agreement or any other Transaction Document has been issued, to have such Governmental Order vacated or lifted.
(d) All analyses, appearances, meetings, discussions, presentations, memoranda, briefs, filings, arguments, and proposals made by or on behalf of either party before any Governmental Authority or the staff or regulators of any Governmental Authority, in connection with the transactions contemplated hereunder (but, for the avoidance of doubt, not including any interactions between Target or Parent with Governmental Authorities in the ordinary course of business, any disclosure which is not permitted by Law or any disclosure containing confidential
information) shall be disclosed to the other party hereunder in advance of any filing, submission or attendance, it being the intent that the parties will consult and cooperate with one another, and consider in good faith the views of one another, in connection with any such analyses, appearances, meetings, discussions, presentations, memoranda, briefs, filings, arguments, and proposals. Each party shall give notice to the other party with respect to any meeting, discussion, appearance or contact with any Governmental Authority or the staff or regulators of any Governmental Authority, with such notice being sufficient to provide the other party with the opportunity to attend and participate in such meeting, discussion, appearance or contact.
(e) Notwithstanding the foregoing, nothing in this Section 6.03 shall require, or be construed to require, Parent, the Surviving Corporation or any of their Affiliates to agree to (i) sell, hold, divest, discontinue or limit, before or after the Closing Date, any assets, businesses or interests of Parent, the Surviving Corporation or any of their Affiliates; (ii) any conditions relating to, or changes or restrictions in, the operations of any such assets, businesses or interests which, in either case, could reasonably be expected to result in a Material Adverse Effect or materially and adversely impact the economic or business benefits to Parent or the Surviving Corporation of the transactions contemplated by this Agreement and the other Transaction Documents; or (iii) any material modification or waiver of the terms and conditions of this Agreement.
Section 6.04 Books and Records .
(a) In order to facilitate the resolution of any claims made against or incurred by Target prior to the Closing, or for any other reasonable purpose, for a period of five years after the Closing, Parent shall (or shall cause the Surviving Corporation to):
(i) retain the Books and Records (including personnel files) relating to periods prior to the Closing in a manner reasonably consistent with the prior practices of Target; and
(ii) upon reasonable notice, afford the Stockholder Representative reasonable access (including the right to make, at the Stockholders expense, photocopies), during normal business hours, to such Books and Records.
(b) Notwithstanding the foregoing, neither Parent nor the Surviving Corporation shall be obligated to provide the Stockholders Representatives with access to any books or records (including personnel files) pursuant to this Section 6.04 where such access would violate any Law.
Section 6.05 Tax Matters .
(a) Preparation and Filing of Tax Returns; Payment of Taxes .
(i) At their expense, the Target Parties shall prepare and timely file or shall cause to be prepared and timely filed all Tax Returns for Target and Telemed due on or prior to the Closing. The Target Parties shall make or cause to be made all payments required with respect to any such Tax Returns. Unless otherwise required by Law, all Tax Returns shall be
filed in a manner consistent with past practice and on a basis consistent with the last previous similar Tax Return.
(ii) At its expense, Parent shall prepare and timely file or shall cause to be prepared and timely filed, all Tax Returns for the Surviving Corporation required to be filed after the Closing Date. Parent shall make or cause to be made all payments required with respect to any such Tax Returns, subject to the reimbursement rights specified below. The Target shall inform Parent of any past practices affecting the Tax Liability of Target or the Stockholders, which Parent will continue to follow for any Tax Return covering the Straddle Period provided that the past practices are reasonable and do not subject Parent to adverse Tax consequences. In absence of such information, Parent will use common Tax practices and professional Tax judgment to prepare Targets Tax Returns covering the Straddle Period.
(iii) In the case of Taxes that are payable with respect to a taxable period that begins on or before the Closing Date and ends after the Closing Date (a Straddle Period ), the portion of any such Tax that is allocable to the portion of the period ending on and including the Closing Date (and which Taxes shall be borne by Target) shall be:
(A) in the case of Taxes that are either (x) based upon or related to income or receipts or (y) imposed in connection with any sale or other transfer or assignment of property (real or personal, tangible or intangible), deemed equal to the amount which would be payable if the taxable year ended on and included the Closing Date (an interim closing of the books); and
(B) in the case of Taxes imposed on a periodic basis with respect to the assets of Target or any of its Subsidiaries, or otherwise measured by the level of any item, deemed to be the amount of such Taxes for the entire period (or, in the case of such Taxes determined on an arrears basis, the amount of such Taxes for the immediately preceding period), multiplied by a fraction the numerator of which is the number of calendar days in the period ending on and including the Closing Date and the denominator of which is the number of calendar days in such Straddle Period.
(iv) At least 15 days prior to the date on which any Straddle Period Tax Return is to be filed, the Parent shall submit such Tax Return to the Stockholder Representative for the Stockholder Representatives review and approval, which approval will not be unreasonably withheld, conditioned or delayed; and shall be deemed granted if no written objection is received within such 15 day period; provided that in the event the Stockholder Representative objects (or does not provide its approval) to the filing of any such Straddle Period Tax Return and Parent submits such Straddle Period Tax Return notwithstanding such objection, the Stockholders shall not be liable to Parent for any amounts arising from the filing of such Straddle Period Tax Return.
(b) Cooperation . After the Closing Date, each Target Party, on one hand, and Parent, on the other hand, shall:
(i) Use commercially reasonable efforts to cooperate fully in preparing for any audits of, or disputes with taxing authorities regarding, any Tax Returns relating to the Business and make available to the other and to any taxing authority as reasonably requested all information, records, and documents relating to liabilities for, or exemption from, Taxes associated with the Business as set forth in this Agreement. Any information or documents provided under this Section 6.05(b) shall be kept confidential by the party receiving such information or documents, except as may otherwise be necessary in connection with the filing of Tax Returns or in connection with administrative or judicial proceedings relating to Taxes;
(ii) Make available to the other, as reasonably requested and available, personnel responsible for preparing or maintaining information, records and documents in connection with Taxes as well as any related litigation;
(iii) Preserve all such information, records, and documents until the expiration of any applicable statutes of limitation or extensions thereof and as otherwise required by Law; and
(iv) Provide timely notice to the other in writing of any pending or threatened Tax audits or assessments related to the Business for periods beginning prior to the Closing Date, and furnish the other with copies of all correspondence received from any taxing authority in connection with any Tax audit or information request with respect to any such period.
(c) Tax Sharing Agreements . All tax sharing agreements or similar agreements with respect to or involving Target or Telemed shall be terminated as of the Closing Date and, after the Closing Date, Parent and the Surviving Corporation shall not be bound thereby or have any Liability thereunder.
Section 6.06 Public Announcements . Unless otherwise required by applicable Law (based upon the reasonable advice of counsel), no party to this Agreement shall make any public announcements in respect of this Agreement or the transactions contemplated hereby or otherwise communicate with any news media without the prior written consent of both Parent and the Stockholder Representative (which consent shall not be unreasonably withheld or delayed), and the parties shall cooperate as to the timing and contents of any such announcement.
Section 6.07 Stockholder and Employee Claims . Stockholder Representative shall provide notice to Parent promptly following receipt (and in no event later than five Business Days following the date of receipt) of any Stockholder and Employee Claim.
Section 6.08 CONSENT OF PRINCIPALS; WAIVER OF APPRAISAL AND DISSENTERS RIGHTS . BY EXECUTION HEREOF, EACH PRINCIPAL HEREBY KNOWINGLY AND FREELY (I) CONSENTS TO THE MERGER AND THE OTHER TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT ON THE TERMS AND CONDITIONS SET FORTH HEREIN, (II) WAIVES ANY AND ALL RIGHTS OF FIRST REFUSAL, FIRST OFFER, APPROVAL, LIQUIDATION PROCEEDS PREFERENCE, NOTICE OR SIMILAR RIGHTS, IF ANY, SUCH PRINCIPAL MAY HAVE ARISING OUT OF OR IN CONNECTION WITH THE MERGER, AND (III) WAIVES ANY ALL APPRAISAL AND DISSENTERS RIGHTS UNDER THE DGCL IN CONNECTION WITH
THE MERGER AND THE OTHER TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PRINCIPAL HAS REVIEWED AND UNDERSTANDS THE TERMS AND CONDITIONS OF THIS AGREEMENT AND IS HEREBY ENCOURAGED TO, HAS HAD THE OPPORTUNITY TO, AND TO THE EXTENT SUCH PRINCIPAL DEEMED NECESSARY DID, SEEK AND RELY UPON THE ADVICE OF SUCH PRINCIPALS OWN INDEPENDENT COUNSEL IN THE NEGOTIATION AND ADOPTION OF THIS AGREEMENT.
Section 6.09 Further Assurances . Following the Closing, each of the parties hereto shall, and shall cause their respective Affiliates to, execute and deliver such additional documents, instruments, conveyances and assurances and take such further actions as may be reasonably required to carry out the provisions hereof and give effect to the transactions contemplated by this Agreement and the other Transaction Documents.
ARTICLE VII
[RESERVED]
ARTICLE VIII
INDEMNIFICATION
Section 8.01 Survival . Subject to the limitations and other provisions of this Agreement, the representations and warranties contained herein shall survive the Closing and shall remain in full force and effect until the date that is two years from the Closing Date; provided, that (i) the representations and warranties in Section 4.01 (Organization and Capitalization), Section 4.02 (Authority), Section 5.01 (Organization) and Section 5.02 (Authority) shall survive indefinitely (the representations described in clause (i), the Fundamental Representations ), and (ii) the representations and warranties in Section 4.03 (No Conflicts), Section 4.12 (Intellectual Property), Section 4.17 (Compliance with Laws; Permits), Section 4.18 (Environmental Matters), Section 4.19 (Employee Benefit Matters), Section 4.21 (Taxes), Section 4.22 (Brokers), Section 4.28 (Solvency), Section 5.03 (No Conflicts; Consents) and Section 5.04 (Brokers) shall survive for the full period of all applicable statutes of limitations (giving effect to any waiver, mitigation or extension thereof). All covenants of the parties contained herein shall survive the Closing until performed in accordance with their terms. Notwithstanding the foregoing, any claims asserted in writing by notice from the non-breaching party to the breaching party prior to the expiration date of the applicable survival period shall not thereafter be barred by the expiration of the relevant representation, warranty or covenant and such claims shall survive until finally resolved. Notwithstanding the foregoing, any claims arising from fraud or criminal activity with respect to a representation, warranty or covenant hereunder shall not be limited by the survival period described above, and shall continue until the later of the expiration of the survival period set forth above for such representation, warranty or convent or the expiration of the statute of limitations for such fraud or criminal activity.
Section 8.02 Indemnification by the Stockholders . Subject to the other terms and conditions of this ARTICLE VIII , the Stockholders, severally and not jointly, shall indemnify and defend each of Parent and its Affiliates (including, after the Effective Time, the Surviving Corporation) and their respective Representatives (collectively, the Parent Indemnitees )
against, and shall hold each of them harmless from and against, and shall pay and reimburse each of them for, any and all Losses incurred or sustained by, or imposed upon, the Parent Indemnitees based upon, arising out of, with respect to or by reason of:
(a) any inaccuracy in or breach of any of the Fundamental Representations of Target as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date);
(b) any inaccuracy in or breach of any of the representations or warranties of Target contained in this Agreement (other than the Fundamental Representations), as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date);
(c) any breach or non-fulfillment of any covenant, agreement or obligation to be performed by Target (at or prior to the Effective Time) or by such Stockholder (but not by any other Stockholder) pursuant to this Agreement, the other Transaction Documents or any certificate or instrument delivered by or on behalf of Target Parties or such Stockholder pursuant to this Agreement;
(d) any Stockholder and Employee Claims;
(e) any Closing Transaction Expenses in excess of the amounts set forth on the Pre-Closing Statement, to the extent not paid by the Target Parties at Closing;
(f) any Liability based upon, resulting from or arising out of any promise or instrument contemplating the issuance of equity, equity appreciation, Target Options, Phantom Equity Rights, or similar rights with respect to Target, including without limitation with respect to all such rights listed on Section 2.10(b) of the Disclosure Schedule (collectively, the Option Liabilities ); or
(g) any Liability based upon, resulting from or arising out of any Contract or other agreement between any Target Party or any of their respective Affiliates and Edison or any of its respective Affiliates (including, without limitation, any Liabilities related to the actual or alleged breach or violation of any representation, warranty, covenant, agreement or obligation of any Target Party or its Affiliates thereunder) including without limitation in connection with that certain Letter of Intent dated June 4, 2013 by and among Edison, Target, Morgenthau, Promociones and Ricardo Weisz (collectively, the Edison Liabilities ).
Section 8.03 Indemnification by Parent . Subject to the other terms and conditions of this ARTICLE VIII , Parent shall indemnify and defend each of the Stockholders, their respective Affiliates and their respective Representatives (collectively, the Stockholder Indemnitees ) against, and shall hold each of them harmless from and against, and shall pay and reimburse each of them for, any and all Losses incurred or sustained by, or imposed upon, the Stockholder Indemnitees based upon, arising out of, with respect to or by reason of:
(a) any inaccuracy in or breach of any of the Fundamental Representations of Parent as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date);
(b) any inaccuracy in or breach of any of the representations or warranties of Parent contained in this Agreement (other than the Fundamental Representations), as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date);
(c) any breach or nonfulfillment of any covenant, agreement or obligation to be performed by Parent pursuant to this Agreement; or
(d) the business, operations, properties, assets or obligations of Parent or of the Surviving Corporation arising on or after the Closing Date.
Section 8.04 Certain Limitations . Except with respect to claims arising from fraud or criminal activity, Option Liabilities, Edison Liabilities or any inaccuracy in or breach of Section 4.01 or Section 4.06 (which claims shall not be subject to the limitations set forth in this Section 8.04 ), the indemnification provided for in Section 8.02 and Section 8.03 shall be subject to the following limitations:
(a) The Stockholders shall not be liable to the Parent Indemnitees for indemnification under Section 8.02 until the aggregate amount of all Losses in respect of indemnification under Section 8.02 exceeds $175,000.00, in which event the Stockholders shall be required to pay or be liable for all such Losses from the first dollar thereof.
(b) Parent shall not be liable to the Stockholder Indemnitees for indemnification under Section 8.03 until the aggregate amount of all Losses in respect of indemnification under Section 8.03 exceeds $175,000.00, in which event Parent shall be required to pay or be liable for all such Losses from the first dollar thereof.
(c) The maximum aggregate amount of all Losses for which the Stockholders shall be liable pursuant to Section 8.02 shall not exceed $13,500,000.00, provided, however that the maximum aggregate amount of all Losses for which the Stockholders shall be liable pursuant to Section 8.02(b) shall not exceed $3,550,000. In the case of any Loss, the liability of any Stockholder pursuant to Section 8.02 shall be limited to such Stockholders Participating Percentage of such Loss. In addition, the aggregate amount of all Losses for which a Stockholder may be liable (including such Stockholders pro-rata portion of Losses paid from the Escrow Account) shall be further limited to such Stockholders Net Allocated Share.
(d) The maximum aggregate amount of all Losses for which Parent shall be liable pursuant to Section 8.03 shall not exceed $13,500,000.00; provided, however, that the maximum aggregate amount of all Losses (other than those related to claims arising from fraud) for which Parent shall be liable pursuant to Section 8.03(b) shall not exceed $3,550,000.00.
(e) The amount of Losses for which indemnification is provided for under this Agreement shall be reduced by (i) any amounts actually received by the Indemnified Party as a result of any indemnification, contribution or other payment by a third party, (ii) any insurance proceeds or other similar amounts actually received by an Indemnified Party with respect to such Losses (any amounts described in clause (i) or (ii), Third Party Payments ).
(f) If the amount of any Loss, at any time subsequent to the making of any indemnification payment on account of such Loss, is reduced by any Third Party Payment, the amount of such reduction shall promptly be repaid by the Indemnified Party to the Indemnifying Party.
(g) Each Indemnified Party shall take all reasonable actions to mitigate all Losses and to timely make and diligently pursue any claims for insurance, tax benefits and other payments available from third parties with respect to Losses for which it seeks indemnification hereunder.
(h) No party shall have any obligation to provide indemnification hereunder for any punitive or consequential damages.
(i) No claim for indemnification may be made and no indemnification shall be required to the extent that such Loss was accrued or reflected on the Financial Statements.
(j) The obligations of the Stockholders under Section 8.02 shall be satisfied exclusively out of the Escrow Amount pursuant to the terms of the Escrow Agreement until the Escrow Amount is exhausted, and may thereafter be satisfied by payment directly from the Stockholders, subject to the limitations herein.
(k) In no event shall an indemnitee be entitled to recover with respect to the same Loss more than once pursuant to this Agreement (whether through indemnification, a reduction in Aggregate Merger Consideration, third party recover or otherwise), it being the intent of the parties to avoid double-counting in this regard.
Section 8.05 Indemnification Procedures . The party making a claim under this ARTICLE VIII is referred to as the Indemnified Party , and the party against whom such claims are asserted under this ARTICLE VIII is referred to as the Indemnifying Party .
(a) Third Party Claims . If any Indemnified Party receives notice of the assertion or commencement of any Action made or brought by any Person who is not a party to this Agreement or an Affiliate of a party to this Agreement or a Representative of the foregoing (a Third Party Claim ) against such Indemnified Party with respect to which the Indemnifying Party is obligated to provide indemnification under this Agreement, the Indemnified Party shall give the Indemnifying Party reasonably prompt written notice thereof, but in any event not later than 30 calendar days after receipt of such notice of such Third Party Claim. The failure to give such prompt written notice shall not, however, relieve the Indemnifying Party of its indemnification obligations, except and only to the extent that the Indemnifying Party forfeits rights or defenses by reason of such failure. Such notice by the Indemnified Party shall describe the Third Party Claim in reasonable detail, shall include copies of all material written evidence thereof and shall indicate the estimated amount, if reasonably practicable, of the Loss that has been or may be sustained by the Indemnified Party. The Indemnifying Party shall have the right
to participate in, or by giving written notice to the Indemnified Party, to assume the defense of any Third Party Claim at the Indemnifying Partys expense and by the Indemnifying Partys own counsel, and the Indemnified Party shall cooperate in good faith in such defense; provided, that if the Indemnifying Party is a Stockholder, such Indemnifying Party shall not have the right to defend or direct the defense of any such Third Party Claim to the extent that it seeks an injunction or other equitable relief against the Indemnified Party. In the event that the Indemnifying Party assumes the defense of any Third Party Claim, subject to Section 8.05(b) , it shall have the right to take such action as it deems reasonably necessary to avoid, dispute, defend, appeal or make counterclaims pertaining to any such Third Party Claim in the name and on behalf of the Indemnified Party. The Indemnified Party shall have the right to participate in the defense of any Third Party Claim with counsel selected by it subject to the Indemnifying Partys right to control the defense thereof. The fees and disbursements of such counsel shall be at the expense of the Indemnified Party. If the Indemnifying Party elects not to compromise or defend such Third Party Claim, fails to promptly notify the Indemnified Party in writing of its election to defend as provided in this Agreement, or fails to diligently prosecute the defense of such Third Party Claim, the Indemnified Party may, subject to Section 8.05(b) , pay, compromise, defend such Third Party Claim and seek indemnification for any and all Losses based upon, arising from or relating to such Third Party Claim. The Indemnified Party and the Indemnifying Party shall cooperate with each other in all reasonable respects in connection with the defense of any Third Party Claim, including making available (subject to the provisions of Section 6.02 ) records relating to such Third Party Claim and furnishing, without expense (other than reimbursement of expenses) to the defending party, management employees of the non-defending party as may be reasonably necessary for the preparation of the defense of such Third Party Claim. Notwithstanding anything to the contrary, for purposes of this Section 8.05 , any Stockholder and Employee Claims shall be deemed to be demands made by a third party and shall constitute Third Party Claims.
(b) Settlement of Third Party Claims . Notwithstanding any other provision of this Agreement, the Indemnifying Party shall not enter into settlement of any Third Party Claim without the prior written consent of the Indemnified Party, except as provided in this Section 8.05(b) . If a firm offer is made to settle a Third Party Claim without leading to liability or the creation of a financial or other obligation on the part of the Indemnified Party and provides, in customary form, for the unconditional release of each Indemnified Party from all liabilities and obligations in connection with such Third Party Claim and the Indemnifying Party desires to accept and agree to such offer, the Indemnifying Party shall give written notice to that effect to the Indemnified Party. If the Indemnified Party fails to consent to such firm offer within ten days after its receipt of such notice, the Indemnified Party may continue to contest or defend such Third Party Claim and in such event, the maximum liability of the Indemnifying Party, including fees and expenses incurred thereafter, as to such Third Party Claim shall not exceed the amount of such settlement offer. If the Indemnified Party fails to consent to such firm offer and also fails to assume defense of such Third Party Claim within 30 days after the receipt of such firm offer, the Indemnifying Party may settle the Third Party Claim upon the terms set forth in such firm offer to settle such Third Party Claim. If the Indemnified Party has assumed the defense of such Third Party Claim pursuant to Section 8.05(a) , it shall not agree to any settlement without the written consent of the Indemnifying Party (which consent shall not be unreasonably withheld or delayed).
(c) Direct Claims . Any Action by an Indemnified Party on account of a Loss which does not result from a Third Party Claim (a Direct Claim ) shall be asserted by the Indemnified Party giving the Indemnifying Party reasonably prompt written notice thereof, but in any event not later than 30 days after the Indemnified Party becomes aware of such Direct Claim. The failure to give such prompt written notice shall not, however, relieve the Indemnifying Party of its indemnification obligations, except and only to the extent that the Indemnifying Party forfeits rights or defenses by reason of such failure. Such notice by the Indemnified Party shall describe the Direct Claim in reasonable detail, shall include copies of all material written evidence thereof and shall indicate the estimated amount, if reasonably practicable, of the Loss that has been or may be sustained by the Indemnified Party. The Indemnifying Party shall have 20 days after its receipt of such notice to respond in writing to such Direct Claim, which response may include a request for additional information. The Indemnified Party shall allow the Indemnifying Party and its professional advisors to investigate the matter or circumstance alleged to give rise to the Direct Claim, and whether and to what extent any amount is payable in respect of the Direct Claim and the Indemnified Party shall assist the Indemnifying Partys investigation by giving such information and assistance (including access to the Indemnified Partys premises and personnel and the right to examine and copy any accounts, documents or records) as the Indemnifying Party or any of its professional advisors may reasonably request. If the Indemnifying Party does not respond within such 20 day period, the Escrow Agent shall provide the Indemnifying Party of notice of expiration of such 20 day period (a Waiver Notice ). If Indemnifying Party does not deliver to the Escrow Agent and Indemnified Party an objection disputing the Direct Claim or any portion of the amount claimed in the Direct Claim within five (5) Business Days after the date of receipt of such Waiver Notice, then (i) Indemnifying Party shall be conclusively deemed to have acknowledged the correctness of the Direct Claim, and (ii) the Escrow Agent shall, within three (3) Business Days following the expiration of such five (5) Business Day period, release to Indemnified Party from the Escrow Account the amount of the Direct Claim specified in the notice of the Direct Claim with respect to which Indemnifying Party did not timely submit an objection.
(d) If the Indemnifying Party timely delivers an objection to the Direct Claim or seeks additional information regarding the Direct Claim, and if such claim or claims described therein shall not have been resolved or compromised between the Indemnifying Party and the Indemnified Party within five (5) Business Days following notice of non-response from the Escrow Agent, then the Indemnified Party shall be free to pursue such remedies as may be available to the Indemnified Party on the terms and subject to the provisions of this Agreement.
Section 8.06 Payments . Once a Loss is agreed (or deemed to be agreed) to by the Indemnifying Party or finally adjudicated to be payable pursuant to this ARTICLE VIII , the Indemnifying Party shall satisfy its obligations within 15 Business Days of such agreement or final, non-appealable adjudication by providing written instruction to the Escrow Agent to release funds from Escrow Account to pay such Loss, or in the event there are not sufficient funds in the Escrow Account, then by wire transfer of immediately available funds. The parties hereto agree that should an Indemnifying Party not make full payment of any such obligations within such 15 Business Day period, any amount payable shall accrue interest from and including the date of agreement of the Indemnifying Party or final, non-appealable adjudication to and including the date such payment has been made at a rate per annum equal to the statutory rate of interest in New York for judgments on the date of such agreement or final, non-
appealable adjudication. Such interest shall be calculated daily on the basis of a 365 day year and the actual number of days elapsed.
Section 8.07 Tax Treatment of Indemnification Payments . All indemnification payments made under this Agreement shall be treated by the parties as an adjustment to the Aggregate Merger Consideration for Tax purposes, unless otherwise required by Law.
Section 8.08 Effect of Investigation . The representations, warranties and covenants of the Indemnifying Party, and the Indemnified Partys right to indemnification with respect thereto, shall not be affected or deemed waived by reason of any investigation made by or on behalf of the Indemnified Party (including by any of its Representatives) or by reason of the fact that the Indemnified Party or any of its Representatives knew or should have known that any such representation or warranty is, was or might be inaccurate, as the case may be.
Section 8.09 Exclusive Remedies . Subject to Section 10.11 , the parties acknowledge and agree that their sole and exclusive remedy with respect to any and all claims (other than those related to claims arising from fraud, criminal activity or willful misconduct) for any breach of any representation, warranty, covenant, agreement or obligation set forth herein or otherwise relating to the subject matter of this Agreement, shall be pursuant to the indemnification provisions set forth in this ARTICLE VIII . Nothing in this Section 8.09 shall limit any Persons right to seek and obtain any equitable relief to which any Person shall be entitled or to seek any remedy on account of any partys fraudulent, criminal or willful misconduct.
Section 8.10 Authority of the Stockholder Representative . Notwithstanding anything in this ARTICLE VIII to the contrary, and as more particularly set forth in ARTICLE IX , the Stockholder Representative shall have the power to execute, deliver, acknowledge, certify and file any documents, give and receive any notices, negotiate or enter into compromises or disputes, and take any and all actions such Stockholder Representative may determine to be necessary, on behalf of any Stockholder or other Stockholder Indemnitee in connection with this ARTICLE VIII .
Section 8.11 Calculation of Losses . For purposes of this ARTICLE VIII , to the extent it is determined that a representation or warranty has been breached and the Parent Indemnitees or the Stockholder Indemnitees are entitled to be indemnified therefor pursuant to the terms of this ARTICLE VIII , then for the purposes of determining the amount of any Losses relating to such breach (and only for such purpose and, for the avoidance of doubt, not for the purpose of determining whether a breach has occurred), the breached representation or warranty shall be read without regard to any qualifications or exceptions relating to or referring to the terms material, materiality, in all material respects, Material Adverse Effect or any similar term or phrase contained in or otherwise applicable to any such representation or warranty.
ARTICLE IX
STOCKHOLDER REPRESENTATIVE
Section 9.01 Appointment of Stockholder Representative; Power of Attorney .
(a) Each Stockholder hereby irrevocably nominates, constitutes and appoints Douglas L. OKeefe as the Stockholder Representative and as the agent, agent for service of process and true and lawful attorney in fact of such Stockholder with full power of substitution, to act in the name, place and stead of such Stockholder with respect to all matters under this Agreement and the transactions contemplated by this Agreement. Such powers shall include, without limitation, the taking by the Stockholder Representative of any and all actions and the making of any decisions required or permitted to be taken or made by any Stockholder under this Agreement, including the exercise of the power to: (i) execute, deliver, acknowledge, certify and file (in the name of any or all of such Stockholders or otherwise) any and all documents and to take any and all actions that the Stockholder Representative may, in his sole discretion, determine to be necessary, desirable or appropriate in connection with this Agreement (including negotiating, entering into compromises or settlements of and resolving disputes with respect to any matters covered in Section 2.13 and ARTICLE VIII ); (ii) give and receive notices and communications under this Agreement; (iii) authorize the payment of fees, expenses and distributions, including, without limitation, any fees, expenses or distributions out of the Stockholder Representative Holdback Amount; and (iv) execute amendments (and additional documents related thereto) to this Agreement on behalf of such Stockholders generally consistent with the transaction contemplated hereby, the execution thereof shall be conclusive evidence of such determination. Douglas L. OKeefe hereby accepts his appointment as the Stockholder Representative.
(b) Each Stockholder hereby acknowledges and agrees that the Stockholder Representative Holdback Amount shall be withheld and paid directly to an account maintained by the Stockholder Representative (or a financial institution selected by the Stockholder Representative) as a fund for the fees and expenses (including, without limitation, any legal fees and expenses) of the Stockholder Representative incurred in connection with this Agreement, with any balance of the Stockholder Representative Holdback Amount not utilized for such purposes to be remitted to the Stockholders in accordance with their Participating Percentages. The Stockholder Representative will, if so requested in writing by any Stockholder, provide such Stockholder with a written report describing in reasonable detail the amount of any fees, expenses, distributions, or other remittances made out of the Stockholder Representative Holdback Amount; provided, however, that the Stockholder Representative will not have any obligation to provide any such written report to any particular Stockholder any more than two times during any rolling twelve month period.
Section 9.02 Irrevocable Appointment . The power of attorney granted in Section 9.01 is (a) coupled with an interest and is irrevocable and (b) shall survive the death, incapacity or dissolution of each of the Stockholders.
Section 9.03 Reliance .
(a) Notwithstanding anything to the contrary contained in this Agreement, Parent and any Parent Indemnitees shall be entitled to deal exclusively with the Stockholder Representative on all matters relating to this Agreement, including, without limitation, ARTICLE VIII , and each Parent Indemnitee shall be entitled to deal exclusively with the Stockholder Representative in respect of all such matters, and each of them shall be entitled to rely conclusively (without further evidence of any kind whatsoever) on any document executed or purported to be executed on behalf of any Stockholder by the Stockholder Representative in respect of such matters, and on any other action taken or purported to be taken on behalf of any Stockholder by the Stockholder Representative, as fully binding upon such Stockholder.
(b) Notwithstanding anything to the contrary contained in this Agreement, any notice or communication delivered by Parent to Stockholder Representative shall, as between Parent, on the one hand, and the Stockholders, on the other hand, be deemed to have been delivered to all Stockholders. Parent shall be entitled to rely exclusively upon any communication or writings given or executed by Stockholder Representative in connection with any claims for indemnity and shall not be liable in any manner whatsoever for any action taken or not taken in reliance upon the actions taken or not taken or communications or writings given or executed by Stockholder Representative.
Section 9.04 Replacement . The Stockholder Representative may at any time designate a replacement Stockholder Representative with the consent of the Parent (which will not be unreasonably withheld, conditioned or delayed), and each Stockholder, by virtue of his or her execution and delivery of this Agreement, hereby consents to such replacement Stockholder Representative. If the Stockholder Representative shall die, become disabled or otherwise be unable to fulfill his responsibilities as representative of the Stockholders, then the Stockholders shall, by majority vote, within thirty (30) days after such death or disability, appoint a successor representative (with the consent of Parent, which will not be unreasonably withheld, conditioned or delayed). Any such successor shall become the Stockholder Representative for all purposes under this Agreement.
ARTICLE X
MISCELLANEOUS
Section 10.01 Expenses . Except as otherwise expressly provided herein, all costs and expenses, including, without limitation, fees and disbursements of counsel, financial advisors and accountants, incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such costs and expenses, whether or not the Closing shall have occurred.
Section 10.02 Notices . All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given (a) when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by facsimile of a PDF document (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next Business Day if sent after normal business hours
of the recipient or (d) on the third day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective parties at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance with this Section 10.02 ):
If to Target:
Consult A Doctor, Inc.
846 Lincoln Avenue
Miami Beach, Florida 33140
Facsimile: 305-372-7475
Attention: President
with a copy to:
Carey Rodriguez Greenberg OKeefe LLP
1395 Brickell Avenue
Suite 700
Miami, Florida 33131
Facsimile: 305-372-7475
Attention: Douglas L. OKeefe, Esq.
If to Stockholder Representative:
c/o Carey Rodriguez Greenberg OKeefe LLP
1395 Brickell Avenue
Suite 700
Facsimile: 305-372-7475
Attention: Douglas L. OKeefe, Esq.
If to Parent:
Teladoc, Inc.
One Sound Shore Drive, Suite 300
Greenwich, Connecticut 06830
Facsimile: 1-203-769-1544
Attention: Paul D. Squire, Esq.
with a copy to:
Jackson Walker L.L.P.
Bank of America Plaza
901 Main Street, Suite 6000
Dallas, Texas 75202
Facsimile: (214) 661-6688
Attention: James S. Ryan III, Esq.
Section 10.03 Interpretation . For purposes of this Agreement, (a) the words include, includes and including shall be deemed to be followed by the words without limitation; (b) the word or is not exclusive; and (c) the words herein, hereof, hereby, hereto and hereunder refer to this Agreement as a whole. Unless the context otherwise requires, references herein: (x) to Articles, Sections, Disclosure Schedules and Exhibits mean the Articles and Sections of, and Disclosure Schedules and Exhibits attached to, this Agreement; (y) to an agreement, instrument or other document means such agreement, instrument or other document as amended, supplemented and modified from time to time to the extent permitted by the provisions thereof and (z) to a statute means such statute as amended from time to time and includes any successor legislation thereto and any regulations promulgated thereunder. This
Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted. The Disclosure Schedules and Exhibits referred to herein shall be construed with, and as an integral part of, this Agreement to the same extent as if they were set forth verbatim herein.
Section 10.04 Headings . The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.
Section 10.05 Severability . If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or unenforceable, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible.
Section 10.06 Entire Agreement . This Agreement and the other Transaction Documents constitute the sole and entire agreement of the parties to this Agreement with respect to the subject matter contained herein and therein, and supersede all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter. In the event of any inconsistency between the statements in the body of this Agreement and those in the other Transaction Documents, the Exhibits and Disclosure Schedules (other than an exception expressly set forth as such in the Disclosure Schedules), the statements in the body of this Agreement will control.
Section 10.07 Successors and Assigns . This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns. No party may assign its rights or obligations hereunder without the prior written consent of Parent and the Stockholder Representative, which consent shall not be unreasonably withheld or delayed; provided, however, that Parent may, without the prior written consent of Stockholder Representative, assign all or any portion of its rights under this Agreement (i) prior to the Closing Date, to one or more of its direct or indirect wholly-owned subsidiaries, (ii) to a successor of the Parent, by consolidation, merger or operation of law, (iii) to a purchaser of all or substantially all of the Parents assets or (iv) to a lender of the Parent as collateral. No assignment shall relieve the assigning party of any of its obligations hereunder.
Section 10.08 No Third-party Beneficiaries . Except as provided in ARTICLE VIII , this Agreement is for the sole benefit of the Stockholders of Target, the parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.
Section 10.09 Amendment and Modification; Waiver . This Agreement may only be amended, modified or supplemented by an agreement in writing signed by Parent and the Stockholder Representative. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. No waiver by
any party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.
Section 10.10 Governing Law; Waiver of Jury Trial .
(a) This Agreement shall be governed by and construed in accordance with the internal laws of the State of Florida without giving effect to any choice or conflict of law provision or rule (whether of the State of Florida or any other jurisdiction).
(b) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT OR THE OTHER TRANSACTION DOCUMENTS IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION, (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 10.10(b) .
Section 10.11 Specific Performance . The parties agree that irreparable damage would occur if any provision of this Agreement were not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy to which they are entitled at law or in equity.
Section 10.12 Counterparts . This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.
[SIGNATURE PAGE FOLLOWS]
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.
|
CONSULT A DOCTOR, INC. |
|
|
|
|
|
By: |
/s/ Jack Karabees |
|
Name: |
Jack Karabees |
|
Title: |
President |
|
|
|
|
TELADOC, INC. |
|
|
|
|
|
By: |
/s/ Jason Gorevic |
|
Name: |
Jason Gorevic |
|
Title: |
Chief Executive Officer |
|
|
|
|
|
|
|
/s/ Wolf Shlagman |
|
|
Wolf Shlagman |
|
|
|
|
|
|
|
|
/s/ John J. Karabees |
|
|
John J. Karabees |
|
|
|
|
|
MORGENTHAU ACCELERATOR FUND, LP |
|
|
|
|
|
By: |
/s/ Michael Andzel |
|
Name: |
Michael Andzel |
|
Title: |
Managing Member |
|
|
|
|
|
|
|
/s/ Arturo Castillo |
|
|
Arturo Castillo |
|
|
|
|
|
PROMOCIONES BURSATILES, S.A. |
|
|
|
|
|
By |
/s/ Roberto Solis |
|
Name: |
Roberto Solis |
|
Title: |
President |
|
|
|
|
NEW WORLD ANGELS VI (CONSULT A DOCTOR), LLC |
|
|
|
|
|
By |
/s/ Ricardo Weisz |
|
Name: |
Ricardo Weisz |
|
Title: |
Manager |
|
/s/ Douglas L. OKeefe |
|
Douglas L. OKeefe, solely in his capacity as Stockholder Representative |
Exhibit 2.2
AGREEMENT AND PLAN OF MERGER
among
AMERIDOC, LLC,
DAVID E. LINDSEY, MICHAEL R. THOMPSON,
DAVID E. LINDSEY, AS MEMBER REPRESENTATIVE,
AND
TELADOC, INC.,
dated as of
May 1, 2014
TABLE OF CONTENTS
ARTICLE I DEFINITIONS |
2 |
|
|
|
|
ARTICLE II TRANSACTIONS AND TERMS OF THE MERGER |
15 |
|
|
|
|
Section 2.01 |
The Merger |
15 |
Section 2.02 |
Certificate of Incorporation and Bylaws |
15 |
Section 2.03 |
Directors and Officers |
16 |
Section 2.04 |
Conversion of Interests |
16 |
Section 2.05 |
Merger Consideration |
16 |
Section 2.06 |
No Further Rights |
17 |
Section 2.07 |
Purchase Price Adjustment |
18 |
Section 2.08 |
Third Party Consents |
21 |
|
|
|
ARTICLE III CLOSING |
22 |
|
|
|
|
Section 3.01 |
Closing |
22 |
Section 3.02 |
Closing Deliverables |
22 |
|
|
|
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE TARGET |
25 |
|
|
|
|
Section 4.01 |
Organization, Qualification and Capitalization of Target; APN |
25 |
Section 4.02 |
Authority |
26 |
Section 4.03 |
No Violation or Breach; Consents |
27 |
Section 4.04 |
Financial Statements |
27 |
Section 4.05 |
Books and Records |
28 |
Section 4.06 |
Undisclosed Liabilities |
28 |
Section 4.07 |
Absence of Certain Changes, Events and Conditions |
28 |
Section 4.08 |
Material Contracts |
30 |
Section 4.09 |
Title to Assets; Condition and Sufficiency |
31 |
Section 4.10 |
Real Property |
32 |
Section 4.11 |
Intellectual Property |
33 |
Section 4.12 |
Accounts Receivable and Accounts Payable |
36 |
Section 4.13 |
Customers and Suppliers |
36 |
Section 4.14 |
Insurance |
37 |
Section 4.15 |
Legal Proceedings; Governmental Orders |
38 |
Section 4.16 |
Compliance with Laws; Permits |
38 |
Section 4.17 |
Environmental Matters |
40 |
Section 4.18 |
Employee Benefit Matters |
40 |
Section 4.19 |
Employment Matters |
42 |
Section 4.20 |
Taxes |
43 |
Section 4.21 |
Brokers |
46 |
Section 4.22 |
Network Redundancy and Computer Back Up |
46 |
Section 4.23 |
Privacy of Customer Information |
46 |
Section 4.24 |
Inspections and Investigations |
46 |
Section 4.25 |
Rates and Reimbursement Policies |
46 |
Section 4.26 |
No Disagreements with Accountants and Lawyers |
47 |
Section 4.27 |
Solvency |
47 |
Section 4.28 |
Virtus Agreement |
47 |
Section 4.29 |
Full Disclosure |
47 |
|
|
|
ARTICLE IV-A REPRESENTATIONS AND WARRANTIES OF THE MEMBERS |
47 |
|
|
|
|
Section 4.01-A |
Ownership |
47 |
Section 4.02-A |
Authority |
48 |
Section 4.03-A |
No Breach; Consents |
48 |
Section 4.04-A |
Brokers |
48 |
Section 4.05-A |
Full Disclosure |
49 |
|
|
|
ARTICLE V REPRESENTATIONS AND WARRANTIES OF PURCHASER |
49 |
|
|
|
|
Section 5.01 |
Organization of Purchaser |
49 |
Section 5.02 |
Authority of Purchaser |
49 |
Section 5.03 |
No Conflicts; Consents |
49 |
Section 5.04 |
Brokers |
50 |
Section 5.05 |
Legal Proceedings |
50 |
|
|
|
ARTICLE VI COVENANTS |
50 |
|
|
|
|
Section 6.01 |
Conduct of Business |
50 |
Section 6.02 |
Other Actions |
51 |
Section 6.03 |
Access to Information |
52 |
Section 6.04 |
Exclusivity; No Shop; Break-Up Fee |
52 |
Section 6.05 |
Notices of Certain Events |
52 |
Section 6.06 |
Reasonable Best Efforts; Approvals and Consents |
53 |
Section 6.07 |
Confidentiality |
54 |
Section 6.08 |
Books and Records |
54 |
Section 6.09 |
Tax Matters |
55 |
Section 6.10 |
Public Announcements |
57 |
Section 6.11 |
CONSENT OF MEMBERS; WAIVER OF APPRAISAL AND DISSENTERS RIGHTS |
58 |
Section 6.12 |
Further Assurances |
58 |
Section 6.13 |
APN |
58 |
Section 6.14 |
Benefit Plans |
58 |
Section 6.15 |
Target Lease |
58 |
Section 6.16 |
Healthcare Information Laws Compliance Investigations |
59 |
Section 6.17 |
AmeriDoc Tail Insurance Policy |
59 |
Section 6.18 |
Ameridoc.net |
59 |
Section 6.19 |
Contractual Matters |
59 |
Section 6.20 |
Consents |
59 |
|
|
|
ARTICLE VII CONDITIONS TO THE MERGER |
59 |
|
|
|
|
Section 7.01 |
Conditions to the Obligations of Each Party |
59 |
Section 7.02 |
Conditions to the Obligations of Purchaser |
60 |
Section 7.03 |
Conditions to the Obligations of Target and the Members |
60 |
|
|
|
ARTICLE VIII TERMINATION |
61 |
|
|
|
|
Section 8.01 |
Termination |
61 |
Section 8.02 |
Effect of Termination |
62 |
|
|
|
ARTICLE IX INDEMNIFICATION |
62 |
|
|
|
|
Section 9.01 |
Survival |
62 |
Section 9.02 |
Indemnification by the Members |
63 |
Section 9.03 |
Indemnification by Purchaser |
64 |
Section 9.04 |
Certain Limitations |
65 |
Section 9.05 |
Indemnification Procedures |
66 |
Section 9.06 |
Offsets and Payments |
68 |
Section 9.07 |
Tax Treatment of Indemnification Payments |
68 |
Section 9.08 |
Effect of Investigation |
68 |
Section 9.09 |
Exclusive Remedies |
69 |
Section 9.10 |
Authority of the Member Representative |
69 |
Section 9.11 |
Calculation of Losses |
69 |
Section 9.12 |
Pooled Claims |
69 |
|
|
|
ARTICLE X MEMBER REPRESENTATIVE |
70 |
|
|
|
|
Section 10.01 |
Appointment of Member Representative; Power of Attorney |
70 |
Section 10.02 |
Irrevocable Appointment |
71 |
Section 10.03 |
Reliance |
71 |
Section 10.04 |
Replacement |
72 |
|
|
|
ARTICLE XI MISCELLANEOUS |
72 |
|
|
|
|
Section 11.01 |
Expenses |
72 |
Section 11.02 |
Notices |
72 |
Section 11.03 |
Interpretation |
73 |
Section 11.04 |
Headings |
73 |
Section 11.05 |
Severability |
73 |
Section 11.06 |
Entire Agreement |
74 |
Section 11.07 |
Successors and Assigns |
74 |
Section 11.08 |
No Third-party Beneficiaries |
74 |
Section 11.09 |
Amendment and Modification; Waiver |
74 |
Section 11.10 |
Governing Law; Waiver of Jury Trial; Venue |
75 |
Section 11.11 |
Specific Performance |
75 |
Section 11.12 |
Counterparts |
75 |
Section 11.13 |
Letter of Intent |
76 |
Section 11.14 |
Privilege |
76 |
LIST OF EXHIBITS
Exhibits :
Exhibit A-1 |
Form of Delaware Certificate of Merger |
Exhibit A-2 |
Form of Florida Certificate of Merger |
Exhibit B |
Form of Purchaser Note |
Exhibit C |
Form of Subordination Agreement |
Exhibit D |
Form of Working Capital Statement |
Exhibit E |
Form of Target Opinion |
Exhibit F |
Form of Lindsey Employment Agreement |
Exhibit G |
Form of Noncompetition Agreement |
Exhibit H |
Form of Release Agreement |
Exhibit I |
Contracts to be Terminated |
Exhibit J |
Form 8594 Estimated |
AGREEMENT AND PLAN OF MERGER
This Agreement and Plan of Merger (this Agreement ), dated as of May 1, 2014, is entered into by and among Teladoc, Inc., a Delaware corporation ( Purchaser ), David E. Lindsey, in his capacity as representative for the Members (the Member Representative ), AmeriDoc, LLC, a Florida limited liability company ( Target ), David E. Lindsey ( Lindsey ) and Michael R. Thompson ( Thompson , and collectively with Lindsey, the Members ) (the Members and Target are sometimes referred to herein as a Target Party and collectively as the Target Parties ).
RECITALS
WHEREAS, Target is engaged in the business of providing access to telemedicine and telehealth services to its customers (the Business );
WHEREAS, as of the date of this Agreement, the Members and Lindenbrook Associates, LLC, a New Jersey limited liability company ( Lindenbrook ) collectively own one hundred percent (100%) of the Targets issued and outstanding units of membership interest (the Target Units );
WHEREAS, Target and Lindsey entered into that certain Assignment Agreement, Release and Waiver dated as of April 30, 2014 (the Lindenbrook Assignment Agreement ), with Lindenbrook and each of Kevin Faherty, an individual residing in the State of New Jersey, Barry Forester, an individual residing in the State of New Jersey, and Raymond J. Marszalowicz, an individual residing in the State of New Jersey (collectively, the Lindenbrook Owners ), whereby, effective immediately prior to the Merger (defined below), Lindsey will purchase all of the Target Units owned by Lindenbrook so that, immediately prior to the Merger, the Members will collectively one hundred percent (100%) of the issued and outstanding Target Units;
WHEREAS, Target will merge directly with and into Purchaser (the Merger ), with Purchaser continuing as the surviving corporation;
WHEREAS, the board of directors of Purchaser and the manager of Target have, on the terms and subject to the conditions set forth in this Agreement, (a) determined and declared that the Merger is advisable to, and in the best interest of, each such Person and its respective equityholders, (b) authorized and approved this Agreement, the Merger and the consummation of the transactions contemplated hereby, and (c) in the case of Targets manager, has recommended the adoption and approval of this Agreement and the Merger by the Members, in accordance with the Florida Limited Liability Company Act, as amended (the FLLCA );
WHEREAS, Targets Members have adopted and approved of this Agreement and the Merger in accordance with the FLLCA;
WHEREAS, concurrently with the execution of this Agreement, Purchaser, the Member Representative, Target, Lindsey, Thompson and TeleMedServices, LLC, a Texas limited liability company owned by Lindsey and Thompson ( TeleMed ), have entered into an Agreement and Plan of Merger (the TeleMed Merger Agreement ) whereby, concurrently with the Merger, TeleMed will be merged with and into Purchaser (the TeleMed Merger ); and
WHEREAS, the parties hereto desire to make certain representations, warranties, covenants and agreements in connection with the Merger and to prescribe various conditions to the Merger.
NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
ARTICLE I
DEFINITIONS
The following terms have the meanings specified or referred to in this ARTICLE I :
409A Authorities has the meaning set forth in Section 4.18(j) .
Accounts Receivable means all accounts or notes receivable held by Target as of the Closing Date, and any security, claim, remedy or other right related to any of the foregoing.
Action means any claim, action, cause of action, demand, lawsuit, arbitration, inquiry, audit, notice of violation, proceeding, litigation, citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether at law or in equity.
Affiliate of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first Person. The term control (including the terms controlled by and under common control with) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.
Aggregate Merger Consideration has the meaning set forth in Section 2.05(a) .
Agreement has the meaning set forth in the preamble.
AmeriDoc Note Portion means the $3,499,500 of the $3,500,000 original principal amount of the Purchaser Note.
Annual Financial Statements has the meaning set forth in Section 4.04 .
APN means AmeriDoc Physician Network, LLC, a Florida limited liability company which is, as of the date of this Agreement, is a wholly-owned Subsidiary of Target.
APN Divestment has the meaning set forth in Section 3.02(a)(xv) .
Balance Sheet has the meaning set forth in Section 4.04 .
Balance Sheet Date has the meaning set forth in Section 4.04 .
Benefit Agreement means any employment, deferred compensation, consulting, severance, change of control, termination, retention, indemnification, loan or similar agreement between the Target and any Participant.
Benefit Plan means any employment, bonus, pension, profit sharing, retirement, deferred compensation, incentive compensation, stock ownership, equity or equity-based compensation, paid time off, perquisite, fringe benefit, vacation, change of control, severance, retention, disability, death benefit, hospitalization, medical, welfare benefit or other plan, program, policy, arrangement, agreement or understanding (whether or not legally binding) sponsored, maintained, contributed to or required to be sponsored, maintained or contributed to by the Target, providing benefits to any Participant, but not including any Benefit Agreement.
Books and Records means all books and records of Target, including, but not limited to, books of account, ledgers and general, financial and accounting records, machinery and equipment maintenance files, customer lists, customer purchasing histories, price lists, distribution lists, supplier lists, production data, quality control records and procedures, customer complaints and inquiry files, research and development files, records and data (including all correspondence with any Governmental Authority), sales material and records (including pricing history, total sales, terms and conditions of sale, sales and pricing policies and practices), strategic plans, internal financial statements, marketing and promotional surveys, material and research and Intellectual Property files relating to the Intellectual Property Assets and the Intellectual Property Licenses.
Broker has the meaning set forth in Section 4.21 .
Business has the meaning set forth in the recitals.
Business Day means any day except Saturday, Sunday or any other day on which commercial banks located in Dallas, Texas are authorized or required by Law to be closed for business.
Closing has the meaning set forth in Section 3.01 .
Closing Accrued Tax Amount means the sum, without duplication, of all unpaid Taxes (whether accrued or otherwise) of Target with respect to all periods ending on or prior to the Closing Date.
Closing Balance Sheet has the meaning set forth in Section 2.07(c)(i)(A) .
Closing Date has the meaning set forth in Section 3.01 .
Closing Indebtedness means the amount of all Indebtedness of Target outstanding as of the Closing Date and immediately prior to the Effective Time. Notwithstanding the foregoing definition of Closing Indebtedness, in order to avoid duplication of any deductions to the calculation of Aggregate Merger Consideration: (a) to the extent any Indebtedness included in Current Liabilities and taken into account in the calculation of Closing Working Capital, such Indebtedness shall not be included as an item of Closing Indebtedness, and (b) to the extent any Taxes relating to Indebtedness are included in the calculation of Closing Accrued Tax Amount
and taken into account in the calculation of Aggregate Merger Consideration, such Taxes shall not be included as an item of Closing Indebtedness. For avoidance of doubt, Closing Indebtedness shall include (a) the entire amount owed by Target to Li as set forth in the applicable Payoff Letter, (b) the entire amount owed by Target to Roy Whitehead as of the Effective Time as set forth in the applicable Payoff Letter, (c) the entire amount owed by Target to Wells Fargo Bank, N.A. as of the Effective Time, as set forth in the applicable Payoff Letter (d) the entire amount owed by Target to Lindsey as of the Effective Time, as set forth in the applicable Payoff Letter (e) the entire amount owed by Target to Innovative as of the Effective Time as set forth in the applicable Payoff Letter, and (f) the entire amount owed by Target to the Lindenbrook Owners as set forth in the Lindenbrook Assignment Agreement, and each of the foregoing items (a) through (f) shall not be taken into account in the calculation of Closing Working Capital or Closing Accrued Tax Amount.
Closing Payment Amounts means the amount set forth next to each Members name in the wire instructions delivered pursuant to Section 2.05 .
Closing Statement has the meaning set forth in Section 2.07(c)(i) .
Closing Transaction Expenses means Transaction Expenses of Target incurred in connection with this Agreement, the Transaction Documents and the transactions contemplated hereby and thereby that remain unpaid at the Closing.
Closing Working Capital has the meaning set forth in Section 2.07(a) .
Code means the Internal Revenue Code of 986, as amended.
Contracts means all contracts, leases, deeds, mortgages, licenses, instruments, notes, commitments, undertakings, indentures, joint ventures and all other agreements, commitments and legally binding arrangements, whether written or oral.
Couto means Gregory J. Couto.
Couto Agreement means that certain Member Interest Purchase Agreement dated December 24, 2013 between Lindsey and Couto.
Couto Claims means any and all Losses incurred by Purchaser or any of its Affiliates (including, following the Effective Time, the Surviving Corporation) as a result of any claim brought by or for the benefit of Couto or any of his Affiliates in respect of Coutos status as former member of Target or arising out of or relating to the Couto Agreement, this Agreement, the Merger and the transactions contemplated hereby and thereby (including (i) any such matters relating to the exercise of any rights or remedies in connection with the exercise of dissenters rights, appraisal rights or any similar rights in connection with this Agreement or the Merger, and (ii) any such matters arising out of or related to the Targets organizational documents), including, without limitation, (x) any of the foregoing arising from matters disclosed to Purchaser or its Affiliates or otherwise referenced in this Agreement, and whether any related claim arises before or after the Closing, (y) whether such matters are known or unknown, contingent or otherwise, whether accrued, liquidated, matured or unmatured, and (z) all costs of
investigation, defense, insurance claims processing, and insurance deductibles associated therewith.
Couto Payment Amount has the meaning set forth in Section 2.05(b)(iii) .
Current Assets means the sum of the line items of the balance sheet of the Target that are listed on the Form of Working Capital Statement and calculated in accordance with GAAP.
Current Liabilities means the sum of the line items of the balance sheet of the Target that are listed on the Form of Working Capital Statement and calculated in accordance with GAAP.
Debt Payoff Recipients has the meaning set forth in Section 2.05(b)(i) .
Delaware Certificate of Merger means a certificate of merger in the form attached hereto as Exhibit A-1 .
DGCL means the Delaware General Corporation Law, as amended.
Direct Claim has the meaning set forth in Section 9.05(c) .
Disclosure Schedules means the Disclosure Schedules delivered by Target concurrently with the execution and delivery of this Agreement.
Disputed Amounts has the meaning set forth in Section 2.07(d)(iii) .
Dollars or $ means the lawful currency of the United States.
Effective Time means the time at which both (i) the Delaware Certificate of Merger is filed and becomes effective with the Secretary of State of the State of Delaware in accordance with the DGCL, and (ii) the Florida Certificate of Merger is filed and becomes effective with the Florida Department of State in accordance with the FLLCA (or at such later time as shall be agreed upon by Purchaser and Target and set forth in the Delaware Certificate of Merger and Florida Certificate of Merger).
Encumbrance means any charge, claim, community property interest, pledge, condition, equitable interest, lien (statutory or other), option, security interest, mortgage, casement, encroachment, right of way, right of first refusal, or restriction of any kind, including any restriction on use, voting, transfer, receipt of income or exercise of any other attribute of ownership.
Engaged Professional has the meaning set forth in Section 4.16(b) .
Environmental Claim means any Action, Governmental Order, lien, fine, penalty, or, as to each, any settlement or judgment arising therefrom, by or from any Person alleging liability of whatever kind or nature (including liability or responsibility for the costs of enforcement proceedings, investigations, cleanup, governmental response, removal or remediation, natural resources damages, property damages, personal injuries, medical monitoring, penalties,
contribution, indemnification and injunctive relief) arising out of, based on or resulting from: (a) the presence, Release of, or exposure to, any Hazardous Materials; or (b) any actual or alleged non-compliance with any Environmental Law or term or condition of any Environmental Permit.
Environmental Law means any applicable Law, and any Governmental Order or binding agreement with any Governmental Authority: (a) relating to pollution (or the cleanup thereof) or the protection of natural resources, endangered or threatened species, human health or safety, or the environment (including ambient air, soil, surface water or groundwater, or subsurface strata); or (b) concerning the presence of, exposure to, or the management, manufacture, use, containment, storage, recycling, reclamation, reuse, treatment, generation, discharge, transportation, processing, production, disposal or remediation of any Hazardous Materials. The term Environmental Law includes, without limitation, the following (including their implementing regulations and any state analogs): the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended by the Superfund Amendments and Reauthorization Act of 1986, 42 U.S.C. §§ 9601 et seq.; the Solid Waste Disposal Act, as amended by the Resource Conservation and Recovery Act of 1976, as amended by the Hazardous and Solid Waste Amendments of 1984, 42 U.S.C. §§ 6901 et seq.; the Federal Water Pollution Control Act of 1972, as amended by the Clean Water Act of 1977, 33 U.S.C. §§ 1251 et seq.; the Toxic Substances Control Act of 1976, as amended, 15 U.S.C. §§ 2601 et seq.; the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. §§ 11001 et seq.; the Clean Air Act of 1966, as amended by the Clean Air Act Amendments of 1990, 42 U.S.C. §§ 7401 et seq.; and the Occupational Safety and Health Act of 1970, as amended, 29 U.S.C. §§ 651 et seq.
Environmental Notice means any written directive, notice of violation or infraction, or notice respecting any Environmental Claim relating to actual or alleged non-compliance with any Environmental Law or any term or condition of any Environmental Permit.
Environmental Permit means any Permit, letter, clearance, consent, waiver, closure, exemption, decision or other action required under or issued, granted, given, authorized by or made pursuant to Environmental Law.
Equity Interest and equity security mean any equity security as such term is defined in the Securities and Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
ERISA means the Employee Retirement Income Security Act of 1974, as amended.
ERISA Affiliate means any trade or business, whether or not incorporated, which together with the Target is treated as a single employer under Section 414(b) or (c) of the Code.
Estimated Closing Accrued Tax Amount has the meaning set forth in Section 2.07(b)(i)(C) .
Estimated Closing Balance Sheet has the meaning set forth in Section 2.07(b)(i)(A) .
Estimated Closing Indebtedness has the meaning set forth in Section 2.07(b)(i)(D) .
Estimated Closing Working Capital has the meaning set forth in Section 2.07(b)(i)(B) .
Estimated Post-Closing Adjustment Amount has the meaning set forth in Section 2.07(c)(ii) .
Final Closing Accrued Tax Amount has the meaning set forth in Section 2.07(c)(ii) .
Final Closing Indebtedness has the meaning set forth in Section 2.07(c)(ii) .
Final Closing Working Capital has the meaning set forth in Section 2.07(c)(ii) .
Final Post-Closing Adjustment Amount has the meaning set forth in Section 2.07(c)(ii) .
Financial Statements has the meaning set forth in Section 4.04 .
FLLCA has the meaning set forth in the recitals.
Florida Certificate of Merger means a certificate of merger in the form attached hereto as Exhibit A-2 .
Form of Working Capital Statement has the meaning set forth in Section 2.07(a) .
Fundamental Representations has the meaning set forth in Section 9.01 .
GAAP means United States generally accepted accounting principles in effect from time to time.
Governmental Authority means any federal, state, local or foreign government or political subdivision thereof, or any agency or instrumentality of such government or political subdivision, or any self-regulated organization or other non-governmental regulatory authority or quasi-governmental authority (to the extent that the rules, regulations or orders of such organization or authority have the force of Law), or any arbitrator, court or tribunal of competent jurisdiction.
Governmental Order means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any Governmental Authority.
Hazardous Materials means: (a) any material, substance, chemical, waste, product, derivative, compound, mixture, solid, liquid, mineral or gas, in each case, whether naturally occurring or manmade, that is hazardous, acutely hazardous, toxic, or words of similar import or regulatory effect under Environmental Laws; and (b) any petroleum or petroleum-derived products, radon, radioactive materials or wastes, asbestos in any form, lead or lead-containing materials, urea formaldehyde foam insulation and polychlorinated biphenyls.
Healthcare Information Laws has the meaning set forth in Section 4.16(c) .
Healthcare Information Losses has the meaning set forth in Section 9.04(c) .
Income Tax means all federal, state and local income or profits Taxes, Taxes measured by income, profits or earned surplus, excise Taxes and other governmental charges arising from income, profits or other revenue similar in nature to any of the foregoing, including any interest, penalties or other additions to Tax that may become payable in respect thereof, imposed by any Governmental Authority.
Indebtedness means any of the following of Target: (a) any indebtedness for borrowed money (including any obligation for principal, interest, premiums, penalties, fees, expenses and breakage costs), (b) any obligations evidenced by bonds, debentures, notes or other similar instruments, (c) all interest expense accrued but unpaid on or relating to any such obligations described in clauses (a) and (b) above, (d) any obligations to pay the deferred purchase price of property or services, except trade accounts payable, (e) any obligations, contingent or otherwise, under acceptance credit, letters of credit or similar facilities, and (f) unpaid fees, prepayment or redemption premiums or penalties or breakage costs associated with the repayment of the types of obligations described in clauses (a) through (e) above, and (g) all outstanding obligations of the types described in clauses (a) through (f) above of any Person, the payment for which Target is or may be responsible or liable, directly or indirectly, as obligor, guarantor or surety, including guarantees of such obligations; provided, however, that Indebtedness shall not include any accrued income Tax Liabilities.
Indemnified Party has the meaning set forth in Section 9.05 .
Indemnifying Party has the meaning set forth in Section 9.05 .
Independent Accountants has the meaning set forth in Section 2.07(d)(iii) .
Innovative has the meaning set forth in Section 6.15 .
Insolvent has the meaning set forth in Section 4.27 .
Insurance Policies has the meaning set forth in Section 4.14 .
Intellectual Property means all of the following and similar intangible property and related proprietary rights, interests and protections, however arising, pursuant to the Laws of any jurisdiction throughout the world: (a) trademarks, service marks, trade names, brand names, logos, trade dress and other proprietary indicia of goods and services, whether registered or unregistered, and all registrations and applications for registration of such trademarks, including intent-to-use applications, all issuances, extensions and renewals of such registrations and applications and the goodwill connected with the use of and symbolized by any of the foregoing; (b) interest domain names, whether or not trademarks. registered in any top-level domain by any authorized private registrar or Governmental Authority; (c) original works of authorship in any medium of expression, whether or not published, all copyrights (whether registered or unregistered), all registrations and applications for registration of such copyrights, and all issuances, extensions and renewals of such registrations and applications; (d) confidential information, formulas, designs, devices, technology, know-how, research and development, inventions, methods, processes, compositions and other trade secrets, whether or not patentable; (e) patented and patentable designs and inventions, all design, plant and utility patents, letters patent, utility models, pending patent applications and provisional applications and all issuances,
divisions, continuations, continuations-in-part, reissues, extensions, reexaminations and renewals of such patents and applications; (f) computer software (including all data and related documentation), including any rights or licenses therein or thereto; and (g) all rights to sue and recover and retain damages, costs and attorneys fees for past, present and future infringement relating to any of the foregoing and any other rights relating to any of the foregoing.
Intellectual Property Assets means all Intellectual Property that is owned by Target.
Intellectual Property Licenses means all licenses, sublicenses and other agreements by or through which other Persons, including Targets Affiliates, grant Target exclusive or non-exclusive rights or interests in or to any Intellectual Property.
Intellectual Property Registrations means all Intellectual Property Assets that are subject to any issuance, registration, application or other filing by, to or with any Governmental Authority or authorized private registrar in any jurisdiction, including registered trademarks, domain names and copyrights, issued and reissued patents and pending applications for any of the foregoing.
Interim Balance Sheet has the meaning set forth in Section 4.04 .
Interim Balance Sheet Date has the meaning set forth in Section 4.04 .
Interim Financial Statements has the meaning set forth in Section 4.04 .
Knowledge of each Member or any other similar knowledge qualification means the actual knowledge of such Member or Members or any officer thereof, after due inquiry and reasonable investigation.
Knowledge of Target or Targets Knowledge or any other similar knowledge qualification means the actual knowledge of David E. Lindsey, Michael R. Thompson, and Elizabeth Whitehead, in each case after due inquiry and reasonable investigation.
Law means any statute, law, ordinance, regulation, rule, code, order, constitution, treaty, common law, judgment, decree, other requirement or rule of law of any Governmental Authority.
Leased Real Property has the meaning set forth in Section 4.10(b) .
Leases has the meaning set forth in Section 4.10(b) .
Li means Wei Li.
Li Agreement means that certain Member Interest Purchase Agreement dated December 24, 2013 between Target and Li.
Li Claims means any and all Losses incurred by Purchaser or any of its Affiliates (including, following the Effective Time, the Surviving Corporation) as a result of any claim brought by or for the benefit of Li or any of his Affiliates in respect of Lis status as former
member of TeleMed or arising out of or relating to the Li Agreement, this Agreement, the TeleMed Merger Agreement, the Merger, the TeleMed Merger and the transactions contemplated hereby and thereby including, without limitation, (x) any of the foregoing arising from matters disclosed to Purchaser or its Affiliates or otherwise referenced in this Agreement, and whether any related claim arises before or after the Closing, (y) whether such matters are known or unknown, contingent or otherwise, whether accrued, liquidated, matured or unmatured, and (z) all costs of investigation, defense, insurance claims processing, and insurance deductibles associated therewith.
Liabilities means liabilities, obligations or commitments of any nature whatsoever, asserted or unasserted, known or unknown, absolute or contingent, accrued or unaccrued, matured or unmatured or otherwise.
Lindenbrook has the meaning set forth in the recitals.
Lindenbrook Assignment Agreement has the meaning set forth in the recitals.
Lindenbrook Claims means any and all Losses incurred by Purchaser or any of its Affiliates (including, following the Effective Time, the Surviving Corporation) as a result of any claim brought by or for the benefit of Lindenbrook, a Lindenbrook Owner or any of their respective Affiliates in respect of Lindenbrooks status as former member of Target or arising out of or relating to the Lindenbrook Assignment Agreement, this Agreement, the Merger and the transactions contemplated hereby and thereby (including (i) any such matters relating to the exercise of any rights or remedies in connection with the exercise of dissenters rights, appraisal rights or any similar rights in connection with this Agreement or the Merger, and (ii) any such matters arising out of or related to the Targets organizational documents), including, without limitation, (x) any of the foregoing arising from matters disclosed to Purchaser or its Affiliates or otherwise referenced in this Agreement, and whether any related claim arises before or after the Closing, (y) whether such matters are known or unknown, contingent or otherwise, whether accrued, liquidated, matured or unmatured, and (z) all costs of investigation, defense, insurance claims processing, and insurance deductibles associated therewith.
Lindenbrook Owners has the meaning set forth in the recitals.
Lindenbrook Payment Amount has the meaning set forth in Section 2.05(b)(ii) .
Lindsey has the meaning set forth in the preamble.
Lindsey Employment Agreement has the meaning set forth in Section 3.02(a)(xii) .
Losses means losses, damages, Liabilities, deficiencies, diminution in value, Actions, judgments, interest, awards, penalties, fines, costs or expenses of whatever kind, including reasonable attorneys fees and the cost of enforcing any right to indemnification hereunder and the cost of pursuing any insurance providers.
Material Adverse Change means any event, occurrence, fact, condition or change that (i) has a material adverse effect on the Business, properties, assets, liabilities, results of operations or financial condition of the Target and TeleMed taken as a whole or (ii) prevents the
Target or TeleMed from consummating the Merger and the TeleMed Merger; provided , however , that none of the following shall be deemed either alone or in combination to constitute, and none of the following shall be taken into account in determining whether there has been a Material Adverse Change:
(1) any change, event, occurrence or state of facts relating to the global, U.S. or regional economy; financial, credit or capital markets (including changes in interest or currency exchange rates and any suspension in trading in securities generally); political conditions in general; or the industry in which the Target or TeleMed operate, including changes thereto as are caused by terrorist activities, entry into or material worsening of war or armed hostilities, or other national or international calamity, except to the extent such changes or developments have a disproportionate impact on the Target and TeleMed, taken as a whole, relative to other industry participants;
(2) any change, event, occurrence or state of facts that directly arises out of or results from the announcement or pendency of this Agreement or the TeleMed Merger Agreement or any of the transactions contemplated thereby, including member litigation or disruption or loss of customer business or supplier or employee relationships that is directly related to or directly arises out of or results from the announcement or pendency of this Agreement or the TeleMed Merger Agreement or any of the transactions contemplated thereby;
(3) any changes or effects arising out of or resulting from actions taken or the failure to take actions by the Target, TeleMed or APN with Purchasers consent or in accordance with the request or instructions of Purchaser or as otherwise required to be taken by the Target, TeleMed or APN pursuant to the terms of this Agreement;
(4) in and of itself, any failure to meet internal projections or forecasts of the Target, TeleMed or the Purchaser;
(5) any legal proceedings made or brought by any of the current or former members of the Target or TeleMed (on their own behalf or on behalf of the Target or TeleMed) the Target or TeleMed arising out of the Merger or the TeleMed Merger or in connection with any other transactions contemplated by this Agreement or the TeleMed Merger Agreement;
(6) changes in GAAP or applicable accounting requirements or principles (or the interpretation thereof) which occur or become effective after the date of this Agreement; and
(7) any matters set forth in the Disclosure Schedules.
Material Adverse Effect means any event, occurrence, fact, condition or change that is, or could reasonably be expected to become, individually or in the aggregate, materially adverse to (a) the Business, results of operations, conditions (financial or otherwise) or assets of the Target, (b) the aggregate value of the Target Units, (c) the aggregate value of the Targets assets or properties or (d) the ability of the Target Parties to consummate the transactions contemplated hereby on a timely basis.
Material Contracts has the meaning set forth in Section 4.08(a) .
Material Customer Contracts has the meaning set forth in Section 4.08(a)(ix) .
Material Customers has the meaning set forth in Section 4.13 .
Member has the meaning set forth in the preamble.
Member Indemnitees has the meaning set forth in Section 9.03 .
Member Representative has the meaning set forth in the preamble.
Member Representative Holdback Amount means the sum of $125,000, to be deposited to the account specified by Member Representative prior to the Closing.
Members Fundamental Representations has the meaning set forth in Section 9.01 .
Merger has the meaning set forth in the recitals.
Noncompetition Agreement has the meaning set forth in Section 3.02(d) .
Nonqualified Deferred Compensation Plan has the meaning set forth in Section 4.18(j) .
Open Source Materials has the meaning set forth in Section 4.11 .
Participant means any current or former director, manager, member, officer, employee or consultant of the Target or APN.
Participating Percentage means, with respect to each Member, the percentage set forth opposite such Members name on Section 1.1 of the Disclosure Schedules.
Payoff Letters has the meaning set forth in Section 2.07(b)(i)(D) .
Permits means all permits, licenses, franchises, approvals, authorizations, registrations, certificates, variances and similar rights obtained, or required to be obtained, from Governmental Authorities.
Permitted Encumbrances has the meaning set forth in Section 4.09 .
Person means an individual, corporation, partnership, joint venture, limited liability company, Governmental Authority, unincorporated organization, trust, association or other entity.
Pooled Note Amount has the meaning set forth in Section 9.12(a) .
Post-Closing Adjustment has the meaning set forth in Section 2.07(c)(ii) .
Post-Closing Participating Percentage means 100% with respect to Lindsey and 0% with respect to Thompson.
Pre-Closing Statement has the meaning set forth in Section 2.07(b)(i) .
Pre-Closing Tax Period means any taxable period ending on or before the Closing Date and, with respect to any taxable period beginning before and ending after the Closing Date, the portion of such taxable period ending on and including the Closing Date.
Purchaser has the meaning set forth in the preamble.
Purchaser Indemnitees has the meaning set forth in Section 9.02 .
Purchaser Note means the Purchaser Note in the original principal amount of $3,500,000 made payable to the order of Lindsey to be executed and delivered at the Closing in the form of that attached hereto as Exhibit B .
Purchasers Accountants means Fox, Byrd and Company, P.C.
Release means any actual or threatened release, spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, dumping, abandonment, disposing or allowing to escape or migrate into or through the environment (including, without limitation, ambient air (indoor or outdoor), surface water, groundwater, land surface or subsurface strata or within any building, structure, facility or fixture).
Release Agreement has the meaning set forth in Section 3.02(d)(ii) .
Representative means, with respect to any Person, any and all directors, managers, general partners, officers, employees, consultants, financial advisors, counsel, accountants and other agents of such Person.
Resolution Period has the meaning set forth in Section 2.07(d)(ii) .
Review Period has the meaning set forth in Section 2.07(d)(i) .
Securities Act means the Securities Act of 1933, as amended.
Statement of Objections has the meaning set forth in Section 2.07(d)(ii) .
Straddle Period has the meaning set forth in Section 6.09(a)(iii) .
Subordination Agreement means the Subordination Agreement between Lindsey and Silicon Valley Bank, a California corporation, in the form attached hereto as Exhibit C .
Subsidiary with respect to any Person (the Owner ), any corporation or other Person of which Equity Interests having the power to elect a majority of that corporations or other Persons board of directors or similar governing body, or otherwise having the power to direct the business and policies of that corporation or other Person are held by the Owner or one or more of its Subsidiaries.
Surviving Corporation means Purchaser, as the surviving corporation in the Merger.
Target has the meaning set forth in the preamble.
Target Intellectual Property has the meaning set forth in Section 4.11(a) .
Target Lease has the meaning set forth in Section 6.15 .
Target Operating Agreement has the meaning set forth in Section 4.01(e) .
Target Opinion has the meaning set forth in Section 3.02(a)(iv) .
Target Ownership Interests has the meaning set forth in Section 4.01(c) .
Target Party and Target Parties have the meanings set forth in the preamble.
Target Units has the meaning set forth in the recitals.
Target Working Capital has the meaning set forth in Section 2.07(a) .
Targets Accountants means The Burns Firm.
Tax Return means any return, declaration, report, claim for refund, information return or statement or other document relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof.
Taxes means all federal, state, local, foreign and other income, gross receipts, sales, use, production, ad valorem, transfer, documentary, franchise, registration, profits, license, lease, service, service use, withholding, payroll, employment, unemployment, estimated, excise, severance, environmental, stamp, occupation, premium, property (real or personal), real property windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatsoever, together with any interest, additions or penalties with respect thereto and any interest in respect of such additions or penalties.
TeleMed has the meaning set forth in the recitals.
TeleMed Divestment has the meaning set forth in Section 3.02(a)(xix) .
TeleMed Merger has the meaning set forth in the recitals.
TeleMed Merger Agreement has the meaning set forth in the recitals.
TeleMed Note Portion has the meaning set forth in Section 9.12(a) .
Termination Date has the meaning set forth in Section 8.01(c)(ii) .
Third Party Claim has the meaning set forth in Section 9.05(a) .
Third Party Payments has the meaning set forth in Section 9.04(e) .
Thompson has the meaning set forth in the preamble.
Transaction Documents means this Agreement, the Purchaser Note, the Subordination Agreement, the Noncompetition Agreements, the Release Agreements and the other agreements, instruments and documents required to be delivered at the Closing.
Transaction Expenses means the sum of the following without duplication, all unpaid (whether or not accrued and whether or not disclosed) fees, costs, expenses (including attorneys, accountants, financial advisors or finders fees) or similar amounts that are owed or incurred on or prior to the Effective Time by Target in connection with the negotiation of this Agreement and the other Transaction Documents, and the consummation of the transactions contemplated hereby.
Union has the meaning set forth in Section 4.19(b) .
Virtus Exclusivity Restriction has the meaning set forth in Section 4.28 .
WARN Act means the federal Worker Adjustment and Retraining Notification Act of 1988, and similar state, local and foreign Laws related to plant closings, relocations, mass layoffs and employment losses.
Working Capital has the meaning set forth in Section 2.07(a) .
ARTICLE II
TRANSACTIONS AND TERMS OF THE MERGER
Section 2.01 The Merger . Upon the terms and subject to the conditions of this Agreement, and in accordance with the relevant provisions of the DGCL and the FLLCA, Target shall be merged with and into Purchaser at the Effective Time. From and after the Effective Time, the separate corporate existence of Target shall cease and Purchaser shall continue as the Surviving Corporation. The Merger shall have the effects set forth in the DGCL, the FLLCA and this Agreement. At the Closing, Target and Purchaser shall cause the Delaware Certificate of Merger to be executed, acknowledged and filed with the Secretary of State of the State of Delaware, cause the Florida Certificate of Merger to be executed, acknowledged and filed with the Florida Department of State and make all other filings and recordings and take such other actions as required by the DGCL or the FLLCA in connection with the Merger. The Merger shall be consummated by filing the Delaware Certificate of Merger with the Secretary of State of the State of Delaware and by filing the Florida Certificate of Merger with the Florida Department of State, as is required by, and executed in accordance with, the relevant provisions of the DGCL and the FLLCA, respectively.
Section 2.02 Certificate of Incorporation and Bylaws .
(a) The certificate of incorporation of the Surviving Corporation immediately following the Effective Time shall be the same as the certificate of incorporation of the Purchaser immediately prior to the Effective Time.
(b) The bylaws of the Surviving Corporation immediately following the Effective Time shall be the same as the bylaws of Purchaser immediately prior to the Effective Time.
Section 2.03 Directors and Officers .
(a) The directors of the Surviving Corporation immediately following the Effective Time shall be the same as the directors of Purchaser immediately prior to the Effective Time.
(b) The officers of the Surviving Corporation immediately following the Effective Time shall be the same as the officers of Purchaser immediately prior to the Effective Time.
Section 2.04 Conversion of Interests . On the terms and subject to the conditions of this Agreement, at the Effective Time (and after giving effect to the transactions contemplated by the Lindenbrook Assignment Agreement), by virtue of the Merger and without any action on the part of Target, Purchaser, or the Equity Interest owners of either of the foregoing, the Equity Interests of the constituent entities shall be converted as follows:
(a) Target Unit .
(i) Each Target Unit that is issued and outstanding immediately prior to the Effective Time shall be canceled, extinguished and converted into, and each Member shall become entitled to receive, without interest, an amount in cash equal to such Members Closing Payment Amount (payable in the manner provided in accordance with Section 2.05(b)(vii) ) and the right to such Members applicable pro-rata portion (based upon such Members Post-Closing Participating Percentage) of (a) any positive Post-Closing Adjustment, (b) the AmeriDoc Note Portion and (c) the Member Representative Holdback Amount, in each case when and to the extent such amounts are distributed to Members pursuant to this Agreement.
(ii) At Closing, Purchaser shall pay, or shall cause to be paid to each Member, the consideration payable in respect of such Target Units as provided in Section 2.05(b)(vii) .
(b) Purchaser Stock . Each share of capital stock of Purchaser issued and outstanding immediately prior to the Effective Time shall remain issued and outstanding from and after the Effective Time.
Section 2.05 Merger Consideration .
(a) Merger Consideration . The aggregate merger consideration to be paid by Purchaser by reason of the Merger (the Aggregate Merger Consideration ) shall be an amount in cash equal to the result of the following:
(i) Sixteen Million Nine Hundred Ninety Thousand and 00/100 Dollars ($16,990,000);
(ii) either ( x ) if the Final Closing Working Capital is greater than the target Working Capital, plus the amount equal to the Final Closing Working Capital minus the Target Working Capital, or ( y ) if the Final Closing Working Capital is less than the Target Working Capital, minus an amount equal to the Target Working Capital minus the Final Closing Working Capital;
(iii) minus the Final Closing Accrued Tax Amount;
(iv) minus the aggregate amount of Final Closing Indebtedness to the extent not included in Final Closing Working Capital or in the Final Closing Accrued Tax Amount; and
(v) minus the aggregate amount of Closing Transaction Expenses to the extent not included in Final Closing Working Capital, in each case without duplication or double counting.
(b) Payment and Deliveries at Closing . Purchaser shall make, or cause to be made, the following payments and deliveries at Closing, with each payment to be made by wire transfer of immediately available funds pursuant to wire transfer instructions delivered to Purchaser prior to the Effective Time, unless otherwise designated by the payee thereof:
(i) to the accounts of Persons to whom the Closing Indebtedness is owed (the Debt Payoff Recipients ), an amount equal to the Closing Indebtedness owing to such Debt Payoff Recipients as set forth in the Payoff Letters or in the Lindenbrook Assignment Agreement, which payments, in the aggregate, shall be sufficient to satisfy any and all obligations of Target with respect to any Closing Indebtedness;
(ii) to Lindenbrook by wire transfer to an account designated by it of Two Million Seven Hundred Thirty-Nine Thousand Nine Hundred Ninety-Nine Dollars ($2,739,999) (the Lindenbrook Payment Amount ), which amount shall reduce Lindseys Closing Payment Amount.
(iii) To Couto by wire transfer to an account designated by him of Two Hundred Ninety-Seven Thousand Dollars ($297,000) (the Couto Payment Amount ), which amount shall reduce Lindseys Closing Payment Amount.
(iv) to the accounts of Persons to whom Closing Transaction Expenses are owed as designated in the Pre-Closing Statement, an amount equal to the Closing Transaction Expenses owing to such Persons:
(v) to Lindsey, the executed Purchaser Note;
(vi) to the Member Representative, by wire transfer of immediately available funds into an account designated by the Member Representative, the Member Representative Holdback Amount; and
(vii) to each Member (or to such other Persons on behalf of such Member as are directed by such Member), with respect to such Members Target Units, an amount equal to each Members Closing Payment Amount, it being understood that Lindseys Closing Payment Amount has been reduced by the Lindenbrook Payment Amount and the Couto Payment Amount.
Section 2.06 No Further Rights . From and after the Effective Time, no Target Units shall be deemed to be outstanding, and former holders of such Target Units shall cease to have any rights with respect thereto except as provided herein.
Section 2.07 Purchase Price Adjustment .
(a) Working Capital Adjustments Generally . The parties have contemplated that the Working Capital of Target as of the Effective Time (the Closing Working Capital ) will be zero dollars ($0) (the Target Working Capital ). Working Capital means, as of any given date, Current Assets minus Current Liabilities, in each case, as of such date, calculated in accordance with GAAP and the Form of Working Capital Statement attached hereto as Exhibit D (the Form of Working Capital Statement ) but does not include the Closing Accrued Tax Amount.
(b) Delivery of Pre-Closing Statement .
(i) Not less than two (2) Business Days prior to the Closing Date, Target shall have delivered to Purchaser a statement, which statement shall be in substantially the form of Section 2.07 of the Disclosure Schedules (the Pre-Closing Statement ), attaching the following items and certifying as to Targets good faith preparation and calculation of the following items:
(A) an unaudited estimated consolidated balance sheet of Target as of 11:59 P.M., Dallas, Texas time, on the Closing Date (the Estimated Closing Balance Sheet );
(B) an estimate of the Closing Working Capital based on the Estimated Closing Balance Sheet (the Estimated Closing Working Capital ), together with such schedules and data with respect to the determination of the Estimated Closing Working Capital as may be appropriate to support such calculation of Estimated Closing Working Capital;
(C) an estimate of the Closing Accrued Tax Amount (the Estimated Closing Accrued Tax Amount ), together with a list of each component item thereof, and such schedules and data with respect to the determination of the Estimated Closing Accrued Tax Amount as may be appropriate to support such calculation;
(D) a statement setting forth an estimate of each item of Closing Indebtedness (the Estimated Closing Indebtedness ), together with such schedules and data with respect to the determination of the Estimated Closing Indebtedness as may be appropriate to support such calculation of Estimated Closing Indebtedness, along with pay off letters therefor which contain a release of Target and are reasonably satisfactory to Purchaser ( Payoff Letters ) and wire instructions for each Person to whom Closing Indebtedness is owed;
(E) a statement setting forth all Closing Transaction Expenses (together with invoices therefor and wire instructions), as derived
from invoices provided by the Persons entitled to payment on account thereof; and
(c) Post-Closing Adjustment .
(i) Within 45 days after the Closing Date, Purchaser shall prepare and deliver to the Member Representative a statement, which statement shall be substantially in the form of Section 2.07 of the Disclosure Schedules (the Closing Statement ), attaching the following items and certifying as to Purchasers good faith preparation and calculation of the following items:
(A) an unaudited consolidated balance sheet of Target as of 11:59 P.M., Dallas, Texas time, on the Closing Date (the Closing Balance Sheet );
(B) the Closing Working Capital based on the Closing Balance Sheet, together with a calculation of the variance between the Estimated Closing Working Capital and Closing Working Capital;
(C) the Closing Accrued Tax Amount (including each component item), together with a calculation of the variance between the Estimated Closing Accrued Tax Amount and the Closing Accrued Tax Amount;
(D) the Closing Indebtedness (including each component item), together with a calculation of the variance between the Estimated Closing Indebtedness and the Closing Indebtedness; and
(E) a calculation of the Post-Closing Adjustment.
(ii) After each of the Closing Working Capital, Closing Accrued Tax Amount, and Closing Indebtedness has been finally determined in accordance with this Section 2.07 (the Closing Working Capital, Closing Accrued Tax Amount and Closing Indebtedness, in each case, as so finally determined being referred to herein as the Final Closing Working Capital , Final Closing Accrued Tax Amount , and Final Closing Indebtedness ), the Aggregate Merger Consideration shall be, if necessary, further adjusted to reflect the Post-Closing Adjustment, as follows: The Final Post-Closing Adjustment Amount shall be an amount equal to the Final Closing Working Capital, minus the Final Closing Accrued Tax Amount, and minus the Final Closing Indebtedness. The Estimated Post-Closing Adjustment Amount shall be an amount equal the Estimated Closing Working Capital, minus the Estimated Closing Accrued Tax Amount, and minus the Estimated Closing Indebtedness. If the Final Post-Closing Adjustment Amount is greater than the Estimated Post-Closing Adjustment Amount, Purchaser shall pay (or shall cause the Surviving Corporation to pay) to the Members (on a pro rata basis in accordance with their respective Post-Closing Participating Percentages) an amount equal to the absolute value of the difference between the Final Post-Closing Adjustment Amount and the Estimated Post-Closing Adjustment Amount (the Post-Closing Adjustment ). If the Final Post-Closing Adjustment Amount is less than the Estimated Post-Closing Adjustment Amount,
Purchaser shall be entitled to payment of an amount equal to the Post-Closing Adjustment in accordance with Section 2.07(d)(vi) below.
(d) Examination and Review .
(i) Examination . After receipt of the Closing Statement, Member Representative shall have 30 days (the Review Period ) to review the Closing Statement. During the Review Period, Member Representative and Targets Accountants shall have full access during normal business hours to the relevant books and records of the Surviving Corporation, the personnel of, and work papers prepared by, the Surviving Corporation and/or Purchasers Accountants to the extent that they relate to the Closing Statement and to such historical financial information (to the extent in Surviving Corporations possession) relating to the Closing Statement as Member Representative may reasonably request for the purpose of reviewing the Closing Statement and preparing a Statement of Objections (defined below), provided , that such access shall be in a manner that does not interfere with the normal business operations of Purchaser or the Surviving Corporation.
(ii) Objection . On or prior to the last day of the Review Period, Member Representative may object to the Closing Statement by delivering to Purchaser a written statement setting forth Member Representatives objections in reasonable detail, indicating each disputed item or amount and the basis for Member Representatives disagreement therewith (the Statement of Objections ). If Member Representative fails to deliver the Statement of Objections before the expiration of the Review Period, the Closing Statement, the Post-Closing Adjustment and the other calculations reflected in the Closing Statement shall be deemed to have been accepted by Member Representative. If Member Representative delivers the Statement of Objections before the expiration of the Review Period, Purchaser and Member Representative shall use commercially reasonable efforts to negotiate a resolution of such objections within 30 days after the delivery of the Statement of Objections (the Resolution Period ), and, if the same are so resolved within the Resolution Period, the Post-Closing Adjustment, the Closing Statement and the calculations reflected in the Closing Statement, with such changes as may have been previously agreed in writing by Purchaser and Member Representative, shall be final and binding.
(iii) Resolution of Disputes . If Member Representative and Purchaser fail to reach an agreement with respect to all of the matters set forth in the Statement of Objections before expiration of the Resolution Period, then any amounts remaining in dispute ( Disputed Amounts ) shall be submitted for resolution to an impartial firm of independent certified public accountants mutually selected by Purchaser and Member Representative, other than Targets Accountants or Purchasers Accountants (the Independent Accountants ) who, acting as experts and not arbitrators, shall (on the basis of the Closing Statement, Statement of Objections and this Agreement) resolve the Disputed Amounts only and make any adjustments to the Post-Closing Adjustment and the Closing Statement. The parties hereto agree that all adjustments shall be made without regard to materiality. The Independent Accountants shall only decide the specific items under dispute by the parties and their decision for each Disputed Amount must be within the range of values assigned to each such item in the Closing Statement and the Statement of Objections, respectively.
(iv) Fees of the Independent Accountants . Fees and expenses of the Independent Accountants shall be paid 50% by the Member Representative from the Member Representative Holdback Amount (or, if insufficient funds remain in the Member Representative Holdback Amount, by the Members on a pro rata basis in accordance with their respective Post-Closing Participating Percentages) and 50% by Purchaser within three (3) days following written notice by the Member Representative or the Surviving Corporation.
(v) Determination by Independent Accountants . The Independent Accountants shall make a determination as soon as practicable within 30 days (or such other time as the Purchaser and Member Representative shall agree in writing) after their engagement, and their resolution of the Disputed Amounts and their adjustments to the Closing Statement, Post-Closing Adjustment and/or the other calculations set forth in the Closing Statement shall be conclusive and binding upon the parties hereto.
(vi) Payments of Post-Closing Adjustment . Any payment of the Post-Closing Adjustment shall be due within the time periods set forth below after the calculations set forth in the Closing Statement become final and binding in accordance with clauses (ii)-(v) above. Any amount payable to the Members in respect of their Target Units pursuant to Section 2.07(c)(ii) shall be paid to them (via wire transfer of immediately available funds, using the same payment instructions that were used in making payments to them pursuant to Section 2.05(b)(vii) ) pro-rata pursuant to each Members respective Post-Closing Participating Percentage within five (5) Business Days after the calculations set forth in the Closing Statement become final and binding in accordance with clauses (ii)-(v) above. Any amount due to Purchaser pursuant to Section 2.07(c)(ii) , shall be paid automatically at such time as the calculations set forth in the Closing Statement become final and binding in accordance with clauses (i)-(v) above by an automatic offset to the outstanding principal balance of the Purchaser Note to the extent that there is still an outstanding principal balance pursuant to the terms of the Purchaser Note. To the extent there is not a sufficient outstanding principal balance under the Purchaser Note, the deficiency shall be paid (within the five (5) Business Day period after the calculations set forth in the Closing Statement become final and binding in accordance with clauses (i)-(v) above) by the Members (on a pro rata basis in accordance with their Post-Closing Participating Percentages) by wire transfer of immediately available funds to such account as directed by the Purchaser.
(e) Adjustments for Tax Purposes . Any payments made pursuant to Section 2.07 shall be treated as an adjustment to the Aggregate Merger Consideration by the parties for Tax purposes, unless otherwise required by Law.
Section 2.08 Third Party Consents . To the extent that Targets rights under any Contract, Permit or other asset do not inure to the benefit of the Surviving Corporation by way of the Merger without the consent of another Person which has not been obtained, then the Member Representative, at the Members expense, shall use its reasonable best efforts to obtain any such required consent(s) as promptly as possible. If any such consent shall not be obtained or if the Merger would impair the Surviving Corporations rights under the Contract, Permit or asset in question so that the Surviving Corporation would not in effect acquire the benefit of all such rights, the Member Representative, to the maximum extent permitted by Law, shall act after the Closing as the Surviving Corporations agent in order to obtain for the Surviving Corporation the benefits thereunder and shall, at the request of the Surviving Corporation, cooperate, to the
maximum extent permitted by Law and the applicable Contract or Permit, with the Surviving Corporation in any other reasonable arrangement designed to provide such benefits to the Surviving Corporation. Notwithstanding any provision in this Section 2.08 to the contrary, nothing will affect the liability, if any, of any Target Party pursuant to this Agreement for failing to disclose the need for, or for failing to obtain, such consent or approval.
ARTICLE III
CLOSING
Section 3.01 Closing . Subject to the terms and conditions of this Agreement, the consummation of the transactions contemplated by this Agreement (the Closing ) shall take place at the offices of Jackson Walker LLP, 901 Main Street, Suite 6000, Dallas, Texas 75202, at 10:00 a.m., Dallas, Texas time, upon the later of (i) May 2, 2014, (ii) or as soon as practicable (and in any event within three (3) Business Days) after the satisfaction or, to the extent permitted hereunder, waiver of all of the conditions to the Merger set forth in ARTICLE VII (other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or, to the extent permitted hereunder, waiver of all such conditions), unless this Agreement has been terminated pursuant to its terms or unless another time or date is mutually agreed to in writing by Target and the Member Representative. The date on which the Closing is to occur is herein referred to as the Closing Date .
Section 3.02 Closing Deliverables
(a) At the Closing, Target shall deliver to Purchaser the following:
(i) [intentionally deleted];
(ii) a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Target certifying that attached thereto are true and complete copies of all resolutions adopted by the managers and Members of Target authorizing the execution, delivery and performance of this Agreement and the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby (including approval by all of the Members of this Agreement, the Merger and the other transactions contemplated hereby), and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated hereby and thereby;
(iii) a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Target certifying the names and signatures of the officers of Target authorized to sign this Agreement, the Transaction Documents and the other documents to be delivered hereunder and thereunder;
(iv) an original legal opinion of Munsch Hardt Kopf & Harr PC and Carney Stanton PL as Florida counsel, covering the matters set forth on Exhibit E (the Target Opinion );
(v) a good standing certificate (or its equivalent) for Target from the secretary of state or similar Governmental Authority of the jurisdiction under the Laws in which Target is
organized and of each jurisdiction in which Target is qualified to do business as a foreign entity, in each case dated as of a date that is not more than ten (10) days prior to the Closing Date;
(vi) such documentation or other evidence reasonably satisfactory to Purchaser that all of the Permits, consents, approvals, authorizations and clearances listed in Section 4.03 of the Disclosure Schedules and designated thereon as Required Consents have been obtained;
(vii) such documentation or other evidence reasonably satisfactory to Purchaser that Target shall have taken all action reasonably required to cause the termination of all of the Contracts listed in Section 3.02(a)(vii) of the Disclosure Schedules;
(viii) such documentation or other evidence reasonably satisfactory to Purchaser that Target shall have taken all action reasonably required to cause the termination of all of its Benefit Plans;
(ix) resignation letters, duly executed, by each manager and officer of Target;
(x) the TeleMed Merger Agreement duly executed by TeleMed, the Member Representative, Lindsey and Thompson, together with such evidence and other documentation reasonably satisfactory to Purchaser that the closing of the transactions contemplated by the TeleMed Merger Agreement (including the TeleMed Merger) shall occur concurrently with the Closing;
(xi) the Lindenbrook Assignment Agreement duly executed by each party thereto;
(xii) an Employment Agreement in the form attached hereto as Exhibit F (the Lindsey Employment Agreement ), duly executed by Lindsey;
(xiii) a release (in form and substance reasonably satisfactory to Purchaser) duly executed by each Broker, (i) acknowledging that all fees payable to such Broker due to the consummation of this Agreement have been paid and (ii) releasing Purchaser, the Surviving Corporation and Target from any claims in connection therewith;
(xiv) such other customary instruments of transfer, assumption, filings or documents, in form and substance reasonably satisfactory to Purchaser, as may be required to give effect to this Agreement;
(xv) evidence that prior to Closing, Target distributed one hundred percent (100%) of the issued and outstanding Equity Interests of APN (free and clear of any Encumbrances) to Lindsey and Thompson (collectively, the APN Divestment );
(xvi) an agreement signed by Innovative in form and substance mutually satisfactory to Purchaser and Innovative related to the shared assets listed in Section 4.09(a) of the Disclosure Schedules and the shared contracts listed on Section 4.11(c) of the Disclosure Schedules;
(xvii) evidence that AmeriDoc International Solutions, LLC has changed its name to a name not including Ameridoc;
(xviii) an agreement signed by Lindenbrook in form and substance satisfactory to Purchaser pursuant to which Lindenbrook agrees to cooperate fully with the Surviving Corporation in responding to any investigation conducted by a Governmental Authority or Target or Surviving Corporation customer regarding compliance by Target or APN with Healthcare Information Laws prior to the Effective Time;
(xix) evidence that prior to Closing, Target distributed one hundred percent (100%) of the membership interests in TeleMed owned by Target to Lindsey and Thompson (the TeleMed Divestment );
(xx) the Subordination Agreement executed by Lindsey; and
(xxi) the Purchaser Note executed by Lindsey.
(b) At the Closing, Purchaser shall deliver to Target and the Member Representative, unless otherwise specified below, the following:
(i) the Purchaser Note duly executed by Purchaser;
(ii) a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Purchaser certifying that attached thereto are true and complete copies of all resolutions adopted by the board of directors of Purchaser authorizing the execution, delivery and performance of this Agreement and the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby, and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated hereby and thereby;
(iii) a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Purchaser certifying the names and signatures of the officers of Purchaser authorized to sign this Agreement, the Transaction Documents and the other documents to be delivered hereunder and thereunder;
(iv) the TeleMed Merger Agreement duly executed by Purchaser;
(v) the Lindsey Employment Agreement, duly executed by Purchaser;
(vi) the two checks payable to Frost Insurance Agency as required by Sections 6.13 and 6.17 ; and
(vii) the Subordination Agreement executed by Silicon Valley Bank and countersigned by Purchaser.
(c) At the Closing, Purchaser shall make, or cause the Surviving Corporation to make, the payments described in Section 2.05(b) .
(d) At the Closing, each of the Members shall deliver to Purchaser:
(i) A Noncompetition/Nonsolicitation Agreement in the form of Exhibit G attached hereto (the Noncompetition Agreement ) duly executed by such Member; and
(ii) A Release in the form of Exhibit H attached hereto (the Release Agreement ) duly executed by such Member.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF THE TARGET
Except as set forth in the correspondingly numbered Section of the Disclosure Schedules, Target represents and warrants to Purchaser that the statements contained in this ARTICLE IV are true and correct as of the date hereof and as of the Closing.
Section 4.01 Organization, Qualification and Capitalization of Target; APN .
(a) Target is a limited liability company duly organized, validly existing and in good standing under the Laws of the State of Florida. Target has full limited liability company power and authority to own, operate or lease the properties and assets now owned, operated or leased by it and to carry on its business as currently conducted by it. Section 4.01(a) of the Disclosure Schedules sets forth each jurisdiction in which Target is licensed or qualified to do business. Except as specified in Section 4.01(a) of the Disclosure Schedules, Target is duly licensed or qualified to do business and is in good standing in each jurisdiction in which the ownership of its assets or the operation of its business as currently conducted makes such licensing or qualification necessary.
(b) Immediately prior to the Effective Time, the authorized Equity Interests of Target consist of one million (1,000,000) Target Units, of which one hundred (100) Target Units are issued and outstanding. As of the Effective Time, there are no existing (i) options, warrants, calls, subscriptions or other rights, convertible securities, agreements or commitments of any character obligating the Target to issue, transfer or sell any Equity Interest in, the Target, (ii) contractual obligations of the Target to repurchase, redeem or otherwise acquire any Equity Interests of the Target, or (iii) voting trusts or similar agreements to which the Target is a party with respect to the voting of the Equity Interests of the Target.
(c) Section 4.01(c) of the Disclosure Schedules contains a full, complete and accurate schedule of the registered and beneficial holders of all of the issued and outstanding Equity Interests of Target of as of the date of this Agreement and as of the Effective Time (after giving effect to the Transactions contemplated by the Lindenbrook Assignment Agreement) (the Target Ownership Interests ). The Target Ownership Interests have been duly authorized and validly issued and are fully paid and non-assessable. Except for the Target Ownership Interests, there are no outstanding Equity Interests or other equity securities of Target, including (i) securities which are convertible into or exchangeable for any Equity Interests of Target, (ii) Contracts, arrangements, commitments or restrictions entered into by the Target relating to the issuance, sale, transfer, purchase or obtaining of Equity Interests of Target, or (iii) options, warrants, rights, calls or commitments of any character granted or issued by Target governing the issuance of its Equity Interests. None of the Target Ownership Interests were issued in violation
of the Securities Act or any other Law. There are no outstanding or authorized equity appreciation, phantom equity, profit participation, or similar rights with respect to Target. Except as set forth in Section 4.01(c) of the Disclosure Schedules, there are no (i) voting trusts, proxies, or other Contracts entered into by the Target with respect to the voting of the Target Ownership Interests, or (ii) obligations of Target to repurchase, redeem or otherwise acquire any Target Ownership Interest or to provide funds to, or make any investment (in the form of a loan, capital contribution or otherwise) in, the any other Person.
(d) Except as set forth in Section 4.01(d) of the Disclosure Schedules, Target (i) does not have any Subsidiaries other than APN, (ii) does not own any Equity Interests in any other Person, including AmeriDoc International Solutions, LLC, (iii) does not provide medical services through any Person, or (iv) is not party to any services or similar agreement with any professional association or entity regarding telemedicine or telehealth services; provided that it is acknowledged that, prior to the APN Divestment Target and APN provide medical services through APN and the Engaged Professionals.
(e) Attached as Section 4.01(e) of the Disclosure Schedules is a true and complete copy of the Second Amended & Restated Operating Agreement of Target dated March 29, 2012 ( Target Operating Agreement ), which is in full force and effect as of the date hereof and the Closing.
(f) At all times prior to the APN Divestment (i) one hundred percent (100%) of the issued and outstanding Equity Interests in APN were owned by Target, free and clear of any Encumbrances, and (ii) the sole business conducted by APN was to contract with the Engaged Professionals who would provide telehealth and/or telemedicine services to the Targets members, and to perform APNs respective obligations under such contracts to such Engaged Professionals, Target and Targets members.
(g) As of the date of this Agreement (but not as of the Effective Time) Lindenbrook is the sole record owner of good and marketable to the respective Target Ownership Interests set forth on Section 4.01(c) of the Disclosure Schedules, set forth opposite its name. As of the date of this Agreement, there are no voting trusts, proxies or similar agreements to which Target is a party with respect to the voting of the Lindenbrook Equity Interests in the Target or Contracts, arrangements, commitments, options, warrants, calls, rights or restrictions entered into by the Target with respect to the Lindenbrook Equity Interest in Target relating to the sale, transfer, purchase or redemption of such Equity Interest except the Target Operating Agreement and the Lindenbrook Assignment Agreement. Except as set forth in the Lindenbrook Assignment Agreement and the Target Operating Agreement, Target has not granted to any Person any right of first refusal, preemptive right, subscription right or similar right with respect to Lindenbrooks Equity Interests in Target.
Section 4.02 Authority . Target has full corporate power and authority to enter into this Agreement and the other Transaction Documents to which Target is a party, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery by Target of this Agreement and any other Transaction Document to which Target is a party, the performance by Target of its obligations hereunder and thereunder and the consummation by Target of the transactions contemplated hereby and thereby
have been duly authorized by all requisite limited liability company action on the part of Target. This Agreement has been duly executed and delivered by Target, and (assuming due authorization, execution and delivery by Purchaser) this Agreement constitutes a legal, valid and binding obligation of Target enforceable against Target in accordance with its terms. When each other Transaction Document to which Target is or will be a party has been duly executed and delivered by Target (assuming due authorization, execution and delivery by Purchaser), such Transaction Document will constitute a legal and binding obligation of Target enforceable against it in accordance with its terms.
Section 4.03 No Violation or Breach; Consents . The execution, delivery and performance by Target of this Agreement and the other Transaction Documents to which it is a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not: (a) result in a violation or breach of, or default under, any provision of the certificate of formation, company agreement or other organizational documents of Target or any resolution adopted by the governing body or owners of Target; (b) result in a violation or breach of any provision of any Law or Governmental Order applicable to Target, the Target Units or Targets business or assets; (c) except as set forth in Section 4.03 of the Disclosure Schedules, require the consent, notice or other action by any Person under, result in a violation or breach of, constitute a default or an event that, with or without notice or lapse of time or both, would constitute a default under, result in the acceleration of or create in any party the right to accelerate, terminate, modify or cancel any Contract or Permit to which Target is a party or by which Target or Targets business is bound or to which any of its assets are subject (including any Material Contract); or (d) result in the creation or imposition of any Encumbrance other than Permitted Encumbrances on Targets assets or the Target Units. Other than the filing of the Delaware Certificate of Merger with the Secretary of State of the State of Delaware and the filing of the Florida Certificate of Merger with the Florida Department of State, no consent, approval, Permit, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required by or with respect to Target in connection with the execution and delivery of this Agreement or any of the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby.
Section 4.04 Financial Statements . Complete copies of the audited financial statements of Target consisting of the balance sheet as of December 31 in each of the years 2012 and 2013 and the related statements of income and retained earnings, Members equity and cash flow for the years then ended (the Annual Financial Statements ), and unaudited financial statements of Target consisting of the balance sheet as of March 31, 2014 and the related statements of income and retained earnings, Members equity and cash flow for the three (3) month period then ended (the Interim Financial Statements and together with the Annual Financial Statements, the Financial Statements ) are included in Section 4.04 of the Disclosure Schedules. The Financial Statements have been prepared in accordance with GAAP applied on a consistent basis throughout the period involved, subject, in the case of the Interim Financial Statements, to normal and recurring year-end adjustments (the effect of which will not be materially adverse) and the absence of notes (that, if presented, would not differ materially from those presented in the Annual Financial Statements). The Financial Statements are based on the books and records of Target, and fairly and accurately present the financial condition of Target as of the respective dates they were prepared and the results of the operations of Target for the periods indicated. The balance sheet of Target as of December 31, 2013 is referred to
herein as the Balance Sheet and the date thereof as the Balance Sheet Date and the balance sheet of Target as of March 31, 2014 is referred to herein as the Interim Balance Sheet and the date thereof as the Interim Balance Sheet Date .
Section 4.05 Books and Records . The books of account and other financial records of Target, all of which have been made available to Purchaser, are complete and correct and represent actual, bona fide transactions and have been maintained in accordance with sound business practices and the requirements of Law, including the maintenance of a commercially reasonable system of internal controls.
Section 4.06 Undisclosed Liabilities . Target has no Liabilities, except those which (a) are adequately reflected or reserved against in the Balance Sheet as of the Balance Sheet Date, (b) are not required by GAAP to be reflected or reserved on the Balance Sheet, and (c) have been incurred in the ordinary course of business consistent with past practice since the Balance Sheet Date and which are not, individually or in the aggregate, material in amount.
Section 4.07 Absence of Certain Changes, Events and Conditions . Except as set forth in Section 4.07 of the Disclosure Schedules, since the Balance Sheet Date, there has not been any of the following with respect to Target or APN:
(a) event, occurrence or development that has had, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect;
(b) change in the authorized or issued Equity Interests of Target;
(c) amendment to the governing documents of Target;
(d) declaration or payment of any distributions on or in respect of any of Target Ownership Interests or redemption, purchase or acquisition of any Target Ownership Interests;
(e) material change in any method of accounting or accounting practice for Target, except as required by GAAP or as disclosed in the notes to the Financial Statements;
(f) material change in cash management practices and policies, practices and procedures with respect to collection of Accounts Receivable, establishment of reserves for uncollectible Accounts Receivable, accrual of Accounts Receivable, inventory control, prepayment of expenses, payment of trade accounts payable, accrual of other expenses, deferral of revenue and acceptance of customer deposits;
(g) entry into any Contract that would constitute a Material Contract;
(h) incurrence, assumption or guarantee of any indebtedness for borrowed money except unsecured current obligations and Liabilities incurred in the ordinary course of business consistent with past practice;
(i) transfer, assignment, sale or other disposition of any of the assets shown or reflected in the Balance Sheet, except for sales of inventory in the ordinary course of business;
(j) cancellation of any debts or claims or amendment, termination or waiver of any rights;
(k) transfer, assignment or grant of any license or sublicense of any material rights under or with respect to any Target Intellectual Property, Intellectual Property Assets or Intellectual Property Licenses other than non-exclusive licenses granted in the ordinary course of business;
(l) material damage, destruction or loss, or any material interruption in use, of any Targets assets whether or not covered by insurance;
(m) acceleration, termination, material modification to or cancellation of any Material Contract or Permit;
(n) material capital expenditures;
(o) imposition of any Encumbrance upon any of the Target Ownership Interests or the assets of Target;
(p) (i) grant of any bonuses, whether monetary or otherwise, or increase in any wages, salary, severance, pension or other compensation or benefits in respect of any employees, officers, directors, independent contractors or consultants, other than as provided for in any written agreements or required by applicable Law, (ii) change in the terms of employment for any employee or any termination of any employees for which the annual wages exceed $50,000, or (iii) action to accelerate the vesting or payment of any compensation or benefit for any employee, officer, director, consultant or independent contractor;
(q) adoption, modification or termination of any: (i) employment, severance, retention or other agreement with any current or former employee, officer, director, independent contractor or consultant, (ii) Benefit Plan, or (iii) collective bargaining or other agreement with a Union, in each case whether written or oral;
(r) any loan to (or forgiveness of any loan to), or entry into any other transaction with, any directors, officers or employees;
(s) adoption of any plan of merger, consolidation, reorganization, liquidation or dissolution or filing of a petition in bankruptcy under any provisions of federal or state bankruptcy Law or consent to the filing of any bankruptcy petition against it under any similar Law;
(t) purchase, lease or other acquisition of the right to own, use or lease any property or assets for an amount in excess of $10,000 individually (in the case of a lease, per annum) or $25,000 in the aggregate (in the case of a lease, for the entire term of the lease, not including any option term), except for purchases of supplies in the ordinary course of business consistent with past practice; or
(u) any Contract to do any of the foregoing, or any action or omission that would or would reasonably be expected to result in any of the foregoing.
Section 4.08 Material Contracts .
(a) Section 4.08(a) of the Disclosure Schedules lists each of the following Contracts (x) by which any of the Target Ownership Interests are bound or affected or (y) to which Target is a party or by which it is bound (such Contracts, together with all Leases listed or otherwise disclosed in Section 4.10(b) of the Disclosure Schedules and all Contracts relating to Intellectual Property set forth in Section 4.11(c) and Section 4.11(e) of the Disclosure Schedules, being Material Contracts ):
(i) all Contracts involving aggregate consideration in excess of $25,000 on an annual basis;
(ii) all Contracts (including employment agreements) which cannot be cancelled without a penalty or without more than 60 days notice;
(iii) all Contracts that require Target to purchase or sell a stated portion of the requirements or outputs or that contain take or pay provisions;
(iv) all Contracts that provide for the assumption of any Tax, environmental or other Liability of any Person;
(v) all Contracts that relate to the acquisition or disposition of any business, a material amount of Equity Interests or assets of any other Person or any real property (whether by merger, sale of stock, sale of assets or otherwise) other than previous term sheets regarding sales of Target Units that were terminated;
(vi) all broker, distributor, dealer, manufacturers representative, franchise, agency, sales promotion, market research, marketing consulting and advertising Contracts;
(vii) except for Contracts relating to trade payables, all Contracts relating to indebtedness (including, without limitation, guarantees) exceeding $5,000 individually or $15,000 in the aggregate;
(viii) all Contracts with any Governmental Authority;
(ix) all Contracts with customers, insurers, employers, managed care entities, payors or other purchasers of services from Target from which Target derives at least $35,000 in annual revenues (the Material Customer Contracts );
(x) all Contracts that limit or purport to limit the ability of Target to compete in any line of business or with any Person or in any geographic area or during any period of time;
(xi) all joint venture, partnership or similar Contracts;
(xii) all Contracts for the sale of any of the Target Ownership Interests or for the grant to any Person of any option, right of first refusal or preferential or similar right to purchase any of the Target Ownership Interests;
(xiii) all powers of attorney with respect to the Target or any of the Target Ownership Interests;
(xiv) all collective bargaining agreements or Contracts with any Union;
(xv) all Contracts under which the consequences of a default or termination could reasonably be expected to have a Material Adverse Effect;
(xvi) all Contracts with physicians and healthcare providers, or otherwise involving the provision of medical services; and
(xvii) all Contracts that include notice requirements related to a breach or potential breach of Healthcare Information Laws.
(b) Each Material Contract is valid and binding on Target, and to the Knowledge of Target, to the each other party thereto in accordance with its terms and is in full force and effect. Except as set forth in Section 4.08(b) of the Disclosure Schedule, Target has duly performed in all material respects its obligations under each Material Contract to which it is a party (to the extent that such obligations to perform have accrued). Neither Target, nor to the Knowledge of Target, any other party thereto, is in breach of or default under (or is alleged to be in breach of or default under), or has provided or received any notice of any intention to terminate, any Material Contract. To the Knowledge of Target, no counterparty to any Material Contract intends to terminate such Material Contract prior to the scheduled expiration of term of such Material Contract, decline renewal following the current term of such Material Contract or to materially alter the terms on which business is conducted under such Material Contract. No event or circumstance has occurred that, with notice or lapse of time or both, would or would reasonably be expected to constitute an event of default by Target under any Material Contract or result in a termination thereof or would or would reasonably be expected to cause or permit the acceleration or other changes of any right or obligation or the loss of any benefit thereunder. Complete and correct copies of each Material Contract (including all modifications, amendments and supplements thereto and waivers thereunder) have been made available to Purchaser. Except as set forth in Section 4.08(b) of the Disclosure Schedules, there are no disputes pending or, to the Knowledge of Target, threatened under any Material Contract or any other Contract to which Target is a party or by which its assets or the Target Ownership Interests are bound.
(c) Section 4.08(c) of the Disclosure Schedules sets forth all contracts to which APN was a party or by which its assets or business were bound immediately prior to the occurrence of the APN Divestment.
(d) Except as set forth in Section 4.08(d) of the Disclosure Schedules, Target is not a party to any Contract with Health Tech International Solutions, LLC f/k/a AmeriDoc International Solutions, LLC.
Section 4.09 Title to Assets; Condition and Sufficiency .
(a) Except as set forth in Section 4.09(a) of the Disclosure Schedules, Target has good, marketable and valid title to, or a valid leasehold interest in, all of the assets used thereby in connection with its business or otherwise purported to be owned or leased thereby. All such
assets (including leasehold interests) are free and clear of Encumbrances except for the following (collectively referred to as Permitted Encumbrances ):
(i) liens for Taxes not yet due and payable or being contested in good faith by appropriate procedures and for which there are adequate accruals or reserves on the Balance Sheet and the Interim Balance Sheet;
(ii) mechanics, carriers, workmens, repairmens or other like liens arising or incurred in the ordinary course of business consistent with past practice or amounts that are not delinquent and which are not, individually or in the aggregate, material to Target and for which there are adequate accruals or reserves on the Balance Sheet and the Interim Balance Sheet; and
(iii) workers or unemployment compensation liens arising in the ordinary course of business, which are not delinquent or past due.
(b) The furniture, fixture, machinery, equipment, vehicles and other items of tangible personal property used by the Target in connection with its business is in good operating condition and repair, are free from latent and patent defects, conform to all Laws and are adequate for the uses to which they are being put, and none of such items of tangible personal property is in need of maintenance or repairs except for ordinary, routine maintenance and repairs that are not material in nature or cost and except for such assets which have a zero value on the Targets Interim Balance Sheet. All tangible personal property used in connection with Targets business is in the possession of the Target. The assets owned or leased by the Target are sufficient for the continued conduct of the Business after the Closing in substantially the same manner as conducted prior to the Closing and constitute all of the rights, property and assets necessary to conduct the Business as currently conducted except for the assets set forth in Section 4.01(f) of the Disclosure Schedules.
Section 4.10 Real Property .
(a) Target does not own, or have an ownership interest in, nor has Target or APN ever owned, any real property.
(b) Section 4.10(b) of the Disclosure Schedules sets forth each parcel of real property leased by Target and used in or necessary for the conduct of its business as currently conducted (together with all rights, title and interest of Target in and to leasehold improvements relating thereto, including, but not limited to, security deposits, reserves or prepaid rents paid in connection therewith, collectively, the Leased Real Property ), and a true and complete list of all leases, subleases, licenses, concessions and other agreements (whether written or oral), including all amendments, extensions renewals, guaranties and other agreements with respect thereto, pursuant to which Target holds any Leased Real Property (collectively, the Leases ). Target has delivered to Purchaser a true and complete copy of each Lease. With respect to each Lease:
(i) such Lease is valid, binding, enforceable and in full force and effect, and Target enjoys peaceful and undisturbed possession of the Leased Real Property;
(ii) Target is not in breach or default under such Lease, and no event has occurred or circumstance exists which, with the delivery of notice, passage of time or both, would constitute such a breach or default, and Target has paid all rent due and payable under such Lease;
(iii) Target has not received nor given any notice of any default or event that with notice or lapse of time, or both, would constitute a default by Target under any of the Leases and, to the Knowledge of Target, no other party is in default thereof, and no party to any Lease has exercised any termination rights with respect thereto;
(iv) Except as set forth on Section 4.10(b)(iv) of the Disclosure Schedules, Target has not subleased, assigned or otherwise granted to any Person the right to use or occupy such Leased Real Property or any portion thereof; and
(v) Target has not pledged, mortgaged or otherwise granted an Encumbrance on its leasehold interest in any Leased Real Property.
(c) Target has not received any notice of (i) violations of building codes and/or zoning ordinances or other governmental or regulatory Laws affecting the Leased Real Property, (ii) existing, pending or threatened condemnation proceedings affecting the Leased Real Property, or (iii) existing, pending or threatened zoning, building code or other moratorium proceedings, or similar matters which could reasonably be expected to adversely affect the ability to operate the Leased Real Property as currently operated. No material portion of any Leased Real Property has been damaged or destroyed by fire or other casualty.
Section 4.11 Intellectual Property .
(a) The term Target Intellectual Property means all of the Intellectual Property material to the operation of Targets business as it is currently conducted, and as contemplated to be conducted, including (i) all Intellectual Property Registrations and (ii) all Intellectual Property Assets that are not registered but that are material to the operation of Targets business, all of which Intellectual Property Registrations and Intellectual Property Assets are listed on Section 4.11(a) of the Disclosure Schedules. All required filings and fees related to the Intellectual Property Registrations have been timely filed with and paid to the relevant Governmental Authorities and authorized registrars, and all Intellectual Property Registrations are otherwise in good standing. Target has provided Purchaser with true and complete copies of file histories, documents, certificates, office actions, correspondence and other materials related to all Intellectual Property Registrations.
(b) Target owns all right, title and interest in and to the Intellectual Property Assets, free and clear of Encumbrances. Without limiting the generality of the foregoing, Target has entered into binding, valid and enforceable written agreements with every current and former employee and independent contractor who contributed to or otherwise worked on the creation of any Intellectual Property Assets, whereby such employees and independent contractors (i) irrevocably assign to Target, any ownership interest and right they may have in the Intellectual Property Assets; and (ii) acknowledge Target, as applicable, exclusive ownership of all Intellectual Property Assets. Target has provided Purchaser with true and complete copies of
all such agreements. Target is in material compliance with all legal requirements applicable to the Intellectual Property Assets and the ownership and use thereof. With respect to each of the Intellectual Property Assets, except as specified in Section 4.11(b) of the Disclosure Schedules, (i) each Intellectual Property Asset is not subject to any outstanding injunction, judgment, order, decree, ruling, or charge; (ii) no Action is pending or, to the Knowledge of Target, is threatened which challenges the legality, validity, enforceability, use, or ownership of the Intellectual Property Assets; (iii) Target has not agreed to indemnify any Person for or against any interference, infringement, misappropriation, or other conflict with respect to the Intellectual Property Assets; and (iv) no loss or expiration of the Intellectual Property Assets is pending or, to the Knowledge of Target, threatened, except for patents or trademarks expiring at the end of their statutory terms or domain registrations expiring at the end of their contractual terms.
(c) Section 4.11(c) of the Disclosure Schedules lists all material Intellectual Property Licenses and the third party that owns the Intellectual Property subject to such Intellectual Property Licenses. Target has provided Purchaser with true and complete copies of all such material Intellectual Property Licenses. All such material Intellectual Property Licenses are valid, binding and enforceable between Target, and the other parties thereto, and Target, and to the Knowledge of Target, such other parties are in full compliance with the terms and conditions of such Intellectual Property Licenses. Target has obtained and possesses valid licenses to use all of the software programs present on the computers and other software-enabled electronic devices owned or leased thereby or that have otherwise been provided to their employees for their use in connection their employment.
(d) The Intellectual Property as currently or formerly owned, licensed or used by Target, and the conduct of their respective businesses as currently and formerly conducted by Target and APN have not, do not and will not infringe, violate or misappropriate the Intellectual Property of any Person. Target has not received any communication, and no Action has been instituted, settled or, to the Knowledge of Target, threatened that alleges any such infringement, violation or misappropriation, and none of the Target Intellectual Property is subject to any outstanding Governmental Order.
(e) Section 4.11(e) of the Disclosure Schedules lists all licenses, sublicenses and other agreements pursuant to which Target grants rights or authority to any Person with respect to any Target Intellectual Property. Target has provided Purchaser with true and complete copies of all such agreements. All such agreements are valid, binding and enforceable between Target, and the other parties thereto, and Target, and, to the Knowledge of Target, such other parties are in full compliance with the terms and conditions of such agreements. To the Knowledge of Target, no Person has infringed, violated or misappropriated, or is infringing, violating or misappropriating, any Intellectual Property Assets.
(f) Target has taken all necessary action to maintain and protect all of the Intellectual Property Assets so as not to adversely affect the validity or enforceability thereof in any material respect.
(g) Target does not use any inventions of any of their employees made prior to their employment by Target. Each employee has assigned to Target all Intellectual Property rights, if any, he or she developed while employed by Target.
(h) Section 4.11(h) of the Disclosure Schedules contains an accurate and complete list of all software that is distributed as open source software or under a similar licensing or distribution model (including but not limited to the GNU General Public License) ( Open Source Materials ) included by Target in any of Targets software, including Targets software in which such Open Source Materials are used and including whether (and, if so, how) the Open Source Materials were modified and/or distributed by Target. Target has not (i) incorporated Open Source Materials into, or combined Open Source Materials with, any of Targets software, or (ii) distributed Open Source Materials in conjunction with any of Targets software in the case of (i) or (ii) in such a manner as to create obligations for Target with respect to the Target Intellectual Property except for required copyright documents or grant or purport to grant, to any third party, any right or immunity with respect to any Target Intellectual Property (including any requirement that other software that is Target Intellectual Property and is incorporated into, derived from or distributed with such Open Source Materials be (A) disclosed or distributed in source code form, (B) licensed for the purpose of making derivative works, or (C) redistributable at no charge).
(i) Targets owned and licensed software and the related computer hardware used in connection with its business is adequate in all material respects, when taken together with its other assets, to run its business in the same manner (after taking into account the divestment of APN) as such business is now conducted.
(j) Target and APN complied in all material respects with all privacy regulations as mandated by Law and/or as required by third parties, as well as all privacy regulations set forth within the Targets or APNs privacy policies and websites.
(k) Target has taken reasonable and appropriate steps to protect and preserve the confidentiality of the trade secrets that comprise any part of the Target Intellectual Property, and to the Knowledge of Target, there have not occurred any unauthorized uses, disclosures or infringements of any such trade secrets by any Person. All use and disclosure by Target of trade secrets owned by another Person have been pursuant to the terms of a written agreement with such Person or was otherwise lawful. Without limiting the foregoing, Target has a policy requiring employees and certain consultants and contractors to execute a confidentiality and assignment agreement substantially in Targets standard form previously provided to Purchaser. Target has taken reasonable steps to enforce such policy consistent with standard industry practices.
(l) The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby will not result in (i) Target granting to any third party other than Purchaser any rights or licenses to any Intellectual Property or Intellectual Property rights, (ii) any right of termination or cancellation under any Intellectual Property agreement, or (iii) the imposition of any Encumbrance on any Target Intellectual Property.
(m) To the Knowledge of Target, no government funding, facilities of a university, college, other educational institution or research center or funding from third parties was used in the development of any Intellectual Property Asset. To the Knowledge of Target, no employee of Target who was involved in, or who contributed to, the creation or development of any Intellectual Property Assets, has performed services for the government, university, college, or
other educational institution or research center during a period of time during which such employee was also performing services for Target.
Section 4.12 Accounts Receivable and Accounts Payable .
(a) The Accounts Receivable reflected on the Interim Balance Sheet and the Accounts Receivable arising after the date thereof and on or before the Closing (a) have arisen from bona fide transactions entered into by Target involving the sale of goods or the rendering of services in the ordinary course of business consistent with past practice; (b) constitute only valid, undisputed claims of Target not subject to Encumbrances or claims of set-off or other defenses or counterclaims; and (c) subject a reserve for bad debts shown on the Interim Balance Sheet or, with respect to Accounts Receivable arising after the Interim Balance Sheet Date, subject to a reserve for bad debts shown on the accounting records of Target delivered to Purchaser prior to the Closing, are collectible in full, without any set-off, within 120 days after the later of the billing date or the date the services were provided. The reserve for bad debts shown on the Interim Balance Sheet or, with respect to Accounts Receivable arising after the Interim Balance Sheet Date, on the accounting records of Target have been determined in accordance with GAAP, consistently applied, subject to normal year-end adjustments and the absence of disclosures normally made in footnotes. Section 4.12(a) of the Disclosure Schedules sets forth a complete and accurate list of all Accounts Receivable as of the Interim Balance Sheet Date, including the aging of each Account Receivable. No account debtor with respect to any of such Accounts Receivable is a Governmental Authority (including any Federal healthcare program). The Target has not received notice of the bankruptcy or insolvency of the account debtor of any Accounts Receivable. None of such Accounts Receivable is evidenced by a judgment or chattel paper.
(b) All accounts payable reflected on the Interim Balance Sheet or arising thereafter and on or before the Closing are the result of bona fide transactions in the ordinary course of business and have been paid, are not yet due or payable or are otherwise subject to good faith dispute by Target and described on Section 4.12(b) of the Disclosure Schedules. Since the Balance Sheet Date, neither Target has altered in any material respects their practices for the payment of such accounts payable.
Section 4.13 Customers and Suppliers.
(a) Section 4.13(a) of the Disclosure Schedules sets forth with respect to Target (i) each customer (including without limitation any insurer, managed care entity, payor, employer, or other provider) who has accounted for aggregate gross revenue of Target in an amount greater than or equal to $10,000 during the twenty four (24) months ended February 28, 2014 (collectively, the Material Customers ); and (ii) the amount of consideration paid by each Material Customer during such periods. Except as specified in Section 4.13(a) of the Disclosure Schedules, Target has not received any notice that any of the Material Customers has ceased, or intends to cease after the Closing, to use the goods or services of Target, or to otherwise terminate or materially reduce its relationship with Target. Each Material Customer has transacted business with Target and otherwise acted substantially in accordance with the terms of its Contract consistent with the established course of conduct over the last twenty four (24) months. Except as specified in Section 4.13(a) of the Disclosure Schedules, since
February 28, 2013, no Material Customer has sought a material reduction in the prices it currently pays for services of Target, the level or scope of services it receives from Target or any other material modification of any payment term or other material term applicable to its purchases of services from Target or APN.
(b) Section 4.13(b) of the Disclosure Schedules sets forth with respect to Target and APN (i) each supplier or vendor to whom Target and APN paid aggregate consideration for goods or services rendered in an amount greater than or equal to $10,000 during the twenty-four (24) months ended February 28, 2014 (collectively, the Material Suppliers ); and (ii) the amount of purchases from each Material Supplier during such periods. Except as specified in Section 4.13(b) of the Disclosure Schedules, no Target Party has received any notice that any of the Material Suppliers has ceased, or intends to cease, to supply goods or services to Target or APN, or to otherwise terminate or materially reduce its relationship with Target or APN. Each Material Supplier has transacted business with Target and APN and otherwise acted substantially in accordance with the terms of its Contract consistent with the established course of conduct over the last twenty-four (24) months. Except as specified in Section 4.13(b) of the Disclosure Schedules, since February 28, 2013, no Material Supplier has sought a material increase in the prices it currently charges for services or products it provides to Target or APN, the level or scope of products or services it provides to Target or APN or any other material modification of any payment term or other material term applicable to its sales of products or services to Target or APN.
Section 4.14 Insurance . Section 4.14 of the Disclosure Schedules sets forth (a) a true and complete list of all current policies or binders of fire, liability, medical malpractice, product liability, umbrella liability, real and personal property, workers compensation, vehicular, fiduciary liability and other casualty, property and other insurance maintained by Target or APN (collectively, the Insurance Policies ); (b) each Insurance Policys applicable deductibles, coverage limits and whether or not such Insurance Policy provides coverage on an occurrence basis; and (c) a list of all pending claims and the claims history for Target and APN for the past five (5) years. To the Knowledge of Target, there are no grounds to believe that Target will not be able to renew such insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost. There are no claims related to Target or APN pending under any such Insurance Policies as to which coverage has been questioned, denied or disputed or in respect of which there is an outstanding reservation of rights. Target has not received any written notice of cancellation of, premium increase with respect to, or alteration of coverage under, any of such Insurance Policies, that has not been cured or withdrawn. All premiums due on such Insurance Policies have either been paid or, if not yet due, accrued. All such Insurance Policies (a) are in full force and effect and enforceable in accordance with their terms; (b) are provided by carriers who have an A.M. Best rating of at least A+; and (c) have not been subject to any lapse in coverage. Neither Target nor APN is in default under, or has otherwise failed to comply with, in any material respect, any provision contained in any such Insurance Policy. Neither Target nor APN has reached or exceeded its policy limits for any insurance policy in effect at any time during the past five (5) years. The Insurance Policies are of the type and in the amounts customarily carried by Persons conducting a business similar to Targets business and are sufficient for compliance with all applicable Laws and Contracts to which Target is a party or by
which it is bound. True and complete copies of the Insurance Policies have been made available to Purchaser.
Section 4.15 Legal Proceedings; Governmental Orders .
(a) Except as specified in Section 4.15(a) of the Disclosure Schedules, there is not currently, nor within the last three (3) years have there been, any Actions pending or, to the Knowledge of Target, threatened (a) against, related to or involving Target, APN, or their respective businesses, or any officer, director, employee or agent of Target or APN relating to Target, APN or their respective businesses, or the Target Ownership Interests; (b) that challenge or seek to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement or the Transaction Documents; or (c) that would otherwise reasonably be expected to have a Material Adverse Effect. To the Knowledge of Target, no event has occurred or circumstances exist that may give rise to, or serve as a basis for, any such Action. There is no Action pending by Target or APN, or which Target or, to the Knowledge of Target, APN, intends to initiate.
(b) Except as specified in Section 4.15(a) of the Disclosure Schedules, there are no outstanding or, to the Knowledge of Target, threatened Governmental Orders and no unsatisfied judgments, penalties or awards against, relating to or affecting the Target, APN, or their respective businesses or any officer, director, employee or agent of Target or APN, or the Target Ownership Interests.
Section 4.16 Compliance with Laws; Permits .
(a) Except as specified in Section 4.16(a) of the Disclosure Schedules, each of Target, APN and their respective businesses has been operated at all times since its inception, and currently is, in compliance in all material respects with all Laws or other rules or regulations of any Governmental Authority applicable to Target, APN, their respective businesses or the Target Ownership Interests, or by which any property, business or asset of Target or APN is bound or affected, relating to the operation of its business as heretofore conducted, including without limitation: (i) Laws or other rules or regulations of any Governmental Authority governing any federal health care program, including without limitation the Medicare and Medicaid programs and Law relating to health care fraud and abuse and referrals, including, without limitation: (A) the Anti-Kickback Law, 42 U.S.C. § 1320a 7b, 42 C.F.R. § 1001.952, (B) the Civil Monetary Penalties Law, 42 U.S.C. § 1320a 7a, (C) the physician self-referral prohibition, 42 U.S.C. § 1395nn, 42 C.F.R. § 411.351 et seq., (D) the False Claims Act, 31 U.S.C. § 3729 et seq., (E) the CHAMPUS statute (10 U.S.C. § 1071 et seq.), (F) the False Statement Accountability Act (18 U.S.C. § 1001), and (G) the Program Fraud Civil Penalties Act (31 U.S.C. § 3810 et seq.); (ii) state Laws or other rules or regulations relating to health care fraud and abuse and referrals; (iii) state Laws or other rules or regulations relating to Medicaid or any other state health care or health insurance programs; (iv) state Laws or other rules or regulations (including those rules and regulations followed by state boards of medicine) relating to the unlawful practice of medicine by physicians or corporations, aiding or abetting the unlicensed practice of medicine, unprofessional conduct, false, deceptive or misleading advertising, filling prescriptions or providing medical care across state lines, fee-splitting, or the payment of referral fees; (v) federal or state Laws or other rules or regulations relating to the manner of handling, processing, and timely paying claims for payment for health care items or
services; and (vi) other federal or state Laws or other rules or regulations relating to fraudulent, abusive or unlawful practices connected in any way with the provision of health care items or services or the billing or payment for such items or services.
(b) Since its inception, neither Target, APN nor any director, officer, employee or agent thereof, with respect to actions taken on behalf of Target or APN, or to the Knowledge of the Target, any physician employed by or under contract with Target or APN (an Engaged Professional ) with respect to actions taken on behalf of Target or APN (i) has been assessed a civil money penalty under Section 1128A of the Social Security Act (42 U.S.C. § 1320a 7a) or any regulations promulgated thereunder, (ii) has been excluded from participation in any federal health care program or state health care program (as such terms are defined by the Social Security Act), (iii) has been convicted of any criminal offense or has engaged in any act or conduct that would be a grounds for mandatory or permissive exclusion from participation in any federal health care program under Section 1128 of the Social Security Act (42 U.S.C. § 1320a 7), or (iv) is a party to or subject to any Action concerning any of the matters described above in clauses (i) through (iii).
(c) Target, APN, their respective businesses and each Engaged Professional, is in material compliance, to the extent applicable, with the terms and provisions of all Laws or other rules or regulations of any Governmental Authority relating to patient or individual healthcare information, including, without limitation, the Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104 191, as amended, and any rules or regulations promulgated thereunder and similar state Laws (collectively, the Healthcare Information Laws ). Except as specified in Section 4.16(c) of the Disclosure Schedules, Target and APN have (i) undertaken all surveys, audits, inventories, reviews, analyses, or assessments (including any necessary risk assessments) on all privacy, security and other areas reasonably required for compliance under all Healthcare Information Laws to the extent applicable to Targets and APNs operations as heretofore conducted, and (ii) taken all steps reasonably necessary to be in compliance with all Healthcare Information Laws to the extent applicable to Targets and APNs operations as heretofore conducted. At April 23, 2014, approximately 1,950,000 persons were registered and eligible for services provided by Target and during the three months ended March 31, 2014, the number of consults by such persons with Engaged Professionals was approximately 2,000 for informational consults and 13,100 for diagnostic consults.
(d) All Permits required for Target, APN, and each Engaged Professional to conduct their respective businesses as currently conducted or for the ownership and use of their respective assets have been obtained by Target, APN and each Engaged Professional and are valid and in full force and effect. Each of Target, APN and each Engaged Professional is in material compliance with all such Permits, and there are no provisions in, or Contracts relating to, any such Permits which preclude or restrict Target or APN from operating their respective businesses as they are currently operated. All fees and charges with respect to such Permits as of the date hereof and as of the Closing Date have been paid in full. Section 4.16(d) of the Disclosure Schedules lists all current Permits issued to Target or APN, including the names of the Permits and their respective dates of issuance and expiration. No event has occurred that, with or without notice or lapse of time or both, would reasonably be expected to result in the revocation, suspension, lapse or limitation of any Permit required to be set forth in Section 4.16(d) of the Disclosure Schedules.
(e) None of Target, APN, nor any Engaged Professional acting on their behalf has performed services for, nor received payment for services from, any Governmental Authority (including any federal healthcare program).
Section 4.17 Environmental Matters.
(a) The operations of Target, APN and their respective businesses are currently and have at all times been in compliance with all Environmental Laws. Target has not received from any Person, with respect to Target, APN or their respective businesses, any: (i) Environmental Notice or Environmental Claim; or (ii) written request for information pursuant to Environmental Law, which, in each case, either remains pending or unresolved, or is the source of ongoing obligations or requirements.
(b) There has been no Release of Hazardous Materials by Target, APN, their Affiliates or any of their respective Representatives in contravention of Environmental Law with respect to the business of Target or APN on any real property currently or formerly owned, leased or operated by Target or APN, and Target has not received an Environmental Notice that any of the business of Target or APN or real property currently or formerly owned, leased or operated by Target or APN (including soils, groundwater, surface water, buildings and other structure located thereon) has been contaminated with any Hazardous Material which could reasonably be expected to result in an Environmental Claim against, or a violation of Environmental Law or term of any Environmental Permit by, Target or APN.
(c) Neither Target nor APN has retained or assumed, by Contract or operation of Law, any Liabilities or obligations of third parties under Environmental Law.
Section 4.18 Employee Benefit Matters.
(a) Section 4.18(a) of the Disclosure Schedules sets forth a correct and complete list of all Benefit Plans and Benefit Agreements.
(b) Neither the Target nor APN nor any ERISA Affiliate of either of them has at any time contributed to or has any obligation to contribute to, or has any Liability with respect to (i) any multiemployer plan, as that term is defined in Section 4001 of ERISA; (ii) any employee benefit plan subject to Title IV of ERISA or Section 412 of the Code; (iii) any multiple employer welfare arrangement within the meaning of Section 3(40) of ERISA; or (iv) any Benefit Plan that is or is intended to be qualified under Section 401(a), 408(a) or 408(b) of the Code or any trust that is related to a Benefit Plan and intended to be Tax exempt under Section 501(a) of the Code. Each Benefit Plan has been administered, in all material respects, in accordance with its terms. The Target, APN and all the Benefit Plans are all in compliance with the applicable provisions of ERISA, the Code and all other applicable Laws, including Laws of foreign jurisdictions, except where such failure to comply will not result in a Material Adverse Effect. With respect to each Benefit Plan and Benefit Agreement, the Target and APN have provided to Participants all material communications or disclosures required by Law or by the terms of such Benefit Plan or Benefit Agreement, except where such failure to comply will not result in a Material Adverse Effect.
(c) Except as may be required by applicable Law, or as contemplated under this Agreement, neither the Target nor APN has announced any plan or commitment to create any additional Benefit Plans which are intended to cover employees or former employees of the Target or APN or to amend or modify any existing Benefit Plan which covers or has covered employees or former employees of the Target or APN, or to create, amend or modify any Benefit Agreement.
(d) To the extent applicable, correct and complete copies of the following have been delivered or made available to Purchaser by the Target: (i) all Benefit Plans and Benefit Agreements (including all amendments and attachments thereto); (ii) written summaries of any Benefit Plan and any Benefit Agreement not in writing; (iii) all related trust documents; (iv) all insurance Contracts or other funding arrangements; (v) the most recent annual report (Form 5500) filed with the Internal Revenue Service; (vi) the most recent determination letter from the Internal Revenue Service, if any; and (vii) the most recent summary plan description and any summary of material modification thereto.
(e) To the Knowledge of the Target, there are (i) no investigations, examinations, audits or proceedings by any Governmental Authority with respect to or involving any Benefit Plan or any fiduciary thereof, and, (ii) not any facts that would reasonably be expected to give rise to any such investigation, examination, audit or proceeding. There are no Actions, claims, suits or proceeding against or involving any Benefit Plan or Benefit Agreement or asserting any rights or claims to benefits under any Benefit Plan or Benefit Agreement (except claims for benefits payable in the normal operation of the Benefit Plan or Benefit Agreement), and, to the Knowledge of the Target, there are not any facts that would reasonably be expected to give rise to any such Action, claim, suit or proceeding.
(f) With respect to each Benefit Plan, (i) (A) there has not occurred prior to the date hereof any prohibited transaction (within the meaning of Section 406 of ERISA or Section 4975 of the Code) that could subject the Target or APN or any of their respective employees to any material liability and (B) following the date hereof and prior to the Effective Time, there will not occur any prohibited transaction (within the meaning of Section 406 of ERISA or Section 4975 of the Code) that could subject Purchaser of the Surviving Corporation or any of their respective employees to any Liabilities and (ii) neither the Target nor APN nor any of their directors, employees or agents has engaged in any transaction or acted in a manner, or failed to act in a manner, that would reasonably be expected to subject the Target or APN or any of their respective employees to liability for breach of fiduciary duty under ERISA or any other applicable Law.
(g) Section 4.18(g) of the Disclosure Schedules discloses whether each Benefit Plan and each Benefit Agreement that is an employee welfare benefit plan is (i) unfunded or self-insured, (ii) funded through a welfare benefit fund, as such term is defined in Section 419(e) of the Code, or other funding mechanism, or (iii) insured.
(h) None of the execution and delivery of this Agreement nor the Transaction Documents, the obtaining of the approval of the Members or the consummation of the Merger or any other transaction contemplated hereby or thereby (whether alone or as a result of any termination of employment on or following the Effective Time) will, except as expressly
contemplated by this Agreement, (i) entitle any Participant to severance, termination, retention, change in control or similar compensation or benefits, (ii) accelerate the time of payment or vesting, or trigger any payment or funding (through a grantor trust or otherwise) of, compensation or benefits under, increase the amount payable or trigger any other material obligation pursuant to any Benefit Plan or Benefit Agreement, or (iii) prohibit any Benefit Plan or Benefit Agreement from being amended or terminated.
(i) The Target and APN have correctly classified each individual who performs services for the Target or APN as a common law employee, an independent contractor, or a leased employee, as applicable, in accordance with the provisions of each Benefit Plan, and in accordance with ERISA, the Code, and other applicable Laws.
(j) Each Benefit Plan and each Benefit Agreement that is a nonqualified deferred compensation plan within the meaning of Section 409A(d)(1) of the Code (a Nonqualified Deferred Compensation Plan ) subject to Section 409A of the Code was, as of January 1, 2005, in good faith compliance with Section 409A of the Code and the then applicable guidance issued by the Internal Revenue Service thereunder (together, the 409A Authorities ). Since December 31, 2008, each Nonqualified Deferred Compensation Plan has remained in documentary and operational compliance with the 409A Authorities. No Participant is entitled to any gross-up, make-whole or other additional payment from the Target or APN in respect of any Tax (including federal, state, local or foreign income, excise or other Taxes (including Taxes imposed under Sections 280G and 409A of the Code)) or interest or penalty related thereto.
(k) Other than payments or benefits that may be made to the Persons listed in Section 4.18(l) of the Disclosure Schedules, no amount or other entitlement or economic benefit that could be received (whether in cash or property or the vesting of property) as a result of the execution and delivery of this Agreement or the Transaction Documents, the obtaining of the approval of the Members or the consummation of the Merger or any other transaction contemplated hereby or thereby (alone or in combination with any other event, including as a result of termination of employment on or following the Effective Time) by or for the benefit of any Person who is a disqualified individual (as defined in Treasury Regulations Section 1.280G-1) with respect to the Target under any Benefit Plan, Benefit Agreement or otherwise would be characterized as an excess parachute payment (as defined in Section 280G(b)(1) of the Code).
(l) With respect to each Benefit Plan that is an employee welfare benefit plan (as such term is defined in Section 3(1) of ERISA), all premiums or other payments for all periods ending on or before the Effective Time have been paid or accrued in accordance with GAAP.
Section 4.19 Employment Matters .
(a) Section 4.19(a) of the Disclosure Schedules contains a list of all Persons who are currently employees, independent contractors or consultants of Target (including all Engaged Professionals currently engaged or employed by Target), and sets forth for each such individual the following: (i) name; (ii) title or position (including whether full or part time); (iii) hire date; (iv) current annual base compensation rate; (v) commission, bonus or other incentive-based compensation; and (vi) a description of the fringe benefits currently provided to each such
individual. Except as set forth on Section 4.19(a) of the Disclosure Schedules, Target is not a party to any employee agreement, independent contractor agreement or other Contract with any employee or independent contractor. As of the date hereof, all compensation, including wages, commissions and bonuses payable to employees, independent contractors or consultants of Target (including all Engaged Professionals, if any) for services performed on or prior to the date hereof have been paid in full, and as of the Closing Date, all compensation, including wages, commissions and bonuses payable to employees, independent contractors or consultants of Target (including all Engaged Professionals, if any) for services performed on or prior to the Closing Date will have been paid in full.
(b) Target is not, or has ever been, a party to, bound by, or negotiating any collective bargaining agreement or other Contract with a union, works council or labor organization (collectively, Union ), and there is not now, nor have there ever been, any Union representing or purporting to represent any employee of Target, and, to the Knowledge of Target, no Union or group of employees is seeking or has sought to organize employees for the purpose of collective bargaining. Except as set forth in Section 4.19(b) of the Disclosure Schedules, there is not, nor has there ever been, any threat of, any strike, slowdown, work stoppage, lockout, concerted refusal to work overtime or other similar labor disruption or dispute affecting Target or any employees, independent contractors or consultants of Target (including any Engaged Professionals, if any).
(c) Each of Target and APN is and has been in material compliance with all applicable Laws pertaining to employment and employment practices, including all Laws relating to labor relations, equal employment opportunities, fair employment practices, employment discrimination, harassment, retaliation, reasonable accommodation, disability rights or benefits, immigration, wages, hours, overtime compensation, child labor, hiring, promotion and termination of employees, working conditions, meal and break periods, privacy, health and safety, workers compensation, leaves of absence and unemployment insurance. All employees of Target or APN classified as exempt under the Fair Labor Standards Act and state and local wage and hour laws are properly classified. There are no Actions against Target or APN pending, or to the Knowledge of Target, threatened to be brought or filed, by or with any Governmental Authority or arbitrator in connection with the employment of any current or former applicant, employee, consultant or independent contractor of Target or APN, including, without limitation, any claim relating to unfair labor practices, employment discrimination, harassment, retaliation, equal pay, wages and hours or any other employment related matter arising under applicable Laws.
(d) Target has complied in all respects with the WARN Act.
Section 4.20 Taxes . Except as set forth in Section 4.20 of the Disclosure Schedules:
(a) All Tax Returns required to be filed by Target or APN prior to Closing for any Pre-Closing Tax Period have been timely filed. Such Tax Returns are true, complete and correct in all material respects. All Taxes due and owing by Target or APN prior to Closing (whether or not shown on any Tax Return) have been timely paid.
(b) Target and APN have withheld and paid each Tax required to have been withheld and paid in connection with amounts paid or owing to any employee, independent contractor, creditor, customer, Member or other party, and complied with all information reporting and backup withholding provisions of applicable Law.
(c) Target and APN have delivered or made available to Purchaser (i) complete and correct copies of all Tax Returns of Target and APN relating to Taxes for all taxable periods for which the applicable statute of limitations has not yet expired, (ii) complete and correct copies of all private letter rulings, revenue agent reports, information document requests, notices of proposed deficiencies, deficiency notices, protests, petitions, closing agreements, settlement agreements, pending ruling requests and any similar documents submitted by, received by, or agreed to by or on behalf of Target or APN relating to Taxes for any taxable period for which the statute of limitations has not yet expired, and (iii) complete and correct copies of all material agreements, rulings, settlements or other Tax documents with or from any Governmental Authority relating to Tax incentives of the Target or APN.
(d) No extensions or waivers of statutes of limitations have been given or requested with respect to any Taxes of Target or APN.
(e) All deficiencies asserted, or assessments made, against Target or APN as a result of any examinations by any taxing authority have been fully paid.
(f) Neither Target nor APN is a party to any Action by any taxing authority. There are no pending or, to the Knowledge of Target, threatened Actions by any taxing authority against or involving Target, APN, their respective businesses or the Target Ownership Interests.
(g) Neither Target nor APN is (or within the past three (3) calendar years has been) a party to any engagement relating to the sharing of Tax benefits or Liabilities.
(h) Neither Target nor APN has been informed by any jurisdiction that such entity has not filed a Tax Return that the jurisdiction believes Target or APN was required to file.
(i) Neither Target nor APN is or has ever been a member of a group of Persons with which it has filed (or been required to file) consolidated, combined or unitary Tax Returns except for any consolidated, combined or unitary Tax Return with Target as the common parent. Neither Target nor APN has any actual or potential liability under Treasury Regulations Section 1.1502-6 (or any comparable or similar provision of state, local or foreign Law), as a transferee or successor, pursuant to any contractual obligation, or otherwise for any Taxes of any Person other than Target or APN.
(j) There are no Encumbrances for Taxes upon any of the assets of Target or APN nor, to the Knowledge of Target, is any taxing authority in the process of imposing any Encumbrances for Taxes on any of the assets of Target or APN (other than for current Taxes not yet due and payable).
(k) Neither Target nor APN is, or has been, a United States real property holding corporation within the meaning of Section 897(c) of the Code during the applicable period specified in Code Section 897(c)(1)(A)(ii).
(l) Neither Target nor APN is, or has been, a party to, or a promoter of, a reportable transaction within the meaning of Section 6707A(c)(1) of the Code and Treasury Regulations Section 1.6011-4(b).
(m) None of the assets of Target or APN are tax-exempt use property within the meaning of Section 168(h) of the Code.
(n) The consummation of the transactions contemplated by this Agreement will not result in any liability to Target, APN, Purchaser, or the Surviving Corporation for transfer, documentary, sales, use, stamp, registration, value added and other such Taxes and fees (including any penalties and interest) incurred in connection with this Agreement and the Transaction Documents (including any real property transfer Tax and any other similar Tax).
(o) Neither Target nor APN (i) is a party to any joint venture, partnership, or other arrangement that is treated as a partnership for federal income Tax purposes, (ii) has made an entity classification (check-the-box) election under Section 7701, (iii) is or has ever been a shareholder of a controlled foreign corporation as defined in Section 957 of the Code (or any similar provision of state, local or foreign Law), or (iv) is or has ever been an owner in a passive foreign investment company within the meaning of Section 1297 of the Code.
(p) Neither Target nor APN has a request for a private letter ruling, a request for administrative relief, a request for technical advice, a request for a change of any method of accounting, or any other similar request that is in progress or pending with any Governmental Authority with respect to Taxes or Tax Returns.
(q) Neither Purchaser nor the Surviving Corporation shall be required to include an item of income, or exclude an item of deduction, for any period after the Closing Date as a result of: (i) an installment sale transaction by Target or APN occurring on or before the Closing governed by Section 453 of the Code (or any similar provision of state, local or non-U.S. Laws); (ii) a transaction by Target or APN occurring on or before the Closing Date reported as an open transaction for U.S. federal Income Tax purposes (or any similar doctrine under state, local or non-U.S. Laws); (iii) any prepaid amounts received on or prior to the Closing Date by Target or APN; (iv) a change in any Targets or APNs method of accounting on or prior to the Closing Date; or (v) an agreement entered into by Target or APN with any Governmental Authority (including a closing agreement under Section 7121 of the Code) on or prior to the Closing Date. Neither Target nor APN has made an election (including a protective election) pursuant to Section 108(i) of the Code. Neither Target nor APN has any long-term contracts that are subject to a method of accounting provided for in Section 460 of the Code.
(r) Neither Target nor APN has made any payment, nor is obligated to make any payment or is a party to any agreement, Contract, arrangement or plan that could obligate it to make any payment, that may be treated as an excess parachute payment under Section 280G of the Code.
(s) Except as set forth on Section 4.20 of the Disclosure Schedules, neither Target nor APN is a party to any agreement to pay, gross up or otherwise indemnify any employee,
consultant or independent contractor for any Taxes, including potential Taxes imposed under Sections 409A or 4999 of the Code, incurred with respect to services provided to Target or APN.
(t) Target has since its formation been treated as a partnership for federal income tax purposes. APN has been since its formation treated as a disregarded entity for federal income Tax purposes. No Governmental Authority has challenged the federal income Tax treatment of APN.
Section 4.21 Brokers . Except as provided in Section 4.21 of the Disclosure Schedules (any Persons required to be listed on Section 4.21 of the Disclosure Schedules being referred to herein as a Broker ), no broker, finder or investment banker is entitled to any brokerage, finders or other fee or commission in connection with the transactions contemplated by this Agreement or any other Transaction Document based upon arrangements made by or on behalf of the Target.
Section 4.22 Network Redundancy and Computer Back Up . Except as could not reasonably be expected to have a Material Adverse Effect, Target has made backups of all computer software and databases utilized by it and maintains such software and databases at a secure off site location. Target has established a data recovery plan sufficient to restore service in a commercially reasonable amount of time in the event of a critical system failure or employs a remote failover system.
Section 4.23 Privacy of Customer Information . Neither Target nor APN uses any of the customer information it receives through its website or otherwise in a manner violative of the Targets and APNs privacy policy or the privacy rights of its customers under applicable Law.
Section 4.24 Inspections and Investigations . Except as set forth and described in Section 4.24 of the Disclosure Schedules, (i) neither Target, APN nor any Engaged Professional or other Person affiliated with the Target or APN or who has provided services to Target or APN during the past seven (7) years, has been the subject of any inspection, investigation, survey, audit, monitoring or other form of review by any Governmental Authority, trade association, professional review organization, accrediting organization or certifying agency based upon any alleged improper activity on the part of Target, APN or such individual where such alleged improper activity related to the operations of Target or APN, nor has Target or APN received any notice of deficiency during the past seven (7) years in connection with the operations of the Target or APN; (ii) there are not presently any outstanding deficiencies or orders of any Governmental Authority having jurisdiction over Target, APN or any of their assets or properties, or requiring conformity to any applicable agreement, Law, regulation, ordinance or bylaw; and (iii) there is not any notice of any claim, requirement or demand of any licensing or certifying agency or other third party supervising or having authority over the Target, APN or their assets or properties of non-conformance or failure to comply with any existing Law, code, rule, regulation or standard.
Section 4.25 Rates and Reimbursement Policies . Except for ethical limitations, the jurisdictions in which Target and APN conduct business do not currently impose any restrictions or limitations on rates which may be charged to patients receiving services provided by Target or APN. Neither Target nor APN has any rate appeal currently pending before any Governmental
Authority. Target has no Knowledge of any applicable Law, which has been enacted, promulgated, or issued within the twenty four (24) months preceding the date of this Agreement requiring Target to obtain any necessary authorization for its Business as currently conducted (excluding the business of APN) which it does not currently have which could reasonably be expected to have a Material Adverse Effect if the Target failed to obtain such necessary authorization.
Section 4.26 No Disagreements with Accountants and Lawyers . Except as set forth in Section 4.26 of the Disclosure Schedules, there are no disagreements of any kind presently existing, or reasonably anticipated by the Target to arise, between the accountants and lawyers formerly or presently engaged by Target or APN, and Target and APN are current with respect to any fees owed to their accountants and lawyers.
Section 4.27 Solvency . Neither Target nor APN is Insolvent, or will be rendered Insolvent by any of the transactions contemplated by this Agreement. As used in this Section, Insolvent means that the sum of the debts and other probable Liabilities of a Person exceeds the present fair saleable value of such Persons assets.
Section 4.28 Virtus Agreement . The Virtus Exclusivity Restriction (defined below) has expired in accordance with its terms. For purposes of this Agreement, the term Virtus Exclusivity Restriction means that portion of the Ameridoc Producer Appointment Agreement between Target and Virtus Benefits, LLC, a Delaware limited liability company, as amended, providing that Save and except any persons or entities that have existing relationships with AMERIDOC, or are recruited by such persons or entities (and any business submitted to AMERIDOC by and through such persons or entities), AMERIDOC will by phone call and email refer all, and not less than all, prospects located in the states of Alabama, Kentucky, North Carolina, South Carolina, and Tennessee that contact AMERIDOC directly via phone call, email or website contact, to Producer for contracting under Producers commissions hierarchy.
Section 4.29 Full Disclosure . To the Knowledge of Target, no representation or warranty by any Target Party in this Agreement and no statement contained in the Disclosure Schedules to this Agreement or in any certificate or other document furnished or to be furnished to Purchaser pursuant to this Agreement contains any untrue statement of a material fact, or omits to state a material fact necessary to make the statements contained therein, in light of the circumstances in which they are made, not misleading.
ARTICLE IV-A
REPRESENTATIONS AND WARRANTIES OF THE MEMBERS
Each Member represents and warrants to the Purchaser that the statements contained in this ARTICLE IV-A are true and correct with respect to such Member as of the date hereof and as of the Closing.
Section 4.01-A Ownership . The Member is the sole record and beneficial owner of good and marketable to the respective Target Ownership Interest set forth on Section 4.01(c) of the Disclosure Schedules, set forth opposite his or its name, free and clear of any Encumbrances. As of the Effective Time, there are no voting trusts, proxies or similar
agreements to which the Member is a party with respect to the voting of the Equity Interests of the Target or Contracts, arrangements, commitments, options, warrants, calls, rights or restrictions entered into by a Member with respect to its Equity Interest in Target relating to the sale, transfer, purchase or redemption of such Equity Interest except the Target Operating Agreement. Except as set forth in the Target Operating Agreement, the Member has not granted to any Person any right of first refusal, preemptive right, subscription right or similar right with respect to such Members Target Ownership Interests.
Section 4.02-A Authority . The Member is of the age of majority and has full power and authority and is competent to enter into this Agreement and the other Transaction Documents to which such Member is a party, to carry out its obligations hereunder and thereunder, and to consummate the transactions contemplated hereby and thereby. This Agreement has been duly executed and delivered by the Member, and (assuming due authorization, execution and delivery by Purchaser) this Agreement constitutes a legal, valid and binding obligation of the Member enforceable against the Member in accordance with its terms. When each other Transaction Document to which the Member is or will be a party has been duly executed and delivered by such Member (assuming due authorization, execution and delivery by Purchaser), such Transaction Document will constitute a legal and binding obligation of such Member enforceable against him or it in accordance with its terms.
Section 4.03-A No Breach; Consents . The execution, delivery and performance by the Member of this Agreement and the other Transaction Documents to which he or it is a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not: (a) result in a violation or breach of, or default under, any provision of the certificate of formation, company agreement or other organizational documents of the Member or any resolution adopted by the governing body or owners of the Member; (b) result in a violation or breach of any provision of any Law or Governmental Order applicable to the Member, or the Members Target Units; (c) except as set forth in Section 4.03 of the Disclosure Schedules, require the consent, notice or other action by any Person under, result in a violation or breach of, constitute a default or an event that, with or without notice or lapse of time or both, would constitute a default under, result in the acceleration of or create in any party the right to accelerate, terminate, modify or cancel any Contract or Permit to which the Member is a party or by which the Member or the Members Target Units is bound or to which any of its assets are subject; (d) result in the creation or imposition of any Encumbrance other than Permitted Encumbrances on the Target Units. Other than the filing of the Delaware Certificate of Merger with the Secretary of State of the State of Delaware and the filing of the Florida Certificate of Merger with the Florida Department of State, no consent, approval, Permit, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required by or with respect to the Member in connection with the execution and delivery of this Agreement or any of the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby.
Section 4.04-A Brokers . No broker, finder or investment banker is entitled to any brokerage, finders or other fee or commission in connection with the transactions contemplated by this Agreement or any other Transaction Document based upon arrangements made by or on behalf of the Member.
Section 4.05-A Full Disclosure . To the Knowledge of each Member, no representation or warranty by the Member in this Agreement and no statement contained in the Disclosure Schedules to this Agreement or with respect to such Member in any certificate or other document furnished or to be furnished to Purchaser pursuant to this Agreement contains any untrue statement of a material fact, or omits to state a material fact necessary to make the statements contained therein, in light of the circumstances in which they are made, not misleading.
ARTICLE V
REPRESENTATIONS AND WARRANTIES OF PURCHASER
Purchaser represents and warrants to the Target that the statements contained in this ARTICLE V are true and correct as of the date hereof and as of the Closing.
Section 5.01 Organization of Purchaser . Purchaser is a corporation duly organized, validly existing and in good standing under the Laws of the State of Delaware.
Section 5.02 Authority of Purchaser . Purchaser has full corporate power and authority to enter into this Agreement and the other Transaction Documents to which it is a party, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery by Purchaser of this Agreement and any other Transaction Document to which it is a party, the performance by it of its obligations hereunder and thereunder and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all requisite corporate action on the part of Purchaser. This Agreement has been duly executed and delivered by Purchaser, and (assuming due authorization, execution and delivery by the Target Parties) this Agreement constitutes a legal, valid and binding obligation of Purchaser enforceable against Purchaser in accordance with its terms. When each other Transaction Document to which Purchaser is or will be a party has been duly executed and delivered thereby (assuming due authorization, execution and delivery by each other party thereto), such Transaction Document will constitute a legal and binding obligation of Purchaser, as applicable, enforceable against it in accordance with its terms.
Section 5.03 No Conflicts; Consents . The execution, delivery and performance by Purchaser of this Agreement and the other Transaction Documents to which it is a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not: (a) conflict with or result in a violation or breach of, or default under, any provision of the certificate of incorporation, by-laws or other organizational documents of Purchaser; (b) conflict with or result in a violation or breach of any provision of any Law or Governmental Order applicable to Purchaser; or (c) require the consent, notice or other action by any Person under any Contract to which Purchaser is a party. Other than the filing of the Delaware Certificate of Merger with the Secretary of State of the State of Delaware and the filing of the Florida Certificate of Merger with the Florida Department of State, no consent, approval, Permit, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required by or with respect to Purchaser in connection with the execution and delivery of this Agreement and the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby.
Section 5.04 Brokers . No broker, finder or investment banker is entitled to any brokerage, finders or other fee or commission in connection with the transactions contemplated by this Agreement or any other Transaction Document based upon arrangements made by or on behalf of Purchaser.
Section 5.05 Legal Proceedings . There are no Actions pending or, to Purchasers knowledge, threatened against or by Purchaser, or any Affiliate of Purchaser that challenge or seek to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement. No event has occurred or circumstances exist that may give rise or serve as a basis for any such Action.
ARTICLE VI
COVENANTS
Section 6.01 Conduct of Business . Target shall, during the period from the date of this Agreement until the earlier to occur of the Effective Time or the termination of this Agreement in accordance with its terms, except as expressly contemplated by this Agreement or as required by applicable Law or with the prior written consent of Purchaser, conduct its business in the ordinary course of business consistent with past practice, and, to the extent consistent therewith, Target shall use its commercially reasonable best efforts to preserve substantially intact its business organization, to keep available the services of its officers and employees, to preserve its present relationships with customers, suppliers, vendors, distributors, resellers, licensors, licensees and other Persons having business relationships with it. Without limiting the generality of the foregoing, between the date of this Agreement and the Effective Time, except as otherwise expressly contemplated by this Agreement (including, but not limited to, the APN Divestment and the TeleMed Divestment) or the Lindenbrook Assignment Agreement, or as required by applicable Law, Target shall not, without the prior written consent of Purchaser (which consent shall not be unreasonably withheld):
(a) amend its certificate of formation or the Target Operating Agreement;
(b) (i) repurchase, redeem or otherwise acquire any Target Ownership Interests, (ii) declare, set aside or pay any distribution (whether in cash, Target Units, property or otherwise) in respect of, or enter into any Contract with respect to the voting of, any Target Ownership Interests;
(c) issue, sell, pledge, dispose of or encumber any Target Ownership Interests;
(d) except as required by applicable Law or by any Benefit Plan or Contract in effect as of the date of this Agreement, (i) increase the compensation payable or that could become payable by the Target to its Representatives, other than increases in compensation made in the ordinary course of business consistent with past practice, (ii) enter into any new or amend in any material respect, any existing employment, severance, retention or change in control agreement with any of its past or present Representatives, or (iii) establish, adopt, enter into, amend, terminate, exercise any discretion under, or take any action to accelerate rights under any Benefit Plans, or make any contribution to any Benefit Plan, other than contributions required by Law,
the terms of such Benefit Plans as in effect on the date hereof or that are made in the ordinary course of business consistent with past practice;
(e) acquire, by merger, consolidation, acquisition of stock or assets, or otherwise, any business or Person or division thereof or make any loans, advances or capital contributions to or investments in any Person;
(f) (i) transfer, license, sell, lease or otherwise dispose of any assets (whether by way of merger, consolidation, sale of stock or assets, or otherwise), provided that the foregoing shall not prohibit the Target and its Subsidiaries from transferring, licensing, selling, leasing or disposing of obsolete equipment or assets being replaced, in each case in the ordinary course of business consistent with past practice, or (ii) adopt or effect a plan of complete or partial liquidation, dissolution, restructuring, recapitalization or other reorganization;
(g) repurchase, prepay or incur any indebtedness for borrowed money or guarantee any such indebtedness of another Person;
(h) enter into or amend or modify in any material respect, or consent to the termination of (other than at its stated expiry date), any Material Contract;
(i) institute, settle or compromise any Actions pending or threatened before any arbitrator, court or other Governmental Authority involving the payment of monetary damages by the Target;
(j) except as required by applicable Law or to change from cash basis to accrual, make any material change in any method of financial accounting principles or practices;
(k) (i) settle or compromise any material Tax claim, audit or assessment, (ii) make or change any material Tax election, change any annual Tax accounting period, adopt or change any method of Tax accounting, (iii) amend any material Tax Returns or file claims for material Tax refunds, or (iv) enter into any material closing agreement, surrender in writing any right to claim a material Tax refund, offset or other reduction in Tax liability or consent to any extension or waiver of the limitation period applicable to any material Tax claim or assessment relating to Target;
(l) enter into any material agreement, agreement in principle, letter of intent, memorandum of understanding or similar Contract with respect to any joint venture, strategic partnership or alliance;
(m) abandon, encumber, convey title (in whole or in part), exclusively license or grant any right or other licenses to Targets Intellectual Property Assets, other than in the ordinary course of business consistent with past practice; or
(n) agree or commit to do any of the foregoing.
Section 6.02 Other Actions . From the date of this Agreement until the earlier to occur of the Effective Time or the termination of this Agreement in accordance with its terms, neither Purchaser nor any of the Target Parties shall take, or agree or commit to take, any action that
would reasonably be expected to, individually or in the aggregate, prevent, materially delay or materially impede the consummation of the Merger or the other transactions contemplated by this Agreement.
Section 6.03 Access to Information . From the date of this Agreement until the earlier to occur of the Effective Time or the termination of this Agreement in accordance with its terms, Target shall afford to Purchaser and its Representatives reasonable access, at reasonable times and in a manner as shall not unreasonably interfere with the business or operations of Target, to the Representatives, officers, employees, accountants, agents, properties, offices and other facilities and to all books, records, Contracts and other assets of Target, and Target shall furnish promptly to Purchaser such other information concerning the business and properties of Target as Purchaser may reasonably request from time to time. Target shall not be required to provide access to or disclose information where such access or disclosure would contravene any Law (it being agreed that the parties shall use their reasonable best efforts to cause such information to be provided in a manner that would not result in such contravention).
Section 6.04 Exclusivity; No Shop; Break-Up Fee . As required by that certain letter of intent between Purchaser and Target dated as of February 11, 2014, and in consideration of the substantial expenditures of time, effort and money to be undertaken by Purchaser in connection with the preparation and execution of this Agreement and the other Transaction Documents, the various reviews and due diligence investigations referred to herein, Target hereby undertakes and agrees that for the period beginning on February 11, 2014 and terminating on the earlier to occur of the Effective Time or the termination of this Agreement in accordance with its terms (the Restriction Period ), Target and the Members shall not (x) enter into or conduct any discussions or communications of any kind with any other prospective purchaser or third party for the purchase of any of Target Ownership Interests or the assets of Target or the merger of Target or other similar transaction with Target (collectively, a Transaction ), (y) solicit or encourage (including by way of furnishing any non-public information concerning Targets business, properties or assets) any proposal regarding a Transaction. In the event an unsolicited Transaction or other similar proposal for or regarding Target is received during the Restriction Period by Target or the Members, Target shall promptly notify Purchaser and provide Purchaser with detailed information about any such proposal. In the event that Target agrees to a Transaction with another Person during the Restriction Period or the sixty (60) day period thereafter, Target shall be obligated to pay to Purchaser the sum of One Million Dollars ($1,000,000). Such sum shall be immediately due and payable upon the execution of any document related to any such transaction.
Section 6.05 Notices of Certain Events . Purchaser shall notify the Target Parties, and the Target Parties shall notify Purchaser, promptly of (i) any notice or other communication from any Person alleging that the consent of such Person is or may be required in connection with the transactions contemplated by this Agreement, (ii) any notice or other communication from any Governmental Authority in connection with the transactions contemplated by this Agreement, (iii) any Actions commenced, or to such partys knowledge, threatened, against the Purchaser or ay Target Party, as applicable, that are related to the transactions contemplated by this Agreement, and (iv) any event, change or effect between the date of this Agreement and the Effective Time which causes or is reasonably likely to cause the failure of the conditions set forth in Section 7.02 (in the case of the Target Parties) or Section 7.03 (in the case of Purchaser),
to be satisfied. In no event shall (x) the delivery of any notice by a party pursuant to this Section 6.05 limit or otherwise affect the respective rights, obligations, representations, warranties, covenants or agreements of the parties or the conditions to the obligations of the parties under this Agreement, or (y) disclosure by any party be deemed to amend or supplement the Disclosure Schedules or constitute an exception to any representation or warranty.
Section 6.06 Reasonable Best Efforts; Approvals and Consents .
(a) Upon the terms and subject to the conditions set forth in this Agreement, each of the parties hereto use its reasonable best efforts to take, or cause to be taken, all actions, and to do, or cause to be done, and to assist and cooperate with the other parties in doing, all things necessary, proper or advisable to consummate and make effective, and to satisfy all conditions to, in the most expeditious manner practicable, the transactions contemplated by this Agreement
(b) Each party hereto shall, as promptly as possible, (i) make, or cause or be made, all filings and submissions required under any Law applicable to such party or any of its Affiliates; and (ii) use reasonable best efforts to obtain, or cause to be obtained, all consents, authorizations, orders and approvals from all Governmental Authorities that may be or become necessary for the performance of its obligations pursuant to this Agreement and the other Transaction Documents. Each party shall cooperate fully with the other parties and their Affiliates in promptly seeking to obtain all such consents, authorizations, orders and approvals. The parties hereto shall not willfully take any action that will have the effect of delaying, impairing or impeding the receipt of any required consents, authorizations, orders and approvals.
(c) Target and Purchaser shall use reasonable best efforts to give all notices to, and obtain all consents from, all third parties that are described in Section 4.03 of the Disclosure Schedules.
(d) Without limiting the generality of the parties undertakings pursuant to subsections (a) and (b) above, each of the parties hereto shall use all reasonable best efforts to:
(i) respond to any inquiries by any Governmental Authority regarding antitrust or other matters with respect to the transactions contemplated by this Agreement or any other Transaction Document;
(ii) avoid the imposition of any order or the taking of any action that would restrain, alter or enjoin the transactions contemplated by this Agreement or any other Transaction Document; and
(iii) in the event any Governmental Order adversely affecting the ability of the parties to consummate the transactions contemplated by this Agreement or any other Transaction Document has been issued, to have such Governmental Order vacated or lifted.
(e) All analyses, appearances, meetings, discussions, presentations, memoranda, briefs, filings, arguments, and proposals made by or on behalf of either party before any Governmental Authority or the staff or regulators of any Governmental Authority, in connection with the transactions contemplated hereunder (but, for the avoidance of doubt, not including any interactions between Target or Purchaser with Governmental Authorities in the ordinary course
of business, any disclosure which is not permitted by Law or any disclosure containing confidential information) shall be disclosed to the other party hereunder in advance of any filing, submission or attendance, it being the intent that the parties will consult and cooperate with one another, and consider in good faith the views of one another, in connection with any such analyses, appearances, meetings, discussions, presentations, memoranda, briefs, filings, arguments, and proposals. Each party shall give notice to the other party with respect to any meeting, discussion, appearance or contact with any Governmental Authority or the staff or regulators of any Governmental Authority, with such notice being sufficient to provide the other party with the opportunity to attend and participate in such meeting, discussion, appearance or contact.
(f) Notwithstanding the foregoing, nothing in this Section 6.06 shall require, or be construed to require, Purchaser, the Surviving Corporation or any of their Affiliates to agree to (i) sell, hold, divest, discontinue or limit, before or after the Closing Date, any assets, businesses or interests of Purchaser, the Surviving Corporation or any of their Affiliates; (ii) any conditions relating to, or changes or restrictions in, the operations of any such assets, businesses or interests which, in either case, could reasonably be expected to result in a Material Adverse Effect or materially and adversely impact the economic or business benefits to Purchaser or the Surviving Corporation of the transactions contemplated by this Agreement and the other Transaction Documents; or (iii) any material modification or waiver of the terms and conditions of this Agreement.
Section 6.07 Confidentiality . From and after the Closing, each Member shall, and shall cause its Affiliates to, hold, and shall use its reasonable best efforts to cause its or their respective Representatives to hold, in confidence any and all confidential information, whether written or oral, concerning the Target or its business. Each Member and the Purchaser agree that information concerning the Target and its business is not confidential to the extent that such Member can show that such information (a) is generally available to and known by the public through no fault of such Member, any of its Affiliates or their respective Representatives; or (b) is lawfully acquired by such Member, any of its Affiliates or their respective Representatives from and after the Closing from sources which to the Knowledge of each Member are not prohibited from disclosing such information by a legal, contractual or fiduciary obligation. If any Member or any of its Affiliates or their respective Representatives are compelled to disclose any information by judicial or administrative process or by other requirements of Law, such Member shall promptly notify Purchaser in writing and shall disclose only that portion of such information which such Member is advised by its counsel in writing is legally required to be disclosed, provided that such Member shall use reasonable best efforts to obtain an appropriate protective order or other reasonable assurance that confidential treatment will be accorded such information. With respect to Lindsey, in the event of a conflict between the provisions of this Section 6.07 and the provisions of the Confidentiality Agreement for Employees entered into between Lindsey and Purchaser at Closing, the provisions of the Confidentiality Agreement for Employees shall control.
Section 6.08 Books and Records .
(a) In order to facilitate the resolution of any claims made against or incurred by Target prior to the Closing, or for any other reasonable purpose, for a period of two (2) years
after the Closing (unless a longer period is required by applicable Law), Purchaser shall (or shall cause the Surviving Corporation to):
(i) retain the Books and Records (including personnel files) relating to periods prior to the Closing in a manner reasonably consistent with the prior practices of Target; and
(ii) upon reasonable notice, afford the Member Representative and the Targets Accountants reasonable access (including the right to make, at the Members expense, photocopies), during normal business hours, to such Books and Records.
(b) Notwithstanding the foregoing, neither Purchaser nor the Surviving Corporation shall be obligated to provide the Members Representatives with access to any books or records (including personnel files) pursuant to this Section 6.08 where such access would violate any Law.
Section 6.09 Tax Matters .
(a) Preparation and Filing of Tax Returns; Payment of Taxes .
(i) At their expense, the Target shall prepare and timely file or shall cause to be prepared and timely filed all Tax Returns for Target and APN due on or prior to the Closing and all Tax Returns for Income Taxes for all Pre-Closing Tax Periods. The Members shall make or cause to be made all payments required with respect to any such Tax Returns to the extent any such Taxes are not included in the Closing Accrued Tax Amount. Unless otherwise required by Law, all Tax Returns shall be filed in a manner consistent with past practice and on a basis consistent with the last previous similar Tax Return.
(ii) At its expense, Purchaser shall prepare and timely file or shall cause to be prepared and timely filed, all Tax Returns for Target and the Surviving Corporation required to be filed after the Closing Date except for Tax Returns required to be filed by the Target Parties under Section 6.09(a)(i) . Purchaser shall make or cause to be made all payments required with respect to any such Tax Returns, subject to the reimbursement rights specified below. Target shall inform Purchaser of any past practices affecting the Tax Liability of Target or the Members, which Purchaser will continue to follow for any Tax Return covering a Straddle Period provided that the past practices are reasonable and do not subject Purchaser to adverse Tax consequences. In absence of such information, Purchaser will use common Tax practices and professional Tax judgment to prepare Targets Tax Returns covering the Straddle Period.
(iii) In the case of Taxes that are payable with respect to a taxable period that begins on or before the Closing Date and ends after the Closing Date (a Straddle Period ), the portion of any such Tax that is allocable to the portion of the period ending on and including the Closing Date (and which Taxes shall be borne by the Members) shall be:
(A) in the case of Taxes that are either (x) based upon or related to income or receipts or (y) imposed in connection with any sale or other transfer or assignment of property (real or personal, tangible or intangible), deemed equal to the amount which would be
Payable if the taxable year ended on and included the Closing Date (an interim closing of the books); and
(B) in the case of Taxes imposed on a periodic basis with respect to the assets of Target or APN, or otherwise measured by the level of any item, deemed to be the amount of such Taxes for the entire period (or, in the case of such Taxes determined on an arrears basis, the amount of such Taxes for the immediately preceding period), multiplied by a fraction the numerator of which is the number of calendar days in the period ending on and including the Closing Date and the denominator of which is the number of calendar days in such Straddle Period.
(iv) At least 15 days prior to the date on which any Straddle Period Tax Return is to be filed, the Purchaser shall submit such Tax Return to the Member Representative for the Member Representatives review and approval, which approval will not be unreasonably withheld, conditioned or delayed; and shall be deemed granted if no written objection is received within such 15 day period. If Member Representative timely objects to the filing of any such Straddle Period Tax Return, Purchaser and the Member Representative shall use their commercially reasonable efforts to negotiate a resolution of such objections, provided that if a resolution is not reached within ten (10) days following Purchasers receipt of the Member Representatives written objection, Purchaser may proceed to file such Straddle Period Tax Return without change.
(b) Cooperation . After the Closing Date, each Target Party, on one hand, and Purchaser, on the other hand, shall:
(i) Use commercially reasonable efforts to cooperate fully in preparing for any audits of, or disputes with taxing authorities regarding, any Tax Returns relating to the Target, APN or their businesses and make available to the other and to any taxing authority as reasonably requested all information, records, and documents relating to Liabilities for, or exemption from, Taxes associated with Target, APN or their businesses as set forth in this Agreement. Any information or documents provided under this Section 6.09(b) shall be kept confidential by the party receiving such information or documents, except as may otherwise be necessary in connection with the filing of Tax Returns or in connection with administrative or judicial proceedings relating to Taxes;
(ii) Make available to the other, as reasonably requested and available, personnel responsible for preparing or maintaining information, records and documents in connection with Taxes as well as any related litigation;
(iii) Preserve all such information, records, and documents until the expiration of any applicable statutes of limitation or extensions thereof and as otherwise required by Law; and
(iv) Provide timely notice to the other in writing of any pending or threatened Tax audits or assessments related to Target, APN or their businesses for periods beginning prior
to the Closing Date, and furnish the other with copies of all correspondence received from any taxing authority in connection with any Tax audit or information request with respect to any such period.
(c) Purchaser shall not file an amended Tax Return for the Target or APN or file a claim for refund for any Pre-Closing Tax Period without the written consent of Member Representative, which consent will not be unreasonably withheld.
(d) Any Tax refunds that are received by the Purchaser, the Surviving Corporation, APN or any Affiliate thereof, and any amounts credited against Taxes to which Purchaser, the Surviving Corporation, APN or any Affiliate thereof becomes entitled, that relate to Pre-Closing Tax Periods shall be for the account of the Members, and the Surviving Corporation shall pay over to the Members based upon their Post-Closing Participating Percentages any such refund or amount of such credit within fifteen (15) days after receipt (with respect to any Tax refund) or the payment of the Taxes against which the applicable credit applies (with respect to any Tax credit).
(e) No portion of the Aggregate Merger Consideration shall be allocated for U.S. federal income tax purposes to any covenant not to compete under this Agreement or otherwise, except to the extent required by any applicable Law as reasonably determined by Purchaser and Members Representative in good faith.
(f) The Aggregate Merger Consideration shall be allocated among the assets of Target in the manner required by Section 1060 of the Code. Purchaser and the Member Representative agree to negotiate in good faith to attempt to agree in writing upon such an allocation promptly following closing based on the estimated allocation set forth on Exhibit J . Purchaser and the Member Representative agree to timely file IRS Form 8594 based on the final allocation of the Aggregate Merger Consideration. Purchaser and the Member Representative each agree that they will not take any position inconsistent with such allocation in preparing Tax Returns or other forms filed with any taxing authority that relate to the transactions evidenced by this Agreement without the written consent of the other party to this Agreement or unless specifically required by applicable Law or pursuant to a determination by an applicable taxing authority.
(g) Notwithstanding anything herein to the contrary, in no event shall Purchaser or the Surviving Corporation be responsible for the payment of any Tax relating to or arising out of (i) the APN Divestment or any action of APN occurring after the APN divestment, or (ii) the TeleMed Divestment, all of which shall be the responsibility of the Members.
Section 6.10 Public Announcements . Unless otherwise required by applicable Law (based upon the reasonable advice of counsel), no party to this Agreement shall make any public announcements in respect of this Agreement or the transactions contemplated hereby or otherwise communicate with any news media without the prior written consent of both Purchaser and the Member Representative (which consent shall not be unreasonably withheld or delayed), and the parties shall cooperate as to the timing and contents of any such announcement.
Section 6.11 CONSENT OF MEMBERS; WAIVER OF APPRAISAL AND DISSENTERS RIGHTS . BY EXECUTION HEREOF, EACH MEMBER HEREBY KNOWINGLY AND FREELY (I) CONSENTS TO THE MERGER AND THE OTHER TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT ON THE TERMS AND CONDITIONS SET FORTH HEREIN, (II) WAIVES ANY AND ALL RIGHTS OF FIRST REFUSAL, FIRST OFFER, NOTICE, APPROVAL, LIQUIDATION PROCEEDS PREFERENCE, NOTICE OR SIMILAR RIGHTS, IF ANY, SUCH MEMBER MAY HAVE ARISING OUT OF OR IN CONNECTION WITH THE MERGER, AND (III) WAIVES ANY ALL APPRAISAL AND DISSENTERS RIGHTS UNDER THE FLLCA IN CONNECTION WITH THE MERGER AND THE OTHER TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH MEMBER HAS REVIEWED AND UNDERSTANDS THE TERMS AND CONDITIONS OF THIS AGREEMENT AND IS HEREBY ENCOURAGED TO, HAS HAD THE OPPORTUNITY TO, AND TO THE EXTENT SUCH MEMBER DEEMED NECESSARY DID, SEEK AND RELY UPON THE ADVICE OF SUCH MEMBERS OWN INDEPENDENT COUNSEL IN THE NEGOTIATION AND ADOPTION OF THIS AGREEMENT.
Section 6.12 Further Assurances . Following the Closing, each of the parties hereto shall, and shall cause their respective Affiliates to, execute and deliver such additional documents, instruments, conveyances and assurances and take such further actions as may be reasonably required to carry out the provisions hereof and give effect to the transactions contemplated by this Agreement and the other Transaction Documents.
Section 6.13 APN . After the Effective Time, Lindsey shall cause APN to cease conducting any business except as is reasonably necessary to carry out the transactions contemplated by this Agreement and to obtain 36 months of extended reporting coverage on the Medical Professional Liability Insurance Policy that is described in Section 4.14 of the Disclosure Schedules. Purchaser shall issue to Lindsey at Closing a check in the amount of $65,279.20 payable to Frost Insurance Agency which Lindsey shall cause APN to use for the purchase of such extended reporting coverage.
Section 6.14 Benefit Plans . As of the Effective Time, Target will, at its expense or at the expense of the applicable Benefit Plan, (i) terminate the participation of employees of Target from all Benefit Plans and (ii) take such actions as are necessary to make, or cause such Benefit Plans to make, timely appropriate distributions to such employees to the extent required or permitted by, and in accordance with, such Benefit Plans and applicable Law. With respect to such employees, Target will fully fund all benefits provided under any Benefit Plan intended to be qualified under Sections 401 or 403 of the Code maintained or contributed to by Target or any of their Affiliates within thirty (30) days after Closing. This Section 6.14 shall survive Closing.
Section 6.15 Target Lease . Lindsey agrees to cause Target to assign to Innovative Health Insurance Partners, LLC ( Innovative ) Targets obligations under that certain Office Building Lease dated June 13, 2012 by and between CRT Signature Place, L.P. as Landlord and Target, as Tenant (the Target Lease ), including the security deposit paid under the Target Lease ($15,694.56), such assignment to occur prior to or as soon as practicable following Closing. In the event of such assignment, Lindsey shall cause Innovative to allow the Surviving Corporation to use that portion of the premises covered by the Lease currently used by Target
until May 31, 2015, and the Surviving Corporation will be obligated to pay Innovative $10,000 per month on or before the first day of each month beginning June 1, 2014 and ending May 1, 2015 for such use. In the event that Lindsey is unable to effect such assignment, the Members agree to indemnify and hold harmless the Purchaser Indemnitees for all payments required to be made by the Surviving Corporation under the Target Lease (including payments made pursuant to this Section 6.15 ) in excess of $120,000.
Section 6.16 Healthcare Information Laws Compliance Investigations . Each Member agrees that from and after the date of this Agreement, such Member shall cooperate with the reasonable requests of the Surviving Corporation, as applicable, in responding to any investigation conducted by (i) a Governmental Authority or (ii) Target or Surviving Corporation customer, or (iii) Surviving Corporation related to compliance by Target with Healthcare Information Laws prior to the Effective Time. The Surviving Corporation shall pay the reasonable attorneys fees and expenses incurred by a Member in connection with such cooperation, provided that the attorneys retained by such Member have been approved in advance in writing by the Surviving corporation, such approval not to be unreasonably withheld, conditioned or delayed. No Member shall be required to take any action under this Section 6.16 that would waive his attorney client privilege or any other privilege or legal protection that is available to him with respect to such investigation.
Section 6.17 AmeriDoc Tail Insurance Policy . Lindsey shall purchase tail coverage under Targets Directors and Officers Liability Insurance Policy described in Section 4.14 of the Disclosure Schedules covering a 36-month period commencing September 23, 2014. Purchaser shall issue to Lindsey at Closing a check in the amount of $5,039.00 payable to Frost Insurance Agency which Lindsey shall use for the purchase of such extended coverage.
Section 6.18 Ameridoc.net . Following Closing, Lindsey will use his reasonable best efforts to cause Brandon Foster to transfer to Lindsey the Ameridoc.net domain name. Promptly after such transfer, Lindsey shall transfer the Ameridoc.net domain name to Purchaser.
Section 6.19 Contractual Matters . Lindsey shall cause the Contracts listed on Exhibit I attached hereto be terminated within sixty-five (65) days following Closing.
Section 6.20 Consents . Lindsey shall obtain the consent of Venture Connections, Inc. under the Administrative and Marketing Services Agreement dated November 8, 2011 between Target and Venture Connections, Inc. to the consummation of the Merger within sixty (60) days following Closing.
ARTICLE VII
CONDITIONS TO THE MERGER
Section 7.01 Conditions to the Obligations of Each Party . The obligations of Purchaser, Target, and the Members to consummate the Merger are subject to the satisfaction of the condition that Governmental Authority having jurisdiction over any party hereto shall have enacted, issued, promulgated, enforced or entered any Laws or Governmental Orders, whether
temporary, preliminary or permanent, that make illegal, enjoin or otherwise prohibit consummation of the Merger or the other transactions contemplated by this Agreement.
Section 7.02 Conditions to the Obligations of Purchaser . The obligations of Purchaser to consummate the Merger are subject to the satisfaction or waiver (where permissible) of the following additional conditions:
(a) Representations and Warranties . Except for those representations or warranties where their failure to be true and correct does not cause a Material Adverse Change: (i) the representations and warranties of Target and the Members contained in this Agreement shall be true and correct as of the Effective Time, as though made on and as of the Effective Time, except to the extent (other than the Targets Fundamental Representations or the Members Fundamental Representations) expressly made as of a specified earlier date, in which case as of such earlier date, and (ii) Targets Fundamental Representations and the Members Fundamental Representations shall be true and correct in all respects as of the date hereof and as of the Effective Time, as though made on and as of the Effective Time.
(b) Agreements and Covenants . Target and the Members shall have performed or complied in all material respects with all agreements and covenants required by this Agreement to be performed or complied with by them on or prior to the Effective Time except for those covenants and agreements, the failure to which to perform or comply does not cause a Material Adverse Change.
(c) Material Adverse Change . No Material Adverse Change shall have occurred since the date of this Agreement.
(d) Closing Deliveries . Purchaser shall have received each of the Closing deliveries set forth in Sections 3.02(a)(ii) , (iii) , (iv) , (vi) , (vii) , (x) , (xi) , (xii) , (xiii) , (xv) , (xvi) , (xix) , (xx) and (xxi) and 3.02(d) .
Section 7.03 Conditions to the Obligations of Target and the Members . The obligations of the Target and the Members to consummate the Merger are subject to the satisfaction or waiver (where permissible) of the following additional conditions:
(a) Representations and Warranties . Except for those representations and warranties where their failure to be true and correct would not materially adversely affect the ability of Purchaser to fulfill its financial obligations under this Agreement: (i) the representations and warranties of Purchaser contained in this Agreement shall be true and correct as of the Effective Time, as though made on and as of the Effective Time, except to the extent (other than the Purchasers Fundamental Representations) expressly made as of as a specified earlier date, in which case as of such earlier date, and (ii) Purchasers Fundamental Representations shall be true and correct in all respects as of the date hereof and at the Effective Time, as though made on and as of the Effective Time.
(b) Agreements and Covenants . Purchaser shall have performed or complied in all material respects with all agreements and covenants required by this Agreement to be performed or complied with by it on or prior to the Effective Time, except as would not materially adversely affect the ability of Purchaser to fulfill its financial obligations under this Agreement.
(c) Closing Deliveries . Target and the Member Representative shall have received each of the Closing deliveries set forth in Section 3.02(b) .
(d) Closing Consideration . Purchaser shall have delivered, or caused the Surviving Corporation to deliver, the payments required by Section 3.02(c) .
ARTICLE VIII
TERMINATION
Section 8.01 Termination . This Agreement may be terminated and the Merger and the other transactions contemplated hereby may be abandoned at any time prior to the Effective Time, notwithstanding any requisite approval and adoption of this Agreement and such transactions by the Members of Target, as follows:
(a) by mutual written consent of Purchaser, Target and the Member Representative;
(b) by either Purchaser or Target if any Governmental Authority having jurisdiction over any party hereto shall have enacted, issued, promulgated, enforced or entered any Laws or Governmental Orders, whether temporary, preliminary or permanent, that make illegal, enjoin or otherwise prohibit consummation of the Merger or the other transactions contemplated by this Agreement;
(c) by Purchaser if:
(i) Purchaser is not then in breach of any provision of this Agreement and Target or any Member has breached any representation, warranty or covenant contained in this Agreement that would give rise to the failure of any of the conditions specified in Section 7.02 , and Purchaser shall have notified Target and the Member Representative of such breach, and, if of a type which can be cured, such breach has continued without cure for a period of ten (10) days after the notice of breach;
(ii) any of the conditions set forth in Section 7.01 or Section 7.02 shall not have been fulfilled by May 15, 2014 (the Termination Date ), unless such failure shall be due to the failure of Purchaser to perform or comply with any of the covenants, agreements or conditions hereof to be performed or complied with by them prior to the Closing; or
(iii) a Material Adverse Change has occurred after the date of this Agreement.
(d) by Target or the Member Representative if:
(i) The Target Parties are not then in breach of any provision of this Agreement and Purchaser has materially breached any representation, warranty or covenant contained in this Agreement that would give rise to the failure of any of the conditions specified in Section 7.03 , and Target and the Member Representative have notified Purchaser of such breach, and, if of a type which can be cured, such breach has continued without cure for a period of ten (10) days after the notice of breach, or
(ii) any of the conditions set forth in Section 7.01 or Section 7.03 shall not have been fulfilled by the Termination Date, unless such failure shall be due to the failure of any Target Party to perform or comply with any of the covenants, agreements or conditions hereof to be performed or complied with by it prior to the Closing.
Section 8.02 Effect of Termination . In the event of the termination of this Agreement pursuant to Section 8.01 , this Agreement shall forthwith become void, and there shall be no liability under this Agreement on the part of any party hereto, except that nothing herein shall relieve any party from liability for any willful breach of any of its representations, warranties, covenants or agreements set forth in this Agreement prior to such termination; provided , however , that the terms of ARTICLE X and ARTICLE XI shall survive any termination of this Agreement. Additionally, the terms of Section 6.04 shall survive any termination of this Agreement other than a termination by Target or Member Representative pursuant to Section 8.01(d) . The obligations of Purchaser set forth in the mutual non-disclosure and confidentiality letter agreement dated January 28, 2014 shall survive the execution and termination of this Agreement.
ARTICLE IX
INDEMNIFICATION
Section 9.01 Survival . Subject to the limitations and other provisions of this Agreement, the representations and warranties contained herein shall survive the Closing and shall remain in full force and effect until the date that is twenty-four (24) months from the Closing Date; provided , that (i) the representations and warranties in Section 4.01-A (Ownership), Section 4.02-A (Authority), Section 4.04-A (Brokers) (collectively, the Members Fundamental Representations ), Section 4.01 (Organization, Qualification and Capitalization of Target; APN), Section 4.02 (Authority), Section 4.09(a) (Title to Assets), Section 4.21 (Brokers), Section 5.01 (Organization), Section 5.02 (Authority) and Section 5.04 (Brokers) shall survive indefinitely (the representations, collectively described in clause (i), the Fundamental Representations ), and (ii) the representations and warranties in Section 4.03-A (No Breach; Consents), Section 4.03 (No Breach; Consents), Section 4.11 (Intellectual Property), Section 4.16 (Compliance with Laws; Permits), Section 4.17 (Environmental Matters), Section 4.18 (Employee Benefit Matters), Section 4.20 (Taxes), Section 4.27 (Solvency), and Section 5.03 (No Conflicts; Consents) shall survive until thirty (30) days following the expiration of the full period of all applicable statutes of limitations (giving effect to any waiver, mitigation or extension thereof). All covenants of the parties contained herein shall survive the Closing until performed in accordance with their terms. Notwithstanding the foregoing, any claims asserted in writing by notice from the non-breaching party to the breaching party prior to the expiration date of the applicable survival period shall not thereafter be barred by the expiration of the relevant representation, warranty or covenant and such claims shall survive until finally resolved. Notwithstanding the foregoing, any claims arising from fraud, criminal activity or willful misconduct with respect to a representation, warranty or covenant hereunder shall not be limited by the survival period described above.
Section 9.02 Indemnification by the Members . Subject to the other terms and conditions of this ARTICLE IX , the Members;
(a) jointly and severally, shall indemnify and defend each of Purchaser and its Affiliates (including, after the Effective Time, the Surviving Corporation), their respective Representatives and each of their successors and permitted assigns (collectively, the Purchaser Indemnitees ) against, and shall hold each of them harmless from and against, and shall pay and reimburse each of them for, any and all Losses incurred or sustained by, or imposed upon, the Purchaser Indemnitees based upon, arising out of, with respect to or by reason of:
(i) any inaccuracy in or breach of any of the Fundamental Representations of Target as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date);
(ii) any inaccuracy in or breach of any of the representations or warranties of Target contained in this Agreement (other than the Fundamental Representations), the other Transaction Documents or any other certificate furnished by the Target, as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date);
(iii) any breach or non-fulfillment of any covenant, agreement or obligation to be performed by Target (at or prior to the Effective Time) pursuant to this Agreement, the other Transaction Documents or any certificate or instrument delivered by the Target pursuant to this Agreement;
(iv) any Closing Transaction Expenses in excess of the amounts set forth on the Pre-Closing Statement, to the extent not paid by the Target or such Member at Closing;
(v) any violation or alleged violation by the Company or APN of Healthcare Information Laws;
(vi) any Lindenbrook Claims;
(vii) any Couto Claims;
(viii) any Li Claims;
(ix) any breach by Lindenbrook or the Lindenbrook Owners of the Lindenbrook Assignment Agreement;
(x) any breach by Couto of the Couto Agreement;
(xi) any breach by Li of the Li Agreement;
(xii) the operation of APNs business, or any act or omission of APN or its Representatives (in their capacity as such), whether before or after Closing, including without limitation the APN Divestment.
(b) Subject to the other terms and conditions of this ARTICLE IX , the Members, severally and not jointly, shall indemnify and defend each of the Purchaser Indemnitees against, and shall hold each of them harmless from and against, and shall pay and reimburse each of them for, any and all Losses incurred or sustained by, or imposed upon, the Purchaser Indemnitees based upon, arising out of, with respect to or by reason of:
(i) any inaccuracy in or breach of any of the Members Fundamental Representations made by such Member as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date);
(ii) any inaccuracy in or breach of any of the representations or warranties of such Member contained in this Agreement (other than the Members Fundamental Representations), the other Transaction Documents or any other certificate furnished by such Member, as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date); and
(iii) any breach or non-fulfillment of any covenant, agreement or obligation to be performed by such Member pursuant to this Agreement, the other Transaction Documents or any certificate or instrument delivered by such Member pursuant to this Agreement.
Section 9.03 Indemnification by Purchaser . Subject to the other terms and conditions of this ARTICLE IX , Purchaser shall indemnify and defend each of the Members, their respective Affiliates (excluding, after the Effective Time, the Target), their respective Representatives and each of their respective successors and permitted assigns (collectively, the Member Indemnitees ) against, and shall hold each of them harmless from and against, and shall pay and reimburse each of them for, any and all Losses incurred or sustained by, or imposed upon, the Member Indemnitees based upon, arising out of, with respect to or by reason of:
(a) any inaccuracy in or breach of any of the Fundamental Representations of Purchaser as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date);
(b) any inaccuracy in or breach of any of the representations or warranties of Purchaser contained in this Agreement (other than the Fundamental Representations), the other Transaction Documents or any certificate furnished by or on behalf of Purchaser pursuant to this Agreement, as of the date such representation or warranty was made or as if such representation
or warranty was made on and as of the Closing Date (except for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date); and
(c) any breach or non-fulfillment of any covenant, agreement or obligation to be performed by Purchaser pursuant to this Agreement.
Section 9.04 Certain Limitations . Except with respect to claims arising from fraud or criminal activity, the indemnification provided for in Section 9.02 and Section 9.03 shall be subject to the following limitations:
(a) The Members shall not be liable to the Purchaser Indemnitees for indemnification under Section 9.02(a) or Section 9.02(b) (other than for breach of Section 6.15 or indemnification under Section 9.02(a)(iv) or under Section 9.02(a)(v) ) until the aggregate amount of (i) all Losses in respect of indemnification under Section 9.02(a) and Section 9.02(b) , plus (ii) all Losses in respect of indemnification under Section 9.02(a) and Section 9.02(b) of the TeleMed Merger Agreement, collectively exceeds $100,000.00, in which event the Members shall be required to pay and be liable for all such Losses from the first dollar thereof.
(b) The Purchaser shall not be liable to the Member Indemnitees for indemnification under Section 9.03(a) or Section 9.03(b) until the aggregate amount of (i) all Losses in respect of indemnification under Section 9.03(a) and Section 9.03(b) , plus (ii) all Losses in respect of indemnification under Section 9.03(a) and Section 9.03(b) of the TeleMed Merger Agreement, collectively exceeds $100,000.00, in which event Purchaser shall be required to pay and be liable for all such Losses from the first dollar thereof.
(c) The maximum aggregate amount of all Losses for which the Members shall be liable pursuant to Section 9.02(a) and Section 9.02(b) shall not exceed $10,000,000.00 (less any amounts previously paid by the Members pursuant to Section 9.02(a) and Section 9.02(b) of the TeleMed Merger Agreement), provided, however that (x) the maximum aggregate amount of all Losses for which the Members shall be liable pursuant to Section 9.02(a)(ii) , (vi) , (vii) , (viii) , (ix) , (x) and (xi) and Section 9.02(b)(ii) shall not exceed $2,500,000 (less any amounts previously paid by the Members pursuant to Section 9.02(a)(ii) and 9.02(b)(ii) of the TeleMed Merger Agreement) and (y) the maximum aggregate amount of all Losses for which the Members shall be liable pursuant to Section 9.02(a)(v) and (xii) ( Healthcare Information Losses ) shall not exceed the sum of (i) all Healthcare Information Losses up to $2,000,000 plus (ii) fifty percent (50%) of all Healthcare Information Losses in excess of $2,500,000 but less than $5,000,000. Additionally, the Losses for which the Members shall be liable pursuant to Section 9.02(a)(ix) , (x) and (xi) shall be limited to fifty percent (50%) of all costs incurred by the Purchaser Indemnitees to enforce Purchasers rights (as successor in interest to Target or otherwise) as the result of the breaches described in Section 9.02(a)(ix) , (x) and (xi) . Except as set forth in Section 9.12 , the aggregate amount of all Losses for which a Member may be liable (including such Members pro-rata portion of Losses offset from the Purchaser Note) pursuant to Section 9.02(a) and Section 9.02(b) , shall be further limited to such Members Participating Percentage multiplied by $10,000,000.
(d) The maximum aggregate amount of all Losses for which Purchaser shall be liable pursuant to Section 9.03(a) and Section 9.03(b) shall not exceed $10,000,000.00 (less any amounts previously paid by Purchaser pursuant to Section 9.03(a) and Section 9.03(b) of the TeleMed Merger Agreement); provided, however, that the maximum aggregate amount of all Losses for which Purchaser shall be liable pursuant to Section 9.03(b) shall not exceed $2,500,000 (less any amounts previously paid by Purchaser pursuant to Section 9.03(b) of the TeleMed Merger Agreement).
(e) The amount of Losses for which indemnification is provided for under this Agreement shall be reduced by (i) any amounts actually received by the Indemnified Party as a result of any indemnification, contribution or other payment by a third party, and (ii) any insurance proceeds or other similar amounts actually received by an Indemnified Party with respect to such Losses (any amounts described in clause (i) or (ii), Third Party Payments ). If the amount of any Loss, at any time subsequent to the making of any indemnification payment on account of such Loss, is reduced by any Third Party Payment, the amount of such reduction shall promptly be repaid by the Indemnified Party to the Indemnifying Party.
(f) The amount of any Losses for which indemnification is provided under this Agreement shall be reduced by any amounts actually received by any Indemnified Party in respect of the Tax year of the Loss, directly or through a Subsidiary, in the form of a Tax refund or a reduction in Tax paid in respect to claims related to such Losses in the year of the Loss.
(g) The obligations of the Members under Section 9.02 , specifically including Thompsons obligations, shall be satisfied exclusively from offsets against the outstanding principal balance of the Purchaser Note pursuant to the terms of the Purchaser Note until the outstanding principal balance of the Purchaser Note is exhausted, and may thereafter be satisfied by payment directly from the Members, subject to the limitations herein. Interest due under the Purchaser Note shall not be subject to offset or to being withheld, except as provided in the Subordination Agreement.
Section 9.05 Indemnification Procedures . The party making a claim under this ARTICLE IX is referred to as the Indemnified Party , and the party against whom such claims are asserted under this ARTICLE IX is referred to as the Indemnifying Party .
(a) Third Party Claims . If any Indemnified Party receives notice of the assertion or commencement of any Action made or brought by any Person who is not a party to this Agreement or an Affiliate of a party to this Agreement or a Representative of the foregoing (a Third Party Claim ) against such Indemnified Party with respect to which the Indemnifying Party is obligated to provide indemnification under this Agreement, the Indemnified Party shall give the Indemnifying Party reasonably prompt written notice thereof, but in any event not later than 30 calendar days after receipt of such notice of such Third Party Claim. The failure to give such prompt written notice shall not, however, relieve the Indemnifying Party of its indemnification obligations, except and only to the extent that the Indemnifying Party forfeits rights or defenses by reason of such failure. Such notice by the Indemnified Party shall describe the Third Party Claim in reasonable detail, shall include copies of all material written evidence thereof and shall indicate the estimated amount, if reasonably practicable, of the Loss that has been or may be sustained by the Indemnified Party. The Indemnifying Party shall have the right
to participate in, or by giving written notice to the Indemnified Party, to assume the defense of any Third Party Claim at the Indemnifying Partys expense and by the Indemnifying Partys own counsel, and the Indemnified Party shall cooperate in good faith in such defense; provided , that if the Indemnifying Party is a Member, such Indemnifying Party shall not have the right to defend or direct the defense of any such Third Party Claim that, to the extent that it seeks an injunction or other equitable relief against the Indemnified Party. In the event that the Indemnifying Party assumes the defense of any Third Party Claim, subject to Section 9.05(b) , it shall have the right to take such action as it deems reasonably necessary to avoid, dispute, defend, appeal or make counterclaims pertaining to any such Third Party Claim in the name and on behalf of the Indemnified Party. The Indemnified Party shall have the right to participate in the defense of any Third Party Claim with counsel selected by it subject to the Indemnifying Partys right to control the defense thereof. The fees and disbursements of such counsel shall be at the expense of the Indemnified Party, provided , that if in the reasonable opinion of counsel to the Indemnified Party, (A) there are legal defenses available to an Indemnified Party that are different from or additional to those available to the Indemnifying Party; or (B) there exists a conflict of interest between the Indemnifying Party and the Indemnified Party that cannot be waived, the Indemnifying Party shall be liable for the reasonable fees and expenses of counsel to the Indemnified Party in each jurisdiction for which the Indemnified Party determines counsel is required. If the Indemnifying Party elects not to compromise or defend such Third Party Claim, fails to promptly notify the Indemnified Party in writing of its election to defend as provided in this Agreement, is prohibited from defending the Third Party Claim in accordance with this Section, or fails to diligently prosecute the defense of such Third Party Claim, the Indemnified Party may, subject to Section 9.05(b) , pay, compromise, defend such Third Party Claim and seek indemnification for any and all Losses based upon, arising from or relating to such Third Party Claim. The Indemnified Party and the Indemnifying Party shall cooperate with each other in all reasonable respects in connection with the defense of any Third Party Claim, including making available (subject to the provisions of Section 6.07 ) records relating to such Third Party Claim and furnishing, without expense (other than reimbursement of expenses) to the defending party, management employees of the non-defending party as may be reasonably necessary for the preparation of the defense of such Third Party Claim.
(b) Settlement of Third Party Claims . Notwithstanding any other provision of this Agreement, the Indemnifying Party shall not enter into settlement of any Third Party Claim without the prior written consent of the Indemnified Party, unless a firm offer is made to settle a Third Party Claim without leading to liability or the creation of a financial or other obligation on the part of the Indemnified Party and provides, in customary form, for the unconditional release of each Indemnified Party from all Liabilities and obligations in connection with such Third Party Claim. If the Indemnified Party has assumed the defense of such Third Party Claim pursuant to Section 9.05(a) , it shall not agree to any settlement without the written consent of the Indemnifying Party (which consent shall not be unreasonably withheld or delayed).
(c) Direct Claims . Any Action by an Indemnified Party on account of a Loss which does not result from a Third Party Claim (a Direct Claim ) shall be asserted by the Indemnified Party giving the Indemnifying Party reasonably prompt written notice thereof, but in any event not later 30 days alter the Indemnified Party becomes aware of such Direct Claim. The failure to give such prompt written notice shall not, however, relieve the Indemnifying Party of its indemnification obligations, except and only to the extent that the Indemnifying Party forfeits
rights or defenses by reason of such failure. Such notice by the Indemnified Party shall describe the Direct Claim in reasonable detail, shall include copies of all material written evidence thereof and shall indicate the estimated amount, if reasonably practicable, of the Loss that has been or may be sustained by the Indemnified Party. The Indemnifying Party shall have 20 days after its receipt of such notice to respond in writing to such Direct Claim. The Indemnified Party shall allow the Indemnifying Party and its professional advisors to investigate the matter or circumstance alleged to give rise to the Direct Claim, and whether and to what extent any amount is payable in respect of the Direct Claim, and the Indemnified Party shall assist the Indemnifying Partys investigation by giving such information and assistance (including access to the Indemnified Partys premises and personnel and the right to examine and copy any accounts, documents or records) as the Indemnifying Party or any of its professional advisors may reasonably request. If the Indemnifying Party does not respond within such 20 day period, then (i) Indemnifying Party shall be conclusively deemed to have acknowledged the correctness of the Direct Claim, and (ii) and the amount of such Direct Claim shall be paid to the Indemnified Party with 15 Business Days following the expiration of such 20 day period in accordance with Section 9.06 . If the Indemnifying Party timely delivers an objection to the Direct Claim or seeks additional information regarding the Direct Claim, then the Indemnified Party shall be free to pursue such remedies as may be available to the Indemnified Party on the terms and subject to the provisions of this Agreement, but shall not make any offsets against the outstanding principal balance of the Purchaser Note or, except as provided in the Subordination Agreement, withhold any interest payments except as provided in Section 9.06 .
Section 9.06 Offsets and Payments . Once a Loss is agreed (or deemed to be agreed) to by the Indemnifying Party or finally adjudicated to be payable pursuant to this ARTICLE IX , the Indemnifying Party shall satisfy its obligations within 15 Business Days of such agreement or final, non-appealable adjudication by providing written instruction to the Purchaser and the Member Representative to offset against the outstanding principal amounts due under the Purchaser Note to pay such Loss, or in the event there is not sufficient outstanding principal, then by wire transfer of immediately available funds. The parties hereto agree that should an Indemnifying Party not make full payment of any such obligations within such 15 Business Day period, any amount payable shall accrue interest from and including the date of agreement of the Indemnifying Party or final, non-appealable adjudication to and including the date such payment has been made at a rate per annum equal to the statutory rate of interest in Texas for judgments on the date of such agreement or final, non-appealable adjudication. Such interest shall be calculated daily on the basis of a 365 day year and the actual number of days elapsed.
Section 9.07 Tax Treatment of Indemnification Payments . All indemnification payments made under this Agreement shall be treated by the parties as an adjustment to the Aggregate Merger Consideration for Tax purposes, unless otherwise required by Law.
Section 9.08 Effect of Investigation . The representations, warranties and covenants of the Indemnifying Party, and the Indemnified Partys right to indemnification with respect thereto, shall not be affected or deemed waived by reason of any investigation made by or on behalf of the Indemnified Party (including by an Representatives) or by reason of the fact that the Indemnified Party or any of its Representatives knew or should have known that any such representation or warranty is, was or might be inaccurate, as the case may be.
Section 9.09 Exclusive Remedies . From and after the Closing, the parties acknowledge and agree that their sole and exclusive remedy with respect to any and all claims (other than those related to claims arising from fraud, criminal activity or willful misconduct) whether in contract, tort or otherwise for any breach of any representation, warranty, covenant, agreement or obligation set forth herein or otherwise relating to the subject matter of this Agreement, shall be pursuant to the indemnification provisions set forth in this ARTICLE IX . Nothing in this Section 9.09 shall limit any Persons right to seek and obtain any equitable relief to which any Person shall be entitled or to seek any remedy on account of any partys fraud, criminal activity or willful misconduct.
Section 9.10 Authority of the Member Representative . Notwithstanding anything in this ARTICLE IX to the contrary, and as more particularly set forth in ARTICLE X , the Member Representative shall have the power to execute, deliver, acknowledge, certify and file any documents, give and receive any notices, negotiate or enter into compromises or disputes, and take any and all actions such Member Representative may determine to be necessary, on behalf of any Member or other Member Indemnitee in connection with this ARTICLE IX .
Section 9.11 Calculation of Losses . For purposes of this ARTICLE IX , to the extent it is determined that a representation or warranty has been breached and the Purchaser Indemnitees or the Member Indemnitees are entitled to be indemnified therefor pursuant to the terms of this ARTICLE IX , then for the purposes of determining the amount of any Losses relating to such breach (and only for such purpose and, for the avoidance of doubt, not for the purpose of determining whether a breach has occurred), the breached representation or warranty shall be read without regard to any qualifications or exceptions relating to or referring to the terms material, materiality, in all material respects, Material Adverse Effect or any similar term or phrase contained in or otherwise applicable to any such representation or warranty.
Section 9.12 Pooled Claims . The parties acknowledge and agree that, notwithstanding anything herein to the contrary:
(a) The AmeriDoc Note Portion and the TeleMed Note Portion (as defined in the TeleMed Merger Agreement) shall be evidenced by the Purchaser Note and shall collectively constitute the ` Pooled Note Amount . The Pooled Note Amount will be commonly and equally available, without priority or limitation between this Agreement and the TeleMed Merger Agreement, to satisfy and pay Losses subject to indemnification pursuant to Section 9.02 of this Agreement and Section 9.02 of the TeleMed Merger Agreement, and any adjustment to the Aggregate Merger Consideration in favor of Purchaser pursuant to Section 2.07 of this Agreement. As an example to illustrate the application of this provision, if there are Losses for which the Members have an indemnification obligation under this Agreement but previous claims for Losses have exhausted the AmeriDoc Note Portion as evidenced by the Purchaser Note, then the Purchaser Indemnitees would be entitled to have their Losses satisfied and paid under this Agreement from the TeleMed Note Portion, if amounts remain thereunder.
(b) Purchaser, on behalf of itself and the other Purchaser Indemnitees, shall be entitled to offset against any portion of the Pooled Note Amount, any Losses for which such Persons are entitled to indemnification pursuant to Section 9.02 .
ARTICLE X
MEMBER REPRESENTATIVE
Section 10.01 Appointment of Member Representative; Power of Attorney .
(a) Each Member hereby irrevocably nominates, constitutes and appoints David E. Lindsey as the Member Representative and as the agent, agent for service of process and true and lawful attorney in fact of such Member with full power of substitution, to act in the name, place and stead of such Member with respect to all matters under this Agreement or the Purchaser Note and the transactions contemplated by this Agreement and David E. Lindsey hereby accepts such appointment. Such powers shall include, without limitation, the taking by the Member Representative of any and all actions and the making of any decisions required or permitted to be taken or made by any Member under this Agreement, the Purchaser Note and the Subordination Agreement, including the exercise of the power to: (i) execute, deliver, acknowledge, certify and file (in the name of any or all of such Members or otherwise) any and all documents and to take any and all actions that the Member Representative may, in his sole discretion, determine to be necessary, desirable or appropriate in connection with this Agreement or the Purchaser Note (including negotiating, entering into compromises or settlements of and resolving disputes with respect to any matters covered in Section 2.07 and ARTICLE IX ); (ii) give and receive notices and communications under this Agreement and the Purchaser Note; (iii) authorize the payment of fees, expenses and distributions, including, without limitation, any fees, expenses or distributions out of the Member Representative Holdback Amount; (iv) execute amendments (and additional documents related thereto) to this Agreement and the Purchaser Note on behalf of such Members generally consistent with the transaction contemplated hereby, the execution thereof shall be conclusive evidence of such determination; (v) as Members Representative, to enforce and protect the rights and interests of the Members (including the Members Representative, in its capacity as a Member) in connection with any claims asserted in connection with this Agreement or the Purchaser Note, including defending all claims for indemnification made by Purchaser Indemnitees, consenting to, compromising or settling any indemnification claims of Purchaser Indemnitees, conducting negotiations with Purchaser and its Representatives regarding such claims, and engaging counsel, accountants or other Representatives in connection with the foregoing matters, and, in connection therewith, to (A) assert any claim or institute any action, proceeding or investigation; (B) investigate, defend, contest or litigate any claim, action, proceeding or investigation initiated by Purchaser, the Surviving Corporation or any Person, or by any federal, state or local Governmental Authority against the Members Representative and/or any of the Members, and receive process on behalf of any or all the Members in any such claim, action, proceeding or investigation and compromise or settle on such terms as the Members Representative shall determine to be appropriate, and give receipts, releases and discharges with respect to, any such claim, action, proceeding, or investigation; (C) file any proofs of debt, claims and petitions as the Members Representative may deem advisable or necessary; and (D) file and prosecute appeals from any decision, judgment or award rendered in any such action, proceeding or investigation, it being agreed that the Members Representative shall not have any obligation to take any such actions, and shall not have any liability for any failure to take any such actions; and (vi) to make such determinations and take such actions as are provided in Section 2.07 or ARTICLE IX .
(b) In connection with this Agreement, and any instrument, agreement or document relating hereto or thereto (including the Purchaser Note), and in exercising or failing to exercise all or any of the powers conferred upon the Members Representative hereunder (A) the Members Representative shall incur no responsibility whatsoever to any Member by reason of any error in judgment or other act or omission performed or omitted hereunder or any such other agreement, instrument or document, excepting only responsibility for any act taken which represents gross negligence or willful misconduct and (B) the Members Representative shall be entitled to rely on the advice of counsel, public accounts or other independent experts experienced in the matter at issue, and any error in judgment or other act or omission of the Members Representative pursuant to such advice shall, in no event subject the Members Representative to liability to any Member.
(c) All of the immunities and powers granted to the Members Representative under this Agreement shall survive the Closing and/or termination of this Agreement, the repayment or cancellation of the Purchaser Note and the termination of the Subordination Agreement.
(d) Each Member hereby acknowledges and agrees that the Member Representative Holdback Amount shall be withheld and paid directly to an account maintained by the Member Representative (or a financial institution selected by the Member Representative) as a fund for the fees and expenses (including, without limitation, any legal fees and expenses) of the Member Representative incurred in connection with this Agreement or in connection with his services as Member Representative under the TeleMed Merger Agreement, with any balance of the Member Representative Holdback Amount not utilized for such purposes to be remitted to the Members in accordance with their Post-Closing Participating Percentages. The Member Representative will, if so requested in writing by any Member, provide such Member with a written report describing in reasonable detail the amount of any fees, expenses, distributions, or other remittances made out of the Member Representative Holdback Amount; provided, however, that the Member Representative will not have any obligation to provide any such written report to any particular Member any more than two times during any rolling twelve (12) month period.
Section 10.02 Irrevocable Appointment . The power of attorney granted in Section 10.01 is (a) coupled with an interest and is irrevocable and (b) shall survive the death, incapacity, incompetency, dissolution, liquidation or bankruptcy of any of the Members.
Section 10.03 Reliance .
(a) Notwithstanding anything to the contrary contained in this Agreement, Purchaser and any Purchaser Indemnitees shall be entitled to deal exclusively with the Member Representative on all matters relating to this Agreement, including, without limitation, ARTICLE IX , and each Purchaser Indemnitee shall be entitled to deal exclusively with the Member Representative in respect of all such matters, and each of them shall be entitled to rely conclusively (without further evidence of any kind whatsoever) on any document executed or purported to be executed on behalf of any Member by the Member Representative in respect of such matters, and on any other action taken or purported to be taken on behalf of any Member by the Member Representative, as fully binding upon such Member.
(b) Notwithstanding anything to the contrary contained in this Agreement, any notice or communication delivered by Purchaser to Member Representative shall, as between Purchaser, on the one hand, and the Members, on the other hand, be deemed to have been delivered to all Members. Purchaser shall be entitled to rely exclusively upon any communication or writings given or executed by Member Representative in connection with any claims for indemnity and shall not be liable in any manner whatsoever for any action taken or not taken in reliance upon the actions taken or not taken or communications or writings given or executed by Member Representative.
Section 10.04 Replacement . The Member Representative may at any time designate a replacement Member Representative with the consent of Purchaser (which will not be unreasonably withheld, conditioned or delayed), and each Member, by virtue of his or her execution and delivery of this Agreement, hereby consents to such replacement Member Representative. If the Member Representative shall die, become disabled or otherwise be unable to fulfill his responsibilities as representative of the Members, then the Members (or in the case of the death or disability of Lindsey, his heirs or personal representative voting his former membership interest) shall, by majority vote, within thirty (30) days after such death or disability, appoint a successor representative (with the consent of Purchaser, which will not be unreasonably withheld, conditioned or delayed). Any such successor shall become the Member Representative for all purposes under this Agreement.
ARTICLE XI
MISCELLANEOUS
Section 11.01 Expenses . Except as otherwise expressly provided herein, all costs and expenses, including, without limitation, fees and disbursements of counsel, financial advisors and accountants, incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such costs and expenses, whether or not the Closing shall have occurred.
Section 11.02 Notices . All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given (a) when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by email of a PDF document (with confirmation of transmission) if sent during normal hours of the recipient, and on the next Business Day if sent after normal business hours of the recipient; or (d) on the third day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective parties at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance with this Section 11.02 ):
If to Target: |
David E. Lindsey |
|
14785 Preston Rd., Ste. 975 |
|
Dallas, TX 75254 |
|
Email: DLindsey@AmeriDoc.com |
with a copy to: |
Munsch Hardt Kopf & Harr PC |
|
500 N. Akard St. |
|
Suite 3800 |
|
Dallas, TX 75201-6659 |
|
Email: mhainsfurther@munsch.com |
|
Attention: A. Michael Hainsfurther |
|
|
If to Member Representative: |
David E. Lindsey |
|
14785 Preston Rd., Ste. 975 |
|
Dallas, TX 75254 |
|
Email: DLindsey@AmeriDoc.com |
|
|
If to Purchaser: |
Teladoc, Inc. |
|
One Sound Shore Drive, Suite 300 |
|
Greenwich, Connecticut 06830 |
|
Email: tseaman@teladoc.com |
|
Attention: General Counsel |
|
|
with a copy to: |
Jackson Walker L.L.P. |
|
Bank of America Plaza |
|
901 Main Street, Suite 6000 |
|
Dallas, Texas 75202 |
|
Email: jryan@jw.com |
|
Attention: James S. Ryan III, Esq. |
Section 11.03 Interpretation . For purposes of this Agreement, (a) the words include, includes and including shall be deemed to be followed by the words without limitation; (b) the word or is not exclusive; and (c) the words herein, hereof, hereby, hereto and hereunder refer to this Agreement as a whole. Unless the context otherwise requires, references herein: (x) to Articles, Sections, Disclosure Schedules and Exhibits mean the Articles and Sections of. and Disclosure Schedules and Exhibits attached to, this Agreement; (y) to an agreement, instrument or other document means such agreement, instrument or other document as amended, supplemented and modified from time to time to the extent permitted by the provisions thereof; and (z) to a statute means such statute as amended from time to time and includes any successor legislation thereto and any regulations promulgated thereunder. This Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted. The Disclosure Schedules and Exhibits referred to herein shall be construed with, and as an integral part of, this Agreement to the same extent as if they were set forth verbatim herein.
Section 11.04 Headings . The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.
Section 11.05 Severability . If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon such determination that any term or other provision is
invalid, illegal or unenforceable, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible.
Section 11.06 Entire Agreement . This Agreement and the other Transaction Documents constitute the sole and entire agreement of the parties to this Agreement with respect to the subject matter contained herein and therein, and supersede all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter. In the event of any inconsistency between the statements in the body of this Agreement and those in the other Transaction Documents, the Exhibits and Disclosure Schedules (other than an exception expressly set forth as such in the Disclosure Schedules), the statements in the body of this Agreement will control.
Section 11.07 Successors and Assigns . This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns. No party may assign (directly or indirectly, by operation of law or otherwise) its rights or obligations hereunder without the prior written consent of Purchaser and the Member Representative, which consent shall not be unreasonably withheld or delayed; provided, however, that Purchaser may, without the prior written consent of Member Representative, assign all or any portion of its rights under this Agreement (i) to a successor of the Purchaser, by consolidation, merger or operation of law, (ii) to a purchaser of all or substantially all of the Purchasers assets, or (iii) to a lender of Purchaser as collateral. No assignment shall relieve the assigning party of any of its obligations hereunder.
Section 11.08 No Third-party Beneficiaries . Except as provided in ARTICLE IX , this Agreement is for the sole benefit of the Members of Target, the parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.
Section 11.09 Amendment and Modification; Waiver . This Agreement may only be amended, modified or supplemented by an agreement in writing signed by Purchaser and the Member Representative. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. No waiver by any party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.
Section 11.10 Governing Law; Waiver of Jury Trial; Venue .
(a) This Agreement shall be governed by and construed in accordance with the internal laws of the State of Texas without giving effect to any choice or conflict of law provision or rule (whether of the State of Texas or any other jurisdiction).
(b) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT OR THE OTHER TRANSACTION DOCUMENTS IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION, (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION (b) .
THE PARTIES HERETO AGREE THAT ALL DISPUTES, ACTIONS, SUITS AND PROCEEDINGS ARISING OUT OF OR RELATING TO THIS AGREEMENT MUST BE BROUGHT EXCLUSIVELY IN A STATE OR FEDERAL DISTRICT COURT LOCATED IN DALLAS COUNTY, TEXAS (COLLECTIVELY THE DESIGNATED COURTS ). EACH PARTY HERETO HEREBY CONSENTS AND SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE DESIGNATED COURTS. NO ACTION, SUIT OR PROCEEDING WITH RESPECT TO THIS AGREEMENT MAY BE BROUGHT IN ANY OTHER FORUM. EACH PARTY HEREBY IRREVOCABLY WAIVES ALL CLAIMS OF IMMUNITY FROM JURISDICTION AND ANY OBJECTION WHICH SUCH PARTY MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUIT, ACTION OR PROCEEDING IN ANY DESIGNATED COURT, INCLUDING ANY RIGHT TO OBJECT ON THE BASIS THAT ANY DISPUTE, ACTION, SUIT OR PROCEEDING BROUGHT IN THE DESIGNATED COURTS HAS BEEN BROUGHT IN AN IMPROPER OR INCONVENIENT FORUM OR VENUE.
Section 11.11 Specific Performance . The parties agree that irreparable damage would occur if any provision of this Agreement were not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy to which they are entitled at law or in equity.
Section 11.12 Counterparts . This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means
of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.
Section 11.13 Letter of Intent . Upon execution of this Agreement, that certain letter of intent dated February 11, 2014, executed by Purchaser and Target shall automatically terminate and be of no further force and effect.
Section 11.14 Privilege . All attorney client privileged communications of the Company relating to the terms of the transactions contemplated by this Agreement shall inure to the benefit of the members of the Company, prior to consummation of the transaction, and the Purchaser, as successor-in-interest to the Company, shall have no right, title and interest therein.
[SIGNATURE PAGE FOLLOWS]
IN WITNESS WHEREOF , the parties hereto have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.
|
AMERIDOC, LLC |
|
|
|
|
|
By |
/s/ David E. Lindsey |
|
Name: David E. Lindsey |
|
|
Tide: Managing Member |
|
|
|
|
|
|
|
|
TELADOC, INC. |
|
|
|
|
|
By |
/s/ Mark Hirschhorn |
|
Name: Mark Hirschhorn |
|
|
Title: Chief Financial Officer |
|
|
|
|
|
|
|
|
/s/ David E. Lindsey |
|
|
David E. Lindsey |
|
|
|
|
|
|
|
|
/s/ Michael R. Thompson |
|
|
Michael R. Thompson |
|
|
|
|
|
|
|
|
/s/ David E. Lindsey |
|
|
David E. Lindsey, solely in his capacity as |
|
|
Member Representative |
[Signature Page to Agreement and Plan of Merger]
Exhibit 2.3
AGREEMENT AND PLAN OF
MERGER
among
TELADOC, INC.,
STAT HEALTH,
LLC,
STAT HEALTH SERVICES
INC.,
and
JOHN BARRAVECCHIA, AS EQUITYHOLDER
REPRESENTATIVE
dated as of
May 22, 2015
TABLE OF CONTENTS
ARTICLE I |
DEFINITIONS |
2 |
|
|
|
ARTICLE II |
TRANSACTIONS AND TERMS OF THE MERGER |
19 |
|
|
|
Section 2.01 |
The Merger |
19 |
Section 2.02 |
Certificate of Formation and Limited Liability Company Agreement |
19 |
Section 2.03 |
Managers and Officers |
19 |
Section 2.04 |
Conversion of Interests |
19 |
Section 2.05 |
Merger Consideration |
21 |
Section 2.06 |
No Further Rights |
23 |
Section 2.07 |
Merger Consideration Adjustment |
23 |
Section 2.08 |
Dissenting Shares |
27 |
Section 2.09 |
Surrender and Payment |
27 |
Section 2.10 |
No Fractional Shares |
29 |
Section 2.11 |
Withholding |
29 |
Section 2.12 |
Lost Certificates |
29 |
Section 2.13 |
Adjustments for Splits and Dividends |
29 |
Section 2.14 |
Stock Transfer Books |
29 |
Section 2.15 |
Third Party Consents |
30 |
Section 2.16 |
Consideration Spreadsheet |
30 |
Section 2.17 |
Escrow Arrangements |
31 |
|
|
|
ARTICLE III |
CLOSING |
35 |
|
|
|
Section 3.01 |
Closing |
35 |
Section 3.02 |
Closing Deliverables |
35 |
|
|
|
ARTICLE IV |
REPRESENTATIONS AND WARRANTIES OF THE TARGET |
38 |
|
|
|
Section 4.01 |
Organization, Qualification and Capitalization of Target |
38 |
Section 4.02 |
Authority |
40 |
Section 4.03 |
No Conflicts; Consents |
41 |
Section 4.04 |
Financial Statements |
41 |
Section 4.05 |
Books and Records |
42 |
Section 4.06 |
Undisclosed Liabilities |
42 |
Section 4.07 |
Absence of Certain Changes, Events and Conditions |
42 |
Section 4.08 |
Material Contracts |
44 |
Section 4.09 |
Title to Assets; Condition and Sufficiency |
46 |
Section 4.10 |
Real Property |
47 |
Section 4.11 |
Intellectual Property |
48 |
Section 4.12 |
Accounts Receivable and Accounts Payable |
50 |
Section 4.13 |
Customers and Suppliers |
51 |
Section 4.14 |
Insurance |
52 |
Section 4.15 |
Legal Proceedings; Governmental Orders |
52 |
Section 4.16 |
Compliance with Laws; Permits |
53 |
Section 4.17 |
Environmental Matters |
55 |
Section 4.18 |
Employee Benefit Matters |
56 |
Section 4.19 |
Employment Matters |
58 |
Section 4.20 |
Taxes |
59 |
Section 4.21 |
Bank Accounts |
62 |
Section 4.22 |
Network Redundancy and Computer Back Up |
62 |
Section 4.23 |
No Disagreements with Accountants and Lawyers |
62 |
Section 4.24 |
Solvency |
62 |
Section 4.25 |
Interested Party Transactions |
62 |
Section 4.26 |
Anti-Terrorism Laws |
62 |
Section 4.27 |
Brokers |
63 |
Section 4.28 |
Information Statement |
63 |
|
|
|
ARTICLE V |
[RESERVED] |
63 |
|
|
|
ARTICLE VI |
REPRESENTATIONS AND WARRANTIES OF PURCHASER AND MERGER SUB |
63 |
|
|
|
Section 6.01 |
Organization of Purchaser and Merger Sub |
63 |
Section 6.02 |
Authority of Purchaser and Merger Sub |
64 |
Section 6.03 |
No Conflicts; Consents |
64 |
Section 6.04 |
Brokers |
64 |
Section 6.05 |
Financial Statements |
65 |
Section 6.06 |
Litigation |
65 |
Section 6.07 |
Financing |
65 |
Section 6.08 |
Intellectual Property |
65 |
Section 6.09 |
Taxes |
66 |
Section 6.10 |
No Material Change |
66 |
Section 6.11 |
Status of Purchaser Common Stock to be Issued |
66 |
Section 6.12 |
No Audit or Investigation |
66 |
Section 6.13 |
Compliance with Law |
66 |
Section 6.14 |
Information Statement |
67 |
Section 6.15 |
Capitalization of Purchaser |
67 |
|
|
|
ARTICLE VII |
COVENANTS |
67 |
|
|
|
Section 7.01 |
Conduct of Business |
67 |
Section 7.02 |
Other Actions |
69 |
Section 7.03 |
Access to Information |
69 |
Section 7.04 |
Exclusivity; No Shop; Break-Up Fee |
69 |
Section 7.05 |
Notices of Certain Events |
70 |
Section 7.06 |
Efforts; Approvals and Consents |
71 |
Section 7.07 |
Confidentiality |
72 |
Section 7.08 |
Tax Matters |
73 |
Section 7.09 |
Public Announcements |
75 |
Section 7.10 |
[Reserved] |
75 |
Section 7.11 |
Further Assurances |
75 |
Section 7.12 |
Benefit Plans |
75 |
Section 7.13 |
Healthcare Information Laws Compliance Investigations |
76 |
Section 7.14 |
Directors and Officers Indemnification |
76 |
Section 7.15 |
Equityholder and Employee Claims |
76 |
Section 7.16 |
Stockholders Consent |
76 |
Section 7.17 |
Securities Law Compliance |
78 |
Section 7.18 |
Plan of Reorganization |
78 |
|
|
|
ARTICLE VIII |
CONDITIONS TO THE MERGER |
79 |
|
|
|
Section 8.01 |
Conditions to the Obligations of Each Party |
79 |
Section 8.02 |
Conditions to the Obligations of Purchaser and Merger Sub |
80 |
Section 8.03 |
Conditions to the Obligations of Target |
81 |
|
|
|
ARTICLE IX |
TERMINATION |
82 |
|
|
|
Section 9.01 |
Termination |
82 |
Section 9.02 |
Effect of Termination |
83 |
|
|
|
ARTICLE X |
INDEMNIFICATION |
83 |
|
|
|
Section 10.01 |
Survival |
83 |
Section 10.02 |
Escrow Fund; Indemnification by the Stockholders and Optionholders |
83 |
Section 10.03 |
Indemnification by Purchaser |
84 |
Section 10.04 |
Certain Limitations |
85 |
Section 10.05 |
Indemnification Procedures |
86 |
Section 10.06 |
Payments |
88 |
Section 10.07 |
Tax Treatment of Indemnification Payments |
89 |
Section 10.08 |
Effect of Investigation |
89 |
Section 10.09 |
Exclusive Remedies |
89 |
Section 10.10 |
Authority of the Equityholder Representative |
89 |
Section 10.11 |
Calculation of Losses |
89 |
Section 10.12 |
Breach of Transmittal Letter |
90 |
|
|
|
ARTICLE XI |
EQUITYHOLDER REPRESENTATIVE |
90 |
|
|
|
Section 11.01 |
Appointment of Equityholder Representative; Power of Attorney |
90 |
Section 11.02 |
Irrevocable Appointment |
92 |
Section 11.03 |
Reliance |
92 |
Section 11.04 |
Replacement |
92 |
|
|
|
ARTICLE XII |
MISCELLANEOUS |
93 |
|
|
|
Section 12.01 |
Escrow |
93 |
Section 12.02 |
Expenses |
93 |
Section 12.03 |
Notices |
93 |
Section 12.04 |
Interpretation |
94 |
Section 12.05 |
Headings |
95 |
Section 12.06 |
Severability |
95 |
Section 12.07 |
Entire Agreement |
95 |
Section 12.08 |
Successors and Assigns |
95 |
Section 12.09 |
No Third-party Beneficiaries |
95 |
Section 12.10 |
Amendment and Modification; Waiver |
95 |
Section 12.11 |
Governing Law; Waiver of Jury Trial; Venue |
96 |
Section 12.12 |
Specific Performance |
97 |
Section 12.13 |
Counterparts |
97 |
LIST OF EXHIBITS
Exhibits :
Exhibit A Form of Certificate of Merger
Exhibit B Form of Escrow Agreement
Exhibit C Form of Working Capital Statement
Exhibit D Form of Pre-Closing Statement
Exhibit E Form of Letter of Transmittal
Exhibit F Form of Option Termination Agreement
Exhibit G Form of Target Opinion
Exhibit H Form of Roga Employment Agreement
Exhibit I Form of Noncompetition Agreement
AGREEMENT AND PLAN OF MERGER
This Agreement and Plan of Merger (this Agreement ), dated as of May 22, 2015, is entered into by and among (i) Teladoc, Inc., a Delaware corporation ( Purchaser ), (ii) Stat Health, LLC, a Delaware limited liability company ( Merger Sub ), (iii) Stat Health Services Inc., a Delaware corporation ( Target ), and (iv) John Barravecchia, not in his individual capacity, but as an agent of the Stockholders and Optionholders of Target (the Equityholder Representative ).
RECITALS
WHEREAS, Target is engaged in the business of providing access to telemedicine and telehealth services to its customers (the Business );
WHEREAS, Purchaser has formed Merger Sub as a wholly owned subsidiary of Purchaser;
WHEREAS, the parties intend that Target be merged with and into Merger Sub, with Merger Sub surviving that merger as a wholly owned subsidiary of Purchaser on the terms and subject to the conditions set forth herein (the Merger );
WHEREAS, the board of directors of Target (the Target Board ) has (a) determined that this Agreement and the transactions contemplated hereby, including the Merger, are in the best interests of the Target and its stockholders, (b) unanimously approved and declared advisable this Agreement and the transactions contemplated hereby, including the Merger, and (c) resolved to recommend adoption of this Agreement by the stockholders of Target in accordance with the Delaware General Corporation Law (the DGCL );
WHEREAS, as of the date of this Agreement, the Principals collectively own (a) 68.59% of the issued and outstanding shares of Targets Series A Convertible Preferred Stock, $0.001 par value per share (the Target Preferred Stock ), and (b) 94.01% of the issued and outstanding shares of Targets Common Stock, $0.001 par value per share (the Target Common Stock , and together with the Target Preferred Stock, the Target Shares );
WHEREAS, concurrently with the execution and delivery of this Agreement, and as a condition and material inducement to Purchasers and Merger Subs willingness to enter into this Agreement, each Principal has executed a written consent, dated as of the date of this Agreement, pursuant to which such Principal has, among other things, voted all of the Equity Interests of Target that such Principal owns to approve the principal terms of the Merger and this Agreement;
WHEREAS, following the execution of this Agreement, Target shall seek to obtain, in accordance with Section 228 of the DGCL, a written consent (the Written Consent ) containing the affirmative vote of the Principals approving this Agreement, the Merger and the transactions contemplated hereby in accordance with Section 251 of the DGCL and the Target Charter Documents (the Target Stockholder Approval );
WHEREAS, the board of directors of Purchaser has (a) determined that this Agreement and the transactions contemplated hereby, including the Merger, are in the best interests of Purchaser and its stockholders and Merger Sub, and (b) approved and declared advisable this Agreement and the transactions contemplated hereby, including the Merger; and
WHEREAS, the Purchaser, as the sole member of Merger Sub, and the managers of Merger Sub have (a) determined that this Agreement and the transactions contemplated hereby, including the Merger, are in the best interests of Merger Sub, and (b) approved and declared advisable this Agreement and the transactions contemplated hereby, including the Merger;
WHEREAS, the parties hereto intend that the Merger qualify as a reorganization under section 368(a)(1)(A) of the Code; and
WHEREAS, the parties hereto desire to make certain representations, warranties, covenants and agreements in connection with the Merger and to prescribe various conditions to the Merger.
NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
ARTICLE I
DEFINITIONS
The following terms have the meanings specified or referred to in this ARTICLE I :
Accredited Investor means an accredited investor, as such term is defined in Regulation D.
Accounts Receivable means all accounts or notes receivable held by Target as of the Closing Date, and any security, claim, remedy or other right related to any of the foregoing.
Action means any claim, action, cause of action, demand, lawsuit, arbitration, inquiry, audit, notice of violation, proceeding, litigation, citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether at law or in equity.
Adjusted Per Share Cash Closing Consideration has the meaning set forth in Section 2.05(b)(vii)(A) .
Adjusted Per Share Stock Closing Consideration has the meaning set forth in Section 2.05(b)(vii)(B) .
Adjustment has the meaning set forth in Section 2.07(c)(ii) .
Adjustment Disputed Amounts has the meaning set forth in Section 2.07(d)(iii) .
Adjustment Resolution Period has the meaning set forth in Section 2.07(d)(ii) .
Adjustment Review Period has the meaning set forth in Section 2.07(d)(i) .
Adjustment Statement of Objections has the meaning set forth in Section 2.07(d)(ii) .
Affiliate of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first Person. The term control (including the terms controlled by and under common control with) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.
Aggregate Merger Consideration has the meaning set forth in Section 2.05(a) .
Aggregate Option Payment Amount has the meaning set forth in Section 2.04(b)(i) .
Agreement has the meaning set forth in the preamble.
Anti-Terrorism Law has the meaning set forth in Section 4.26 .
Applicable Survival Period has the meaning set forth in Section 10.01 .
Balance Sheet has the meaning set forth in Section 4.04 .
Balance Sheet Date has the meaning set forth in Section 4.04 .
Benefit Agreement means any employment, deferred compensation, consulting, severance, change of control, termination, retention, indemnification, loan or similar agreement between the Target and any Participant.
Benefit Plan means any employment, bonus, pension, profit sharing, retirement, deferred compensation, incentive compensation, stock ownership, equity or equity-based compensation, paid time off, perquisite, fringe benefit, vacation, change of control, severance, retention, disability, death benefit, hospitalization, medical, welfare benefit or other plan, program, policy, arrangement, agreement or understanding (whether or not legally binding) sponsored, maintained, contributed to or required to be sponsored, maintained or contributed to by the Target, providing benefits to any Participant, but not including any Benefit Agreement.
Books and Records means all books and records of Target, including, but not limited to, books of account, ledgers and general, financial and accounting records, machinery and equipment maintenance files, customer lists, customer purchasing histories, price lists, distribution lists, supplier lists, production data, quality control records and procedures, customer complaints and inquiry files, research and development files, records and data (including all correspondence with any Governmental Authority), sales material and records (including pricing history, total sales, terms and conditions of sale, sales and pricing policies and practices), strategic plans, internal financial statements, marketing and promotional surveys, material and research and Intellectual Property files relating to the Intellectual Property Assets and the Intellectual Property Licenses.
Break-up Fee has the meaning set forth in Section 7.04 .
Business has the meaning set forth in the recitals.
Business Day means any day except Saturday, Sunday or any other day on which commercial banks located in Dallas, Texas are authorized or required by Law to be closed for business.
Cap has the meaning set forth in Section 10.04(c) .
Cash Conversion Share means each Target Share designated as a Cash Conversion Share on Schedule X attached hereto (as it may be updated in accordance with Section 2.16 ); provided, however, that all Target Shares held by any Stockholder who is not an Accredited Investor shall constitute Cash Conversion Shares for purposes of this Agreement, regardless of whether such Target shares are designated as Cash Conversion Shares or Stock Conversion Shares on Schedule X .
Cash Percentage has the meaning set forth in Section 2.17(c)(i) .
Cash Transfer Date has the meaning set forth in Section 2.05(b)(v) .
Certificate of Merger means a certificate of merger in the form attached hereto as Exhibit A .
Certificates has the meaning set forth in Section 2.09(a) .
Closing has the meaning set forth in Section 3.01 .
Closing Accrued Tax Amount means the sum, without duplication, of all unpaid Taxes (whether accrued or otherwise) of Target with respect to all Pre-Closing Tax Periods.
Closing Balance Sheet has the meaning set forth in Section 2.07(c)(i)(A) .
Closing Date has the meaning set forth in Section 3.01 .
Closing Indebtedness means the amount of all Indebtedness of Target outstanding as of the Closing Date and immediately prior to the Effective Time.
Closing Payment Amount has the meaning set forth in Section 2.05(c)(i) .
Closing Statement has the meaning set forth in Section 2.07(c)(i) .
Closing Transaction Expenses means Transaction Expenses of Target incurred in connection with this Agreement, the Transaction Documents and the transactions contemplated hereby and thereby that remain unpaid at the Closing.
Closing Working Capital has the meaning set forth in Section 2.07(a) .
Code means the Internal Revenue Code of 1986, as amended.
Compliance Plan has the meaning set forth in Section 4.16(c) .
Consideration Spreadsheet has the meaning set forth in Section 2.16(a) .
Contracts means all contracts, leases, deeds, mortgages, licenses, instruments, notes, commitments, undertakings, indentures, joint ventures and all other agreements, commitments and legally binding arrangements, whether written or oral.
Criminal Activity of Purchaser and/or Merger Sub means with respect to Purchaser and/or Merger Sub, as applicable, the commission of a felony or crime punishable by imprisonment by Purchaser, Merger Sub and/or their respective Representatives, in each case in connection with (i) Purchasers business, or (ii) the transactions contemplated by this Agreement.
Criminal Activity of Target means with respect to Target, the commission of a felony or crime punishable by imprisonment by Target and/or its Representatives, in each case in connection with (i) Targets business, or (ii) the transactions contemplated by this Agreement.
Current Assets means cash and cash equivalents, Accounts Receivable, inventory and prepaid expenses, but excluding (a) the portion of any prepaid expense of which the Surviving Company will not receive the benefit following the Closing, and (b) deferred Tax assets, determined in accordance with GAAP applied using the same accounting methods, practices, principles, policies and procedures, with consistent classifications, judgments and valuation and estimation methodologies that were used in the preparation of the Form of Working Capital Statement.
Current Liabilities means accounts payable, accrued Taxes (except to the extent included in the Closing Accrued Tax Amount) and accrued expenses (including amounts under Targets credit card, amounts payable to Engaged Professionals and accrued bonuses), but excluding deferred Tax liabilities, Transaction Expenses and the current portion of any Indebtedness of Target, determined in accordance with GAAP applied using the same accounting methods, practices, principles, policies and procedures, with consistent classifications, judgments and valuation and estimation methodologies that were used in the preparation of the Form of Working Capital Statement.
D&O Obligations any obligations or claims with respect to any rights to indemnification, advancement or reimbursement of expenses and exculpation from liabilities for acts or omissions occurring at or prior to the Effective Time in favor of the current or former directors or officers of Target, whether pursuant to the Target Charter Documents, an indemnification agreement or otherwise, or in favor of the current or former agents of Target pursuant to the Target Charter Documents.
D&O Tail Policy has the meaning set forth in Section 7.14 .
Debt Payoff Recipients has the meaning set forth in Section 2.05(b)(i) .
Designated Courts has the meaning set forth in Section 12.11(b) .
DGCL has the meaning set forth in the recitals.
Direct Claim has the meaning set forth in Section 10.05(c) .
Dissenting Shares has the meaning set forth in Section 2.08 .
DLLCA has the meaning set forth in Section 2.01 .
Dollars or $ means the lawful currency of the United States.
Effective Time means the time at which Certificate of Merger is filed and becomes effective with the Secretary of State of the State of Delaware in accordance with the DGCL and DLLCA (or at such later time as shall be agreed upon by Purchaser and Target and set forth in the Certificate of Merger).
EMP Contracts has the meaning set forth in Section 3.02(a)(xxi) .
Encumbrance means any charge, claim, community property interest, pledge, condition, equitable interest, lien (statutory or other), option, security interest, mortgage, easement, encroachment, right of way, right of first refusal, or restriction of any kind, including any restriction on use, voting, transfer, receipt of income or exercise of any other attribute of ownership
Engaged Professional has the meaning set forth in Section 4.16(b) .
Environmental Claim means any Action, Governmental Order, lien, fine, penalty, or, as to each, any settlement or judgment arising therefrom, by or from any Person alleging liability of whatever kind or nature (including liability or responsibility for the costs of enforcement proceedings, investigations, cleanup, governmental response, removal or remediation, natural resources damages, property damages, personal injuries, medical monitoring, penalties, contribution, indemnification and injunctive relief) arising out of, based on or resulting from: (a) the presence, Release of, or exposure to, any Hazardous Materials; or (b) any actual or alleged non-compliance with or liability under any Environmental Law or term or condition of any Environmental Permit.
Environmental Law means any applicable Law, and any Governmental Order or binding agreement with any Governmental Authority: (a) relating to pollution (or the cleanup thereof) or the protection of natural resources, endangered or threatened species, human health or safety, or the environment (including ambient air, soil, surface water or groundwater, or subsurface strata); or (b) concerning the presence of, exposure to, or the management, manufacture, use, containment, storage, recycling, reclamation, reuse, treatment, generation, discharge, transportation, processing, production, disposal or remediation of any Hazardous Materials. The term Environmental Law includes, without limitation, the following (including their implementing regulations and any similar state Laws): the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended by the Superfund Amendments
and Reauthorization Act of 1986, 42 U.S.C. §§ 9601 et seq.; the Solid Waste Disposal Act, as amended by the Resource Conservation and Recovery Act of 1976, as amended by the Hazardous and Solid Waste Amendments of 1984, 42 U.S.C. §§ 6901 et seq.; the Federal Water Pollution Control Act of 1972, as amended by the Clean Water Act of 1977, 33 U.S.C. §§ 1251 et seq.; the Toxic Substances Control Act of 1976, as amended, 15 U.S.C. §§ 2601 et seq.; the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. §§ 11001 et seq.; the Clean Air Act of 1966, as amended by the Clean Air Act Amendments of 1990, 42 U.S.C. §§ 7401 et seq.; and the Occupational Safety and Health Act of 1970, as amended, 29 U.S.C. §§ 651 et seq.
Environmental Notice means any written directive, notice of violation or infraction, or notice respecting any Environmental Claim relating to actual or alleged non-compliance with or liability under any Environmental Law or any term or condition of any Environmental Permit.
Environmental Permit means any Permit, letter, clearance, consent, waiver, closure, exemption, decision or other action required under or issued, granted, given, authorized by or made pursuant to Environmental Law.
Equity Interest and equity security mean any equity security as such term is defined in the Securities and Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
Equityholder and Employee Claims means any and all Losses incurred by Purchaser, Merger Sub, the Surviving Company or any of their Affiliates as a result of any claim brought by or for the benefit of any Principal, Stockholder, Optionholder or former stockholder of Target, current or former holders of options, warrants or other Equity Interests of Target or employee or former employee of Target, in respect of such Persons status as such relating to events, facts, conditions or circumstances existing or arising prior to the Effective Time or in connection with this Agreement, the Transaction Documents, the Merger, the transactions contemplated hereby or thereby (including (i) any such matters relating to the exercise of any rights or remedies by any Principal, Stockholder or Optionholder in connection with the exercise of dissenters rights, appraisal rights or any similar rights in connection with this Agreement or the Merger, (ii) any such matters arising out of or related to the Target Charter Documents or Targets Benefit Plans, employment agreements with employees or otherwise, and (iii) any claims with respect to any such Persons right to the Aggregate Merger Consideration (or any portion thereof) or with respect to the calculations set forth in the Consideration Spreadsheet), including, without limitation, (x) any of the foregoing arising from matters disclosed to Purchaser, Merger Sub or their Affiliates or otherwise referenced in this Agreement, and whether any related claim arises before or after the Closing, (y) whether such matters are known or unknown, contingent or otherwise, whether accrued, liquidated, matured or unmatured, and (z) all costs of investigation, defense, insurance claims processing, and insurance deductibles associated therewith.
Equityholder Representative has the meaning set forth in the preamble.
Equityholder Representative Holdback Amount means the sum of Two Hundred Fifty Thousand and No/100 Dollars ($250,000.00), to be deposited to the account specified by Equityholder Representative prior to the Closing.
ERISA means the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.
ERISA Affiliate means all employers (whether or not incorporated) that would be treated together with Target or any of its Affiliates as a single employer within the meaning of Section 414 of the Code.
Escrow Account has the meaning set forth in Section 2.17(a)(i) .
Escrow Agent means Wilmington Trust, N.A., a national banking association.
Escrow Agreement means the Escrow Agreement to be entered into by Purchaser, Equityholder Representative and the Escrow Agent at the Closing, substantially in the form of Exhibit B .
Escrow Amount means Six Million One Hundred Thousand and No/100 Dollars ($6,100,000.00), consisting of the Escrow Shares and the Escrow Cash.
Escrow Cash means an amount equal to the (i) Per Share Escrow Amount, multiplied by (ii) the sum of (x) the total number of Cash Conversion Shares, plus (y) the total number of shares of Target Common Stock that would be issuable upon exercise of all of the outstanding Options immediately prior to the Effective Time.
Escrow Fund has the meaning set forth in Section 2.17(a)(i) .
Escrow Shares means a number of shares of Purchaser Common Stock equal to (i) the Per Share Escrow Shares multiplied by (ii) the total number of Stock Conversion Shares.
Estimated Adjustment Amount has the meaning set forth in Section 2.07(c)(ii) .
Estimated Closing Accrued Tax Amount has the meaning set forth in Section 2.07(b)(i)(C) .
Estimated Closing Balance Sheet has the meaning set forth in Section 2.07(b)(i)(A) .
Estimated Closing Indebtedness has the meaning set forth in Section 2.07(b)(i)(D) .
Estimated Closing Working Capital has the meaning set forth in Section 2.07(b)(i)(B) .
Exchange Property has the meaning set forth in Section 2.17(a)(v) .
Executive Order has the meaning set forth in Section 4.26 .
Final Adjustment Amount has the meaning set forth in Section 2.07(c)(ii) .
Final Closing Accrued Tax Amount has the meaning set forth in Section 2.07(c)(ii) .
Final Closing Indebtedness has the meaning set forth in Section 2.07(c)(ii) .
Final Closing Working Capital has the meaning set forth in Section 2.07(c)(ii) .
Final Determination has the meaning set forth in Section 12.01 .
Final Release Date has the meaning set forth in Section 2.17(b) .
Financial Statements has the meaning set forth in Section 4.04 .
Form of Working Capital Statement has the meaning set forth in Section 2.07(a) .
Fraud of Purchaser and/or Merger Sub means with respect to Purchaser and/or Merger Sub, as applicable, an actual and intentional fraud by Purchaser, Merger Sub and/or their respective Representatives with the intention that Target rely thereon to its detriment.
Fraud of Target means with respect to Target, an actual and intentional fraud by Target or its Representatives with intention that Purchaser and/or Merger Sub rely thereon to its/their detriment.
Fully Diluted Shares means the sum (rounded to the nearest thousandth) of (i) the aggregate number of Target Shares that are issued and outstanding immediately prior to the Effective Time, plus (ii) the total number of Target Shares that would be issuable upon exercise of all of the outstanding Options immediately prior to the Effective Time, whether or not then exercisable.
Fundamental Representations has the meaning set forth in Section 10.01 .
GAAP means United States generally accepted accounting principles in effect from time to time, consistently applied.
Governmental Authority means any federal, state, local or foreign government or political subdivision thereof, or any agency or instrumentality of such government or political subdivision, or any self-regulated organization or other non-governmental regulatory authority or quasi-governmental authority (to the extent that the rules, regulations or orders of such organization or authority have the force of Law), or any arbitrator, court or tribunal of competent jurisdiction.
Governmental Order means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any Governmental Authority.
Hazardous Materials means: (a) any material, substance, chemical, waste, product, derivative, compound, mixture, solid, liquid, mineral or gas, in each case, whether naturally occurring or manmade, that is regulated or subject to liability under Environmental Laws; and
(b) any petroleum or petroleum-derived products, radon, radioactive materials or wastes, asbestos in any form, lead or lead-containing materials, urea formaldehyde foam insulation, and polychlorinated biphenyls.
Healthcare Information Laws has the meaning set forth in Section 4.16(c) .
HIPAA has the meaning set forth in Section 4.16(c) .
Indemnification Agreement has the meaning set forth in Section 3.02(a)(ix) .
Income Tax means all federal, state and local income or profits Taxes, Taxes measured by income, profits or earned surplus, excise Taxes and other governmental charges arising from income, profits or other revenue similar in nature to any of the foregoing, including any interest, penalties or other additions to Tax that may become payable in respect thereof, imposed by any Governmental Authority.
Indebtedness means any of the following of Target: (a) any indebtedness for borrowed money (including any obligation for principal, interest, premiums, penalties, fees, expenses and breakage costs), (b) any obligations evidenced by bonds, debentures, notes or other similar instruments, (c) all interest expense accrued but unpaid on or relating to any such obligations described in clauses (a) and (b) above, (d) any obligations to pay the deferred purchase price of property or services, except trade accounts payable, (e) any obligations, contingent or otherwise, under acceptance credit, letters of credit or similar facilities, (f) unpaid fees, prepayment or redemption premiums or penalties or breakage costs associated with the repayment or prepayment of the types of obligations described in clauses (a) through (e) above, and (g) all outstanding obligations of the types described in clauses (a) through (f) above of any Person, the payment for which Target is or may be responsible or liable, directly or indirectly, as obligor, guarantor or surety, including guarantees of such obligations.
Indemnification Determination has the meaning set forth in Section 10.06 .
Indemnified Party has the meaning set forth in Section 10.05 .
Indemnifying Party has the meaning set forth in Section 10.05 .
Independent Accountants has the meaning set forth in Section 2.07(d)(iii) .
Information Statement has the meaning set forth in Section 7.16(a) .
Insolvent has the meaning set forth in Section 4.24 .
Insurance Policies has the meaning set forth in Section 4.14 .
Intellectual Property means all intellectual property and industrial property rights and assets, and all rights, interests and protections that are associated with, similar to, or required for the exercise of, any of the foregoing, however arising, pursuant to the Laws of any jurisdiction throughout the world, whether registered or unregistered, including any and all: (a) trademarks,
service marks, trade names, brand names, certification marks, logos, trade dress, assumed names, design rights and other similar designations of source, sponsorship, association or origin, together with the goodwill connected with the use thereof and symbolized thereby, and all registrations, applications and renewals for, any of the foregoing; (b) internet domain names, whether or not trademarks, registered in any top-level domain by any authorized private registrar or Governmental Authority, web addresses, web pages, websites and related content, accounts with Twitter, Facebook, Instagram, Google+, and other social media companies and the content found thereon and related thereto, and URLs; (c) works of authorship, expressions, designs, logos and design registrations, whether or not copyrightable, including copyright, author, performer, moral and neighboring rights, and all registrations, applications for registration and renewals or extensions of such copyrights; (d) inventions, discoveries, trade secrets, business and technical information and know-how, databases, data collections, non-public information, formulae, processes, procedures, research records, records of invention, test information, market surveys and other confidential and proprietary information, whether patentable or not, and all rights therein; (e) patents (including all reissues, divisionals, provisionals, continuations and continuations-in-part, re-examinations, renewals, substitutions and extensions thereof), patent applications, and other patent rights and any other Governmental Authority-issued indicia of invention ownership (including inventors certificates, petty patents and patent utility models); (f) software, including all types of computer software programs, operating systems, application programs, software tools, firmware (including all types of firmware, firmware specifications, mask works, circuit layouts and hardware descriptions) and software imbedded in equipment, including both object code and source code, application programming interfaces, architecture, files, records, schematics and all written or electronic data, documentation and materials that explain the structure or use of software or that were used in the development of software, including software specifications, or are used in the operation of the software (including logic diagrams, flow charts, procedural diagrams, error reports, manuals and training materials, look- up tables and databases), whether patentable or not; (g) semiconductor chips and mask works; and (h) any claims or causes of action (pending, threatened or which could be filed) arising out of any infringement or misappropriation of any of the foregoing.
Intellectual Property Assets means all Intellectual Property that is owned by Target.
Intellectual Property Licenses means all licenses, sublicenses and other agreements by or through which other Persons, including Targets Affiliates, grant Target exclusive or non- exclusive rights or interests in or to any Intellectual Property.
Intellectual Property Registrations means all Intellectual Property Assets that are subject to any issuance, registration, application or other filing by, to or with any Governmental Authority or authorized private registrar in any jurisdiction, including registered trademarks, domain names and copyrights, issued and reissued patents and pending applications for any of the foregoing.
Interim Balance Sheet has the meaning set forth in Section 4.04 .
Interim Balance Sheet Date has the meaning set forth in Section 4.04 .
IRA Joinders has the meaning set forth in Section 3.02(a)(xiv) .
Knowledge of Target or Targets Knowledge means, with respect to any executive officer or director of Target, the actual knowledge of such Persons, in each case after due inquiry and reasonable investigation.
Law means any statute, law, ordinance, regulation, rule, code, order, constitution, treaty, common law, judgment, decree, other requirement or rule of law of any Governmental Authority.
Leased Real Property has the meaning set forth in Section 4.10(b) . Leases has the meaning set forth in Section 4.10(b) .
Letter of Transmittal has the meaning set forth in Section 2.09(a) .
Liabilities means liabilities, obligations or commitments of any nature whatsoever, asserted or unasserted, known or unknown, absolute or contingent, accrued or unaccrued, matured or unmatured or otherwise.
Losses means losses, damages, Liabilities, deficiencies, Actions, judgments, interest, awards, penalties, fines, costs or expenses of whatever kind, including reasonable attorneys fees and the cost of enforcing any right to indemnification hereunder and the cost of pursuing any insurance providers.
Material Adverse Effect means any event, result, occurrence, effect, fact, condition or change that is, or could reasonably be expected to become, individually or in the aggregate, materially adverse to (a) the Business, results of operations, conditions (financial or otherwise), capitalization, assets or liabilities of the Target, (b) the aggregate value of the Target Shares or Options, (c) the value of the Targets assets or properties, (d) the ability of the Target to consummate the transactions contemplated hereby on a timely basis or (e) Purchasers or the Surviving Companys ability to operate the business of Target after Closing in the manner operated by Target before Closing; provided, however, that none of the following constitute, or will be considered in determining whether there has occurred, a Material Adverse Effect: (i) changes resulting from the announcement of the transactions contemplated hereby; (ii) changes in GAAP or the interpretation thereof; (iii) changes that are the result of economic factors affecting the national or world economy; or (iv) changes made by Target at the request of Purchaser or Merger Sub or required by Purchaser or Merger Sub pursuant to this Agreement.
Material Contracts has the meaning set forth in Section 4.08(a) .
Material Customers has the meaning set forth in Section 4.13(a) .
Material Suppliers has the meaning set forth in Section 4.13(b) .
Merger has the meaning set forth in the recitals.
Merger Sub has the meaning set forth in the preamble.
New Shares has the meaning set forth in Section 2.17(a)(iii) .
Noncompetition Agreements has the meaning set forth in Section 3.02(a)(xviii) .
Option means any option to purchase Target Common Stock granted under any Stock Option Plan and still outstanding as of immediately prior to the Effective Time.
Option Exercise Proceeds means the aggregate amount that would be payable to Target in cash by the Optionholders to purchase shares of Target Common Stock if, immediately prior to the Effective Time, such Optionholders exercised all of the then outstanding Options, whether or not then exercisable, by paying the exercise price therefor in cash.
Option Payment Amount has the meaning set forth in Section 2.04(b)(i) .
Option Termination Agreement has the meaning set forth in Section 2.09(b) .
Optionholder means a holder of an Option.
Partial Release Amount has the meaning set forth in Section 2.17(b) .
Partial Release Date has the meaning set forth in Section 2.17(b) .
Participant means any current or former director, manager, member, officer, employee or consultant of the Target.
Participating Percentage means, with respect to each Stockholder or Optionholder, the percentage equal to (i) the sum of (x) the number of Target Shares held by such Stockholder or Optionholder immediately prior to the Closing plus (y) the number of Target Shares issuable upon the exercise of all Options held by such Stockholder or Optionholder immediately prior to the Closing, divided by (ii) the number of Fully Diluted Shares immediately prior to the Closing.
Payoff Letters has the meaning set forth in Section 2.07(b)(i)(D) .
Per Share Cash Closing Consideration has the meaning set forth in Section 2.05(c)(ii) .
Per Share Escrow Amount means an amount equal to the Escrow Amount divided by the number of Fully Diluted Shares.
Per Share Escrow Shares means an amount equal to the Per Share Escrow Amount divided by the Purchaser Stock Price.
Per Share Stock Closing Consideration has the meaning set forth in Section 2.05(c)(iii) .
Permits means all permits, licenses, franchises, approvals, authorizations, registrations, certificates, variances and similar rights obtained, or required to be obtained, from Governmental Authorities.
Permitted Encumbrances has the meaning set forth in Section 4.09 .
Person means an individual, corporation, partnership, joint venture, limited liability company, Governmental Authority, unincorporated organization, trust, association or other entity.
Post-Closing Tax Period means any taxable period beginning after the Closing Date and, with respect to any taxable period beginning before and ending after the Closing Date, the portion of such taxable period beginning on the first day after the Closing Date.
Pre-Closing Statement has the meaning set forth in Section 2.07(b)(i) .
Pre-Closing Tax Period means any taxable period ending on or before the Closing Date and, with respect to any taxable period beginning before and ending after the Closing Date, the portion of such taxable period ending on and including the Closing Date.
Principal shall mean each of (i) EMP Holdings, Ltd., (ii) Quad/Med, LLC, (iii) the Alan C. and Ilana D. Roga Living Trust, and (iv) the Barravecchia Family Trust.
Profit Sharing Agreements means that certain (i) Settlement and Release Agreement, dated May 8, 2015, by and between Target and Stat Doctors Arizona, PLLC, an Arizona professional limited liability company ( SDAZ ); and (ii) Amendment to Detailed Definitive Agreements, dated January 1, 2015, by and between Target and EMP Stat Doctors of Ohio, Ltd., an Ohio limited liability company and all of its affiliated companies, including but not limited to, EMP Management Group, Ltd (collectively, EMP ), with respect to those certain Detailed Definitive Agreements referenced therein, including the Master Agreement, the License Agreement, the Administrative Services Agreement, the Sub-Administrative Services Agreement, the Investors Rights Agreement, and the Provider Agreement (each as defined therein), all dated on or about February 8, 2011.
Profit Sharing Claims means any and all Losses incurred by any Purchaser Indemnitees as a result of any claim brought by or for the benefit of any Profit Sharing Party or any of their respective Affiliates in respect of any Profit Sharing Partys status as a provider group of Target or arising out of or relating to any Profit Sharing Agreement or the transactions contemplated thereby, including, without limitation, (x) any of the foregoing arising from matters disclosed to Target, Merger Sub or their Affiliates or otherwise referenced in this Agreement, and whether any related claim arises before or after the Closing, (y) whether such matters are known or unknown, contingent or otherwise, whether accrued, liquidated, matured or unmatured, and (z) all costs of investigation, defense, insurance claims processing, and insurance deductibles associated therewith.
Profit Sharing Parties means (i) SDAZ; and (ii) EMP.
Profit Sharing Payment Amount has the meaning set forth in Section 2.05(b)(ii).
Prohibited Transaction means any of the following (other than the transactions contemplated by this Agreement): (i) any merger, consolidation, share exchange, business combination, recapitalization, liquidation, dissolution or other similar transaction involving the Target; (ii) any sale, lease, exchange, transfer or other disposition of all or a substantial part of the assets of the Target; (iii) any sale, exchange, transfer or other disposition of any Equity Interests of Target (except sales or transfers of Equity Interests of Target among the existing Stockholders of Target or those otherwise permitted by Section 7.01 ); (iv) any tender offer or exchange offer for Equity Interests of Target, or the filing of a registration statement under the Securities Act in connection therewith; or (v) any solicitation in opposition to approval and adoption of this Agreement by any Target or any Stockholder or Optionholder.
Purchaser has the meaning set forth in the preamble.
Purchaser Annual Financial Statements has the meaning set forth in Section 6.05 . Purchaser Charter Documents means the certificate of incorporation and by-laws of Purchaser, the Purchaser Investors Rights Agreement and other organizational documents of Purchaser.
Purchaser Common Stock means common stock, par value $0.001 per share, of Purchaser.
Purchaser Disclosure Schedules means the Disclosure Schedules delivered by Purchaser and Merger Sub concurrently with the execution and delivery of this Agreement.
Purchaser Financial Statements has the meaning set forth in Section 6.05 .
Purchaser Indemnitees has the meaning set forth in Section 10.02 .
Purchaser Intellectual Property has the meaning set forth in Section 6.08 .
Purchaser Interim Financial Statements has the meaning set forth in Section 6.05 .
Purchaser Investors Rights Agreement means the Fifth Amended and Restated Investors Rights Agreement of Purchaser, dated September 10, 2014 (as amended).
Purchaser Material Adverse Effect means any event, result, occurrence, effect, fact, condition or change that is, or could reasonably be expected to become, individually or in the aggregate, materially adverse to (a) the business, results of operations, conditions (financial or otherwise), capitalization, assets or liabilities of the Purchaser, (b) the aggregate value of the Aggregate Merger Consideration, (c) the value of the Purchasers assets or properties, or (d) the ability of Purchaser or Merger Sub to consummate the transactions contemplated hereby on a timely basis; provided, however, that none of the following constitute, or will be considered in determining whether there has occurred, a Purchaser Material Adverse Effect: (i) changes resulting from the announcement of the transactions contemplated hereby; (ii) changes in GAAP
or the interpretation thereof; or (iii) changes that are the result of economic factors affecting the national or world economy;
Purchaser Stock Price has the meaning set forth in Section 2.05(c)(iv) .
Purchaser Stock Trading Value has the meaning set forth in Section 2.17(c)(iii) .
Purchasers Accountants means Ernst & Young.
Regulation D has the meaning set forth in Section 4.28 .
Release means any actual or threatened release, spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, dumping, abandonment, disposing or allowing to escape or migrate into or through the environment (including, without limitation, ambient air (indoor or outdoor), surface water, groundwater, land surface or subsurface strata or within any building, structure, facility or fixture).
Representative means, with respect to any Person, any and all directors, managers, general partners, officers, employees, consultants, financial advisors, counsel, accountants and other agents of such Person.
Restricted Party has the meaning set forth in Section 4.26 .
Restriction Period has the meaning set forth in Section 7.04 .
Roga Employment Agreement has the meaning set forth in Section 3.02(a)(x) .
Securities Act means the Securities Act of 1933, as amended.
Soliciting Materials has the meaning set forth in Section 4.28 .
Stock Conversion Share means each Target Share designated as a Stock Conversion Share on Schedule X attached hereto; provided, however, that all Target Shares held by any Stockholder who is not an Accredited Investor shall constitute Cash Conversion Shares for purposes of this Agreement, regardless of whether such Target shares are designated as Cash Conversion Shares or Stock Conversion Shares on Schedule X .
Stock Option Plans means the following equity incentive plans of Target (as amended): (i) 2010 Equity Incentive Plan Plan A, (ii) 2010 Equity Incentive Plan Plan B, (iii) 2009 Equity Incentive Plan Plan A, and (iv) the Amended and Restated 2009 Equity Incentive Plan Plan B.
Stock Percentage has the meaning set forth in Section 2.17(c)(i) .
Stockholder means a holder of Target Shares.
Stockholder Notice has the meaning set forth in Section 7.16(c) .
Straddle Period has the meaning set forth in Section 7.08(a)(ii) .
Straddle Period Tax Return means any Tax Return for a Taxable Period that includes the Straddle Period.
Subsidiary with respect to any Person (the Owner ), any corporation or other Person of which Equity Interests having the power to elect a majority of that corporations or other Persons board of directors or similar governing body, or otherwise having the power to direct the business and policies of that corporation or other Person, are held by the Owner or one or more of its Subsidiaries.
Surviving Company has the meaning set forth in Section 2.01 .
Target has the meaning set forth in the preamble.
Target 401(k) Plan has the meaning set forth in Section 7.12 .
Target Board has the meaning set forth in the recitals.
Target Charter Documents has the meaning set forth in Section 4.01(f) .
Target Common Stock has the meaning set forth in the recitals.
Target Disclosure Schedules means the Disclosure Schedules delivered by Target concurrently with the execution and delivery of this Agreement.
Target Indemnitees has the meaning set forth in Section 10.03 .
Target Intellectual Property has the meaning set forth in Section 4.11(a) .
Target Investors Rights Agreement means the Stat Health Services Inc. Amended and Restated Investors Rights Agreement, dated February 27, 2014 (as amended).
Target Opinion has the meaning set forth in Section 3.02(a)(iv) .
Target Ownership Interests has the meaning set forth in Section 4.01(b) .
Target Preferred Stock has the meaning set forth in the recitals.
Target Shares has the meaning set forth in the recitals.
Target Stockholder Approval has the meaning set forth in the recitals.
Target Stockholders Agreement means the First Amended and Restated Stockholders Agreement of Target, dated February 27, 2014 (as amended).
Target Working Capital has the meaning set forth in Section 2.07(a) .
Targets Accountants means McGladrey LLP.
Tax Return means any return, declaration, report, claim for refund, information return or statement or other document relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof.
Taxes means all federal, state, local, foreign and other income, gross receipts, sales, use, production, ad valorem, transfer, documentary, franchise, registration, profits, license, lease, service, service use, withholding, payroll, employment, unemployment, estimated, excise, severance, environmental, stamp, occupation, premium, property (real or personal), real property gains, windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatsoever, together with any interest, additions or penalties with respect thereto and any interest in respect of such additions or penalties.
Termination Date has the meaning set forth in Section 9.01(c)(ii) .
Third Party Claim has the meaning set forth in Section 10.05(a) .
Third Party Payments has the meaning set forth in Section 10.04(e) .
Transaction Documents means this Agreement, the Escrow Agreement, the Noncompetition Agreements, the Roga Employment Agreement, the Letters of Transmittal, the Option Termination Agreements and the other agreements, instruments and documents required to be delivered at the Closing.
Transaction Expenses means the sum of the following without duplication, all unpaid (whether or not accrued and whether or not disclosed) fees, costs, expenses (including attorneys, accountants, financial advisors, brokers, investment bankers or finders fees) or similar amounts that are owed or incurred on or prior to the Effective Time by Target in connection with the negotiation of this Agreement and the other Transaction Documents, and the consummation of the transactions contemplated hereby and thereby, as well as the unpaid costs of the D&O Tail Policy, if any, referenced in Section 7.14(b) .
Unaudited Annual Financial Statements has the meaning set forth in Section 4.04 .
Unaudited Financial Statements has the meaning set forth in Section 4.04 .
Unaudited Interim Financial Statements has the meaning set forth in Section 4.04 .
Union has the meaning set forth in Section 4.19(b) .
Unresolved Amount has the meaning set forth in Section 2.17(b) .
WARN Act means the federal Worker Adjustment and Retraining Notification Act of 1988, and similar state, local and foreign Laws related to plant closings, relocations, mass layoffs and employment losses.
Working Capital has the meaning set forth in Section 2.07(a) .
Written Consent has the meaning set forth in the recitals.
Ziegler has the meaning set forth in Section 4.27 .
ARTICLE II
TRANSACTIONS AND TERMS OF THE MERGER
Section 2.01 The Merger . On the terms and subject to the conditions set forth in this Agreement, and in accordance with the DGCL and the Delaware Limited Liability Company Act (as amended, the DLLCA ), at the Effective Time, (a) Target will merge with and into Merger Sub, and (b) the separate corporate existence of Target will cease and Merger Sub will continue its corporate existence under the DLLCA as the surviving company in the Merger and a wholly owned Subsidiary of Purchaser (sometimes referred to herein as the Surviving Company ). The Merger shall have the effects set forth in the DGCL, DLLCA and this Agreement. At the Closing, Target, Purchaser and Merger Sub shall cause the Certificate of Merger to be executed, acknowledged and filed with the Secretary of State of the State of Delaware and make all other filings and recordings and take such other actions as required by the DGCL and the DLLCA in connection with the Merger.
Section 2.02 Certificate of Formation and Limited Liability Company Agreement . The certificate of formation of the Surviving Company immediately following the Effective Time shall be the same as the certificate of formation of Merger Sub immediately prior to the Effective Time, and the limited liability company agreement of the Surviving Company immediately following the Effective Time shall be the same as the limited liability company agreement of Merger Sub immediately prior to the Effective Time.
Section 2.03 Managers and Officers . The managers of the Surviving Company immediately following the Effective Time shall be the same as the managers of Merger Sub immediately prior to the Effective Time, and the officers of the Surviving Company immediately following the Effective Time shall be the same as the officers of Merger Sub immediately prior to the Effective Time.
Section 2.04 Conversion of Interests . On the terms and subject to the conditions of this Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of Target, Purchaser, Merger Sub or the Equity Interest owners, the Equity Interests of the constituent entities shall be converted as follows:
(a) Target Shares.
(i) At the Effective Time, Target Shares owned by Target (as treasury stock or otherwise) or any of its direct or indirect wholly owned Subsidiaries shall automatically be cancelled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor.
(ii) Target Shares issued and outstanding immediately prior to the Effective Time (other than (i) Shares to be cancelled and retired in accordance with Section 2.04(a)(i) , and (ii) Dissenting Shares) shall be converted into, and each Stockholder holding such Target Shares shall be entitled to, the right to receive (a)(x) for each Target Share that is a Cash Conversion Share, an amount in cash (without interest) equal to the Adjusted Per Share Cash Closing Consideration (payable in the manner provided in accordance with Section 2.05(b)(vii)(A) and Section 2.09 ), and (y) for each Target Share that is a Stock Conversion Share, a number of shares of Purchaser Common Stock equal to the Adjusted Per Share Stock Closing Consideration (payable in the manner provided in accordance with Section 2.05(b)(vii)(B) and Section 2.09 ), and (b) the right to such Stockholders (A) Participating Percentage of any positive Adjustment, (B) Participating Percentage of the Equityholder Representative Holdback Amount, (C) Cash Percentage of the Escrow Cash (and any interest thereon), and (D) Stock Percentage of the Escrow Shares (and any dividend and other amounts paid in respect thereof), in each case when and to the extent such amounts are distributed to Stockholders pursuant to this Agreement and the Escrow Agreement.
(b) Treatment of Stock Options and Corporate Actions.
(i) At the Effective Time, each Option that is unexercised immediately prior to the Effective Time, whether or not then vested or exercisable, shall be, by virtue of the Merger and without any action on the part of Purchaser, Merger Sub, Target, the Optionholder or any other Person, cancelled and each Optionholder shall cease to have any rights with respect thereto other than the right to receive with respect to Options (a) an amount in cash, without interest, equal to the product of (x) the aggregate number of Target Shares subject to such Option, multiplied by (y) the excess of the Adjusted Per Share Cash Closing Consideration over the per share exercise price under such Option (such amount being referred to as the Option Payment Amount , and the aggregate of all such amounts with respect to all Optionholders being referred to as the Aggregate Option Payment Amount ), and (b) the right to such Optionholders (A) Participating Percentage of any positive Adjustment, (B) Participating Percentage of the Equityholder Representative Holdback Amount, and (C) Cash Percentage of the Escrow Cash (and any interest thereon), in each case when and to the extent such amounts are distributed to the Optionholders pursuant to this Agreement. After the Effective Time, each Optionholder shall only be entitled to the payments described in this Section 2.04(b)(i) .
(ii) On or before to the Effective Time, Target (and the Target Board and/or the compensation committee thereof, as applicable) shall adopt any resolutions and take any actions necessary to (i) effectuate the provisions of Section 2.04(b)(i) and (ii) cause the Stock Option Plans to terminate on or before to Effective Time.
(c) Merger Sub Membership Interests. Each membership interest of Merger Sub issued and outstanding immediately prior to the Effective Time shall remain issued and outstanding from and after the Effective Time and shall thereafter constitute membership interests of the Surviving Company.
(d) Purchaser Stock. Each share of capital stock of Purchaser issued and outstanding immediately prior to the Effective Time shall remain issued and outstanding from and after the Effective Time.
Section 2.05 Merger Consideration.
(a) Merger Consideration. The agreed value of the aggregate merger consideration to be paid by Purchaser by reason of the Merger (the Aggregate Merger Consideration ) shall be an amount equal to the result of the following:
(i) Thirty Million Five Hundred Thousand and 00/100 Dollars ($30,500,000.00);
(ii) either ( x ) if the Final Closing Working Capital is greater than the Estimated Closing Working Capital, plus an amount equal to the Final Closing Working Capital minus the Estimated Closing Working Capital, or ( y ) if the Final Closing Working Capital is less than the Estimated Closing Working Capital, minus the absolute value of the Final Closing Working Capital minus the Estimated Closing Working Capital;
(iii) plus the Option Exercise Proceeds;
(iv) minus the Final Closing Accrued Tax Amount;
(v) minus the aggregate amount of Final Closing Indebtedness;
(vi) minus the Profit Sharing Payment Amount; and
(vii) minus the aggregate amount of Closing Transaction Expenses.
(b) Payment and Consideration. Purchaser shall make, or cause to be made, the following payments and deliveries at Closing (or at such other time as provided in this Section 2.05(b) or in Sections 2.08 , 2.09 or 2.12 ):
(i) to the accounts of Persons to whom the Closing Indebtedness is owed (the Debt Payoff Recipients ), an amount equal to the Closing Indebtedness owing to such Debt Payoff Recipients as set forth in the Payoff Letters, which payments, in the aggregate, shall be sufficient to satisfy any and all obligations of Target with respect to any Closing Indebtedness;
(ii) to the Profit Sharing Parties, in the respective percentages set forth on Schedule 2.05(b)(ii) attached hereto and by wire transfer to the accounts designated by the Profit Sharing Parties, the amount of $631,080 (the Profit Sharing Payment Amount );
(iii) to the accounts of Persons to whom Closing Transaction Expenses are owed as designated in the Pre-Closing Statement, an amount equal to the Closing Transaction Expenses owing to such Persons;
(iv) to the Equityholder Representative, by wire transfer of immediately available funds at Closing into an account designated by the Equityholder Representative, the Equityholder Representative Holdback Amount;
(v) to the Escrow Agent, by (A) delivery of validly issued certificate(s) representing Purchaser Common Stock at Closing, the Escrow Shares, and (B) by wire transfer of immediately available funds on the first Business Day that is sixty (60) days following the Effective Time (the Cash Transfer Date ), the Escrow Cash;
(vi) to the Targets designee payroll service provider, by wire transfer of immediately available funds at Closing an amount equal to the Aggregate Option Payment Amount; and
(vii) to each Stockholder, with respect each Target Share held by such Stockholder (other than with respect to Dissenting Shares) and at the times set forth in Section 2.09 :
(A) for each Target Shares that is a Cash Conversion Share an amount in cash equal to the result of (x) the Per Share Cash Closing Consideration, less (y) the Per Share Escrow Amount (the Adjusted Per Share Cash Closing Consideration ); and
(B) for each Target Share that is a Stock Conversion Share a number of shares of Purchaser Common Stock equal to the result of (x) the Per Share Stock Closing Consideration, less (y) the Per Share Escrow Shares (the Adjusted Per Share Stock Closing Consideration ).
(c) Relevant Definitions.
(i) Closing Payment Amount means an amount equal to result of (x) the Aggregate Merger Consideration (calculated using (A) the Estimated Closing Working Capital in lieu of the Final Closing Working Capital for purposes of Section 2.05(a)(ii) , (B) the Estimated Closing Accrued Tax Amount in lieu of the Final Closing Accrued Tax Amount for purposes of Section 2.05(a)(iv) , and (C) the Estimated Closing Indebtedness in lieu of the Final Closing Indebtedness for purposes of Section 2.05(a)(v)) minus (y) the Equityholder Representative Holdback Amount.
(ii) Per Share Cash Closing Consideration means an amount of cash equal to the quotient obtained by dividing (i) the Closing Payment Amount, by (ii) the number of Fully Diluted Shares.
(iii) Per Share Stock Closing Consideration means a number of shares of Purchaser Common Stock equal to the quotient obtained by dividing (i) the Per Share Cash Closing Consideration, by (ii) the Purchaser Stock Price.
(iv) Purchaser Stock Price means $6.982121134 (subject to adjustment to reflect appropriately the effect of any stock split, reverse stock split, stock dividend, extraordinary cash dividends, reorganization, recapitalization, reclassification, combination, exchange of shares or other like).
Section 2.06 No Further Rights . From and after the Effective Time, no Target Shares or Options shall be deemed to be outstanding, and former holders of such Target Shares or Options shall cease to have any rights with respect thereto except as provided herein.
Section 2.07 Merger Consideration Adjustment .
(a) Working Capital Adjustments Generally. The parties have contemplated that the Working Capital of Target as of the Effective Time (the Closing Working Capital ) will be Zero Dollars ($0) (the Target Working Capital ). Working Capital means, as of any given date, Targets Current Assets minus Targets Current Liabilities, in each case, as of such date, calculated in accordance with GAAP and the Form of Working Capital Statement attached hereto as Exhibit C (the Form of Working Capital Statement ).
(b) Delivery of Pre-Closing Statement.
(i) No later than five (5) Business Days prior to the Closing Date, Target shall deliver to Purchaser a statement, which statement shall be in substantially the form attached hereto as Exhibit D (the Pre-Closing Statement ), attaching the following items and certifying as to Targets good faith preparation and calculation of the following items:
(A) an unaudited estimated consolidated balance sheet of Target as of 11:59 P.M., Dallas, Texas time, on the Closing Date (the Estimated Closing Balance Sheet );
(B) an estimate of the Closing Working Capital based on the Estimated Closing Balance Sheet (the Estimated Closing Working Capital ), together with such schedules and data with respect to the determination of the Estimated Closing Working Capital as may be appropriate to support such calculation of Estimated Closing Working Capital;
(C) an estimate of the Closing Accrued Tax Amount (the Estimated Closing Accrued Tax Amount ), together with a list of each component item thereof, and such schedules and data with respect to the determination of the Estimated Closing Accrued Tax Amount as may be appropriate to support such calculation;
(D) a statement setting forth an estimate of each item of Closing Indebtedness (the Estimated Closing Indebtedness ), together with such schedules and data with respect to the determination of the Estimated Closing
Indebtedness as may be appropriate to support such calculation of Estimated Closing Indebtedness, along with pay off letters for the Closing Indebtedness which contain a release of Target and are reasonably satisfactory to Purchaser ( Payoff Letters ), along with wire instructions for each Person to whom Closing Indebtedness is owed; and
(E) a statement setting forth all Closing Transaction Expenses (together with invoices therefor and wire instructions), as derived from invoices provided by the Persons entitled to payment on account thereof.
(c) Adjustment.
(i) Within ninety (90) days after the Closing Date, Purchaser shall prepare and deliver to the Equityholder Representative a statement, which statement shall be substantially in the form of the Pre-Closing Statement (but with appropriate adjustments) (the Closing Statement ), attaching the following items and certifying as to Purchasers preparation and calculation of the following items:
(A) an unaudited consolidated balance sheet of Target as of 11:59 P.M., Dallas, Texas time, on the Closing Date (the Closing Balance Sheet );
(B) the Closing Working Capital based on the Closing Balance Sheet, together with a calculation of the variance between the Estimated Closing Working Capital and Closing Working Capital;
(C) the Closing Accrued Tax Amount, together with a calculation of the variance between the Estimated Closing Accrued Tax Amount and the Closing Accrued Tax Amount;
(D) the Closing Indebtedness, together with a calculation of the variance between the Estimated Closing Indebtedness and the Closing Indebtedness; and
(E) a calculation of the Adjustment.
(ii) After each of the Closing Working Capital, Closing Accrued Tax Amount, and Closing Indebtedness has been finally determined in accordance with Section 2.07(d) (the Closing Working Capital, Closing Accrued Tax Amount and Closing Indebtedness, in each case, as so finally determined being referred to herein as the Final Closing Working Capital , Final Closing Accrued Tax Amount , and Final Closing Indebtedness ), the Aggregate Merger Consideration shall be, if necessary, further adjusted to reflect the Adjustment, as
follows: The Final Adjustment Amount shall be an amount equal to the Final Closing Working Capital, minus the Final Closing Accrued Tax Amount, and minus the Final Closing Indebtedness. The Estimated Adjustment Amount shall be an amount equal to the Estimated Closing Working Capital, minus the Estimated Closing Accrued Tax Amount, and minus the Estimated Closing Indebtedness. If the Final Adjustment Amount is greater than the Estimated Adjustment Amount, Purchaser shall pay (or shall cause the Surviving Company to pay) to the Stockholders and Optionholders (on a pro rata basis in accordance with their respective Participating Percentages) an amount in cash equal to the absolute value of the difference between the Final Adjustment Amount and the Estimated Adjustment Amount (the Adjustment ). If the Final Adjustment Amount is less than the Estimated Adjustment Amount, Purchaser shall be entitled to payment of an amount equal to the Adjustment in accordance with Section 2.07(d)(vi) below.
(d) Examination and Review.
(i) After receipt of the Closing Statement, Equityholder Representative shall have thirty (30) days (the Adjustment Review Period ) to review the Closing Statement. During the Adjustment Review Period, Equityholder Representative and Targets Accountants shall have full access during normal business hours to the relevant books and records of the Surviving Company, the personnel of, and work papers prepared by, the Surviving Company and/or Purchasers Accountants to the extent that they relate to the Closing Statement and to such historical financial information (to the extent in Surviving Companys possession) relating to the Closing Statement as Equityholder Representative may reasonably request for the purpose of reviewing the Closing Statement and preparing an Adjustment Statement of Objections (defined below).
(ii) On or prior to the last day of the Adjustment Review Period, Equityholder Representative may object to the Closing Statement by delivering to Purchaser a written statement setting forth Equityholder Representatives objections in reasonable detail, indicating each disputed item or amount and the basis for Equityholder Representatives disagreement therewith (the Adjustment Statement of Objections ). If Equityholder Representative fails to deliver the Adjustment Statement of Objections before the expiration of the Adjustment Review Period, the Closing Statement, the Adjustment and the other calculations reflected in the Closing Statement shall be deemed to have been accepted by Equityholder Representative. If Equityholder Representative delivers the Adjustment Statement of Objections before the expiration of the Adjustment Review Period, Purchaser and Equityholder Representative shall use commercially reasonable efforts to negotiate a resolution of such objections within 30 days after the delivery of the Adjustment Statement of Objections (the Adjustment Resolution Period ), and, if the same are so resolved within the Adjustment Resolution Period, the Adjustment, the Closing Statement and the calculations reflected in the Closing Statement, with such changes as may have been previously agreed in writing by Purchaser and Equityholder Representative, shall be final and binding. Equityholder Representative and Purchaser may mutually agree in writing to extend the term of the Adjustment Resolution Period.
(iii) If Equityholder Representative and Purchaser fail to reach an agreement with respect to all of the matters set forth in the Adjustment Statement of Objections before
expiration of the Adjustment Resolution Period, then any amounts remaining in dispute ( Adjustment Disputed Amounts ) shall be submitted for resolution to an impartial firm of independent certified public accountants mutually selected by Purchaser and Equityholder Representative, other than Targets Accountants or Purchasers Accountants (the Independent Accountants ) who, acting as experts and not arbitrators, shall (on the basis of the Closing Statement, Adjustment Statement of Objections and this Agreement) resolve the Adjustment Disputed Amounts only and make any adjustments to the Adjustment and the Closing Statement. The parties hereto agree that all adjustments shall be made without regard to materiality. The Independent Accountants shall only decide the specific items under dispute by the parties and their decision for each Adjustment Disputed Amount must be within the range of values assigned to each such item in the Closing Statement and the Adjustment Statement of Objections, respectively.
(iv) Fees and expenses of the Independent Accountants shall be paid 50% by the Equityholder Representative from the Equityholder Representative Holdback Amount (or, if insufficient funds remain in the Equityholder Representative Holdback Amount, directly by the Stockholders and Optionholders) and 50% by Purchaser.
(v) The Independent Accountants shall make a determination as soon as practicable within 30 days (or such other time as the Purchaser and Equityholder Representative shall agree in writing) after their engagement, and their resolution of the Adjustment Disputed Amounts and their adjustments to the Closing Statement, Adjustment and/or the other calculations set forth in the Closing Statement shall be conclusive and binding upon the parties hereto.
(vi) Any payment of the Adjustment shall be due within the time periods set forth below after the calculations set forth in the Closing Statement become final and binding in accordance with clauses (ii) (v) above. Any amount payable to the Stockholders pursuant to Section 2.07(c)(ii) shall be paid to them (via wire transfer of immediately available funds, using the same payment instructions that were used in making payments to them pursuant to Section 2.05(b) ) pro-rata pursuant to each Stockholders respective Participating Percentage within five (5) Business Days after the calculations set forth in the Closing Statement become final and binding in accordance with clauses (ii) (v) above. Any amount payable to the Optionholders pursuant to Section 2.07(c)(ii) shall be paid to Targets payroll provider designee within five (5) Business Days after the calculations set forth in the Closing Statement become final and binding in accordance with clauses (ii) (v) above, and thereafter promptly remitted by such payroll provider to the Optionholders pro-rata pursuant to each Optionholders respective Participating Percentage. If any amount is due to Purchaser pursuant to Section 2.07(c)(ii) , then (A) Purchaser and the Equityholder Representative shall first jointly instruct the Escrow Agent to disburse such amount (which shall be satisfied first in cash and second, to the extent insufficient cash remains in the Escrow Fund, in Escrow Shares or Exchange Property, as applicable) from the Escrow Fund , and (B) to the extent that any amounts remain due following such disbursement in accordance with clause (A), within the five (5) Business Day period after the calculations set forth in the Closing Statement become final and binding in accordance with clauses (i)-(v) above, such remaining amounts shall be paid by the Stockholders and
Optionholders by wire transfer of immediately available funds to such account as directed by the Purchaser.
(e) Adjustments for Tax Purposes. Any payments made pursuant to Section 2.07 shall be treated as an adjustment to the Aggregate Merger Consideration by the parties for Tax purposes, unless otherwise required by Law.
Section 2.08 Dissenting Shares . Notwithstanding any provision of this Agreement to the contrary, Target Shares issued and outstanding immediately prior to the Effective Time (other than Target Shares cancelled in accordance with Section 2.04(a)(i) ) and held by a holder who has not voted in favor of adoption of this Agreement or consented thereto in writing and who has properly exercised appraisal rights of such Target Shares in accordance with Section 262 of the DGCL (such Target Shares being referred to collectively as the Dissenting Shares until such time as such holder fails to perfect or otherwise loses such holders appraisal rights under the DGCL with respect to such Target Shares) shall not be converted into a right to receive a portion of the Merger Consideration, but instead shall be entitled to only such rights as are granted by Section 262 of the DGCL; provided, however, that if, after the Effective Time, such holder fails to perfect, withdraws or loses such holders right to appraisal pursuant to Section 262 of the DGCL or if a court of competent jurisdiction shall determine that such holder is not entitled to the relief provided by Section 262 of the DGCL, such Target Shares shall be treated as if they had been converted as of the Effective Time into the right to receive the portion of the Aggregate Merger Consideration, if any, to which such holder is entitled pursuant to Section 2.04(a)(ii) and the Equityholder Representative, without interest thereon. Target shall provide Purchaser with prompt written notice of any demands received by Target for appraisal of Target Shares, any withdrawal of any such demand and any other demand, notice or instrument delivered to Target prior to the Effective Time pursuant to the DGCL that relates to such demand. The Equityholder Representative shall have the right to lead all negotiations and proceedings with respect to such demands. Except with the prior written consent of Purchaser, Target shall not make any payment with respect to, or settle or offer to settle, any such demands.
Section 2.09 Surrender and Payment.
(a) Target Shares. As promptly as practicable following the date hereof and in any event not later than fifteen (15) Business Days thereafter and concurrently with the delivery of the Information Statement, Target shall mail to each holder of Target Shares a letter of transmittal in substantially the form attached as Exhibit E (a Letter of Transmittal ) and instructions for use in effecting the surrender of certificates formerly representing Target Shares ( Certificates ) in exchange for the applicable portion of Aggregate Merger Consideration pursuant to Section 2.04(a)(ii) . IT IS ACKNOWLEDGED THAT THE LETTER OF TRANSMITTAL CONTAINS A RELEASE FROM EACH STOCKHOLDER AS MORE PARTICULARLY SET FORTH IN SECTION 6 THEREOF, AND THAT (I) SUCH RELEASE CONSTITUTES A MATERIAL INDUCEMENT FOR PURCHASER AND MERGER SUB TO ENTER INTO THIS AGREEMENT AND CONSUMMATE THE MERGER, AND (II) A PORTION OF THE AGGREGATE MERGER CONSIDERATION IS BEING PAID IN CONSIDERATION OF SUCH RELEASE. Target and the Equityholder Representative shall forward any such Letters of Transmittal and Certificates to Purchaser on the Closing Date or, if
later, promptly following receipt thereof. Purchaser shall, no later than the later of (i) the Closing Date or (ii) five (5) Business Days after receipt of a Certificate, together with a Letter of Transmittal and all attachments thereto (including a Release Agreement, IRA Joinder and Written Consent) duly completed and validly executed in accordance with the instructions thereto, and any other customary documents that Purchaser may reasonably require in connection therewith, deliver (in cash and/or whole shares of Purchaser Common Stock, as applicable) to the holder of such Certificate the applicable consideration as provided in Section 2.04(a)(ii) with respect to such Certificate so surrendered and the Certificate shall forthwith be cancelled. Until so surrendered, each outstanding Certificate that prior to the Effective Time represented Target Shares (other than Dissenting Shares) shall be deemed from and after the Effective Time, for all purposes, to evidence the right to receive the portion of the Aggregate Merger Consideration as provided in Section 2.04(a)(ii) . If after the Effective Time, any Certificate is presented to Purchaser or the Surviving Company, it shall be cancelled and exchanged as provided in this Section 2.09(a) .
(b) Options. As promptly as practicable following the date hereof and in any event not later than fifteen (15) Business Days thereafter and concurrently with the delivery of the Information Statement, Target shall mail to each Optionholder an option termination agreement substantially in the form attached as Exhibit F (an Option Termination Agreement ) and instructions for completing, executing and returning such Option Termination Agreement in exchange for the applicable portion of the Aggregate Merger Consideration pursuant to Section 2.04(b)(i) . IT IS ACKNOWLEDGED THAT THE OPTION TERMINATION AGREEMENT CONTAINS A RELEASE FROM EACH OPTIONHOLDER AS MORE PARTICULARLY SET FORTH IN SECTION 7 THEREOF, AND THAT (I) SUCH RELEASE CONSTITUTES A MATERIAL INDUCEMENT FOR PURCHASER AND MERGER SUB TO ENTER INTO THIS AGREEMENT AND CONSUMMATE THE MERGER, AND (II) A PORTION OF THE AGGREGATE MERGER CONSIDERATION IS BEING PAID IN CONSIDERATION OF SUCH RELEASE. Target and the Equityholder Representative shall promptly forward such Option Termination Agreements to Purchaser at Closing or, if later promptly following the receipt thereof. Purchaser shall, no later than the later of (i) the Closing Date or (ii) five (5) Business Days after receipt of an Option Termination Agreement and all attachments thereto duly completed and validly executed in accordance with the instructions thereto and any other customary documents that Purchaser may reasonably require in connection therewith, cause Targets payroll provider, on behalf of Target, to deliver such Optionholder the cash amount such Optionholder has the right to receive pursuant to Section 2.04(b)(i).
(c) Rights to Escrow Fund and Equityholder Representative Holdback Amount. Each Stockholder and Optionholder shall also be entitled to any amounts that may be payable in the future in respect of the Target Shares formerly represented by such Certificate and the cancelled Options from the Escrow Cash, Escrow Shares and Equityholder Representative Holdback Amount as provided in this Agreement and the Escrow Agreement and on account of any positive Adjustment, at the respective time, in the respective percentages and subject to the contingencies specified herein and therein.
(d) No Interest . Except as otherwise expressly provided herein, no interest will be paid or accrued on the amounts payable upon the surrender of the Certificates or Options.
(e) Taxes. If delivery of any consideration in respect of cancelled stock certificates is to be made to a Person other than the Person in whose name a surrendered certificate is registered, it shall be a condition to such payment that the certificate so surrendered shall be properly endorsed or shall be otherwise in proper form for transfer and that the Person requesting such payment shall have paid any transfer and other Taxes required by reason of such payment in a name other than that of the registered holder of the certificate surrendered or shall have established to the reasonable satisfaction of Purchaser that such Tax either has been paid or is not payable.
Section 2.10 No Fractional Shares . No certificates or scrip representing fractional shares of Purchaser Common Stock shall be issued upon the surrender for exchange of Certificates, and in lieu thereof, any fractional share of Purchaser Common Stock shall be rounded up or down, as appropriate, to the nearest whole share of Purchaser Common Stock; provided that, prior to applying the preceding sentence with respect to any holder of Target Shares, all Target Shares held by such holder shall be aggregated, taking into account all Certificates formerly representing Target Shares, and the aggregate number of Target Shares represented thereby.
Section 2.11 Withholding . Each of the Purchaser, Merger Sub and the Surviving Company shall be entitled to deduct and withhold from the consideration otherwise payable to any Person pursuant to this Agreement such amounts as may be required to be deducted and withheld with respect to the making of such payment under any provision of Tax Law. To the extent that amounts are so deducted and withheld by Purchaser, Merger Sub or the Surviving Company, as the case may be, such amounts shall be treated for all purposes of this Agreement as having been paid to the Person in respect of which Purchaser, Merger Sub or the Surviving Company, as the case may be, made such deduction and withholding.
Section 2.12 Lost Certificates . If any Certificate shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the Person claiming such Certificate to be lost, stolen or destroyed and, if required by Purchaser, an agreement by such Person to indemnity against any claim that may be made against it with respect to such Certificate, Purchaser shall issue, in exchange for such lost, stolen or destroyed Certificate, the Aggregate Merger Consideration applicable thereto to be delivered in respect of the Target Shares formerly represented by such Certificate as contemplated under this ARTICLE II .
Section 2.13 Adjustments for Splits and Dividends . The Aggregate Merger Consideration shall be equitably adjusted to reflect appropriately the effect of any stock split, reverse stock split, stock dividend (including any dividend or distribution of securities convertible into Purchaser Common Stock or Target Shares), extraordinary cash dividends, reorganization, recapitalization, reclassification, combination, exchange of shares or other like change with respect to Purchaser Common Stock or Target Shares occurring on or after the date hereof and prior to the payment or delivery of the applicable Aggregate Merger Consideration.
Section 2.14 Stock Transfer Books . Upon the execution of this Agreement, the stock transfer books of Target shall be closed and there shall be no further registration, issuances or transfers of Target Shares or Options thereafter on the records of Target. From and after the
Effective Time, the holders of Target Shares evidenced by Certificates and Options outstanding immediately prior to the Effective Time shall cease to have any rights with respect to such Target Shares or Options, except as otherwise provided in this Agreement or by Law. On or after the Effective Time, any Certificates or Options presented to Purchaser for any reason shall be cancelled and exchanged for the Aggregate Merger Consideration to which the holders thereof are entitled pursuant to this ARTICLE II .
Section 2.15 Third Party Consents . To the extent that Targets rights under any Contract, Permit or other asset do not inure to the benefit of the Surviving Company by way of the Merger without the consent of another Person which has not been obtained, then the Equityholder Representative, at the Stockholders and Optionholders expense, shall use its reasonable best efforts to obtain any such required consent(s) as promptly as possible. If any such consent shall not be obtained or if the Merger would impair the Surviving Companys rights under the Contract, Permit or asset in question so that the Surviving Company would not in effect acquire the benefit of all such rights, the Equityholder Representative, to the maximum extent permitted by Law, shall act after the Closing as the Surviving Companys agent in order to obtain for the Surviving Company the benefits thereunder and shall cooperate, to the maximum extent permitted by Law and the applicable Contract or Permit, with the Surviving Company in any other reasonable arrangement designed to provide such benefits to the Surviving Company.
Section 2.16 Consideration Spreadsheet .
(a) Preparation. At least five (5) Business Days before the Closing and concurrently with the delivery of the Pre-Closing Statement, Target shall prepare and deliver to Purchaser a spreadsheet (the Consideration Spreadsheet ), certified by the Chief Financial Officer of Target, which shall set forth, as of the Closing Date and immediately prior to the Effective Time, the following:
(i) the names, addresses and wire instructions of all Stockholders and the number of Stock Conversion Shares and Cash Conversion Shares held by such Persons
(ii) an updated version of Schedule X , reflecting, amongst other things, any transfers of Target Shares or any adjustments to the Aggregate Merger Consideration in accordance with this Agreement;
(iii) the names, addresses and wire instructions of all Optionholders, together with the number of Target Shares subject to Options held by such Optionholders, the grant date and exercise price for such Options;
(iv) detailed calculations of the Aggregate Merger Consideration, Per Share Cash Closing Consideration, Per Share Stock Closing Consideration, Adjusted Per Share Cash Closing Consideration and Adjusted Per Share Stock Closing Consideration;
(v) the amount of cash and Purchaser Common Stock deliverable to each Stockholder and Optionholder at Closing;
(vi) the amount of Escrow Cash and Escrow Shares contributed by each Stockholder and Optionholder in to the Escrow Account; and
(vii) each Stockholders and Optionholders Participating Percentage, Stock Percentage and Cash Percentage.
(b) Reliance. The parties agree that Purchaser and Merger Sub shall be entitled to rely on the Consideration Spreadsheet in making payments under this Agreement and Purchaser and Merger Sub shall not be responsible for the calculations or the determinations regarding such calculations in such Consideration Spreadsheet.
Section 2.17 Escrow Arrangements .
(a) Escrow Fund.
(i) At the Effective Time, each of Purchaser, the Surviving Company, the Equityholder Representative and the Escrow Agent shall enter into the Escrow Agreement. Purchaser shall deposit a stock certificate (issued in the name of the Equityholder Representative) reflecting the Escrow Shares (at the Closing) and the Escrow Cash (on the Cash Transfer Date) into escrow pursuant to the Escrow Agreement. The Escrow Agent shall hold the Escrow Shares and Escrow Cash and all interest, dividends and other amounts earned thereon not required to be distributed to the Stockholders or Optionholders pursuant to Section 2.17(a)(iii) (collectively, the Escrow Fund ) in an escrow account (the Escrow Account ) for purposes of securing any amounts payable by Stockholders and Optionholders under ARTICLE X and Sections 2.07 and 7.08 and certain other amounts payable hereunder in accordance with this Agreement and the Escrow Agreement.
(ii) Any and all interest earned on cash in the Escrow Fund shall be added to the Escrow Fund and shall become a part thereof.
(iii) Except as provided in Section 2.17(a)(v) below, cash dividends, and any non-cash taxable dividends or distributions, on any shares of Purchaser Common Stock in the Escrow Fund shall be distributed to the Stockholders according to their the respective Stock Percentages (defined below), and shall not become a part of the Escrow Fund, provided however that, to the extent aggregate amount of claims for payment under Sections 2.07 or 7.08 or indemnity claims asserted by the Purchaser Indemnitees in good faith pursuant to ARTICLE X exceed the amount then-remaining in the Escrow Fund, such dividends and distributions shall remain in the Escrow Fund and shall be treated as distributed to the Stockholders holding the applicable shares of Purchaser Common Stock according to their respective Stock Percentages for U.S. federal income tax purposes. Any shares of Purchaser Common Stock or other Equity Interests issued or distributed by Purchaser after the Effective Time in a nontaxable transaction ( New Shares ) in respect of Purchaser Common Stock in the Escrow Fund which have not been released from the Escrow Fund shall be added to the Escrow Fund and become a part thereof. The parties hereto agree that the Equityholder Representative, as agent for the Stockholders previously owning Stock Conversion Shares, is the record owner of any stock or other Equity Interests in the Escrow Fund for so long as such stock or Equity Interests remain in the Escrow Fund. Upon distribution to any Person (including the Stockholders) of any stock or
Equity Interests in the Escrow Fund, the Equityholder Representative shall cause ownership of such stock or Equity Interests to be transferred to the distributee thereof. New Shares issued in respect of shares of Purchaser Common Stock which have been released from the Escrow Fund shall not be added to the Escrow Fund but shall be distributed to the record holders thereof.
(iv) For tax reporting and withholding purposes, Equityholder Representative shall be treated as the owner of the cash in the Escrow Fund and shall be liable and responsible for any Taxes due with respect to income earned on such cash. Equityholder Representative shall be entitled to disbursements from the Escrow Amount in respect of Taxes paid by Equityholder Representative in respect of income earned on the Escrow Fund, as more particularly set forth in the Escrow Agreement. Upon the release of any portion of the cash in the Escrow Fund to the Stockholders or Optionholders, a portion of such cash paid from the Escrow Fund shall be treated as interest under the imputed interest rules of the Code.
(v) Notwithstanding anything herein to the contrary, upon any reorganization, recapitalization, reclassification, consolidation, merger or Deemed Liquidation Event (as defined in Purchasers Fourth Amended and Restated Certificate of Incorporation, as in effect on the Closing Date) involving Purchaser in which the Purchaser Common Stock in the Escrow Fund converted into or exchanged for securities, cash or other property (the Exchange Property ), then, following any such reorganization, recapitalization, reclassification, consolidation, merger or Deemed Liquidation Event, then, in lieu of such Purchaser Common Stock, there shall be deposited in the Escrow Fund the kind and amount of Exchange Property issuable upon conversion of such Purchaser Common Stock.
(vi) The Letter of Transmittal and the Option Termination Agreement shall include a Form W-9 or original W-8 IRS tax form which shall be provided to the Escrow Agent prior to the disbursement of interest and the Escrow Agent will file the appropriate 1099 or other required forms pursuant to Federal and State laws. A statement of citizenship will be provided if requested by Escrow Agent. Escrow Agent shall not be responsible for maximizing the yield on the Escrow Fund.
(b) Release of the Escrow Fund. Within ten (10) Business Days following the (i) fifteen (15) month anniversary of the Effective Date (such fifteen (15) month anniversary, the Partial Release Date ), Purchaser and Equityholder Representative shall deliver a joint written direction to the Escrow Agent to release to the Stockholders and Optionholders (in accordance with Section 2.17(c)(i) ) from the Escrow Fund an amount equal to the Partial Release Amount (as defined below) within five (5) Business Days of the date of such joint written direction, and (ii) twenty four (24) month anniversary of the Effective Time (such twenty four (24) month anniversary, the Final Release Date ), all remaining portions of the Escrow Fund (except for the amount of any claims for payment under Sections 2.07 or 7.08 or indemnity claims asserted by the Purchaser Indemnitees pursuant to ARTICLE X prior to the Final Release Date and which remain unpaid, pending or unresolved (an Unresolved Amount )) and any interest, dividends or other amounts accrued thereon shall be released from the Escrow Account and paid over to the Stockholders and Optionholders in accordance with Section 2.17(c)(i) below. Any Unresolved Amount withheld from release after the Final Release Date and finally determined not to be subject to indemnification or payment by the Stockholders or Optionholders in
accordance with this Agreement, shall be released to the Stockholders or Optionholders in accordance with Section 2.17(c)(i) below. For purposes of this Agreement, the term Partial Release Amount means (A) if no claims for payment under Section 7.08 or indemnity claims asserted by Purchaser Indemnitees pursuant to ARTICLE X have been made prior to the Partial Release Date and either resolved in favor of any Purchaser Indemnitee or remain unpaid, pending or unresolved in dispute as of the Partial Release Date, then an amount equal to Three Million Eight Hundred Fifty Thousand and No/100 Dollars ($3,850,000.00), less any amounts paid or payable under Section 2.07 , with any Escrow Shares being distributed pursuant to this clause (A) being valued at the Purchaser Stock Price (subject to adjustment to reflect appropriately the effect of any stock split, reverse stock split, stock dividend, extraordinary cash dividends, reorganization, recapitalization, reclassification, combination, exchange of shares or other like), and (B) in all other circumstances, an amount such that, following the release thereof, the value of the remaining Escrow Fund equals the lesser of (y) the value of the entire Escrow Fund immediately prior to such release, or (x) the sum of (I) Two Million Two Hundred Fifty Thousand and No/100 Dollars ($2,250,000.00), plus (II) any interest previously accrued on the Escrow Fund, plus (III) the amount of any claims for payment under Sections 2.07 or 7.08 or indemnity claims asserted by Purchaser Indemnitees pursuant to ARTICLE X which remain unpaid, pending or unresolved in dispute as of the Partial Release Date.
(c) Disbursements. Notwithstanding anything herein to the contrary:
(i) All amounts subject to release from the Escrow Fund to the Stockholders and Optionholders shall be released (i) first, in the form of Escrow Shares, (ii) second, and to the extent that insufficient Escrow Shares remain in the Escrow Account, in the form of other non-cash property, and (iii) thereafter, to the extent that insufficient non-cash property and Escrow Shares remain in the Escrow Account, in the form of cash. Any cash, stock or other property released from the Escrow Fund to the Stockholders or Optionholders in accordance with this Agreement or the Escrow Agreement shall (A) if Escrow Shares (and dividends or other amounts earned thereon and held in the Escrow Fund), be delivered or paid to the Stockholders in accordance with their respective Stock Percentages (as defined below), and (B) if Escrow Cash (and interest and other amounts earned thereon), be delivered or paid to the Stockholders and Optionholders in accordance with their respective Cash Percentages (as defined below), in each case and pursuant to the wire transfer and delivery instructions set forth in the Consideration Spreadsheet; provided however, that any such amounts payable to the Optionholders shall be paid to Targets payroll provider designee and thereafter promptly remitted (less applicable tax withholding) to the Optionholders. For purposes of this Agreement, (i) the Stock Percentage of a Stockholder shall be equal to a fraction (x) the numerator of which is the number of Stock Conversion Shares held by such Stockholder immediately prior to the Closing, and (y) the denominator of which is aggregate number of Stock Conversion Shares held by all Stockholders immediately prior to the Closing, and (ii) the Cash Percentage of a Stockholder or Optionholder shall be equal to a fraction (x) the numerator of which is the sum of the number of Cash Conversion Shares held by such Stockholder or Optionholder immediately prior to the Closing plus the number of Target Shares issuable upon exercise of all Options held by such Stockholder or Optionholder immediately prior to the Closing, and (y) the denominator of which is the sum of the aggregate number of Cash Conversion Shares held by all Stockholders and Optionholders immediately prior to the Closing plus the aggregate number
of Target Shares issuable upon the exercise of all Options outstanding immediately prior to the Closing.
(ii) In the event that it is determined, in accordance with this Agreement, that Purchaser or any other Purchaser Indemnitee is entitled to disbursement from any cash, stock or other property held in the Escrow Fund, then Purchaser shall receive disbursement first in cash and then, to the extent that insufficient cash remains in the Escrow Account, in Escrow Shares or Exchange Property, as applicable.
(iii) Except as set forth in clause (A) of the definition of Partial Release Amount, for purposes of this Agreement and the Escrow Agreement, (i) each share of Purchaser Common Stock disbursed or released from the Escrow Account shall (A) prior to the Initial Qualified Public Offering of the Purchaser Common Stock be valued at the Purchaser Stock Price (subject to adjustment to reflect appropriately the effect of any stock split, reverse stock split, stock dividend, extraordinary cash dividends, reorganization, recapitalization, reclassification, combination, exchange of shares or other like), and (B) following the Initial Qualified Public Offering of the Purchaser Common Stock and the registration of the Escrow Shares (if any) the Purchaser Stock Trading Value, and (ii) all Exchange Property so disbursed shall be valued at the aggregate Purchaser Stock Price of the Purchaser Common Stock for which such Exchange Property was exchanged or converted. For purposes of this Agreement, the Purchaser Stock Trading Value shall be equal to the volume-weighted average of the trading prices on any national securities exchange on which Purchaser Common Stock is listed for one (1) share of Purchaser Common Stock for the five (5) consecutive trading days immediately preceding the day that is three (3) trading days prior to the disbursement of the applicable Escrow Shares from the Escrow Account (subject to adjustment to reflect appropriately the effect of any stock split, reverse stock split, stock dividend, extraordinary cash dividends, reorganization, recapitalization, reclassification, combination, exchange of shares or other like).
(d) Fees. Purchaser and/or the Surviving Company, on one hand, and the Stockholders and Optionholders (paid from the Equityholder Representative Holdback Amount to the extent available), on the other hand, shall each pay fifty percent (50%) of the fees, expenses and costs associated with establishing and maintaining the Escrow Account in accordance with this Agreement and the Escrow Agreement.
(e) Joint Written Instructions. Purchaser, Merger Sub and the Equityholder Representative agree to promptly provide the Escrow Agent with jointly executed written instructions to disburse or retain the Escrow Amount (or a portion thereof, as applicable) from the Escrow Account in accordance with this Agreement and the Escrow Agreement.
(f) Voting; Proxy. Each of the Stockholders previously holding Stock Conversion Shares shall have voting rights with respect to the shares of Purchaser Common Stock contributed to and held in the Escrow Fund on behalf of such Stockholder (and on any voting securities added to the Escrow Fund in respect of such shares of Purchaser Common Stock), provided, however, that during such time as the shares of Purchaser Common Stock are held in the Escrow Fund on behalf of such Stockholders, such Stockholders will appoint the
Equityholder Representative as such Stockholders proxy and attorney-in-fact to vote, in the Equityholder Representatives discretion, all Purchaser Common Stock held by such Stockholder in the Escrow Fund.
ARTICLE III
CLOSING
Section 3.01 Closing . Subject to the terms and conditions of this Agreement, the consummation of the transactions contemplated by this Agreement (the Closing ) shall take place at the offices of Jackson Walker LLP, 901 Main Street, Suite 6000, Dallas, Texas 75202, at 10:00 a.m., Dallas, Texas time, upon the later of (i) June 16, 2015, (ii) or as soon as practicable (and in any event within three (3) Business Days) after the satisfaction or, to the extent permitted hereunder, waiver of all of the conditions to the Merger set forth in ARTICLE VIII (other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or, to the extent permitted hereunder, waiver of all such conditions), unless this Agreement has been terminated pursuant to its terms or unless another time or date is mutually agreed to in writing by Target and the Equityholder Representative. The date on which the Closing is to occur is herein referred to as the Closing Date .
Section 3.02 Closing Deliverables
(a) At the Closing, Target shall deliver to Purchaser and Merger Sub the following, unless waived by Purchaser:
(i) a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Target certifying that attached thereto are true and complete copies of all resolutions adopted by the directors and stockholders of Target authorizing the execution, delivery and performance of this Agreement and the other Transaction Documents to which Target is party and the consummation of the transactions contemplated hereby and thereby (including the Merger and the other transactions contemplated hereby), and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated hereby and thereby;
(ii) a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Target certifying the names and signatures of the officers of Target authorized to sign this Agreement, the Transaction Documents and the other documents to be delivered by Target hereunder and thereunder;
(iii) a certificate, dated as of the Closing Date and signed by a duly authorized officer of Target, that each of the conditions set forth in Section 8.02(a) , (b), (h) and (i) with respect to Target have been satisfied;
(iv) an original legal opinion of Weiss Brown PLLC covering the matters set forth on Exhibit G (the Target Opinion );
(v) a good standing certificate (or its equivalent) for Target from the secretary of state or similar Governmental Authority of Delaware and of each jurisdiction in which Target
is qualified to do business as a foreign entity, in each case dated as of a date that is not more than ten (10) days prior to the Closing Date;
(vi) such documentation or other evidence reasonably satisfactory to Purchaser that all of the Permits, consents, approvals, authorizations and clearances listed in Section 4.03 of the Disclosure Schedules have been obtained;
(vii) such documentation or other evidence reasonably satisfactory to Purchaser that Target shall have taken all action reasonably required to cause the termination of all of the Contracts listed in Schedule 3.02(a)(vii) , if any;
(viii) such documentation or other evidence reasonably satisfactory to Purchaser that Target shall have taken all action reasonably required to cause the termination of all of its Benefit Plans, if any;
(ix) a resignation letter, duly executed by each director and officer of Target, which resignation letter shall include an acknowledgement that, with respect to the director and officer indemnification agreement previously entered into between Target and such director or officer (the Indemnification Agreement ) (i) no indemnification, reimbursement or advancement of expenses shall be due under the Indemnification Agreement from Purchaser or the Surviving Company in respect of actions or omissions occurring after the Closing, and (ii) Section 9 of the Indemnification Agreement shall only apply to actions or omissions taken prior to the Closing and in such Persons capacity as a director or officer of Target;
(x) an Employment Agreement in the form attached hereto as Exhibit H (the Roga Employment Agreement ), duly executed by Roga;
(xi) the Escrow Agreement duly executed by the Equityholder Representative; (xii) a release (in form and substance reasonably satisfactory to Purchaser) duly executed by Ziegler, (i) acknowledging that, upon payment of the applicable Closing Transaction Expenses due thereto, all fees payable to Ziegler due to the consummation of this Agreement have been paid and (ii) releasing Purchaser, the Surviving Company and Target from any claims in connection therewith;
(xiii) a release (in form and substance reasonably satisfactory to Purchaser) duly executed by each Profit Sharing Party, (i) acknowledging that, upon payment of the respective portion of the Profit Sharing Payment Amount specified in Section 2.05(b)(ii) , all fees payable by Target to such Profit Sharing Party under the Profit Sharing Agreements have been paid and (ii) releasing Purchaser, the Surviving Company and Target from any claims in connection therewith;
(xiv) Joinders in the form attached to the form of Letter of Transmittal (a copy of which is attached hereto as Exhibit E ) (the IRA Joinders ) to the Purchaser Investors Rights Agreement duly executed by each holder of Stock Conversion Shares;
(xv) the Written Consent duly executed by a sufficient number of Stockholders to evidence Targets receipt of the Target Stockholder Approval;
(xvi) Letters of Transmittal duly executed by (i) each Principal, and (ii) Stockholders holding (A) at least ninety-five percent (95%) of the issued and outstanding shares of Target Preferred Stock and (B) at least ninety-five percent (95%) of the issued and outstanding shares of Target Common Stock;
(xvii) Option Termination Agreements duly executed by (i) each Principal who is an Optionholder, and (ii) Optionholders holding Options to purchase at least ninety-five percent (95%) of total number of Target Shares subject to purchase upon the exercise of all outstanding Options;
(xviii) Noncompetition/Nonsolicitation Agreements in the form of Exhibit I attached hereto (the Noncompetition Agreements ) duly executed by each Stockholder or Optionholder set forth on Schedule 3.02(a)(xviii) attached hereto;
(xix) an affidavit, dated as of the Effective Time, setting forth Targets name, address and federal employer identification number and stating under penalties of perjury that Target is not and has not during the previous five (5) years been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code;
(xx) Intentionally Omitted;
(xxi) a release and termination agreement (in form and substance reasonably satisfactory to Purchaser) duly executed by Target and the counterparties to the Contracts set forth in Schedule 3.02(a)(xxi) (collectively, the EMP Contracts ), whereby such counterparties, (i) agree that the EMP Contracts are terminated immediately prior to the Effective Time, (ii) acknowledge that all fees payable by Target to such counterparties under the EMP Contracts have been paid and (iii) release Purchaser, the Surviving Company and Target from any claims in connection therewith; and
(xxii) such other customary instruments of transfer, assumption, filings or documents, in form and substance reasonably satisfactory to Purchaser, as may be required to give effect to this Agreement.
(b) At the Closing, Purchaser and Merger Sub shall deliver to the Equityholder Representative, unless otherwise specified below, the following:
(i) the Escrow Agreement duly executed by Purchaser, Merger Sub and the Escrow Agent;
(ii) a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Purchaser and Merger Sub certifying that attached thereto are true and complete copies of all resolutions adopted by the boards of directors, stockholders, managers and members (as applicable) of Purchaser and Merger Sub authorizing the execution, delivery and performance of this Agreement and the other Transaction Documents and the consummation of
the transactions contemplated hereby and thereby, and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated hereby and thereby;
(iii) a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Purchaser and Merger Sub certifying the names and signatures of the officers of Purchaser and Merger Sub authorized to sign this Agreement, the Transaction Documents and the other documents to be delivered by Purchaser and Merger Sub hereunder and thereunder;
(iv) a certificate, dated as of the Closing Date and signed by a duly authorized officer of Purchaser and Merger Sub, that each of the conditions set forth in Section 8.03(a) and (b) have been satisfied;
(v) the Roga Employment Agreement, duly executed by Purchaser; (vi) the IRA Joinders, duly executed by Purchaser; and
(vii) Letter of instruction to Purchasers transfer agent, if any, regarding issuance of the Purchaser Common Stock.
(c) At the Closing (or at such later times as specified therein), Purchaser shall make, or cause the Surviving Company to make, the payments and deliveries described in Section 2.05(b) .
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF
THE TARGET
Except as set forth in the correspondingly numbered Section of the Target Disclosure Schedules (which disclosures shall reference the specific sections and subsections below, as applicable, but shall also qualify other sections or subsections in this Article IV and in the Target Disclosure Schedules to the extent it is reasonably apparent on its face from a reading of the disclosure item that the disclosure is applicable to the other section or subsection), Target represents and warrants to Purchaser and Merger Sub that the statements contained in this ARTICLE IV are true and correct.
Section 4.01 Organization, Qualification and Capitalization of Target .
(a) Target is a corporation duly organized, validly existing and in good standing under the Laws of the State of Delaware. Target has full corporate power and authority to own, operate or lease the properties and assets now owned, operated or leased by it and to carry on its business as it has been and as currently conducted by it. Section 4.01(a) of the Target Disclosure Schedules sets forth each jurisdiction in which Target is licensed or qualified to do business. Target is duly licensed or qualified to do business and is in good standing in each jurisdiction in which the ownership of its assets or the operation of its business as currently conducted makes such licensing or qualification necessary, except where Targets failure to qualify to do business or be in good standing would not be reasonably likely to have, individually, or in the aggregate, a Material Adverse Effect.
(b) The authorized capital stock of Target consists of (i) 23,000,000 shares of Target Preferred Stock (of which 22,602,794 shares are issued and outstanding as of the close of business on the date of this Agreement and none of which shares are held by Target in treasury), and (ii) 32,000,000 shares of Target Common Stock (of which 2,244,371 shares are issued and outstanding as of the close of business on the date of this Agreement and none of which shares are held by Target in treasury). Section 4.01(b) of the Target Disclosure Schedules sets forth a full, complete and accurate schedule of the holders of all of the issued and outstanding Equity Interests of Target as of the date of this Agreement (the Target Ownership Interests ), including (i) the name of each Person that is the registered owner of any Target Shares and the number of Target Shares (on both an outstanding and an as-converted to Target Common Stock basis) owned by such Person, and (ii) a list of all holders of outstanding Options, including the number of shares of Target Common Stock subject to each such Option, the grant date and exercise price for such Option, the date on which such Option expires and the Stock Option Plan pursuant to which such Option was granted. Each Option was granted in compliance with all applicable Laws and all of the terms and conditions of the applicable Stock Option Plan pursuant to which it was issued. Each Option was granted with an exercise price per share equal to or greater than the fair market value of the underlying shares on the date of grant and has a grant date identical to the date on which the Target Board or compensation committee actually awarded the Option. Each Option qualifies for the tax and accounting treatment afforded to such Option in the Targets Tax Returns and financial statements, respectively, and does not trigger any liability for the Optionholder under Section 409A of the Code. Each Option will be fully- vested and exercisable as of the Effective Time. Target has delivered to Purchaser true and complete copies of the standard form of option agreement for the Options and any stock option agreements that differ from such standard form.
(c) Except as set forth on Section 4.01(c) of the Target Disclosure Schedule, there are no existing (i) options, warrants, calls, subscriptions, preemptive rights or other rights, convertible securities, agreements or commitments of any character obligating the Target to issue, transfer or sell any Equity Interest in the Target, (ii) contractual obligations of the Target to repurchase, redeem or otherwise acquire any Equity Interests of the Target, (iii) voting trusts, proxies or similar agreements with respect to the voting of the Equity Interests of the Target, or (iv) Contracts, arrangements, commitments or restrictions to which Target or, to Targets Knowledge, any other Person, is a party relating to the issuance, sale, transfer or purchase of Equity Interests in Target. There are no declared or accrued but unpaid dividends with respect to any Target Shares.
(d) The Target Ownership Interests (as set forth on Section 4.01(d) of the Target Disclosure Schedules) are held of record on Targets records as set forth on Section 4.01(d) of the Target Disclosure Schedules, and such Target Ownership Interests are free and clear of any Encumbrances established by Target or, to the Knowledge of Target, any other Person. The Target Ownership Interests have been duly authorized and validly issued and are fully paid and non-assessable. None of the Target Ownership Interests were issued in violation of the Securities Act or any other Law. There are no outstanding or authorized equity appreciation, phantom equity, profit participation, change of control bonus or similar rights with respect to Target. There are no obligations of Target to provide funds to, or make any investment (in the form of a loan, capital contribution or otherwise) in, the any other Person.
(e) Target (i) does not have any Subsidiaries, (ii) does not own any Equity Interests in any other Person, (iii) does not provide medical services through any Person, and (iv) except as set forth on Section 4.01(e) of the Target Disclosure Schedules, is not party to any services or similar agreement with any professional association or entity regarding telemedicine, telehealth, behavior health or other medical services; provided that it is acknowledged that Target provides medical services through the Engaged Professionals.
(f) Attached as Section 4.01(f) of the Target Disclosure Schedules are true and complete copies of the certificate of incorporation and by-laws of Target, the Target Investors Rights Agreement, the Target Stockholders Agreement and other organizational documents of Target (collectively, the Target Charter Documents ), each of which is in full force and effect as of the date hereof and the Closing and Target is not in default under or in violation of any provision of the Target Charter Documents. The minute books or similar record books (containing the records of meetings or actions of the Target Board and stockholders) of Target (all of which have been delivered to Purchaser) are correct and complete and accurately reflect all actions by the Target Board (and committees thereof) and stockholders with respect to transactions referenced therein.
(g) All distributions, dividends, repurchases and redemptions of the capital stock (or other Equity Interests) of Target were undertaken in compliance with the Target Charter Documents then in effect, any agreement to which the Target then was a party and in compliance with applicable Law.
(h) Except as set forth on Section 4.01(h) of the Target Disclosure Schedules, no outstanding Target Shares are subject to vesting or forfeiture rights or repurchase by Target.
Section 4.02 Authority .
(a) Target has full corporate power and authority to enter into this Agreement and the other Transaction Documents to which Target is a party, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery by Target of this Agreement and any other Transaction Document to which Target is a party, the performance by Target of its obligations hereunder and thereunder and the consummation by Target of the transactions contemplated hereby and thereby have been duly authorized by all requisite corporate action on the part of Target. This Agreement has been duly executed and delivered by Target, and (assuming due authorization, execution and delivery by Purchaser and Merger Sub) this Agreement constitutes a legal, valid and binding obligation of Target enforceable against Target in accordance with its terms, except as such enforceability may be limited by principles of public policy and subject to the laws of general application relating to bankruptcy, insolvency and the relief of debtors. When each other Transaction Document to which Target is or will be a party has been duly executed and delivered by Target (assuming due authorization, execution and delivery by Purchaser and Merger Sub), such Transaction Document will constitute a legal and binding obligation of Target enforceable against it in accordance with its terms, except as such enforceability may be limited by principles of public policy and subject to the laws of general application relating to bankruptcy, insolvency and the relief of debtors.
(b) The Target Board, by resolutions duly adopted in accordance with the Target Charter Documents at a meeting duly called and held and not subsequently rescinded or modified in any way, or through an action by unanimous written consent, has duly (i) determined that this Agreement and the Merger are fair to and in the best interests of Target and its stockholders, (ii) approved this Agreement and the Merger and declared their advisability, and (iii) recommended that the stockholders of Target approve and adopt this Agreement and approve the Merger.
(c) Other than the appropriate approval by the Target Board described in Section 4.02(b) above, the Target Stockholder Approval is the only vote of the holders of any class or series of Equity Interests of Target necessary to approve, authorize, and adopt this Agreement, the Merger and the other transactions contemplated hereby.
Section 4.03 No Conflicts; Consents . The execution, delivery and performance by Target of this Agreement and the other Transaction Documents to which it is a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not: (a) conflict with or result in a violation or breach of, or default under, any provision of the certificate of incorporation, bylaws or other Target Charter Documents or any resolution adopted by the governing body or owners of Target; (b) conflict with or result in a violation or breach of any provision of any Law or Governmental Order applicable to Target, the Target Ownership Interests, the Business or Targets assets; (c) except as set forth in Section 4.03 of the Target Disclosure Schedules, require the consent, notice or other action by any Person under, conflict with, result in a violation or breach of, constitute a default or an event that, with or without notice or lapse of time or both, would constitute a default under, result in the acceleration of or create in any party the right to accelerate, terminate, modify or cancel any Contract or Permit to which Target is a party or by which Target is bound or to which any of its assets are subject (including any Material Contract); or (d) result in the creation or imposition of any Encumbrance other than Permitted Encumbrances on Targets assets or the Target Ownership Interests. Other than the filing of the Certificate of Merger with the Secretary of State of the State of Delaware, no consent, approval, Permit, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required by or with respect to Target in connection with the execution and delivery of this Agreement or any of the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby.
Section 4.04 Financial Statements . Complete copies of the unaudited financial statements of Target consisting of the balance sheet as of December 31 in each of the years 2012, 2013 and 2014 and the related statements of income and retained earnings, stockholders equity and cash flow for the years then ended (the Unaudited Annual Financial Statements ), and unaudited financial statements of Target consisting of the balance sheet as of March 31, 2015 and the related statements of income and retained earnings, stockholders equity and cash flow for the three (3)-month period then ended (the Unaudited Interim Financial Statements and together with the Unaudited Annual Financial Statements, the Unaudited Financial Statements ) are included in Section 4.04 of the Target Disclosure Schedules. Complete copies of the audited financial statements of Target consisting of the balance sheet as of December 31, 2014 and the related statement of income and retained earnings, stockholders equity, and cash flow for the year then ended (the Audited Financial Statements ) will, once completed, be included in Section 4.04 of the Target Disclosure Schedules. The Audited Financial Statements
and the Unaudited Financial Statements are based on the books and records of Target, and present fairly, in all material respects, the financial condition of Target as of the respective dates they were prepared and the results of the operations of Target for the periods indicated. The balance sheet of Target as of December 31, 2014 is referred to herein as the Balance Sheet and the date thereof as the Balance Sheet Date and the balance sheet of Target as of March 31, 2015 is referred to herein as the Interim Balance Sheet and the date thereof as the Interim Balance Sheet Date . Target maintains a standard system of accounting for the Business that will result in financial statement reporting in accordance with GAAP. Target has made available to Purchaser complete and correct copies of, all written descriptions of, and all policies, manuals and other documents promulgating, such internal accounting controls. Target has no Knowledge of (A) any significant deficiencies in the design or operation of internal controls which could affect in a material manner Targets ability to record, process, summarize and report financial data or (B) any fraud, whether or not material, that involves management or other employees who have a significant role in Targets internal controls.
Section 4.05 Books and Records . The books of account and other financial records of Target, all of which have been made available to Purchaser, are complete and correct and represent actual, bona fide transactions and have been maintained in accordance with sound business practices and the requirements of Law, including the maintenance of an adequate system of internal controls.
Section 4.06 Undisclosed Liabilities . Target has no Liabilities of a type required to be reflected on a balance sheet prepared in accordance with GAAP, except those which (a) are adequately reflected or reserved against in the Balance Sheet as of the Balance Sheet Date, (b) have been incurred in the ordinary course of business consistent with past practice (whether or not such Liabilities are required to be recorded in the Unaudited Financial Statements or the Audited Financial Statements) since the Balance Sheet Date and which are not, individually or in the aggregate, material in amount or (c) are Liabilities that are otherwise expressly disclosed in the Target Disclosure Schedules.
Section 4.07 Absence of Certain Changes, Events and Conditions . Except as set forth in Section 4.07 of the Target Disclosure Schedules, since the Balance Sheet Date, there has not been any of the following with respect to Target:
(a) event, occurrence or development that has had, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect;
(b) change in the authorized or issued Equity Interests of Target;
(c) amendment to the Target Charter Documents or any term of any outstanding Equity Interest of Target;
(d) declaration or payment of any dividends or distributions on or in respect of any of Target Ownership Interests or redemption, purchase or acquisition of any Target Ownership Interests;
(e) material change in any method of accounting or accounting practice for Target, except as required by GAAP or as disclosed in the notes to the Financial Statements;
(f) material change in cash management practices and policies, practices and procedures with respect to collection of Accounts Receivable, establishment of reserves for uncollectible Accounts Receivable, accrual of Accounts Receivable, inventory control, prepayment of expenses, payment of trade accounts payable, accrual of other expenses, deferral of revenue and acceptance of customer deposits;
(g) entry into any Contract that would constitute a Material Contract;
(h) incurrence, assumption or guarantee of any indebtedness for borrowed money except unsecured current obligations and Liabilities incurred in the ordinary course of business consistent with past practice;
(i) transfer, assignment, sale or other disposition of any of the assets shown or reflected in the Balance Sheet; rights;
(j) cancellation of any debts or claims or amendment, termination or waiver of any
(k) transfer, assignment or grant of any license or sublicense of any material rights under or with respect to any Target Intellectual Property, Intellectual Property Assets or Intellectual Property Licenses other than non-exclusive licenses granted in the ordinary course of business;
(l) material damage, destruction or loss, or any material interruption in use, of any Targets assets, whether or not covered by insurance;
(m) acceleration, termination, material modification to or cancellation of any Material Contract or Permit;
(n) material capital expenditures;
(o) any capital investment in, or any loan to, any other Person;
(p) imposition of any Encumbrance upon the assets of Target;
(q) (i) grant of any bonuses, whether monetary or otherwise, or increase in any wages, salary, severance, pension or other compensation or benefits in respect of any employees, officers, directors, independent contractors or consultants, other than as provided for in any written agreements or required by applicable Law, (ii) change in the terms of employment for any employee or any termination of any employees for which the annual wages exceed $50,000, or (iii) action to accelerate the vesting or payment of any compensation or benefit for any employee, officer, director, consultant or independent contractor;
(r) adoption, modification or termination of any: (i) employment, severance, retention or other agreement with any current or former employee, officer, director, independent contractor or consultant, (ii) Benefit Plan, or (iii) collective bargaining or other agreement with a Union, in each case whether written or oral;
(s) any loan to (or forgiveness of any loan to), or entry into any other transaction with, any stockholders, directors, officers or employees;
(t) entry into a new line of business or abandonment or discontinuance of existing lines of business;
(u) adoption of any plan of merger, consolidation, reorganization, liquidation or dissolution or filing of a petition in bankruptcy under any provisions of federal or state bankruptcy Law or consent to the filing of any bankruptcy petition against it under any similar Law;
(v) purchase, lease or other acquisition of the right to own, use or lease any property or assets for an amount in excess of $10,000 individually (in the case of a lease, per annum) or $25,000 in the aggregate (in the case of a lease, for the entire term of the lease, not including any option term), except for purchases of supplies in the ordinary course of business consistent with past practice;
(w) acquisition by merger or consolidation with, or by purchase of a substantial portion of the assets or stock of, or by any other manner, any business or any Person or any division thereof;
(x) action by Target to make, change or rescind any Tax election, amend any Tax Return or take any position on any Tax Return, take any action, or enter into any other transaction that would have the effect of increasing the Tax liability or reducing any Tax asset of Purchaser or the Surviving Company in respect of any Post-Closing Tax Period; or
(y) any Contract to do any of the foregoing, or any action or omission that would or would reasonably be expected to result in any of the foregoing.
Section 4.08 Material Contracts .
(a) Section 4.08(a) of the Target Disclosure Schedules lists each of the following Contracts to which Target is a party (such Contracts, together with all Leases listed or otherwise disclosed in Section 4.10(b) of the Target Disclosure Schedules and all Contracts relating to Intellectual Property set forth in Section 4.11(c) and Section 4.11(e) of the Target Disclosure Schedules, being Material Contracts ):
(i) all Contracts which create or could create a future payment obligation involving aggregate consideration in excess of $25,000;
(ii) all employment agreements and Contracts with employees, independent contractors or consultants (or similar arrangements, including any bonus or severance arrangements);
(iii) all Contracts (including employment agreements) which cannot be cancelled without a penalty or without more than 60 days notice;
(iv) all Contracts that require Target to purchase or sell a stated portion of the requirements or outputs or that contain take or pay provisions;
(v) all Contracts that provide for the indemnification of any Person or the assumption of any Tax, environmental or other Liability of any Person;
(vi) all Contracts that relate to the acquisition or disposition of any business, a material amount of Equity Interests or assets of any other Person or any real property (whether by merger, sale of stock, sale of assets or otherwise);
(vii) all broker, distributor, dealer, manufacturers representative, franchise, agency, sales promotion, market research, marketing consulting, advertising or similar Contracts;
(viii) except for Contracts relating to trade payables, all Contracts relating to Indebtedness (including, without limitation, guarantees);
(ix) all management contracts (excluding contracts for employment) and contracts with brokers or other consultants, including the Profit Sharing Agreements and any other Contracts involving the payment of royalties or other amounts calculated based upon the revenues or income of Target or income or revenues related to any product of Target;
(x) all Contracts with any Governmental Authority;
(xi) all Contracts with customers, insurers, employers, managed care entities, payors or other purchasers of services from Target;
(xii) all Contracts that limit or purport to limit the ability of Target to compete in any line of business or with any Person or in any geographic area or during any period of time, other than any Contract entered into in connection with the transactions contemplated hereby;
(xiii) all joint venture, partnership or similar Contracts;
(xiv) all Contracts for the sale of any of the Target Ownership Interests or for the grant to any Person of any option, right of first refusal or preferential or similar right to purchase any of the Target Ownership Interests;
(xv) all powers of attorney with respect to the Target or any of the Target Ownership Interests;
(xvi) all collective bargaining agreements or Contracts with any Union;
(xvii) all Contracts with EMP, any Engaged Professionals, physicians and healthcare providers, or otherwise involving the provision of medical services;
(xviii) all Contracts that include notice requirements related to a breach or potential breach of Healthcare Information Laws;
(xix) all Contracts with Material Customers or Material Suppliers; and
(xx) any other Contract which is material to Target or the Target Ownership Interests and not previously disclosed pursuant to this Section 4.08(a) .
(b) Each Material Contract is valid and binding on Target, and to the Knowledge of Target, to the each other party thereto in accordance with its terms and is in full force and effect. Target has duly performed all of its obligations under each Material Contract to which it is a party (to the extent that such obligations to perform have accrued). Neither Target nor, to the Knowledge of Target, any other party thereto, is in breach of or default under (or is alleged to be in breach of or default under), or has provided or received any notice of any intention to terminate, any Material Contract. To the Knowledge of Target, no counterparty to any Material Contract intends to terminate such Material Contract prior to the scheduled expiration of term of such Material Contract, decline renewal following the current term of such Material Contract or to materially alter the terms on which business is conducted under such Material Contract. No event or circumstance has occurred that, with notice or lapse of time or both, would or would reasonably be expected to constitute an event of default by Target under any Material Contract or result in a termination thereof or would or would reasonably be expected to cause or permit the acceleration or other changes of any right or obligation or the loss of any benefit thereunder. Complete and correct copies of each Material Contract (including all modifications, amendments and supplements thereto and waivers thereunder) have been delivered to Purchaser. There are no disputes pending or, to the Knowledge of Target, threatened under any Material Contract or any other Contract to which Target is a party or by which its assets or the Target Ownership Interests are bound.
(c) Section 4.08(c) of the Target Disclosure Schedule sets forth (i) Targets standard form of customer Contract, (ii) Targets standard form of Contract with Engaged Professionals, and (iii) a list and description of all Contracts with customers or Engaged Professionals, as applicable, that deviate from such forms in any material respect.
Section 4.09 Title to Assets; Condition and Sufficiency .
(a) Target has good, marketable and valid title to, or a valid leasehold interest in, all of the assets used or held for use thereby in connection with its business or otherwise purported to be owned or leased thereby. All such assets (including leasehold interests) are free and clear of Encumbrances except for the following (collectively referred to as Permitted Encumbrances ):
(i) liens for Taxes not yet due and payable or being contested in good faith by appropriate procedures and, in each case, for which there are adequate accruals or reserves, on the Balance Sheet and the Interim Balance Sheet;
(ii) mechanics, carriers, workmens, repairmens or other like liens arising or incurred in the ordinary course of business consistent with past practice or amounts that are not delinquent and which are not, individually or in the aggregate, material to Target and for which there are adequate accruals or reserves, on the Balance Sheet and the Interim Balance Sheet; and
(iii) workers or unemployment compensation liens arising in the ordinary course of business, which are not delinquent or past due.
(b) The buildings, structures, furniture, fixtures, machinery, equipment, vehicles and other items of tangible personal property used or held for use by the Target in connection with its business are in good operating condition and repair, are free from latent and patent defects, conform to all Laws and are adequate for the uses to which they are being put, and none of such items of tangible personal property is in need of maintenance or repairs except for ordinary, routine maintenance and repairs that are not material in nature or cost. All tangible personal property used or held for use in connection with Targets business is in the possession of the Target. The assets owned or leased by the Target are sufficient for the continued conduct of the Business after the Closing in substantially the same manner as conducted prior to the Closing and constitute all of the rights, property and assets necessary to conduct the Business as currently conducted.
Section 4.10 Real Property.
(a) Target does not own, or have an ownership interest in, nor has Target ever owned, any real property.
(b) Section 4.10(b) of the Target Disclosure Schedules sets forth any real property leased by Target as of the date hereof and as of the Closing Date, and used in or necessary for the conduct of the Business as currently conducted (together with all rights, title and interest of Target in and to leasehold improvements relating thereto, including, but not limited to, security deposits, reserves or prepaid rents paid in connection therewith, collectively, the Leased Real Property ), and a true and complete list of all leases, subleases, licenses, concessions and other agreements (whether written or oral), including all amendments, extensions renewals, guaranties and other agreements with respect thereto, pursuant to which Target holds any Leased Real Property (collectively, the Leases ). Target has delivered to Purchaser a true and complete copy of each Lease. With respect to each Lease:
(i) such Lease is valid, binding, enforceable and in full force and effect and Target enjoys peaceful and undisturbed possession of the Leased Real Property;
(ii) Target is not in breach or default under such Lease, and no event has occurred or circumstance exists which, with the delivery of notice, passage of time or both, would constitute such a breach or default, and Target has paid all rent due and payable under such Lease;
(iii) Target has not received nor given any notice of any default or event that with notice or lapse of time, or both, would constitute a default by Target under any of the Leases and, to the Knowledge of Target, no other party is in default thereof, and no party to any Lease has exercised any termination rights with respect thereto;
(iv) Target has not subleased, assigned or otherwise granted to any Person the right to use or occupy such Leased Real Property or any portion thereof; and
(v) Target has not pledged, mortgaged or otherwise granted an Encumbrance on its leasehold interest in any Leased Real Property.
(c) Target has not received any notice of (i) violations of building codes and/or zoning ordinances or other governmental or regulatory Laws affecting the Leased Real Property, (ii) existing, pending or threatened condemnation proceedings affecting the Leased Real Property, or (iii) existing, pending or threatened zoning, building code or other moratorium proceedings, or similar matters which could reasonably be expected to adversely affect the ability to operate the Leased Real Property as currently operated. No portion of any Leased Real Property has been damaged or destroyed by fire or other casualty.
Section 4.11 Intellectual Property.
(a) The term Target Intellectual Property means all of the Intellectual Property necessary for or material to the operation of Targets business as it is currently conducted, and as contemplated to be conducted, including (i) all Intellectual Property Registrations and (ii) all Intellectual Property Assets that are not registered but that are material to the operation of Targets business, all of which Intellectual Property Registrations and Intellectual Property Assets are listed on Section 4.11(a) of the Target Disclosure Schedules. All required filings and fees related to the Intellectual Property Registrations have been timely filed with and paid to the relevant Governmental Authorities and authorized registrars, and all Intellectual Property Registrations are otherwise in good standing. Target has provided Purchaser with true and complete copies of file histories, documents, certificates, office actions, correspondence and other materials related to all Intellectual Property Registrations. Target owns, or is licensed or otherwise has the right to use all Target Intellectual Property (in each case, without payments to third parties and free and clear of any Encumbrances).
(b) Target owns all right, title and interest in and to the Intellectual Property Assets, free and clear of Encumbrances. Without limiting the generality of the foregoing, Target has entered into binding, valid and enforceable written agreements with every current and former employee and independent contractor, whereby such employees and independent contractors (i) irrevocably assign or otherwise transfer to Target any ownership interest and right they may have in the Intellectual Property Assets; and (ii) acknowledge Target as the exclusive owner of all Intellectual Property Assets. Target has provided Purchaser with true and complete copies of all such agreements. Target is in compliance with all legal requirements applicable to the Intellectual Property Assets and the ownership and use thereof. With respect to each of the Intellectual Property Assets, (i) each Intellectual Property Asset is not subject to any outstanding injunction, judgment, order, decree, ruling, or charge; (ii) no Action is pending or, to the
Knowledge of Target, is threatened which challenges the legality, validity, enforceability, use, or ownership of the Intellectual Property Assets; (iii) Target has not agreed to indemnify any Person for or against any interference, infringement, misappropriation, or other conflict with respect to the Intellectual Property Assets; and (iv) no loss or expiration of the Intellectual Property Assets is pending or, to the Knowledge of Target, threatened, except for copyrights, patents and trademarks expiring at the end of their statutory terms or domain registrations expiring at the end of their contractual terms.
(c) Section 4.11(c) of the Target Disclosure Schedules lists all material Intellectual Property Licenses and the third party that owns the Intellectual Property subject to such Intellectual Property Licenses. Target has provided Purchaser with true and complete copies of all such material Intellectual Property Licenses. All such material Intellectual Property Licenses are valid, binding and enforceable between Target and the other parties thereto, and Target, and to the Knowledge of Target, such other parties are in full compliance with the terms and conditions of such Intellectual Property Licenses. Target has obtained and possesses valid licenses to use all of the software programs present on the computers and other software-enabled electronic devices owned or leased thereby or that have otherwise been provided to their employees for their use in connection their employment.
(d) The Intellectual Property as currently or formerly owned, licensed or used by Target, and the conduct of its business as currently and formerly conducted thereby, do not and will not infringe, violate or misappropriate the Intellectual Property of any Person. Target has not received any communication, and no Action has been instituted, settled or, to the Knowledge of Target, threatened that alleges any such infringement, violation or misappropriation, and none of the Intellectual Property Assets is subject to any outstanding Governmental Order.
(e) Section 4.11(e) of the Target Disclosure Schedules lists all licenses, sublicenses and other agreements pursuant to which Target grants rights or authority to any Person with respect to any Target Intellectual Property. Target has provided Purchaser with true and complete copies of all such agreements. All such agreements are valid, binding and enforceable between Target and the other parties thereto. Target and, to the Knowledge of Target, such other parties are in full compliance with the terms and conditions of such agreements. To the Knowledge of Target, no Person has infringed, violated or misappropriated, or is infringing, violating or misappropriating, any Intellectual Property Assets.
(f) Target has taken all necessary action to maintain and protect all of the Intellectual Property Assets so as not to adversely affect the validity or enforceability thereof. Target does not use any inventions of any of its employees made prior to their employment by Target. Each employee and independent contractor has assigned to Target all Intellectual Property rights related to the Target or its business, if any, he, she or it developed while employed or engaged by Target, subject to statutory exclusions. No Engaged Professional owns or has created any Intellectual Property Assets.
(g) Target has not embedded any open source, copyright or community source code in any of its products generally available or in development, including but not limited to any libraries or code licensed under any license arrangement.
(h) Targets owned and licensed software and the related computer hardware used in connection with the Business is adequate in all material respects, when taken together with its other assets, to run the Business in the same manner as the Business is now conducted.
(i) Target has complied with all privacy regulations as mandated by Law and/or as required by third parties, as well as all privacy regulations set forth within the Targets privacy policies and websites.
(j) Target has taken reasonable and appropriate steps to protect and preserve the confidentiality of the trade secrets that comprise any part of the Target Intellectual Property and, to the Knowledge of Target, there have not occurred any unauthorized uses, disclosures or infringements of any such trade secrets by any Person. All use and disclosure by Target of trade secrets owned by another Person have been pursuant to the terms of a written agreement with such Person or was otherwise lawful. Without limiting the foregoing, Target has a policy requiring employees and certain consultants and contractors to execute a confidentiality and assignment agreement substantially in Targets standard form previously provided to Purchaser. Target has taken reasonable steps to enforce such policy consistent with standard industry practices.
(k) The execution and delivery of this Agreement and the Transaction Documents and the consummation of the transactions contemplated hereby and thereby will not result in (i) Target granting to any third party other than Purchaser any rights or licenses to any Intellectual Property or Intellectual Property rights, (ii) any right of termination or cancellation under any Intellectual Property agreement, or (iii) the imposition of any Encumbrance on any Target Intellectual Property.
(l) No government funding, facilities of a university, college, other educational institution or research center or funding from third parties was used in the development of any Intellectual Property Asset. To the Knowledge of Target, no employee of Target who was involved in, or who contributed to, the creation or development of any Intellectual Property Assets, has performed services for the government, university, college, or other educational institution or research center during a period of time during which such employee was also performing services for Target.
Section 4.12 Accounts Receivable and Accounts Payable .
(a) The Accounts Receivable reflected on the Interim Balance Sheet and the Accounts Receivable arising after the date thereof and on or before the Closing (a) have arisen from bona fide transactions entered into by Target involving the sale of goods or the rendering of services in the ordinary course of business consistent with past practice; (b) constitute only valid, undisputed claims of Target not subject to Encumbrances or claims of set-off or other defenses or counterclaims; and (c) subject to a reserve for bad debts shown on the Interim Balance Sheet or, with respect to Accounts Receivable arising after the Interim Balance Sheet Date, on the accounting records of Target delivered to Purchaser prior to the Closing, are collectible in full, without any set-off, within seventy-five (75) days after billing. The reserve for bad debts shown on the Interim Balance Sheet or, with respect to Accounts Receivable arising after the Interim
Balance Sheet Date, on the accounting records of Target delivered to Purchaser have been determined in accordance with GAAP, consistently applied, subject to normal year-end adjustments and the absence of disclosures normally made in footnotes. Section 4.12(a) of the Target Disclosure Schedules sets forth a complete and accurate list of all Accounts Receivable as of April 30, 2015, including the aging of each Account Receivable. No account debtor with respect to any of such Accounts Receivable is a Governmental Authority (including any Federal healthcare program). Target has not received notice of the bankruptcy or insolvency of the account debtor of any Accounts Receivable. None of such Accounts Receivable is evidenced by a judgment or chattel paper.
(b) All accounts payable reflected on the Interim Balance Sheet or arising thereafter and on or before the Closing are the result of bona fide transactions in the ordinary course of business and have been paid, are not yet due or payable or are otherwise subject to good faith dispute by Target and described on Section 4.12(b) of the Target Disclosure Schedules. Since the Balance Sheet Date, Target has not altered in any material respect its practices for the payment of such accounts payable.
Section 4.13 Customers and Suppliers .
(a) Section 4.13(a) of the Target Disclosure Schedules sets forth (i) each customer of Target (including without limitation any insurer, managed care entity, payor, employer, or other provider) who has accounted for aggregate gross revenue of Target in an amount greater than or equal to $25,000 during the twenty four (24) months ended April 30, 2015 (collectively, the Material Customers ); and (ii) the amount of consideration paid by each Material Customer during such periods. Target has not received any notice, or has reason to believe, that any of the Material Customers has ceased, or intends to cease after the Closing, to use the goods or services of Target, or to otherwise terminate or materially reduce its relationship with Target. Each Material Customer has transacted business with Target and otherwise acted substantially in accordance with the terms of its Contract consistent with the established course of conduct over the last twenty four (24) months. No Material Customer has sought a material reduction in the prices it currently pays for services of Target, the level or scope of services it receives from Target or any other material modification of any payment term or other material term applicable to its purchases of services from Target, and, to the Knowledge of Target, there are no facts which may reasonably be expected to indicate that any material adverse change may occur in the business relationship with any Material Customer.
(b) Section 4.13(b) of the Target Disclosure Schedules sets forth with respect to Target (i) each supplier or vendor (including Engaged Professionals) to whom Target paid aggregate consideration for goods or services rendered in an amount greater than or equal to $25,000 during the twenty-four (24) months ended April 30, 2015 (collectively, the Material Suppliers ); and (ii) the amount of purchases from each Material Supplier during such periods. Target has not has received any notice or has reason to believe that any of the Material Suppliers has ceased, or intends to cease, to supply goods or services to Target, or to otherwise terminate or materially reduce its relationship with Target. Each Material Supplier has transacted business with Target and otherwise acted substantially in accordance with the terms of its Contract consistent with the established course of conduct over the last twenty-four (24) months. No
Material Supplier has sought a material increase in the prices it currently charges for services or products it provides to Target, the level or scope of products or services it provides to Target or any other material modification of any payment term or other material term applicable to its sales of products or services to Target, and, to the Knowledge of Target, there are no facts which may reasonably be expected to indicate that any material adverse change may occur in the business relationship with any Material Supplier.
Section 4.14 Insurance . Section 4.14 of the Target Disclosure Schedules sets forth (a) a true and complete list of all current policies or binders of fire, liability, medical malpractice, product liability, umbrella liability, real and personal property, workers compensation, vehicular, directors and officers liability, fiduciary liability, cyber liability, and other casualty, property and other insurance maintained by Target as of the date of this Agreement and the Closing Date (collectively, the Insurance Policies ); (b) each Insurance Policys applicable deductibles and coverage limits and whether or not such Insurance Policy provides coverage limits on an occurrence basis; and (c) a list of all pending claims and the claims history for Target for the past three (3) years. To the Knowledge of Target, there are no grounds to believe that Target will not be able to renew such insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue the Business without a significant increase in cost. There are no claims related to Target pending under any such Insurance Policies as to which coverage has been questioned, denied or disputed or in respect of which there is an outstanding reservation of rights. Target has not received any written notice of cancellation of, premium increase with respect to, or alteration of coverage under, any of such Insurance Policies. All premiums due on such Insurance Policies have either been paid or, if not yet due, accrued. All such Insurance Policies (a) are in full force and effect and enforceable in accordance with their terms; (b) are provided by carriers who have an A.M. Best rating of at least A+; and (c) have not been subject to any lapse in coverage. Target is not in default under, and has not otherwise failed to comply with, any provision contained in any such Insurance Policy. Target has not reached or exceeded its policy limits for any insurance policy in effect at any time during the past five (5) years. The Insurance Policies are of the type and in the amounts customarily carried by Persons conducting a business similar to the Business and are sufficient for compliance with all applicable Laws and Contracts to which Target is a party or by which it is bound. True and complete copies of the Insurance Policies have been delivered to Purchaser.
Section 4.15 Legal Proceedings; Governmental Orders .
(a) Except as specified in Section 4.15(a) of the Target Disclosure Schedules, there is not currently, nor within the last five (5) years have there been, any Actions pending or, to the Knowledge of Target, threatened (a) against, related to or involving Target, its business, its assets, or any officer, director, employee, Stockholder, Optionholder, any Engaged Professional or agent of Target, in each case relating to Target, its business, or its assets; (b) that challenge or seek to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement or the Transaction Documents; or (c) that would otherwise reasonably be expected to have a Material Adverse Effect. To the Knowledge of Target, no event has occurred or circumstances exist that may give rise to, or serve as a basis for, any such Action. There is no Action pending by Target or which Target intends to initiate.
(b) Except as specified in Section 4.15(b) of the Target Disclosure Schedules, there are no outstanding or, to the Knowledge of Target, threatened Governmental Orders and no unsatisfied judgments, penalties or awards against, relating to or affecting the Target or its business, any officer, director, employee, Stockholder, Optionholder, or any Engaged Professional or agent, of Target.
Section 4.16 Compliance with Laws; Permits .
(a) Except as specified in Section 4.16(a) of the Target Disclosure Schedules, Target and its business has been operated at all times since its inception, and currently is, in compliance, in all material respects, with all Laws or other rules or regulations of any Governmental Authority applicable to Target, its business or the Target Ownership Interests, or by which any property or asset of Target is bound, relating to the operation of its business as heretofore conducted, including without limitation: (i) Laws or other rules or regulations of any Governmental Authority governing any federal health care program, including without limitation the Medicare and Medicaid programs and Law relating to health care fraud and abuse and referrals, including, without limitation: (A) the Anti-Kickback Law, 42 U.S.C. § 1320a7b, 42 C.F.R. § 1001.952, (B) the Civil Monetary Penalties Law, 42 U.S.C. § 1320a7a, (C) the physician self-referral prohibition, 42 U.S.C. § 1395nn, 42 C.F.R. § 411.350 et seq., (D) the False Claims Act, 31 U.S.C. § 3729 et seq., (E) the CHAMPUS statute (10 U.S.C. § 1071 et seq.), (F) the False Statement Accountability Act (18 U.S.C. § 1001), and (G) the Program Fraud Civil Penalties Act (31 U.S.C. § 3801 et seq.); (ii) federal and state Laws or other rules or regulations relating to health care fraud and abuse and referrals; (iii) federal and state Laws or other rules or regulations relating to Medicare, Medicaid or any other state health care or health insurance programs; (iv) federal and state Laws or other rules or regulations (including those rules and regulations followed by state boards of medicine) relating to the unlawful practice of medicine by physicians or corporations, aiding or abetting the unlicensed practice of medicine, unprofessional conduct, false, deceptive or misleading advertising, filling prescriptions or providing medical care across state lines, fee-splitting, or the payment of referral fees; (v) federal or state Laws or other rules or regulations relating to the manner of handling, processing, and timely paying claims for payment for health care items or services; and (vi) other federal or state Laws or other rules or regulations relating to fraudulent, abusive or unlawful practices connected in any way with the provision of health care items or services or the billing or payment for such items or services.
(b) Since its inception, neither Target, nor any director, officer, employee, psychiatrist, psychologist, social worker, counselor, physician or other healthcare professional employed or engaged by or under contract with Target or by another Person (including, without limitation, EMP) on behalf or for the benefit of Target (an Engaged Professional ) with respect to actions taken on behalf of Target (i) has been assessed a civil money penalty under Section 1128A of the Social Security Act (42 U.S.C. § 1320a 7a) or any regulations promulgated thereunder, (ii) has been barred or excluded from participation in any federal health care program or state health care program (as such terms are defined by the Social Security Act), (iii) has been convicted of any criminal offense or has engaged in any act or conduct that would be a grounds for mandatory or permissive exclusion from participation in any federal health care program
under Section 1128 of the Social Security Act (42 U.S.C. § 1320a 7), or (iv) is a party to or subject to any Action concerning any of the matters described above in clauses (i) through (iii).
(c) Target, its business and each Engaged Professional is in compliance, to the extent applicable, with the terms and provisions of all Laws or other rules or regulations of any Governmental Authority relating to patient or individual healthcare information, including, without limitation, the Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104 191, as amended by the Health Information Technology for Economic and Clinical Health Act ( HIPAA ), and any rules or regulations promulgated thereunder and similar state Laws (collectively, the Healthcare Information Laws ). Target has (i) undertaken all necessary surveys, audits, inventories, reviews, analyses, or assessments (including any necessary risk assessments) on all privacy, security and other areas required for compliance under all Healthcare Information Laws to the extent applicable to Targets operations as heretofore conducted, (ii) taken all steps necessary to be in compliance with all Healthcare Information Laws to the extent applicable to Targets operations as heretofore conducted (the Compliance Plan ), (iii) adopted all appropriate policies and procedures and conducted all training required to implement reasonable administrative, physical and technical safeguards to protect the confidentiality, integrity, and availability of any individual healthcare information, and implemented those provisions of the Compliance Plan to ensure that Target, the Business and each Engaged Professional are and will remain in compliance with all Healthcare Information Laws, (iv) not suffered, a breach of unsecured protected health information or successful security incident as defined in HIPAA, nor has Target had reason to investigate any possible breach or incident, and (v) not received any complaint from an individual patient or any agency enforcing any Healthcare Information Law alleging a breach or any violation of and Healthcare Information Law.
(d) All Permits required for Target and each Engaged Professional, to conduct the Business as currently conducted or for the ownership and use of Targets assets have been obtained by Target and each Engaged Professional, and are valid and in full force and effect. Each of Target and each Engaged Professional is in compliance with all such Permits, and there are no provisions in, or Contracts relating to, any such Permits which preclude or restrict Target from operating the Business as currently operated. All fees and charges with respect to such Permits as of the date hereof and as of the Closing Date have been paid in full. Section 4.16(d) of the Target Disclosure Schedules lists all current Permits issued to Target in connection with the Business, including the names of the Permits and their respective dates of issuance and expiration. No event has occurred that, with or without notice or lapse of time or both, would reasonably be expected to result in the revocation, suspension, lapse, limitation or cancellation of any Permit required to be set forth in Section 4.16(d) of the Target Disclosure Schedules. Target uses commercially reasonable measures to assure that each Engaged Professional is properly licensed to conduct business with Target.
(e) Neither Target nor any Engaged Professional acting on its behalf has performed services for, nor received payment for services from, any Governmental Authority (including any federal healthcare program).
(f) Target does not use or disclose any of the customer information it receives through its website or otherwise in a manner violative of the Targets privacy policy or Compliance Plan or the privacy rights of its customers under applicable Law.
(g) Except as set forth and described in Section 4.16(g) of the Target Disclosure Schedules, (i) neither Target nor, with respect to any services provided to or for the benefit of Target, any Engaged Professional or other Person affiliated with Target, has been the subject of any inspection, investigation, survey, audit, monitoring or other form of review by any Governmental Authority, trade association, professional review organization, accrediting organization or certifying agency based upon any alleged improper activity on the part of Target or such Person, nor has Target received any written notice of deficiency in connection with the operations of the Target; (ii) there are not presently any outstanding notices of deficiency or orders of any Governmental Authority having jurisdiction over Target or any of its assets or properties, or requiring conformity to any applicable agreement, Law, regulation, ordinance or bylaw; and (iii) there is not any written notice of any claim, requirement or demand of any licensing or certifying agency or other third party supervising or having authority over the Target or its assets or properties of non-conformance or failure to comply with any existing Law, code, rule, regulation or standard.
(h) Except for ethical limitations, the jurisdictions in which Target conducts the Business do not currently impose any restrictions or limitations on rates which may be charged to patients receiving services provided by or on behalf of Target. Target does not have any rate appeal currently pending before any Governmental Authority. Target has no Knowledge of any applicable Law, which has been enacted, promulgated, or issued within the twenty four (24) months preceding the date of this Agreement, or of any such legal requirement proposed or pending in the jurisdictions in which Target conducts the Business, which could have a Material Adverse Effect or which could require Target to obtain any necessary authorization which it does not currently have.
(i) At April 30, 2015, 627,438 persons were eligible for services provided by Target as set forth in Targets eligibility file system and were invoiced accordingly by Target, and during the four (4) months ended April 30, 2015, the number of consults by such Persons with Engaged Professionals was approximately 6,700 consults.
Section 4.17 Environmental Matters .
(a) Target and its business are currently and have at all times been in compliance with all and not subject to liability under any Environmental Laws. Target has not received from any Person, with respect to Target or its business, any: (i) Environmental Notice or Environmental Claim; or (ii) written request for information pursuant to Environmental Law, which, in each case, either remains pending or unresolved, or is the source of ongoing obligations or requirements.
(b) There has been no Release of Hazardous Materials in contravention of or subject to liability under Environmental Law with respect to the business of Target or on any real property currently or formerly owned, leased or operated by Target, and Target has not received
an Environmental Notice or Environmental Claim that any of the business of Target or real property currently or formerly owned, leased or operated by Target (including soils, groundwater, surface water, buildings and other structure located thereon) has been contaminated with any Hazardous Material.
(c) Target has not retained or assumed, by Contract or operation of Law, any Liabilities or obligations of third parties under Environmental Law.
Section 4.18 Employee Benefit Matters.
(a) Section 4.18(a) of the Target Disclosure Schedules sets forth a correct and complete list of all Benefit Plans and Benefit Agreements.
(b) Each Benefit Plan that is intended to be qualified under Section 401(a) of the Code, and each trust that is related to a Benefit Plan and intended to be Tax exempt under Section 501(a) of the Code, has been determined by the Internal Revenue Service to be qualified under Section 401(a) of the Code or exempt from taxation under Section 501(a) of the Code or Target has received an opinion letter from the Internal Revenue Service with respect to the compliance in form of such Benefit Plan documents with Section 401(a) of the Code and, to the Knowledge of Target, nothing has occurred that would adversely affect the qualification or Tax exemption of any such Benefit Plan or related trust. Each Benefit Plan has been administered in accordance with its terms. Target and all the Benefit Plans are all in compliance with the applicable provisions of ERISA, the Code and all other applicable Laws, including Laws of foreign jurisdictions. With respect to each Benefit Plan and Benefit Agreement, Target has provided to Participants all material communications or disclosures required by Law or by the terms of such Benefit Plan or Benefit Agreement.
(c) No Benefit Plan or employee benefit plan maintained by an ERISA Affiliate (i) is subject to Title IV of ERISA or Section 412 of the Code or is a multiemployer pension plan (within the meaning of Section 3(37) or 4001(a)(3) of ERISA) or a multiple employer plan (within the meaning of Section 4063 of ERISA) or (ii) provides for post-retirement or other post- employment welfare benefits (other than health care continuation coverage as required by applicable Law). Neither the Target nor any other Person that, together with the Target, is treated as a single employer under Section 414 of the Code has sponsored, maintained, contributed to or been required to contribute to any such plan.
(d) Except as may be required by applicable Law, or as contemplated under this Agreement, Target has not announced any plan or commitment to create any additional Benefit Plans which are intended to cover employees or former employees of the Target or to amend or modify any existing Benefit Plan which covers or has covered employees or former employees of the Target, or to create, amend or modify any Benefit Agreement.
(e) To the extent applicable, correct and complete copies of the following have been delivered to Purchaser by Target: (i) all Benefit Plans and Benefit Agreements (including all amendments and attachments thereto); (ii) written summaries of any Benefit Plan and any Benefit Agreement not in writing; (iii) all related trust documents; (iv) all insurance Contracts or other funding arrangements; (v) the most recent annual report (Form 5500) filed with the Internal
Revenue Service; (vi) the most recent determination letter from the Internal Revenue Service, if any; and (vii) the most recent summary plan description and any summary of material modification thereto.
(f) There are no investigations, examinations, audits or proceedings by any Governmental Authority with respect to or involving any Benefit Plan or any fiduciary thereof, and, to the Knowledge of Target, there are not any facts that would reasonably be expected to give rise to any such investigation, examination, audit or proceeding. There are no Actions, claims, suits or proceeding against or involving any Benefit Plan or Benefit Agreement or asserting any rights or claims to benefits under any Benefit Plan or Benefit Agreement (except claims for benefits payable in the normal operation of the Benefit Plan or Benefit Agreement), and, to the Knowledge of Target, there are not any facts that would reasonably be expected to give rise to any such Action, claim, suit or proceeding.
(g) With respect to each Benefit Plan, (i) (A) there has not occurred prior to the Closing Date any prohibited transaction (within the meaning of Section 406 of ERISA or Section 4975 of the Code) that could subject the Target or its employees to any material liability and (B) following the Closing Date, there will not occur any prohibited transaction (within the meaning of Section 406 of ERISA or Section 4975 of the Code) that could subject Purchaser or the Surviving Company or any of their respective employees to any Liabilities and (ii) neither the Target nor any of its directors, employees, Engaged Professionals or agents has engaged in any transaction or acted in a manner, or failed to act in a manner, that would reasonably be expected to subject the Target or any of its employees to liability for breach of fiduciary duty under ERISA or any other applicable Law.
(h) Section 4.18(h) of the Target Disclosure Schedules discloses whether each Benefit Plan and each Benefit Agreement that is an employee welfare benefit plan is (i) unfunded or self-insured, (ii) funded through a welfare benefit fund, as such term is defined in Section 419(e) of the Code, or other funding mechanism, or (iii) insured.
(i) None of the execution and delivery of this Agreement nor the Transaction Documents, the obtaining of the approval of Targets stockholders or the consummation of the Merger or any other transaction contemplated hereby or thereby (whether alone or as a result of any termination of employment on or following the Effective Time) will, except as expressly contemplated by this Agreement, (i) entitle any Participant to severance, termination, retention, change in control or similar compensation or benefits, (ii) accelerate the time of payment or vesting, or trigger any payment or funding (through a grantor trust or otherwise) of, compensation or benefits under, increase the amount payable or trigger any other material obligation pursuant to any Benefit Plan or Benefit Agreement, or (iii) prohibit any Benefit Plan or Benefit Agreement from being amended or terminated.
(j) Target has correctly classified each individual who performs services for Target as a common law employee, an independent contractor, or a leased employee, as applicable, in accordance with the provisions of each Benefit Plan, and in accordance with ERISA, the Code, and other applicable Laws.
(k) Each Benefit Plan and each Benefit Agreement that is a nonqualified deferred compensation plan within the meaning of Section 409A(d)(1) of the Code subject to Section 409A of the Code has been at all times administered, operated and maintained in all respects in accordance with its terms and according to the requirements of Section 409A of the Code and the regulations promulgated thereunder, except for any failure that, individually or in the aggregate, has not and would not result in a material liability to Target or any of its Affiliates; no Person is entitled to receive any additional payment from the Target or any of its Affiliates as a result of the imposition of any Taxes under Section 409A of the Code.
(l) No amount or other entitlement or economic benefit that could be received (whether in cash or property or the vesting of property) as a result of the execution and delivery of this Agreement or the Transaction Documents, the obtaining of the approval of Targets stockholders or the consummation of the Merger or any other transaction contemplated hereby or thereby (alone or in combination with any other event, including as a result of termination of employment on or following the Effective Time) by or for the benefit of any Person who is a disqualified individual (as defined in Treasury Regulations Section 1.280G-1) with respect to the Target under any Benefit Plan, Benefit Agreement or otherwise would be characterized as an excess parachute payment (as defined in Section 280G(b)(1) of the Code).
(m) With respect to each Benefit Plan that is an employee pension benefit plan (as such term is defined in Section 3(2) of ERISA), all contributions (including all employer contributions and employee salary reduction contributions) that are due have been made within the time periods prescribed by ERISA and the Code, and all contributions for any period ending on or before the Effective Time which are not yet due have been made to each such employee pension benefit plan or accrued in accordance with GAAP. With respect to each Benefit Plan that is an employee welfare benefit plan (as such term is defined in Section 3(1) of ERISA), all premiums or other payments for all periods ending on or before the Effective Time have been paid or accrued in accordance with GAAP.
(n) Target and its Affiliates offer to their full-time employees (and their dependents) the opportunity to enroll in minimum essential coverage under an eligible employer sponsored plan (as defined in Code Section 5000A(f)(2)) as necessary to avoid the imposition of assessable payments under Code Section 4980H(a) and (b).
Section 4.19 Employment Matters.
(a) Section 4.19(a) of the Target Disclosure Schedules contains a list of all Persons who are currently employees, independent contractors or consultants of Target (including all Engaged Professionals currently engaged or employed by Target or by any third party, including EMP, on behalf of Target), and sets forth for each such individual the following: (i) name; (ii) title or position (including whether full or part time); (iii) hire date; (iv) current annual base compensation rate; (v) commission, bonus or other incentive based compensation; (vi) a description of the fringe benefits currently provided to each such individual; and (vii) the professional licenses held by such individual. Except as set forth on Section 4.19(a) of the Target Disclosure Schedules, Target is not a party to any employee agreement, independent contractor agreement or other Contract with any employee or independent contractor. As of the
date hereof, all compensation, including wages, commissions and bonuses payable to employees, independent contractors or consultants of Target (including all Engaged Professionals) for services performed on or prior to the date hereof have been paid in full, and as of the Closing Date, all compensation, including wages, commissions and bonuses payable to employees, independent contractors or consultants of Target (including all Engaged Professionals) for services performed on or prior to the Closing Date will have been paid in full.
(b) Target is not, and has never been, a party to, bound by, or negotiating any collective bargaining agreement or other Contract with a union, works council or labor organization (collectively, Union ), and there is not now, nor has there ever been, any Union representing or purporting to represent any employee of Target, and, to the Knowledge of Target, no Union or group of employees is seeking or has sought to organize employees for the purpose of collective bargaining. Except as set forth in Section 4.19(b) of the Target Disclosure Schedules, there is not, nor has there ever been, any threat of, any strike, slowdown, work stoppage, lockout, concerted refusal to work overtime or other similar labor disruption or dispute affecting Target or any employees, independent contractors or consultants of Target (including any Engaged Professionals). Target has no duty to bargain with any Union.
(c) Target is and has been in compliance, in all material respects, with all applicable Laws pertaining to employment and employment practices, including all Laws relating to labor relations, equal employment opportunities, fair employment practices, employment discrimination, harassment, retaliation, reasonable accommodation, disability rights or benefits, immigration, wages, hours, overtime compensation, child labor, hiring, promotion and termination of employees, working conditions, meal and break periods, privacy, health and safety, workers compensation, leaves of absence and unemployment insurance. All employees of Target classified as exempt under the Fair Labor Standards Act and state and local wage and hour Laws are properly classified. There are no Actions against Target pending, or to the Knowledge of Target, threatened to be brought or filed, by or with any Governmental Authority or arbitrator in connection with the employment of any current or former applicant, employee, consultant or independent contractor of Target, including, without limitation, any claim relating to unfair labor practices, employment discrimination, harassment, retaliation, equal pay, wages and hours or any other employment related matter arising under applicable Laws.
(d) Target has complied in all respects with the WARN Act.
Section 4.20 Taxes . Except as set forth in Section 4.20 of the Target Disclosure Schedules:
(a) All Tax Returns required to be filed by Target prior to Closing for any Pre- Closing Tax Period have been timely filed. Such Tax Returns are true, complete and correct in all respects. All Taxes due and owing by Target (whether or not shown on any Tax Return) have been timely paid.
(b) The unpaid Taxes of Target for all Tax periods do not exceed the Estimated Closing Accrued Tax Amount.
(c) Target has withheld and paid each Tax required to have been withheld and paid in connection with amounts paid or owing to any employee, independent contractor, creditor, customer, Engaged Professional, stockholder, optionholder or other party, and complied with all information reporting and backup withholding provisions of applicable Law.
(d) Target has delivered to Purchaser (i) complete and correct copies of all Tax Returns of Target relating to Taxes for all taxable periods for which the applicable statute of limitations has not yet expired, (ii) complete and correct copies of all private letter rulings, revenue agent reports, information document requests, notices of proposed deficiencies, deficiency notices, protests, petitions, closing agreements, settlement agreements, pending ruling requests and any similar documents submitted by, received by, or agreed to by or on behalf of Target relating to Taxes for any taxable period for which the statute of limitations has not yet expired, and (iii) complete and correct copies of all material agreements, rulings, settlements or other Tax documents with or from any Governmental Authority relating to Tax incentives of the Target.
(e) No extensions or waivers of statutes of limitations have been given or requested with respect to any Taxes of Target.
(f) All deficiencies asserted, or assessments made, against Target as a result of any examinations by any taxing authority have been fully paid.
(g) Target is not party to any Action by any taxing authority. There are no pending or, to the Knowledge of Target, threatened Actions by any taxing authority against or involving Target or its business.
(h) Target is not, nor has it ever been, a party to any engagement relating to the sharing of Tax benefits or Liabilities.
(i) Target has not been informed by any jurisdiction that it has not filed a Tax Return that the jurisdiction believes Target was required to file.
(j) Target is not and has never been a member of a group of Persons with which it has filed (or been required to file) consolidated, combined or unitary Tax Returns. Target has no actual or potential liability under Treasury Regulations Section 1.1502-6 (or any comparable or similar provision of state, local or foreign Law), as a transferee or successor, pursuant to any contractual obligation, or otherwise for any Taxes of any Person other than Target.
(k) There are no Encumbrances for Taxes upon any of the assets of Target nor, to the Knowledge of Target, is any taxing authority in the process of imposing any Encumbrances for Taxes on any of the assets of Target (other than for current Taxes not yet due and payable).
(l) Target is not and has never been a United States real property holding corporation within the meaning of Section 897(c) of the Code during the applicable period specified in Code Section 897(c)(1)(A)(ii).
(m) Target is not and has never been a party to, or a promoter of, a reportable transaction within the meaning of Section 6707A(c)(1) of the Code and Treasury Regulations Section 1.6011-4(b).
(n) None of the assets of Target are tax-exempt use property within the meaning of Section 168(h) of the Code.
(o) The consummation of the transactions contemplated by this Agreement will not result in any liability to Target for transfer, documentary, sales, use, stamp, registration, value added and other such Taxes and fees (including any penalties and interest) incurred in connection with this Agreement and the other Transaction Documents (including any real property transfer Tax and any other similar Tax).
(p) Target (i) is not a party to any joint venture, partnership, or other arrangement that is treated as a partnership for federal income Tax purposes, (ii) has not made an entity classification (check-the-box) election under Section 7701, (iii) is not and has never been a shareholder of a controlled foreign corporation as defined in Section 957 of the Code (or any similar provision of state, local or foreign Law) and (iv) is not and has never been an owner in a passive foreign investment company within the meaning of Section 1297 of the Code.
(q) Target does not have a request for a private letter ruling, a request for administrative relief, a request for technical advice, a request for a change of any method of accounting, or any other similar request that is in progress or pending with any Governmental Authority with respect to Taxes or Tax Returns.
(r) Neither Purchaser nor the Surviving Company shall be required to include an item of income, or exclude an item of deduction, for any period after the Closing Date as a result of: (i) an installment sale transaction by Target occurring on or before the Closing governed by Section 453 of the Code (or any similar provision of state, local or non-U.S. Laws); (ii) a transaction by Target occurring on or before the Closing Date reported as an open transaction for U.S. federal Income Tax purposes (or any similar doctrine under state, local or non-U.S. Laws); (iii) any prepaid amounts received on or prior to the Closing Date by Target; (iv) a change in Targets method of accounting on or prior to the Closing Date; or (v) an agreement entered into by Target with any Governmental Authority (including a closing agreement under Section 7121 of the Code) on or prior to the Closing Date. Target has not made an election (including a protective election) pursuant to Section 108(i) of the Code. Target has no long-term contracts that are subject to a method of accounting provided for in Section 460 of the Code.
(s) Target has not made any payment, nor is obligated to make any payment or is a party to any agreement, Contract, arrangement or plan that could obligate it to make any payment, that may be treated as an excess parachute payment under Section 280G of the Code.
(t) Target is not a party to any agreement to pay, gross up or otherwise indemnify any employee, consultant or independent contractor for any Taxes, including potential Taxes imposed under Sections 409A or 4999 of the Code, incurred with respect to services provided to Target.
(u) Target has not distributed to its securityholders any stock or other Equity Interests of a controlled corporation, nor have Equity Interests of Target been distributed, in a transaction to which Section 355 of the Code applies.
(v) Target has since its formation been treated as a Subchapter C Corporation for federal income tax purposes. No Governmental Authority has challenged the federal income Tax treatment of Target. No election is pending to change the income Tax treatment of Target.
Section 4.21 Bank Accounts . Section 4.21 of the Target Disclosure Schedules sets forth (a) the name of each bank, trust corporation or other financial institution and stock or other broker with which Target has an account, credit line or safe deposit box or vault and (b) the names of all Persons authorized to draw thereon or to have access to any safe deposit box or vault.
Section 4.22 Network Redundancy and Computer Back Up. Target has made backups of all computer software and databases utilized by it and maintains such software and databases at a secure off-site location. Target has established a data recovery plan sufficient to restore service in a commercially reasonable amount of time and in compliance with all Healthcare Information Laws in the event of a critical system failure or employs a remote failover system.
Section 4.23 No Disagreements with Accountants and Lawyers . There are no disagreements of any kind presently existing, or reasonably anticipated by Target to arise, between the accountants and lawyers formerly or presently engaged by Target, and Target is current with respect to any fees owed to their accountants and lawyers.
Section 4.24 Solvency . Target is not Insolvent, and will not be rendered Insolvent by any of the transactions contemplated by this Agreement. As used in this Section 4.24 , Insolvent means that the sum of the debts and other probable Liabilities of a Person exceeds the present fair saleable value of such Persons assets.
Section 4.25 Interested Party Transactions . Except as set forth in Section 4.25 of the Target Disclosure Schedules, no director, officer, Principal, five percent (5%) (or greater) stockholder or Affiliate of Target has or has had, directly or indirectly, (i) an economic interest in any Person that has furnished or sold, or furnishes or sells, services or products that Target furnishes or sells; (ii) an economic interest in any Person that purchases from or sells or furnishes to, Target, any goods or services; (iii) a beneficial interest in any Material Contract; or (iv) any contractual or other arrangement with Target (other than in its capacity as director, officer, stockholder, Principal or Affiliate). Target has not (i) extended or maintained credit, arranged for the extension of credit or renewed an extension of credit in the form of a personal loan to or for any director or executive officer (or equivalent thereof) of Target, or (ii) materially modified any term of any such extension or maintenance of credit.
Section 4.26 Anti-Terrorism Laws . Target (a) is not, or is not controlled by, a Restricted Party (defined below), (b) has not borrowed funds from a Restricted Party which would reasonably be expected to result in a breach by it of any Anti-Terrorism Law, or (c) is not in breach of or is the subject of any action or investigation under any Anti-Terrorism Law
relating to the breach by it of any Anti-Terrorism Law. For purposes hereof, (i) Restricted Party means any Person listed in the Annex to the Executive Order, on the Specially Designated Nationals and Blocked Persons list maintained by the Office of Foreign Assets Control of the United States Department of the Treasury, or in any successor list to either of the foregoing; (ii) Anti-Terrorism Law means each of the Executive Order, the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001, Public Law 107-56 (commonly known as the USA Patriot Act), the Money Laundering Control Act of 1986, Public Law 99-570, and any similar Law enacted in the United States of America subsequent to the date of this Agreement; and (iii) Executive Order means Executive Order No. 13224 of September 23, 2001 - Blocking Property and Prohibiting Transactions With Persons Who Commit, Threaten To Commit, or Support Terrorism.
Section 4.27 Brokers . Except for B.C. Ziegler and Company ( Ziegler ), no broker, finder or investment banker is entitled to any brokerage, finders or other fee or commission in connection with the transactions contemplated by this Agreement or any other Transaction Document based upon arrangements made by or on behalf of the Target.
Section 4.28 Information Statement . Effective as of the date that information is provided by Target, Target represents and warrants that all information provided by Target for inclusion in any materials to be submitted to the Stockholders in connection with the solicitation of the Target Stockholder Approval, including the Information Statement (the Soliciting Materials ), complies in all material respects with Regulation D promulgated under the Securities Act ( Regulation D ) and does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading.
ARTICLE V
[RESERVED]
ARTICLE VI
REPRESENTATIONS AND WARRANTIES OF PURCHASER AND MERGER SUB
Except as set forth in the correspondingly numbered Section of the Purchaser Disclosure Schedules (which disclosures shall reference the specific sections and subsections below, as applicable, but shall also qualify other sections or subsections in this ARTICLE VI and in the Purchaser Disclosure Schedules to the extent it is reasonably apparent on its face from a reading of the disclosure item that the disclosure is applicable to the other section or subsection), Purchaser and Merger Sub represent and warrant to Target that the statements contained in this ARTICLE VI are true and correct.
Section 6.01 Organization of Purchaser and Merger Sub . Purchaser is a corporation duly organized, validly existing and in good standing under the Laws of the State of Delaware. Merger Sub is a limited liability company duly organized, validly existing and in good standing under the Laws of the State of Delaware. Each of Purchaser and Merger Sub has full corporate power and authority to own, operate, or lease the properties and assets now owned, operated, or leased by it and to carry on its business as it has been and as currently conducted by it. Each of
Purchaser and Merger Sub is duly licensed or qualified to do business and is in good standing in each jurisdiction in which the ownership of its assets or the operation of its business as currently conducted makes such licensing or qualification necessary, except where Purchasers or Merger Subs failure to qualify to do business or be in good standing would not be reasonably likely to have, individually, or in the aggregate, a Purchaser Material Adverse Effect.
Section 6.02 Authority of Purchaser and Merger Sub . Each of Purchaser and Merger Sub has full power and authority to enter into this Agreement and the other Transaction Documents to which either Purchaser or Merger Sub is a party, to carry out their obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery by Purchaser and Merger Sub of this Agreement and any other Transaction Document to which either Purchaser or Merger Sub is a party, the performance by Purchaser and Merger Sub of their obligations hereunder and thereunder and the consummation by Purchaser and Merger Sub of the transactions contemplated hereby and thereby have been duly authorized by all requisite corporate action on the part of Purchaser and Merger Sub. This Agreement has been duly executed and delivered by Purchaser and Merger Sub, and (assuming due authorization, execution and delivery by the Target) this Agreement constitutes a legal, valid and binding obligation of Purchaser and Merger Sub enforceable against Purchaser and Merger Sub in accordance with its terms except as such enforceability may be limited by principles of public policy and subject to the laws of general application relating to bankruptcy, insolvency and the relief of debtors. When each other Transaction Document to which Purchaser or Merger Sub is or will be a party has been duly executed and delivered thereby (assuming due authorization, execution and delivery by each other party thereto), such Transaction Document will constitute a legal and binding obligation of Purchaser and Merger Sub, as applicable, enforceable against it in accordance with its terms except as such enforceability may be limited by principles of public policy and subject to the laws of general application relating to bankruptcy, insolvency and the relief of debtors.
Section 6.03 No Conflicts; Consents . Except as set forth on Section 6.03 of the Purchaser Disclosure Schedules, the execution, delivery and performance by Purchaser and Merger Sub of this Agreement and the other Transaction Documents to which each is a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not: (a) conflict with or result in a violation or breach of, or default under, any provision of the Purchaser Charter Documents; (b) conflict with or result in a violation or breach of any provision of any Law or Governmental Order applicable to Purchaser or Merger Sub; or (c) require the consent, notice or other action by any Person under any Contract to which Purchaser or Merger Sub is a party. Other than the filing of the Certificate of Merger with the Secretary of State of the State of Delaware, no consent, approval, Permit, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required by or with respect to Purchaser or Merger Sub in connection with the execution and delivery of this Agreement and the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby.
Section 6.04 Brokers . No broker, finder or investment banker is entitled to any brokerage, finders or other fee or commission in connection with the transactions contemplated
by this Agreement or any other Transaction Document based upon arrangements made by or on behalf of Purchaser or Merger Sub.
Section 6.05 Financial Statements . Complete copies of the audited financial statements of Purchaser consisting of the balance sheet as of December 31 in each of the years 2013 and 2014 and the related statements of income and retained earnings, stockholders equity and cash flow for the years then ended (the Purchaser Annual Financial Statements ), and unaudited financial statements of Purchaser consisting of the balance sheet as of March 31, 2015 and the related statements of income and retained earnings, stockholders equity and cash flow for the three (3)-month period then ended (the Purchaser Interim Financial Statements and together with the Purchaser Annual Financial Statements, the Purchaser Financial Statements ) are included in Section 6.05 of the Purchaser Disclosure Schedules. The Purchaser Financial Statements have been prepared in accordance with GAAP applied on a consistent basis throughout the period involved, subject, in the case of the Purchaser Interim Financial Statements, to normal and recurring year-end adjustments (the effect of which will not be materially adverse) and the absence of footnotes. Except as set forth on Section 6.05 of the Purchaser Disclosure Schedules, there has been no material change in Purchasers accounting policies since the December 31, 2014.
Section 6.06 Litigation . Except as set forth in Section 6.06 of the Purchaser Disclosure Schedules, there is no Action pending or, to the actual knowledge of Purchaser or Merger Sub, threatened, against Purchaser or Merger Sub, respectively, or that challenge or seek to prevent, enjoin, or otherwise delay the transactions contemplated by this Agreement or the Transaction Documents. Except as set forth in Section 6.06 of the Purchaser Disclosure Schedules, neither Purchaser or Merger Sub is subject to any outstanding Governmental Order that, in either case, would be reasonably likely, individually or in the aggregate, to have a Purchaser Material Adverse Effect.
Section 6.07 Financing . Purchaser will, at the Effective Time, have sufficient currently available funds on hand (including, for these purposes, funds that currently may be drawn down under existing lines of credit), to consummate the Merger, including, without limitation, to (a) pay the aggregate Per Share Cash Closing Consideration pursuant to this Agreement, and (b) pay all outstanding fees and expenses of Purchaser and Merger Sub in connection with the Merger.
Section 6.08 Intellectual Property . Purchaser and its Subsidiaries own or possess valid and enforceable rights to use all trademarks, service marks, trade names, trade dress, domain names, patents, inventions, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), software, publicity rights, privacy rights and all other intellectual property (including all goodwill associated with, and registrations and applications for registration of, any of the foregoing) (collectively, Purchaser Intellectual Property ) material to the conduct of the business of Purchaser and its Subsidiaries taken as a whole, as conducted or proposed to be conducted, and the conduct of their respective businesses does not infringe, misappropriate, or violate any intellectual property rights of others in any material respect. To Purchasers actual knowledge, no party has materially infringed, misappropriated or otherwise violated any
Intellectual Property owned by or exclusively licensed to Purchaser or any of its subsidiaries. There is no material pending, or to Purchasers actual knowledge, threatened, action, suit, proceeding or claim by others (A) alleging that Purchaser is infringing, misappropriating or otherwise violating any Intellectual Property of others, or (B) challenging Purchasers or its Subsidiaries rights in or to, or the validity, enforceability, scope or ownership of, any Purchaser Intellectual Property owned by or licensed to Purchaser or its subsidiaries;
Section 6.09 Taxes. Except as set forth on Section 6.09 of the Purchaser Disclosure Schedule, Purchaser has filed all Tax Returns that are required to have been filed with appropriate Governmental Authorities. Except as set forth on Section 6.09 of the Purchaser Disclosure Schedule, all such Tax Returns were true and correct in all material respects at the time made. Purchaser has paid or established reserves (such reserves are adequate for Taxes due or accrued as of the date hereof) for all income, franchise, and other Taxes due and payable by it on or before the Effective Time. Purchaser has no actual knowledge of any assessments or adjustments pending or threatened against Purchaser for any period.
Section 6.10 No Material Change . Except as set forth in Section 6.10 of the Purchaser Disclosure Schedule, between March 31, 2015 and the date of this Agreement, there has not occurred any Purchaser Material Adverse Effect.
Section 6.11 Status of Purchaser Common Stock to be Issued . The shares of Purchaser Common Stock to be issued as a portion of the Aggregate Merger Consideration will be reserved for issuance prior to issuance and, when issued, will be duly authorized and validly issued, fully paid, nonassessable, and free of preemptive or other similar rights. The issuance of the Purchaser Common Stock pursuant to this Agreement will not be integrated with the issuance of any other Equity Interest under the Act or the rules and regulations of the SEC thereunder, in either case so as to subject such offering, issuance, or sale of the Purchaser Common Stock to the registration provisions of the Act. The offer, sale, and issuance of the Purchaser Common Stock pursuant to this Agreement will be exempt from the registration requirements of the Securities Act, and will have been registered or qualified (or are exempt from registration and qualification) under the registration, permit, or qualification requirements of all applicable state securities laws. Neither Purchaser, Merger Sub, nor any Purchaser Related Person is a bad actor within the meaning of Rule 506(d) promulgated under the Act. Purchaser Related Person means a person or entity, that, with respect to Purchaser, is covered by the Bad Actor disqualification provision of Rule 506(d) of the Securities Act.
Section 6.12 No Audit or Investigation . To the actual knowledge of Purchaser, neither Purchaser nor Merger Sub is or has, within the last five (5) years, been the target or subject of any audit, inspection, inquiry or investigation by the SEC or the IRS relating to any actual illegal activity on the part of any of Purchaser, Merger Sub, their Subsidiaries or any of their respective officers or directors.
Section 6.13 Compliance with Law . Except as specified in Section 6.13 of the Purchaser Disclosure Schedules, Purchaser, Merger Sub, and their business currently is in compliance with all Laws or other rules or regulations of any Governmental Authority applicable to Purchaser, Merger Sub, their business, or by which any property or asset of Purchaser or
Merger Sub is bound, relating to the operation of their business as heretofore conducted, except where Purchasers or Merger Subs failure to maintain compliance would not be reasonably likely to have, individually or in the aggregate, a Purchaser Material Adverse Effect.
Section 6.14 Information Statement . Effective as of the date that such information is provided by Purchaser, Purchaser represents that all information provided by Purchaser for inclusion in the Soliciting Materials complies in all material respects with Regulation D and does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading.
Section 6.15 Capitalization of Purchaser . Section 6.15 of the Purchaser Disclosure Schedules sets forth a schedule of the aggregate issued and outstanding Equity Interests of Purchaser as of the date of this Agreement on both a class-by-class and an as-converted-to- Purchaser Common Stock basis. Except for the obligation, pursuant to certain employment agreements and employee offer letters, to issue options to acquire shares of Purchaser Common Stock in an aggregate amount which does not exceed the remaining shares reserved for issuance under Teladocs Second Amended and Restated Stock Incentive Plan (as amended), there are no existing rights to acquire from Purchaser or other contractual obligations of Purchaser to issue any Equity Interest of Purchaser. There are no outstanding or authorized equity appreciation or phantom equity rights with respect to Purchaser.
ARTICLE VII COVENANTS
Section 7.01 Conduct of Business. Target shall, during the period from the date of this Agreement until the earlier to occur of the Effective Time or the termination of this Agreement in accordance with its terms, except as expressly contemplated by this Agreement or as required by applicable Law or with the prior written consent of Purchaser, conduct its business in the ordinary course of business consistent with past practice, and, to the extent consistent therewith, use its commercially reasonable efforts to preserve substantially intact its business organization, to keep available the services of its officers and employees, to preserve its present relationships with customers, suppliers, vendors, distributors, resellers, licensors, licensees, Engaged Professionals and other Persons having business relationships with it. Without limiting the generality of the foregoing, between the date of this Agreement and the Effective Time, except as otherwise expressly contemplated by this Agreement or as required by applicable Law, Target shall not, without the prior written consent of Purchaser:
(a) amend Targets certificate of incorporation or any other Target Charter Documents;
(b) (i) repurchase, redeem or otherwise acquire any Equity Interests of Target, (ii) declare, set aside or pay any dividend or other distribution (whether in cash, Equity Interests of Target, property or otherwise) in respect of, or enter into any Contract with respect to the voting of, any Equity Interests of Target or (iii) reclassify, combine, split or subdivide any Equity Interests of Target;
(c) issue, sell, pledge, dispose of, grant or encumber any Equity Interests of Target, other than (i) the issuance of shares of Target Common Stock upon the conversion, in accordance with the Target Charter Documents, of Target Preferred Stock issued and outstanding on the date hereof, or (ii) the issuance of shares of Target Common Stock in accordance with the exercise (in accordance with the terms of such stock options, warrants or other rights) of stock options, warrants, or other rights outstanding on the date hereof;
(d) except as required by applicable Law or by any Benefit Plan or Contract in effect as of the date of this Agreement, (i) increase the compensation payable or that could become payable by the Target to its Representatives, independent contractors or any Engaged Professionals, other than increases in compensation made in the ordinary course of business consistent with past practice, (ii) enter into any new or amend in any material respect, any existing employment, severance, retention or change in control agreement with any of its past or present Representatives, or (iii) establish, adopt, enter into, amend, terminate, exercise any discretion under, or take any action to accelerate rights under any Benefit Plans, or make any contribution to any Benefit Plan, other than contributions required by Law, the terms of such Benefit Plans as in effect on the date hereof or that are made in the ordinary course of business consistent with past practice;
(e) (i) acquire (including, without limitation, by merger, consolidation, acquisition of stock or assets, or otherwise) any business, Person, division thereof or other significant amount of assets or (ii) make any loans, advances or capital contributions to or investments in any Person;
(f) (i) transfer, license, sell, lease or otherwise dispose of any assets (whether by way of merger, consolidation, sale of stock or assets, or otherwise) of Target or (ii) cause or permit to exist any Encumbrance on the assets of Target;
(g) repurchase, prepay, incur or guarantee any Indebtedness;
(h) amend or modify in any material respect, or consent to the termination of (other than at its stated expiry date), any Material Contract;
(i) institute, settle or compromise any Actions pending or threatened before any Governmental Authority;
(j) except as required by applicable Law, make any material change in any method of financial accounting principles or practices;
(k) (i) settle or compromise any Tax claim, audit or assessment, (ii) make or change any Tax election, change any annual Tax accounting period, adopt or change any method of Tax accounting, (iii) amend any material Tax Returns or file claims for material Tax refunds, or (iv) enter into any closing agreement, surrender in writing any right to claim a Tax refund, offset or other reduction in Tax liability or consent to any extension or waiver of the limitation period applicable to any Tax claim or assessment relating to Target;
(l) enter into any agreement, agreement in principle, letter of intent, memorandum of understanding or similar Contract with respect to any joint venture, strategic partnership or alliance;
(m) abandon, encumber, convey title (in whole or in part), exclusively license or grant any right or other licenses to Target Intellectual Property;
(n) cause the voluntary or involuntary liquidation, reorganization or winding up of the Target;
(o) authorize or make capital expenditures which are greater than $25,000 individually or $100,000 in the aggregate;
(p) hire or otherwise enter into an arrangement with an employee or Engaged Professional, other than in the ordinary course of business consistent with past practice and in an amount less than Sixty Thousand Dollars ($60,000); or
(q) agree, commit or announce an intention to do any of the foregoing.
Section 7.02 Other Actions. From the date of this Agreement until the earlier to occur of the Effective Time or the termination of this Agreement in accordance with its terms, none of Purchaser, Merger Sub, nor Target shall take, or agree or commit to take, any action that would reasonably be expected to, individually or in the aggregate, prevent, materially delay or materially impede the consummation of the Merger or the other transactions contemplated by this Agreement.
Section 7.03 Access to Information . From the date of this Agreement until the earlier to occur of the Effective Time or the termination of this Agreement in accordance with its terms, Target shall afford to Purchaser and its Representatives access, at reasonable times and in a manner as shall not unreasonably interfere with the business or operations of Target, to the Representatives, offices and other facilities and to all books, records, Contracts and other assets of Target, and Target shall furnish promptly to Purchaser and its Representatives such other information concerning Target as Purchaser may reasonably request from time to time. Target shall not be required to provide access to or disclose information where such access or disclosure would contravene any Law (it being agreed that the parties shall use their commercially reasonable efforts to cause such information to be provided in a manner that would not result in such contravention).
Section 7.04 Exclusivity; No Shop; Break-Up Fee .
(a) Target and its Representatives immediately shall cease and cause to be terminated all existing discussions or (formal or informal) negotiations with any Persons (other than Purchaser, Merger Sub and their Affiliates and Representatives) conducted heretofore with respect to a Prohibited Transaction. Target shall not release any Person (other than Purchaser, Merger Sub and their Affiliates and Representatives) from, or waive any provision of, any confidentiality or standstill agreement to which it is a party and Target shall also agree to promptly request each Person that has heretofore executed a confidentiality agreement in connection with its consideration of acquiring (whether by merger, acquisition of stock or assets or otherwise) Target, if any, to return (or if permitted by the applicable confidentiality agreement, destroy) all confidential information heretofore furnished to such Person by or on behalf of Target and, if requested by Purchaser, to enforce such Persons obligation to do so.
(b) In consideration of the substantial expenditures of time, effort and money to be undertaken by Purchaser in connection with the preparation and execution of this Agreement and the other Transaction Documents and due diligence investigations, Target hereby undertakes and agrees that for the period commencing on the date of this Agreement and terminating upon the earlier of the Effective Time or the termination of this Agreement in accordance with its terms (the Restriction Period ), Target shall not, and it shall cause its Stockholders, Optionholders and Representatives not to (i) maintain, enter into or conduct any negotiations, discussions or have any other communications of any kind with any Person (other than Purchaser, Merger Sub and their respective Affiliates and Representatives) regarding or in pursuit of a Prohibited Transaction, (ii) solicit, initiate, encourage or otherwise facilitate (including by way of furnishing any non-public information concerning the Business or Targets properties or assets) any inquiry or proposal regarding a Prohibited Transaction. Target shall notify Purchaser as promptly as practicable (and in any event within one (1) Business Day after the Target becomes aware thereof), orally and in writing, if any proposal or offer, or any inquiry or contact with any Person with respect thereto, regarding a Prohibited Transaction is made, specifying the material terms and conditions thereof and the identity of the Person making such proposal or offer or inquiry or contact (including material amendments or proposed material amendments) and shall provide Purchaser with a copy of any such written offer or inquiry. Target shall provide Purchaser with at least forty eight (48) hours prior notice (or such lesser prior notice as is provided to the members of the Target Board) of any meeting of the Target Board at which it is reasonably expected to consider any Prohibited Transaction. In the event that Target or any Stockholder, Optionholder or Representative of Target agrees to a Prohibited Transaction with another party during the Restriction Period or fifteen (15) days thereafter, Target shall be obligated to pay to Purchaser the sum of One Million Dollars and No/100 ($1,000,000.00) (the Break-up Fee ). The Break-up Fee shall be due and payable concurrently with the execution of any definitive agreement providing for a Prohibited Transaction. Notwithstanding anything to the contrary in this Agreement, the parties hereby acknowledge that in the event that the Break-up Fee pursuant to this Section 7.04 becomes payable and is paid by Target pursuant to this Section 7.04 , the Break-up Fee shall be paid by Target to Purchaser and Merger Sub as liquidated damages, and shall be Purchasers and Merger Subs sole and exclusive remedy pursuant to this Agreement and the Transaction Documents with respect to Targets entry into a Prohibited Transaction. The parties agree that quantifying Losses arising from Targets entry into a Prohibited Transaction is inherently difficult and further stipulate that the Break-up Fee is not a penalty, but rather a reasonable measure of Losses, based upon the management time and expenses incurred in pursuing the transactions contemplated by this Agreement and given the nature of the Losses that may result.
Section 7.05 Notices of Certain Events.
(a) From the date of this Agreement until the earlier to occur of the Effective Time or the termination of this Agreement in accordance with its terms, Target shall notify Purchaser promptly of (A) any notice or other communication from any Person alleging that the consent of such Person is or may be required in connection with the transactions contemplated by this Agreement, (B) any notice or other communication from any Governmental Authority in connection with the transactions contemplated by this Agreement, (C) any Actions commenced or threatened against, relating to or involving Target or, to Targets Knowledge, any Stockholder
or Optionholder (in their capacities as such), and (D) any fact, event, change or effect which (x) has or could be expected to have, individually or in the aggregate, a Material Adverse Effect, (y) has resulted in, or could reasonably be expected to result in, any representation or warranty made by Target hereunder or, to Targets Knowledge, by any Stockholder or Optionholder under any Letter of Transmittal or Option Cancellation Agreement not being true and correct or (z) has resulted in, or could reasonably be expected to result in, the failure of any of the conditions set forth in ARTICLE VIII to be satisfied. In no event shall the delivery of any notice pursuant to this Section 7.05(a) limit or otherwise affect the respective rights, obligations, representations, warranties, covenants or agreements of the parties or the conditions to the obligations of the parties under this Agreement including with respect to indemnification.
(b) From the date of this Agreement until the earlier to occur of the Effective Time or the termination of this Agreement in accordance with its terms, Target shall prepare unaudited monthly balance sheets and related unaudited monthly statements of income and retained earnings in the ordinary course of business, and promptly deliver such monthly statements to Purchaser (at which time such statements shall be attached to Section 4.04 of the Target Disclosure Schedules and shall constitute Interim Financial Statements for purposes of this Agreement).
(c) From the date of this Agreement until the earlier to occur of the Effective Time or the termination of this Agreement in accordance with its terms, Target shall give Purchaser prompt notice of any stockholder or other Equity Interest holder Action against Target or its officers or directors, and Target shall not settle any such Action without the prior consent of Purchaser, which shall not be unreasonably withheld, delayed or conditioned. Except as expressly stated otherwise in this Section 7.05(c) , the party named in any stockholder or other Equity Interest holder Action shall control and make all decisions related to such stockholder Action.
Section 7.06 Efforts; Approvals and Consents.
(a) Upon the terms and subject to the conditions set forth in this Agreement, each of the parties hereto shall use commercially reasonable efforts to take, or cause to be taken, all actions, and to do, or cause to be done, and to assist and cooperate with the other parties in doing, all things necessary, proper or advisable to consummate and make effective, and to satisfy, in the most expeditious manner practicable, all conditions to the transactions contemplated by this Agreement.
(b) Each party hereto shall, as promptly as practicable, (i) make, or cause or be made, all filings and submissions required under any Law applicable to such party or any of its Affiliates; and (ii) use reasonable best efforts to take, or cause to be taken, all appropriate action, and to do, or cause to be done, all things necessary, proper or advisable under applicable Laws or otherwise to consummate and make effective the Merger, including, without limitation, using its commercially reasonable efforts to obtain, or cause to be obtained, all consents, authorizations, orders and approvals from all Governmental Authorities or other Persons that may be or become necessary or advisable for the performance of its obligations pursuant to this Agreement and the other Transaction Documents. Each party shall cooperate fully with the other parties and their
Affiliates in promptly seeking to obtain all such consents, authorizations, orders and approvals. The parties hereto shall not willfully take any action that will have the effect of delaying, impairing or impeding the receipt of any required consents, authorizations, orders and approvals.
(c) Without limiting the generality of the parties undertakings pursuant to subsections (a) and (b) above, each of the parties hereto shall use commercially reasonable efforts to:
(i) respond to any inquiries by any Governmental Authority regarding antitrust or other matters with respect to the transactions contemplated by this Agreement or any other Transaction Document;
(ii) avoid the imposition of any order or the taking of any action that would restrain, alter or enjoin the transactions contemplated by this Agreement or any other Transaction Document; and
(iii) in the event any Governmental Order adversely affecting the ability of the parties to consummate the transactions contemplated by this Agreement or any other Transaction Document has been issued, to have such Governmental Order vacated or lifted.
(d) Notwithstanding the foregoing, nothing in this Section 7.06 shall require, or be construed to require, Purchaser, the Surviving Company, Merger Sub or any of their Affiliates to enter into any consent decree, hold separate orders or other arrangements, that (i) requires any such Person to sell, hold, divest, discontinue or limit, before or after the Closing Date, any assets, businesses or interests of Purchaser, the Surviving Company, Merger Sub or any of their Affiliates; (ii) includes any conditions relating to, or changes or restrictions in, the operations of any such assets, businesses or interests; or (iii) requires any material modification or waiver of the terms and conditions of this Agreement.
(e) If any fair price, business combination or control share acquisition statute or other similar statute or regulation is or may become applicable to the Merger, Purchaser, Merger Sub or Target, as applicable, shall take such actions as are necessary so that the transactions contemplated by this Agreement may be consummated as promptly as practicable on the terms contemplated hereby and otherwise act to eliminate or minimize the effects of any such statute or regulation on the Merger.
Section 7.07 Confidentiality . From and after the Closing, Target shall cause its Affiliates and Representatives to, hold in strict confidence any and all documents or information, whether written or oral, concerning the Target or its business. The parties agree that information concerning the Target and its business is not confidential to the extent that Target can show that such information (a) is generally available to and known by the public through no fault of Target or any of its Affiliates or their respective Representatives; or (b) is lawfully acquired by Target or any of its Affiliates or their respective Representatives from and after the Closing from sources which are not prohibited from disclosing such information by a legal, contractual or fiduciary obligation. If Target or any of its Affiliates or their respective Representatives are compelled to disclose any information by judicial or administrative process or by other requirements of Law, Target shall promptly notify Purchaser in writing and shall disclose only
that portion of such information which Target is advised by its counsel in writing is legally required to be disclosed, provided that Target shall use commercially reasonable efforts to obtain an appropriate protective order or other reasonable assurance that confidential treatment will be accorded such information.
Section 7.08 Tax Matters.
(a) Preparation and Filing of Tax Returns; Payment of Taxes.
(i) At its expense, Target shall prepare and timely file or shall cause to be prepared and timely filed all Tax Returns for Target due on or prior to the Closing. Target shall make or cause to be made all payments required with respect to any such Tax Returns to the extent any such Taxes are not included in the Closing Accrued Tax Amount. Unless otherwise required by Law, all such Tax Returns shall be prepared in a manner consistent with past practice and on a basis consistent with the last previous similar Tax Return. At least 15 days prior to the date on which any such Tax Return is to be filed, Target shall submit such Tax Return to Purchaser for Purchasers review and approval, which shall be deemed granted if no written objection is received within such 15 day period. If Purchaser timely objects to the filing of any such Tax Return, Purchaser and the Equityholder Representative shall use their commercially reasonable efforts to negotiate a resolution of such objections, provided that if a resolution is not reached within ten (10) days following the Targets receipt of the Purchasers written objection, Target may proceed to file such Tax Return without change.
(ii) Purchaser shall prepare and timely file or shall cause to be prepared and timely filed, all Tax Returns for the Surviving Company and for Target required to be filed after the Closing Date. Purchaser shall make or cause to be made all payments required with respect to any such Tax Returns, provided that, to the extent that any such Taxes are not included in the Closing Accrued Tax Amount, Purchaser shall be entitled to reimbursement from the Stockholders and Optionholders for (x) any such Taxes that are payable with respect to a Pre- Closing Tax Period, and (y) any such Taxes that are payable with respect to a taxable period that begins on or before the Closing Date and ends after the Closing Date (a Straddle Period ) and which are allocable to the Stockholders and Optionholders in accordance with Section 7.08(a)(iii) below. If any amount is due to Purchaser by the Stockholders and Optionholders pursuant this Section, then (A) Purchaser and the Equityholder Representative shall first jointly instruct the Escrow Agent to disburse such amount (which may be satisfied in cash, stock, other property or a combination thereof, at Purchasers discretion) from the Escrow Fund , and (B) to the extent that any amount remains due following such disbursement in accordance with clause (A), such amount shall immediately be paid by the Stockholders and Optionholders by wire transfer of immediately available funds to such account as directed by the Purchaser.
(iii) In the case of Taxes that are payable with respect to a Straddle Period, the portion of any such Tax that is allocable to the portion of the period ending on and including the Closing Date (and which Taxes shall be borne by the Stockholders and Optionholders) shall be:
(A) in the case of Taxes that are either (x) based upon or related to income or receipts or (y) imposed in connection with any sale or
other transfer or assignment of property (real or personal, tangible or intangible), deemed equal to the amount which would be payable if the taxable year ended on and included the Closing Date (an interim closing of the books); and
(B) in the case of Taxes imposed on a periodic basis with respect to the assets of Target, or otherwise measured by the level of any item, deemed to be the amount of such Taxes for the entire period (or, in the case of such Taxes determined on an arrears basis, the amount of such Taxes for the immediately preceding period), multiplied by a fraction the numerator of which is the number of calendar days in the period ending on and including the Closing Date and the denominator of which is the number of calendar days in such Straddle Period.
(iv) At least 15 days prior to the date on which any Pre-Closing Tax Period or Straddle Period Tax Return is to be filed, the Purchaser shall submit such Tax Return to the Equityholder Representative for the Equityholder Representatives review and approval, which approval will not be unreasonably withheld, conditioned or delayed; and shall be deemed granted if no written objection is received within such 15 day period. If Equityholder Representative timely objects to the filing of any such Pre-Closing Tax Period or Straddle Period Tax Return, Purchaser and the Equityholder Representative shall use their commercially reasonable efforts to negotiate a resolution of such objections, provided that if a resolution is not reached within ten (10) days following Purchasers receipt of the Equityholder Representatives written objection, Purchaser may proceed to file such Pre-Closing Tax Period or Straddle Period Tax Return without change.
(b) Cooperation. After the Closing Date, Target and the Equityholder Representative, on one hand, and Purchaser and the Surviving Company, on the other hand, shall:
(i) Use commercially reasonable efforts to cooperate fully in preparing for any audits of, or disputes with taxing authorities regarding, any Tax Returns relating to Target, the Surviving Company or their businesses and make available to the other and to any taxing authority as reasonably requested all information, records, and documents relating to Liabilities for, or exemption from, Taxes associated with Target, the Surviving Company or their businesses as set forth in this Agreement. Any information or documents provided under this Section 7.08(b) shall be kept confidential by the party receiving such information or documents, except as may otherwise be necessary in connection with the filing of Tax Returns or in connection with administrative or judicial proceedings relating to Taxes;
(ii) Make available to the other, as reasonably requested and available, personnel responsible for preparing or maintaining information, records and documents in connection with Taxes as well as any related litigation;
(iii) Preserve all such information, records, and documents until the expiration of any applicable statutes of limitation or extensions thereof and as otherwise required by Law; and
(iv) Provide timely notice to the other in writing of any pending or threatened Tax audits or assessments related to Target, the Surviving Company or their businesses for periods beginning prior to the Closing Date, and furnish the other with copies of all correspondence received from any taxing authority in connection with any Tax audit or information request with respect to any such period.
(c) Tax Sharing Agreements. All tax sharing agreements or similar agreements with respect to or involving Target shall be terminated as of the Closing Date and, after the Closing Date, Purchaser and the Surviving Company shall not be bound thereby or have any Liability thereunder.
Section 7.09 Public Announcements . Unless otherwise required by applicable Law (based upon the reasonable advice of counsel), no party to this Agreement shall make any public announcements in respect of this Agreement or the transactions contemplated hereby or otherwise communicate with any news media without the prior written consent of both Purchaser and the Equityholder Representative (which consent shall not be unreasonably withheld or delayed), and the parties shall cooperate as to the timing and contents of any such announcement.
Section 7.10 [Reserved].
Section 7.11 Further Assurances . Following the Closing, each of the parties hereto shall, and shall cause their respective Affiliates to, execute and deliver such additional documents, instruments, conveyances and assurances and take such further actions as may be reasonably required to carry out the provisions hereof and give effect to the transactions contemplated by this Agreement and the other Transaction Documents.
Section 7.12 Benefit Plans. As of the Effective Time, Target will, at its expense or at the expense of the applicable Benefit Plan, (i) terminate the participation of employees of Target from all Benefit Plans and (ii) take such actions as are necessary to make, or cause such Benefit Plans to make, timely appropriate distributions to such employees to the extent required or permitted by, and in accordance with, such Benefit Plans and applicable Law. In furtherance of the foregoing, Target will, at its expense or at the expense of the applicable Benefit Plan, adopt resolutions terminating, effective no later than the day prior to the Effective Time, any Benefit Plan which is intended to meet the requirements of Section 401(k) of the Code, and which is sponsored, or contributed to, by the Target or any of its Subsidiaries (collectively, the Target 401(k) Plan). At the Closing, the Target shall provide to Purchaser (a) executed resolutions of the Target Board authorizing such termination, and (b) an executed amendment to the Target 401(k) Plan sufficient to assure compliance with all applicable requirements of the Code and regulations thereunder so that the tax-qualified status of the Target 401(k) Plan will be maintained at the time of termination. Target will fully fund and distribute all benefits provided under any Target 401(k) Plan intended to be qualified under Sections 401 of the Code
maintained or contributed to by Target or any of its Affiliates within thirty (30) days after Closing. This Section 7.12 shall survive Closing.
Section 7.13 Healthcare Information Laws Compliance Investigations . Target shall use commercially reasonable efforts to cause each Principal, after the date of this Agreement, to cooperate with the reasonable requests of the Surviving Company or Purchaser at the Surviving Companys or Purchasers expense, as applicable, in responding to any investigation conducted by (i) a Governmental Authority or (ii) a Target or Surviving Company customer, or (iii) Surviving Company or Purchaser related to compliance by Target with Healthcare Information Laws or other Laws prior to the Effective Time.
Section 7.14 Directors and Officers Indemnification. Prior to the Closing, Target shall obtain and fully pay for tail insurance policies with a claims period of at least six (6) years from the Effective Time with at least the same coverage and amount and containing terms and conditions that are not less advantageous to the directors and officers of Target as Targets existing policies with respect to claims arising out of or relating to events which occurred before or at the Effective Time (including in connection with the transactions contemplated by this Agreement) (the D&O Tail Policy ). Target shall bear the cost of the D&O Tail Policy, and such costs, to the extent not paid prior to the Closing, shall be included in the determination of Transaction Expenses. During the term of the D&O Tail Policy, Purchaser shall not (and shall cause the Surviving Company not to) take any action following the Closing to cause the D&O Tail Policy to be cancelled or any provision therein to be amended or waived; provided, that neither Purchaser, the Surviving Corporation nor any Affiliate thereof shall be obligated to pay any premiums or other amounts in respect of such D&O Tail Policy. During the term of the D&O Tail Policy, Purchaser and the Surviving Company shall not adopt, amend or modify the Surviving Companys charter documents in a manner that would result in the termination or limitation of the indemnification protections provided under the Target Charter Documents to Targets officers, directors, and agents immediately prior to the Effective Time. Notwithstanding anything herein to the contrary, in no event will any current or former director, officer or agent of Target be entitled to indemnification or advancement or reimbursement of expenses from Purchaser or the Surviving Company in respect of any Losses that are subject to indemnification in their capacity as a Stockholder or Optionholder pursuant to this Agreement or any other Transaction Document.
Section 7.15 Equityholder and Employee Claims . Target and the Equityholder Representative shall provide notice to Purchaser and Merger Sub promptly following receipt (and in no event later than five (5) Business Days following the date of receipt) of any Equityholder and Employee Claim.
Section 7.16 Stockholders Consent .
(a) In connection with seeking the Target Stockholder Approval, within fifteen (15) Business Days following the execution of this Agreement, Target shall deliver an information statement describing this Agreement, the Merger and the other transactions contemplated hereby (the form and substance of which shall be mutually agreed by Target and Purchaser) to the Stockholders for the purpose of soliciting the Target Stockholder Approval and acknowledging
the conversion of the Target Preferred Stock into shares of Target Common Stock (such information statement, together with the attachments thereto, the Information Statement ). Additionally, a copy of the Information Statement shall be delivered by Target to the Optionholders. Purchaser and Target agree to provide promptly to the other such information concerning its business and financial statements and affairs as, in the reasonable judgment of the providing party or its counsel, may be required or appropriate for inclusion in the Information Statement or in any amendments or supplements to the Information Statement. Each of the parties hereto will promptly advise the other parties in writing if at any time prior to the Effective Time any party shall obtain knowledge of any facts that might make it necessary or appropriate to amend or supplement the Information Statement or any other Soliciting Materials in order to make the statements contained or incorporated by reference therein not misleading or to comply with applicable Law. The Target Board will recommend to the Stockholders that such Stockholders adopt this Agreement and the transactions contemplated hereby, and the Information Statement shall contain such recommendation, as well as the conclusion of the Target Board that the terms and conditions of the Merger are in the best interests of the Stockholders in the opinion of the Target Board. The Information Statement shall provide the Stockholders to whom it is sent with notice to Stockholders of their dissent and appraisal rights pursuant to Section 262 of the DGCL. The Information Statement shall include therewith a copy of Section 262 of Delaware Law and all such other information as Purchaser shall reasonably request, and shall be sufficient in form and substance to start the twenty (20) day period during which a Stockholder must demand appraisal of such Persons Target Shares as contemplated by Section 262(d)(2) of the DGCL. Notwithstanding anything to the contrary contained herein, Purchaser and Target shall not include in the Information Statement any information with respect to Purchaser, Merger Sub or their respective Affiliates or Representatives, the form and content of which information shall not have been approved by Purchaser prior to such inclusion. The Target Board shall not alter, modify, change or revoke its approval of this Agreement, the Merger and the transactions contemplated hereby, nor shall Target or the Target Board encourage or solicit the Stockholders to alter, modify, change or revoke their approval of this Agreement, the Merger and the transactions contemplated hereby. All Soliciting Materials submitted to the Stockholders in accordance with this Section 7.16(a) shall be subject to Purchasers advance review and reasonable approval.
(b) Target shall use its commercially reasonable efforts to obtain, as soon as practicable following the delivery of the Information Statement, the Target Stockholder Approval pursuant to the Written Consent. Promptly following receipt of the Written Consent, Target shall deliver a copy of such Written Consent to Purchaser.
(c) Promptly following, but in no event later than fifteen (15) Business Days after, receipt of the Written Consent executed by the Principals, Target shall prepare and mail a notice (the Stockholder Notice ) to every Stockholder that did not execute the Written Consent.
(d) In addition, Target shall submit for approval by the Stockholders by the requisite vote (and in a manner reasonably satisfactory to Purchaser) any payments or benefits that Purchaser determines may constitute a parachute payment pursuant to Section 280G of the Code, such that all such payments and benefits shall not be deemed to be parachute payments pursuant to Section 280G of the Code or shall be exempt from such treatment under such Section
280G, and deliver to Purchaser evidence reasonably satisfactory to Purchaser that a vote of Stockholders was held in conformance with Section 280G and the regulations thereunder, or that such requisite Stockholder approval has not been obtained with respect to any payment or benefit that may be deemed to constitute a parachute payment within the meaning of Section 280G of the Code and as a consequence, that such parachute payment shall not be made or provided.
Section 7.17 Securities Law Compliance .
(a) The shares of Purchaser Common Stock issuable to the Stockholders pursuant to this Agreement are intended to be issued pursuant to an exemption or exemptions from registration under Regulation D and the exemption from qualification under the Laws of applicable state securities laws. The certificates for shares of Purchaser Common Stock to be issued in the Merger shall bear appropriate legends to identify such privately placed shares as being restricted under the Securities Act and to comply with applicable state securities laws.
(b) As promptly as practical after the Closing, Purchaser shall prepare and make such filings as are required under applicable blue sky laws relating to the transactions contemplated by this Agreement. The Equityholder Representative shall assist Purchaser as may be necessary to provide Purchaser the information necessary to enable it to comply with the securities and blue sky laws relating to the transactions contemplated by this Agreement.
(c) The shares of Purchaser Common Stock to be issued in connection with this Agreement have not been registered under the Securities Act and/or state securities blue sky laws. The offering of the shares of Purchaser Common Stock contemplated hereby is to be effected pursuant to an exemption from the registration requirements imposed by such laws and Purchaser is under no obligation to register the shares of Purchaser Common Stock.
(d) Prior to the Closing Date, at the request of Purchaser, Target shall use its commercially reasonable efforts to cause each Stockholder and Optionholder to execute and deliver to Purchaser such instruments and do and perform such acts and things as may be necessary or desirable for complying with all applicable securities Laws and other Laws. Target shall inform the Stockholders and Optionholder of the confidential nature of this Agreement.
(e) Purchaser shall include in its listing application, if any, to be filed with a national securities exchange all of the shares of Purchaser Common Stock to be issued in the Merger.
Section 7.18 Plan of Reorganization. This Agreement is intended to constitute a plan of reorganization within the meaning of section 1.368-2(g) of the income tax regulations promulgated under the Code. From and after the date of this Agreement and until the Effective Time, each party hereto shall use its commercially reasonable efforts to cause the Merger to qualify, and will not knowingly take any action, cause any action to be taken, fail to take any action or cause any action to fail to be taken which action or failure to act could prevent the Merger from qualifying, as a reorganization within the meaning of Section 368(a) of the Code.
ARTICLE VIII
CONDITIONS TO THE
MERGER
Section 8.01 Conditions to the Obligations of Each Party . The obligations of Purchaser, Merger Sub, and Target to consummate the Merger are subject to the satisfaction of the following conditions:
(a) Laws and Governmental Orders. No Governmental Authority having jurisdiction over any party hereto shall have enacted, issued, promulgated, enforced or entered any Laws or Governmental Orders, whether temporary, preliminary or permanent, that make illegal, enjoin or otherwise prohibit consummation of the Merger or the other transactions contemplated by this Agreement.
(b) Target Stockholder Approval. This Agreement and the transactions contemplated hereby shall have been approved by a Target Stockholder Approval.
(c) Purchaser Stockholder Approval. This Agreement and the transactions contemplated hereby shall have been approved by Purchasers stockholders in accordance with the Purchaser Charter Documents.
(d) Dissenters Rights. Holders of no more than five percent (5%) of the outstanding shares of Target Common Stock and five percent (5%) of the outstanding shares of Target Preferred Stock as of immediately prior to the Effective Time, in the aggregate, shall remain entitled to exercise statutory appraisal rights pursuant to Section 262 of the DGCL with respect to such Target Shares.
(e) Preliminary Injunction. There shall have been issued by a court of competent jurisdiction in favor of Purchaser a preliminary injunction (which preliminary injunction remains in effect) enjoining the enforcement and implementation of amended Rule 190.8.1(L) of Title 22 of the Texas Administrative Code, as adopted by the Texas Medical Board on April 10, 2015.
(f) Pursuit of Qualified Public Offering. Purchaser shall not have elected to abandon or delay the proposed Initial Qualified Public Offering (defined below) of the Purchaser Common Stock in a manner that would cause the Initial Qualified Public Offering to close after August 5, 2015. For purposes of this Agreement, the term Initial Qualified Public Offering shall mean the initial sale of shares of Purchaser Common Stock to the public in a bona-fide firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act. Nothing in this Section 8.01(f) shall constitute a guaranty by Purchaser or Merger Sub that an Initial Qualified Public Offering of the Purchaser Common Stock will occur by a particular date, if at all.
(g) Amendment to Purchasers Charter Documents. Purchasers Board of Directors and stockholders shall have approved in accordance with Purchasers Charter Documents, and Purchaser shall have filed with the Secretary of State of the State of Delaware, an amendment to Purchasers Fourth Amended and Restated Certificate of Incorporation (as amended) to increase the number of authorized shares of Purchaser Common Stock from 73,559,000 to 77,559,000.
Section 8.02 Conditions to the Obligations of Purchaser and Merger Sub . The obligations of Purchaser and Merger Sub to consummate the Merger are subject to the satisfaction or waiver (where permissible) of the following additional conditions:
(a) Representations and Warranties. The representations and warranties of Target contained in this Agreement and any certificate or other writing delivered pursuant hereto shall be true and correct in all respects (in the case of any representation or warranty qualified by materiality or Material Adverse Effect) or in all material respects (in the case of any representation or warranty not qualified by materiality or Material Adverse Effect) on and as of the date of this Agreement (or the applicable certificate or instrument) and the Closing Date with the same effect as though made at and as of such date (except those representations and warranties that address matters only as of a specified date, the accuracy of which shall be determined as of that specified date in all respects). The certificate described in Section 3.02(a)(ii) shall provide that the Audited Financial Statements have been prepared in accordance with GAAP applied on a consistent basis throughout the period involved.
(b) Agreements and Covenants. Target shall have performed or complied in all material respects with all agreements and covenants required by this Agreement and the other Transaction Documents to be performed or complied with by it on or prior to the Effective Time.
(c) Material Adverse Effect. From the date of this Agreement, there shall not have occurred any Material Adverse Effect, nor shall any event or events have occurred that, individually or in the aggregate, with or without the lapse of time, could reasonably be expected to result in a Material Adverse Effect.
(d) Closing Deliveries. Purchaser shall have received each of the Closing deliveries set forth in Section 3.02(a) .
(e) Required Consents. All consents, approvals and authorizations legally required to be obtained by Target to consummate the Merger shall have been obtained from and made with all Governmental Authorities and all consents from third parties under any Material Contract or other material agreement, Contract, Permit, lease or other instrument to which Target is a party or by which it is bound required as a result of the transactions contemplated by this Agreement shall have been obtained.
(f) Silicon Valley Bank Consent. All consents, approvals and authorizations required to be obtained by Purchaser and Merger Sub from Silicon Valley Bank as a result of the transactions contemplated by this Agreement shall have been obtained.
(g) Intentionally Omitted.
(h) Securities Law Compliance. The transactions contemplated by this Agreement relating to the issuance of shares of Purchaser Common Stock in the Merger shall have (a) satisfied the requirements for such shares to be exempt from registration under the Securities Act pursuant to Regulation D and (b) shall have satisfied one or more exemptions under all applicable state securities laws.
(i) Audited Financial Statements. Ernst & Young shall have completed its audit of Targets financial statements for year ended December 31, 2014.
(j) Roga Investigative Report. There shall be no criminal activity or other material negative disclosures with respect to Alan Roga (as determined by Purchaser in its reasonable discretion, but excluding any matters which have been previously disclosed in the Target Disclosure Schedules) contained in the investigative report being performed by HireRight.
(k) Employee Promissory Notes. The Promissory Notes executed by Alan and Illana Roga and John and Lynette Barravecchia in favor of Target (as more particularly described in Section 4.01(c) of the Target Disclosure Schedules) shall have been repaid, forgiven, or otherwise satisfied in full.
(l) Bank Account Signatories. Effective as of the Closing, Alan Roga and John Barravecchia shall have been replaced as the authorized signatories on Targets bank accounts (including those bank accounts described on Section 4.21 of the Target Disclosure Schedules) with such Persons as Purchaser shall designate.
Section 8.03 Conditions to the Obligations of Target . The obligations of the Target to consummate the Merger are subject to the satisfaction or waiver (where permissible) of the following additional conditions:
(a) Representations and Warranties. The representations and warranties of Purchaser and Merger Sub contained in this Agreement and any certificate or other writing delivered pursuant hereto shall be true and correct in all respects (in the case of any representation or warranty qualified by materiality) or in all material respects (in the case of any representation or warranty not qualified by materiality) on and as of the date of this Agreement and the Closing Date with the same effect as though made at and as of such date (except those representations and warranties that address matters only as of a specified date, the accuracy of which shall be determined as of that specified date in all respects).
(b) Agreements and Covenants. Purchaser and Merger Sub shall have performed or complied in all material respects with all agreements and covenants required by this Agreement and the other Transaction Documents to be performed or complied with by them on or prior to the Effective Time.
(c) Closing Deliveries. Target and the Equityholder Representative shall have received each of the Closing deliveries set forth in Section 3.02(b) .
(d) Closing Consideration. Purchaser shall have delivered, or caused the Surviving Company to deliver, the payments required by Section 3.02(c) to be delivered on or before Closing.
ARTICLE IX TERMINATION
Section 9.01 Termination . This Agreement may be terminated and the Merger and the other transactions contemplated hereby may be abandoned at any time prior to the Effective Time, notwithstanding any requisite approval and adoption of this Agreement and such transactions by any party, as follows:
(a) by mutual written consent of Purchaser, Target and the Equityholder Representative;
(b) by either Purchaser, on one hand, or Target and Equityholder Representative, on the other hand, if any Governmental Authority having jurisdiction over any party hereto shall have enacted, issued, promulgated, enforced or entered any Laws or Governmental Orders that make illegal, enjoin or otherwise prohibit consummation of the Merger or the other transactions contemplated by this Agreement;
(c) by Purchaser if:
(i) Neither Purchaser nor Merger Sub is then in breach of any provision of this Agreement and Target has breached any representation, warranty or covenant contained in this Agreement that would give rise to the failure of any of the conditions specified in Section 8.02 , and Purchaser shall have notified Target and the Equityholder Representative of such breach, and, if of a type which can be cured, such breach has continued without cure for a period of fifteen (15) days after the notice of breach;
(ii) any of the conditions set forth in Section 8.01 or 8.02 shall not have been fulfilled by August 5, 2015 (the Termination Date ), unless such failure shall be due to the failure of Purchaser or Merger Sub to perform or comply with any of the covenants, agreements or conditions hereof to be performed or complied with by them prior to the Closing; or
(iii) a Material Adverse Effect has occurred after the date of this Agreement.
(d) by Target or the Equityholder Representative if:
(i) Target is not then in breach of any provision of this Agreement and Purchaser or Merger Sub has materially breached any representation, warranty or covenant contained in this Agreement that would give rise to the failure of any of the conditions specified in Section 8.03 , and Target has notified Purchaser of such breach, and, if of a type which can be cured, such breach has continued without cure for a period of fifteen (15) days after the notice of breach, or
(ii) any of the conditions set forth in Section 8.01 or Section 8.03 shall not have been fulfilled by the Termination Date, unless such failure shall be due to the failure of Target to perform or comply with any of the covenants, agreements or conditions hereof to be performed or complied with by it prior to the Closing.
Section 9.02 Effect of Termination . In the event of the termination of this Agreement pursuant to Section 9.01 , this Agreement shall forthwith become void, and there shall be no liability under this Agreement on the part of any party hereto, except that nothing herein shall relieve any party from liability for any willful breach of any of its representations, warranties, covenants or agreements set forth in this Agreement prior to such termination; provided, however, that the terms of ARTICLE XI and ARTICLE XII shall survive any termination of this Agreement. Additionally, the terms of Section 7.04 shall survive any termination of this Agreement. The obligations of the Purchaser and Target set forth in the Confidentiality Agreement dated on or about January 29, 2015 shall survive the execution and termination of this Agreement.
ARTICLE X INDEMNIFICATION
Section 10.01 Survival . Subject to the limitations and other provisions of this Agreement, the representations and warranties contained herein shall survive the Closing and shall remain in full force and effect until the date that is twenty-four (24) months from the Closing Date; provided, that (i) the representations and warranties in Section 4.01 (Organization, Qualification and Capitalization of Target), Section 4.02 (Authority), Section 4.09(a) (Title to Assets), Section 4.24 (Solvency), Section 4.27 (Brokers) , Section 6.01 (Organization), Section 6.02 (Authority of Purchaser and Merger Sub), Section 6.04 (Brokers), and Section 6.11 (Status of Purchaser Common Stock to be Issued) shall survive indefinitely (the representations, collectively described in clause (i), the Fundamental Representations ), and (ii) the representations and warranties in Section 4.17 (Environmental Matters), Section 4.18 (Employee Benefit Matters), and Section 4.20 (Taxes) shall survive until thirty (30) days following the expiration of the full period of all applicable statutes of limitations (giving effect to any waiver, mitigation or extension thereof). All covenants of the parties contained herein shall survive the Closing until performed in accordance with their terms. Notwithstanding the foregoing, any claims arising from Fraud of Target or Fraud of Purchaser and/or Merger Sub, as applicable, or from Criminal Activity of Target and/or Criminal Activity of Purchaser and/or Merger Sub, as applicable, shall not be limited by the survival period described above. The period for which a representation or warranty, covenant or agreement survives the Closing pursuant to this Section 10.01 is referred to herein as the Applicable Survival Period . In the event notice of claim for indemnification under Section 10.02 or Section 10.03 is timely given, in accordance with Section 10.05 , within the Applicable Survival Period, the representation or warranty, covenant or agreement that is the subject of such indemnification claim shall survive with respect to such claim until such claim is finally resolved in accordance with this Agreement.
Section 10.02 Escrow Fund; Indemnification by the Stockholders and Optionholders . Subject to the other terms and conditions of this ARTICLE X , the Stockholders and Optionholders, severally (based on each such Stockholders and Optionholders Participating Percentage, but subject in all respects to Section 2.17(c)(i) ) and not jointly, shall indemnify and defend each of Purchaser, Merger Sub, the Surviving Company and their respective Affiliates, their respective Representatives and each of their successors and permitted assigns (collectively, the Purchaser Indemnitees ) against, and shall hold each of them harmless from and against, and shall pay and reimburse each of them for, any and all
Losses incurred or sustained by, or imposed upon, the Purchaser Indemnitees based upon, arising out of, with respect to or by reason of:
(a) any breach of any of the Fundamental Representations of Target as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date);
(b) any breach of any of the representations or warranties of Target contained in this Agreement (other than the Fundamental Representations), or any other certificate furnished by Target hereunder, as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date);
(c) any breach or non-fulfillment of any covenant, agreement or obligation to be performed by Target pursuant to this Agreement or any certificate or instrument delivered by the Target pursuant to this Agreement;
(d) any Closing Transaction Expenses in excess of the amounts set forth on the Pre- Closing Statement, to the extent not paid by Target concurrently with Closing; or
(e) any Equityholder and Employee Claims; (f) any D&O Obligations;
(g) any Taxes of Target for any Pre-Closing Tax Period, except and to the extent such Taxes have been included in the calculation of the Estimated Closing Accrued Tax Amount or the Final Closing Accrued Tax Amount;
(h) any Profit Sharing Claims;
(i) fifty percent (50%) of any severance payments that may be payable under the employment agreements and offer letters described in Schedule 10.02(i) attached hereto (as in effect as of the Closing), in the event that the applicable employee resigns or is terminated as an employee within the first six (6) months following the Closing; and
(j) any amounts paid to the holders of Dissenting Shares, including any interest required to be paid thereon, that are in excess of what such holders would have received hereunder had such holders not been holders of Dissenting Shares.
Section 10.03 Indemnification by Purchaser . Subject to the other terms and conditions of this ARTICLE X , Purchaser shall indemnify and defend each of the Stockholders and Optionholders, their respective Affiliates (excluding, after the Effective Time, Purchaser or the Surviving Company), their respective Representatives and each of their respective successors and permitted assigns (collectively, the Target Indemnitees ) against, and shall hold each of
them harmless from and against, and shall pay and reimburse each of them for, any and all Losses incurred or sustained by, or imposed upon, the Target Indemnitees based upon, arising out of, with respect to or by reason of:
(a) any breach of any of the Fundamental Representations of Purchaser or Merger Sub as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date);
(b) any breach of any of the representations or warranties of Purchaser or Merger Sub contained in this Agreement (other than the Fundamental Representations) or any certificate furnished by or on behalf of Purchaser or Merger Sub pursuant to this Agreement, as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date); and
(c) any breach or non-fulfillment of any covenant, agreement or obligation to be performed by Purchaser or Merger Sub pursuant to this Agreement.
Section 10.04 Certain Limitations . Except with respect to claims arising from Fraud of Target or Fraud of Purchaser and/or Merger Sub, as applicable, or from Criminal Activity of Target and/or Criminal Activity of Purchaser and/or Merger Sub, as applicable, the indemnification provided for in Section 10.02 and Section 10.03 , as applicable, shall be subject to the following limitations:
(a) The Stockholders and Optionholders shall not be liable to the Purchaser Indemnitees for indemnification under Section 10.02(b) until the aggregate amount of all Losses in respect of indemnification under Section 10.02(b) exceeds Two Hundred Thousand and No/100 Dollars ($200,000.00), in which event the Stockholders and Optionholders shall be required to pay and be liable for all such Losses from the first dollar thereof.
(b) Purchaser shall not be liable to the Target Indemnitees for indemnification under Section 10.03(b) until the aggregate amount of all Losses in respect of indemnification under Section 10.03(b) exceeds Two Hundred Thousand and No/100 Dollars ($200,000.00), in which event Purchaser shall be required to pay and be liable for all such Losses from the first dollar thereof.
(c) The maximum aggregate amount of all Losses for which the Stockholders and Optionholders shall be liable pursuant to Section 10.02(b) shall not exceed Six Million One Hundred Thousand and No/100 Dollars ($6,100,000.00) (the Cap ). Additionally, (i) the aggregate amount of Losses for which all Stockholders and Optionholders may be liable pursuant to Section 10.02 shall not exceed the Aggregate Merger Consideration; and (ii) the aggregate amount of Losses for which any Stockholder or Optionholder may be liable pursuant to Section 10.02 shall be limited to an amount equal to the Aggregate Merger Consideration multiplied by such Stockholders or Optionholders Participating Percentage. For purposes of
determining whether the limitations set forth in this Section have been met, all shares of Purchaser Common Stock delivered in satisfaction of an indemnification claim will be valued in accordance with Section 2.17(c)(iii) .
(d) The maximum aggregate amount of all Losses for which Purchaser shall be liable pursuant to Section 10.03(b) shall not exceed the Cap. The maximum aggregate amount of all Losses for which Purchaser shall be liable pursuant to Section 10.03 shall not exceed the Aggregate Merger Consideration.
(e) The amount of Losses for which indemnification is provided for under this Agreement shall be reduced by (i) any amounts actually received by the Indemnified Party as a result of any indemnification, contribution or other payment by a third party, and (ii) any insurance proceeds (including any proceeds from the D&O Tail Policy), less any applicable premium increases, or other similar amounts actually received by an Indemnified Party with respect to such Losses, in each case less any costs incurred in pursuing and obtaining such amounts (any amounts described in clause (i) or (ii), Third Party Payments ). If the amount of any Loss, at any time subsequent to the making of any indemnification payment on account of such Loss, is reduced by any Third Party Payment, the amount of such reduction shall promptly be repaid by the Indemnified Party to the Indemnifying Party.
(f) No Indemnified Party shall be entitled to indemnification hereunder for any Losses arising from breach of any representation, warranty, covenant or agreement set forth herein (and the amount of any Losses incurred in respect of such breach shall not be included in the calculation of any limitation on indemnification set forth herein) to the extent that such Losses have previously been included (as a reduction) in the calculation of the Estimated Closing Working Capital or the Final Closing Working Capital.
(g) The Indemnified Parties shall not have the right to be indemnified for any Losses under this ARTICLE X to the extent they are in the nature of punitive, special or exemplary damages or diminution in value damages, in each case except to the extent such Losses are paid by the Indemnified Party to an unrelated third party.
Section 10.05 Indemnification Procedures . The party making a claim under this ARTICLE X is referred to as the Indemnified Party , and the party against whom such claims are asserted under this ARTICLE X is referred to as the Indemnifying Party .
(a) Third Party Claims . If any Indemnified Party receives notice of the assertion or commencement of any Action made or brought by any Person who is not a party to this Agreement or an Affiliate of a party to this Agreement or a Representative of the foregoing (a Third Party Claim ) against such Indemnified Party with respect to which the Indemnifying Party is obligated to provide indemnification under this Agreement, the Indemnified Party shall give the Indemnifying Party reasonably prompt written notice thereof, but in any event not later than 30 calendar days after receipt of such notice of such Third Party Claim. The failure to give such prompt written notice shall not, however, relieve the Indemnifying Party of its indemnification obligations, except and only to the extent that the Indemnifying Party is materially prejudiced by such failure. Such notice by the Indemnified Party shall describe the
Third Party Claim in reasonable detail, shall include copies of all material written evidence thereof and shall indicate the estimated amount, if reasonably practicable, of the Loss that has been or may be sustained by the Indemnified Party. The Indemnifying Party shall have the right to participate in, or by giving written notice to the Indemnified Party within 20 days following delivery of written notice of this Third Party Claim from the Indemnified Party, to assume the defense of any Third Party Claim at the Indemnifying Partys expense and by the Indemnifying Partys own counsel, and the Indemnified Party shall cooperate in good faith in such defense; provided, that if the Indemnifying Party is a Stockholder or Optionholder, such Indemnifying Party shall not have the right to defend or direct the defense of any such Third Party Claim (x) that is asserted by a Person that is a customer or supplier of the Surviving Company or Purchaser, or (y) to the extent that it seeks an injunction or other equitable relief against the Indemnified Party. In the event that the Indemnifying Party assumes the defense of any Third Party Claim, subject to Section 10.05(b) , it shall have the right to take such action as it deems reasonably necessary to avoid, dispute, defend, appeal or make counterclaims pertaining to any such Third Party Claim in the name and on behalf of the Indemnified Party. The Indemnified Party shall have the right to participate in the defense of any Third Party Claim with counsel selected by it subject to the Indemnifying Partys right to control the defense thereof. The fees and disbursements of such counsel shall be at the expense of the Indemnified Party, provided, that if in the reasonable opinion of counsel to the Indemnified Party, (A) there are legal defenses available to an Indemnified Party that are different from or additional to those available to the Indemnifying Party; or (B) there exists a conflict of interest between the Indemnifying Party and the Indemnified Party that cannot be waived, the Indemnifying Party shall be liable for the reasonable fees and expenses of counsel to the Indemnified Party in each jurisdiction for which the Indemnified Party determines counsel is required. If the Indemnifying Party elects not to compromise or defend such Third Party Claim, fails to promptly notify the Indemnified Party in writing of its election to defend as provided in this Agreement, is prohibited from defending the Third Party Claim in accordance with this Section, or fails to diligently prosecute the defense of such Third Party Claim, the Indemnified Party may, subject to Section 10.05(b) , pay, compromise, defend such Third Party Claim and seek indemnification for any and all Losses based upon, arising from or relating to such Third Party Claim. The Indemnified Party and the Indemnifying Party shall cooperate with each other in all reasonable respects in connection with the defense of any Third Party Claim, including making available records relating to such Third Party Claim and furnishing, without expense (other than reimbursement of expenses) to the defending party, management employees of the non-defending party as may be reasonably necessary for the preparation of the defense of such Third Party Claim. Notwithstanding anything herein to the contrary, for purposes of this Section 10.05 , any Equityholder and Employee Claims shall be deemed to be demands made by a third party and shall constitute Third Party Claims.
(b) Settlement of Third Party Claims . Notwithstanding any other provision of this Agreement, the Indemnifying Party shall not enter into settlement of any Third Party Claim without the prior written consent of the Indemnified Party, unless a firm offer is made to settle a Third Party Claim without leading to liability or the creation of a financial or other obligation on the part of the Indemnified Party and provides, in customary form, for the unconditional release of each Indemnified Party from all Liabilities and obligations in connection with such Third Party Claim. If the Indemnified Party has assumed the defense of such Third Party Claim
pursuant to Section 10.05(a) , it shall not agree to any settlement without the written consent of the Indemnifying Party (which consent shall not be unreasonably withheld or delayed).
(c) Direct Claims . Any Action by an Indemnified Party on account of a Loss which does not result from a Third Party Claim (a Direct Claim ) shall be asserted by the Indemnified Party giving the Indemnifying Party reasonably prompt written notice thereof, but in any event not later than 30 days after the Indemnified Party becomes aware of such Direct Claim. The failure to give such prompt written notice shall not, however, relieve the Indemnifying Party of its indemnification obligations, except and only to the extent that the Indemnifying Party is materially prejudiced by such failure. Such notice by the Indemnified Party shall describe the Direct Claim in reasonable detail, shall include copies of all material written evidence thereof and shall indicate the estimated amount, if reasonably practicable, of the Loss that has been or may be sustained by the Indemnified Party. The Indemnifying Party shall have 30 days after its receipt of such notice to respond in writing to such Direct Claim. The Indemnified Party shall allow the Indemnifying Party and its professional advisors to investigate the matter or circumstance alleged to give rise to the Direct Claim, and whether and to what extent any amount is payable in respect of the Direct Claim, and the Indemnified Party shall assist the Indemnifying Partys investigation by giving such information and assistance (including access to the Indemnified Partys premises and personnel and the right to examine and copy any accounts, documents or records) as the Indemnifying Party or any of its professional advisors may reasonably request. If the Indemnifying Party does not respond within such 30 day period, then (i) Indemnifying Party shall be conclusively deemed to have acknowledged the correctness of the Direct Claim, and (ii) and the amount of such Direct Claim shall be paid to the Indemnified Party with 15 Business Days following the expiration of such 30 day period in accordance with Section 10.06 . If the Indemnifying Party timely delivers an objection to the Direct Claim or seeks additional information regarding the Direct Claim, then the Indemnified Party shall be free to pursue such remedies as may be available to the Indemnified Party on the terms and subject to the provisions of this Agreement.
Section 10.06 Payments . Once a Loss is agreed (or deemed to be agreed) to by the Indemnifying Party or finally adjudicated to be payable pursuant to this ARTICLE X (any such agreement, deemed agreement or final adjudication, an Indemnification Determination ), Indemnifying Party shall satisfy its obligations by wire transfer of immediately available funds within 15 Business Days of such Indemnification Determination; provided, however, in the event that the Indemnifying Party is a Stockholder or Optionholder, Purchaser shall first require that all or any portion of such Loss be satisfied from the Escrow Fund in accordance with Section 12.01 . The parties hereto agree that should an Indemnifying Party not make (or, with respect to a payment from the Escrow Fund, direct the Escrow Agent to make) full payment of any such obligation within such 15 Business Day period, any amount payable shall accrue interest from and including the date of the Indemnification Determination to and including the date such payment has been made at a rate per annum equal to the statutory rate of interest in Delaware for judgments on the date of such agreement or final, non-appealable adjudication. Such interest shall be calculated daily on the basis of a 365 day year and the actual number of days elapsed.
Section 10.07 Tax Treatment of Indemnification Payments . All indemnification payments made under this Agreement shall be treated by the parties as an adjustment to the Aggregate Merger Consideration for Tax purposes, unless otherwise required by Law.
Section 10.08 Effect of Investigation . The representations, warranties and covenants of the Indemnifying Party, and the Indemnified Partys right to indemnification with respect thereto, shall not be affected or deemed waived by reason of any investigation made by or on behalf of the Indemnified Party (including by any of its Representatives) or by reason of the fact that the Indemnified Party or any of its Representatives know or should have known that any such representation or warranty is, was or might be inaccurate, as the case may be.
Section 10.09 Exclusive Remedies . From and after the Closing, the parties acknowledge and agree that their sole and exclusive remedy with respect to any and all claims (other than those related to claims arising from Fraud of Target and Fraud of Purchaser and/or Merger Sub, as applicable, or claims arising from Criminal Activity of Target and/or Criminal Activity of Purchaser and/or Merger Sub, as applicable) whether in contract, tort or otherwise for any breach of any representation, warranty, covenant, agreement or obligation set forth herein or otherwise relating to the subject matter of this Agreement, the Soliciting Materials or any certificate delivered in connection herewith, shall be pursuant to the indemnification provisions set forth in this ARTICLE X . For purposes of clarity, indemnification and liability with respect to any Losses under or related to a Transaction Document (including, without limitation, the Letters of Transmittal and Option Termination Agreements) other than this Agreement, the Soliciting Materials or any certificate delivered in connection herewith, shall be governed by the terms of such Transaction Document and shall not be subject to this Section 10.09 . Nothing in this Section 10.09 shall limit any Persons right to seek and obtain any equitable relief to which any Person shall be entitled or to seek any remedy on account of Fraud of Target or Fraud of Purchaser and/or Merger Sub, as applicable, or on account of Criminal Activity of Target and/or Criminal Activity of Purchaser and/or Merger Sub, as applicable.
Section 10.10 Authority of the Equityholder Representative. Notwithstanding anything in this ARTICLE X to the contrary, and as more particularly set forth in ARTICLE XI , the Equityholder Representative shall have the power to execute, deliver, acknowledge, certify and file any documents, give and receive any notices, negotiate or enter into compromises or disputes, and take any and all actions such Equityholder Representative may determine to be necessary, on behalf of any Stockholder, Optionholder, Principal or other Target Indemnitee in connection with this ARTICLE X .
Section 10.11 Calculation of Losses . For purposes of this ARTICLE X , to the extent it is determined that a representation or warranty has been breached and the Purchaser Indemnitees or the Target Indemnitees are entitled to be indemnified therefor pursuant to the terms of this ARTICLE X , then for the purposes of determining the amount of any Losses relating to such breach (and only for such purpose and, for the avoidance of doubt, not for the purpose of determining whether a breach has occurred), the breached representation or warranty shall be read without regard to any qualifications or exceptions relating to or referring to the terms material, materiality, in all material respects, Material Adverse Effect or any similar term or phrase contained in or otherwise applicable to any such representation or warranty.
Section 10.12 Breach of Transmittal Letter . Notwithstanding anything to the contrary contained herein, in no event shall the Target or any Purchaser Indemnitee have any right to seek indemnification against the Stockholders or Optionholders under this Agreement for the breach or non-fulfillment by any other Stockholder or Optionholder of any representation, warranty, covenant or other obligation of such Stockholder or Optionholder set forth in their respective Transmittal Letter.
ARTICLE XI EQUITYHOLDER REPRESENTATIVE
Section 11.01 Appointment of Equityholder Representative; Power of Attorney .
(a) Each Stockholder and Optionholder hereby irrevocably nominates, constitutes and appoints John Barravecchia as the Equityholder Representative and as the agent, agent for service of process and true and lawful attorney in fact of such Stockholder or Optionholder with full power of substitution, to act in the name, place and stead of such Stockholder or Optionholder with respect to all matters under this Agreement, the Escrow Agreement and the transactions contemplated by this Agreement and the Escrow Agreement, and John Barravecchia hereby accepts such appointment. Such powers shall include, without limitation, the taking by the Equityholder Representative of any and all actions and the making of any decisions required or permitted to be taken or made by any Stockholder or Optionholder under this Agreement, including the exercise of the power to: (i) execute, deliver, acknowledge, certify and file (in the name of any or all of such Stockholders or Optionholders or otherwise) any and all documents and to take any and all actions that the Equityholder Representative may, in his sole discretion, determine to be necessary, desirable or appropriate in connection with this Agreement and the Escrow Agreement (including negotiating, entering into compromises, releases or settlements of and resolving disputes with respect to any matters covered in Section 2.07 , Section 7.08 and ARTICLE X ); (ii) give and receive notices and communications under this Agreement and the Escrow Agreement; (iii) authorize the payment of fees, expenses and distributions, including, without limitation, any fees, expenses or distributions out of the Equityholder Representative Holdback Amount; (iv) execute amendments (and additional documents related thereto) to this Agreement and the Escrow Agreement on behalf of such Stockholders or Optionholders generally consistent with the transaction contemplated hereby, the execution thereof shall be conclusive evidence of such determination, provided, however, that no such amendment may purport to bind any Principal to a restrictive covenant regarding non-competition or to expand such Principals indemnification obligations without the consent of such Principal; (v) as Equityholder Representative, to enforce and protect the rights and interests of the Stockholders and Optionholders (including the Equityholder Representative, in his capacity as a Principal) in connection with any claims asserted in connection with this Agreement and the Escrow Agreement, including defending all claims for indemnification made by Purchaser Indemnitees, consenting to, compromising, releasing or settling any indemnification claims of Purchaser Indemnitees, conducting negotiations with Purchaser and its Representatives regarding such claims, and engaging counsel, accountants or other Representatives in connection with the foregoing matters, and, in connection therewith, to (A) assert any claim or institute any action, proceeding or investigation; (B) investigate, defend, contest or litigate any claim, action, proceeding or investigation initiated by Purchaser, the Surviving Company or any Person, or by
any federal, state or local Governmental Authority against the Equityholder Representative and/or any of the Stockholders or Optionholders and receive process on behalf of any or all the Stockholders or Optionholders in any such claim, action, proceeding or investigation and compromise or settle on such terms as the Equityholder Representative shall determine to be appropriate, and give receipts, releases (including general releases of all claims arising on or before the date of release) and discharges with respect to, any such claim, action, proceeding, or investigation; (C) file any proofs of debt, claims and petitions as the Equityholder Representative may deem advisable or necessary; and (D) file and prosecute appeals from any decision, judgment or award rendered in any such action, proceeding or investigation, it being agreed that the Equityholder Representative shall not have any obligation to take any such actions, and shall not have any liability for any failure to take any such actions; and (vi) to make such determinations and take such actions as are provided in Section 2.07 , Section 7.08 and ARTICLE X .
(b) In connection with this Agreement, and any instrument, agreement or document relating hereto or thereto (including, without limitation, the Escrow Agreement), and in exercising or failing to exercise all or any of the powers conferred upon the Equityholder Representative hereunder (A) the Equityholder Representative shall incur no responsibility whatsoever to any Stockholder or Optionholder by reason of any error in judgment or other act or omission performed or omitted hereunder or any such other agreement, instrument or document, excepting only responsibility for any act taken which represents gross negligence or willful misconduct and (B) the Equityholder Representative shall be entitled to rely on the advice of counsel, public accounts or other independent experts experienced in the matter at issue, and any action taken (or not taken) on the advice of such counsel or experts shall, as to the Stockholders and Optionholders provide conclusive evidence of Equityholder Representatives exercise of good faith, and in no event subject the Equityholder Representative to liability to any Stockholder or Optionholder with respect to any such action or inaction.
(c) All of the immunities and powers granted to the Equityholder Representative under this Agreement shall survive the Closing and/or termination of this Agreement and the termination of the Escrow Agreement.
(d) Each Stockholder and Optionholder hereby acknowledges and agrees that the Equityholder Representative Holdback Amount shall be withheld and paid directly to an account maintained by the Equityholder Representative (or a financial institution selected by the Equityholder Representative) as a fund for the fees and expenses (including, without limitation, any legal fees and expenses) of the Equityholder Representative incurred in connection with this Agreement, with any balance of the Equityholder Representative Holdback Amount not utilized for such purposes to be remitted to the Stockholders and Optionholders in accordance with their Participating Percentages. The Equityholder Representative will, if so requested in writing by any Stockholder or Optionholder, provide such Stockholder or Optionholder with a written report describing in reasonable detail the amount of any fees, expenses, distributions, or other remittances made out of the Equityholder Representative Holdback Amount; provided, however, that the Equityholder Representative will not have any obligation to provide any such written report to any particular Stockholder or Optionholder any more than two times during any rolling twelve (12) month period.
(e) In additional to the other rights granted to the Equityholder Representative in this Agreement, Stockholder and Optionholder acknowledges and agrees that (i) if such Stockholder or Optionholder breaches any of the representations and warranties set forth in such Stockholders or Optionholders Letter of Transmittal or Option Termination Agreement, or (ii) if such Stockholder or Optionholder breaches any agreement or covenant set forth herein or in this Agreement, which, in either case, results in a claim for indemnification by a Purchaser Indemnitee under Section 10.02 , then the Equityholder Representative shall be entitled to withhold and withdraw for payment to the Purchaser Indemnitee any amounts otherwise owing to such Stockholder or Optionholder from the Escrow Cash, Escrow Shares and Equityholder Representative Holdback Amount to offset in whole or in part, such Stockholders or Optionholders indemnification obligations hereunder (which shall not be a breach of the Equityholder Representatives obligations under this ARTICLE XI ).
Section 11.02 Irrevocable Appointment . The power of attorney granted in Section 11.01 is (a) coupled with an interest and is irrevocable and (b) shall survive the death, incapacity or incompetency of any of the Stockholders or Optionholders.
Section 11.03 Reliance .
(a) Notwithstanding anything to the contrary contained in this Agreement, Purchaser and any Purchaser Indemnitees shall be entitled to deal exclusively with the Equityholder Representative on all matters relating to this Agreement and the Escrow Agreement, including, without limitation, Section 2.07 , Section 7.08 and ARTICLE X hereof, and each Purchaser Indemnitee shall be entitled to deal exclusively with the Equityholder Representative in respect of all such matters, and each of them shall be entitled to rely conclusively (without further evidence of any kind whatsoever) on any document executed or purported to be executed on behalf of any Stockholder or Optionholder by the Equityholder Representative in respect of such matters, and on any other action taken or purported to be taken on behalf of any Stockholder or Optionholder by the Equityholder Representative, as fully binding upon such Stockholder or Optionholder.
(b) Notwithstanding anything to the contrary contained in this Agreement, any notice or communication delivered by Purchaser or Merger Sub to Equityholder Representative shall, as between Purchaser or Merger Sub, on the one hand, and the Stockholders or Optionholders, on the other hand, be deemed to have been delivered to all Stockholders or Optionholders. Purchaser and Merger Sub shall be entitled to rely exclusively upon any communication or writings given or executed by Equityholder Representative in connection with any claims for indemnity and shall not be liable in any manner whatsoever for any action taken or not taken in reliance upon the actions taken or not taken or communications or writings given or executed by Equityholder Representative.
Section 11.04 Replacement . The Equityholder Representative may at any time designate a replacement Equityholder Representative with the consent of Purchaser (which will not be unreasonably withheld, conditioned or delayed), and each Stockholder and Optionholder, by virtue of his or her execution and delivery of this Agreement, hereby consents to such replacement Equityholder Representative. If the Equityholder Representative shall die, become
disabled or otherwise be unable to fulfill his responsibilities as representative of the Stockholders or Optionholders, then the Stockholders or Optionholders shall, by voting in accordance with their Participating Percentages, within thirty (30) days after such death or disability, appoint a successor representative (with the consent of Purchaser, which will not be unreasonably withheld, conditioned or delayed). Any such successor shall become the Equityholder Representative for all purposes under this Agreement.
ARTICLE XII
MISCELLANEOUS
Section 12.01 Escrow . Notwithstanding anything herein or in any other Transaction Document to the contrary, in the event that (i) the calculations set forth in the Closing Statement become final and binding in accordance with Section 2.07(d) and thereby result in any amounts being payable by the Stockholders and Optionholders pursuant to Section 2.07(c)(ii) , (ii) the Stockholders or Optionholders are required to reimburse Purchaser for any Taxes in accordance with Section 7.08(a)(ii) or (iii) there shall occur an Indemnification Determination that any amounts are payable by any Stockholder or Optionholder to any Purchaser Indemnitee pursuant to ARTICLE X (any event described in clause (i) or (ii), a Final Determination ), Purchaser shall, prior to seeking payment of such amounts directly from the Stockholders or Optionholders, satisfy all or any portion of the amount payable pursuant to such Final Determination by disbursement from the Escrow Account, and Purchaser shall remit such disbursement amount to the Purchaser Indemnitee(s) to whom amount is due. If the amount remaining Escrow Fund is insufficient to cover the amounts then owed to the Purchaser Indemnitees (as set forth in the applicable Final Determination), Purchaser may, subject to the limitations set forth in ARTICLE X , demand payment of such amount directly from any Stockholder or Optionholder, who shall then pay such amount within fifteen (15) days following such demand.
Section 12.02 Expenses . Except as otherwise expressly provided herein, all costs and expenses, including, without limitation, fees and disbursements of counsel, financial advisors and accountants, incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such costs and expenses, whether or not the Closing shall have occurred.
Section 12.03 Notices . All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given (a) when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by email of a PDF document (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next Business Day if sent after normal business hours of the recipient; or (d) on the third (3rd) day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective parties at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance with this Section 12.03 ):
Section 12.04 Interpretation . For purposes of this Agreement, (a) the words include, includes and including shall be deemed to be followed by the words without limitation; (b) the word or is not exclusive; and (c) the words herein, hereof, hereby, hereto and hereunder refer to this Agreement as a whole. Unless the context otherwise requires, references herein: (x) to Articles, Sections, Target Disclosure Schedules and Exhibits mean the Articles and Sections of, and Target Disclosure Schedules and Exhibits attached to, this Agreement; (y) to an agreement, instrument or other document means such agreement, instrument or other document as amended, supplemented and modified from time to time to the extent permitted by the provisions thereof; and (z) to a statute means such statute as amended from time to time and includes any successor legislation thereto and any regulations promulgated thereunder. This Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any
instrument to be drafted. The Target Disclosure Schedules and Exhibits referred to herein shall be construed with, and as an integral part of, this Agreement to the same extent as if they were set forth verbatim herein.
Section 12.05 Headings . The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.
Section 12.06 Severability . If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or unenforceable, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible.
Section 12.07 Entire Agreement . This Agreement and the other Transaction Documents constitute the sole and entire agreement of the parties to this Agreement with respect to the subject matter contained herein and therein, and supersede all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter. In the event of any inconsistency between the statements in the body of this Agreement and those in the other Transaction Documents, the Exhibits and Target Disclosure Schedules (other than an exception expressly set forth as such in the Target Disclosure Schedules), the statements in the body of this Agreement will control.
Section 12.08 Successors and Assigns . This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns. No party may assign (directly or indirectly, by operation of law or otherwise) its rights or obligations hereunder without the prior written consent of Purchaser and the Equityholder Representative, which consent shall not be unreasonably withheld or delayed; provided, however, that Purchaser or Merger Sub may, without the prior written consent of Equityholder Representative, assign all or any portion of its rights under this Agreement (i) following the Effective Time, to a successor of the Purchaser or Merger Sub, by consolidation, merger or operation of law, (ii) following the Effective Time, to a purchaser of all or substantially all of the Purchasers or Merger Subs assets, or (iii) to a lender of Purchaser or Merger Sub as collateral. No assignment shall relieve the assigning party of any of its obligations hereunder.
Section 12.09 No Third-party Beneficiaries . Except as provided in ARTICLE X , this Agreement is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.
Section 12.10 Amendment and Modification; Waiver . Prior to the Effective Time, this Agreement may only be amended, modified, or supplemented by an agreement in writing signed by the Parties hereto. Following the Effective Time, this Agreement may only be
amended, modified or supplemented by an agreement in writing signed by Purchaser and the Equityholder Representative. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. No waiver by any party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.
Section 12.11 Governing Law; Waiver of Jury Trial; Venue .
(a) This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction).
(b) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT OR THE OTHER TRANSACTION DOCUMENTS IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION, (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 12.11(b) .
THE PARTIES HERETO AGREE THAT ALL DISPUTES, ACTIONS, SUITS AND PROCEEDINGS ARISING OUT OF OR RELATING TO THIS AGREEMENT MUST BE BROUGHT EXCLUSIVELY IN A STATE OR FEDERAL DISTRICT COURT LOCATED IN DELAWARE (COLLECTIVELY THE DESIGNATED COURTS ). EACH PARTY HERETO HEREBY CONSENTS AND SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE DESIGNATED COURTS. NO ACTION, SUIT OR PROCEEDING WITH RESPECT TO THIS AGREEMENT MAY BE BROUGHT IN ANY OTHER FORUM. EACH PARTY HEREBY IRREVOCABLY WAIVES ALL CLAIMS OF IMMUNITY FROM JURISDICTION AND ANY OBJECTION WHICH SUCH PARTY MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUIT, ACTION OR PROCEEDING IN ANY DESIGNATED COURT, INCLUDING ANY RIGHT TO OBJECT ON THE BASIS THAT ANY DISPUTE, ACTION, SUIT OR PROCEEDING BROUGHT IN THE DESIGNATED
COURTS HAS BEEN BROUGHT IN AN IMPROPER OR INCONVENIENT FORUM OR VENUE.
Section 12.12 Specific Performance . The parties agree that irreparable damage would occur if any provision of this Agreement were not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy to which they are entitled at law or in equity.
Section 12.13 Counterparts . This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.
[SIGNATURE PAGE FOLLOWS]
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.
|
TARGET: |
|
|
|
|
|
TELADOC, INC. |
|
|
|
|
|
By |
/s/ Alan C. Roga |
|
|
|
|
|
Dr. Alan C. Roga |
|
|
Chief Executive Officer |
|
|
|
|
|
|
|
PURCHASER: |
|
|
|
|
|
TELADOC, INC. |
|
|
|
|
|
By |
/s/ Jason Gorevic |
|
|
|
|
|
Jason Gorevic |
|
|
Chief Executive Officer |
|
|
|
|
MERGER SUB: |
|
|
|
|
|
STAT HEALTH, LLC |
|
|
|
|
|
By |
/s/ Mark Hirschhorn |
|
|
|
|
|
Mark Hirschhorn |
|
|
Manager |
|
|
|
|
EQUITYHOLDER REPRESENTATIVE: |
|
|
|
|
|
By |
/s/ John Barravecchia |
|
|
|
|
|
|
|
John Barravecchia, (not in his individual |
|
|
capacity, but as an agent of the |
|
|
Stockholders and Optionholders |
|
|
pursuant to the terms of this Agreement) |
Exhibit 10.8
TELADOC, INC.
SECOND AMENDED AND RESTATED
STOCK INCENTIVE PLAN
TABLE OF CONTENTS
|
|
Page |
|
|
|
ARTICLE 1. |
ESTABLISHMENT, PURPOSE, AND DURATION |
1 |
|
|
|
1.1 |
Establishment of the Plan |
1 |
1.2 |
Purpose of the Plan |
1 |
1.3 |
Duration of the Plan |
1 |
|
|
|
ARTICLE 2. |
DEFINITIONS |
1 |
|
|
|
ARTICLE 3. |
ADMINISTRATION |
5 |
|
|
|
3.1 |
The Committee |
5 |
3.2 |
Authority of the Committee |
5 |
3.3 |
Decisions Binding |
6 |
|
|
|
ARTICLE 4. |
SHARES SUBJECT TO THE PLAN |
6 |
|
|
|
4.1 |
Number of Shares |
6 |
4.2 |
Lapsed Awards |
6 |
4.3 |
Adjustments In Authorized Shares |
6 |
|
|
|
ARTICLE 5. |
ELIGIBILITY AND PARTICIPATION |
7 |
|
|
|
ARTICLE 6. |
STOCK OPTIONS |
7 |
|
|
|
6.1 |
Grant of Options |
7 |
6.2 |
Agreement |
7 |
6.3 |
Option Price |
7 |
6.4 |
Duration of Options |
8 |
6.5 |
Exercise of Options |
8 |
6.6 |
Payment |
8 |
6.7 |
Limited Transferability |
8 |
6.8 |
Stockholder Rights |
9 |
|
|
|
ARTICLE 7. |
BENEFICIARY DESIGNATION |
9 |
|
|
|
ARTICLE 8. |
RIGHTS OF EMPLOYEES |
9 |
|
|
|
8.1 |
Employment |
9 |
8.2 |
Participation |
9 |
|
|
|
ARTICLE 9. |
AMENDMENT, MODIFICATION AND TERMINATION |
9 |
|
|
|
9.1 |
Amendment, Modification and Termination |
9 |
9.2 |
Awards Previously Granted |
10 |
9.3 |
Compliance With Code Section 162(m) |
10 |
ARTICLE 10. |
WITHHOLDING |
10 |
|
|
|
10.1 |
Tax Withholding |
10 |
10.2 |
Share Withholding |
10 |
|
|
|
ARTICLE 11. |
INDEMNIFICATION |
10 |
|
|
|
ARTICLE 12. |
SUCCESSORS |
11 |
|
|
|
ARTICLE 13. |
LEGAL CONSTRUCTION |
11 |
|
|
|
13.1 |
Gender and Number |
11 |
13.2 |
Severability |
11 |
13.3 |
Requirements of Law |
11 |
13.4 |
Regulatory Approvals and Listing |
11 |
13.5 |
Securities Law Compliance |
11 |
13.6 |
Governing Law |
12 |
TELADOC, INC.
SECOND AMENDED AND RESTATED
STOCK INCENTIVE PLAN
ARTICLE 1. ESTABLISHMENT, PURPOSE, AND DURATION
1.1 Establishment of the Plan . Teladoc, Inc., a Delaware corporation (hereinafter referred to as the Company ), hereby establishes this Second Amended and Restated Stock Incentive Plan (this Plan ), which fully amends and restates that certain stock option and incentive award plan known as the TelaDoc, Inc. Amended and Restated Stock Incentive Plan, as set forth herein. This Plan permits the grant of Incentive Stock Options and Nonqualified Stock Options.
This Plan shall become effective on the date it is approved by the Companys Board of Directors (the Effective Date ), and shall remain in effect as provided in Section 1.3 .
1.2 Purpose of the Plan . The purpose of this Plan is to secure for the Company and its stockholders the benefits of the incentive inherent in stock ownership in the Company by employees, directors, and consultants or other individuals who perform services for the Company or its Affiliates, who are responsible for its future growth and continued success. This Plan promotes the success and enhances the value of the Company by linking the personal interests of Participants (as defined below) to those of the Companys stockholders, and by providing Participants with an incentive for outstanding performance. This Plan is further intended to provide flexibility to the Company in its ability to motivate, attract and retain the services of Participants upon whose judgment, interest and special effort the successful conduct of its operation largely depends.
1.3 Duration of the Plan . This Plan shall commence on the Effective Date, and shall remain in effect, subject to the right of the Board to amend or terminate this Plan at any time pursuant to Article 9 , until December 31, 2014.
ARTICLE 2. DEFINITIONS
Whenever used in this Plan, the following terms shall have the meanings set forth below:
(a) Affiliate means (i) each of TelaDoc Physicians, P.A., a Texas professional association, and (ii) any entity during any period in which it is a subsidiary corporation (as that term is defined in Code Section 424(f)) with respect to the Company
(b) Agreement means an agreement entered into by each Participant and the Company, setting forth the terms and provisions applicable to Awards granted to Participants under this Plan.
(c) Award means, individually or collectively, a grant under this Plan of Incentive Stock Options or Nonqualified Stock Options.
(d) Beneficial Owner or Beneficial Ownership shall have the meaning ascribed to such term in Rule 13d-3 of the Exchange Act.
(e) Board or Board of Directors means the Board of Directors of the Company.
(f) Change in Control means any of the following events:
(i) The acquisition (other than from the Company) by any Person of Beneficial Ownership of fifty percent (50%) or more of the combined voting power of the Companys then outstanding voting securities; provided, however, that for purposes of this Section 2(f) , the term Person shall not include any person who on the date hereof owns 25% or more of the combined voting power of the Companys outstanding securities, and a Change in Control shall not be deemed to occur solely because fifty percent (50%) or more of the combined voting power of the Companys then outstanding securities is acquired by (i) a trustee or other fiduciary holding securities under one or more employee benefit plans maintained by the Company or any of its subsidiaries, or (ii) any corporation, which, immediately prior to such acquisition, is owned directly or indirectly by the stockholders of the Company in the same proportion as their ownership of stock in the Company immediately prior to such acquisition.
(ii) Approval by stockholders of the Company of (1) a merger or consolidation involving the Company if the stockholders of the Company, immediately before such merger or consolidation do not, as a result of such merger or consolidation, own, directly or indirectly, more than fifty percent (50%) of the combined voting power of the then outstanding voting securities of the corporation resulting from such merger or consolidation in substantially the same proportion as their ownership of the combined voting power of the voting securities of the Company outstanding immediately before such merger or consolidation, or (2) a complete liquidation or dissolution of the Company or an agreement for the sale or other disposition of all or substantially all of the assets of the Company.
(iii) A change in the composition of the Board such that the individuals who, as of the Effective Date, constitute the Board (such Board shall be hereinafter referred to as the Incumbent Board ) cease for any reason to constitute at least a majority of the Board; provided, however, for purposes of this Section 2(f) that any individual who becomes a member of the Board subsequent to the Effective Date whose election, or nomination for election by the Companys stockholders, was approved by a vote of at least a majority of those individuals who are members of the Board and who were also
members of the Incumbent Board (or deemed to be such pursuant to this proviso) shall be considered as though such individual were a member of the Incumbent Board; but, provided, further, that any such individual whose initial assumption of office occurs as a result of either an actual or threatened election contest (as such terms are used in Rule 14a-11 of Regulation 14A promulgated under the Exchange Act, including any successor to such Rule), or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board, shall not be so considered as a member of the Incumbent Board.
(g) Code means the Internal Revenue Code of 1986, as amended from time to time, or any successor act thereto.
(h) Committee shall have the meaning ascribed to such term in Section 3.1 .
(i) Common Stock means the common stock of the Company, par value $.001 per share.
(j) Company shall have the meaning ascribed to such term in Section 1.1 .
(k) Director means any individual who is a member of the Board of Directors of the Company.
(l) Effective Date shall have the meaning ascribed to such term in Section 1.1 .
(m) Employee means any employee of the Company or any of its Affiliates. Directors who are not otherwise employed by the Company or its Affiliates are not considered Employees under this Plan.
(n) Exchange Act means the Securities Exchange Act of 1934, as amended from time to time, or any successor act thereto.
(o) Fair Market Value shall be determined as follows:
(i) If, on the relevant date, the Shares are traded on a national or regional securities exchange or on Nasdaq and closing sale prices for the Shares are customarily quoted, on the basis of the closing sale price on the principal securities exchange on which the Shares may then be traded or, if there is no such sale on the relevant date, then on the immediately preceding day on which a sale was reported;
(ii) If, on the relevant date, the Shares are not listed on any securities exchange or traded on Nasdaq, but nevertheless are publicly traded and reported on Nasdaq without closing sale prices for the Shares being customarily quoted, on the basis of the mean between the
closing bid and asked quotations in such other over-the-counter market as reported by Nasdaq; but, if there are no bid and asked quotations in the over-the-counter market as reported by Nasdaq on that date, then the mean between the closing bid and asked quotations in the over-the-counter market as reported by Nasdaq on the immediately preceding day such bid and asked prices were quoted; and
(iii) If, on the relevant date, the Shares are not publicly traded as described in (i) or (ii), on the basis of the good faith determination of the Committee.
(p) Immediate Family shall have the meaning ascribed to such term in Section 6.7 .
(q) Incentive Stock Option or ISO means an option to purchase Shares granted under Article 6 which is designated as an Incentive Stock Option and is intended to meet the requirements of Section 422 of the Code,
(r) Insider shall mean an Employee who is, on the relevant date, an officer or a directors or a ten percent (10%) Beneficial Owner of any class of the Companys or its Affiliates equity securities that is registered pursuant to Section 12 of the Exchange Act or any successor provision, as officer and director are defined under Section 16 of the Exchange Act,
(s) Named Executive Officer means a Participant who, as of the date of vesting and/or payout of an Award is one of the group of covered employees, as defined in the regulations promulgated under Code Section 162(m), or any successor statute.
(t) Nasdaq means The Nasdaq Stock Market.
(u) Nonqualified Stock Option or NQSO means an option to purchase Shares granted under Article 6 , and which is not intended to meet the requirements of Code Section 422.
(v) Option means an Incentive Stock Option or a Nonqualified Stock Option.
(w) Option Price means the price at which a Share may be purchased by a Participant pursuant to an Option, as determined by the Committee.
(x) Participant means an Employee, a Director, a consultant or other individual who performs services for the Company or any of its Affiliates, and who has been granted an Award under this Plan which is outstanding.
(y) Person shall have the meaning ascribed to such term in Section 3(a)(9) of the Exchange Act and used in Sections 13(d) and 14(d) thereof, including a group as defined in Section 13(d) thereof.
(z) Plan shall have the meaning ascribed to such term in Section 1.1 .
(aa) Shares means the shares of Common Stock of the Company (including any new, additional or different stock or securities resulting from the changes described in Section 4.3 ).
ARTICLE 3. ADMINISTRATION
3.1 The Committee . This Plan shall be administered by the Board or Compensation Committee of the Board, or by any other committee, subcommittee or Person appointed by the Board that is granted authority to administer this Plan (hereinafter, the Committee ). Subject to the Committees charter, the members of the Committee shall be appointed from time to time by, and shall serve at the discretion of, the Board of Directors.
3.2 Authority of the Committee . Subject to the provisions of this Plan, the Committee shall have full power to select the Employees, Directors, consultants and other individuals who perform services for the Company or its Affiliates who shall participate in this Plan (who may change from year to year); determine the size and types of Awards; determine the terms and conditions of Awards in a manner consistent with this Plan (including conditions on the exercisability of all or a part of an Option and/or conditions regarding the forfeiture or repurchase of all or a part of an Option or Shares issued upon the exercise of an Option upon cessation of a Participants service to the Company or its Affiliates); construe and interpret this Plan and any agreement or instrument entered into under this Plan; establish, amend or waive rules and regulations for this Plans administration; and (subject to the provisions of Article 9 ) amend the terms and conditions of any outstanding Award to the extent such terms and conditions are within the discretion of the Committee as provided in this Plan, including accelerating the time any Option may be exercised and establishing different terms and conditions relating to the effect of the termination of a Participants employment by or provision of services to the Company or its Affiliates. Without limiting the generality of the foregoing, as a condition to the issuance of any Award, the Committee may, in its discretion, require the applicable Participant to agree (as part of such Participants Agreement or otherwise) that in the event that such Participant ceases to be employed, engaged or retained by the Company or its Affiliates for any reason, then all Options granted or awarded to such Participant (of whatever nature and whether held by such Participant or by one or more of such Participants) and Shares issued upon exercise of such Options which as of the date of termination: (i) have not vested or have vested but are subject (in accordance with the applicable Agreement or this Plan) to automatic forfeiture or cancellation upon cessation of such Participants employment or engagement, will be cancelled (and no consideration will be paid by the Company therefor), (ii) have vested and are not subject (in accordance with the applicable Agreement or this Plan) to automatic forfeiture or cancellation upon cessation of the Participants employment or engagement, will be subject to repurchase by the Company, at the option of the Board, at a price equal (A) with respect to an Option, the aggregate Fair Market Value of the Shares underlying such Option less the aggregate Option Price payable under such Option in respect of such Shares,
and (B) with respect to Shares issued upon the exercise of Options, the aggregate Fair Market Value of the Shares. Further, the Committee shall make all other determinations which may be necessary or advisable in the Committees opinion for the administration of this Plan. All expenses of administering this Plan shall be borne by the Company.
3.3 Decisions Binding . All determinations and decisions made by the Committee pursuant to the provisions of this Plan and all related orders and resolutions of the Board shall be final, conclusive and binding on all Persons, including the Company, its Affiliates, their respective stockholders and equity owners, Employees, Participants and their respective estates and beneficiaries.
ARTICLE 4. SHARES SUBJECT TO THE PLAN
4.1 Number of Shares . Subject to adjustment as provided in Section 4.3 , the total number of Shares available for grant of all Awards under this Plan shall be equal to eight million sixty three thousand one hundred twenty six (8,063,126) Shares. The Shares may, in the discretion of the Company, be either authorized but unissued Shares or Shares held as treasury shares, including Shares purchased by the Company, whether on the market or otherwise. The following rules shall apply for purposes of the determination of the number of Shares available for grant under this Plan:
(a) The grant of an Option shall reduce the Shares available for grant under this Plan by the number of Shares subject to such Award.
(b) While an Option is outstanding, it shall be counted against the authorized pool of Shares, regardless of its vested status,
4.2 Lapsed Awards . If any Award granted under this Plan is canceled, terminates, expires or lapses for any reason, or if Shares are withheld in payment of the Option Price or for withholding taxes, any Shares subject to such Award or that are withheld shall again be available for the grant of an Award under this Plan. However, in the event that prior to an Awards cancellation, termination, expiration or lapse, the holder of such Award at any time received one or more benefits of ownership pursuant to such Award (as defined by the Securities and Exchange Commission, pursuant to any rule or interpretation promulgated under Section 16 of the Exchange Act), the Shares subject to such Award shall not again be made available for re-granting under this Plan.
4.3 Adjustments In Authorized Shares . In the event of any change in corporate capitalization, such as a stock split, or a corporate transaction, such as any merger, consolidation, separation, including a spin-off, or other distribution of stock or property of the Company, any reorganization (whether or not such reorganization comes within the definition of such term in Code Section 368) or any partial or complete liquidation of the Company, such adjustment shall be made in the number and class of Shares which may be delivered under this Plan, and in tire number and class of and for price of Shares subject to outstanding Awards granted under this Plan, as may be determined to be appropriate by the Committee, in its sole discretion, to prevent dilution or enlargement of rights; provided, however, that the number of Shares subject to any
Award shall always be a whole number and the Committee shall make such adjustments as are necessary to insure Awards of whole Shares.
ARTICLE 5. ELIGIBILITY AND PARTICIPATION
Any key Employee of the Company or any Affiliate, including any such Employee who is also a Director of the Company or a director of any of its Affiliates, any non-employee Director, and any consultant or other individual who performs services for the Company or any of its Affiliates, whose judgment, initiative and efforts contribute or may be expected to contribute materially to the successful performance of the Company or any of its Affiliates shall be eligible to receive an Award under this Plan. In determining the individuals to whom such an Award shall be granted and the number of Shares which may be granted pursuant to that Award, the Committee shall take into account the duties of the respective individual, his or her present and potential contributions to the success of the Company and its Affiliates, and such other factors as the Committee shall deem relevant in connection with accomplishing the purpose of this Plan.
ARTICLE 6. STOCK OPTIONS
6.1 Grant of Options . Subject to the terms and provisions of this Plan, Options may be granted to Participants at any time and from time to time as shall be determined by the Committee. The Committee shall have discretion in determining the number of Shares subject to Options granted to each Participant. No Participant may be granted ISOs (under this Plan and all other incentive stock option plans of the Company and any of its Affiliate) which are first exercisable in any calendar year for Common Stock having an aggregate Fair Market Value (determined as of the date an Option is granted) that exceeds $100,000. The preceding annual limit shall not apply to NQSOs. The Committee may grant a Participant ISOs, NQSOs or a combination thereof, and may vary such Awards among Participants; provided that only an Employee of the Company (but not an Employee of an Affiliate) may be granted ISOs.
6.2 Agreement . Each Option grant shall be evidenced by an Agreement that shall specify the Option Price, the duration of the Option, the number of Shares to which the Option pertains and such other provisions as the Committee shall determine. The Option Agreement shall further specify whether the Award is intended to be an ISO or an NQSO. Any portion of an Option that is not designated as an ISO or otherwise fails or is not qualified as an ISO (even if designated as an ISO) shall be a NQSO.
6.3 Option Price . The Option Price for each grant of an ISO shall not be less than one hundred percent (100%) of the Fair Market Value of a Share on the date the Option is granted. In no event, however, shall any Participant who owns (within the meaning of Section 424(d) of the Code) stock of the Company possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company be eligible to receive an ISO at an Option Price less than one hundred ten percent (110%) of the Fair Market Value of a Share on the date the ISO is granted. The Option Price for each grant of a NQSO shall be established by the Committee and, in its discretion, may be less than the Fair Market Value of a Share on the date the Option is granted, but only if such Option complies with the requirements of Code Section 409A.
6.4 Duration of Options . Each Option shall expire at such time as the Committee shall determine at the time of grant; provided, however, that no Option shall be exercisable later than the tenth (10th) anniversary date of its grant; provided, further, however, that any ISO granted to any Participant who at such time owns (within the meaning of Section 424(d) of the Code) stock of the Company possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company, shall not be exercisable later than the fifth (5th) anniversary date of its grant.
6.5 Exercise of Options . Options granted under this Plan shall be exercisable at such times and be subject to such restrictions and conditions as the Committee shall in each instance approve, including conditions related to the Participants employment by or provision of services to the Company or any of its Affiliates, which need not be the same for each grant or for each Participant. Each Option shall be exercisable for such number of Shares and at such time or times, including periodic installments, as may be determined by the Committee at the time of the grant. The Committee may provide in the Agreement for automatic accelerated vesting and other rights upon the occurrence of a Change in Control of the Company. Except as otherwise provided in the Agreement, the right to purchase Shares that are exercisable in periodic installments shall be cumulative so that when the right to purchase any Shares has accrued, such Shares or any part thereof may be purchased at any time thereafter until the expiration or termination of the Option.
6.6 Payment . Options shall be exercised by the delivery of a written notice of exercise to the Company, setting forth the number of Shares with respect to which the Option is to be exercised, accompanied by full payment for the Shares. The Option Price upon exercise of any Option shall be payable to the Company in full, either: (a) in cash, (b) cash equivalent approved by the Committee, (c) if approved by the Committee, by tendering previously acquired Shares or delivering a certification of ownership of such Shares) having an aggregate Fair Market Value at the time of exercise equal to the total Option Price (provided that the Shares which are tendered must have been held by the Participant for six (6) months, if required for accounting purposes, and for the period required by law, if any, prior to their tender to satisfy the Option Price), or (d) by a combination of (a), (b) and (c). The Committee also may allow cashless exercises as permitted under Federal Reserve Boards Regulation T, subject to applicable securities law restrictions, or by any other means which the Committee determines to be consistent with this Plans purpose and applicable law. As soon as practicable after receipt of a written notification of exercise and full payment, the Company shall deliver to the Participant, in the Participants name, Share certificates in an appropriate amount based upon the number of Shares purchased under the Option(s), and may place appropriate legends on the certificates representing such Shares.
6.7 Limited Transferability . If permitted by the Committee in the Agreement, a Participant may transfer an Option granted hereunder, including, but not limited to, transfers to members of his or her Immediate Family (as defined below), to one or more trusts for the benefit of such Immediate Family members, or to one or more partnerships where such Immediate Family members are the only partners, if (i) the Participant does not receive any consideration in any form whatsoever for such transfer, (ii) such transfer is permitted under applicable tax laws, and (iii) if the Participant is an Insider, such transfer is permitted under Rule 16b-3 of the Exchange Act as in effect from time to time. Any Option so transferred shall continue to be
subject to the same terms and conditions in the hands of the transferee as were applicable to said Option immediately prior to the transfer thereof. Any reference in any such Agreement to the employment by or provision of services to the Company or any of its Affiliates by the Participant shall continue to refer to the employment of or provision of services by, the transferring Participant. For purposes hereof, Immediate Family shall mean the Participant and the Participants spouse, children and grandchildren. Any Option that is granted pursuant to any Agreement that did not initially expressly allow the transfer of said Option and that has not been amended to expressly permit such transfer, shall not be transferable by the Participant other than by will or by the laws of descent and distribution and such Option thus shall be exercisable in the Participants lifetime only by the Participant.
6.8 Stockholder Rights . No Participant shall have any rights as a stockholder with respect to Shares subject to an Option until the issuance of such Shares to the Participant pursuant to the exercise of such Option.
ARTICLE 7. BENEFICIARY DESIGNATION
To the extent applicable, each Participant under this Plan may, from time to time, name any beneficiary or beneficiaries (who may be mined contingently or successively) to whom any benefit under this Plan is to be paid in case of his or her death before he or she receives any or all of such benefit. Each such designation shall revoke all prior designations by the same Participant, shall be in a form prescribed by the Company and shall be effective only when filed by the Participant, in writing, with the Company during the Participants lifetime. In the absence of any such designation, benefits remaining unpaid at the Participants death shall be paid to the Participants estate. If required, the spouse of a married Participant domiciled in a community property jurisdiction shall join in any designation of a beneficiary or beneficiaries other than the spouse.
ARTICLE 8. RIGHTS OF EMPLOYEES
8.1 Employment . Nothing in this Plan shall interfere with or limit in any way the right of the Company or any of its Affiliates to terminate any Participants employment by, or provision of services to, the Company or such Affiliate at any time, nor confer upon any Participant any right to continue in the employ or service of the Company or any of its Affiliates. For purposes of this Plan and any Agreement issued pursuant hereto, transfer of employment of a Participant between the Company and any one of its Affiliates (or between Affiliates) shall not be deemed a termination of employment.
8.2 Participation . No Employee shall have the right to be selected to receive an Award under this Plan, or, having been so selected, to be selected to receive a future Award.
ARTICLE 9. AMENDMENT, MODIFICATION AND TERMINATION
9.1 Amendment, Modification and Termination . The Board may, at any time and from time to time, alter, amend, suspend or terminate this Plan in whole or in part; provided, that, unless approved by the holders of a majority of the outstanding shares of the Companys preferred stock, par value $.001 per share, and Common Stock, voting together as a single class on an as-converted basis, no amendment shall be made to this Plan if such amendment would
(a) materially modify the eligibility requirements provided in Article 5 ; (b) increase the total number of Shares (except as provided in Section 4.3 ) which may be granted -under this Plan; (c) extend the term of this Plan; or (d) amend this Plan in any other manner which the Board, in its discretion, determines should become effective only if approved by the stockholders even if such stockholder approval is not expressly required by this Plan or by law.
9.2 Awards Previously Granted . No termination, amendment or modification of this Plan shall adversely affect in any material way any Award previously granted under this Plan, without the written consent of the Participant holding such Award. The Committee shall, with the written consent of the Participant holding such Award, have the authority to cancel Awards outstanding and grant replacement Awards therefor.
9.3 Compliance With Code Section 162(m) . At all times when the Committee determines that compliance with Code Section 162(m) is required or desired, all Awards granted under this Plan to Named Executive Officers shall comply with the requirements of Code Section 162(m). In addition, in the event that changes are made to Code Section 162(m) to permit greater flexibility with respect to any Award or Awards under this Plan, the Committee may, subject to this Article 9 , make any adjustments it deem appropriate.
ARTICLE 10. WITHHOLDING
10.1 Tax Withholding . The Company shall have the power and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy federal, state and local taxes (including the Participants FICA obligation) required by law to be withheld with respect to any taxable event arising in connection with an Award under this Plan.
10.2 Share Withholding . With respect to withholding required upon the exercise of Options, or upon any other taxable event arising as a result of Awards granted hereunder which are to be paid in the form of Shares, Participants may elect, subject to the approval of the Committee, to satisfy the withholding requirement, in whole or in part, by having the Company withhold Shares having a Fair Market Value on the date the tax is to be determined equal to the minimum statutory total tax which could be imposed on the transaction. All elections shall be irrevocable, made in writing, signed by the Participant, and elections by Insiders shall additionally comply with all legal requirements applicable to Share transactions by such Participants.
ARTICLE 11. INDEMNIFICATION
Each individual who is or shall have been a member of the Committee, or the Board, shall be indemnified and held harmless by the Company against and from any loss, cost, liability or expense that may be imposed upon or reasonably incurred by him or her in connection with or resulting from any claim, action, suit or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action taken or failure to act under this Plan and against and from any and all amounts paid by him or her in settlement thereof, with the Companys approval, or paid by him in satisfaction of any judgment in any such action, suit or proceeding against him, provided he shall give the Company an opportunity, at its own expense, to handle and defend the same before he undertakes to handle and defend it on his own behalf.
The foregoing right of indemnification shall be in addition to any other rights of indemnification to which such individuals may be entitled under the Companys Certificate of Incorporation or Bylaws, as a matter of law, or otherwise, or any power that the Company may have to indemnify them or hold them harmless.
ARTICLE 12. SUCCESSORS
All obligations of the Company under this Plan, with respect to Awards granted hereunder, shall be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation or otherwise, of all or substantially all of the business and/or assets of the Company.
ARTICLE 13. LEGAL CONSTRUCTION
13.1 Gender and Number . Except where otherwise indicated by the context, any masculine term used herein shall also include the feminine; the plural shall include the singular and the singular shall include the plural.
13.2 Severability . If any provision of this Plan shall be held illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining parts of this Plan, and this Plan shall be construed and enforced as if the illegal or invalid provision had not been included.
13.3 Requirements of Law . The granting of Awards and the issuance of Shares under this Plan shall be subject to all applicable laws, rules and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.
13.4 Regulatory Approvals and Listing . The Company shall not be required to issue any certificate or certificates for Shares under this Plan prior to (i) obtaining any approval from any governmental agency which the Company shall, in its discretion, determine to be necessary or advisable, (ii) the admission of such Shares to listing on any national securities exchange or Nasdaq on which the Companys Shares may be listed, and (iii) the completion of any registration or other qualification of such Shares under any state or federal law or ruling or regulation of any governmental body which the Company shall, in its sole discretion, determine to be necessary or advisable.
Notwithstanding any other provision set forth in this Plan, if required by the then-current Section 16 of the Exchange Act, any derivative security or equity security offered pursuant to this Plan to any Insider may not be sold or transferred for at least six (6) months after the date of grant of such Award. The terms equity security and derivative security shall have the meanings ascribed to them in the then-current Rule 16(a) under the Exchange Act.
13.5 Securities Law Compliance . With respect to Insiders, transactions under this Plan are intended to comply with all applicable conditions of Rule 16b-3 or its successors under the Exchange Act. To the extent any provisions of this Plan or action by the Committee fails to so comply, it shall be deemed null and void, to the extent permitted by law and deemed advisable by the Committee.
13.6 Governing Law . To the extent not preempted by Federal law, this Plan, the entire relationship of the parties hereto, all agreements hereunder and any litigation between them (whether grounded in contract, tort, statute, law or equity), shall be construed in accordance with and governed by the laws of the State of Delaware without giving effect to its conflicts of laws principles.
AS APPROVED BY THE BOARD OF DIRECTORS OF TELADOC, INC. ON OCTOBER 17, 2013,
|
TELADOC, INC. |
|
|
|
|
|
|
|
|
By: |
/s/ Jason Gorevic |
|
Name: Jason Gorevic |
|
|
Title: Chief Executive Officer |
Exhibit 10.9
TELADOC, INC.
STOCK OPTION AGREEMENT
Unless otherwise defined herein, the terms defined in the Teladoc, Inc. Amended and Restated Stock Incentive Plan, as amended to date (the Plan) shall have the same defined meanings in this Option Agreement.
I. NOTICE OF STOCK OPTION GRANT
Optionees Name and Address:
The undersigned Optionee has been granted an Option to purchase Common Stock of the Company, subject to the terms and conditions of the Plan and this Option Agreement, as follows:
Vesting Schedule :
This Option shall be exercisable, in whole or in part, according to the following vesting schedule:
The Option will vest over a four (4) year period, with twenty-five (25%) percent or «M_25_vest» of such shares vesting on the Vesting Commencement Date set forth above, and the remaining shares vesting in equal (monthly) installments of «Monthly_Vest» shares per month over the
following thirty-six (36) months.
Termination Period :
This Option shall be exercisable for ninety (90) days after Optionee ceases to be a Service Provider, provided, however, if the Optionee ceases to be a Service Provider as a result of termination for cause, this Option shall terminate immediately and Optionee shall forfeit all rights to exercise this Option. The term for cause as used herein shall mean (i) the failure of the Optionee to observe or perform (other than by reason of illness, injury or incapacity) any of the terms of his employment, (ii) the failure of the Optionee to comply fully with the lawful directives of the Companys board or senior officers, (iii) willful misconduct, (iv) material neglect of the Companys business, (v) conviction of a felony or other crime involving moral turpitude, or (vi) misappropriation of funds. Upon Optionees death or Disability, this Option may be exercised for one year after Optionee ceases to be a Service Provider. In no event may Optionee exercise this Option after the Term/Expiration Date as provided above.
II. AGREEMENT
1. Grant of Option . The Plan Administrator of the Company hereby grants to the Optionee named in the Notice of Grant (the Optionee), an option (the Option) to purchase the number of Shares set forth in the Notice of Grant, at the exercise price per Share set forth in the Notice of Grant (the Exercise Price), and subject to the terms and conditions of the Plan, which is incorporated herein by reference. Subject to Article 6.5 of the Plan, in the event of a conflict between the terms and conditions of the Plan and this Option Agreement, the terms and conditions of the Plan shall prevail.
If designated in the Notice of Grant as an Incentive Stock Option (ISO), this Option is intended to qualify as an Incentive Stock Option as defined in Section 422 of the Code. Nevertheless, to the extent that it exceeds the $100,000 rule of Code Section 422(d), this Option shall be treated as a Nonqualified Stock Option (NSO).
2. Exercise of Option .
(a) Right to Exercise . This Option shall be exercisable during its term in accordance with the Vesting Schedule set out in the Notice of Grant and with the applicable provisions of the Plan and this Option Agreement.
(b) Method of Exercise . This Option shall be exercisable by delivery of an exercise notice in the form attached as Exhibit A (the Exercise Notice) which shall state the election to exercise the Option, the number of Shares with respect to which the Option is being exercised, and such other representations and agreements as may be required by the Company. The Exercise Notice shall be accompanied by payment of the aggregate Exercise Price as to all exercised Shares. This Option shall be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by the aggregate Exercise Price.
No Shares shall be issued pursuant to the exercise of an Option unless such issuance and such exercise complies with Applicable Laws. Assuming such compliance, for income tax purposes the Shares shall be considered transferred to the Optionee on the date on which the Option is exercised with respect to such Shares.
3. Method of Payment . Payment of the aggregate Exercise Price shall be by any of the following, or a combination thereof, at the election of the Optionee:
(a) cash or check;
(b) consideration received by the Company under a formal cashless exercise program adopted by the Company in connection with the Plan; or
(c) surrender of other Shares which, (i) in the case of Shares acquired upon exercise of an option, have been owned by the Optionee for more than six (6) months on the date of surrender, and (ii) have a Fair Market Value on the date of surrender equal to the aggregate Exercise Price of the Exercised Shares.
4. Restrictions on Exercise . This Option may not be exercised if the issuance of such Shares upon such exercise or the method of payment of consideration for such shares would constitute a violation of any Applicable Law.
5. Non-Transferability of Option . This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised during the lifetime of Optionee only by Optionee. The terms of the Plan and this Option Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of the Optionee.
6. Term of Option . This Option may be exercised only within the term set out in the Notice of Grant, and may be exercised during such term only in accordance with the Plan and the terms of this Option.
7. Lock-Up Period . Optionee hereby agrees that, if so requested by the Company or any representative of the underwriters (the Managing Underwriter) in connection with any registration of the offering of any securities of the Company under the Securities Act, Optionee shall not sell or otherwise transfer any Shares or other securities of the Company during the 180-day period (or such other period as may be requested in writing by the Managing Underwriter and agreed to in writing by the Company) (the Market Standoff Period) following the effective date of a registration statement of the Company filed under the Securities Act. Such restriction shall apply only to the first registration statement of the Company to become effective under the Securities Act that includes securities to be sold on behalf of the Company to the public in an underwritten public offering under the Securities Act. The Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such Market Standoff Period.
8. Transfer Restrictions Upon Exercise . Upon exercise, the Optionee agrees, as a condition hereof, to execute a joinder to , and agree to be bound by, the then effective Investors Rights Agreement regarding the Company and certain of its stockholders (the IRA), which joinder shall be in form and substance acceptable to the Company. Optionee hereby agrees and acknowledges that, notwithstanding anything in the Option Agreement to the contrary, upon execution of the IRA in accordance with this Section 8, he shall be bound by the restrictions (including restrictions on transfer) set forth in the IRA.
9. Tax Consequences . The exercise of this Option and the subsequent disposition of the Shares may cause the Optionee to be subject to federal and state taxation. The Optionee should consult a tax advisor before exercising this Option or disposing of the shares purchased hereunder.
10. Entire Agreement; Governing Law . The Plan is incorporated herein by reference. The Plan and this Option Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and Optionee with respect to the subject matter hereof, and may not be modified adversely to the Optionees interest except by means of a writing signed by the Company and Optionee. This agreement is governed by the internal substantive laws but not the choice of law rules of Delaware.
11. No Guarantee of Continued Service . OPTIONEE ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER). OPTIONEE FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH OPTIONEES RIGHT OR THE COMPANYS RIGHT TO TERMINATE OPTIONEES RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE.
Optionee acknowledges receipt of a copy of the Plan and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts this Option subject to all of the terms and provisions thereof. Optionee has reviewed the Plan and this Option in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Option and fully understands all provisions of the Option. Optionee hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan or this Option. Optionee further agrees to notify the Company upon any change in the residence address indicated below.
EXHIBIT A
TELADOC, INC.
STOCK OPTION EXERCISE NOTICE
Teladoc, Inc.
Attention: President
1. Exercise of Option . Effective as of today, , , the undersigned (Optionee) hereby elects to exercise Optionees option to purchase shares of the Common Stock (the Shares) of Teladoc, Inc. (the Company) under and pursuant to the Amended and Restated Stock Incentive Plan (as amended to date, the Plan) and the Stock Option Agreement dated , (the Option Agreement).
2. Delivery of Payment . Purchaser herewith delivers to the Company the full purchase price of the Shares, as set forth in the Option Agreement.
3. Representations of Optionee . Optionee acknowledges that Optionee has received, read and understood the Plan and the Option Agreement and agrees to abide by and be bound by their terms and conditions.
4. Rights as Shareholder . Until the issuance of the Shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a shareholder shall exist with respect to the Optioned Stock, notwithstanding the exercise of the Option. The Shares shall be issued to the Optionee as soon as practicable after the Option is exercised. No adjustment shall be made for a dividend or other right for which the record date is prior to the date of issuance except as provided in Article 6 of the Plan.
5. Tax Consultation . Optionee understands that Optionee may suffer adverse tax consequences as a result of Optionees purchase or disposition of the Shares. Optionee represents that Optionee has consulted with any tax consultants Optionee deems advisable in connection with the purchase or disposition of the Shares and that Optionee is not relying on the Company for any tax advice.
6. Optionees Representations . Optionee represents to the Company that Optionee is acquiring these shares for Optionees own account and not with a view to resale or distribution. Optionee understands that the Shares are restricted
securities within the meaning of the Securities Act of 1933, as amended (the Securities Act), and may not be transferred or resold except pursuant to registration under the Securities Act or an exemption therefrom.
7. Restrictive Legends and Stop-Transfer Orders .
(a) Legends . Optionee understands and agrees that the Company shall cause the legends set forth below or legends substantially equivalent thereto, to be placed upon any certificate(s) evidencing ownership of the Shares together with any other legends that may be required by the Company or by state or federal securities laws:
THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE ACT) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COMPANY COUNSEL SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE THEREWITH.
THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AND A RIGHT OF FIRST REFUSAL HELD BY THE ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE STOCK OPTION AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH TRANSFER RESTRICTIONS AND RIGHT OF FIRST REFUSAL ARE BINDING ON TRANSFEREES OF THESE SHARES.
8. Stop-Transfer Notices . Optionee agrees that, in order to ensure compliance with the restrictions referred to herein, the Company may issue appropriate stop transfer instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records.
9. Refusal to Transfer . The Company shall not be required (i) to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or (ii) to treat as owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred.
10. Successors and Assigns . The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth, this Agreement shall be binding upon Optionee and his or her heirs, executors, administrators, successors and assigns.
11. Interpretation . Any dispute regarding the interpretation of this Agreement shall be submitted by Optionee or by the Company forthwith to the Administrator which shall review such dispute at its next regular meeting. The resolution of such a dispute by the Administrator shall be final and binding on all parties.
12. Governing Law; Severability . This Agreement shall be governed by the internal substantive laws but not the choice of law rules, of Delaware.
13. Entire Agreement . The Plan and Option Agreement are incorporated herein by reference. This Agreement, the Plan, the Option Agreement and the Investment Representation Statement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and Optionee with respect to the subject matter hereof, and may not be modified adversely to the Optionees interest except by means of a writing signed by the Company and Optionee.
Submitted by: |
|
Accepted by: |
||
|
|
|
||
OPTIONEE |
|
TELADOC, INC. |
||
|
|
|
||
|
|
By: |
|
|
Signature |
|
|
|
|
|
|
|
|
|
Print Name |
|
Title: |
|
|
|
|
|
||
Address: |
|
|
|
|
|
|
Date Received: |
|
|
Exhibit 10.17
AGREEMENT
THIS AGREEMENT (the Agreement ) is made and entered as of February 27, 2014 (the Effective Date ), by and between Teladoc, Inc., a Delaware corporation (the Company ), and David B. Snow, Jr. (the Director).
WHEREAS, concurrently herewith, the Director has been elected as a member of the Board of Directors of the Company (the Board );
WHEREAS, in connection with such election, the Director and the Company desire to set forth certain agreements with respect to the terms and conditions of the Directors service as a member of the Board.
NOW, THEREFORE, in consideration of the mutual covenants contained herein, the sufficiency of which is acknowledged, the parties hereto agree as follows:
Section 1. Appointment of Director . Effective as of the Effective Date, the Director has been elected by the Companys stockholders as a Member of the Board. The Director hereby agrees to serve the Company in that position upon the terms and conditions hereinafter set forth.
Section 2. Section 2. Duties; Status.
2.1 Duties . During the Directorship Term, the Director shall serve as a member of the Board, and the Director shall exercise his best efforts to attend all Board meetings, serve on appropriate subcommittees and boards of directors of any subsidiary corporations as reasonably requested by the Board, make himself available to the Company at mutually convenient times and places, attend external meetings and presentations, as appropriate and convenient, and to perform such duties, services and responsibilities and have the authority commensurate with such position. In his performance of these responsibilities, the Director shall devote sufficient time and efforts to the affairs of the Company to perform his obligations under this Agreement.
2.2 Status . The Directors status during the Directorship Term shall not, for any purpose, be that of an employee or agent with authority to bind the Company in any respect. This is a personal services contract for the services of Director, and the Director cannot satisfy the terms and conditions of this Agreement by making anyone else available to perform the Directors services. The Company will report all payments to be made hereunder on Forms 1099 as payments to the Director for independent contracting services, and will not report any payments on Form W-2 to the Director.
Section 3. Compensation and Related Matters .
3.1 Cash Compensation . As compensation for the performance of the Directors services hereunder, during the Directorship Term the Company shall pay to the Director cash directors fees in the amount of $10,000 per calendar quarter (prorated for any partial calendar quarter), payable within fifteen (15) days following the completion of each calendar quarter during the Directorship Term.
3.2 Equity Compensation . Effective as of the Effective Date, the Company shall grant to the Director a nonqualified stock option ( Option ) to purchase one hundred forty thousand (140,000) shares of common stock, par value $0.01 per share, of the Company (Common Stock). The Option, which shall be granted under the Teladoc, Inc. Second Amended and Restated Stock Incentive Plan (as amended), shall be evidenced by a stock option agreement entered into by the Director and the Company (the Option Agreement ), substantially in the form attached hereto as Exhibit A . The exercise price of the Option shall be the per share fair market value of the Common Stock as of the date of grant of the Option, as determined by the Board (or the Compensation Committee thereof).
3.3 Travel Expenses . The Company shall pay or reimburse the Director for all commercially reasonable out-of-pocket travel expenses that the Director incurs during the Directorship Term in performing his duties set forth in this Agreement upon presentation of reasonable documentation and in accordance with the expense reimbursement policy of the Company in effect from time to time.
3.4 Insurance Coverage . To the extent that the Company maintains an insurance policy or policies providing liability insurance for members of the Companys Board, the Director shall be covered by such policy or policies in accordance with its or their terms to the same extent of the coverage provided to any other member of the Board under such policy or policies.
3.5 No Withholding . All payments and other consideration made or provided to the Director under this Agreement or otherwise shall be made or provided without withholding or deduction of any kind, and the Director shall assume sole responsibility for discharging all tax and other obligations associated therewith.
3.6 Survival . All payment obligations of the Company set forth in this Agreement shall survive the termination of this Agreement until such time as the Director has been paid all sums as may be due under this Agreement.
Section 4. Directorship Term . The Director shall serve as a director of the Company until his successor is duly elected or appointed, or until his earlier death or resignation or removal in the manner prescribed by the Companys Second Amended and Restated Bylaws, Third Amended and Restated Certificate of Incorporation, and Fourth Amended and Restated Investors Rights Agreement (as each of the same may be amended from time to time) (the period of the Directors service on the Board, herein referred to as the Directorship Term ). The Director acknowledges that he will serve as a member of the Board at the sole discretion of the Companys stockholders, and that nothing herein shall be construed to require the Director to serve on the Board for any particular period of time or to be reelected to the Board following the termination or expiration of his current term of service.
Section 5. Unauthorized Disclosure; Non-Solicitation; Non-Competition; Proprietary Rights .
5.1 Covenants . The Director agrees that he will not, directly or indirectly: (a) at any time during the Directorship Term or at any time thereafter, disclose, reveal, divulge or
communicate to any other Person or use or otherwise exploit for the Directors own or any other Persons account any Confidential or Proprietary Information (other than in the course of the Directors service with the Company) except for Permitted Disclosures; (b) at any time during the Directorship Term and thereafter during the Restriction Period, in any way materially interfere with the relationship between the Company or any of its subsidiaries, on the one hand, and any officer, director or employee of the Company or any of its subsidiaries, on the other hand; or induce or attempt to induce, or cause any officer, director or employee of the Company or any of its subsidiaries to leave the employment of the Company or any of its subsidiaries or violate the terms of his or her contracts or employment agreements with the Company or any of its subsidiaries or hire any employee of the Company or any of its subsidiaries; (c) at any time during the Directorship Term and thereafter during the Restriction Period, induce, or attempt to induce, any customer, client, salesperson, distributor, reseller, supplier, vendor, representative, agent, licensee or other Person transacting business with the Company or any of its subsidiaries to reduce or cease doing business with the Company or any of its subsidiaries, or in any way to interfere with the relationship between any such customer, client, salesperson, distributor, reseller, supplier, vendor, representative, agent, licensee or business relation, on the one hand, and the Company or any of its subsidiaries, on the other hand; or (d) at any time during the Directorship Term and thereafter during the Restriction Period, engage in any Competitive Activity in the Companys Market Area; provided that in the event that the Director is deemed to be engaged in any Competitive Activity due to the Company Business changing after the date of this Agreement, at the Companys option, (1) the Director and the Company shall engage in discussions to resolve such issue and appropriately amend this Agreement to allow the Director to remain a member of the Board or (ii) the Director shall resign as a member of the Board at the request of the Company and will engage in an orderly transition and departure as a member of the Board.
5.2 Defined Terms . For purposes of this Agreement:
(a) Competitive Activity shall mean, directly or indirectly, owning, managing, operating, controlling, or participating in the ownership, management (including, without limitation, serving on a board of directors or board of managers), operation or control of any business, whether in corporate, proprietorship or partnership form or otherwise, engaged in a Competing Business; provided , that, in no event shall the restrictions set forth in this Section 5 restrict the Director from owning shares of stock of any corporation having a class of equity securities traded on a national securities exchange or on the Nasdaq Stock Market which represent, in the aggregate, not more than two percent (2%) of such corporations fully-diluted shares.
(b) Companys Market Area shall mean (a) anywhere in the United States and (b) in any other country where the Company does business during the Directorship Term, regardless of the physical location of the Directors principal office.
(c) Company Business shall mean the business of providing telehealth services and such other business as the Company or its subsidiaries shall engage in during the Directorship Term.
(d) Competing Business shall mean the business of engaging in, developing, implementing, providing, performing, marketing and/or selling any products or services that compete, directly or indirectly, with the Company Business.
(e) Confidential or Proprietary Information shall mean any confidential information with respect to the Company Business, including methods of operation, pending or completed acquisitions of any company, division, product line or other business unit, prices, fees, costs, plans, designs, technology, inventions, trade secrets, know-how, software, marketing methods, policies, plans, personnel, customers, suppliers, competitors, markets or other specialized information or proprietary matters. The term Confidential or Proprietary Information does not include, and there shall be no obligation hereunder with respect to, information that (a) is generally available to the public on or before the Effective Date, (b) becomes generally available to the public other than as a result of a disclosure by the Director not otherwise permissible hereunder or (c) the Director learns from other sources where, to the Directors knowledge after making reasonable inquiry with respect to the particular matter in question, such sources are not restricted by any confidentiality obligation to the Company or any of its affiliates.
(f) Permitted Disclosure shall mean the disclosure of Confidential or Proprietary Information (a) made with the prior written consent of the Company; or (b) required to be disclosed by law or legal process; provided , however , that in the event disclosure is required by law or legal process, the Director shall, to the extent reasonably possible, provide the Company with prompt notice of such requirement prior to making any disclosure so that the Company may seek an appropriate protective order.
(g) Person shall mean an individual, a corporation, a partnership, a limited liability company, an association, a trust or any other entity or organization, including a government or political subdivision or an agency or instrumentality thereof.
(h) Restriction Period shall mean in the event that the Directors service with the Company terminates for any reason, the period commencing on the date of the Directors termination of service and ending on the twelve (12) month anniversary of such termination.
5.3 Confidentiality of this Agreement . Other than with respect to information required to be disclosed by applicable law, the parties hereto agree not to disclose the terms of this Agreement to any Person; provided each party may disclose this Agreement and/or any of its terms such partys immediate family, financial advisors and attorneys, so long as every such Person to whom such party makes such disclosure agrees not to disclose the terms of this Agreement further.
5.4 Remedies . The Director agrees that any material breach of the terms of this Section 5 would result in irreparable injury and damage to the Company for which the Company would have no adequate remedy at law; the Director therefore also agrees that in the event of said breach or any threat of breach, the Company shall be entitled to an immediate injunction and restraining order to prevent such breach and/or threatened breach and/or continued breach by the Director and/or any and all Persons acting for and/or with the Director,
without having to prove damages, in addition to any other remedies to which the Company may be entitled at law or in equity. The terms of this Section shall not prevent the Company from pursuing any other available remedies for any breach or threatened breach hereof, including, without limitation, the recovery of damages from the Director. The Director and the Company further agree that the provisions of the covenants contained in this Section 5 are reasonable and necessary to protect the businesses of the Company and its affiliates because of the Directors access to Confidential or Proprietary Information and the Directors material participation in the operation of such businesses.
Section 6. Representations . The Director represents and warrants that, as of the Effective Date, (a) he is not subject to any contract, arrangement, policy or understanding, or to any statute, governmental rule or regulation, that in any way limits his ability to enter into and fully perform his obligations under this Agreement and (b) he is otherwise unable to enter into and fully perform his obligations under this Agreement.
Section 7. Miscellaneous .
7.1 Amendments and Waivers . This Agreement and any of the provisions hereof may be amended, waived (either generally or in a particular instance and either retroactively or prospectively), modified or supplemented, in whole or in part, only by written agreement signed by the parties hereto; provided , that, the observance of any provision of this Agreement may be waived in writing by the party that will lose the benefit of such provision as a result of such waiver. The waiver by any party hereto of a breach of any provision of this Agreement shall not operate or be construed as a further or continuing waiver of such breach or as a waiver of any other or subsequent breach, except as otherwise explicitly provided for in such waiver. Except as otherwise expressly provided herein, no failure on the part of any party to exercise, and no delay in exercising, any right, power or remedy hereunder, or otherwise available in respect hereof at law or in equity, shall operate as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such party preclude any other or further exercise thereof or the exercise of any other right, power or remedy.
7.2 Assignment; No Third-Party Beneficiaries . This Agreement, and the Directors rights and obligations hereunder, may not be assigned by the Director, and any purported assignment by the Director in violation hereof shall be null and void. Nothing in this Agreement shall confer upon any Person not a party to this Agreement any rights or remedies of any nature or kind whatsoever under or by reason of this Agreement.
7.3 Notices . Unless otherwise provided herein, all notices, requests, demands, claims and other communications provided for under the terms of this Agreement shall be in writing. Any notice, request, demand, claim or other communication hereunder shall be sent by (a) personal delivery (including receipted courier service) or overnight delivery service, (b) facsimile or email during normal business hours, with confirmation of receipt, (c) reputable commercial overnight delivery service courier or (d) registered or certified mail, return receipt requested, postage prepaid and addressed to the intended recipient as set forth below:
(i) |
If to the Director, to: |
|
|
|
David B. Snow, Jr, |
|
23 Cedar Gate Road |
|
Darien, CT 06820 |
|
Phone: (203) 247-0743 |
|
dbsnowjr@aol.com |
|
|
(ii) |
If to the Company, to: |
|
|
|
Teladoc, Inc. |
|
One Sound Shore Drive, Suite 300 |
|
Greenwich, CT 06830 |
|
Attn: General Counsel |
|
Fax: (203) 769-1544 |
|
Phone: (203) 742-1637 |
|
Email: tseaman@teladoc.com |
|
|
|
With a copy (which shall not constitute notice) to: |
|
|
|
Jackson Walker L.L.P. |
|
901 Main Street, Suite 6000 |
|
Dallas, TX 75202 |
|
Attn: James S. Ryan, III |
|
Fax: (214) 661-6688 |
|
Email: j ryan@j w.com |
All such notices, requests, consents and other communications shall be deemed to have been given when received. Any party may change its facsimile number or its address to which notices, requests, demands, claims and other communications hereunder are to be delivered by giving the other parties hereto notice in the manner set forth herein.
7.4 Offset . Whenever the Company is to pay any sum to the Director hereunder, any amounts that the Director owes the Company or its subsidiaries may be deducted from that sum before payment.
7.5 Governing Law; Venue . This Agreement shall be construed and enforced in accordance with, and the rights and obligations of the parties hereto shall be governed by, the laws of the State of Connecticut, without giving effect to the conflicts of law principles thereof. Exclusive venue for any dispute arising out of or related to this Agreement shall be the state and federal courts located in Fairfield County, Connecticut. The parties hereto waive any challenge to personal jurisdiction or venue (including without limitation a challenge based on inconvenience) in Fairfield County, Connecticut, and specifically consent to the jurisdiction of the state and federal courts located in Fairfield County, Connecticut.
7.6 Severability . Whenever possible, each provision or portion of any provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law but the invalidity or unenforceability of any provision or portion of any
provision of this Agreement in any jurisdiction shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of this Agreement, including that provision or portion of any provision, in any other jurisdiction.
7.7 Entire Agreement . This Agreement and the Option Agreement shall constitute the entire agreement between the parties, and supersede all prior representations, agreements and understandings (including any prior course of dealings), both written and oral, between the parties with respect to the subject matter hereof and thereof
7.8 Counterparts . This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all such counterparts shall together constitute one and the same instrument.
7.9 Binding Effect . This Agreement shall inure to the benefit of, and be binding on, the successors and permitted assigns of each of the parties, including, without limitation, the Directors heirs and the personal representatives of the Directors estate and any successor to all or substantially all of the business and/or assets of the Company.
[ Remainder of this page intentionally left blank ]
IN WITNESS WHEREOF, the undersigned have executed this Agreement, effective as of the Effective Date.
|
COMPANY: |
|
|
|
|
|
TELADOC, INC. |
|
|
|
|
|
|
|
|
By: |
/s/Jason Gorevic |
|
Name: Jason Gorevic |
|
|
Title: Chief Executive Officer |
|
|
|
|
|
|
|
|
DIRECTOR: |
|
|
|
|
|
|
|
|
/s/ David B. Snow Jr. |
|
|
David B. Snow, Jr. |
Exhibit 10.18
AGREEMENT
THIS AGREEMENT (the Agreement ) is made and entered as of September 10, 2014 (the Effective Date ), by and between Teladoc, Inc., a Delaware corporation (the Company ), and Senator William H. Frist, M.D. (the Director ).
WHEREAS, concurrently herewith, the Director has been elected as a member of the Board of Directors of the Company (the Board );
WHEREAS, in connection with such election, the Director and the Company desire to set forth certain agreements with respect to the terms and conditions of the Directors service as a member of the Board.
NOW, THEREFORE, in consideration of the mutual covenants contained herein, the sufficiency of which is acknowledged, the parties hereto agree as follows:
Section 1. Appointment of Director. Effective as of the Effective Date, the Director has been elected by the Companys stockholders as a Member of the Board. The Director hereby agrees to serve the Company in that position upon the terms and conditions hereinafter set forth.
Section 2. Duties; Status.
2.1 Duties . During the Directorship Term, the Director shall serve as a member of the Board, and the Director shall exercise his best efforts to attend all Board meetings, serve on appropriate subcommittees and boards of directors of any subsidiary corporations as reasonably requested by the Board, make himself available to the Company at mutually convenient times and places, attend external meetings and presentations, as appropriate and convenient, and to perform such duties, services and responsibilities and have the authority commensurate with such position. In his performance of these responsibilities, the Director shall devote sufficient time and efforts to the affairs of the Company to perform his obligations under this Agreement.
2.2 Status. The Directors status during the Directorship Term shall not, for any purpose, be that of an employee or agent with authority to bind the Company in any respect. This is a personal services contract for the services of Director, and the Director cannot satisfy the terms and conditions of this Agreement by making anyone else available to perform the Directors services. The Company will report all payments to be made hereunder on Forms 1099 as payments to the Director for independent contracting services, and will not report any payments on Form W-2 to the Director.
Section 3. Compensation and Related Matters.
3.1 Cash Compensation. As compensation for the performance of the Directors services hereunder, during the Directorship Term the Company shall pay to the Director cash directors fees in the amount of $10,000 per calendar quarter (prorated for any partial calendar quarter), payable within fifteen (15) days following the completion of each calendar quarter during the Directorship Term.
3.2 Equity Compensation. Effective as of the Effective Date, the Company shall grant to the Director a nonqualified stock option ( Option ) to purchase one hundred forty thousand (140,000) shares of common stock, par value $0.01 per share, of the Company ( Common Stock ). The Option, which shall be granted under the Teladoc, Inc. Second Amended and Restated Stock Incentive Plan (as amended), shall be evidenced by a stock option agreement entered into by the Director and the Company (the Option Agreement ), substantially in the form attached hereto as Exhibit A . The exercise price of the Option shall be the per share fair market value of the Common Stock as of the date of grant of the Option, as determined by the Board (or the Compensation Committee thereof).
3.3 Travel Expenses. The Company shall pay or reimburse the Director for all commercially reasonable out-of-pocket travel expenses that the Director incurs during the Directorship Term in performing his duties set forth in this Agreement upon presentation of reasonable documentation and in accordance with the expense reimbursement policy of the Company in effect from time to time.
3.4 Insurance Coverage. To the extent that the Company maintains an insurance policy or policies providing liability insurance for members of the Companys Board, the Director shall be covered by such policy or policies in accordance with its or their terms to the same extent of the coverage provided to any other member of the Board under such policy or policies.
3.5 No Withholding. All payments and other consideration made or provided to the Director under this Agreement or otherwise shall be made or provided without withholding or deduction of any kind, and the Director shall assume sole responsibility for discharging all tax and other obligations associated therewith.
3.6 Survival. All payment obligations of the Company set forth in this Agreement shall survive the termination of this Agreement until such time as the Director has been paid all sums as may be due under this Agreement.
Section 4. Directorship Term. The Director shall serve as a director of the Company until his successor is duly elected or appointed, or until his earlier death or resignation or removal in the manner prescribed by the Companys Second Amended and Restated Bylaws, Third Amended and Restated Certificate of Incorporation, and Fourth Amended and Restated Investors Rights Agreement (as each of the same may be amended from time to time) (the period of the Directors service on the Board, herein referred to as the Directorship Term ). The Director acknowledges that he will serve as a member of the Board at the sole discretion of the Companys stockholders, and that nothing herein shall be construed to require the Director to serve on the Board for any particular period of time or to be re-elected to the Board following the termination or expiration of his current term of service.
Section 5. Unauthorized Disclosure; Non-Solicitation; Non-Competition; Proprietary Rights.
5.1 Covenants. The Director agrees that he will not, directly or indirectly: (a) at any time during the Directorship Term or at any time thereafter, disclose, reveal, divulge or communicate to any other Person or use or otherwise exploit for the Directors own or
any other Persons account any Confidential or Proprietary Information (other than in the course of the Directors service with the Company) except for Permitted Disclosures; (b) at any time during the Directorship Term and thereafter during the Restriction Period, in any way materially interfere with the relationship between the Company or any of its subsidiaries, on the one hand, and any officer, director or employee of the Company or any of its subsidiaries, on the other hand; or induce or attempt to induce, or cause any officer, director or employee of the Company or any of its subsidiaries to leave the employment of the Company or any of its subsidiaries or violate the terms of his or her contracts or employment agreements with the Company or any of its subsidiaries or hire any employee of the Company or any of its subsidiaries; (c) at any time during the Directorship Term and thereafter during the Restriction Period, induce, or attempt to induce, any customer, client, salesperson, distributor, reseller, supplier, vendor, representative, agent, licensee or other Person transacting business with the Company or any of its subsidiaries to reduce or cease doing business with the Company or any of its subsidiaries, or in any way to interfere with the relationship between any such customer, client, salesperson, distributor, reseller, supplier, vendor, representative, agent, licensee or business relation, on the one hand, and the Company or any of its subsidiaries, on the other hand; or (d) at any time during the Directorship Term and thereafter during the Restriction Period, engage in any Competitive Activity in the Companys Market Area; provided that the Directors service on the Boards listed on Exhibit B hereto or his work as an adjunct professor of Cardiac Surgery at Vanderbilt University and clinical professor of Surgery at Meharry Medical College or his serving on the advisory committees for global health at Duke, Harvard, and the Massachusetts General Hospital(Existing Activities) shall not be deemed a competitive activity as of the date hereof; and provided further that in the event that the Director is deemed to be engaged in any Competitive Activity due to the Company Business changing or the nature or scope of the Existing Activities changing after the date of this Agreement, at the Companys option, (i) the Director and the Company shall engage in discussions to resolve such issue and appropriately amend this Agreement to allow the Director to remain a member of the Board or (ii) the Director shall resign as a member of the Board at the request of the Company and will engage in an orderly transition and departure as a member of the Board.
5.2 Defined Terms. For purposes of this Agreement:
(a) Competitive Activity shall mean, directly or indirectly, owning, managing, operating, controlling, or participating in the ownership, management (including, without limitation, serving on a board of directors or board of managers), operation or control of any business, whether in corporate, proprietorship or partnership form or otherwise, engaged in a Competing Business; provided , that, in no event shall the restrictions set forth in this Section 5 restrict the Director from owning shares of stock of any corporation having a class of equity securities traded on a national securities exchange or on the Nasdaq Stock Market which represent, in the aggregate, not more than two percent (2%) of such corporations fully-diluted shares.
(b) Companys Market Area shall mean (a) anywhere in the United States and (b) in any other country where the Company does business during the Directorship Term, regardless of the physical location of the Directors principal office.
(c) Company Business shall mean the business of providing telehealth services and such other business as the Company or its subsidiaries shall engage in during the Directorship Term.
(d) Competing Business shall mean the business of engaging in, developing, implementing, providing, performing, marketing and/or selling any products or services that compete, directly or indirectly, with the Company Business.
(e) Confidential or Proprietary Information shall mean any confidential information with respect to the Company Business, including methods of operation, pending or completed acquisitions of any company, division, product line or other business unit, prices, fees, costs, plans, designs, technology, inventions, trade secrets, know-how, software, marketing methods, policies, plans, personnel, customers, suppliers, competitors, markets or other specialized information or proprietary matters. The term Confidential or Proprietary Information does not include, and there shall be no obligation hereunder with respect to, information that (a) is generally available to the public on or before the Effective Date, (b) becomes generally available to the public other than as a result of a disclosure by the Director not otherwise permissible hereunder or (c) the Director learns from other sources where, to the Directors knowledge after making reasonable inquiry with respect to the particular matter in question, such sources are not restricted by any confidentiality obligation to the Company or any of its affiliates.
(f) Permitted Disclosure shall mean the disclosure of Confidential or Proprietary Information (a) made with the prior written consent of the Company; or (b) required to be disclosed by law or legal process; provided , however , that in the event disclosure is required by law or legal process, the Director shall, to the extent reasonably possible, provide the Company with prompt notice of such requirement prior to making any disclosure so that the Company may seek an appropriate protective order.
(g) Person shall mean an individual, a corporation, a partnership, a limited liability company, an association, a trust or any other entity or organization, including a government or political subdivision or an agency or instrumentality thereof.
(h) Restriction Period shall mean in the event that the Directors service with the Company terminates for any reason, the period commencing 011 the date of the Directors termination of service and ending on the twelve (12) month anniversary of such termination.
5.3 Confidentiality of this Agreement. Other than with respect to information required to be disclosed by applicable law, the parties hereto agree not to disclose the terms of this Agreement to any Person; provided each party may disclose this Agreement and/or any of its terms such partys immediate family, financial advisors and attorneys, so long as every such Person to whom such party makes such disclosure agrees not to disclose the terms of this Agreement further.
5.4 Remedies. The Director agrees that any material breach of the terms of this Section 5 would result in irreparable injury and damage to the Company for which
the Company would have no adequate remedy at law; the Director therefore also agrees that in the event of said breach or any threat of breach, the Company shall be entitled to an immediate injunction and restraining order to prevent such breach and/or threatened breach and/or continued breach by the Director and/or any and all Persons acting for and/or with the Director, without having to prove damages, in addition to any other remedies to which the Company may be entitled at law or in equity. The terms of this Section shall not prevent the Company from pursuing any other available remedies for any breach or threatened breach hereof, including, without limitation, the recovery of damages from the Director. The Director and the Company further agree that the provisions of the covenants contained in this Section 5 are reasonable and necessary to protect the businesses of the Company and its affiliates because of the Directors access to Confidential or Proprietary Information and the Directors material participation in the operation of such businesses.
Section 6. Representations. The Director represents and warrants that, as of the Effective Date, (a) he is not subject to any contract, arrangement, policy or understanding, or to any statute, governmental rule or regulation, that in any way limits his ability to enter into and fully perform his obligations under this Agreement and (b) he is otherwise unable to enter into and fully perform his obligations under this Agreement.
Section 7. Miscellaneous.
7.1 Amendments and Waivers. This Agreement and any of the provisions hereof may be amended, waived (either generally or in a particular instance and either retroactively or prospectively), modified or supplemented, in whole or in part, only by written agreement signed by the parties hereto; provided , that, the observance of any provision of this Agreement may be waived in writing by the party that will lose the benefit of such provision as a result of such waiver. The waiver by any party hereto of a breach of any provision of this Agreement shall not operate or be construed as a further or continuing waiver of such breach or as a waiver of any other or subsequent breach, except as otherwise explicitly provided for in such waiver. Except as otherwise expressly provided herein, no failure on the part of any party to exercise, and no delay in exercising, any right, power or remedy hereunder, or otherwise available in respect hereof at law or in equity, shall operate as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such party preclude any other or further exercise thereof or the exercise of any other right, power or remedy.
7.2 Assignment; No Third-Party Beneficiaries. This Agreement, and the Directors rights and obligations hereunder, may not be assigned by the Director, and any purported assignment by the Director in violation hereof shall be null and void. Nothing in this Agreement shall confer upon any Person not a party to this Agreement any rights or remedies of any nature or kind whatsoever under or by reason of this Agreement.
7.3 Notices. Unless otherwise provided herein, all notices, requests, demands, claims and other communications provided for under the terms of this Agreement shall be in writing. Any notice, request, demand, claim or other communication hereunder shall be sent by (a) personal delivery (including receipted courier service) or overnight delivery service, (b) facsimile or email during normal business hours, with confirmation of receipt, (c) reputable
commercial overnight delivery service courier or (d) registered or certified mail, return receipt requested, postage prepaid and addressed to the intended recipient as set forth below:
(i) |
If to the Director, to: |
|
|
|
|
|
|
Dr. William H. Frist, M.D. |
|
|
2525 West End Avenue, Suite 1250 |
|
|
Nashville, TN 37203 |
|
|
Fax: (615) 369-8444 |
|
|
Phone: (615)369-8441 |
|
|
Email: bfrist@wfrist.com |
|
|
|
(ii) |
If to the Company, to: |
|
|
|
|
|
|
Teladoc, Inc. |
|
|
One Sound Shore Drive, Suite 300 |
|
|
Greenwich, CT 06830 |
|
|
Attn: General Counsel |
|
|
Fax:(203) 769-1544 |
|
|
Phone: (203) 742-1637 |
|
|
Email: tseaman@teladoc.com |
|
|
|
|
|
With a copy (which shall not constitute notice) to: |
|
|
|
|
|
Jackson Walker L.L.P. |
|
|
901 Main Street, Suite 6000 |
|
|
Dallas, TX 75202 |
|
|
Attn: James S. Ryan, III |
|
|
Fax: (214) 661-6688 |
|
|
Email: jryan@jw.com |
All such notices, requests, consents and other communications shall be deemed to have been given when received. Any party may change its facsimile number or its address to which notices, requests, demands, claims and other communications hereunder are to be delivered by giving the other parties hereto notice in the manner set forth herein.
7.4 Offset. Whenever the Company is to pay any sum to the Director hereunder, any amounts that the Director owes the Company or its subsidiaries may be deducted from that sum before payment.
7.5 Governing Law; Venue. This Agreement shall be construed and enforced in accordance with, and the rights and obligations of the parties hereto shall be governed by, the laws of the State of Delaware, without giving effect to the conflicts of law principles thereof. Exclusive venue for any dispute arising out of or related to this Agreement shall be the state and federal courts located in Fairfield County, Connecticut. The parties hereto waive any challenge to personal jurisdiction or venue (including without limitation a challenge based on inconvenience) in Fairfield County, Connecticut, and specifically consent to the jurisdiction of the state and federal courts located in Fairfield County, Connecticut.
7.6 Severability. Whenever possible, each provision or portion of any provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law but the invalidity or unenforceability of any provision or portion of any provision of this Agreement in any jurisdiction shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of this Agreement, including that provision or portion of any provision, in any other jurisdiction.
7.7 Entire Agreement. This Agreement and the Option Agreement shall constitute the entire agreement between the parties, and supersede all prior representations, agreements and understandings (including any prior course of dealings), both written and oral, between the parties with respect to the subject matter hereof and thereof.
7.8 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all such counterparts shall together constitute one and the same instrument.
7.9 Binding Effect. This Agreement shall inure to the benefit of, and be binding on, the successors and permitted assigns of each of the parties, including, without limitation, the Directors heirs and the personal representatives of the Directors estate and any successor to all or substantially all of the business and/or assets of the Company.
[Remainder of this page intentionally left blank]
IN WITNESS WHEREOF, the undersigned have executed this Agreement, effective as of the Effective Date.
|
COMPANY : |
|
|
|
|
|
TELADOC, INC. |
|
|
|
|
|
By: |
/s/ Jason Gorevic |
|
Name: |
Jason Gorevic |
|
Title: |
Chief Executive Officer |
|
|
|
|
|
|
|
DIRECTOR: |
|
|
|
|
|
/s/ William H. First |
|
|
Senator William H. Frist, M.D. |
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption "Experts" and to the use of our report dated March 24, 2015 (except for Note 18, as to which the date is June 4, 2015), in the Registration Statement (Form S-1) and related Prospectus of Teladoc, Inc. for the registration of shares of its common stock.
/s/ Ernst & Young LLP
New York, New York
June 10, 2015
Consent of Independent Auditors
We consent to the reference to our firm under the caption "Experts" and to the use of our reports dated March 24, 2015, with respect to the consolidated financial statements of Consult A Doctor, Inc. and AmeriDoc, LLC included in the Registration Statement (Form S-1) and related Prospectus of Teladoc, Inc. for the registration of shares of its common stock.
/s/ Ernst & Young LLP
New York, New York
June 10, 2015
Consent of Independent Auditors
We consent to the reference to our firm under the caption "Experts" and to the use of our report dated June 5, 2015, with respect to the financial statements of Stat Health Services Inc. included in the Registration Statement (Form S-1) and related Prospectus of Teladoc, Inc. for the registration of shares of its common stock.
/s/ Ernst & Young LLP
Denver,
Colorado
June 10, 2015